-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FDLp/4SbjEokSmzS7gZwZwwdkuwaf33EnlllHY9nhKLxv0sNzJ41M0XRGhUgY/pa we+2Gbz2UQKZwaJkEsbSIg== 0000010427-07-000025.txt : 20070207 0000010427-07-000025.hdr.sgml : 20070207 20070207165303 ACCESSION NUMBER: 0000010427-07-000025 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20051231 FILED AS OF DATE: 20070207 DATE AS OF CHANGE: 20070207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAUSCH & LOMB INC CENTRAL INDEX KEY: 0000010427 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 160345235 STATE OF INCORPORATION: NY FISCAL YEAR END: 1226 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04105 FILM NUMBER: 07588820 BUSINESS ADDRESS: STREET 1: BAUSCH & LOMB INCORPORATED STREET 2: ONE BAUSCH & LOMB PLACE CITY: ROCHESTER STATE: NY ZIP: 14604-2701 BUSINESS PHONE: 5853386000 MAIL ADDRESS: STREET 1: ONE BAUSCH & LOMB PLACE STREET 2: P O BOX 54 CITY: ROCHESTER STATE: NY ZIP: 14604-2701 10-K 1 form10-k.htm BAUSCH & LOMB INCORPORATED 10-K PERIOD ENDING DECEMBER 31, 2005 Bausch & Lomb Incorporated 10-K Period Ending December 31, 2005


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)

FORM 10-K


x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2005       

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________________ to                                  &# 160; 

Commission file number 1-4105         

BAUSCH & LOMB INCORPORATED
(Exact name of registrant as specified in its charter)
 

 
NEW YORK
16-0345235
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
   
ONE BAUSCH & LOMB PLACE, ROCHESTER, NY
14604-2701
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code 585.338.6000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Name of each exchange on which registered
Common Stock, $0.40 par value   
New York Stock Exchange   
   
   

Securities registered pursuant to section 12(g) of the Act:

None                                           & #160;                                            
(Title of class)

                                                   
(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
o Yes x No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
o Yes x No




PAGE 2

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
o Yes x No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer x   Accelerated filer o   Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
o Yes x No

The aggregate market value of the voting stock, computed using the average bid and asked price of such stock, held by non-affiliates of the registrant as of June 2005 was $4,066,870,420. For the sole purpose of making this calculation, the term "non-affiliate" has been interpreted to exclude directors and officers. Such interpretation is not intended to be and should not be construed to be, an admission by Bausch & Lomb Incorporated or such directors or officers that such directors and officers are "affiliates" of Bausch & Lomb Incorporated, as that term is defined under the Securities Act of 1933.
The number of shares of Voting Stock of the registrant, outstanding as of January 27, 2007, was 54,338,016, consisting of 54,308,836 shares of Common stock and 29,180 shares of Class B stock, which are identical with respect to dividend and liquidation rights and vote together as a single class for all purposes.

DOCUMENTS INCORPORATED BY REFERENCE

Part III

Not applicable.




PAGE 3

Table of Contents
Part I
 
Page
     
Item 1.
Business
4
     
Item 1A.
Risk Factors
9
     
Item 1B.
Unresolved Staff Comments
22
     
Item 2.
Properties
22
     
Item 3.
Legal Proceedings
22
     
Item 4.
Submission of Matters to a Vote of Security Holders
26
     
Part II
   
     
Item 5.
Market for Bausch & Lomb Incorporated's Common Stock, Related Shareholder Matters and Issuer Purchases of Equity Securities
28
     
Item 6.
Selected Financial Data
29
     
Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
29
     
Item 7A.
Quantitative and Qualitative Disclosures about Market Risk
60
     
Item 8.
Financial Statements and Supplementary Data
60
     
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
117
     
Item 9A.
Controls and Procedures
117
     
Item 9B.
Other Information
122
     
Part III
   
     
Item 10.
Directors and Executive Officers of Bausch & Lomb Incorporated
123
     
Item 11.
Executive Compensation
130
     
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
138
     
Item 13.
Certain Relationships and Related Transactions
140
     
Item 14.
Principal Accounting Fees and Services
142
     
Part IV
   
     
Item 15.
Exhibits and Financial Statement Schedules
143
     
Signatures
 
144
Exhibit Index
 
149
Exhibits
 
(Attached to the Report on Form 10-K)




PAGE 4

Part I

Item 1.  Business

Unless the context indicates otherwise, the terms "we", "our" "ours" and "the Company" are used herein to refer to Bausch & Lomb Incorporated and its consolidated subsidiaries. All dollar amounts in Part I of this Form 10-K, except for per share data, are expressed in millions unless specified otherwise, and earnings per share are presented on a diluted basis.

(a) Restatement of Previously Issued Financial Statements

The Company restated its consolidated financial statements, as more fully discussed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement to the consolidated financial statements included in this Annual Report on Form 10-K. The Company restated its consolidated balance sheet, its consolidated statements of income, of changes in shareholders' equity and of cash flows as of December 25, 2004 and for the fiscal years 2003 and 2004. In addition, the Company restated selected financial data as of 2003, 2002 and 2001 and for fiscal years 2002 and 2001. See Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K and beginning shareholders' equity for the impact of the restatement for periods prior to 2001. The impact of the restated financial results for the first and second quarterly periods of 2005 and the quarterly periods of 2004 are also presented in Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K.
The restatement corrects for errors made in the application of generally accepted accounting principles (GAAP), including revenue recognition, accounting for reserves, accounting for foreign currency adjustments, accounting for income taxes including income taxes payable, tax reserves, deferred income tax assets and liabilities, related valuation allowances and income tax expense, and the accounting for the Company's Long-Term Deferred Compensation Plan. For a discussion of the significant restatement adjustments and the background leading to these adjustments see Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement and Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K.
After filing this report, the Company will work toward filing its Quarterly Reports on Form 10-Q for the third quarter of 2005 and the first, second and third quarters of 2006 and its Annual Report on Form 10-K for 2006. While the Company is working diligently to complete the filings referred to, there can be no assurance as to when the Company will be current in its reporting obligations.

(b) General Development of Business

Founded in 1853 and incorporated in the State of New York in 1908, we are a world leader in the development, manufacture and marketing of eye health products, including contact lenses, contact lens care solutions and ophthalmic surgical and pharmaceutical products.
We made no significant acquisitions or dispositions of businesses in either 2003 or 2004. In the fourth quarter of 2005, we acquired a 70-percent controlling interest in Shandong Chia Tai Freda Pharmaceutical Group (Freda), the leading ophthalmic pharmaceutical company in China, from Sino Biopharmaceutical Ltd. The total purchase price for the Freda acquisition was $255, or $248 net of cash acquired. Freda primarily develops, manufactures and markets medications used to treat ocular inflammation and infection, glaucoma and dry eye. We believe the acquisition has accelerated our expansion into the rapidly growing ophthalmic pharmaceuticals market in China and provides a national pharmaceuticals sales and distribution network, a locally compliant manufacturing facility, and expertise in regulatory affairs and product development.

(c) Financial Information about Operating Segments

Information concerning sales, operating earnings and assets attributable to each of our operating segments is set forth in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K under the section entitled Net Sales and Income by Business Segment and Geographic Region and in Item 8. Financial Statements and Supplementary Data under Note 5 — Business Segment and Geographic Information of this Annual Report on Form 10-K. This information is incorporated herein by reference.




PAGE 5

(d) Narrative Description of Business

Operating Segments We are organized into five business segments: three commercial geographic segments and two additional segments managed globally (Research & Development and Global Operations & Engineering). Commercial regions are responsible for the sale and marketing of our products within their defined geographies (the Americas; Europe, Middle East and Africa [Europe]; and Asia). The Research & Development segment is responsible for activities associated with research, preclinical development, new product development, clinical affairs, medical affairs, regulatory affairs, and product quality. The Global Operations & Engineering segment is responsible for demand planning, engineering, manufacturing, logistics and procurement.

Products In each geographic region, we market products in five product categories: contact lenses, lens care products, ophthalmic pharmaceuticals, cataract and vitreoretinal surgery, and refractive surgery.

Contact Lenses We pioneered the development of soft contact lens technology and are one of the largest manufacturers of contact lenses in the world. Our product portfolio is one of the broadest in the industry and includes traditional, planned replacement disposable, daily disposable, multifocal, and toric soft contact lenses and rigid gas permeable (RGP) materials. These products are marketed by our own sales force and through distributors to licensed eye care professionals and health product retailers under the Bausch & Lomb, Boston, Medalist, PureVision and SofLens brand names. Major competitors in the contact lens market include CIBA Vision Corporation (a subsidiary of Novartis AG) (CIBA); CooperVision (a subsidiary of The Cooper Companies, Inc.); and Vistakon, Inc. (a subsidiary of Johnson & Johnson).
Net sales of contact lenses constituted 31 percent of our total revenues in fiscal year 2005, growing 9 percent from the prior year. This growth rate compares to overall estimated contact lens market growth in the mid-to-upper single digits.
We believe that contact lenses will be a growth driver over the next several years, due to our strong portfolio of specialty contact lenses and the market’s rapid conversion to contact lenses made of silicone hydrogel materials. In the specialty business, our SofLens Toric lens, a planned replacement lens for people with astigmatism, and our SofLens Multi-Focal lens for people with presbyopia, are leading products in their categories worldwide. In 2005, we introduced in the United States and Europe Nike MAXSIGHT sport-tinted contact lenses, specialty lenses designed to aid visual performance in athletic settings. In Japan, we launched Medalist II, a two-week disposable spherical (or non-specialty) lens, and a redesigned version of Medalist One Day daily disposable contact lenses in 2006; and Medalist Multi-Focal contact lenses in the fourth quarter of 2006.
Silicone hydrogel contact lenses are becoming an increasingly larger portion of the overall market. Based on syndicated data and internal estimates, we believe that approximately 40 percent of new fit and refit prescriptions for spherical contact lenses in the United States in the fourth quarter of 2005 were for silicone hydrogel contact lenses, about double the rate in the prior year period. In 2005, we reintroduced our PureVision line of silicone hydrogel contact lenses into the U.S. market and further expanded the geographic reach of PureVision Toric contact lenses in Europe and Asia. In 2006, we introduced PureVision Multi-Focal, the first presbyopia correcting lens made of this new generation of materials. We also received approval to market the PureVision line in Japan, and anticipate a commercial launch in 2007.
Our future development efforts in contact lenses will concentrate on new silicone hydrogel offerings featuring novel materials, surface treatments and optical design characteristics.

Lens Care Our lens care portfolio includes multipurpose solutions, cleaning and conditioning solutions for RGP lenses, re-wetting drops and saline solutions. We are a global leader in market share for lens care products, which we market through our own sales force and distributors to licensed eye care professionals, health product retailers, independent pharmacies, drug stores, food stores and mass merchandisers. Our strategy is to outpace market trends and increase our share through continued leadership in the multipurpose segment, the only growing category in the overall lens care market. Prior to the May 2006 withdrawal of ReNu with MoistureLoc solution (MoistureLoc), our flagship brand, ReNu, had the leading market position in this segment in the United States. Subsequent to the withdrawal, we lost about 10 market share points in the United States, placing us behind Alcon, Inc. in the multipurpose segment of the market. We are currently executing brand rebuilding initiatives to recoup some of that lost market share. Our Boston brand of products for RGP lens care holds a commanding market share worldwide. Major competitors in the lens care category include Advanced Medical Optics, Inc. (AMO); Alcon, Inc.; and CIBA.



PAGE 6

Net sales of lens care products constituted 22 percent of our total revenues in fiscal year 2005, with sales flat from the prior year, and included the impact of the launch of ReNu MultiPlus in Japan, where it is among the most technologically advanced lens care products on the market. In 2005, the global market exhibited no growth to low-single digit declines. Our reported sales include the impact of our recalling MoistureLoc following an increase in reported fungal infections among contact lens wearers in the United States and certain Asian markets. In accordance with GAAP, we recorded certain items associated with the recall in our 2005 financial results. The charges related to: customer returns; consumer rebates; returned products; disposal and write-off of inventory; and costs associated with the notification to customers and consumers required in market withdrawal instances. The adjustments were recorded as third-quarter events, because that is the earliest reporting period for which we have not filed quarterly financial results on Form 10-Q. See further discussion in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K.

Pharmaceuticals Our pharmaceuticals product category includes generic and branded prescription ophthalmic pharmaceuticals, ocular vitamins and over-the-counter (OTC) medications. Pharmaceutical products are marketed by our sales force and distributed through wholesalers, independent pharmacies, drug stores, food stores, mass merchandisers and hospitals. Our key pharmaceutical trademarks are Bausch & Lomb, Alrex, Indocollyre, Liposic, Lotemax, Moisten, Mioclear, Ocuvite, PreserVision, Retisert and Zylet. The ophthalmic pharmaceuticals market is significantly fragmented. Major competitors include Alcon, Inc.; Allergan, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; and Santen Incorporated.
Net sales of pharmaceuticals products comprised 25 percent of consolidated revenues in fiscal year 2005, representing growth of 11 percent in a market we estimate to be growing in the mid-to-upper single digits. During the fourth quarter we completed the acquisition of Freda, which accounted for approximately four-percentage points of our reported growth.
Our longer-term strategy in pharmaceuticals is to build a pipeline and launch new proprietary prescription drugs, but that takes time, considering the development, regulatory review and approval process. Nearer term, we are focused on growing the consumer health portion of the business by launching new OTC eye care products, expanding the geographic availability of existing products, and developing and launching new entries in our nutritionals portfolio.
Until recently, our nutritionals business has been aimed toward a specific ocular condition — age-related macular degeneration (AMD), with our PreserVision line of ocular vitamins. Scientific literature suggests that nutritional products can be used to improve or even prevent a variety of other conditions. In 2004, we launched in Europe a nutritional product containing Omega-3 and Omega-6 fatty acids, naturally occurring substances found in fish oils and certain plants. Studies have linked higher intake of fatty acids with a reduction in symptoms of dry eye. We have also identified other potential formulations, and expect to launch a proprietary nutritional formulation for diabetics as early as 2007. A nutritional formulation for people over age 50 was launched in 2006. By the end of 2007, our portfolio of nutritionals products should contain products that target not only general eye health, AMD, diabetes and dry eye; but also other ocular conditions.
Elsewhere in our OTC portfolio, we expect to introduce a long-lasting dry eye product later in 2007. In 2006, we repositioned our lines of general eye care products under the Bausch & Lomb Advanced Eye Relief sub-brand. We are also working on ways to deliver products in a preservative-free multi-dose system to fulfill doctors’ desire for safer, gentler preservative-free products and consumers’ preferences for the convenience of bottled drops over single-use vials.
Turning to prescription pharmaceuticals, in 2005 in the United States we launched Zylet, a combination anti-inflammatory/anti-infective product containing loteprednol etabonate and tobramycin, and Retisert, our drug delivery implant to treat posterior segment uveitis.

Cataract and Vitreoretinal Surgery Cataract surgery is one of the most commonly performed surgical procedures. Our cataract and vitreoretinal offerings include a broad line of intraocular lenses (IOLs) as well as the Millennium and Stellaris lines of phacoemulsification equipment. (Phacoemulsification is the procedure by which the patient's natural lens is extracted during cataract surgery.) We also sell disposable surgical packs and instruments that are used during the procedure. Our cataract and vitreoretinal surgery products and equipment are marketed by our sales force and through distributors to ophthalmic surgeons, hospitals and ambulatory surgery centers. We believe we have developed substantial professional recognition for our products marketed under the Bausch & Lomb, Akreos, AMVISC, Millennium, SofPort and Storz trademarks. We are the third largest manufacturer of cataract and vitreoretinal products. Major competitors in the category include AMO and Alcon, Inc.



PAGE 7

Cataract and vitreoretinal net sales increased 6 percent and comprised 16 percent of our fiscal 2005 revenues. The overall cataract and vitreoretinal market is estimated to be growing in the mid-single digits. Our goal in the cataract and vitreoretinal category is to improve our market share position.
In 2005, we introduced an advanced optics version of our successful Akreos acrylic IOL in markets outside the United States and globally introduced the Easy-Load Lens Delivery System for our SofPort Advanced Optics (AO) silicone IOL. In 2006, we enhanced our SofPort line of IOLs with the introduction of technology that blocks harmful violet light. We also launched in certain markets outside the United States a new acrylic IOL on our Akreos platform that can be inserted through an incision of less than two millimeters — 33 percent smaller than most incisions today. In 2007, we expect to bring our newest Akreos Advance Optics (AO) lens into the large U.S. market. Beyond IOLs, our new phacoemulsification platform, Stellaris, was recently cleared for sale in the United States by the Food and Drug Administration. We expect to launch Stellaris in the first half of 2007. Designed specifically from customer input and feedback, it incorporates ergonomic improvements and better fluidics to facilitate faster turnaround between surgeries. It is also capable of performing cataract surgery using incisions smaller than two millimeters. Finally, we are pursuing surgical solutions for presbyopic correction, targeting our development and external partnering efforts on products designed to allow the eye to focus at all distances.

Refractive Surgery Products in this category include lasers, microkeratomes, diagnostic equipment and other products used in the LASIK (Laser in-situ Keratomileusis) surgical procedure. Our refractive surgery products are marketed by our sales force and through distributors to ophthalmic surgeons, hospitals and ambulatory surgery centers. We believe we have developed substantial professional recognition of our refractive surgery products and equipment marketed under the Hansatome, Technolas and Zyoptix trademarks. We are the second largest manufacturer of refractive surgery products. Major competitors include Alcon, Inc.; AMO; Intralase Corp.; and Moria S.A.
Net sales of refractive surgery products accounted for 6 percent of our 2005 revenues and declined 8 percent from 2004.
Our strategy is to improve our market share of LASIK and other refractive surgical procedures in the United States and to increase the number of custom LASIK procedures in markets outside the United States, which will increase our annuity stream of revenues from procedural fees and microkeratome blades. This would have the added benefit of increasing profitability, as annuity products generally carry higher operating margins than capital equipment. Our Hansatome and Zyoptix XP microkeratomes, the precision cutting tools to create the corneal flap, are the most widely used microkeratomes today. We also manufacture and market the disposable blades that are replaced after each LASIK procedure. The Zyoptix XP microkeratome was launched in 2005 along with networked service solutions for our laser, which allow us to remotely monitor product performance and alert our service team to perform preventive maintenance before a problem occurs. In 2006, we launched enhancements to the algorithms used in our Zyoptix personalized LASIK procedure which will improve procedure efficiency, ease of use, clinical outcome and predictability, and in 2007 we plan to make available an Epi-LASIK option for our Zyoptix microkeratomes.

Suppliers and Customers We purchase the materials and components for each of our product categories from a wide variety of suppliers. We believe that the loss of any one supplier would not adversely affect our business to a significant extent.
Our five product categories have different customer bases, from local drug stores to hospital chains to independent practitioners and group purchasing and other managed care organizations. No material part of our business, taken as a whole, is dependent upon a single or a few customers.

Patents and Licenses We actively pursue technology development and acquisition as a means to enhance our competitive position. In the aggregate our patents are of material importance to our business taken as a whole and no single patent or patent license or group of patent licenses relating to any particular product or process is material to any segment or to the business as a whole, except for our license agreement with CIBA Vision AG related to the sale of our PureVision contact lens products.

Trademarks The trademarks of Bausch & Lomb Incorporated and its subsidiary companies are italicized throughout this report and include: Akreos, Alrex, AMVISC, Bausch & Lomb, Bausch & Lomb Advanced Eye Relief, Boston, Easy-Load, Hansatome, Indocollyre, Liposic, Lotemax, Medalist, Millennium, Mioclear, Moisten, MoistureLoc, Ocuvite, PreserVision, PureVision, ReNu, ReNu MultiPlus, Retisert, SofLens, SofLens59, SofPort, Storz, Technolas, Zylet and Zyoptix. All other brands or product names are trademarks of their respective owners.




PAGE 8

Seasonality and Working Capital Because of the nature of the products sold, we are not significantly impacted by seasonality issues. In general, the working capital requirements in each of our segments are typical of those businesses.

Competition and Markets We market each of our product categories throughout the world. Each category is highly competitive in both U.S. and non-U.S. markets. For all products, we compete on the basis of product performance, quality, technology, price, service, warranty and reliability.

Research and Development Research and development constitutes an important part of our activities. Research and development expenditures included in continuing operations totaled $177 in 2005, $163 in 2004 and $150 in 2003. To ensure we have a robust pipeline of new products to support future growth initiatives, we intend to continue to increase our level of spending for research and development activities.

Government Regulation Our products are subject to regulation by governmental authorities in the United States and other markets. These authorities, including the Food and Drug Administration (FDA) in the United States, generally require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacturing of products, as well as product labeling and marketing. In most cases, significant resources must be spent to bring a new product to market in compliance with these regulations. The regulation of pharmaceutical products and medical devices, both in the United States and in other markets, has historically been subject to change. Delays in the regulatory approval process may result in delays in coming to market with new products and extra costs to satisfy regulatory requirements.

Environment Our facilities and operations are subject to federal, state and local environmental and occupational health and safety requirements of the United States and foreign countries, including those relating to discharges of substances into the air, water and land, the handling, storage and disposal of wastes and the cleanup of properties affected by pollutants. While we are unable to predict what legislation or regulations may be adopted or enacted in the future with respect to environmental protection and waste disposal, existing legislation and regulations have had no material adverse effect on our capital expenditures, earnings or competitive position. Capital expenditures for property, plant and equipment for environmental control facilities were not material during 2005 and are not anticipated to be material in 2006.

Employee Relations As of December 31, 2005, we employed approximately 13,700 people throughout the world, including approximately 3,800 in the United States. In general, we believe our employee relations to be very good. Less than five percent of our U.S. employees (mainly in our surgical products manufacturing facilities) are represented by unions.

(d) Financial Information about Foreign and Domestic Operations

Information as to sales and long-lived assets attributable to U.S. and non-U.S. geographic regions is set forth under the section entitled Geographic Region in Item 8. Financial Statements and Supplementary Data under Note 5 — Business Segment and Geographic Information of this Annual Report on Form 10-K and is incorporated herein by reference.

(e) Available Information

Our internet address is http://www.bausch.com. Our filings with the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are accessible free of charge on our web site as soon as reasonably practicable after we electronically file or furnish the material to the SEC. The public may read or copy any materials we file or furnish with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549 or may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Moreover, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding reports we file or furnish electronically with them at http://www.sec.gov. Additionally, our Corporate Governance Guidelines, Code of Business Conduct and Ethics and charters of the Executive, Audit, Compensation and Nominating and Governance Committees of our Board of Directors are available at http://www.bausch.com/en_US/corporate/ir/general/board_members.aspx. This information is also available in print to any shareholder requesting it.



PAGE 9

Item 1A.  Risk Factors

The business, prospects and value of the Company are subject to a number of risk factors, which are identified in this filing and have been identified by us in a number of our filings with the SEC, including our Form 12b-25, filed August 8, 2006, and Form 8-K, filed on September 20, 2006.

(a) Risks Related to Our Business and Industry

The markets for our eye care products are intensely competitive and new medical and technological developments may reduce the need for our products. The eye care industry is characterized by continuous product development. Our success and future growth depend, in part, on our ability to develop products which are more effective in treating conditions of the eye or that incorporate the latest technologies. In addition, we must be able to manufacture and effectively market those products and convince a sufficient number of consumers and eye care practitioners to use them. Our existing products face the risk of obsolescence if a new product is introduced by one of our competitors or if we announce a new product that, in either case, represents a substantial improvement over our existing products. Similarly, if we fail to make sufficient investments in research and development programs or if we focus on technologies that do not lead to more effective or acceptable products, our current and planned products may not be accepted in the marketplace or could be surpassed by more effective or advanced products. Conversely, products and new technologies that we develop or that are developed by our competitors may reduce the need for our other existing and future products.
We have numerous competitors in the United States and abroad, including, among others, Alcon, Inc.; Allergan, Inc.; AMO; The Cooper Companies, Inc.; Intralase Corp.; Merck & Co., Inc.; Moria S.A.; Novartis AG; Pfizer Inc.; Santen Incorporated; STAAR Surgical Company; and Vistakon, Inc. (a Johnson & Johnson subsidiary). These competitors may develop technologies and products that are more effective or less costly than any of our current or future products or that could render our products obsolete or noncompetitive. Some of these competitors have substantially more resources and a greater marketing scale than we do. In addition, the medical technology and device industry continues to experience consolidation, resulting in an increasing number of larger and more diversified companies. Among other things, some of these companies can spread their research and development costs over much broader revenue bases and have more resources to influence customer and distributor buying decisions. In addition, some of our competitors may enter into markets in which they do not currently compete with us, such as the announcement of Johnson & Johnson's potential entry into the contact lens solutions business. Our inability to produce and develop products that compete effectively against our competitors' products, or to effectively advertise, promote and market our products against competitors' offerings, could have a material adverse effect on our business.

Resources devoted to research and development may not yield new products that achieve commercial success. We devote substantial resources to research and development. We recently expanded our research and development facilities in Rochester, New York. However, the research and development process is expensive, prolonged and entails considerable uncertainty, especially for companies in the eye care industry. Because of the complexities and uncertainties associated with ophthalmic research and development in particular, and healthcare related research and development in general, products we are currently developing, or that we develop in the future, may not complete the development process or obtain the regulatory approvals required for us to market such products successfully.




PAGE 10

Market acceptance of our products requires, in many cases, that users of our products obtain adequate reimbursement from third-party payers. Managed care organizations and governments continue to place increased emphasis on the delivery of more cost-effective medical therapies. For example, major third-party payers for hospital services, including government insurance plans, Medicare and Medicaid in the United States, and private health care insurers, have substantially revised their payment methodologies during the last few years, resulting in stricter standards for reimbursement of hospital and outpatient charges for some medical procedures, including cataract procedures and intraocular lenses. Managed care organizations restrict the pharmaceutical products that doctors in those organizations can prescribe through the use of formularies (the lists of drugs which physicians are permitted to prescribe to patients in a managed care organization). Failure of our pharmaceutical products to be included on formularies could have an adverse effect on our revenues and profits. This cost-cutting emphasis could adversely affect sales and prices of our products. Physicians, hospitals and other health care providers may be reluctant to purchase our products if they do not receive substantial reimbursement for the cost of our pharmaceutical and surgical products and for procedures performed using our surgical medical device products from third-party payers. Reductions in the prices for our products in response to these trends could reduce our profits.

Federal, state and non-U.S. laws pertaining to healthcare fraud and abuse could materially adversely affect our business and results of operations. Certain of our businesses are subject to various federal, state and non-U.S. laws pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral laws. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in government healthcare programs, including, in the United States, Medicare, Medicaid, Veterans Administration health programs and TRICARE. Such laws and regulations are complex and far-reaching in nature, and, as a result, there can be no assurance that we would not be required in the future to further alter one or more of our practices to be in compliance with these laws. Any violations of these laws or regulations could result in a material adverse effect on our business, financial condition and results of operations. In addition, if there is a change in law, regulation, administrative or judicial interpretation, which renders our practices noncompliant, we may have to change our business practices or our existing business practices could be challenged as unlawful, which could have a material adverse effect on our business, financial condition and results of operations.

Healthcare initiatives and other cost-containment pressures could cause us to sell our products at lower prices, resulting in less revenue to us. Government and private sector initiatives to manage healthcare costs, including price regulation and competitive pricing, are continuing in many countries and regions where we do business, including the United States and Europe. Federal and state programs that reimburse at typically predetermined fixed rates, interpretations of policy and governmental funding restrictions, and legislative proposals restricting payment increases to hospitals and other providers through reimbursement systems, may all decrease or otherwise limit amounts available through reimbursement. We are not able to predict whether new legislation or changes to existing legislation will take effect, whether other changes will be made in the rates prescribed by these governmental programs or, if they are made, what effect that they could have on our business. However, approved governmental rate changes could have a material adverse effect on us, including our prospects for future sales of our products.

Economic conditions and price competition may cause sales of our products used in elective surgical procedures to decline and reduce our profitability. Sales of products used in elective surgical procedures, such as laser refractive surgery, have been and may continue to be adversely impacted by economic conditions. Generally, the costs of elective surgical procedures are borne by individuals without reimbursement from their medical insurance providers or government programs. Accordingly, individuals may be less willing to incur the costs of these procedures in weak or uncertain economic conditions and there may be a decline in the number of these procedures. Sales of our laser refractive surgical equipment and disposable products used in laser refractive surgery have come under pressure during periods of economic uncertainty. A softening in demand for laser refractive surgery could impact us by reducing our profits if customers with whom we have placed laser refractive surgical equipment are unable to make required payments to us.




PAGE 11

If we fail to maintain our relationships with healthcare providers, including ophthalmologists, optometrists, opticians, hospitals, ambulatory surgical centers, corporate optometry chains and group purchasing organizations, customers may not buy our products and our revenue and profitability may decline. We market our products to numerous healthcare providers, including eye care professionals, public and private hospitals, ambulatory surgical centers, corporate optometry chains and group purchasing organizations. We have developed and strive to maintain close relationships with members of each of these groups who assist in product research and development and advise us on how to satisfy the full range of surgeon and patient needs. We rely on these groups to recommend our products to their patients and to other members of their organizations. The failure of our existing products and any new products we may introduce to retain the support of these various groups could have a material adverse effect on our business, financial condition and results of operations.

The majority of our business is conducted outside the United States, subjecting us to additional business risks, including increased costs, market and currency fluctuations, business interruption and changing demands, all of which may result in fluctuations and declines in our sales and profits. Our products are sold in more than 100 countries. We have approximately 13,700 employees in more than 50 countries and more than half of our revenues in 2005 came from customers outside the United States. The results of operations and the financial position of our local operations are generally reported in the relevant local currencies and then translated into U.S. dollars at the applicable exchange rates for inclusion in our consolidated financial statements, exposing us to currency translation risk. In 2005, our most significant currency exposures were to the euro and the Japanese yen. The exchange rates between these and other local currencies and the U.S. dollar may fluctuate substantially. In addition, we are exposed to transaction risk because some of our expenses are incurred in a different currency from the currency in which our revenues are received. Fluctuations in the value of the U.S. dollar against other currencies have had in the past, and may have in the future, an adverse effect on our operating margins and profitability. Economic, social and political conditions, laws, practices and local customs vary widely among the countries in which we sell our products. Our operations outside the United States are subject to a number of risks and potential costs, including lower product margins, less stringent protection of intellectual property and economic, political and social uncertainty in countries in which we operate, especially in emerging markets. Our continued success as a global company depends, in part, on our ability to develop and implement policies and strategies that are effective in anticipating and managing these and other risks in the countries where we do business. These and other risks may have a material adverse effect on our operations in any particular country and on our business as a whole.
Our international operations are, and will continue to be, subject to a number of further risks and potential costs, including:

·  
unexpected changes in foreign regulatory requirements;
·  
differing local product preferences and product requirements;
·  
political and economic instability;
·  
changes in foreign medical reimbursement and coverage policies and programs;
·  
diminished protection of intellectual property in some countries outside the United States;
·  
trade protection measures and import or export licensing requirements;
·  
potential tax costs associated with repatriating cash from our non-U.S. subsidiaries;
·  
difficulty in staffing and managing foreign operations;
·  
differing labor regulations; and
·  
potentially negative consequences from changes in tax laws.

Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations.

If we were to experience an interruption of our manufacturing operations, our business, financial condition and operating results would be materially harmed. Any prolonged disruption in the operation of our manufacturing facilities or those of our third party manufacturers, whether due to technical, labor or other difficulties, contamination, destruction of or damage to any facility or other reasons, could materially harm our business, financial condition and operating results. In 2006, the FDA completed a regulatory inspection of our Greenville, South Carolina facility and concluded that the facility was non-compliant in a number of areas. We have informed the FDA of our efforts to remedy many of the noted deficiencies, but our inability to address the FDA's concerns with the Greenville facility, or the concerns of any regulatory agency with any of our facilities, could have an adverse impact on our performance, financial condition or operating results.

PAGE 12

We rely on independent suppliers for raw materials and we could experience inventory shortages if we were required to use an alternative supplier on short notice. We rely on independent suppliers for key raw materials, consisting primarily of various chemicals and packaging materials. We generally use raw materials available from more than one source. However, because some products require specialized manufacturing procedures, we could experience inventory shortages if we were required to use an alternative manufacturer on short notice. A disruption in the supply of certain raw materials could disrupt production of certain of our products thereby adversely impacting our ability to market and sell such products and our ability to compete.

If we fail to attract, hire and retain qualified personnel, we may not be able to design, develop, market or sell our products or successfully manage our business. Our ability to attract new customers, retain existing customers and pursue our strategic objectives depends on the continued services of our current management, sales, product development and technical personnel and our ability to identify, attract, train and retain similar personnel. Competition for top management personnel generally, and within the health care industry specifically, is intense and we may not be able to recruit and retain the personnel we need. The loss of any one of our management personnel, or our inability to identify, attract, retain and integrate additional qualified management personnel, could make it difficult for us to manage our business successfully and pursue our strategic objectives.
Similarly, competition for skilled sales, product development and technical personnel is intense and we may not be able to recruit and retain the personnel we need. The loss of the services of any key sales, product development and technical personnel, or our inability to hire new personnel with the requisite skills, could restrict our ability to develop new products or enhance existing products in a timely manner, sell products to our customers or manage our business effectively.
We may not be able to hire or retain qualified personnel if we are unable to offer competitive salaries and benefits, or if our stock does not perform well.

(b) Risks Related to Our Financial Condition

Our indebtedness could adversely affect our financial health. We have now and expect to continue to have indebtedness that could:

·  
increase our vulnerability to general adverse economic and industry conditions;
·  
require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions, research and development efforts and other general corporate purposes;
·  
limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;
·  
place us at a competitive disadvantage if any of our competitors have less debt;
·  
limit our ability to borrow additional funds; and
·  
make it more difficult for us to satisfy our obligations with respect to our debt, including our obligation to repay amounts borrowed under our credit facilities or repurchase outstanding public debentures under certain circumstances.

Our credit facilities contain representations, warranties and covenants which if breached could lead to an event of default and could, thereby, accelerate payment of our debt. In addition, our credit facilities contain financial and other restrictive covenants that could limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default which, if not cured or waived, could result in the acceleration of all of our debt.
We have obtained waivers under certain of our bank facilities and with respect to our public debt. Primarily, these waivers are related to our inability to file timely periodic reports with the SEC. See Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and in Item 8. Financial Statements and Supplementary Data under Note 11 — Debt of this Annual Report on Form 10-K. The bank waivers have been extended until April 30, 2007; but public debt waivers expired on January 31, 2007. In early February, we expect to complete a pending consent solicitation extending the public debt waivers to April 30, 2007.




PAGE 13

We are vulnerable to interest rate risk with respect to our debt. We are subject to interest rate risk in connection with the issuance of debt. In order to maintain our desired mix of fixed-rate and variable-rate debt, we may from time to time use interest rate swap agreements and exchange fixed-rate and variable-rate interest payment obligations over the lives of the arrangements, without exchange of the underlying principal amounts. We may not be successful in structuring such swap agreements to effectively manage our risks, which could adversely affect our business, earnings and financial condition.

The market price of our Common stock has been volatile and may continue to be volatile, and the value of any investment may decline. We have experienced and may continue to experience market volatility that has caused and may cause wide fluctuations in the price of our Common stock, which is listed on the New York Stock Exchange (NYSE). The market price may fluctuate in response to many factors including:

·  
our business performance and financial results;
·  
changes in our markets;
·  
pending and threatened litigation against us;
·  
the recall of MoistureLoc from the market;
·  
our restatement of financial statements for prior periods;
·  
the Audit Committee's and/or other Company investigations; and
·  
our assessment of our internal control over financial reporting.

We incur substantial costs with respect to pension benefits and providing healthcare for our employees. Our estimates of liabilities and expenses for pensions and other post-retirement healthcare benefits require the use of assumptions. They include the rate used to discount the future estimated liability, the rate of return on plan assets and several assumptions relating to the employee workforce (salary increases, medical costs, retirement age and mortality). Actual results may differ which may have a material adverse effect on future results of operations, liquidity or shareholders’ equity. In addition, rising healthcare and retirement benefit costs in the United States may put us under significant cost pressure as compared to our competitors, if they can provide the benefits at lower costs.

Changes in accounting may affect our reported earnings and operating income. Generally accepted accounting principles and accompanying pronouncements, implementation guidelines and interpretations for many aspects of our business, such as revenue recognition, accounting for financial instruments, treatment of goodwill or amortizable intangible assets, and accounting for income taxes are highly complex and involve judgments. Changes in these rules, their interpretation, or changes in our products or business could significantly change our reported earnings and operating income and could add significant volatility to those measures, without a comparable underlying change in cash flow from operations.

Catastrophic events may disrupt our business. We have operations and facilities which sell and distribute our products in many parts of the world. Natural events (such as a hurricane or major earthquake), terrorist attack or other catastrophic events could cause delays in developing, manufacturing or selling our products. Such events that occur in major markets where we sell our products could reduce the need for our products in those areas and, as a result impact our sales into those markets. In either case, any such disruption could have a material adverse effect on our business.




PAGE 14

Acquisitions and joint ventures may have an adverse effect on our business. We expect to continue making acquisitions or entering into joint ventures as part of our long-term business strategy. For example, in 2005 we acquired a 70-percent controlling interest in Freda in order to gain additional access to markets in China. Future acquisitions could result in potentially dilutive issuances of equity securities, the incurrence of debt and contingent liabilities and an increase in amortization and/or write-offs of other intangible assets and goodwill, which could have a material adverse effect upon our business, financial condition and results of operations. Risks we could face with respect to acquisitions include, among others:

·  
difficulties in the integration of the operations, technologies, products and personnel of the acquired company and establishment of appropriate accounting controls and reporting procedures and other regulatory compliance procedures;
·  
risks of entering markets in which we have no or limited prior experience;
·  
potential loss of employees;
·  
an inability to identify and consummate future acquisitions on favorable terms or at all;
·  
diversion of management’s attention away from other business concerns;
·  
expenses of any unknown or potential liabilities of the acquired company;
·  
expenses, including restructuring expenses, to shut-down our own locations and/or terminate our employees;
·  
dilution of earnings per share; and
·  
risks inherent in accounting allocations and consequences thereof.

We are in the process of upgrading certain of our management information systems and we cannot ensure that there will not be associated excessive costs or disruption of our business. We have implemented a global management information system at several of our locations and are in the process of implementing that system for most of our businesses worldwide. Many other companies have had significant problems with computer system implementations of this nature and scope. We are using a controlled project plan, and we believe we have assigned adequate staffing and other resources to the project to ensure its successful implementation. However, we cannot provide assurance that the design will meet our current and future business needs or that it will operate as designed. We are heavily dependent on such computer systems, and any failure or delay in the system implementation would cause a substantial interruption to our business, additional expense and loss of sales, customers and profits.

The spending to address the MoistureLoc recall, our investigations and consent solicitations and bank waiver matters could negatively affect our financial performance. Our announced recall of MoistureLoc will result in lost revenues and expenses associated with taking product returns and rebuilding the lens care and non-lens care brands, and has resulted in and may continue to result in market share loss in the lens care category and, potentially, the non-lens care categories. See MoistureLoc risk factors in subsection (d) Risks Related to Regulatory Matters. In addition, we anticipate that higher than normal spending in several areas associated with recent events will negatively impact financial performance. These include, without limitation, (1) higher selling, administrative and general expenses which reflect recall and legal expenses associated with the MoistureLoc situation and pending product liability and shareholder lawsuits, increased marketing expense to support brand rebuilding activities, and professional fees associated with the independent investigations and expanded year-end audit procedures, and (2) higher net financing expenses, which include the consent and waiver fees associated with the consent solicitation and tender offer we completed on June 2, 2006, the consent solicitation completed on September 28, 2006, the consent solicitation we expect to complete in early February 2007 and the several bank waivers obtained in November 2005 and February, May, August and December 2006, and January 2007.
Lens care is the most profitable of our five product categories, and a significant portion of our lens care sales have historically been generated in the United States. As a result, it is anticipated that (1) our U.S. operations will be unprofitable in 2006 and likely beyond, and (2) that no tax benefit will be recorded on U.S. operations as a result of the determination of the need for a valuation allowance that was recorded in 2005 on deferred tax assets (as reported in our Current Report on Form 8-K dated August 7, 2006).
Our 2006 cash flow from operating activities has been negatively impacted by the outflows associated with the MoistureLoc recall, as well as the cost of the investigations and brand rebuilding expenditures. We anticipate that 2006 operating cash flows will be essentially offset by capital expenditures, reflecting costs associated with completing the installation of manufacturing equipment for PureVision contact lenses and expanding our main R&D facility in Rochester, New York.



PAGE 15

We have made certain assumptions and could experience other risks concerning our financial performance. Our financial performance could be adversely impacted if any of our assumptions are incorrect or if we actually experience any of the risks concerning our financial performance that we have identified. Additional specific assumptions and risk factors that could or will impact full year 2007 performance include (1) as it relates to marketing and selling of our products, no significant changes in the competitive landscape; return of our ReNu MultiPlus and ReNu MPS contact lens care products to the Singapore and Hong Kong markets; success of brand rebuilding initiatives, with particular emphasis on Asia, given direct and collateral product line impacts of the MoistureLoc withdrawal in these markets; successful and timely introduction of new products, particularly in our cataract business and in the geographic expansion of contact lens products; lack of further negative price impact from changes in government pricing and reimbursement of our products, including with respect to pharmaceuticals products in Europe; and (2) as it relates to expenses of the business, historical normal expense and spending rates, with moderate increases in actual expenses over prior years; no unusual expense items related to impairment or accelerated depreciation of tangible or intangible assets of the Company; no unusual additional severance or other restructuring expenses associated with changes in our business structure; no unusual additional expenses resulting from investigations or additional review procedures with respect to matters other than those presently outstanding; and no significant settlement of, or judgments adverse to us in contested matters.

(c) Risks Related to Litigation, Actions, Claims, Investigations, Internal Control Deficiencies, the Restatement of Our Financial Statements, the Delay in Filing Our Periodic Reports and Intellectual Property

Unfavorable results in pending and future claims and litigation matters as well as the outcome of pending or future investigations could have an adverse impact on us. We have been named as a party in various lawsuits and are aware of the filing of others. We have identified pending material litigation to which we are a party (or to which our current and certain former officers and directors are parties). See Item 3. Legal Proceedings for further discussion. In some cases, certain present and former officers and directors have also been named as parties in the actions. While we intend to vigorously defend ourselves in these actions, we could be required to pay judgments or settlements in connection with these matters and they could otherwise have a material adverse effect on our business, results of operations, financial condition and liquidity.
In addition to pending litigation matters, we may from time to time learn of alleged non-compliance with laws or regulations or other improprieties through compliance hotlines, communications by employees, former employees or other third parties, as a result of our internal audit procedures, or otherwise. As disclosed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K, in response to such allegations, the Audit Committee conducted certain investigations during 2005 and 2006, which led, among other things, to the restatement of previously reported financial information, and current charges. The restatement, in turn, resulted in our being unable to file timely certain periodic financial information and our obtaining certain waivers from creditors as well as an extension from the NYSE to permit continued trading notwithstanding the delay in filing our 2005 Annual Report on Form 10-K.
The Audit Committee of the Board of Directors is currently investigating the potential U.S. Foreign Corrupt Practices Act implications of our Spanish subsidiary’s providing free product, principally intraocular lenses used in cataract surgery, and other things of value to doctors performing surgical procedures at public hospitals in Spain. This investigation was initiated following reports of potentially improper sales practices by a former employee. The investigation has been voluntarily reported to the Northeast Regional Office of the SEC. We cannot predict the outcome of this pending investigation, and at this time cannot reasonably estimate the potential liability of the Company or its Spanish subsidiary in connection with these matters.
Our policy is to comply with applicable laws and regulations in each jurisdiction in which we operate and, if we become aware of a potential or alleged violation, to conduct an appropriate investigation, to take appropriate remedial action and to cooperate fully with any related governmental inquiry.
We may become parties to, or the subject of, other claims, lawsuits, investigations or inquiries in the future. See Item 3. Legal Proceedings of this Annual Report on Form 10-K.




PAGE 16

We may not have sufficient insurance to cover our liability in our pending litigation claims and future claims either due to coverage limits or as a result of insurance carriers seeking to deny coverage of such claims, which in either case could have a material adverse effect on our business and financial condition. We maintain third party insurance coverage against various liability risks, including securities, shareholder derivative, ERISA, and product liability claims, as well as other claims that form the basis of litigation matters pending against us. While we believe these arrangements are an effective way to ensure against liability risks, the potential liabilities associated with the litigation matters pending against us, or that could arise in the future, could exceed the coverage provided by such arrangements. In addition, our insurance carriers have sought or may seek to rescind or deny coverage with respect to completed investigations or pending or future investigations and actions. If we do not have sufficient coverage under our policies, or if the insurance companies are successful in rescinding or denying coverage to us, our business, results of operations and financial condition may be materially adversely affected.

Our potential indemnification obligations and limitations of our director and officer liability insurance could have a material adverse effect on our business, results of operations and financial condition. Certain of our present and former directors, officers and employees are the subject of lawsuits. Under New York law and our bylaws, we may have an obligation to indemnify our current and former directors, officers and employees in relation to completed investigations or pending and/or future investigations and actions. Indemnification payments that we make may have a material adverse effect on our business, results of operations and financial condition to the extent insurance does not cover our costs. The insurance carriers that provide our directors’ and officers’ liability policies have sought or may seek to rescind or deny coverage with respect to those completed investigations or pending and future investigations and actions, or we may not have sufficient coverage under such policies. If the insurance companies are successful in rescinding or denying coverage to us and/or some of our current directors, officers and employees, or if we do not have sufficient coverage under our policies, our business, results of operations and financial condition may be materially adversely affected.

Our potential liability relating to a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service could have a material adverse effect on our financial results. On May 12, 2006, we received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999, for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of partnership interests are held by certain of our subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10, and increasing a long-term capital gain reported by Wilmington for that tax year by $190. The FPAA also proposes a $550 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of our subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership's partners for the associated tax periods by more than $200, plus penalties and interest. We have not made any financial provision for the asserted additional taxes, penalties or interest as we believe the asserted adjustments are not probable and estimable.
Since 1999, our consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.
On August 7, 2006, we made a petition to the U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006, and we initiated a motion to strike portions of the answer on November 1, 2006. We believe we have numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While we intend to vigorously defend against the asserted adjustments, our failure to succeed in such a defense could significantly increase the liability of the partnership's partners for taxes, plus interest and penalties, which in turn would have a material adverse effect on our financial results and cash flows.




PAGE 17

Management has identified a number of material weaknesses in our internal control over financial reporting. Effective internal control over financial reporting is necessary for compliance with the Sarbanes-Oxley Act of 2002 and appropriate financial reporting. Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process, under the supervision of the Company’s Chief Executive Officer and Chief Financial Officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with GAAP. As disclosed in this Annual Report on Form 10-K, management’s assessment of our internal control over financial reporting identified material weaknesses in various areas as discussed in Item 9A. Controls and Procedures which resulted in the restatement of the Company's 2004, 2003, 2002 and 2001 annual consolidated financial statements and all quarterly periods of 2004 and the first two quarters of 2005. The impact of restatement adjustments identified relating to fiscal years prior to 2003 decreased beginning retained earnings for that year, by $23 net of tax. Several material weaknesses were remediated in 2006 (see Item 9A. Controls and Procedures of this Annual Report on Form 10-K) and we are working to remediate the others as soon as practicable. While the Company has not completed its 2006 internal control evaluation, it is expected that the Company will report one or more material weaknesses in internal control over financial reporting for 2006 when it files its Annual Report on Form 10-K for the year ended December 30, 2006. Delay in the implementation of remedial actions could affect the accuracy or timing of future filings with the SEC and other regulatory authorities.

We may face risks related to the recent restatement of our financial statements. The Company restated its consolidated financial statements, as more fully discussed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement to the consolidated financial statements included in this Annual Report on Form 10-K. The Company restated its consolidated balance sheet, its consolidated statements of income, of changes in shareholders' equity and of cash flows as of December 25, 2004 and for the fiscal years 2003 and 2004. In addition, the Company restated selected financial data as of 2003, 2002 and 2001 and for fiscal years 2002 and 2001. See Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K and beginning shareholders' equity for the impact of the restatement for periods prior to 2001. The impact of the restated financial results for the first and second quarterly periods of 2005 and the quarterly periods of 2004 are also presented in Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K.
Companies that restate their financial statements sometimes face litigation claims, some of which we have already been made aware, and/or SEC proceedings following such a restatement. We could face monetary judgments, penalties or other sanctions which could adversely affect our financial condition and could cause our stock price to decline. See further discussion in Item 3. Legal Proceedings, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and in Item 8. Financial Statements and Supplementary Data under Note 21 — Other Matters of this Annual Report on Form 10-K.

We expect to continue to incur significant expenses related to our internal control over financial reporting and the preparation of our financial statements. We have devoted substantial internal and external resources to the completion of the restatement and our financial statements for the year ended December 31, 2005. As a result of these efforts, along with efforts to complete our assessment of internal control over financial reporting as of December 31, 2005, as required by Section 404 of the Sarbanes-Oxley Act of 2002, we have incurred and expect that we will continue to incur significant incremental fees and expenses for additional auditor services, financial and other consulting services, legal services and debt related waiver fees. While we do not expect fees and expenses relating to the preparation of our financial results in 2007 and future years to be as high as 2005 and 2006, we expect that these fees and expenses will remain significantly higher than historical fees and expenses in this category for the next several quarters. These expenses, as well as the substantial time devoted by our management towards addressing these weaknesses, could have a material adverse effect on our financial condition, results of operations and cash flows.




PAGE 18

We have postponed the filing of this Annual Report and of our Quarterly Reports on Form 10-Q for the quarters ended September 24, 2005, April 1, 2006, July 1, 2006 and September 30, 2006. As a result, we do not have current financial information available and will be limited in our ability to register our securities for offer and sale until we are deemed a current filer with the SEC. As a result, there is a lack of current publicly available financial information concerning the Company. Investors must evaluate whether to purchase or sell our securities in light of the lack of current financial information. We are not in a position to predict at what date current financial information will be available. Accordingly, any investment in our securities involves a high degree of risk. Until current periodic reports and financial statements are filed, we will be precluded from registering our securities with the SEC for offer and sale. This precludes us from raising debt or equity financing in the public markets and will limit our ability to use stock options and other equity-based awards to attract, retain and provide incentives to our employees.

As a result of the delays in filing our periodic reports, we required certain waivers in connection with the delivery of financial statements and related matters under financing arrangements for our public and bank debt. We may require additional waivers in the future, and failure to obtain the necessary waivers could have a material adverse effect on our business, liquidity and financial condition. We have previously obtained certain waivers and may continue to seek additional waivers under our indenture or bank loan agreements. The waivers waive certain potential breaches of representations and covenants under our indenture or bank loan agreements and establish the extended deadlines for the delivery of certain financial reports. Our current waivers under the bank loan agreements expire on April 30, 2007. The waivers applicable to our indenture expired January 31, 2007. In early February, we expect to complete the consent solicitations extending the deadline for expiration of waivers related to our indenture until April 30, 2007. Due to the delays in completing this annual report, we have not been able to issue our 2006 quarterly financial statements within this extended date, which may impact whether we are able to file our 2006 Report on Form 10-K within the extended period, and therefore, we may seek additional waivers under the indenture and the bank loan agreements. It is also uncertain as to whether we can issue our 2007 quarterly financial statements within the deadlines prescribed by the indenture and bank loan agreements.
Under our indenture and certain of our bank loan agreements, the trustee or lenders have the right to notify us if they believe we have breached a representation or covenant under the operative debt instruments and may declare an event of default. If one or more notices of default were to be given, we believe we would have various periods in which to cure such events of default or obtain necessary waivers. If we do not cure the events of default or obtain necessary waivers within the required time periods or certain extended time periods, the maturity of some of our debt could be accelerated and our ability to incur additional indebtedness could be restricted. Moreover, defaults under our indenture and bank loan agreements could trigger cross-default provisions under those and other arrangements. There can be no assurance that any additional waivers will be received on a timely basis, if at all, or that any waivers obtained, including the waivers we have already obtained, will extend for a sufficient period of time to avoid an acceleration event, an event of default or other restrictions on our business operations. The failure to obtain such waivers could have a material adverse effect on our business, liquidity and financial condition.

The delay in filing this Annual Report on Form 10-K with the SEC and any failure to satisfy other NYSE listing requirements could cause the NYSE to commence suspension or delisting procedures with respect to our common stock. As a result of the delay in filing this Annual Report on Form 10-K, we were in breach of certain continued listing requirements of the NYSE. We had received from the NYSE an additional period in which to trade our securities until March 1, 2007 in order for us to file this Annual Report on Form 10-K before that date. Any other failure to satisfy NYSE listing requirements, if not waived by the NYSE, could cause the NYSE to commence suspension or delisting procedures with respect to our common stock. The commencement of any suspension or delisting procedures by the NYSE remains, at all times, at the discretion of the NYSE and would be publicly announced by the NYSE. The delisting of our common stock from the NYSE may have a material adverse effect on us by, among other things, limiting:

·  
the liquidity of our common stock;
·  
the market price of our common stock;
·  
the number of institutional and other investors that will consider investing in our common stock;
·  
the availability of information concerning the trading prices and volume of our common stock;
·  
the number of broker-dealers willing to execute trades in shares of our common stock; and
·  
our ability to obtain equity financing for the continuation of our operations.



PAGE 19

We depend on proprietary technologies, and may not be able to protect our intellectual property rights adequately. We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology. These legal measures afford limited protection and may not prevent our competitors from gaining access to our intellectual property and proprietary information. Any of our patents may be challenged, invalidated, circumvented or rendered unenforceable. Furthermore, we cannot ensure that any pending patent application held by us will result in an issued patent, or that if patents are issued to us, such patents will provide meaningful protection against competitors or competitive technologies. Litigation may be necessary to enforce our intellectual property rights, to protect our trade secrets and to determine the validity and scope of our proprietary rights. Any litigation could result in substantial expense, may reduce our profits and may not adequately protect our intellectual property rights. In addition, we may be exposed to future litigation by third parties based on claims that our products infringe their intellectual property rights. Any litigation or claims against us, whether or not successful, could result in substantial costs and harm our reputation. In addition, intellectual property litigation or claims could force us to do one or more of the following:

·  
cease selling or using any of our products that incorporate the challenged intellectual property, which would adversely affect our revenue;
·  
obtain a license from the holder of the intellectual property right alleged to have been infringed, which license may not be available on reasonable terms, if at all; and
·  
redesign or, in the case of trademark claims, rename our products to avoid infringing the intellectual property rights of third parties, which may not be possible and could be costly and time-consuming if it is possible to do so.

We may license technology from third parties as part of our efforts to develop new products or improve existing products. There can be no assurance that technology, compounds, concepts or other materials that we license will allow us to develop new products or make improvements to existing products, or will result in products available for commercial sale. The failure of licensing arrangements to create new products or make improvements could have a material adverse effect on our business.

Our products could be subject to claims of infringement. Our competitors and others in both the United States and foreign countries, may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make and sell our existing and planned products. Claims that our products infringe the proprietary rights of others often are not asserted until after commencement of commercial sales incorporating our technology.
Significant litigation regarding intellectual property rights exists in our industry. Third parties have made, and it is possible that they will make in the future, claims of infringement against us or our contract manufacturers in connection with their use of our technology. Any claims, even those without merit, could:

·  
be expensive and time consuming to defend;
·  
cause us to cease making, licensing or using products that incorporate the challenged intellectual property;
·  
require us to redesign or reengineer our products, if feasible;
·  
divert management’s attention and resources; or
·  
require us to enter into royalty or licensing agreements in order to obtain the right to use a necessary product, component or process.

Any royalty or licensing agreements, if required, may not be available to us on acceptable terms or at all. A successful claim of infringement against us or our contract manufacturers in connection with the use of our technology, in particular if we are unable to manufacture or sell any of our planned products in any major market, could adversely affect our business.




PAGE 20

(d) Risks Related to Regulatory Matters

We are subject to extensive government regulation that increases our costs and could prevent us from selling our products. The research, development, testing, manufacturing and marketing of our products are subject to extensive governmental regulations. Government regulations include inspection of and controls over testing and manufacturing; safety and environmental controls; efficacy; labeling; advertising and promotion; requirements for record keeping, including for various electronic records and electronic signature programs; and regulation of the sale and distribution of pharmaceutical and medical device products and samples. We are also subject to government regulation with respect to the prices we charge and the rebates we offer to customers. Government regulation substantially increases the cost of developing, manufacturing and selling our products.
In the United States, we must obtain approval from the FDA for each pharmaceutical product that we market and FDA approval or clearance for each medical device that we market. The FDA approval process is typically lengthy and expensive, and approval is never certain. Products distributed outside the United States are also subject to government regulation, which may be equally or more demanding than in the United States. Our new products could take a significantly longer time than we expect to gain regulatory approval or may never gain approval. If a regulatory authority delays approval of a potentially significant product, our market value and operating results may decline, which could have a material adverse effect on our business, operations or financial condition. Even if the FDA or another regulatory agency approves a product, the approval may limit its indicated uses, may otherwise limit our ability to promote, sell and distribute it or may require post-marketing studies.
Currently, we are actively pursuing approval for a number of products from regulatory authorities in a number of countries, including, among others, the United States, countries in the European Union and certain countries in Asia. The clinical trials required to obtain such approvals are complex and expensive and their outcomes are uncertain. We incur substantial expense for, and devote significant time to, clinical trials, yet cannot be certain that the trials will ever result in the commercial sale of a product. Positive results from preclinical studies and early clinical trials do not ensure positive results in later clinical trials that form the basis of an application for regulatory approval. We may suffer significant setbacks in clinical trials, even after earlier clinical trials show promising results. Any of our products may produce undesirable side effects that could cause us or regulatory authorities to interrupt, delay or halt clinical trials of a pharmaceutical or medical device candidate or rescind its regulatory approval, even after the product is in the market. We, the FDA or another regulatory authority may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Non-compliance with applicable regulatory requirements can result in fines, injunctions, penalties, mandatory recalls or seizures, suspensions of production, denial or withdrawal of pre-marketing approvals, or recommendations by the regulatory body against governmental contracts and criminal prosecution, each of which could have a material adverse effect on our business, operations or financial condition.
The FDA and other regulatory agencies also inspect facilities at which we manufacture our products. Failure to meet FDA and other regulations could result in penalties being assessed against us or, in extreme cases, result in the closure of a facility. For example, the FDA recently cited our Greenville, South Carolina facility, where we manufacture lens care products, for a number of non-compliant issues. While we have mechanisms in place to monitor compliance, we cannot ensure that the FDA or other regulatory agencies will not find indications of non-compliance. Fines or other enforcement responses could have a material adverse effect on our business, operations or financial condition.
Our development and marketing of products may fail or be delayed by many factors relative to the requirements for product approval, including, for example, the following:

·  
inability to attract clinical investigators for trials;
·  
inability to recruit patients at the expected rate;
·  
failure of the trials to demonstrate a product's safety or efficacy;
·  
unavailability of FDA or other regulatory agencies' accelerated approval processes;
·  
inability to follow patients adequately after treatment;
·  
changes in the design or formulation of a product;
·  
inability to manufacture sufficient quantities of materials to use for clinical trials;
·  
unforeseen governmental or regulatory delays;
·  
failure of manufacturing facilities to meet regulatory requirements; or
·  
failure of clinical trial management, oversight or implementation to meet regulatory requirements.




PAGE 21

Any such failure or delay, or the impact of a failure or delay, could have a material adverse effect on our business, operations or financial condition.

We have undertaken, and may in the future implement, a product recall or voluntary market withdrawal, or could be required by a governmental authority to do so, and could be exposed to significant product liability claims; we may have to pay significant amounts to those harmed and may suffer from adverse publicity as a result. The manufacturing and marketing of pharmaceuticals, medical devices and surgical equipment and instruments involve an inherent risk that our products may prove to be defective and cause a health risk. In that event, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority. In the past, we have recalled products, such as our MoistureLoc product, voluntarily and we have been required to withdraw products by regulatory authorities and, based on this experience, believe that the occurrence of a recall could result in significant costs to us, potential disruptions in the supply of our products to our customers and adverse publicity, all of which could harm our ability to market our products. A recall of one of our products or a product manufactured by another manufacturer could impair sales of other similar products we market as a result of confusion concerning the scope of the recall. In the event of such actions, we have worked actively with regulatory authorities to coordinate our response and to ensure the health and safety of our customers. We currently rely on a combination of self-insurance and third-party insurance to cover potential product liability exposure. The combination of our insurance coverage, cash flows and reserves may not be adequate to satisfy product liabilities we may incur in the future. Even meritless claims could subject us to adverse publicity, hinder us from securing insurance coverage in the future and require us to incur significant legal fees. Successful product liability claims could have a material adverse effect on our financial condition.

Our worldwide voluntary withdrawal of our ReNu with MoistureLoc product has had an adverse effect on our business, which could continue longer than previously estimated, even permanently. On May 15, 2006, we announced a worldwide voluntary recall of MoistureLoc lens care solution. Our decision was made following an investigation into an increase in fungal infections among contact lens wearers in the United States and certain Asian markets. We have incurred and can be expected to incur substantial costs in connection with the withdrawal of this product, associated investigations, and commercial actions and related legal actions brought against us. Our financial condition has been and will be negatively affected by the impact of sales returns and coupon redemptions estimated with the MoistureLoc recall. Lost MoistureLoc revenues combined with lower revenues for other lens care products, reflecting market share losses caused by trade consumer uncertainty resulting from our investigations into the outbreak of fungal infections among contact lens wearers and subsequent market withdrawal of MoistureLoc, will have an impact on our financial condition. There has been, to date, and could continue to be a negative effect on our non-lens care product categories, primarily in Asia, as a result of the MoistureLoc recall. There can be no assurances that these impacts will not continue in the future. While we intend to vigorously defend ourselves in these actions, as a result of this withdrawal, we have been, and may be in the future, named as a party to claims, lawsuits and other actions that could result in liability exposure, including liability exposure as to which the Company's third party product liability insurance is inadequate, insufficient or unavailable, as highlighted in further detail elsewhere in this report, including in this Item 1A. Risk Factors of this report. Any judgments, settlements or awards of damages could have an adverse effect on our business, earnings and financial condition. See Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Item 8. Financial Statements and Supplementary Data under Note 21 — Other Matters of this Annual Report on Form 10-K.

Our activities involve hazardous materials and emissions and may subject us to environmental liability. Our manufacturing, research and development practices involve the controlled use of hazardous materials. We are subject to federal, state and local laws and regulations in the various jurisdictions in which we have operations governing the use, manufacturing, storage, handling and disposal of these materials and certain waste products. Although we believe that our safety and environmental procedures for handling and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of accidental contamination or injury from these materials. We may also be liable for actions of previous owners on properties we acquire. Remedial environmental actions could require us to incur substantial unexpected costs which would materially and adversely affect our results of operations. If we were involved in a major environmental accident or found to be in substantial non-compliance with applicable environmental laws, we could be held liable for damages or penalized with fines.




PAGE 22

We may incur increased costs or suffer competitive disadvantage as a result of recently enacted and proposed changes in laws and regulations. Recently enacted and proposed changes in the laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act of 2002 and rules implemented or proposed by the SEC and by the NYSE, have resulted in and are expected to continue to result in increased costs to us as a public company. The new rules could make it more difficult or more costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. We are presently evaluating and monitoring developments with respect to new and proposed rules and cannot predict or estimate the amount of the additional costs we may incur or the timing of such costs.


Item 1B.  Unresolved Staff Comments

Not applicable.

Item 2.  Properties

We own and lease a number of important principal physical properties. Our headquarters and one of our manufacturing facilities are located in Rochester, New York. We also have U.S.-based manufacturing facilities in Clearwater, Florida; Greenville, South Carolina; St. Louis, Missouri; and Tampa, Florida. Outside the United States, we have manufacturing facilities in Brazil, China, France, Germany, India, Ireland, Italy and Scotland.
Administrative, marketing, research/laboratory, distribution and warehousing facilities are located in various parts of the world.
We consider our facilities suitable and adequate for the operations involved. All facilities are being productively utilized. The majority of our facilities are being utilized to perform more than one operating function and, as such, may house the functions of multiple segments.


Item 3.  Legal Proceedings

Legal Matters The Company is involved as a party in a number of material matters in litigation, including general litigation related to the restatement of the Company's financial information and the MoistureLoc withdrawal, material intellectual property litigation, and material tax litigation. The Company intends to vigorously defend itself in all of these matters. At this time, the Company is unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations, and matters concerning other allegations of other improprieties. The Company has not made any financial provision for potential liability in connection with these matters.




PAGE 23

Shareholder Securities Class Actions There is a consolidated securities class action, entitled In re Bausch & Lomb Incorporated Securities Litigation, Case Nos. 06-cv-6294 (master file), 06-cv-6295, 06-cv-6296, and 06-cv-6300, pending in Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, four separate shareholder actions were filed between March and May of 2006 in Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a putative class of shareholders who purchased Company stock at allegedly artificially inflated levels between January 27, 2005 and May 3, 2006. Among other things, plaintiffs allege that the defendants issued materially false and misleading public statements regarding the Company's financial condition and operations by failing to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc, thereby inflating the price of Company stock during the alleged class period. Plaintiffs seek unspecified damages. The cases are currently awaiting appointment of lead plaintiff and lead plaintiff's counsel in accordance with the Private Securities Litigation Reform Act. Pursuant to a stipulated schedule ordered by the Court, the lead plaintiff appointed by the Court must file a consolidated amended complaint by the earlier of (a) 45 days after the Company files its Annual Report on Form 10-K for the year ended December 31, 2005, or (b) 90 days after entry of the Court's order appointing the lead plaintiff, provided, however, that, at a minimum, the lead plaintiff will have 45 days after entry of the Court's order appointing the lead plaintiff to file such consolidated amended complaint.

ERISA-Based Class Actions There is a consolidated ERISA class action, entitled In re Bausch & Lomb Incorporated ERISA Litigation, Case Nos. 06-cv-6297 (master file), 06-cv-6315, and 06-cv-6348, pending in the Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, three separate actions were filed between April and May of 2006 in Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a class of participants in the Company's defined contribution 401(k) Plan for whose individual accounts the plan held an interest in Company stock between May 25, 2000 and the present. Among other things, plaintiffs allege that the defendants breached their fiduciary duties to plan participants by allowing the plan to invest in Company Common stock despite the fact that it was allegedly artificially inflated due to the failure to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief. On August 28, 2006, the Court entered an order appointing co-lead plaintiffs and co-lead plaintiffs' counsel. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in the consolidated ERISA action will have until 10 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.

Shareholder Derivative Actions The shareholder derivative actions, in which a shareholder seeks to assert the rights of the Company derivatively against certain present and former officers and directors, fall into two categories: (a) those asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries; and (b) those asserting allegations relating to the MoistureLoc withdrawal.
There is a consolidated derivative action asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries, entitled In re Bausch & Lomb Incorporated Derivative Litigation, Case Nos. 06-cv-6298 (master file) and 06-cv-6299, pending in Federal District Court for the Western District of New York, Rochester Division, against certain present and former officers and directors of the Company, and also naming the Company as nominal defendant. Initially, two separate derivative actions were filed in April 2006 in Federal District Court for the Southern District of New York, and were later transferred to the Western District of New York and consolidated. Among other things, plaintiffs allege that the individual defendants breached their fiduciary duties to the Company by causing or allowing the Company to issue materially false and misleading public statements regarding the Company's financial condition and operations that failed to disclose negative information about the Company's Brazilian and Korean subsidiaries and internal controls, thereby inflating the price of Company stock during the relevant time period. Plaintiffs purport to allege damage to the Company as a result of, among other things, a decrease in the Company's market capitalization, exposure to liability in securities fraud actions, and the costs of internal investigations and financial restatements. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief, including for misappropriation of inside information for personal benefit by certain of the individual defendants. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in this consolidated derivative action will have until 30 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.



PAGE 24

On January 3, 2006, the Company received a demand letter dated December 28, 2005, from a law firm not involved in the now consolidated derivative actions described above, on behalf of a shareholder who also is not involved in the derivative actions, demanding that the Board of Directors bring claims on behalf of the Company based on allegations substantially similar to those that were later alleged in the two derivative actions relating to accounting issues at the Brazilian and Korean subsidiaries. In response to the demand letter, the Board of Directors adopted a board resolution establishing an Evaluation Committee (made up of independent directors) to investigate, review and analyze the facts and circumstances surrounding the allegations made in the demand letter, but reserving to the full Board authority and discretion to exercise its business judgment in respect of the proper disposition of the demand. The Committee has engaged independent outside counsel to advise it.
There are also two purported derivative actions asserting allegations relating to the MoistureLoc withdrawal. The first case, entitled Little v. Zarrella, Case No. 06-cv-6337, was filed in June 2006 in the Federal District Court for the Southern District of New York and was transferred to the Western District of New York, Rochester Division, where it is currently pending against certain directors of the Company, and also naming the Company as nominal defendant. The second case, entitled Pinchuck v. Zarrella, Case No. 06-6377, was filed in June 2006 in the Supreme Court of the State of New York, County of Monroe, where it is currently pending against the directors of the Company, and also naming the Company as nominal defendant. Among other things, plaintiffs in these actions allege that the individual defendants breached their fiduciary duties to the Company in connection with the Company's handling of the MoistureLoc withdrawal. Plaintiffs purport to allege damage to the Company as a result of, among other things, costs of litigating product liability and personal injury lawsuits, costs of the product recall, costs of carrying out internal investigations, and the loss of goodwill and reputation. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief.
Pursuant to a stipulated schedule ordered by the Court, plaintiff in the state-court Pinchuck action served an amended complaint on September 15, 2006 and defendants served a motion to dismiss the amended complaint on November 15, 2006; plaintiff's opposition to the motion was served on January 15, 2007, and defendants' reply is due February 15, 2007. Pursuant to a stipulated schedule ordered by the Court in the federal Little action, plaintiff in that case will have until 60 days after a ruling on a motion to dismiss in the consolidated securities action is entered or, if no such motion is filed, 60 days after defendants' answer to a consolidated amended complaint in the consolidated securities action is filed, to file an amended complaint.

Product Liability Lawsuits As of February 1, 2007, the Company has been served or is aware that it has been named as a defendant in approximately 196 product liability lawsuits pending in various federal and state courts as well as certain other non-U.S. jurisdictions. Of the 196 cases, 117 actions have been filed in U.S. federal courts, 77 cases have been filed in various U.S. state courts and two actions have been filed in non-U.S. jurisdictions. These also include 170 individual actions filed on behalf of individuals who claim they suffered personal injury as a result of using a ReNu solution and 26 putative class actions alleging personal injury as a result of using a ReNu solution and/or violations of one or more state consumer protection statutes. In the personal injury actions, plaintiffs allege liability based on, among other things, negligence, strict product liability, failure to warn and breach of warranty. In the consumer protection actions, plaintiffs seek economic damages, claiming that they were misled to purchase products that were not as safe as advertised. Several lawsuits contain a combination of these allegations. On August 14, 2006, the Judicial Panel on Multidistrict Litigation (JPML) created a coordinated proceeding and transferred an initial set of MoistureLoc product liability lawsuits to the U.S. District Court for the District of South Carolina. The Company has advised the JPML of all federal cases available for transfer and has urged the issuance of conditional transfer orders. As of February 1, 2007, 104 of the 117 federal cases noted above have been transferred to the JPML.

Material Intellectual Property Litigation In October 2005, Rembrandt Vision Technologies, L.P. filed a patent infringement lawsuit against the Company and CIBA Vision Corporation. The action is entitled, Rembrandt Vision Technology, L.P. v. Bausch & Lomb Incorporated and CIBA Vision Corporation, bearing case number 2:05 CV 491, and is pending in the U.S. District Court for the Eastern District of Texas (Marshall Division). Rembrandt asserts that the Company and CIBA have infringed certain of Rembrandt’s oxygen permeability and tear-wettability technology that it claims to be protected by a U.S. Patent No. 5,712,327 entitled “Soft Gas Permeable Lens Having Improved Clinical Performance” (the 327 Patent). Rembrandt claims that the Company infringes the 327 Patent by selling soft gas permeable contact lenses that have tear-wettable surfaces in the United States, which would include the Company’s PureVision silicone hydrogel lens products. The Company denies, and intends to vigorously defend itself against, Rembrandt’s claims. The court has issued a scheduling order and has set a trial date of November 5, 2007.




PAGE 25

Material Tax Litigation As disclosed in Item 8. Financial Statements and Supplementary Data under Note 10 — Provision for Income Taxes of this Annual Report on Form 10-K, on May 12, 2006, the Company received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999, for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of partnership interests are held by certain of our subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10, and increasing a long-term capital gain reported by Wilmington for that tax year by $190. The FPAA also proposes a $550 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of our subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership's partners for the associated tax periods by more than $200, plus penalties and interest. We have not made any financial provision for the asserted additional taxes, penalties or interest as we believe the asserted adjustments are not probable and estimable.
Since 1999, the Company's consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.
On August 7, 2006, we made a petition to the U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006, and we initiated a motion to strike portions of the answer on November 1, 2006. We believe we have numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While we intend to vigorously defend against the asserted adjustments, our failure to succeed in such a defense could significantly increase the liability of the partnership's partners for taxes, plus interest and penalties, which in turn would have a material adverse effect on our financial results and cash flows.

General Litigation Statement From time to time, the Company is engaged in, or is the subject of, various lawsuits, claims, investigations and proceedings, including product liability, patent, trademark, commercial and other matters, in the ordinary course of business.
In addition to pending litigation matters, the Company may from time to time learn of alleged non-compliance with laws or regulations or other improprieties through compliance hotlines, communications by employees, former employees or other third parties, as a result of its internal audit procedures, or otherwise. As disclosed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K, in response to such allegations, the Company's Audit Committee conducted certain investigations during 2005 and 2006, which led, among other things, to the restatement of previously reported financial information and the recording of current charges. The restatement, in turn, resulted in the Company's being unable to file timely certain periodic financial information and the Company's obtaining certain waivers from creditors, as well as an extension from the NYSE to permit continued trading notwithstanding the delay in filing the Company's 2005 Annual Report on Form 10-K.
The Audit Committee of the Board of Directors is currently investigating the potential U.S. Foreign Corrupt Practices Act implications of the Company’s Spanish subsidiary’s providing free product, principally intraocular lenses used in cataract surgery, and other things of value to doctors performing surgical procedures at public hospitals in Spain. This investigation was initiated following reports of potentially improper sales practices by a former employee. The investigation of the Company’s Spanish subsidiary has been voluntarily reported to the Northeast Regional Office of the SEC. We cannot predict the outcome of this pending investigation, and at this time cannot reasonably estimate the potential liability of the Company or its Spanish subsidiary in connection with these matters.
The Company’s policy is to comply with applicable laws and regulations in each jurisdiction in which it operates and, if the Company becomes aware of a potential or alleged violation, to conduct an appropriate investigation, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. There can be no assurance that any pending or future investigation or resulting remedial action will not have a material adverse financial, operational or other effect on the Company.





PAGE 26

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable.

Executive Officers of the Registrant Set forth below are the names, ages (as of December 1, 2006), positions and offices held by and a brief account of the business experience during the past five years of each executive officer.

Name and Age
Position
   
Ronald L. Zarrella (57)
Chairman and Chief Executive Officer since 2001; Executive Vice President and President, General Motors North America, General Motors Corporation (1998-2001).
   
Gerhard Bauer (50)
Senior Vice President, Global Operations and Engineering since May 2006; Vice President, Global Operations and Engineering for Europe (2001-May 2006).
   
Alan H. Farnsworth (54)
Senior Vice President and President, Europe, Middle East and Africa Region since 2001; Corporate Vice President, Pharmaceuticals/Europe (2000-2001).
   
Dwain L. Hahs (54)
Senior Vice President and President Asia Region since May 2006; Senior Vice President, Global Operations and Engineering (2000-2006).
   
Paul G. Howes (52) 1
Senior Vice President and President, Americas Region (2003-2007); Vice President, Mid-Atlantic Business Group, Merck & Co., Inc. (2000-2003); Vice President Sales and Marketing, Specialty Products, Merck & Co., Inc. (1998-2001).
   
John M. Loughlin (56) 2
Senior Vice President since May 2006; Senior Vice President and President Asia Region (2000-2006).
   
Stephen C. McCluski (54)
Senior Vice President and Chief Financial Officer since 1995.
   
David R. Nachbar (44)
Senior Vice President, Human Resources since 2002; Senior Vice President, Human Resources, The St. Paul Companies, Inc. (1998-2002).
   
Robert B. Stiles (57)
Senior Vice President and General Counsel since 1997.
   
Praveen Tyle (46)
Senior Vice President, Research & Development and Chief Scientific Officer since 2004; Group Vice President, Pharmaceutical Sciences and Manufacturing, Biovail Corporation (2003-2004); Vice President, Global Head, Global Pharmaceutical Sciences, Pharmacia Corporation (2001-2003); Vice President, Pharmaceutical Sciences - U.S., Pharmacia Corporation (1999-2001).
   
Evon L. Jones (42)
Corporate Vice President and Chief Information Officer since January 2005; Senior Vice President and Chief Information Officer, The Dial Corporation (2001-2004); Senior Vice President and Chief Information Officer, America West Holdings Corporation (1998-2001).
   
Barbara M. Kelley (60)
Corporate Vice President, Communications and Investor Relations since 2001.
   
Jurij Z. Kushner (56)
Corporate Vice President, Controller since 1995.
   
Brian Levy (55)
Corporate Vice President and Chief Medical Officer since 2004; Vice President, Clinical & Medical Affairs (2000-2004).
   
Angela J. Panzarella (48)
Corporate Vice President, Global Vision Care since 2001.
   



PAGE 27

Gary M. Phillips (40)
Corporate Vice President and Vice President Commercial Operations, U.S. Surgical and Pharmaceuticals since January 2007; Corporate Vice President, Global Pharmaceuticals (2002-2006); Executive Director, Strategic Planning, Novartis Pharmaceuticals (2000-2002).

Efrain Rivera (50)
Corporate Vice President and Treasurer since 2004; Corporate Vice President and Assistant Treasurer (2003-2004); Leave of Absence (2003); Corporate Vice President and President, Latin America and Canada (2002-2003); President, Bausch & Lomb Latin America and General Manager, Bausch & Lomb Mexico (2001-2002); Vice President and Controller, Vision Care (1998-2001).
   
Henry C. Tung (47)
Corporate Vice President, Global Surgical since February 2005; Vice President, New Business Development, Boston Scientific Corporation (2000-February 2005).

1 As announced in our Current Report on Form 8-K, filed January 5, 2007, Paul G. Howes intends to resign from the Company.
2 As announced in April 2006, John M. Loughlin is retiring from the Company.

All officers serve on a year-to-year basis through the day of the annual meeting of shareholders of the Company and there is no arrangement or understanding among any of the officers of the Company and any other persons pursuant to which such officer was selected as an officer.





PAGE 28

Part II

Item 5. Market for Bausch & Lomb Incorporated's Common Stock, Related Shareholder Matters and Issuer Purchases of Equity Securities

The section entitled Dividends as set forth in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K is incorporated herein by reference.
The table entitled Quarterly Stock Prices as set forth in Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K is incorporated herein by reference.

Equity Compensation Plan Information The following table represents options and restricted shares outstanding under the 1990 and 2001 Stock Incentive Plans, the 2003 Long-Term Incentive Plan and the Annual Retainer Stock Plan for Non-Employee Directors as of December 31, 2005:

 
 
Plan Category
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
Weighted Average Exercise Price of Outstanding Options, Warrants and Rights
 
Number of Securities Remaining Available for Future Issuance
Options
     
Equity compensation plans approved by shareholders
5,375,970 1
$50.77
6,313,107 1
       
Equity compensation plans not approved by shareholders
448,267 2
$40.28
- 2
       
Total Options
5,824,237  
$49.96
6,313,107  
       
Restricted Stock Awards
     
Equity compensation plans approved by shareholders
566,268 3
 
-  
       
Equity compensation plans not approved by shareholders
- 2
 
-  
       
Total Restricted Stock Awards
566,268  
 
-  

1
Represents awards issued under the 1990 Stock Incentive Plan and the 2003 Long-Term Incentive Plan. Shares remaining available for issuance consist of 6,243,287 from the 2003 Plan of which no more than 1,619,205 shares may be issued as grants other than options and SARs and 69,820 shares under the Annual Retainer Stock Plan for Non-Employee Directors. There are no shares available under the 1990 Stock Incentive Plan.
2
The 2001 Stock Incentive Plan was approved by the Board of Directors on January 22, 2001. The Plan provides for an annual pool of shares for grant of options and restricted shares equal to two percent of outstanding shares. Eligible participants include all employees but not officers or directors. Options granted under the Plan have an option price equal to 100 percent of the fair market value of the stock on the date of grant and a term of ten years. The options typically vest ratably over three years and restricted shares typically vest 50 percent after two years and 50 percent after three years with vesting contingent upon a continued employment relationship with the Company. Effective January 1, 2003, the Board amended this Plan to allow for no further awards under this Plan.
3
Included in this number are performance share awards that were granted under the 1990 Stock Incentive Plan which upon achievement of performance goals may be distributed immediately or deferred under the Restricted Stock Deferred Compensation Plan as elected by the participant. At December 31, 2005, 278,057 shares had been deferred and will be paid out in shares based on the election made by the participant.





PAGE 29

Issuer purchases of equity securities
 
 
 
Period
 
Total Number of Shares Purchased 1
 
 
Average Price Paid Per Share
Total Number of Shares Purchased as Part of Publicly Announced Programs 2, 3
Maximum Number of Shares that May Yet Be Purchased Under the Programs 2,3
September 25, 2005 - October 22, 2005
1,040
$78.38
-
2,219,838
October 23, 2005 - November 19, 2005
4,674
$79.86
2,830
2,217,008
November 20, 2005 - December 31, 2005
10,067
$79.10
4,707
2,212,301
Total
15,781
$79.28
7,537
2,212,301

1
Shares purchased during the fourth quarter ended December 31, 2005 include purchases pursuant to a publicly announced repurchase program (see footnote 2 below), stock compensation plans and deferred compensation plans.
2
On January 27, 2004, the Board of Directors authorized a program to repurchase up to two million shares of the Company's outstanding Common stock. There is no expiration date for this program. During the fourth quarter ended December 31, 2005, 7,537 shares were repurchased at an average price of $80.70. Shares repurchased after November 2005 were through private transactions with the rabbi trust for the Company's Deferred Compensation Plan.
3
On July 26, 2005, the Board of Directors approved the purchase of up to an additional two million shares of the Company's outstanding Common stock. There is no expiration date for this program, and since its approval no shares have been repurchased.


Item 6.  Selected Financial Data

The table entitled Selected Financial Data as set forth in Item 8. Financial Statements and Supplementary Data under Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K is incorporated herein by reference.


Item 7.  Management's Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis of financial condition and results of operations (MD&A) should be read in conjunction with the accompanying financial statements of Bausch & Lomb Incorporated (“Bausch & Lomb,” “we,” or “the Company”). All dollar amounts in this MD&A, except for per share data, are expressed in millions unless specified otherwise, and earnings per share are presented on a diluted basis.
The MD&A includes a non-GAAP constant-currency measure which we use as a key performance metric in assessing organic business growth trends. Constant-currency results are calculated by translating actual current- and prior-year local currency revenues and expenses at the same predetermined exchange rates. The translated results are then used to determine year-over-year percentage increases or decreases that exclude the impact of currency. Since a significant portion of our revenues are derived in markets outside the United States, we monitor constant-currency performance for Bausch & Lomb in total as well as for each of our business segments. In addition, we use constant-currency results to assess non-U.S. operations' performance against yearly targets for the purpose of calculating bonuses for certain regional employees.
All figures and comparisons in this MD&A reflect restatements of our financial results from 2001 through the second quarter of 2005 that are more fully described in the Recent Developments section below and in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K. The cumulative impact of restatement adjustments increased prior-2001 net earnings by $34.
As more fully described in the Recent Developments section and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event, of this Annual Report on Form 10-K following the close of fiscal year 2005, but prior to the filing of this Annual Report on Form 10-K, we instituted a worldwide recall of ReNu with MoistureLoc contact lens care solution (MoistureLoc). Certain charges associated with this recall were recorded as part of 2005 operating results, while others will be recorded in 2006. In the discussion of 2005 operating performance which follows, we have quantified the charges, and in some cases have provided certain information about growth rates and operating ratios prior to the recording of the charges. We believe this additional disclosure is useful and relevant because it provides a basis for understanding underlying business performance independent of this unusual situation.



PAGE 30

Additionally, during the third quarter of 2005 we disposed of our Woehlk contact lens business in Germany, and in the fourth quarter of 2005 we completed the acquisition of Freda, a Chinese ophthalmic pharmaceuticals company. These events impacted the reported growth rates for our regions and product categories. In certain instances in the discussion of 2005 operating performance which follows, we have disclosed growth rates for the total company, Europe and Asia regions, as well as the contact lens and pharmaceuticals product categories, that are calculated by removing incremental revenues associated with Freda from 2005 and revenues associated with Woehlk from both 2005 and 2004. We believe this additional disclosure is useful and relevant because it provides a basis for understanding and assessing underlying performance of those portions of our business which were fully in place for both periods.


Business Overview

Bausch & Lomb is a global eye health company dedicated to perfecting vision and enhancing life for consumers around the world. We develop, manufacture and sell contact lenses and lens care products, ophthalmic pharmaceuticals and products used in ophthalmic surgery. With products available in more than 100 countries, the Bausch & Lomb name is one of the best known and most respected eye health brands in the world.
Our fiscal quarter consists of 13 weeks, whereby the first and second months of each quarter contain four weeks of results and the third month of each quarter contains five weeks of results. Accordingly, net sales are typically higher in the third month of any given quarter. In addition, the execution of a broad portfolio of our customer incentive programs typically has been higher at the end of each quarter.
We closely monitor and evaluate customer incentives and other customer programs, such as extended credit terms. Should we determine that certain customer programs result in excessive levels of inventory in certain channels of trade (such as retailers, mass merchandisers, wholesalers and distributors) or the risks and rewards have not transferred to the customer, net sales in conjunction with the associated programs would be accounted for as consignment sales. Our revenue recognition policy is further discussed in Item 8. Financial Statements and Supplementary Data under Note 1 — Significant Accounting Policies of this Annual Report on Form 10-K.
We manage the business through five business segments. These include three regional commercial segments (the Americas; Europe, Middle East and Africa [Europe]; and Asia); and two centralized functions (Global Operations & Engineering and Research & Development). The Global Operations & Engineering segment is responsible for manufacturing, distribution, logistics and engineering activities for all product categories in all geographies. The Research & Development segment has global responsibility across all product categories for product research and development, clinical and medical affairs, and regulatory affairs and quality.
Because our products are sold worldwide (with approximately 60 percent of sales derived outside the United States), our reported financial results are impacted by fluctuations in foreign currency exchange rates. At the net sales line, our greatest translation risk exposures are principally to the euro and the Japanese yen. At the earnings level, we are somewhat naturally hedged to the euro because top-line exposures are offset by euro-denominated expenses resulting from manufacturing, research and sales activities in Europe. In general, we do not use financial instruments to hedge translation risk, other than occasionally for the yen. In each of the three years discussed in this MD&A, foreign currency fluctuations have generally provided positive benefits to reported results as compared to constant-currency results, although that trend began to reverse in the second half of 2005.
The eye health market is intensely competitive, characterized by continuous product development, frequent new product introductions and price competition. Our goal is to build upon our already strong presence in this market by:

·  
focusing on research and development programs to yield a robust pipeline;
·  
expanding the geographic reach of key products, especially in under-penetrated markets;
·  
enhancing our organizational capabilities by further implementing disciplined business processes in all areas, particularly sales; and
·  
protecting the equity represented by the Bausch & Lomb brand. In the shorter term, this will include activities to rebuild that equity in certain markets where brand image has suffered following the outbreak of fungal infections among contact lens wearers and the MoistureLoc recall.




PAGE 31

We expect drivers of sales and earnings growth over the next several years to include:

·  
a continued focus on faster growing business segments and the launch of higher-margin new products in each of our product categories;
·  
favorable demographic trends, such as the aging of the population and an increase in the incidence of myopia and presbyopia; and
·  
opportunities to further implement Lean manufacturing techniques and other cost improvements to enhance margins, particularly for contact lenses and intraocular lenses.

We remain focused on bringing innovations to the market to sustain and improve our leading positions and improve overall profitability. Our success and future growth depend, in part, on whether we can develop, efficiently manufacture and effectively market products for the treatment of eye conditions that incorporate the latest technologies.
We devote substantial resources to research and development (R&D). We currently hold approximately 2,100 patents and have approximately 1,900 pending patent applications. The R&D process is expensive, prolonged and entails considerable uncertainty. Because of the complexities and uncertainties associated with ophthalmic R&D, products currently in development may take years to complete, or may not complete the development process or obtain the regulatory approvals required to market them.
Our ability to maintain operating margins (defined as operating income divided by net sales) may be affected by regulatory actions, particularly for pharmaceutical and surgical products. Further, managed care organizations and governments continue to emphasize the delivery of more cost-effective medical therapies. Many third-party payers for hospital services have substantially revised their payment methodologies in recent years, resulting in stricter standards for reimbursement of hospital and outpatient charges.
To offset these developments, we are intensely focused on improving manufacturing efficiency and controlling costs. We believe the profitability improvement initiatives in place since mid-2002 yielded an infrastructure capable of supporting a much higher revenue base than we have historically experienced. Manufacturing initiatives that incorporate Lean principles and automation have yielded gross margin improvements. Our goal also is to manage selling, administrative and general expenses to help support increased levels of R&D spending. Together, these activities are designed to further increase operating margins in the future.


Recent Developments

Restatement of Financial Information As previously disclosed in our Notification of Late Filings on Form 12b-25 with the Securities and Exchange Commission (SEC) on March 17, 2006, May 11, 2006, August 8, 2006 and November 9, 2006, we were unable to file this Annual Report on Form 10-K on a timely basis due to ongoing independent investigations conducted by the Audit Committee of our Board of Directors; expanded year-end procedures that were not complete; expanded procedures with respect to the accounting for income taxes that were not complete; and continued efforts to complete our assessment of our internal control over financial reporting. Our review and evaluation of internal control over financial reporting concluded that we did not maintain effective internal control over financial reporting as of December 31, 2005. For additional information regarding our assessment of internal controls, see Item 9A. Controls and Procedures of this Annual Report on Form 10-K.
As a result of the Audit Committee’s investigations and the expanded year-end procedures and expanded procedures with respect to the accounting for income taxes, we identified errors made in the application of generally accepted accounting principles (GAAP) that impacted previously reported financial statements. Consequently, management determined that our previously issued consolidated financial statements for fiscal years 2003 and 2004 and our financial information for the years ended 2001 and 2002 (including a cumulative increase to 2001 beginning retained earnings of $34) and the first and second quarters of 2005 should be restated to correct for such errors and departures from GAAP. The restated financial statements contained in this Annual Report on Form 10-K contain a number of adjustments associated with revenue recognition, accounting for reserves, accounting for foreign currency adjustments, accounting for income taxes including income taxes payable, tax reserves, deferred income tax assets and liabilities, related valuation allowances and income tax expense, and the accounting for the Company's Long-Term Deferred Compensation Plan. For further details regarding the Audit Committee investigations and restatement of financial results, see Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement and Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) of this Annual Report on Form 10-K.


PAGE 32

Market Withdrawal of MoistureLoc On May 15, 2006, we announced a worldwide voluntary recall of MoistureLoc. Our decision was made following an investigation into increased fungal infections among contact lens wearers in the United States and certain Asian markets. The decision represents a subsequent event occurring prior to filing this Annual Report on Form 10-K, but related to product manufactured and sold in 2005. In accordance with GAAP, we have recorded certain items associated with the recall in our 2005 financial results. The adjustments were recorded as third-quarter events, because that is the earliest reporting period for which we have not filed quarterly financial results on a Quarterly Report on Form 10-Q.
The charges associated with the withdrawal reduced full-year 2005 earnings before income taxes and minority interest by $39, net income by $27, and earnings per share by $0.49. Of the pre-tax amount, $17 related to estimated customer returns and consumer rebates and was recorded as a reduction to net sales; $14 related to costs associated with returned product and the disposal and write-off of inventory, which was recorded as cost of products sold; and $8 related to costs associated with the notification to customers and consumers required in market withdrawal instances, which were recorded as selling, administrative and general expense. Charges include $2 for settled, unlitigated, claims; however, we have not recorded any provisions for potential legal actions related to MoistureLoc because we are not able to predict the outcome of such actions, if any (see further discussion in Item 3. Legal Proceedings, and in Item 8. Financial Statements and Supplementary Data under Note 21 Other Matters of this Annual Report on Form 10-K and the discussion in Legal Matters below).
The decision to withdraw the product will negatively impact 2006 financial performance, and likely beyond. In addition to provisions for sales returns and coupon redemptions that we will record in 2006 associated with the MoistureLoc recall (primarily in Europe), performance will be hampered by the impact from lost MoistureLoc revenues; lower revenues for other lens care products, reflecting market share losses caused by trade and consumer uncertainty; negative collateral effect on our non-lens care product categories, primarily in Asia; and higher expenses associated with the recall, legal expenses associated with product liability lawsuits, and increased promotional expense to regain distribution and brand equity in the lens care category. For an additional discussion on the market withdrawal of MoistureLoc lens care solution, see Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K.

Legal Matters The Company is involved as a party in a number of material matters in litigation, including general litigation related to the restatement of the Company's financial information and the MoistureLoc withdrawal, material intellectual property litigation, and material tax litigation. The Company intends to vigorously defend itself in all of these matters. At this time, the Company is unable to predict the outcome of, and cannot reasonably estimate the impacts of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations, and matters concerning other allegations of other improprieties. The Company has not made any financial provision for potential liability in connection with these matters.

Shareholder Securities Class Actions There is a consolidated securities class action, entitled In re Bausch & Lomb Incorporated Securities Litigation, Case Nos. 06-cv-6294 (master file), 06-cv-6295, 06-cv-6296, and 06-cv-6300, pending in Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, four separate shareholder actions were filed between March and May of 2006 in Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a putative class of shareholders who purchased Company stock at allegedly artificially inflated levels between January 27, 2005 and May 3, 2006. Among other things, plaintiffs allege that defendants issued materially false and misleading public statements regarding the Company's financial condition and operations by failing to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc, thereby inflating the price of Company stock during the class period. Plaintiffs seek unspecified damages. The cases are currently awaiting appointment of lead plaintiff and lead plaintiff's counsel in accordance with the Private Securities Litigation Reform Act. Pursuant to a stipulated schedule ordered by the Court, the lead plaintiff appointed by the Court must file a consolidated amended complaint by the earlier of (a) 45 days after the Company files its Annual Report on Form 10-K for the year ended December 31, 2005, or (b) 90 days after entry of the Court's order appointing the lead plaintiff, provided, however, that, at a minimum, the lead plaintiff will have 45 days after entry of the Court's order appointing the lead plaintiff to file such consolidated amended complaint.




PAGE 33

ERISA-Based Class Actions There is a consolidated ERISA class action, entitled In re Bausch & Lomb Incorporated ERISA Litigation, Case Nos. 06-cv-6297 (master file), 06-cv-6315, and 06-cv-6348, pending in the Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, three separate actions were filed between April and May of 2006 in Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a class of participants in our 401(k) Plan for whose individual accounts the plan held an interest in Company stock between May 25, 2000 and the present. Among other things, plaintiffs allege that the defendants breached their fiduciary duties to plan participants by allowing the plan to invest in Company Common stock despite the fact that it was allegedly artificially inflated due to the failure to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief. On August 28, 2006, the Court entered an order appointing lead plaintiffs and lead plaintiffs' counsel. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in the consolidated ERISA action will have until 10 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.

Shareholder Derivative Actions The shareholder derivative actions, in which a shareholder seeks to assert the rights of the Company derivatively against certain present and former officers and directors, fall into two categories: (a) those asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries; and (b) those asserting allegations relating to the MoistureLoc withdrawal.
There is a consolidated derivative action asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries, entitled In re Bausch & Lomb Incorporated Derivative Litigation, Case Nos. 06-cv-6298 (master file) and 06-cv-6299, pending in Federal District Court for the Western District of New York, Rochester Division, against certain present and former officers and directors of the Company, and also naming the Company as nominal defendant. Initially, two separate derivative actions were filed in April 2006 in Federal District Court for the Southern District of New York, and were later transferred to the Western District of New York and consolidated. Among other things, plaintiffs allege that the individual defendants breached their fiduciary duties to the Company by causing or allowing the Company to issue materially false and misleading public statements regarding the Company's financial condition and operations that failed to disclose negative information about the Company's Brazilian and Korean subsidiaries and internal controls, thereby inflating the price of Company stock during the relevant time period. Plaintiffs purport to allege damage to the Company as a result of, among other things, a decrease in the Company's market capitalization, exposure to liability in securities fraud actions, and the costs of internal investigations and financial restatements. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief, including for misappropriation of inside information for personal benefit by certain of the individual defendants. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in this consolidated derivative action will have until 30 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.
On January 3, 2006, we received a demand letter dated December 28, 2005, from a law firm not involved in the now consolidated derivative actions described above, on behalf of a shareholder who also is not involved in the derivative actions, demanding that the Board of Directors bring claims on behalf of the Company based on allegations substantially similar to those that were later alleged in the two derivative actions relating to accounting issues at our Brazilian and Korean subsidiaries. In response to the demand letter, the Board of Directors adopted a board resolution establishing an Evaluation Committee (made up of independent directors) to investigate, review and analyze the facts and circumstances surrounding the allegations made in the demand letter, but reserving to the full Board authority and discretion to exercise its business judgment in respect of the proper disposition of the demand. The Committee has engaged independent outside counsel to advise it.
There are also two purported derivative actions asserting allegations relating to the MoistureLoc withdrawal. The first case, entitled Little v. Zarrella, Case No. 06-cv-6337, was filed in June 2006 in the Federal District Court for the Southern District of New York and was transferred to the Western District of New York, Rochester Division, where it is currently pending against certain directors of the Company, and also naming the Company as nominal defendant. The second case, entitled Pinchuck v. Zarrella, Case No. 06-6377, was filed in June 2006 in the Supreme Court of the State of New York, County of Monroe, where it is currently pending against the directors of the Company, and also naming the Company as nominal defendant. Among other things, plaintiffs in these actions allege that the individual defendants breached their fiduciary duties to the Company in connection with the Company's handling of the MoistureLoc withdrawal. Plaintiffs purport to allege damage to the Company as a result of, among other things, costs of litigating product liability and personal injury lawsuits, costs of the product recall, costs of carrying out internal investigations, and the loss of goodwill and reputation. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief.



PAGE 34

Pursuant to a stipulated schedule ordered by the Court, plaintiff in the state-court Pinchuck action served an amended complaint on September 15, 2006 and defendants served a motion to dismiss the amended complaint on November 15, 2006; plaintiff's opposition to the motion was served on January 15, 2007, and defendants' reply is due February 15, 2007. Pursuant to a stipulated schedule ordered by the Court in the federal Little action, plaintiff in that case will have until 60 days after a ruling on a motion to dismiss in the consolidated securities action is entered or, if no such motion is filed, 60 days after defendants' answer to a consolidated amended complaint in the consolidated securities action is filed, to file an amended complaint.

Product Liability Lawsuits As of February 1, 2007, the Company has been served or is aware that it has been named as a defendant in approximately 196 product liability lawsuits pending in various federal and state courts as well as certain other non-U.S. jurisdictions. Of the 196 cases, 117 actions have been filed in U.S. federal courts, 77 cases have been filed in various U.S. state courts and two actions have been filed in non-U.S. jurisdictions. These also include 170 individual actions filed on behalf of individuals who claim they suffered personal injury as a result of using a ReNu solution and 26 putative class actions alleging personal injury as a result of using a ReNu solution and/or violations of one or more state consumer protection statutes. In the personal injury actions, plaintiffs allege liability based on, among other things, negligence, strict product liability, failure to warn and breach of warranty. In the consumer protection actions, plaintiffs seek economic damages, claiming that they were misled to purchase products that were not as safe as advertised. Several lawsuits contain a combination of these allegations. On August 14, 2006, the Judicial Panel on Multidistrict Litigation (JPML) created a coordinated proceeding and transferred an initial set of MoistureLoc product liability lawsuits to the U.S. District Court for the District of South Carolina. The Company has advised the JPML of all federal cases available for transfer and has urged the issuance of conditional transfer orders. As of February 1, 2007, 104 of the 117 federal cases noted above have been transferred to the JPML.

Material Intellectual Property Litigation In October 2005, Rembrandt Vision Technologies, L.P. filed a patent infringement lawsuit against the Company and CIBA Vision Corporation. The action is entitled, Rembrandt Vision Technology, L.P. v. Bausch & Lomb Incorporated and CIBA Vision Corporation, bearing case number 2:05 CV 491, and is pending in the U.S. District Court for the Eastern District of Texas (Marshall Division). Rembrandt asserts that the Company and CIBA have infringed certain of Rembrandt’s oxygen permeability and tear-wettability technology that it claims to be protected by a U.S. Patent No. 5,712,327 entitled “Soft Gas Permeable Lens Having Improved Clinical Performance” (the 327 Patent). Rembrandt claims that the Company infringes the 327 Patent by selling soft gas permeable contact lenses that have tear-wettable surfaces in the United States, which would include the Company’s PureVision silicone hydrogel lens products. The Company denies, and intends to vigorously defend itself against, Rembrandt’s claims. The Court has issued a scheduling order and has set a trial date of November 5, 2007.

Material Tax Litigation As disclosed in Item 8. Financial Statements and Supplementary Data under Note 10 — Provision for Income Taxes of this Annual Report on Form 10-K, on May 12, 2006, the Company received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999, for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of partnership interests are held by certain of the Company's subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10, and increasing a long-term capital gain reported by Wilmington for that tax year by $190. The FPAA also proposes a $550 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of the Company's subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership's partners for the associated tax periods by more than $200, plus penalties and interest. The Company has not made any financial provision for the asserted additional taxes, penalties or interest as the Company believes the asserted adjustments are not probable and estimable.
Since 1999, the Company's consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.



PAGE 35

On August 7, 2006, the Company made a petition to the U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006, and the Company initiated a motion to strike portions of the answer on November 1, 2006. The Company believes it has numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While the Company intends to vigorously defend against the asserted adjustments, its failure to succeed in such a defense could significantly increase the liability of the partnership's partner for taxes, plus interest and penalties, which in turn would have a material adverse effect on the Company's financial results and cash flows.

For additional information on these actions, as well as other litigation matters, matters concerning allegations and/or investigations of non-compliance with laws or regulations, and other matters concerning allegations of improprieties, please refer to Item 3. Legal Proceedings and in Item 8. Financial Statements and Supplementary Data under Note 21 — Other Matters of this Annual Report on Form 10-K.


Financial Overview

Reported net income was $19 or $0.35 per share for the year ended December 31, 2005, compared to 2004 net income of $154 or $2.83 per share and 2003 net income of $106 or $1.98 per share. Net income for the year ended December 27, 2003 includes a charge of $1 or $0.02 per share as a cumulative change in accounting principle related to the adoption of Statement of Financial Accounting Standards (SFAS) No. 143. A reconciliation of net income and earnings per share to income and earnings per share before cumulative effect of change in accounting principle is presented below:
 


   
2005
 
2004 (Restated)
 
2003 (Restated)
 
   
Amount
 
Per Share
 
Amount
 
Per Share
 
Amount
 
Per Share
 
Net income
 
$
19.2
 
$
0.35
 
$
153.9
 
$
2.83
 
$
106.0
 
$
1.98
 
Cumulative effect of change in accounting principle, net of taxes, due to adoption of SFAS No. 143
   
-
   
-
   
-
   
-
   
0.9
   
0.02
 
Income before cumulative effect of  change in accounting principle
 
$
19.2
 
$
0.35
 
$
153.9
 
$
2.83
 
$
106.9
 
$
2.00
 
Average Shares Outstanding - Diluted (000s)
         
55,684
         
54,504
         
53,519
 

Our results for 2005 and 2003 were impacted by several significant events, summarized below. There were no significant events impacting 2004 results.
The 2005 significant events in the aggregate reduced reported net income by $160 or $2.87 per share. They included:

·  
A valuation allowance against deferred income tax assets which reduced reported net income by $149, or $2.67 per share, recorded in the third quarter. The need for the allowance resulted from anticipated losses in early future periods attributed to the U.S. entities to which the deferred tax assets relate and uncertainties surrounding when we will return to U.S. profitability. The expected losses result from, among other things, the costs associated with the MoistureLoc recall and its expected impact on 2006 financial results;
·  
Incremental income tax expense of $9, or $0.17 per share, recorded in the third quarter associated with our repatriating foreign earnings under the American Jobs Creation Act of 2004 (AJCA); and
·  
Amortization of inventory step-up totaling $2 before taxes ($1 or $0.03 per share after taxes) related to purchase accounting adjustments associated with the 2005 acquisition of Freda.

For a further discussion of the two income tax related items, see the section entitled Income Taxes below and in Item 8. Financial Statements and Supplementary Data under Note 10 — Provision for Income Taxes of this Annual Report on Form 10-K.



PAGE 36

The 2003 significant events, excluding the $1 loss on adoption of SFAS No. 143 already reflected in net income, in the aggregate increased reported net income by $0.4 or $0.01 per share. They included:

·  
Reversals of severance-related restructuring charges of $6 before taxes ($4 or $0.07 per share after taxes), when certain anticipated termination actions and plant closures did not occur due to increased demand for certain product lines; and
·  
R&D expense of $6 before taxes ($4 or $0.06 per share after taxes) recorded in the fourth quarter associated with acquiring an early-stage pharmaceutical technology we had previously been developing with a third-party partner.


Net Sales and Income by Business Segment and Geographic Region

Geographic Net Sales The following table summarizes net sales by geographic region.

   
 
 
 
Net Sales
 
Percent
Increase
Actual
Dollars
 
Percent
Increase
Constant
Currency
 
Percent of Total Company Net Sales
 
2005
                 
Non-U.S.
 
$
1,462.8
   
7
%
 
6
%
 
62
%
U.S. 1
   
891.0
   
3
%
 
3
%
 
38
%
Total Company 2
 
$
2,353.8
   
5
%
 
5
%
   
                           
2004 (Restated)
                         
Non-U.S.
 
$
1,370.0
   
14
%
 
6
%
 
61
%
U.S. 1
   
863.5
   
6
%
 
6
%
 
39
%
Total Company
 
$
2,233.5
   
11
%
 
6
%
   
                           
2003 (Restated)
                         
Non-U.S.
 
$
1,204.0
   
15
%
 
3
%
 
60
%
U.S. 1
   
814.5
   
7
%
 
7
%
 
40
%
Total Company
 
$
2,018.5
   
12
%
 
5
%
   

1  U.S. revenues represented approximately 90 percent of the Americas segment revenue in each year.
2
2005 amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 —Subsequent Event of this Annual Report on Form 10-K. Charges associated with the recall reduced U.S. net sales by $12.0 and non-U.S. net sales by $5.1, respectively.

Business Segment Net Sales We are organized on a regionally based management structure for commercial operations, with our research and development and product supply functions managed on a global basis. Beginning in 2005, the engineering function, which had previously been part of the research and development segment, became part of the product supply function. Our business segments (after this realignment of the engineering function) are the Americas region; the Europe, Middle East and Africa region (Europe); the Asia region; the Research & Development organization; and the Global Operations & Engineering organization. In each geographic segment, we market products in five categories: contact lens, lens care, pharmaceuticals, cataract and vitreoretinal, and refractive. The contact lens category includes traditional, planned replacement disposable, daily disposable, multifocal, and toric soft lenses and rigid gas permeable (RGP) lenses and materials. The lens care category includes multipurpose solutions, cleaning and conditioning solutions for RGP lenses, re-wetting drops and saline solutions. The pharmaceuticals category includes generic and proprietary prescription ophthalmic drugs, ocular vitamins and over-the-counter medications. The cataract and vitreoretinal category includes intraocular lenses (IOLs), phacoemulsification and vitreoretinal surgical equipment and related disposable products, hand-held surgical instruments, viscoelastics and other products used in cataract and vitreoretinal surgery. The refractive category includes lasers, microkeratomes, diagnostic equipment and other products and equipment used in refractive surgery. There are no transfers of products between product categories.




PAGE 37

Operating income is the primary measure of segment income. Segment income excludes the significant items noted in the Financial Overview. The following table summarizes net sales and operating income by segment and presents consolidated operating income:

   
2005 1
 
2004
 
2003
 
   
 
As Reported
 
Percent of Total Net Sales
 
 
 
Restated
 
Percent of Total Net Sales
 
 
 
Restated
 
Percent of Total Net Sales
 
Net Sales
                         
Americas
 
$
1,005.3
   
43
%
$
960.2
   
43
%
$
903.3
   
45
%
Europe
   
859.9
   
36
%
 
818.9
   
37
%
 
724.4
   
36
%
Asia
   
488.6
   
21
%
 
454.4
   
20
%
 
390.8
   
19
%
   
$
2,353.8
       
$
2,233.5
       
$
2,018.5
       
                                       
Operating Income (Costs)
                                     
Americas
 
$
333.0
       
$
326.1
       
$
282.6
       
Europe
   
250.8
         
251.2
         
201.5
       
Asia
   
123.6
         
128.5
         
106.1
       
Research & Development
   
(200.5
)
       
(180.6
)
       
(166.1
)
     
Global Operations & Engineering
   
(131.7
)
       
(157.2
)
       
(123.1
)
     
Segment Income
   
375.2
         
368.0
         
301.0
       
Corporate Administration 2
   
(89.8
)
       
(88.9
)
       
(73.5
)
     
Restructuring reversals 3
   
-
         
-
         
6.3
       
Other significant charges 4
   
(1.9
)
       
-
         
(5.6
)
     
Operating Income
 
$
283.5
       
$
279.1
       
$
228.2
       

1
2005 amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K. Charges associated with the recall reduced Americas region net sales and operating income by $12.4 and $25.0, respectively; Asia region net sales and operating income by $4.7 and $11.0, respectively; increased Global Operations & Engineering operating costs by $1.2; and increased corporate administration expense by $1.7.
2  Corporate administration costs are discussed in Operating Costs and Expenses.
3  Income associated with certain restructuring plans, as described in Restructuring Charges and Asset Write-offs.
4
Other significant charges in 2005 represent purchase accounting adjustments related to the acquisition of Freda. Other significant charges in 2003 pertain to R&D expense associated with the acquisition of an early-stage pharmaceutical technology.

The following table summarizes net sales by geographic segment:

           
2005 vs. 2004
     
2004 vs. 2003
 
   
 
 
 
2005 1
 
 
 
2004
(Restated)
 
Percent Change
Actual Dollars
 
Percent
Change
Constant
Currency
 
 
 
2003
(Restated)
 
Percent Change
Actual Dollars
 
Percent Change
Constant
Currency
 
                               
Americas
 
$
1,005.3
 
$
960.2
   
5
%
 
4
%
$
903.3
   
6
%
 
6
%
Europe
   
859.9
   
818.9
   
5
%
 
5
%
 
724.4
   
13
%
 
3
%
Asia
   
488.6
   
454.4
   
8
%
 
7
%
 
390.8
   
16
%
 
12
%
Total Company
 
$
2,353.8
 
$
2,233.5
   
5
%
 
5
%
$
2,018.5
   
11
%
 
6
%

1
2005 amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K. Provisions for sales returns and consumer rebates associated with the recall reduced Americas region net sales by $12.4 and Asia region net sales by $4.7.




PAGE 38

2005 Versus 2004 Consolidated net sales increased 5 percent compared to 2004 on both a reported and constant-currency basis. The 2005 amounts include the impact of approximately $17 in customer returns and rebate provisions associated with the voluntary recall of MoistureLoc in Asia and the Americas (see further discussion in Item 8. Financial Statements and Supplementary Data under Note 23 —Subsequent Event of this Annual Report on Form 10-K), which largely offset $18 in incremental revenues from the acquisition of Freda.

·  
Americas segment net sales increased 5 percent from 2004, or 4 percent in constant currency. Those figures include $12 in sales return and consumer rebate provisions associated with the MoistureLoc recall. Excluding those items, Americas segment net sales grew 6 percent, or 5 percent in constant currency. Gains were led by above-market performance for contact lenses and higher sales of cataract surgery products.
·  
Europe segment net sales increased 5 percent on both a reported and constant-currency basis. Gains were led by higher sales of pharmaceutical and vision care products, which more than offset declines for the refractive surgery category and the impact of divesting our German Woehlk contact lens business in the 2005 third quarter. The MoistureLoc product recalled in Europe was both manufactured and sold in 2006; therefore, sales return and customer rebates of $18 associated with the MoistureLoc recall in the Europe segment were not provided for in 2005, but have been expensed in 2006.
·  
The Asia segment reported net sales gains of 8 percent compared to 2004, or 7 percent in constant currency. Those figures include $5 in sales return and consumer rebate provisions associated with the MoistureLoc recall as well as $18 in incremental sales associated with the acquisition of Freda. Excluding those items, Asia segment net sales grew 5 percent, or 4 percent in constant currency, with gains led by higher sales of contact lenses and cataract surgery products.

2004 Versus 2003 Consolidated net sales increased 11 percent on a reported basis and increased 6 percent in constant currency.

·  
Americas segment net sales grew 6 percent from 2003, with gains in all product categories.
·  
Europe segment net sales increased 13 percent, mainly reflecting favorable currency benefits. Constant-currency sales growth was 3 percent. Gains were driven by the contact lens, surgical and pharmaceutical categories. Constant-currency European lens care sales were flat with the prior year, which was encouraging given overall market dynamics.
·  
Asia segment net sales grew 16 percent, or 12 percent on a constant-currency basis. Growth was experienced in all product categories, but especially our lines of vision care products.

A more detailed discussion of net sales trends by geographic region follows.

Americas

The following table summarizes net sales trends for the Americas region by product category:

   
 
2005 vs. 2004 Restated
Percent Increase (Decrease)
 
 
2004 Restated vs. 2003 Restated
Percent Increase
 
   
Actual Dollars 
 
Constant Currency
 
Actual Dollars 
 
Constant Currency
 
Contact Lens
   
15
%
 
14
%
 
8
%
 
7
%
Lens Care 1
   
-
%
 
(1
)%
 
1
%
 
1
%
Pharmaceuticals
   
3
%
 
3
%
 
11
%
 
11
%
Cataract and Vitreoretinal
   
7
%
 
6
%
 
2
%
 
1
%
Refractive
   
(4
)%
 
(6
)%
 
20
%
 
20
%
Total Americas
   
5
%
 
4
%
 
6
%
 
6
%

1
2005 amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K. Provisions for sales returns and consumer rebates associated with the recall reduced Americas region net sales by $12.4.




PAGE 39

2005 Versus 2004

·  
Contact lens category growth reflected the reintroduction of the PureVision brand of silicone hydrogel contact lenses in the United States as well as continued growth for SofLens Toric and SofLens Multi-Focal contact lenses. Moderating that performance was a continued decline in sales of our older, conventional hydrogel two-week contact lenses, reflecting the overall market shift to silicone hydrogel materials. Sales of SofLens Toric contact lenses for people with astigmatism increased more than 10 percent from 2004. As expected, dollar growth for this product has begun to moderate, reflecting the competitive impact of new silicone hydrogel toric offerings. We launched PureVision Toric contact lenses in the United States on a limited basis in October 2005 and reached full commercial distribution in the second quarter of 2006. Sales of SofLens Multi-Focal contact lenses for people with presbyopia grew more than 30 percent in the Americas region in 2005, reflecting our continued leading market position.
·  
Sales in the lens care category were essentially flat mainly due to sales returns and consumer rebate provisions associated with our voluntary recall of MoistureLoc which was reflected as a subsequent event (see Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K for further discussion). Excluding the impact of the recall, Americas region constant-currency lens care sales increased 3 percent, reflecting U.S. market share gains for our lines of multipurpose solutions and higher sales of Boston lens care solutions for RGP contact lenses. As described above, lens care category sales have declined in 2006 in all regions, due to additional charges associated with the MoistureLoc recall combined with market share losses resulting from customer and trade concerns during our investigation into increased fungal infections among contact lens wearers.
·  
Pharmaceuticals sales increases were mainly attributable to incremental sales of Zylet combination eye drops, as well as higher sales of Lotemax steroid eye drops. Those gains were largely offset by expected declines in sales of two non-ophthalmic drugs in our multisource pharmaceuticals portfolio. Prescriptions for our lines of steroid eye drops containing loteprednol etabonate continued to trend positively throughout 2005, with Lotemax and Alrex prescriptions reaching all-time highs. Our vitamins business grew 1 percent in constant currency. As expected, we faced difficult comparisons to the prior year, when we launched PreserVision soft gels and customers were carrying inventories of both tablets and gel formulations. The underlying dynamics of the vitamins market remain strong, with consumption growing more than 15 percent in dollars, and our PreserVision brand continuing to gain market share.
·  
Sales gains for cataract and vitreoretinal products were led by our lines of silicone IOLs, which increased more than 15 percent. That performance was mainly due to our SofPort lines of silicone IOLs, which grew at an even faster rate and benefited from market share gains and strong market acceptance for the SofPort AO IOL featuring an aspheric optics design. Phacoemulsification product sales increased more than 5 percent, reflecting an increase in revenues for Millennium microsurgical systems and disposable products used in cataract surgery procedures. The increase in Millennium net sales reflects primarily a change in the type of system placements in 2005 as compared to the prior year. We placed more units under direct sales agreements in 2005 compared to 2004, when we placed more units under operating lease arrangements requiring revenue to be recognized over a longer period of time.
·  
Sales declines in the refractive category were mainly due to lower sales of lasers and microkeratome blades. These declines were partially offset by higher sales of per-procedure cards, especially those used for Zyoptix personalized vision correction procedures.

2004 Versus 2003

·  
Contact lens sales growth was led by the SofLens Multi-Focal and SofLens Toric brands. SofLens Multi-Focal contact lens sales nearly doubled, and SofLens Toric contact lens revenues grew slightly less than 20 percent and achieved an all-time high share of patient fits in 2004. Performance for these two lines was somewhat tempered by weakness in U.S. two-week disposable SVS products, reflecting market shifts toward competitive silicone hydrogel offerings and our lack of such a product prior to the U.S. reintroduction of the PureVision brand of contact lenses in 2005.
·  
Lens care sales growth was mainly due to our lines of solutions for soft contact lenses, and reflected incremental sales from the initial shipments of MoistureLoc solution in the third quarter. We maintained our leading position in the U.S. market for both multipurpose solutions and rigid gas permeable solutions in 2004.



PAGE 40

·  
Sales gains in the pharmaceuticals category in the Americas region were led by our lines of ocular vitamins, proprietary pharmaceuticals and multisource products. Ocular vitamin sales grew more than 20 percent, with the PreserVision brand up more than 40 percent. Late in the third quarter, we introduced an easy-to-swallow soft gel version of the original AREDS formula, as well as a line extension containing lutein in place of beta carotene. In the proprietary pharmaceuticals portfolio, sales of Alrex and Lotemax steroid drops each grew more than 20 percent in 2004, reflecting more prescriptions written for both products.
·  
Cataract and vitreoretinal category sales growth was due to our lines of IOLs, which registered overall gains of approximately 10 percent. Sales growth in our lines of silicone IOLs, most notably the SofPort brand, were even stronger, at more than 20 percent. IOL performance was partially offset by lower revenues for phacoemulsification products, reflecting a higher mix of equipment placed under operating lease arrangements than in 2003.
·  
Despite a decline in refractive category net sales in the fourth quarter compared to the same period in 2003, full-year 2004 growth reflected incremental sales of U.S. equipment and higher margin per-procedure cards associated with the Zyoptix system for personalized vision correction. We launched that product late in 2003. Other factors contributing to 2004 performance included higher sales of standard LASIK procedure cards and microkeratome blades.

Europe

The following table summarizes net sales trends for the Europe region by product category:

   
 
2005 vs. 2004 Restated
Percent Increase (Decrease) 
 
 
2004 Restated vs. 2003 Restated
Percent Increase
 
   
Actual Dollars 
 
Constant Currency
 
Actual Dollars 
 
Constant Currency
 
Contact Lens
   
5
%
 
5
%
 
14
%
 
4
%
Lens Care
   
6
%
 
8
%
 
9
%
 
-
%
Pharmaceuticals
   
11
%
 
11
%
 
12
%
 
2
%
Cataract and Vitreoretinal
   
2
%
 
2
%
 
16
%
 
6
%
Refractive
   
(13
)%
 
(13
)%
 
16
%
 
7
%
Total Europe
   
5
%
 
5
%
 
13
%
 
3
%

2005 Versus 2004

·  
Contact lens sales comparisons were impacted by the divestiture of our German Woehlk business in the third quarter of 2005. Excluding that impact, contact lens net sales would have grown approximately 8 percent on a reported basis and 9 percent in constant currency. Gains were mainly due to our lines of specialty products and PureVision silicone hydrogel spherical contact lenses. Monthly replacement toric contact lens revenues increased more than 20 percent, with gains coming from a combination of expanded distribution for the PureVision Toric line and high-single-digit growth for SofLens Toric contact lenses. Our multifocal product also posted strong growth, and we continued to gain market share.
·  
Increased lens care sales reflected market share gains, especially for our lines of multipurpose solutions, which grew approximately 10 percent on the continued market acceptance of MoistureLoc prior to the recall. As described above, lens care category sales have declined in 2006 in all regions, due to additional charges associated with the MoistureLoc recall combined with market share losses resulting from customer and trade concerns during our investigation into increased fungal infections among contact lens wearers. We recorded additional charges associated with the MoistureLoc recall for product manufactured and sold in Europe in 2006.
·  
European pharmaceuticals sales growth was mainly attributable to our lines of dry eye products, ocular nutritionals and anti-infective drugs, coupled with expansion into new geographic markets.
·  
Higher cataract and vitreoretinal sales reflected overall strong performance in most markets with the exception of the United Kingdom, where the number of procedures declined in 2005 following government initiatives in the prior year to decrease the number of patients waiting to have the procedure. On a total region basis, growth was largely due to our Akreos line of acrylic IOLs, as well as higher sales of viscoelastics.



PAGE 41

·  
Declines in sales of refractive surgery products in Europe were consistent with overall market trends. Lower sales of equipment and microkeratome blades more than offset increased sales of Zyoptix treatment cards.

2004 Versus 2003

·  
Contact lens sales growth was primarily due to the continued strength and market leading positions for SofLens Toric and SofLens Multi-Focal lenses, growth for the PureVision brand, as well as favorable currency benefits. The PureVision lens franchise grew more than 20 percent in 2004, benefiting from the introduction of PureVision Toric lenses and strong growth in the PureVision SVS line.
·  
Constant-currency European lens care sales declined through the first three quarters of 2004, but rebounded in the fourth quarter following the launch of MoistureLoc, yielding full-year flat constant-currency performance.
·  
Pharmaceuticals gains in Europe were led by higher sales of ocular vitamins, anti-infective and anti-inflammatory products, as well as favorable exchange rate movements, somewhat offset by general sales declines for most other product lines in Germany, where government pharmaceuticals pricing and reimbursement legislation negatively impacted revenues.
·  
Higher sales of cataract and vitreoretinal products mainly reflected gains for phacoemulsification products and IOLs. Revenues from our Akreos line of acrylic IOLs rose more than 30 percent on a constant-currency basis, as European surgeons continued to use more advanced designs and foldable materials. Sales of phacoemulsification products increased approximately 10 percent for the year, excluding favorable currency benefits.
·  
Growth within the refractive product category reflected higher revenues from Zyoptix system upgrades, per-procedure cards, diagnostic equipment and microkeratome blades, as well as favorable currency movements.

Asia

The following table summarizes net sales trends for the Asia region by product category:

   
2005 vs. 2004 Restated
Percent Increase (Decrease)
 
2004 Restated vs. 2003 Restated
Percent Increase
 
   
Actual Dollars 
 
Constant Currency
 
Actual Dollars 
 
Constant Currency
 
Contact Lens
   
8
%
 
7
%
 
17
%
 
11
%
Lens Care 1
   
(5
)%
 
(7
)%
 
13
%
 
9
%
Pharmaceuticals 2
   
NM
   
NM
   
72
%
 
60
%
Cataract and Vitreoretinal
   
16
%
 
13
%
 
19
%
 
14
%
Refractive
   
(7
)%
 
(9
)%
 
13
%
 
10
%
Total Asia
   
8
%
 
7
%
 
16
%
 
12
%

1
2005 amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K. Provisions for sales returns and consumer rebates associated with the recall reduced Asia region net sales by $4.7.
2
NM denotes "not meaningful." 2005 pharmaceuticals category sales include $17.8 incremental revenues from the acquisition of Freda, resulting in a calculated growth rate of more than 100 percent.

2005 Versus 2004

·  
Contact lens sales growth in Asia reflected gains for our lines of specialty and silicone hydrogel lenses, including incremental sales from the launch in Japan of our latest conventional hydrogel two-week disposable lenses. Throughout much of the year, our Chinese contact lens sales growth was lower than historical trends and internal expectations, reflecting, in part, trade disruption following changes we made in some of our distributor programs early in 2005. That business rebounded in the fourth quarter, posting constant-currency growth of approximately 15 percent compared to the same period in 2004. In 2006, the MoistureLoc recall created negative collateral impacts on our non-lens care product lines, especially contact lenses and pharmaceuticals products in China. As a result, Asia region contact lens sales have moderated from levels experienced in 2005.



PAGE 42

·  
Lens care sales declines reflect the sales returns and customer rebate provisions associated with the voluntary recall of MoistureLoc (see Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K for further discussion). Excluding the impact of the recall, Asian constant-currency lens care sales were down 3 percent. Declines in China, due to the same distributor issues discussed above, more than offset 1 percent constant-currency gains in Japan, reflecting the market introduction of ReNu MultiPlus solution. As described above, lens care category sales have declined in 2006 in all regions, due to additional charges associated with the MoistureLoc recall combined with market share losses resulting from customer and trade concerns during our investigation into increased fungal infections among contact lens wearers. In the Asia region, our Chinese business has been most impacted by these events.
·  
Historically we have not had a significant pharmaceuticals business in Asia. In the fourth quarter of 2005 we acquired a controlling interest in Freda. The acquisition should help accelerate our expansion into the rapidly growing Chinese ophthalmic pharmaceuticals market and provide a national pharmaceuticals sales and distribution network. Further information with respect to the Freda acquisition can be found in Item 8. Financial Statements and Supplementary Data under Note 3 — Acquisitions of this Annual Report on Form 10-K. Excluding the Freda acquisition, our Asian pharmaceuticals revenues grew about 20 percent on a constant-currency basis, led by gains for ocular nutritionals.
·  
Growth in the cataract and vitreoretinal category was mainly driven by gains for our lines of IOL and phacoemulsification products. IOL revenues were up strongly, largely due to the continued rollout of the Akreos line of acrylic IOLs throughout the year.
·  
Lower sales in the refractive category in Asia reflected declines in laser and diagnostic equipment sales. Part of this decline was expected, as prior-year results included revenues associated with initial customer adoption of our Zyoptix laser platform.

2004 Versus 2003

·  
Strong contact lens sales gains were registered in most markets, especially Japan, where constant-currency sales were up nearly 10 percent, reflecting the launch of Medalist One Day contact lenses in the first half of 2004 and continued strong sales growth for disposable toric contact lenses. In markets outside of Japan, constant-currency sales grew approximately 15 percent during 2004.
·  
Lens care sales growth was led by our lines of multipurpose solutions, which were up more than 10 percent for the year on a constant-currency basis. We launched MoistureLoc solution in several markets in the fourth quarter, with encouraging response from the trade. Our other ReNu brand solutions continued to perform well in 2004, particularly in China and Japan.
·  
Net sales of pharmaceuticals in Asia were immaterial to our overall results of operations in 2004 and 2003. Sales gains reflected our efforts to expand and introduce our pharmaceutical products in the region, particularly vitamins.
·  
Increased sales of cataract and vitreoretinal products reflected growth in markets outside of Japan, where sales of the SofPort and Akreos lines of IOLs grew strongly, as well as higher sales of phacoemulsification products.
·  
Refractive surgery product sales gains in 2004 were driven by Zyoptix system upgrades, per-procedure cards and microkeratome blades, somewhat offset by fewer new laser placements, reflecting the launch of the Technolas z100 laser in 2003.




PAGE 43

Net Sales by Product Category

The following table presents total Company net sales by product category for the years 2005, 2004 and 2003:

   
 
 
 
 
Net Sales
 
Percent
Increase
(Decrease)
Actual
Dollars
 
Percent
Increase
(Decrease)
Constant
Currency
 
2005
             
Contact Lens
 
$
728.5
   
9
%
 
9
%
Lens Care 1
   
522.2
   
-
%
 
(1
)%
Pharmaceuticals
   
584.8
   
11
%
 
11
%
Cataract and Vitreoretinal
   
377.8
   
6
%
 
5
%
Refractive
   
140.5
   
(8
)%
 
(9
)%
   
$
2,353.8
   
5
%
 
5
%
                     
2004 (Restated)
                   
Contact Lens
 
$
671.0
   
13
%
 
7
%
Lens Care
   
523.3
   
5
%
 
2
%
Pharmaceuticals
   
528.2
   
12
%
 
7
%
Cataract and Vitreoretinal
   
358.2
   
10
%
 
5
%
Refractive
   
152.8
   
17
%
 
13
%
   
$
2,233.5
   
11
%
 
6
%
                     
2003 (Restated)
                   
Contact Lens
 
$
593.2
   
14
%
 
7
%
Lens Care
   
496.5
   
8
%
 
2
%
Pharmaceuticals
   
471.2
   
19
%
 
10
%
Cataract and Vitreoretinal
   
327.1
   
8
%
 
2
%
Refractive
   
130.5
   
(1
)%
 
(7
)%
   
$
2,018.5
   
12
%
 
5
%

1
2005 lens care amounts reflect the impact of the voluntary recall of MoistureLoc discussed in Recent Developments above and in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K. Provisions for sales returns and consumer rebates associated with the recall reduced full-year lens care net sales by $17.1.

2005 Versus 2004 Net sales in 2005 include the impact of approximately $17 in customer returns and rebate provisions associated with the voluntary recall of MoistureLoc (see further discussion in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K), which mostly offset $18 in incremental sales from the acquisition of Freda.

·  
Contact lens sales growth was led by our specialty and silicone hydrogel spherical offerings, which offset continued declines for older technology products. That growth rate reflects the impact of divesting our German Woehlk contact lens business during the third quarter of 2005. Excluding that impact, contact lens net sales would have grown approximately 10 percent.
·  
Sales in the lens care category, which were flat with the prior year, mainly reflected the impact of the MoistureLoc recall. Excluding that impact, lens care sales grew 3 percent on a reported basis and 2 percent in constant currency, with gains for multipurpose solutions in Europe and the Americas region partially offset by declines in Asia.
·  
Full-year pharmaceutical net sales growth includes the impact of the Freda acquisition. Excluding revenues from Freda, growth was approximately 7 percent on both a reported and constant-currency basis. That reflects incremental sales of Zylet combination ophthalmic drops in the United States, combined with higher global sales of ocular vitamins and Lotemax steroid drops containing loteprednol etabonate. Those gains were somewhat offset by sales declines for two non-ophthalmic drugs in our U.S. multisource (generic) pharmaceuticals portfolio.
·  
Cataract and vitreoretinal product category growth was led by gains in IOLs of more than 10 percent on the strength of our SofPort and Akreos lines of foldable IOLs.



PAGE 44

·  
Net sales declines in the refractive category reflected lower equipment and microkeratome blade sales in all regions, partially offset by higher service revenues and sales of per-procedure cards.
·  
As discussed above, the decision to withdraw MoistureLoc will negatively impact 2006 sales performance. In addition to provisions for sales returns and coupon redemptions that we will record (primarily in Europe), performance will be hampered by the impact from lost MoistureLoc revenues; lower revenues for other lens care products, reflecting market share losses caused by trade and consumer uncertainty; and the negative collateral impact on our non-lens care product categories, primarily in Asia.

2004 Versus 2003 The significant drivers of 2004 net sales gains as compared to 2003 include the following.

·  
Contact lens sales growth was attributable to strong gains for the SofLens Toric, SofLens One Day, SofLens Multi-Focal and SofLens59 brands, as well as the PureVision line of contact lenses. Combined, these products represented more than 50 percent of contact lens revenues, benefiting from continued market expansion and share gains.
·  
Lens care sales growth was mainly due to higher sales of all-in-one solutions, particularly in the Americas and Asia regions.
·  
Pharmaceuticals sales growth mainly reflected the continued market success and geographic expansion of the PreserVision and Ocuvite lines of ocular vitamins. Strong gains were also noted in the Americas region for Lotemax and Alrex prescription steroid eye drops. In Europe, growth was tempered by the continued impact of pharmaceuticals pricing legislation in Germany.
·  
Higher sales of cataract and vitreoretinal surgery products were attributable to our lines of IOLs, phacoemulsification products and viscoelastics as well as service revenues.
·  
Refractive surgery revenues increased due to higher sales of per-procedure cards, lasers and microkeratome blades.

Segment Income Segment income excludes certain significant items such as restructuring charges and reversals, asset write-offs and purchase accounting adjustments, as well as corporate administration expenses.

2005 Versus 2004 Segment income increased 2 percent, including a $37 negative impact associated with customer return and consumer rebate provisions and incremental expenses associated with the MoistureLoc recall. Excluding that impact, segment income increased 12 percent, reflecting gross margin expansion resulting from sales mix shifts.
Research & Development segment operating costs increased 11 percent in 2005, reflecting additional headcount and higher spending in support of projects in late-stage development. We remain committed to investing in research and development activities at a higher rate than sales growth. Global Operations & Engineering segment operating costs decreased 16 percent, primarily reflecting changes in foreign currency exchange rates and cost savings realized through restructuring actions and manufacturing initiatives incorporating Lean principles and automation.

2004 Versus 2003 Segment income increased 22 percent due to favorable sales mix in all commercial segments. Continued manufacturing cost savings initiatives, ongoing administrative savings realized through our profitability improvement programs and changes in foreign currency exchange rates also contributed to improved profitability. The 2004 growth was somewhat offset by increased marketing and advertising costs primarily associated with new product launches and increased information technology (IT) expense associated with global systems integration.
Research & Development segment operating costs increased 9 percent in 2004, reflecting our commitment to new product development. Global Operations & Engineering segment operating costs increased 28 percent, primarily due to changes in foreign currency, partially offset by cost savings realized through restructuring actions and manufacturing initiatives incorporating Lean principles and automation.





PAGE 45

Operating Costs and Expenses

The following tables show operating costs and expenses as a percentage of sales:

   
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
   
Percentage of Net Sales
 
Cost of products sold
   
41.8
%
 
41.6
%
 
42.4
%
Selling, administrative and general expenses
   
38.6
%
 
38.6
%
 
39.1
%
Research and development expenses
   
7.5
%
 
7.3
%
 
7.4
%

Cost of products sold was $983 in 2005, $929 in 2004 and $857 in 2003. The 2005 amount includes the cost of sales impact of the MoistureLoc recall ($14) and inventory step-up charges associated with the Freda acquisition ($2). Excluding both of those items, the ratio of cost of products sold to sales would have improved to 40.8 percent, reflecting a favorable sales mix shift toward higher margin products combined with benefits from our ongoing profitability improvement initiatives. Similar trends were responsible for the 2004 gross margin improvement as compared to 2003. Foreign currency exchange rate changes had a slightly negative impact on gross margin during 2005 and a positive impact on gross margin during 2004.
Selling, administrative and general expenses include corporate administration expenses. Absolute spending totaled $910 in 2005, compared to $863 in 2004 and $790 in 2003. The $47 increase in 2005 primarily reflected higher costs associated with selling and marketing, which includes promoting new products. In addition, approximately $13 of costs associated with the MoistureLoc recall, the Audit Committee's independent investigations, expanded year-end procedures and expanded procedures with respect to the accounting for income taxes were essentially offset by lower performance-based compensation expense and lower mark-to-market expense related to certain deferred compensation liabilities invested in our Common stock. As described in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K, expense associated with these liabilities was recorded as part of the financial restatement, resulting in additional compensation expense of $1, $3 and $4 in 2005, 2004 and 2003, respectively. Due to recent declines in our stock price, $4 of mark-to-market income was recorded in the second half of 2005 and an additional $5 of income was recorded in 2006. The 2004 increase in selling, administrative and general expenses reflected the impact of foreign currency exchange rates, higher investments in marketing and advertising, primarily associated with new product launches, increased IT expense in connection with our global systems integration project, Sarbanes-Oxley compliance costs and higher expenses associated with performance-based compensation plans and other employee benefit program expenses.
R&D expenses totaled $177, $163 and $150 in 2005, 2004 and 2003, respectively. A charge of $6 associated with the acquisition of an early-stage pharmaceutical technology contributed to 2003 expense. We expect to continue investing in R&D at a faster rate than sales to support our goal of consistently bringing new products to market to fuel long-term growth.


Non-Operating Income and Expense

Other Income and Expense Interest and investment income was $20 in 2005, $14 in 2004 and $16 in 2003. The increase in 2005 over 2004 primarily related to higher interest rates (somewhat offset by lower average investment balances in 2005) and interest income associated with income tax refunds. Mark-to-market adjustments on assets held in our nonqualified deferred compensation plan represented the majority of the decrease in 2004 when compared to 2003.
Interest expense was $53 in 2005, $50 in 2004 and $55 in 2003. The 2005 increase reflected higher interest rates on variable-rate debt, incremental borrowings in 2005, and the write-off of $3 in unamortized debt issuance costs associated with our convertible debt instruments which became convertible on July 1, 2005 (see further discussion in Item 8. Financial Statements and Supplementary Data under Note 4 — Earnings Per Share of this Annual Report on Form 10-K and in the section entitled Access to Financial Markets below), partially offset by interest expense savings associated with debt retired in 2004 and 2005. As explained in Item 8. Financial Statements and Supplementary Data under Note 12 — Accounting for Derivatives and Hedging Activities of this Annual Report on Form 10-K, we decided to permanently invest an intercompany loan in the Europe region in the third quarter of 2003. That loan was previously hedged by foreign exchange forward contracts classified as cash flow hedges. The 2004 decline in interest expense resulted primarily from the termination of these cash flow hedges, although lower average debt levels and interest rates were also factors.



PAGE 46

We will report higher interest expense in 2006, primarily as a result of increased debt balances, increased interest rates associated with variable rate debt, costs associated with the purchase of outstanding public debt resulting from a tender offer we completed in 2006, and the payment of consent fees associated with consent solicitations we completed in June and September 2006; as well as waiver fees paid to banks in connection with our syndicated revolving credit facility and the $375 unsecured variable-rate term loan arrangement of our Dutch subsidiary (B.V. Term Loan). The consent solicitations and fees are more fully described in the section below entitled Sources of Liquidity.
Net foreign currency losses were $4 in 2005, $1 in 2004 and $13 in 2003. These amounts were primarily associated with our ongoing foreign exchange hedging programs. However, the 2003 amount includes approximately $4 in foreign exchange losses associated with the sale of a Korean entity to a minority interest partner.

Income Taxes

Our reported tax rate for continuing operations was 89.9 percent in 2005 and included the impact of recording a valuation allowance against our U.S. deferred tax assets as described previously and in Item 8. Financial Statements and Supplementary Data under Note 10 — Provision for Income Taxes of this Annual Report on Form 10-K. The reported tax rates for continuing operations were 34.4 percent and 37.3 percent in 2004 and 2003, respectively.
In the third quarter of 2005, we recorded a valuation allowance of $156 with respect to U.S. deferred tax assets. A valuation allowance against deferred tax assets is required when, based upon the weight of the evidence, we determine that it is more likely than not — a probability level of more than 50 percent — that the assets will not be realized. Likelihood of realization is determined using all available positive and negative evidence such as cumulative losses in prior years, losses expected in early future years, and a history of potential tax benefits expiring unused. In making this assessment, more weight is assigned to objectively verifiable evidence, such as cumulative losses in recent years, than to subjective evidence like future projections. In this case, we anticipate losses in early future periods attributable to the U.S. entities to which the deferred tax assets relate and there are uncertainties surrounding when we will return to U.S. profitability. Specifically, expected losses in our U.S. tax entities resulting from, among other things, costs associated with the MoistureLoc withdrawal and the expected impact of the withdrawal on our 2006 results, led us to conclude that a valuation allowance was necessary. In order to realize our deferred tax assets, it will be necessary for us to significantly increase future U.S. taxable income. This adjustment was recorded as a third quarter event because that is the earliest reporting period for which we have not filed quarterly financial results on Form 10-Q. We will continue to assess realizability of our deferred tax assets, including consideration of the reversal of these and other temporary basis differences, future earnings, and prudent and feasible tax planning strategies. If we make a later determination that it is more likely than not that the deferred tax assets for which there is a valuation allowance would be realized, the related valuation allowance would be reduced and a benefit to earnings would be recorded.
On August 3, 2005, we received approval from the U.S. Joint Committee on Taxation that our income tax refund request for tax years ended 1995 through 1997 was approved, concluding the Internal Revenue Service's examination of such years. In connection with the closure of this examination, we recognized $21 of tax benefits related primarily to favorable resolution of tax positions raised during the examination and the reversal of tax reserves associated with our previously divested oral care business.
In addition, on May 12, 2006, we received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999, for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of partnership interests are held by certain of our subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10, and increasing a long-term capital gain reported by Wilmington for that tax year by $190. The FPAA also proposes a $550 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of our subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership’s partners for the associated tax periods by more than $200, plus penalties and interest. We have not made any financial provision for the asserted additional taxes, penalties or interest as we believe the asserted adjustments are not probable and estimable.
Since 1999, our consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.



PAGE 47

On August 7, 2006, we made a petition in U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006 and we initiated a motion to strike portions of the answer on November 1, 2006. We believe we have numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While we intend to vigorously defend against the asserted adjustments, our failure to succeed in such a defense could significantly increase the liability of the partnership's partners for taxes, plus interest and penalties, which in turn would have a material adverse affect on our financial results and cash flows.

Minority Interest Minority interest expense totaled $6, $5 and $3 in 2005, 2004 and 2003, respectively.


Restructuring Charges and Asset Write-offs

Profitability Improvement Program and Transfer of PureVision Contact Lens Manufacturing In July 2002, we announced plans to improve operating profitability through a comprehensive program which included plant closures and consolidations; manufacturing efficiencies and yield enhancements; procurement process enhancements; the rationalization of certain contact lens and surgical product lines; distribution initiatives; and the development of a global IT platform. These plans included the elimination of approximately 465 jobs worldwide associated with those actions. Restructuring charges and asset write-offs of $23 before taxes associated with these initiatives were recorded in the third quarter of 2002. We also recorded a pre-tax amount of $4 during the third quarter of 2002 for severance associated with the elimination of approximately 145 jobs due to the transfer of PureVision contact lens manufacturing from the United States to Waterford, Ireland following a ruling against us in a U.S. patent law suit. During the fourth quarter of 2003, we reversed $6 in severance charges as certain termination actions and plant closures did not occur due to an increased demand for certain product lines.
At the conclusion of the Profitability Improvement Program and the transfer of PureVision contact lens manufacturing, 468 jobs were eliminated. Related expenses of $17 and $3 of asset write-offs were charged against the liability. Cash payments for severance and other related expenses were $11 and $6 in 2003 and 2002, respectively. All actions related to this restructuring plan were completed by the end of 2003.


Liquidity and Financial Resources

We maintained strong liquidity throughout 2005, ending the year with cash and cash equivalents totaling $721, compared to $502 at the end of 2004. The increase was mainly due to borrowings we made in December as part of our program to repatriate foreign profits under the AJCA and positive cash flows from operations, partially offset by cash used for the Freda acquisition, the retirement of maturing debt and higher capital spending.

Cash Flows from Operating Activities We generated cash of $239 from operating activities in 2005, compared to $285 in 2004. The decrease in 2005 was mainly due to higher inventory levels to accommodate new product launches, increased working capital requirements and higher payments under foreign currency contracts; partially offset by lower net cash payments for income taxes and lower U.S. pension plan funding (funding was $11 and $18 in 2005 and 2004, respectively). Average days sales outstanding (DSO) improved to 71 days in 2005, compared to 74 days in 2004.
Cash provided by operating activities totaled $252 in 2003. The increase in 2004 primarily reflected higher earnings and net cash inflows under foreign currency contracts (versus net cash outflows in 2003), partially offset by an increase of $57 in net cash payments for income taxes and an increase in funding of our U.S. pension plan (funding was $18 and $4 in 2004 and 2003, respectively). Average DSO were 74 days in 2004, a decrease from 77 days in 2003, reflecting our continued focus on asset management, particularly in the area of cash collections.

Cash Flows from Investing Activities In 2005, we used $353 for investing activities. These were primarily $227 associated with the acquisition of a controlling interest in Freda and capital spending of $116, representing continued capacity expansion for PureVision contact lenses as well as initial spending associated with an expansion of our U.S. R&D facility.
Net cash used in investing activities of $122 in 2004 and $94 in 2003 primarily represented capital spending in each of those years.




PAGE 48

Cash Flows from Financing Activities On a net basis, we generated $342 in 2005 through financing activities. Cash inflows were mainly attributable to $677 proceeds from new borrowings and $70 received from employee stock option exercises. The new borrowings mainly reflect $425 borrowings outside the United States as part of our program to repatriate foreign profits under the AJCA and $225 in borrowings under our revolving credit agreement, the majority of which were to partially fund the Freda acquisition. These inflows were partially offset by debt repayments of $326, including repayment of the $225 revolver borrowings described above; $45 to purchase shares of our Common stock under our ongoing share repurchase authorization, stock compensation plans and deferred compensation plans of which $40 was used to purchase 537,537 shares of our Common stock at an average price of $75.06 per share; and dividend payments of $28.
In 2004, net cash outflows for financing activities totaled $229. This amount consisted primarily of debt repayments of $197; $77 to repurchase 1,250,162 shares of our Common stock at an average price of $61.27 per share under our ongoing share repurchase authorization; and $28 of dividend payments, partially offset by proceeds of $78 from employee stock option exercises.
Net cash outflows for financing activities were $84 in 2003, consisting primarily of $201 in debt repayments; $41 to repurchase one million shares of our stock; $31 paid in the first quarter to settle forward equity contracts as described in Item 8. Financial Statements and Supplementary Data under Note 18 — Forward Equity Contracts of this Annual Report on Form 10-K; and $28 for dividends. These cash outflows were partially offset by $210 in proceeds from concurrent offerings of notes and convertible notes.

Sources of Liquidity Our total short- and long-term borrowings totaled $993 at the end of 2005 and $647 at the end of 2004. The ratio of total debt to capital was 43.6 percent and 32.2 percent at year-end 2005 and 2004, respectively.
We believe our existing credit facilities, in conjunction with the financing activities mentioned below, provide adequate liquidity to meet our obligations, fund capital expenditures and invest in potential growth opportunities. However, we note that we have obtained and may need in the future to obtain waivers and/or concessions from lenders under existing credit arrangements, as discussed further below, and we note risk factors associated with contingent obligations of the Company, including as noted under the Legal Matters heading in Recent Developments, in this MD&A.

Credit Facilities In July 2005, we replaced our prior $250 syndicated revolving credit facility scheduled to expire in January 2008 with a new five-year, $400 syndicated revolving credit facility. The terms of the new revolving credit facility include our option to increase the limit to $550 at any time during the five-year term. The interest rate under the agreement is based on our credit rating and, at our option, LIBOR or the base rate of one of the lending banks. The new credit facility includes financial covenants similar in nature to covenants contained in the former, which require us to maintain certain EBITDA to interest and debt ratios. In the event a violation of the financial covenants occurs, the facility would not be available for borrowing until the covenant provisions were waived, amended or satisfied. In November 2005, and subsequently in February, May, August and December 2006, and January 2007, we obtained a waiver from our banks of any breach of representation or covenant under the revolving credit agreement or any default associated with the events related to the Brazil and Korea investigations, or from the impact of such events to the extent that they did not result in reductions in after-tax profits of more than $50 in aggregate. The waivers, in the aggregate, also extended the deadline to file our required financial statements for 2005 (including restatements for certain prior periods) and 2006 year to date until April 30, 2007. Delivery of all required financial statements for 2005 was satisfied by the filing of this Annual Report on Form 10-K and delivery of our Annual Report on Form 10-K for fiscal year ending December 30, 2006 by April 30, 2007 will satisfy our obligation to file all 2006 periodic reports. The impact of the Brazil and Korea investigations did not exceed $50 in aggregate as discussed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K. There were no violations of our financial covenants during the fiscal years ended December 31, 2005 or December 25, 2004 under either our former or our new syndicated revolving credit facilities. We had no outstanding borrowings under syndicated revolving credit agreements as of December 31, 2005 or December 25, 2004.
A number of subsidiary companies outside the United States have credit facilities to meet their liquidity requirements. There were $27 of outstanding borrowings under these non-U.S. credit facilities as of December 31, 2005. There were no outstanding borrowings as of December 25, 2004. The non-U.S. credit facilities' covenants require our subsidiaries to make payments when due and to comply with local laws. There were no covenant violations under the non-U.S. credit facilities during the fiscal years ended December 31, 2005 or December 25, 2004.




PAGE 49

Bank Term Loans In November 2005, our Dutch subsidiary entered into a $375 Term Loan (BV Term Loan). The facility involves a syndicate of banks and is guaranteed by us. The December 2005 borrowing under this BV Term Loan was a component of our efforts to repatriate foreign earnings from non-U.S. legal entities under the provisions of the AJCA (see Item 8. Financial Statements and Supplementary Data under Note 10 — Provision for Income Taxes of this Annual Report on Form 10-K for further discussion of the AJCA). Borrowings under the BV Term Loan totaled $375 at December 31, 2005, and are due in December 2010, unless otherwise extended under the terms of the agreement. The interest rate is based on six-month LIBOR and is reset on a semiannual basis. The BV Term Loan includes covenants which require us to maintain certain EBITDA to interest and debt ratios. The initial interest rate was set at 5.0 percent. In February, May, August and December 2006, and January 2007 we obtained waivers from our banks of any breach of representation or covenant under the term loan agreement or any default associated with the events related to the Brazil and Korea investigations, or from the impact of such events to the extent that they did not result in reductions in after-tax profits of more than $50 in aggregate. The waivers also extended the deadline to file required financial statements for 2005 (including restatements for certain prior periods) and 2006 year to date, with the most recent extension being until April 30, 2007. Delivery of required financial statements for 2005 was satisfied by filing this Annual Report on Form 10-K and delivery of our Annual Report on Form 10-K for fiscal year ending December 30, 2006 by April 30, 2007 will satisfy our obligation to file all 2006 periodic reports. The impact of the Brazil and Korea investigations did not exceed $50 in aggregate as further discussed in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K. There were no violations of our financial covenants under the BV Term Loan during the fiscal year ended December 31, 2005.
In July 2005, we agreed to guarantee, on behalf of our Japan subsidiary, a variable-rate bank term loan facility denominated in Japanese yen, in an amount approximately equivalent to $50. This term loan was also established in connection with the repatriation of foreign earnings under the provisions of the AJCA. The facility will mature in July 2010. The outstanding borrowings under this Japan term loan at December 31, 2005 were approximately $48. The Japan term loan covenants require our Japan subsidiary to submit their statutory financial statements to the lenders once a year and to maintain a positive balance of net assets. There were no covenant violations under the Japan term loan during the fiscal year ended December 31, 2005.

Capital Markets Offerings We are required to file periodic financial reports with the SEC to comply with certain covenants in the indenture that pertain to our public debt instruments. As a result of our inability to file timely this Annual Report on Form 10-K and certain quarterly financial statements for 2005 and 2006, we sought waivers from holders of our outstanding debt. In September 2006, we announced a solicitation of consents with respect to all series of outstanding debt securities and outstanding convertible debt. The solicitations sought, for a fee, permission from the holders for amendments to the indenture applicable to each series of notes that would, among other things, extend to January 31, 2007 our deadline to file periodic reports with the SEC and to deliver compliance certificates to the Trustee under each indenture. We received the requisite number of consents for all series of outstanding debt securities and outstanding convertible debt. We did not file the periodic reports due for the periods prior to January 31, 2007 by that date. As a result, the Trustee or the holders of 10 percent of the principal amount of any series of our outstanding debt could give us a notice of default. If we do not file the reports within 60 days after that notice is given, and the Trustee or the holders of 25 percent of the principal amount of any series of the debt outstanding give a further notice, all principal and accrued interest on that series of debt would be due and payable. Such an acceleration of any series of our debt may be satisfied by our payment of principal and accrued interest on that series, but if not otherwise waived, may trigger defaults under other series of public debt or other indebtedness of the Company. We have announced a consent solicitation seeking consents to additional limited waivers of the reporting obligations from the holders of our public debt to extend until April 30, 2007 the period during which we may become current on our periodic reports without potential default under the indenture.
In May 2006, we announced a tender offer and consent solicitation with respect to $384 of outstanding debt, and a consent solicitation with respect to $160 of outstanding convertible debt. The consents requested in this solicitation were similar to the consents in the solicitation announced in September, except that our deadline to file periodic reports with the SEC and to deliver compliance certificates to the Trustee was October 2, 2006. On June 5, 2006, we announced that $116 of the $384 aggregate principal amount of debt had been tendered, and these obligations were repaid. Furthermore, we received the requisite number of consents necessary to grant the waivers sought at that time. In October 2006, we retired an additional $18 of this outstanding debt.



PAGE 50

In December 2004, we completed an offer to exchange up to $160 of variable-rate convertible senior notes due in 2023 (the Old Notes) for an equal amount of 2004 Senior Convertible Securities due 2023 (New Securities). The terms of the New Securities are largely consistent with those of the Old Notes except that settlement upon conversion of the New Securities will be paid in cash up to the principal amount of the converted New Securities with any excess of the conversion value settled in shares of our Common stock. An amount equal to $156 of the Old Notes was tendered in exchange for an equal amount of the New Securities. On June 17, 2005, the conversion right was triggered giving the holders the option to convert the Old Notes and the New Securities beginning July 1, 2005. In the event a holder elects to convert its note, we expect to fund a cash settlement of any such conversion from borrowings under our syndicated revolving credit agreement.
Two tranches of our long-term debt due in 2013 and 2015 allowed remarketing agents to call the debt from the holders in 2003 and 2005, respectively, and in certain cases remarket the debt at a higher interest rate than the then-current market rate. Following a downgrade of our debt rating by Moody's Investors Service in March 2002, the agents exercised their right to put the remarketing agreements back to us. As a result of this action, a $100 tranche of long-term debt, originally due in 2013, matured and was repaid in 2003, and an additional $100 tranche of long-term debt, originally due in 2015, matured and was repaid in 2005.

Access to Financial Markets As of December 31, 2005, our long-term debt was rated BBB by Standard & Poor's and Fitch Ratings, and Baa3 by Moody's Investors Service, and all three rating agencies described our outlook as stable.
Subsequently, on March 23, 2006, Moody’s Investors Service placed our credit rating on review for possible downgrade. This action was prompted by our failure to file timely financial statements with the SEC and by concerns related to the Audit Committee investigations into allegations in Brazil and Korea. Moody’s expanded this ongoing review on April 12, 2006 to include our decision to suspend sales of MoistureLoc solution from our U.S. plant. On December 22, 2006, Moody's affirmed that our credit rating continued to be on review. On February 2, 2007, Moody's lowered our credit rating to Ba1 from Baa3 primarily reflecting Moody's belief that revenue growth for 2007 will be lower than their previous expectations.
On April 11, 2006, Standard & Poor’s affirmed its BBB rating on our debt, but revised its rating outlook to negative from stable, reflecting our decision to suspend shipments of MoistureLoc from our U.S. plant.
On April 12, 2006, Fitch Ratings placed our long-term debt ratings on watch negative, following our decision to suspend shipments of MoistureLoc from our U.S. plant and our announcement of a further delay in the filing of our 2005 Annual Report on Form 10-K. On May 12, 2006, Fitch Ratings lowered our credit rating to BBB- from BBB and it remains on watch negative.
Until current periodic reports and financial statements are filed, we will be precluded from registering our securities with the SEC for offer and sale. This precludes us from raising debt or equity financing in the public markets.

Working Capital Working capital was $618 and $528, respectively, at year-end 2005 and 2004. The current ratio was 1.6 for both periods.

Dividends Dividends on Common stock, declared and payable quarterly, totaled $0.52 per share for the years ended 2005, 2004 and 2003. Total cash dividends of $28 were paid in each year.

Return on Equity and Capital Return on average shareholders' equity was 1.4 percent in 2005, compared to 12.6 percent in 2004 and 10.5 percent in 2003. Return on invested capital was 3.5 percent in 2005, 9.9 percent in 2004, and 8.6 percent in 2003. The decline in ratios in 2005 reflects lower net income resulting from the valuation allowance recorded on deferred income tax assets and the costs associated with the MoistureLoc recall.




PAGE 51

Contractual Cash Obligations At December 31, 2005, we had the following contractual cash obligations due by the following periods:
   
 
 
Total
 
Less than 1 Year
 
 
 
1-3 years
 
 
 
3-5 years
 
More than 5 years
 
Contractual Obligations 1
                     
Short- and long-term debt
 
$
992
 
$
161
 
$
184
 
$
423
 
$
224
 
Purchase obligations 2
   
82
   
49
   
18
   
5
   
10
 
Minimum operating lease commitments
   
76
   
23
   
28
   
15
   
10
 
Total
 
$
1,150
 
$
233
 
$
230
 
$
443
 
$
244
 

1
We had no capital lease obligations at December 31, 2005. Other long-term liabilities reflected on our Balance Sheets consisted primarily of obligations associated with employee benefit plans. (See Critical Accounting Policies for a discussion of our estimated future statutory minimum funding requirements.)
2
Purchase obligations include minimum obligation to purchase goods and services, or to make royalty payments, under agreements that are enforceable and legally binding on us. The amounts above include payments due under a utility contract that can be terminated in the tenth year with the payment of $1. If we choose to terminate the utility contract, the total payments due would decrease by $9.


Off-Balance Sheet Arrangements

We have a minority equity interest valued at $0 on the balance sheet that results from a strategic partnering arrangement entered into during 1999 involving implant technology for treating retinal and other back-of-the-eye diseases. Under the original agreement, we remitted payments to the strategic partner for R&D activities and the achievement of certain milestones such as completion of clinical testing, NDA filings and FDA approvals. As described in Item 8. Financial Statements and Supplementary Data under Note 9 — Related Party Transaction of this Annual Report on Form 10-K, a delay of up to three years in U.S. regulatory filings for the Retisert drug delivery product for the diabetic macular edema indication was announced in May 2003. As a result, we reevaluated our role in the ongoing development and approval process, and decided to conduct and supervise directly the day-to-day development and clinical activities. During the fourth quarter of 2003, we negotiated our arrangement to formalize this change.
We also have an equity investment of $0.2 as of December 31, 2005 and December 25, 2004 recorded as an other long-term asset, associated with a licensing agreement signed during 2002 to develop treatments for ocular infections. During the quarter ended June 28, 2003, we recorded an other-than-temporary impairment charge of $2 based on negative earnings and cash flow trends of the licensor, and inconclusive efforts by the licensor to secure interim financing. The licensing agreement and $4 of preferred stock were canceled in December 2003 in conjunction with our decision to invest in and internally develop this ocular infection technology, which is in late-stage clinical development. As such, we are no longer required to remit payments to the licensor originally due upon the achievement of certain milestones. As a result of our restatement of financial results, as further discussed in Item 8. Financial Statements and Supplementary Data under Note 1 —Significant Accounting Policies of this Annual Report on Form 10-K the $2 impairment charge was determined to be out-of-period as the equity investment was first impaired as of 2001. At that time, we believed the decline in market value was temporary. As the investment did not recover, our restated financial statements reflect a $1 impairment charge in 2001 to adjust the equity investment to its market value at that time; and a $1 impairment charge in 2002 to recognize a further decline in market value, as well as a reversal of the $2 impairment charge originally recorded in June 2003.
As a result of the renegotiation and license cancellation described above, future payments for R&D activities and milestone achievements over the next five years are estimated to be immaterial.
We have obligations under certain guarantees, letters of credit, indemnifications (including indemnification obligations with respect to the MoistureLoc matters and for directors, officers and employees with respect to other matters) and other contracts that contingently require us to make payments to guaranteed parties upon the occurrence of specified events. We believe the likelihood is remote that material payments will be required under these contingencies, and that they do not pose potential risk to our future liquidity, capital resources and results of operations. See Item 8. Financial Statements and Supplementary Data under Note 17 — Commitments and Contingencies of this Annual Report on Form 10-K for further descriptions and discussions regarding our obligations.





PAGE 52

Market Risk

As a result of our global operating and financing activities, we are exposed to changes in interest rates and foreign currency exchange rates that may adversely affect our results of operations and financial position. In seeking to minimize the risks and/or costs associated with such activities, we manage exposure to changes in interest rates and foreign currency exchange rates primarily through the use of derivatives. We do not use financial instruments for trading or other speculative purposes, nor do we use leveraged financial instruments.
We primarily use foreign exchange forward contracts to hedge foreign currency transactions and equity investments in non-U.S. subsidiaries. For contracts outstanding at the end of 2005 and 2004, foreign currencies purchased were primarily euros, British pounds, Hong Kong dollars and Swiss francs. Foreign currencies sold in 2005 were primarily euros, Hong Kong dollars, Japanese yen, Korean won and British pounds. In 2004, foreign currencies sold were primarily euros, British pounds, Japanese yen, Hong Kong dollars, Korean won and Swiss francs. The magnitude and nature of our hedging activities are explained further in Item 8. Financial Statements and Supplementary Data under Note 13 — Financial Instruments of this Annual Report on Form 10-K. A sensitivity analysis to measure the potential impact that a change in foreign currency exchange rates would have on our net income indicates that, if the U.S. dollar strengthened against all foreign currencies by 10 percent, we would realize a loss of approximately $23 on foreign exchange forward contracts outstanding at year-end 2005. Similar analysis conducted at the end of 2004 indicated that, had the U.S. dollar then strengthened against all foreign currencies by 10 percent, we would have realized a loss of approximately $6 on foreign exchange forward contracts outstanding at year-end 2004. Such losses would be substantially offset by gains from the revaluation or settlement of the underlying positions hedged.
We may enter into interest rate swap, interest rate lock and cap agreements to effectively limit exposure to interest rate movements within the parameters of our interest rate hedging policy. For foreign currency-denominated borrowing and investing transactions, cross-currency interest rate swap contracts may be used, which, in addition to exchanging cash flows derived from interest rates, exchange currencies at both inception and termination of the contract. There were no cross-currency interest rate swap contracts outstanding at December 31, 2005 or December 25, 2004. A sensitivity analysis to measure the potential impact that a change in interest rates would have on our net income indicates that a one-percentage point decrease in interest rates, which represents a greater than 10 percent change, would increase our net financial expense by approximately $1 and $3 based on 2005 and 2004 year-end positions, respectively.
Counterparties to the financial instruments discussed above expose us to credit risks to the extent of non-performance. The credit ratings of the counterparties, which consist of a diversified group of high quality investment or commercial banks, are regularly monitored and thus credit loss arising from counterparty non-performance is not anticipated. In addition, there can be no assurances that the arrangements described above will protect the Company against or limit its exposure to all market risks.


Critical Accounting Policies

The accompanying consolidated financial statements and notes to consolidated financial statements contain information that is pertinent to this MD&A. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates and assumptions.
The Company believes that the critical accounting policies discussed below involve additional management judgment due to the sensitivity of the methods, assumptions and estimates necessary in determining the related asset, liability, revenue and expense amounts. The impact of and any risks related to these policies on its business operations are discussed below. Senior management has discussed the development and selection of the critical accounting estimates and the related disclosure included herein with the Audit Committee of the Company's Board of Directors.




PAGE 53

Revenue Recognition The Company recognizes revenue when it is realized or realizable and earned and when substantially all the risks and rewards of ownership have transferred to the customer. The Company believes its revenue recognition policies are appropriate, and that its policies are reflective of complexities arising from customer arrangements. In certain transactions with distributors and wholesalers, substantially all the risks and rewards of ownership do not transfer upon delivery and, accordingly, such shipments are accounted for as consignment sales. For the sale of multiple-element arrangements whereby equipment is combined with services, including maintenance and other elements, such as supplies, the Company allocates to and recognizes revenue from the various elements based on verifiable objective evidence of fair value. Revisions to these determinants of fair value would affect the timing of revenue allocated to the various elements in the arrangement and would impact the results of operations of the Company.
The Company records estimated reductions to revenue for customer incentive programs offered including cash discounts, promotional and advertising allowances, volume discounts, contractual pricing allowances, rebates and specifically established customer product return programs. If market conditions were to change, the Company may take actions to expand these customer offerings, which may result in incremental reductions to revenue. Also, under certain conditions, the Company may offer other customer programs that do not impact revenue such as extended credit terms.
The Company's fiscal quarter consists of 13 weeks, whereby the first and second months of each quarter contain four weeks of results and the third month of each quarter contains five weeks of results. Accordingly, net sales are typically higher in the third month of any given quarter. In addition, the execution of a broad portfolio of customer incentive programs, particularly volume discounts, certain customer rebates and extended credit terms have been higher at the end of each quarter. As a result, net sales for the third month of each quarter in 2005 and 2004 were higher than average net sales for the third month of a quarter if aligned with the fiscal quarter described above. While this trend was consistent among all regions and all product categories, net sales of lens care products and pharmaceuticals in the United States (which are marketed primarily to health product retailers, mass merchandisers, wholesalers and distributors) and net sales of contact lenses and lens care products in Japan (which are marketed primarily to distributors), were the main drivers.
The Company closely monitors and evaluates customer incentives and other customer programs, such as extended credit terms. Should the Company determine that certain customer programs result in excessive levels of inventory in certain channels of trade (such as retailers, mass merchandisers, wholesalers and distributors) or the risks and rewards have not transferred to the customer, net sales in conjunction with the associated programs would be accounted for as consignment sales. As explained in Item 8. Financial Statements and Supplementary Data under Note 2 — Restatement of this Annual Report on Form 10-K, vision care sales in BL Korea from 2002 through 2005; certain vision care transactions with a single distributor in Thailand; vision care transactions with two large distributors in Japan; and vision care and cataract transactions with the distributor network in India are accounted for as consignment sales. See Item 8. Financial Statements and Supplementary Data under Note 1 — Significant Accounting Policies of this Annual Report on Form 10-K for a further discussion of the Company's revenue recognition policy. Reductions to revenues for customer incentive programs, as restated, represented approximately 12 percent, 10 percent and 9 percent of gross customer sales in 2005, 2004 and 2003, respectively.

Provisions for Uncollectible Trade Receivables The Company maintains provisions for uncollectible accounts for estimated losses resulting from the inability of its customers to remit payments. If the financial condition of customers were to deteriorate, thereby resulting in an inability to make payments, additional allowances could be required. The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon customer payment history and current creditworthiness, as determined by the Company's review of customers' current credit information. The Company continuously monitors collections and payments from customers and maintains a provision for estimated credit losses based upon its historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the Company's expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past. Measurement of such losses requires consideration of historical loss experience, including the need to adjust for current conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and financial health of specific customers. The change in the provision for doubtful accounts increased 2005 operating income by $1. In 2004 and 2003, the change in the provision for doubtful accounts decreased operating income by $4 and $3, respectively.
The Company considers all available information in its quarterly assessments of the adequacy of the reserves for uncollectible accounts. If the provision for uncollectible trade receivables were to change by one-percentage point of the Company's gross trade receivables, operating income is estimated to increase or decrease by less than $6.

PAGE 54

Inventory Allowances The Company provides estimated inventory allowances for excess, slow moving and obsolete inventory as well as inventory whose carrying value is in excess of net realizable value. These reserves are based on current assessments about future demands, market conditions and related management initiatives. If market conditions and actual demands are less favorable than those projected by management, additional inventory write-downs may be required. The Company values its inventory at the lower of cost or net realizable market values. The Company regularly reviews inventory quantities on hand and records a provision for excess and obsolete inventory based primarily on estimated forecasts of product demand and production requirements for the next twelve months. Several factors may influence the realizability of its inventories, including decisions to exit a product line, technological change and new product development. These factors could result in an increase in the amount of obsolete inventory quantities on hand. Additionally, estimates of future product demand may prove to be inaccurate, in which case the provision required for excess and obsolete inventory may be understated or overstated. If in the future, the Company determined that its inventory was overvalued, it would be required to recognize such costs in cost of products sold at the time of such determination. Likewise, if the Company determined that its inventory was undervalued, cost of products sold in previous periods could have been overstated and the Company would be required to recognize such additional operating income at the time of sale. While such inventory losses have historically been within the Company's expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same loss rates that it has in the past. Therefore, although the Company makes every effort to ensure the accuracy of forecasts of future product demand, including the impact of planned future product launches, any significant unanticipated changes in demand or technological developments could have a significant impact on the value of its inventory and its reported operating results. The Company recorded $25, $18 and $11 in provisions to the Statements of Income for excess, slow moving and obsolete inventory in 2005, 2004, and 2003, respectively. At this time, management does not believe that anticipated product launches would have a material adverse effect on the recovery of the Company's existing net inventory balances. If the inventory allowance were to change by one-percentage point of the Company's gross inventory, operating income is estimated to increase or decrease by less than $3.

Fair Value of Assets The Company assesses the carrying value of its identifiable intangible assets, long-lived assets and goodwill whenever events or changes in circumstances indicate that the carrying amount of the underlying asset may not be recoverable, or at least annually in the case of goodwill. Certain factors which may occur and indicate that an impairment exists include, but are not limited to: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of the Company's use of the underlying assets; and significant adverse industry or market economic trends. In the event that the carrying value of assets is determined to be unrecoverable, the Company would estimate the fair value of the assets or reporting unit and record an impairment charge for the excess of the carrying value over the fair value. The estimate of fair value requires management to make a number of assumptions and projections, which could include, but would not be limited to, future revenues, earnings and the probability of certain outcomes and scenarios. The Company's policy is consistent with the current accounting guidance as prescribed by SFAS No. 142, Goodwill and Intangible Assets and SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. See Item 8. Financial Statements and Supplementary Data under Note 1 — Significant Accounting Policies of this Annual Report on Form 10-K for a further discussion of SFAS No. 142 and SFAS No. 144. The Company also assesses the fair value of identifiable intangible assets, long-lived assets, goodwill and purchased in-process research and development at the inception of an acquisition.
On May 15, 2006, the Company announced a worldwide voluntary recall of MoistureLoc lens care solution. As explained in Item 8. Financial Statements and Supplementary Data under Note 23 — Subsequent Event of this Annual Report on Form 10-K, the Company determined that this event would more likely than not reduce the fair value of a reporting unit. The Company revised the fair values of each of the reporting units to reflect the anticipated impact of the MoistureLoc recall and concluded that the probability of the voluntary recall reducing the fair value of any reporting unit below its carrying amount was remote. In addition, the Company performed a separate analysis as it relates to its recent acquisition of Freda and determined that the fair value of Freda exceeded its carrying value.




PAGE 55

Restructuring Actions The Company had no open restructuring programs as of December 31, 2005. Prior to 2003, the Company had engaged in several significant restructuring actions, which required the development of formalized plans as they relate to exit activities based on guidance provided by Emerging Issues Task Force (EITF) Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring). These plans required the Company to utilize estimates related to severance and other employee separation costs, lease cancellations and other exit costs. Given the significance and the timing of the execution of such actions, this process was complex and involved periodic reassessments of estimates calculated at the time the original decisions were made. The Company's policies for future restructuring actions, based on guidance provided by SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, which replaced EITF Issue No. 94-3, require recognition of costs associated with exit or disposal activities when they are incurred rather than at the date of a commitment to an exit or disposal plan. Therefore, if employees are not required to render service until they are terminated in order to receive the termination benefits, a liability for the termination benefits would be recognized and measured at its fair value at the communication date. Conversely, if employees are required to render service until they are terminated in order to receive the termination benefits, a liability for the termination benefits would be measured initially at the communication date based on the fair value of the liability as of the termination date. The Company would recognize the liability ratably over the future service period.

Deferred Tax Assets and Reserves The Company evaluates the recoverability of its deferred tax assets on an ongoing basis. This evaluation includes assessing the available positive and negative evidence to determine whether, based on its judgment, the Company believes the assets, or some portion thereof, are more likely than not to be realized. To the extent the Company does not believe the assets will more likely than not be realized, a valuation allowance is recorded. In determining whether, and to what extent, a valuation allowance is required, the Company considers whether it will have sufficient taxable income in the appropriate period and jurisdiction that is also of the appropriate character. Potential sources of taxable income that are evaluated include: (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary differences; (iii) taxable income in prior carryback years; and (iv) tax planning strategies that would be implemented, if necessary. Should the Company determine that it is more likely than not it will realize its deferred tax assets in the future, an adjustment would be required to reduce the existing valuation allowance. Generally, this would result in a corresponding increase to income. Conversely, if the Company determined that it would not be able to realize its deferred tax assets, an adjustment would be required to increase the valuation allowance. Generally, this would result in a decrease to income. Additional tax expense or (benefit) related to changes in the valuation allowance were $121, $21 and $(2) in 2005, 2004 and 2003, respectively.
In the normal course of business, the Company is regularly audited by federal, state and foreign tax authorities, and is periodically challenged regarding the amount of taxes due. These challenges include, among other issues, questions regarding the timing and amount of deductions and the allocation of income among various taxing jurisdictions. The Company believes its tax positions comply with applicable tax law and, if challenged, intends to vigorously defend such positions. As the likelihood of successfully defending many of these positions is uncertain, the Company evaluates these positions and records tax reserves when the likelihood of ultimately sustaining a loss is probable, and the amount of such loss is reasonably estimable. The Company's effective tax rate in a given financial statement period could be materially impacted if the Company prevailed in matters for which reserves have been established, or was required to pay amounts in excess of established reserves.




PAGE 56

Employee Benefits The Company's benefit plans include defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits the employees earn while working, as well as the present value of those benefits. Inherent in these valuations are economic assumptions including expected returns on plan assets, discount rates at which liabilities could be settled, rates of increase of health care costs, rates of future compensation increases as well as employee demographic assumptions such as retirement patterns, mortality and turnover. The actuarial assumptions used may differ materially from actual results due to changing market and economic conditions, higher or lower turnover rates or longer or shorter life spans of participants. Actual results that differ from the actuarial assumptions used are recorded as unrecognized gains and losses. The total unrecognized actuarial losses for the Company defined benefit pension plans and defined benefit postretirement plan as of December 31, 2005 were $112 and $22, respectively. Total unrecognized actuarial losses increased $23 for the defined benefit pension plans and $21 for the defined benefit postretirement plan, primarily due to reductions in the discount rate used to determine benefit obligations and an increase in the assumed life expectancy of plan participants. Unrecognized gains and losses that exceed 10 percent of the greater of the plan’s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated future service period of the plan participants or the period until any anticipated final plan settlements. The Company reviews the assumptions annually and makes any necessary changes. The following is a discussion of the most significant estimates and assumptions used in connection with the Company's U.S. employee benefit plans. See Item 8. Financial Statements and Supplementary Data under Note 14 — Employee Benefits of this Annual Report on Form 10-K for additional information on the Company’s benefit plans.
The expected return on plan assets for the Company's U.S. defined benefit pension plan for 2005 was 8.75 percent and for the defined benefit postretirement plan was 7.75 percent. The fair value of plan assets in the Company's U.S. pension and postretirement benefit plans comprise approximately 74 percent of the fair value of all Company defined benefit plan assets. The expected return reflects the average rate of earnings expected on the funds invested to provide for the benefits included in the benefit obligations. The expected return was developed using forward-looking return assumptions for equity and fixed income asset classes taking into consideration the plan’s mix of actively and passively managed investments. The expected return developed in 2005 was 25 basis points lower than the expected return of 9 percent developed in 2004. The expected return for the postretirement benefit plan is based on the expected return for the U.S. pension plan, reduced by one percent to reflect an estimate of additional administrative costs. A one-percentage point change in the expected return on plan assets would result in an increase or decrease in employee benefit costs of approximately $2.
The discount rate reflects the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants. The discount rate used for the U.S. pension and postretirement benefit plans decreased to 5.5 percent in 2005 from 5.75 percent in 2004 due to changes in market interest rate conditions. The discount rate for the U.S. plans, which comprise approximately 70 percent of the Company’s benefit plan obligations, is based on the Moody’s Aa Corporate Bond Index. The reasonableness of the discount rate was verified through the use of a cash flow model that calculated a discount rate by matching the estimated plan cash flows to the average of pension yield curves constructed of a large population of high quality non-callable corporate bonds. If the discount rate were to decrease by one percent for the U.S. pension and postretirement plans, the plan liabilities would increase by approximately $33 and the expense would increase by approximately $2.
The most important estimate associated with the Company's postretirement plan is the assumed health care cost trend rate. A one-percentage point change in this estimate would increase or decrease the benefit obligation by approximately $9 and the expense would increase or decrease by approximately $1.
Based on the Company's U.S. defined benefit pension plan's current assets and liabilities and using the current statutory minimum funding requirements and interest rates, including the provisions of the Pension Protection Act of 2006, no employer contributions to the pension fund would be required until the years 2009 and 2010 when contributions of approximately $3, and $11 would be required, respectively. Any changes to the assumptions described above or statutory changes including the current IRS methodology would have a significant impact on this estimate.




PAGE 57

Derivative Financial Instruments and Hedging Activity The Company, as a result of its global operating and financing activities, is exposed to changes in interest rates and foreign currency exchange rates that may adversely affect its results of operations and financial position. In seeking to minimize the risks and/or costs associated with such activities, the Company manages exposure to changes in interest rates and foreign currency exchange rates primarily through its use of derivatives. The Company enters into financial derivative instruments only for the purpose of minimizing those risks and thereby reducing volatility in income. Derivative instruments utilized as part of the Company's risk management strategy may include interest rate swaps, locks and caps, and foreign exchange forward contracts and options. All derivatives are recognized on the balance sheet at fair value. The Company establishes the fair value of its derivatives using quoted market prices, which is the preferred method of establishing fair value as prescribed by SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities. The Company uses the quoted market price of an instrument with similar characteristics if none exists for its derivative. Additionally, the Company may also use prescribed valuation techniques such as discounted future cash flows, option pricing models or matrix pricing models to establish fair value in the event quoted market prices of the derivative or of an instrument with similar characteristics are not available. The fair value (also the carrying value) of foreign exchange instruments and interest rate instruments were each a net payable of $2 as of December 31, 2005 and a net receivable of $2 and a net payable of less than $1, respectively, at December 25, 2004. The Company does not employ leveraged derivative instruments, nor does it enter into derivative instruments for trading or speculative purposes. In using derivative instruments, the Company is exposed to credit risk. The Company's derivative instrument counterparties are high quality investment or commercial banks with significant experience with such instruments. The Company manages exposure to counterparty risk by requiring specific minimum credit standards, diversification of counterparties, and by regularly monitoring credit ratings of its counterparties.


Other Matters

Environment The Company believes it is in compliance in all material respects with applicable environmental laws and regulations. The Company is presently involved in remedial and investigatory activities at certain locations in which the Company has been named a responsible party. At all such locations, the Company believes such efforts will not have a material adverse effect on its results of operations or financial position.

New Accounting Guidance In December 2004, the Financial Accounting Standards Board (FASB) issued its standard on accounting for share-based payments, SFAS No. 123 (revised 2004), Share-Based Payment (SFAS No. 123R) which replaced FASB Statement No. 123, Accounting for Stock-Based Compensation, and supercedes APB Opinion No. 25, Accounting for Stock Issued to Employees. SFAS No. 123R requires companies to recognize compensation cost relating to share-based payment transactions, including grants of employee stock options, in the financial statements based on the grant date fair value. The pro forma disclosures previously permitted under SFAS No. 123 will no longer be an alternative to financial statement recognition. SFAS No. 123R is effective for fiscal periods beginning after June 15, 2005. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 (SAB 107) regarding the SEC’s interpretations of SFAS No. 123R and the valuation of share-based payments for public companies. SFAS No. 123R covers a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. The Company adopted SFAS No. 123R in the first quarter of 2006 using the modified prospective application method. Under this method, the Company will apply SFAS No. 123R for new awards granted after the adoption of SFAS No. 123R and any unvested portion of awards that were granted prior to the adoption of SFAS No. 123R. The Company will apply the Black-Scholes model to estimate the fair value of share-based payments to employees, which will then be amortized on a ratable basis over the requisite service period. The Company estimates the impact of new stock-based compensation programs and the adoption of SFAS No. 123R requiring the expensing of stock options will be approximately $13 before taxes in 2006. This compares to a previous estimate of approximately $23 before taxes. The revised estimate reflects the postponement of the 2006 annual stock option grant due to the delay in the Company’s filing of this Annual Report on Form 10-K. The Company’s annual grant typically occurs during the first quarter of each fiscal year. The current estimate is also based on assumptions regarding a number of subjective variables, which include estimating the expected term of stock options and the current volatility of the Company’s stock price.



PAGE 58

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, a replacement of APB Opinion No. 20 and FASB Statement No. 3. SFAS No. 154 requires retrospective application to prior period financial statements for changes in accounting principles, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 also requires that retrospective application of a change in accounting principle be limited to the direct effects of the change. Indirect effects of a change in accounting principle should be recognized in the period of the accounting change. SFAS No. 154 further requires a change in depreciation, amortization or depletion method for long-lived, non-financial assets to be accounted for as a change in accounting estimate effected by a change in accounting principle. SFAS No. 154 will become effective for the Company's fiscal year beginning January 1, 2006.
In June 2005, the FASB issued FASB Staff Position No. FAS 143-1 (FSP FAS 143-1), Accounting for Electronic Equipment Waste Obligations. FSP FAS 143-1 addresses the accounting for obligations associated with the Directive 2002/96/EC on Waste Electrical and Electronic Equipment (the Directive) adopted by the European Union (EU). FSP FAS 143-1 is effective the later of the first reporting period that ends after June 8, 2005 or the date that the EU-member country adopts the law. The obligation arising from the adoption by all EU-member countries in which the Company conducts business did not have a material effect on the Company's financial condition or results of operations.
In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109 (FIN 48). FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company is in the process of evaluating the impact FIN 48 will have on its results of operations and financial position.
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. Specifically, this Statement sets forth a definition of fair value, and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The provisions of SFAS No. 157 are generally required to be applied on a prospective basis, except to certain financial instruments accounted for under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, for which the provisions of SFAS No. 157 should be applied retrospectively. The Company will adopt SFAS No. 157 in the first quarter of 2008 and is still evaluating the effect, if any, on its financial position or results of operations.
In September 2006, the FASB issued SFAS No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106 and 132(R). SFAS No. 158 requires an employer to recognize the funded status of its defined benefit pension and postretirement plans as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. In addition, SFAS No. 158 requires an employer to measure the funded status of a plan as of the date of the employer’s fiscal year-end statement of financial position, which is consistent with the measurement date for the Company’s defined benefit plans. SFAS No. 158 made no changes to the recognition of expense. SFAS No. 158 will be effective as of the fiscal year ending December 30, 2006. The Company has not yet completed its evaluation of the tax effect of adoption of SFAS No. 158. Based on the year-end measurement of plan assets and liabilities, the impact of adopting the provisions of SFAS No. 158, before any tax effect, is expected to be an increase in total liabilities of approximately $12.3, a decrease in total assets of approximately $0.4 and a decrease in accumulated other comprehensive income of approximately $12.7. The decrease in accumulated other comprehensive income will be reported in total shareholders’ equity, net of any tax benefits (including the impact of any valuation allowance deemed appropriate), with the tax benefits reported in deferred tax assets. The adoption of SFAS No. 158 has no impact on financial covenant compliance included in the Company’s debt agreements.
In September 2006, the SEC staff issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). SAB 108 was issued in order to eliminate the diversity in practice surrounding how public companies quantify financial statement misstatements. SAB 108 requires that registrants quantify errors using both a balance sheet and income statement approach and evaluate whether either approach results in a misstated amount that, when all relevant quantitative and qualitative factors are considered, is material. The adoption of this statement is not expected to have a material impact on the Company's consolidated financial condition or results of operations.





PAGE 59

Information Concerning Forward-Looking Statements Forward-looking statements include statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements which are other than statements of historical facts. When used in this discussion, the words “anticipate”, “appears”, “foresee”, “should”, “expect”, “estimate”, “project”, “will”, “are likely” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this report are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve predictions of future Company performance, and are thus dependent on a number of factors including, without limitation, assumptions and data that may be imprecise or incorrect. Specific factors that may impact performance or other predictions of future actions and in many cases those with a material impact, have, in many but not all cases, been identified in connection with specific forward-looking statements. Forward-looking statements are subject to risks and uncertainties including, without limitation: the inability of the Company to achieve the various marketing and selling objectives described above or to achieve the stabilization of expenses described above; the inability to successfully return the Company’s lens care products to certain markets; changes in the competitive landscape; the inability to recoup lost market share; general global and local economic, political and sociological conditions including, without limitation, periods of localized disease outbreak and the effect on economic, commercial, social and political systems caused by natural disasters (such as, without limitation, earthquakes, hurricanes/typhoons, tornadoes and tsunamis); changes in such conditions; the impact of competition, seasonality and general economic conditions in the global lens and lens care, ophthalmic cataract and refractive and pharmaceutical markets where the Company’s businesses compete; effects of war or terrorism; changing currency exchange rates; the general political climate existing between and within countries throughout the world; events affecting the ability of the Company to timely deliver its products to customers, including those which affect the Company’s carriers’ ability to perform delivery services; changing trends in practitioner and consumer preferences and tastes; changes in technology; medical developments relating to the use of the Company’s products; competitive conditions, including entries into lines of business of the Company by new or existing competitors, some of whom may possess resources equal to or greater than those of the Company; the impact of product performance or failure on other products and business lines of the Company; success of the Company's compliance initiatives to detect and prevent violations of law or regulations; the results of pending or future investigations by the Company of alleged failure of the Company to comply with applicable laws or regulations; legal proceedings initiated by or against the Company, including those related to securities and corporate governance matters, products and product liability, commercial transactions, patents and other intellectual property, whether in the United States or elsewhere throughout the world; the impact of Company performance on its financing costs; enactment of new legislation or regulations or changes in application or interpretation of existing legislation or regulations that affect the Company; changes in government regulation of the Company’s products and operations; changes in governmental laws and regulations relating to the import and export of products; government pricing changes and initiatives with respect to healthcare products in the United States and throughout the world; changes in private and regulatory schemes providing for the reimbursement of patient medical expenses; changes in the Company’s credit ratings or the cost of access to sources of liquidity; the Company’s ability to maintain positive relationships with third-party financing resources; the financial well-being and commercial success of key customers, development partners and suppliers; changes in the availability of and other aspects surrounding the supply of raw materials used in the manufacture of the Company’s products; changes in tax rates or policies or in rates of inflation; the uncertainty surrounding the future realization of deferred tax assets; changes in accounting principles and the application of such principles to the Company; the performance by third parties upon whom the Company relies for the provision of goods or services; the ability of the Company to successfully execute marketing strategies; the ability of the Company to secure and maintain intellectual property protections, including patent rights, with respect to key technologies in the United States and throughout the world; the ability of the Company to secure and maintain copyright protections relative to its customer-valued names, trademarks, trade names and other designations in the United States and throughout the world; investment in research and development; difficulties or delays in the development, laboratory and clinical testing, regulatory approval, manufacturing, release or marketing of products; the successful completion and integration of acquisitions by the Company; the successful relocation of certain manufacturing processes; the Company’s implementation of changes in internal controls; the Company’s success in the process of management testing, including the evaluation of results, and auditor attestation of internal controls, as required under the Sarbanes-Oxley Act of 2002; the occurrence of a material weakness in the Company’s internal controls over financial reporting, which could result in a material misstatement of the Company’s financial statements; the Company’s ability to correct any such weakness; the Company’s success in introducing and implementing its enterprise-wide information technology initiatives, including the corresponding impact on internal controls and reporting; the effect of changes within the Company’s organization, including the selection and development of the Company’s management team and such other factors as are described in greater detail in the Company’s filings with the Securities and Exchange Commission, including, without limitation, Item I-A. Risk Factors of this 2005 Annual Report on Form 10-K.



PAGE 60

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

The section entitled Market Risk as set forth in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report on Form 10-K is incorporated herein by reference.


Item 8. Financial Statements and Supplementary Data

Statements of Income

For the Years Ended
December 31, 2005, December 25, 2004 and December 27, 2003
Dollar Amounts in Millions - Except Per Share Data
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
Net Sales
 
$
2,353.8
 
$
2,233.5
 
$
2,018.5
 
                     
Costs and Expenses
                   
Cost of products sold
   
983.1
   
929.2
   
856.8
 
Selling, administrative and general
   
909.7
   
862.7
   
789.9
 
Research and development
   
177.5
   
162.5
   
149.9
 
Reversal of restructuring charges
   
-
   
-
   
(6.3
)
     
2,070.3
   
1,954.4
   
1,790.3
 
Operating Income
   
283.5
   
279.1
   
228.2
 
                     
Other (Income) Expense
                   
Interest and investment income
   
(20.1
)
 
(13.8
)
 
(15.7
)
Interest expense
   
52.8
   
49.6
   
55.2
 
Foreign currency, net
   
4.4
   
0.6
   
13.4
 
     
37.1
   
36.4
   
52.9
 
Income before Income Taxes and Minority Interest
   
246.4
   
242.7
   
175.3
 
Provision for income taxes
   
221.4
   
83.8
   
65.3
 
Minority interest in subsidiaries
   
5.8
   
5.0
   
3.1
 
Income before Cumulative Effect of Change in Accounting Principle
   
19.2
   
153.9
   
106.9
 
                     
Cumulative Effect of Change in Accounting Principle, Net of Taxes
   
-
   
-
   
(0.9
)
Net Income
 
$
19.2
 
$
153.9
 
$
106.0
 
                     
Basic Earnings (Loss) Per Share:
                   
Before Cumulative Effect of Change in Accounting Principle
 
$
0.36
 
$
2.94
 
$
2.04
 
Cumulative Effect of Change in Accounting Principle
   
-
   
-
   
(0.02
)
   
$
0.36
 
$
2.94
 
$
2.02
 
Average Shares Outstanding - Basic (000s)
   
53,146
   
52,433
   
52,426
 
                     
Diluted Earnings (Loss) Per Share:
                   
Before Cumulative Effect of Change in Accounting Principle
 
$
0.35
 
$
2.83
 
$
2.00
 
Cumulative Effect of Change in Accounting Principle
   
-
   
-
   
(0.02
)
   
$
0.35
 
$
2.83
 
$
1.98
 
Average Shares Outstanding - Diluted (000s)
   
55,684
   
54,504
   
53,519
 

See Notes to Financial Statements





PAGE 61

Balance Sheets

December 31, 2005 and December 25, 2004
Dollar Amounts in Millions - Except Per Share Data
 
2005
 
2004
(Restated)
 
Assets
         
Cash and cash equivalents
 
$
720.6
 
$
501.8
 
Trade receivables, less allowances of $16.2 and $22.1, respectively
   
491.7
   
511.4
 
Inventories, net
   
219.8
   
212.1
 
Other current assets
   
124.6
   
108.6
 
Deferred income taxes
   
71.2
   
112.1
 
Total Current Assets
   
1,627.9
   
1,446.0
 
               
Property, Plant and Equipment, net
   
604.4
   
580.8
 
Goodwill
   
799.0
   
682.2
 
Other Intangibles, net
   
273.8
   
204.3
 
Other Long-Term Assets
   
100.3
   
106.9
 
Deferred Income Taxes
   
11.0
   
25.6
 
Total Assets
 
$
3,416.4
 
$
3,045.8
 
               
Liabilities and Shareholders' Equity
             
Notes payable
 
$
0.2
 
$
2.6
 
Current portion of long-term debt
   
161.2
   
100.8
 
Accounts payable
   
88.1
   
94.8
 
Accrued compensation
   
126.0
   
153.3
 
Accrued liabilities
   
495.5
   
453.2
 
Federal, state and foreign income taxes payable
   
137.7
   
109.6
 
Deferred income taxes
   
1.5
   
3.7
 
Total Current Liabilities
   
1,010.2
   
918.0
 
               
Long-Term Debt, less current portion
   
831.2
   
543.3
 
Other Long-Term Liabilities
   
145.9
   
131.9
 
Deferred Income Taxes
   
120.7
   
75.2
 
Total Liabilities
   
2,108.0
   
1,668.4
 
               
Minority Interest
   
24.5
   
14.6
 
               
Commitments and Contingencies (Note 17)
             
               
Common Stock, par value $0.40 per share, 200 million shares authorized 60,427,172 shares issued (60,340,522 shares in 2004)
   
24.1
   
24.1
 
Class B Stock, par value $0.08 per share, 15 million shares authorized, 253,699 shares issued (443,584 shares in 2004)
   
-
   
-
 
Capital in Excess of Par Value
   
102.4
   
105.6
 
Common and Class B Stock in Treasury, at cost, 6,741,731 shares (7,888,001 shares in 2004)
   
(356.3
)
 
(409.2
)
Retained Earnings
   
1,471.6
   
1,480.4
 
Accumulated Other Comprehensive Income
   
50.9
   
167.8
 
Other Shareholders' Equity
   
(8.8
)
 
(5.9
)
Total Shareholders' Equity
   
1,283.9
   
1,362.8
 
Total Liabilities and Shareholders' Equity
 
$
3,416.4
 
$
3,045.8
 

See Notes to Financial Statements





PAGE 62

Statements of Cash Flows
For the Years Ended
December 31, 2005, December 25, 2004 and December 27, 2003
Dollar Amounts in Millions
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
Cash Flows from Operating Activities
             
Net Income
 
$
19.2
 
$
153.9
 
$
106.0
 
Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities
                   
Depreciation
   
98.5
   
99.4
   
98.8
 
Amortization
   
27.3
   
24.9
   
25.6
 
Reversal of restructuring charges
   
-
   
-
   
(6.3
)
Deferred income taxes
   
93.2
   
(21.4
)
 
(21.5
)
Stock-based compensation expense
   
5.3
   
10.2
   
10.7
 
Tax benefits associated with exercise of stock options
   
16.9
   
16.1
   
-
 
Gain from sale of investments available-for-sale
   
-
   
(0.3
)
 
-
 
Loss on divestiture of German Woehlk contact lens business
   
2.3
   
-
   
-
 
Loss on retirement of fixed assets
   
2.4
   
11.0
   
3.2
 
Changes in Assets and Liabilities
                   
Trade receivables
   
5.4
   
(18.9
)
 
(13.7
)
Inventories
   
(16.3
)
 
11.9
   
16.0
 
Other current assets
   
(17.2
)
 
11.9
   
7.9
 
Other long-term assets, including equipment on operating lease
   
(2.7
)
 
(21.6
)
 
(11.1
)
Accounts payable and accrued liabilities
   
(31.9
)
 
59.3
   
(3.8
)
Income taxes payable
   
27.7
   
(24.4
)
 
27.7
 
Other long-term liabilities
   
9.3
   
(27.5
)
 
12.9
 
Net Cash Provided by Operating Activities 1
   
239.4
   
284.5
   
252.4
 
                     
Cash Flows from Investing Activities
                   
Capital expenditures
   
(116.0
)
 
(118.9
)
 
(91.5
)
Net cash paid for acquisition of businesses and other intangibles
   
(236.7
)
 
(2.1
)
 
(6.4
)
Purchase of available-for-sale securities
   
-
   
(43.4
)
 
(19.7
)
Cash received from sale of investments available-for-sale
   
-
   
44.0
   
19.7
 
Other
   
(0.4
)
 
(1.3
)
 
3.8
 
Net Cash Used in Investing Activities
   
(353.1
)
 
(121.7
)
 
(94.1
)
                     
Cash Flows from Financing Activities
                   
Repurchases of Common and Class B shares
   
(45.1
)
 
(79.0
)
 
(72.0
)
Exercise of stock options
   
69.6
   
77.8
   
12.1
 
Net repayments of notes payable
   
(2.1
)
 
0.3
   
(1.1
)
Repayment of long-term debt
   
(325.7
)
 
(196.6
)
 
(200.7
)
Proceeds from issuance of debt
   
676.7
   
0.1
   
210.1
 
Cash paid to minority interests
   
(3.8
)
 
(4.2
)
 
(4.5
)
Payment of dividends
   
(28.1
)
 
(27.6
)
 
(27.7
)
Net Cash Provided by (Used in) Financing Activities
   
341.5
   
(229.2
)
 
(83.8
)
                     
Effect of exchange rate changes on cash and cash equivalents
   
(9.0
)
 
5.6
   
23.0
 
Net Change in Cash and Cash Equivalents
   
218.8
   
(60.8
)
 
97.5
 
                     
Cash and Cash Equivalents, Beginning of Year
   
501.8
   
562.6
   
465.1
 
Cash and Cash Equivalents, End of Year
 
$
720.6
 
$
501.8
 
$
562.6
 
                     
Supplemental Cash Flow Disclosures
                   
Cash paid for interest
 
$
44.9
 
$
48.3
 
$
57.4
 
Net cash payments for income taxes
   
82.1
   
115.2
   
58.2
 
                     
Supplemental Schedule of Non-Cash Financing Activities
                   
Dividends declared but not paid
 
$
7.1
 
$
6.9
 
$
6.8
 

1 Exclusive of acquisitions.

See Notes to Financial Statements



PAGE 63

        Statements of Changes in Shareholders' Equity    
For the Years Ended
December 31, 2005, December 25, 2004 (Restated) and December 27, 2003 (Restated)
Dollar Amounts in Millions
                         
   
Total
 
Common and Class B Stock 1, 2
 
Capital in Excess of Par
 
Treasury Stock
 
Retained Earnings
 
Accumulated Other Compre-hensive (Loss)
Income
 
Other Shareholders' Equity
 
Balance at December 28, 2002 (As reported)
 
$
1,017.8
 
$
24.1
 
$
102.2
 
$
(359.8
)
$
1,298.9
 
$
(38.5
)
$
(9.1
)
Impact of Restatement
   
(12.5
)
 
-
   
4.0
   
(8.3
)
 
(23.3
)
 
15.1
   
-
 
Balance at December 28, 2002 (Restated)
 
$
1,005.3
 
$
24.1
 
$
106.2
 
$
(368.1
)
$
1,275.6
 
$
(23.4
)
$
(9.1
)
Components of comprehensive income
                                           
Net income
   
106.0
   
-
   
-
   
-
   
106.0
   
-
   
-
 
Currency translation adjustments
   
123.5
   
-
   
-
   
-
   
-
   
123.5
   
-
 
Net loss on cash flow hedges
   
(0.2
)
 
-
   
-
   
-
   
-
   
(0.2
)
 
-
 
Reclassification adjustment into net income for net loss on cash flow hedges
   
3.2
   
-
   
-
   
-
   
-
   
3.2
   
-
 
Minimum additional pension liability
   
4.4
   
-
   
-
   
-
   
-
   
4.4
   
-
 
Total comprehensive income 3
   
236.9
                                     
Net change in shares under employee plans (106,426 shares) 4
   
(0.6
)
 
-
   
3.2
   
-
   
-
   
-
   
(3.8
)
Treasury shares issued under employee plans (460,056 shares)
   
15.6
   
-
   
-
   
15.6
   
-
   
-
   
-
 
Treasury shares repurchased (1,758,796 shares)
   
(72.0
)
 
-
   
-
   
(72.0
)
 
-
   
-
   
-
 
Activity related to deferred stock awards held by the rabbi trust under a deferred compensation
program
5
   
(1.7
)
 
-
   
-
   
(1.7
)
 
-
   
-
   
-
 
Amortization of unearned compensation
   
4.8
   
-
   
-
   
-
   
-
   
-
   
4.8
 
Dividends 6
   
(27.5
)
 
-
   
-
   
-
   
(27.5
)
 
-
   
-
 
Balance at December 27, 2003 (Restated)
 
$
1,160.8
 
$
24.1
 
$
109.4
 
$
(426.2
)
$
1,354.1
 
$
107.5
 
$
(8.1
)
Components of comprehensive income
                                           
Net income
   
153.9
   
-
   
-
   
-
   
153.9
   
-
   
-
 
Currency translation adjustments
   
63.7
   
-
   
-
   
-
   
-
   
63.7
   
-
 
Reclassification adjustment into net income for net loss on cash flow hedges
   
1.9
   
-
   
-
   
-
   
-
   
1.9
   
-
 
Minimum additional pension liability
   
(5.3
)
 
-
   
-
   
-
   
-
   
(5.3
)
 
-
 
Total comprehensive income 3
   
214.2
                                     
Net change in shares under employee plans (45,300 shares) 4
   
(6.3
)
 
-
   
(4.1
)
 
-
   
-
   
-
   
(2.2
)
Treasury shares issued under employee plans (1,986,353 shares)
   
97.6
   
-
   
-
   
97.6
   
-
   
-
   
-
 
Treasury shares repurchased (1,293,625 shares)
   
(79.2
)
 
-
   
-
   
(79.2
)
 
-
   
-
   
-
 
Activity related to deferred stock awards held by the rabbi trust under a deferred compensation
program
5
   
(1.1
)
 
-
   
0.3
   
(1.4
)
 
-
   
-
   
-
 
Amortization of unearned compensation
   
4.4
   
-
   
-
   
-
   
-
   
-
   
4.4
 
Dividends 6
   
(27.6
)
 
-
   
-
   
-
   
(27.6
)
 
-
   
-
 
Balance at December 25, 2004 (Restated)
 
$
1,362.8
 
$
24.1
 
$
105.6
 
$
(409.2
)
$
1,480.4
 
$
167.8
 
$
(5.9
)
Components of comprehensive income
                                           
Net income
   
19.2
   
-
   
-
   
-
   
19.2
   
-
   
-
 
Currency translation adjustments
   
(100.2
)
 
-
   
-
   
-
   
-
   
(100.2
)
 
-
 
Reclassification adjustment into net income for net loss on cash flow hedges
   
3.3
   
-
   
-
   
-
   
-
   
3.3
   
-
 
Minimum additional pension liability
   
(20.0
)
 
-
   
-
   
-
   
-
   
(20.0
)
 
-
 
Total comprehensive income 7
   
(97.7
)
                                   
Net change in shares under employee plans (89,750 shares)
   
(10.1
)
 
-
   
(3.8
)
 
-
   
-
   
-
   
(6.3
)
Treasury shares issued under employee plans (1,790,096 shares)
   
100.9
   
-
   
-
   
100.9
   
-
   
-
   
-
 
Treasury shares repurchased (600,464 shares)
   
(44.9
)
 
-
   
-
   
(44.9
)
 
-
   
-
   
-
 
Activity related to deferred stock awards held by the rabbi trust under a deferred compensation program
   
(2.5
)
 
-
   
0.6
   
(3.1
)
 
-
   
-
   
-
 
Amortization of unearned compensation
   
3.4
   
-
   
-
   
-
   
-
   
-
   
3.4
 
Dividends 6
   
(28.0
)
 
-
   
-
   
-
   
(28.0
)
 
-
   
-
 
Balance at December 31, 2005
 
$
1,283.9
 
$
24.1
 
$
102.4
 
$
(356.3
)
$
1,471.6
 
$
50.98
 
$
(8.8
)




PAGE 64

1
There are also 10 thousand shares of $100 par value 4 percent cumulative preferred stock authorized, none of which has been issued.
2      There are also 25 million shares of $1 par value Class A preferred stock authorized, none of which has been issued.
3
See Note 2 — Restatement for a discussion of the impact of restatement regarding the components of total comprehensive income.
4
Activity reflects restatement adjustments associated with the Company's comprehensive review of its accounting for income taxes. The after-tax impact of these adjustments was $1.5 and $(3.9) for 2003 and 2004, respectively.
5  See Note 2 — Restatement for a discussion regarding the Deferred Compensation Plan matter.
6  Cash dividends of $0.52 per share were declared on Common and Class B stock in 2003, 2004 and 2005.
7
Total comprehensive income was reported net of any related tax effects. Amounts of income tax expense for minimum additional pension liability for the year ended December 31, 2005 was $2.3. There was no income tax benefit or expense related to currency translation adjustments and reclassification adjustments for net loss on cash flow hedges as a result of the Company recording a valuation allowance as further discussed in Note 10 — Provision for Income Taxes.
8
Accumulated other comprehensive income was $50.9 at December 31, 2005 and included the following accumulated income (loss) amounts: currency translation adjustment, $116.2; net loss on cash flow hedges, $(1.7); and minimum additional pension liability, $(63.6). Accumulated other comprehensive income was $167.8 at December 25, 2004 and included the following accumulated income (loss) amounts: currency translation adjustment, $216.4; net loss on cash flow hedges, $(5.0); and minimum additional pension liability, $(43.6).

See Notes to Financial Statements





PAGE 65

Notes to Financial Statements
Dollar Amounts in Millions Except Per Share Data

1. Significant Accounting Policies

Company Operations Bausch & Lomb Incorporated (the Company) is a world leader in the development, manufacture and marketing of eye health products, including contact lenses, contact lens care solutions and ophthalmic surgical and pharmaceutical products.
The Company restated its consolidated financial statements for fiscal years 2003 and 2004 and its financial information for the years ended 2001 and 2002 (including a cumulative increase to 2001 beginning retained earnings of $34.0) and the first and second quarters of 2005. See Note 2 — Restatement for a discussion of the nature of the restatement adjustments and the impact on previously issued financial statements.

Basis of Presentation Throughout the consolidated financial statements and accompanying notes, all referenced amounts related to prior periods reflect the balances and amounts on a restated basis.

Principles of Consolidation The financial statements include all majority-owned U.S. and non-U.S. subsidiaries. The consolidation of non-wholly owned subsidiaries results in the recognition of minority interest on the consolidated Balance Sheets and Statements of Income representing the minority shareholders’ interest in the net assets and net income of such subsidiaries. Intercompany accounts, transactions and profits are eliminated. The fiscal year is the 52- or 53-week period ending the last Saturday in December.

Segment Reporting In accordance with Statement of Financial Accounting Standards (SFAS) No. 131, Disclosures about Segments of an Enterprise and Related Information, the Company reports its results consistent with the manner in which financial information is viewed by management for decision-making purposes.
The Company is organized on a regionally based management structure for commercial operations. The research and development and product supply functions of the Company are managed on a global basis. Beginning in 2005, the Company’s engineering function, which had previously been part of the research and development segment, became part of the product supply function. Following the realignment of the engineering function, the Company's segments are the Americas region; the Europe, Middle East and Africa region (Europe); the Asia region; the Research & Development organization and the Global Operations & Engineering organization.

Use of Estimates The financial statements have been prepared in conformity with generally accepted accounting principles (GAAP) and, as such, include amounts based on informed estimates and judgments of management with consideration given to materiality. For example, estimates are used in determining valuation allowances for uncollectible trade receivables, obsolete inventory, deferred income taxes and tax reserves, and in valuing purchased intangible assets. Actual results could differ from those estimates.

Cash Equivalents Cash equivalents include time deposits and highly liquid investments with original maturities of three months or less.

Inventories Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories include the cost of raw materials, labor and manufacturing overhead. The Company provides estimated inventory allowances for excess, slow moving and obsolete inventory as well as inventory whose carrying value is in excess of net realizable value to properly reflect inventory at the lower of cost or market. Allowances for excess, slow moving and obsolete inventory were $30.9 and $30.6 as of December 31, 2005 and December 25, 2004, respectively.

Property, Plant and Equipment Property, plant and equipment, including improvements that significantly add to productive capacity or extend useful life, are recorded at cost, while maintenance and repairs are expensed as incurred. Depreciation is calculated for financial reporting purposes using the straight-line method based on the estimated useful lives of the assets as follows: buildings, 30 to 40 years; machinery and equipment, two to ten years; and leasehold improvements, the shorter of the estimated useful life or the lease periods. In accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the Company assesses all long-lived assets, including property, plant and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Interest cost capitalization associated with various projects commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use.
 

 
PAGE 66

Goodwill and Other Intangibles The Company’s policy is in accordance with current accounting guidance as prescribed by SFAS No. 141, Business Combinations and SFAS No. 142, Goodwill and Intangible Assets. The Company accounts and evaluates its goodwill balances and tests them for impairment in accordance with the provisions of SFAS 142. The Company performs an annual impairment test of goodwill during its fourth fiscal quarter and when an event occurs or circumstances change that would more likely than not reduce the fair value of any of its reporting units below its carrying amount. The impairment test compares the carrying value of the Company’s reporting units to their respective fair values. The Company’s business segments have been identified as the reporting units. Fair value is based on the average of the indications of value derived from the income and market approaches, weighted equally. The income approach measures the fair value by discounting expected cash flows by reporting unit to their present value at a rate of return that is commensurate with their inherent risk. The market approach measures the fair value by analyzing and comparing the operating performance and financial condition of public companies within the ophthalmic pharmaceutical industry and companies subject to similar market conditions adjusted for differences in profitability, financial position, products and markets. The Company completed its annual impairment test on each of its reporting units during the fourth quarters of 2005 and 2004. As the carrying value (including goodwill) of each of the Company's reporting units was less than their respective fair values, goodwill was not considered to be impaired.
The Company assesses the carrying value of its identifiable intangible assets whenever events or changes in circumstances indicate that the carrying amount of the underlying asset may not be recoverable. Certain factors which may occur and indicate that an impairment exists include, but are not limited to the following: significant underperformance relative to expected historical or projected future operating results; significant changes in the manner of the Company’s use of underlying assets; and significant adverse industry or market economic trends. In the event the carrying value of assets is determined to be unrecoverable, the Company would estimate the fair value of the assets and record an impairment charge for the excess of the carrying value over the fair value.
On May 15, 2006, the Company announced a worldwide voluntary recall of MoistureLoc lens care solution. As explained in Note 23 — Subsequent Event, the Company determined that this event would more likely than not reduce the fair value of a reporting unit. The Company revised the fair values of each of the reporting units to reflect the anticipated impact of the MoistureLoc recall and concluded that the probability of the voluntary recall reducing the fair value of any reporting unit below its carrying amount was remote. In addition, the Company performed a separate analysis as it relates to its recent acquisition of Freda and determined that the fair value of Freda exceeded its carrying value.

Revenue Recognition and Related Provisions and Allowances The Company’s revenue recognition policy is in accordance with the requirements of Staff Accounting Bulletin No. 104, Revenue Recognition, corrected copy (SAB 104), Emerging Issues Task Force (EITF) 00-21, Accounting for Revenue Arrangements with Multiple Deliverables, and other applicable revenue recognition guidance and interpretations.
The Company markets products in five product categories: contact lens, lens care, pharmaceuticals, cataract and vitreoretinal, and refractive. The Company recognizes revenue for each of these product categories when it is realized or realizable and earned and when substantially all the risks and rewards of ownership have transferred to the customer. Revenue is considered realized and earned when:

·  
persuasive evidence of an arrangement exists;
·  
delivery has occurred or services have been rendered;
·  
the Company's price to its customers is fixed or determinable; and
·  
collection of the resulting receivable is reasonably assured.




PAGE 67

In addition to the Company’s sales force, distributors and wholesalers are utilized to market and distribute the Company’s products to secondary customers. Revenue from distributors and wholesalers must meet all of the revenue recognition criteria previously discussed. The Company’s revenue recognition policy requires that based on the distributor’s anticipated sell-through, a reasonable base amount of inventory must be established for each distributor or wholesaler that represents a significant amount of the Company’s business. This base amount of inventory is used as a benchmark in assessing total inventory available to secondary customers. In certain transactions with distributors and wholesalers, substantially all the risks and rewards of ownership do not transfer upon delivery and, accordingly, such shipments are accounted for as consignment sales. For the previously described consignment sales, the Company invoices the distributor or wholesaler upon shipment, records deferred revenue at gross invoice sales price and classifies the inventory held by the distributors or wholesalers as consignment inventory at the Company’s cost of such inventory. Deferred revenue for consignment sales was $33.1 and $27.7 as of December 31, 2005 and December 25, 2004, respectively. Balances are included in Accrued Liabilities on the Balance Sheets. Associated consignment inventory was $7.9 and $7.1 as of December 31, 2005 and December 25, 2004, respectively. Balances are included in Inventories on the Balance Sheets. The Company recognizes revenue (net of discounts, rebates, sales allowances and accruals for returns, all of which involve significant estimates and judgments) when the risks and rewards of ownership have transferred but not later than when such inventory is sold to the wholesalers’ or distributors' customers. Also, as explained in the paragraph below entitled Cataract and Vitreoretinal, and Refractive, the Company offers IOLs to surgeons and hospitals on a consignment basis and recognizes revenue when the IOL is implanted during surgery and not upon shipment to the surgeon.
Within each product category the Company has ongoing programs that, under specified conditions, allow customers to return products and, in accordance with SFAS No. 48, Revenue Recognition When Right of Return Exists, records liabilities for estimated returns and allowances at the time revenue is recognized. The Company's liability for estimated returns considers historical trends, the impact of new product launches, the entry of a competitor, product rationalization and the various terms and arrangements offered, including sales with extended credit terms.
Also, within each product category the Company has established certain customer incentive programs such as cash discounts, promotional and advertising allowances, volume discounts, contractual pricing allowances, and rebates and coupons. The Company records an estimated reduction to revenue for these programs in accordance with Emerging Issues Task Force 01-9, Accounting for Consideration Given by a Vendor to a Customer or a Reseller of the Vendor's Products (EITF 01-9). The Company closely monitors and evaluates customer incentives and other customer programs. Should the Company determine that certain customer programs result in excessive levels of inventory in certain channels of trade (such as retailers, mass merchandisers, wholesalers and distributors) or the risks and rewards have not transferred to the customer, net sales in conjunction with the associated programs would be accounted for as consignment sales.
The Company maintains provisions for uncollectible accounts for estimated losses resulting from the inability of its customers to remit payments. The Company continuously monitors collections and payments from customers and maintains a provision for estimated credit losses based upon its historical experience and any specific customer collection issues that have been identified. Amounts billed to customers in sales transactions related to shipping and handling are classified as revenue in accordance with EITF 00-10, Accounting for Shipping and Handling Fees and Costs.
Some of the Company's sales programs are unique to a specific product category. These are discussed below.

Lens and Lens Care The contact lens category includes traditional, planned replacement, daily disposable, multifocal, continuous wear and toric soft lenses and rigid gas permeable lenses and materials. These products are marketed to licensed eye care professionals, health product retailers and distributors. The lens care category includes multipurpose solutions, cleaning and conditioning solutions for RGP lenses, re-wetting drops and saline solutions. These products are marketed to licensed eye care professionals, health product retailers, independent pharmacies, drug stores, food stores, mass merchandisers and distributors. The Company offers co-operative advertising programs within the contact lens and lens care categories. These programs are made available to large retailers and mass merchandisers that provide frequent advertising to their customers. The Company also offers manufacturer's coupons and mail-in rebates to end consumers. These programs are recorded as a reduction in revenue at the time the program is offered in accordance with EITF 01-9 as the fair value of the benefit cannot be reasonably estimated or, in the case of coupons and rebates, the Company does not receive a separable identifiable benefit.




PAGE 68

Pharmaceuticals The pharmaceuticals category includes generic and proprietary prescription ophthalmic drugs, ocular vitamins, and over-the-counter medications. These products are marketed through the Company's sales force and distributed primarily through wholesalers, with additional sales to independent pharmacies, drug stores, food stores, mass merchandisers, hospitals and distributors. The Company enters into contractual pricing agreements with indirect customers that result in rebates to wholesalers and price protection allowances to certain customers. These rebates and allowances are recorded as a reduction in revenue in accordance with EITF 01-9 as the Company does not receive a separable identifiable benefit.

Cataract and Vitreoretinal, and Refractive The cataract and vitreoretinal category includes intraocular lenses (IOLs), phacoemulsification and vitreoretinal surgical equipment and related disposable products, hand-held surgical instruments, viscoelastics and other products used in cataract and vitreoretinal surgery. The refractive category includes lasers, microkeratomes, diagnostic equipment, other products used in refractive surgery and service fees. These products are marketed to ophthalmic surgeons, hospitals, ambulatory surgery centers or vision centers, and distributors. In these product categories, the Company will market disposable and consumable products either individually or in combination with equipment. If sold in combination with equipment, the Company allocates revenue to the separate revenue elements in accordance with EITF 00-21. Revenues from equipment sales are recorded either at the time risk of loss passes to the customer or, in the case of lasers, upon customer acceptance for outright sales and sales-type leasing arrangements, or over the lease term for operating leases in accordance with SAB 104 and SFAS No. 13, Accounting for Leases. Customer acceptance is evidenced by a certificate of installation. The Company offers 12-month warranties on equipment and records a reserve at the time of sale for the cost associated with the warranty in accordance with SFAS No. 5, Accounting for Contingencies. Also in the cataract and vitreoretinal product category, the Company offers IOLs to surgeons and hospitals on a consignment basis. In accordance with SAB 104, the Company recognizes revenue for consignment inventory when the IOL is implanted during surgery and not upon shipment to the surgeon.

Advertising Expense External costs incurred in producing media advertising are expensed the first time the advertising takes place. At December 31, 2005 and December 25, 2004, $2.8 and $2.2 of deferred advertising costs, respectively, were reported as other current assets representing primarily production and design costs for advertising to be run in the subsequent fiscal year. Advertising expenses of $212.4, $205.7 and $186.3 were included in selling, administrative and general expenses for 2005, 2004 and 2003, respectively. Advertising expense for 2005 included $4.5 of expense associated with an announcement of the voluntary recall of MoistureLoc lens care solution from worldwide markets (see Note 23 — Subsequent Event).

Research and Development Costs Internal research and development costs, which are primarily comprised of direct salaries, external consulting fees and occupancy costs, are expensed as incurred. Third-party research and development costs are expensed as the contracted work is performed. Where certain milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed as the milestone results are achieved, up to the point of certain regulatory approvals. In the event payments are made to third parties subsequent to certain regulatory approvals, they are either expensed or capitalized depending upon the nature of the payment. For example, royalty payments are expensed, whereas payments to purchase an associated intangible asset are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization (see Note 8 — Acquired Intangible Assets).

Legal Fees Legal fees are expensed as incurred.




PAGE 69

Stock-Based Compensation The Company has granted stock options to its key employees and non-employee directors under several stock-based compensation plans, with employee grants typically vesting ratably over three years and expiring ten years from the date of grant. Vesting is contingent upon a continued employment relationship with the Company. Director stock option grants are made pursuant to a formula and are vested 100 percent after one year. In addition, the Company issues restricted stock awards to officers and other key personnel with vesting periods up to seven years based on continued employment until applicable vesting dates and, prior to 2005, the attainment of specific performance goals. The Company measures stock-based compensation for option grants under the provisions of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees. Accordingly, given the fixed nature of the equity instruments granted under such plans, no compensation cost has been recognized other than for restricted stock awards. Compensation expense for restricted stock awards is recorded based on applicable vesting criteria, and for those awards with performance goals, as such goals are met. The Company's net income and earnings per share would have been reduced to the pro forma amounts shown below if compensation cost had been determined based on the fair value at the grant dates using the Black-Scholes option-pricing model in accordance with SFAS No. 123, Accounting for Stock-Based Compensation as amended by SFAS No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure:

       
2004
 
2003
 
   
2005
 
(Restated)
 
(Restated)
 
Net income, as reported
 
$
19.2  
 
$
153.9  
 
$
106.0   
 
Stock-based compensation cost included in reported net income, net of tax2
   
3.3
   
6.2
   
6.5
  
Stock-based compensation cost determined under the fair value method for all awards, net of tax2
   
(16.6)1
   
(18.0)1
   
(16.8)1
 
Pro forma net income
 
$
5.9   
 
$
142.1   
 
$
95.7   
 
                     
Basic earnings per share:
                   
As reported
 
$
0.36   
 
$
2.94   
 
$
2.02   
 
Pro forma
   
0.11   
   
2.71   
   
1.83   
 
                     
Diluted earnings per share:
                   
As reported
 
$
0.35   
 
$
2.83   
 
$
1.98   
 
Pro forma
   
0.11   
   
2.61   
   
1.79   
 

1
Amounts reflect the deferred compensation plan restatement adjustments net of tax (see Note 2 — Restatement for further discussion).
2
Net of tax amounts were calculated using the U.S. statutory rate (38.3% in 2005 and 39.0% in 2004 and 2003).

The Company adopted the provisions of SFAS No. 123 (revised 2004), Share-Based Payment on January 1, 2006 (see New Accounting Guidance below for further discussion). See Note 15 — Employee Stock Plans for further discussion regarding the Company’s long-term incentive plan and its provisions.

Comprehensive Income The Company defines comprehensive income as net income plus the sum of currency translation adjustments, unrealized gains/losses on derivative instruments, unrealized holding gains/losses on securities and minimum pension liability adjustments (collectively "other comprehensive income") and presents comprehensive income in the Statements of Changes in Shareholders' Equity.




PAGE 70

Investments in Debt and Equity Securities At the end of 2005 and 2004, the Company held investments in equity securities, which are accounted for using the cost method of accounting. Cost method investments that do not have a readily determined market value, and for which the Company does not have the ability to exercise significant influence, are reviewed periodically for events or changes in circumstances that may have a significant adverse effect on the carrying amount of the investment. Examples of events or circumstances that may indicate that an investment is impaired include, but are not limited to, a significant deterioration in earnings performance; a significant adverse change in the regulatory, economic or technological environment of an investee; or a significant doubt about an investee’s ability to continue as a going concern. If the Company determines that impairment exists and it is other-than-temporary, the carrying value of the investment would be reduced to its estimated fair value and an impairment loss would be recognized in its consolidated Statements of Income. The carrying amounts of these investments were $5.9 and $5.5 as of December 31, 2005 and December 25, 2004, respectively, and are reported in other long-term assets in the accompanying Balance Sheets. The Company bought and sold auction rate securities and variable-rate demand notes for the same principal amounts totaling $43.4 and $19.7 during 2004 and 2003, respectively. At the end of 2005 and 2004, the Company had no investments in debt securities.

Foreign Currency For most subsidiaries outside the United States, the local currency is the functional currency, and translation adjustments are accumulated as a component of other comprehensive income. The accumulated income balances of currency translation adjustments were $116.2, $216.4 and $152.7 at the end of 2005, 2004 and 2003, respectively.
For subsidiaries that operate in U.S. dollars, the U.S. dollar is the functional currency, and gains and losses that result from remeasurement are included in income. Foreign currency translation resulted in a loss of $1.5 in 2005, and gains of $16.6 and $4.3 in 2004 and 2003, respectively.
The Company hedges certain foreign currency transactions, firm commitments and net assets of certain non-U.S. subsidiaries by entering into foreign exchange forward contracts. Gains and losses associated with currency rate changes on forward contracts hedging foreign currency transactions are recorded in income. The effects of foreign currency transactions, including related hedging activities, were losses of $2.9, $17.2 and $17.7 in 2005, 2004 and 2003, respectively.

Derivative Financial Instruments and Hedging Activity In accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, the Company records all derivative instruments on the balance sheet at their respective fair values. Changes in the fair value of derivatives are recorded each period in current income unless the instruments have been designated as cash flow or net investment hedges, in which case such changes are recorded in other comprehensive income. The Company does not apply hedge accounting to contracts that offset foreign exchange exposures related to foreign currency denominated assets and liabilities because they are marked to market through income at the same time that the exposed asset/liability is remeasured through income; both are recorded in foreign exchange loss (gain).
Upon entering into a derivative contract, the Company may designate, as appropriate, the derivative as a fair value hedge, cash flow hedge, foreign currency hedge or hedge of a net investment in a foreign operation. At inception, the Company formally documents the relationship between the hedging instrument and underlying hedged item, as well as risk management objective and strategy. In addition, the Company assesses, both at inception and on an ongoing basis, whether the derivative used in a hedging transaction is highly effective in offsetting changes in the fair value or cash flow of the respective hedged item. When it is determined that a derivative is no longer highly effective as a hedge, the Company will discontinue hedge accounting prospectively.
Fair value hedges may be employed by the Company to hedge changes in the fair value of recognized financial assets or liabilities or unrecognized firm commitments. Changes in the fair value of the derivative instrument and the hedged item attributable to the hedged risk are recognized in income, and will generally be offsetting. The Company attempts to structure fair value hedges so as to qualify for the shortcut method of hedge effectiveness analysis, thereby assuming no ineffectiveness in the hedge relationship. In the event it is determined that the hedging relationship no longer qualifies as an effective fair value hedge, the derivative will continue to be carried on the balance sheet at its fair value, with changes in fair value recorded in income. Upon termination of a derivative in an effective fair value hedge, any associated gain or loss will be an adjustment to income over the remaining life of the hedged item, if any.



PAGE 71

The Company may implement cash flow hedges to protect itself from fluctuation in cash flows associated with recognized variable-rate assets or liabilities or forecasted transactions. Changes in the fair value of the hedging derivative are initially recorded in other comprehensive income, then recognized in income in the same period(s) in which the hedged transaction affects income. The Company attempts to structure cash flow hedges such that all the critical terms of the derivative match the hedged item, thereby assuming no ineffectiveness in the hedge relationship at inception. The Company performs and documents an assessment of hedge effectiveness on a quarterly basis throughout the hedge period. In the event it is determined that the hedging relationship no longer qualifies as an effective cash flow hedge, the derivative will continue to be carried on the balance sheet at its fair value, with changes in fair value recorded in income. If hedge accounting is discontinued because it becomes probable a forecasted transaction will not occur, the derivative will continue to be carried on the balance sheet at its fair value, with changes in fair value recorded in income, and any amounts previously recorded in other comprehensive income will immediately be recorded in income.
The Company may enter into foreign currency derivatives to protect itself from variability in cash flows associated with recognized foreign currency denominated assets or liabilities. Changes in the fair value of the hedging derivative are initially recorded in other comprehensive income, and then recognized in income in the same period(s) in which the hedged transaction affects income.
The Company has numerous investments in foreign subsidiaries, and the net assets of these subsidiaries are exposed to currency exchange rate volatility. To hedge this exposure the Company may utilize foreign exchange forward contracts. Net investment hedges are implemented for material subsidiaries on a selective basis. The effective portion of the change in fair value of the hedging instrument is reported in the same manner as the translation adjustment for the hedged subsidiary; namely, reported in the cumulative translation adjustment section of other comprehensive income. The fair value of the derivative attributable to changes between the forward rate and spot rate is excluded from the measure of hedge effectiveness and that difference is reported in income over the life of the contract. The Company evaluates its hedges of net investments in foreign subsidiaries quarterly for effectiveness and adjusts the value of hedge instruments or redesignates the hedging relationship as necessary.
The Company enters into foreign exchange forward contracts, with terms normally lasting less than six months, to hedge against foreign currency transaction gains and losses on foreign currency denominated assets and liabilities based on changes in foreign currency spot rates. Although allowable, a hedging relationship for this risk has not been designated, as designation will not achieve different financial reporting results. Foreign exchange forward contracts within this category are carried on the balance sheet at fair value with changes in fair value recorded in income.

Deferred Tax Assets and Reserves The Company evaluates the recoverability of its deferred tax assets on an ongoing basis. This evaluation includes assessing the available positive and negative evidence to determine whether, based on its judgment, the Company believes the assets, or some portion thereof, are more likely than not to be realized. To the extent the Company does not believe the assets will more likely than not be realized, a valuation allowance is recorded. In determining whether, and to what extent, a valuation allowance is required, the Company considers whether it will have sufficient taxable income in the appropriate period and jurisdiction that is also of the appropriate character. Potential sources of taxable income that are evaluated include: (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary differences; (iii) taxable income in prior carryback years; and (iv) tax planning strategies that would be implemented, if necessary. Should the Company determine that it is more likely than not it will realize its deferred tax assets in the future, an adjustment would be required to reduce the existing valuation allowance. Generally, this would result in a corresponding increase to income. Conversely, if the Company determined that it would not be able to realize its deferred tax assets, an adjustment would be required to increase the valuation allowance. Generally, this would result in a decrease to income. Additional tax expense or (benefit) related to changes in the valuation allowance were $121, $21 and $(2) in 2005, 2004 and 2003, respectively.
In the normal course of business, the Company is regularly audited by federal, state and foreign tax authorities, and is periodically challenged regarding the amount of taxes due. These challenges include, among other issues, questions regarding the timing and amount of deductions and the allocation of income among various taxing jurisdictions. The Company believes its tax positions comply with applicable tax law and, if challenged, intends to vigorously defend such positions. As the likelihood of successfully defending many of these positions is uncertain, the Company evaluates these positions and records tax reserves when the likelihood of ultimately sustaining a loss is probable, and the amount of such loss is reasonably estimable. The Company's effective tax rate in a given financial statement period could be materially impacted if the Company prevailed in matters for which reserves have been established, or was required to pay amounts in excess of established reserves.
 

 
PAGE 72

Minority Interest The consolidation of non-wholly owned subsidiaries results in the recognition of minority interest on the consolidated Balance Sheets and Statements of Income representing the minority shareholders’ interest in the net assets and net income of such subsidiaries. The minority interest liability at the end of 2005 and 2004 represented outside interests in non-U.S. commercial and manufacturing joint ventures.

New Accounting Guidance In December 2004, the Financial Accounting Standards Board (FASB) issued its standard on accounting for share-based payments, SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R) which replaced FASB Statement No. 123, Accounting for Stock-Based Compensation, and supercedes APB Opinion No. 25, Accounting for Stock Issued to Employees. SFAS No. 123R requires companies to recognize compensation cost relating to share-based payment transactions, including grants of employee stock options, in the financial statements based on the grant date fair value. The pro forma disclosures previously permitted under SFAS No. 123 will no longer be an alternative to financial statement recognition. SFAS No. 123R is effective for fiscal periods beginning after June 15, 2005. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 (SAB 107) regarding the SEC’s interpretations of SFAS No. 123R and the valuation of share-based payments for public companies. SFAS No. 123R covers a wide range of share-based compensation arrangements including share options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. The Company adopted SFAS No. 123R in the first quarter of 2006 using the modified prospective application method. Under this method, the Company will apply SFAS No. 123R for new awards granted after the adoption of SFAS No. 123R and any unvested portion of awards that were granted prior to the adoption of SFAS No. 123R. The Company will apply the Black-Scholes model to estimate the fair value of share-based payments to employees, which will then be amortized on a ratable basis over the requisite service period. The Company estimates the impact of new stock-based compensation programs and the adoption of SFAS No. 123R requiring the expensing of stock options will be approximately $13.3 before taxes in 2006. This compares to a previous estimate of approximately $23.0 before taxes. The revised estimate reflects the postponement of the 2006 annual stock option grant due to the delay in the Company’s filing of this Annual Report on Form 10-K. The Company’s annual grant typically occurs during the first quarter of each fiscal year. The current estimate is also based on assumptions regarding a number of subjective variables, which include estimating the expected term of stock options and the current volatility of the Company’s stock price.
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, a replacement of APB Opinion No. 20 and FASB Statement No. 3. SFAS No. 154 requires retrospective application to prior period financial statements for changes in accounting principles, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 also requires that retrospective application of a change in accounting principle be limited to the direct effects of the change. Indirect effects of a change in accounting principle should be recognized in the period of the accounting change. SFAS No. 154 further requires a change in depreciation, amortization or depletion method for long-lived, non-financial assets to be accounted for as a change in accounting estimate affected by a change in accounting principle. SFAS No. 154 will become effective for the Company's fiscal year beginning January 1, 2006.
In June 2005, the FASB issued FASB Staff Position No. FAS 143-1 (FSP FAS 143-1), Accounting for Electronic Equipment Waste Obligations. FSP FAS 143-1 addresses the accounting for obligations associated with the Directive 2002/96/EC on Waste Electrical and Electronic Equipment (the Directive) adopted by the European Union (EU). FSP FAS 143-1 is effective the later of the first reporting period that ends after June 8, 2005 or the date that the EU-member country adopts the law. The obligation arising from the adoption by all EU-member countries in which the Company conducts business did not have a material effect on the Company's financial condition or results of operations.
In June 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109 (FIN 48). FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company is in the process of evaluating the impact FIN 48 will have on its results of operations and financial position.



PAGE 73

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. Specifically, this Statement sets forth a definition of fair value, and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The provisions of SFAS No. 157 are generally required to be applied on a prospective basis, except to certain financial instruments accounted for under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, for which the provisions of SFAS No. 157 should be applied retrospectively. The Company will adopt SFAS No. 157 in the first quarter of 2008 and is still evaluating the effect, if any, on its financial position or results of operations.
In September 2006, the FASB issued SFAS No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106 and 132(R). SFAS No. 158 requires an employer to recognize the funded status of its defined benefit pension and postretirement plans as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. In addition, SFAS No. 158 requires an employer to measure the funded status of a plan as of the date of the employer’s fiscal year-end statement of financial position, which is consistent with the measurement date for the Company’s defined benefit plans. SFAS No. 158 made no changes to the recognition of expense. SFAS No. 158 will be effective as of the fiscal year ending December 30, 2006. The Company has not yet completed its evaluation of the tax effect of adoption of SFAS No. 158. Based on the year-end measurement of plan assets and liabilities, the impact of adopting the provisions of SFAS No. 158, before any tax effect, is expected to be an increase in total liabilities of approximately $12.3, a decrease in total assets of approximately $0.4 and a decrease in accumulated other comprehensive income of approximately $12.7. The decrease in accumulated other comprehensive income will be reported in total shareholders’ equity, net of any tax benefits (including the impact of any valuation allowance deemed appropriate), with the tax benefits reported in deferred tax assets. The adoption of SFAS No. 158 has no impact on financial covenant compliance included in the Company’s debt agreements.
In September 2006, the SEC staff issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (SAB 108). SAB 108 was issued in order to eliminate the diversity in practice surrounding how public companies quantify financial statement misstatements. SAB 108 requires that registrants quantify errors using both a balance sheet and income statement approach and evaluate whether either approach results in a misstated amount that, when all relevant quantitative and qualitative factors are considered, is material. The adoption of this statement is not expected to have a material impact on the Company's consolidated financial condition or results of operations.

Reclassifications Certain amounts have been reclassified to maintain comparability among the periods presented.


2. Restatement

For the matters discussed below, the Company restated its consolidated financial statements presented in this report as of December 25, 2004 and for fiscal years 2003 and 2004. In addition, the Company restated selected financial data as of 2003, 2002 and 2001 and for fiscal years 2002 and 2001. See Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited) and beginning shareholders' equity for the impact of the restatement for periods prior to 2001. The restatement also reflects certain entries that the Company determined, while not individually or in the aggregate material to the periods in which they were recorded or to the relevant periods, are now required to be recorded in the prior periods to which they relate. For the impact of the restated financial results for the first and second quarterly periods of 2005 and the quarterly periods of 2004, see Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited). The nature and impact of these adjustments are described below. The impact of these adjustments is shown in the following tables.




PAGE 74

Brazil Matters In September 2005, the Audit Committee of the Board of Directors commenced an independent investigation into allegations of misconduct by the management of the Company’s Brazilian subsidiary, BL Industria Otica, Ltda. (BLIO), which had been reported to the Company’s senior management by a BLIO employee pursuant to the Company’s established compliance program. The Company also voluntarily reported these matters to the staff of the Northeast Regional Office of the SEC, which has commenced an informal inquiry. In connection with the Audit Committee investigation of the BLIO matters, the Company learned that the general manager, the controller and other employees of BLIO, in violation of Company policies, engaged in improper management and accounting practices. The Company also learned certain Brazilian tax authorities had made tax assessments relating to or arising from Brazilian VAT, social contribution, income and certain import-related taxes against BLIO for a total of approximately $33.0 in unpaid taxes, interest and penalties which relate back to various earlier periods. Appropriate reserves relating to these assessments were not reflected by BLIO in its subsidiary financial statements, as required by the Company's established policies and procedures. In addition, the Company learned that BLIO had failed to comply with certain local payroll tax obligations and also mischaracterized approximately $0.6 in expenses to fund an approximately $1.5, unauthorized local pension arrangement for the benefit of the general manager, the controller and other members of local management. The Company conducted a further review of these tax matters, and determined that cumulative after-tax charges in periods prior to 2003 through the first half of 2005 of $27.8 were appropriate. The majority of these charges related to and were recorded in 2001, 2002 and 2003. In October 2006, the Company applied for and expects to be granted amnesty from the state government of Sao Paulo, Brazil as to a portion of the penalties and interest associated with one such assessment. As a result, the Company expects to reverse approximately $20 of approximately $27 of penalties and interest expense that were recorded as part of the financial restatement upon formal notification of cancellation by the state government of Sao Paulo, Brazil.

Asia and Other Revenue Recognition Matters

In late November 2005, following employee reports regarding improper sales practices at the Company’s Korean vision care joint venture, BL Korea, the Audit Committee commenced an independent investigation into revenue recognition practices at BL Korea and engaged an outside law firm to assist with the investigation. The investigation was voluntarily reported to the Northeast Regional Office of the SEC. As a result of the Audit Committee’s independent investigation, the Company determined that from 2002 to 2005 sales management at BL Korea, in violation of the Company’s policies, engaged in improper vision care-related sales practices including, at various times, granting customers improper rights to return product, facilitating product exchanges between customers without properly accounting for such exchanges, failing to properly process product returns and granting excessive credit. As a result of these sales practices which violated Company policies, risk of loss of the product did not properly transfer to customers. The Company has determined that pursuant to GAAP, all BL Korea vision care transactions during this period should be recorded as consignment sales.



PAGE 75

In light of the investigations of the Company’s Brazil and Korea subsidiaries, the Company undertook expanded year-end procedures focused on, among other things, revenue recognition and sales practices at certain other subsidiaries. As a result of these procedures, the Company determined that it did not maintain effective controls over certain subsidiaries' relationships with their key distributors, particularly in the Company's Japan and India subsidiaries, and did not maintain effective controls over the installation of refractive laser surgery equipment in multiple locations where the Company does business, to ensure that revenue associated with such distributor and laser sales was recognized in accordance with GAAP. Specifically, the Company determined that the customer arrangements were not adequately reviewed by the appropriate persons at such subsidiaries to identify and provide reasonable assurance regarding the proper application of the appropriate method of revenue recognition. In addition, the Company determined that it did not maintain effective controls to prevent subsidiary management from overriding established financial controls or making errors in the application of policies concerning the accuracy and valuation of accounts receivable and the maintenance of distributor inventory at established threshold levels, as well as regarding administration of credit limits, extensions of credit terms, price discounting, sales returns and exchanges, transfer of the risk of ownership, and sales order entry and control. The Company’s restatement of prior-period financial statements includes additional adjustments relating to revenue recognition for the following matters: the BL Korea vision care sales discussed previously; certain refractive laser sales; certain vision care transactions with a single distributor in Thailand; vision care transactions with two large distributors in Japan; vision care and cataract transactions with the distributor network in India; and the improper handling of certain sales related reserves in China. Of these adjustments, the largest relates to the vision care transactions in Japan which reduced net sales in periods prior to 2003 through the first six months of 2005 by a cumulative total of $12.3 and reduced net earnings by a cumulative total of $5.3. The revenue recognition adjustments for vision care sales in Korea from periods prior to 2003 through the first half of 2005 reduced net sales by a cumulative total of $8.4 and reduced net earnings by a cumulative total of $3.3. All other revenue recognition matter adjustments prior to 2003 through the first six months of 2005 in the aggregate reduced net sales by a cumulative total of $6.7 and reduced net earnings by a cumulative total of $2.5.

Tax Matters In 2005, the Company undertook a comprehensive review of its accounting for income taxes. As a result, the Company’s restatement of prior-period financial statements includes adjustments from periods prior to 2003 through the first six months of 2005 that reduce net earnings by $2.1. These adjustments related primarily to the Company’s determination of deferred income tax assets and liabilities. The most significant adjustment related to the recognition of deferred tax liabilities for outside basis differences in foreign subsidiaries where the earnings of such subsidiaries are not permanently re-invested. This adjustment reduced net earnings by $27.8, the majority of which was recorded prior to 2003. The Company also determined that it had not properly reconciled the tax effects of differences between its financial reporting and tax-based balance sheets to the reported deferred tax assets and liabilities. This adjustment increased net earnings for periods prior to 2003 through the first six months of 2005 by $21.3. In addition, the Company determined that it did not properly account for deferred income tax assets and liabilities related to certain acquired entities, which required an adjustment in periods prior to 2003, and did not properly assess the realizability of certain tax attributes in determining its valuation allowance needs, which required adjustments primarily in periods prior to 2003 and in 2004. These adjustments increased earnings for periods prior to 2003 through the first six months of 2005 by $23.8. Other adjustments related to income taxes payable and income tax expense were also required. These adjustments related primarily to the determination of 2001 income tax related to the Company’s discontinued Eyewear business and the determination of reserves for uncertain tax positions, which reduced net earnings for periods prior to 2003 through the first six months of 2005 by $9.4 and $5.3, respectively. Adjustments from periods prior to 2003 through the first six months of 2005 for other tax matters reduced earnings by $4.7.




PAGE 76

Deferred Compensation Plan The Company determined that the liability associated with the deferral of certain Company stock under its approved Long-Term Deferred Compensation Plan should have been marked to market. Under the Plan, employees have the opportunity to defer stock awards granted under the Company's Long-Term Incentive Plan. Deferred stock awards are held in a rabbi trust and diversification is not permitted. Although it was the Compensation Committee's and the Company’s intention to settle the liability only in shares of the Company’s stock, the Plan document included a clause which allowed the Company to pay the participant upon distribution in Company stock or, at the sole option of the Company, in cash, based upon the market value of the Company Common stock at the time of distribution. EITF 97-14: Accounting for Deferred Compensation Arrangements Where Amounts Earned Are Held in a Rabbi Trust and Invested, outlines four potential scenarios for deferred compensation arrangements and how the obligations and assets held in trust should be accounted for. As the Company’s Plan did not permit diversification and may be settled by the delivery of cash or shares of the Company’s stock, the deferred compensation obligation should be classified as a liability and adjusted with a corresponding charge (or credit) to compensation cost, to reflect the changes in the fair value of the amount owed to the employee. Stock held by the rabbi trust should be classified in equity in a manner similar to the manner in which treasury stock is accounted for and subsequent changes in the fair value of the Company’s stock are not recognized. The Company's restatement of prior-period financial statements includes adjustments from periods prior to 2003 through the first six months of 2005 that reduce net earnings by a cumulative total of $6.2. In May 2006, the Company amended the Plan requiring all future distributions of participant deferrals of stock awards be settled only in shares of Company stock, eliminating the sole option of the Company to settle in cash, and thereby eliminating the requirement under GAAP to recognize subsequent changes in the fair value of Company stock.

Other Items In the course of completing the Audit Committee's previously discussed BL Korea investigation, evidence was discovered that indicated managers in the Company's Asian operations improperly recorded reserve account entries. Therefore, the Audit Committee undertook an investigation into the timing and appropriateness of reserve entries. As a result, the Company has recorded in its financial statements from periods prior to 2003 through the first six months of 2005 cumulative adjustments to net earnings of less than $1 in the aggregate, all of which relate to the Asia Region, for Japan subsidiary litigation reserves and other Asia business-related reserves. In addition, the Company reviewed all significant accounting entries, including out-of-period adjustments, made in the periods covered by the restatement and determined that a number of adjustments were not in accordance with GAAP or belonged in different quarterly periods within the restated periods. The largest of these adjustments related to the reversal of approximately $13.5 of currency translation adjustments (CTA) which had been released to income upon liquidation of certain of the Company's subsidiaries. These transactions should have been viewed as a change in functional currency, rather than as a liquidation. The remaining adjustments, in the aggregate, increased net earnings by a cumulative total of $3.4. In addition, the Company identified certain amounts that were immaterial both individually and in the aggregate from both a quantitative and qualitative perspective that were not included in the restatement.



PAGE 77

The following tables present the impact of the restatement adjustments on the Company’s consolidated Statements of Income for the years ended December 25, 2004 and December 27, 2003:


   
For the Year Ended December 25, 2004
 
   
 
 
As Previously Reported
 
 
 
 
Brazil Matters
 
Asia and Other Revenue Recognition Matters
 
 
 
 
Tax Matters
 
 
 
Deferred Compensation Plan
 
 
 
 
Other Items
 
 
 
 
 
Restated
 
Net Sales
 
$
2,232.3
 
$
-
 
$
(2.6
)
$
-
 
$
-
 
$
3.8
 
$
2,233.5
 
Costs and Expenses
                                           
   Cost of products sold
   
934.9
   
-
   
(1.0
)
 
-
   
-
   
(4.7
)
 
929.2
 
   Selling, administrative and general
   
855.3
   
1.3
   
-
   
-
   
3.1
   
3.0
   
862.7
 
   Research and development
   
162.5
   
-
   
-
   
-
   
-
   
-
   
162.5
 
     
1,952.7
   
1.3
   
(1.0
)
 
-
   
3.1
   
(1.7
)
 
1,954.4
 
Operating Income
   
279.6
   
(1.3
)
 
(1.6
)
 
-
   
(3.1
)
 
5.5
   
279.1
 
Other (Income) Expense
                                           
   Interest and investment income
   
(13.8
)
 
-
   
-
   
-
   
-
   
-
   
(13.8
)
   Interest expense
   
48.4
   
1.0
   
-
   
-
   
-
   
0.2
   
49.6
 
   Foreign currency, net
   
(1.8
)
 
0.3
   
-
   
-
   
-
   
2.1
   
0.6
 
     
32.8
   
1.3
   
-
   
-
   
-
   
2.3
   
36.4
 
Income before Income Taxes and Minority Interest
   
246.8
   
(2.5
)
 
(1.6
)
 
-
   
(3.1
)
 
3.1
   
242.7
 
   Provision for income taxes
   
82.7
   
(0.7
)
 
(0.8
)
 
2.1
   
(1.2
)
 
1.7
   
83.8
 
   Minority interest in subsidiaries
   
4.5
   
-
   
0.5
   
-
   
-
   
-
   
5.0
 
Net Income
 
$
159.6
 
$
(1.8
)
$
(1.3
)
$
(2.1
)
$
(1.9
)
$
1.4
 
$
153.9
 
Basic Earnings Per Share
 
$
3.03
 
$
(0.03
)
$
(0.02
)
$
(0.04
)
$
(0.04
)
$
0.03
 
$
2.94
 
Diluted Earnings Per Share
 
$
2.93
 
$
(0.03
)
$
(0.02
)
$
(0.04
)
$
(0.04
)
$
0.03
 
$
2.83
 




PAGE 78

   
For the Year Ended December 27, 2003
 
   
 
 
As Previously Reported
 
 
 
 
Brazil Matters
 
Asia and Other Revenue Recognition Matters
 
 
 
 
Tax Matters
 
 
 
Deferred Compensation
Plan
 
 
 
 
Other Items
 
 
 
 
 
Restated
 
Net Sales
 
$
2,019.5
 
$
-
 
$
(5.4
)
$
-
 
$
-
 
$
4.4
 
$
2,018.5
 
Costs and Expenses
                                           
   Cost of products sold
   
858.0
   
-
   
(1.9
)
 
-
   
-
   
0.7
   
856.8
 
   Selling, administrative and general
   
782.3
   
7.4
   
(0.3
)
 
-
   
3.7
   
(3.3
)
 
789.9
 
   Research and development
   
149.9
   
-
   
-
   
-
   
-
   
-
   
149.9
 
   Restructuring (reversal) charges and asset write-offs
   
(6.3
)
 
-
   
-
   
-
   
-
   
-
   
(6.3
)
     
1,783.9
   
7.4
   
(2.2
)
 
-
   
3.7
   
(2.6
)
 
1,790.3
 
Operating Income
   
235.6
   
(7.4
)
 
(3.3
)
 
-
   
(3.7
)
 
7.1
   
228.2
 
Other (Income) Expense
                                           
   Interest and investment income
   
(15.7
)
 
-
   
-
   
-
   
-
   
-
   
(15.7
)
   Interest expense
   
54.2
   
1.0
   
-
   
-
   
-
   
-
   
55.2
 
   Foreign currency, net
   
0.1
   
-
   
-
   
-
   
-
   
13.3
   
13.4
 
     
38.6
   
1.0
   
-
   
-
   
-
   
13.3
   
52.9
 
Income before Income Taxes and Minority Interest
   
197.0
   
(8.4
)
 
(3.3
)
 
-
   
(3.7
)
 
(6.2
)
 
175.3
 
   Provision for income taxes
   
67.0
   
(0.9
)
 
(0.8
)
 
(0.7
)
 
(1.5
)
 
2.2
   
65.3
 
   Minority interest in subsidiaries
   
3.6
   
-
   
(0.5
)
 
-
   
-
   
-
   
3.1
 
Income before Cumulative Effect of Change in
    Accounting Principle
   
126.4
   
(7.5
)
 
(2.1
)
 
0.7
   
(2.3
)
 
(8.4
)
 
106.9
 
Cumulative Effect of Change in Accounting Principle,
   Net of Taxes
   
(0.9
)
 
-
   
-
   
-
   
-
   
-
   
(0.9
)
Net Income
 
$
125.5
 
$
(7.5
)
$
(2.1
)
$
0.7
 
$
(2.3
)
$
(8.4
)
$
106.0
 
Basic Earnings Per Share
 
$
2.37
 
$
(0.14
)
$
(0.04
)
$
0.01
 
$
(0.04
)
$
(0.16
)
$
2.02
 
Diluted Earnings Per Share
 
$
2.34
 
$
(0.14
)
$
(0.04
)
$
0.01
 
$
(0.04
)
$
(0.16
)
$
1.98
 


Adjustments identified relating to fiscal years prior to 2003 are reflected in beginning retained earnings in the accompanying Statement of Changes in Shareholders’ Equity. The cumulative impact of these adjusting entries decreased 2003 beginning retained earnings by $23.3 net of tax, and primarily represent adjustments relating to the Brazil matters and the Company's comprehensive review of its accounting for income taxes (see Note 22 — Quarterly Results, Stock Prices and Selected Financial Data (Unaudited)) for the impact of restatement on individual years.




PAGE 79

    The following table presents the impact of the restatement adjustments on the Company’s consolidated Balance Sheets as of December 25, 2004:


   
December 25, 2004
 
   
As Previously Reported
 
Effect of Restatement
 
Restated
 
Assets
             
Cash and cash equivalents
 
$
501.8
 
$
-
 
$
501.8
 
Trade receivables, less allowances of $22.1
   
511.4
   
-
   
511.4
 
Inventories, net
   
204.4
   
7.7
   
212.1
 
Other current assets
   
95.7
   
12.9
   
108.6
 
Deferred income taxes
   
67.2
   
44.9
   
112.1
 
Total Current Assets
   
1,380.5
   
65.5
   
1,446.0
 
                     
Property, Plant and Equipment, net
   
580.9
   
(0.1
)
 
580.8
 
Goodwill
   
736.3
   
(54.1
)
 
682.2
 
Other Intangibles, net
   
204.3
   
-
   
204.3
 
Other Long-Term Assets
   
108.7
   
(1.8
)
 
106.9
 
Deferred Income Taxes
   
11.4
   
14.2
   
25.6
 
Total Assets
 
$
3,022.1
 
$
23.7
 
$
3,045.8
 
                     
Liabilities and Shareholders' Equity
                   
Notes payable
 
$
-
 
$
2.6
 
$
2.6
 
Current portion of long-term debt
   
100.8
   
-
   
100.8
 
Accounts payable
   
93.6
   
1.2
   
94.8
 
Accrued compensation
   
149.1
   
4.2
   
153.3
 
Accrued liabilities
   
390.8
   
62.4
   
453.2
 
Federal, state and foreign income taxes payable
   
97.8
   
11.8
   
109.6
 
Deferred income taxes
   
0.4
   
3.3
   
3.7
 
Total Current Liabilities
   
832.5
   
85.5
   
918.0
 
                     
Long-Term Debt, less current portion
   
543.3
   
-
   
543.3
 
Other Long-Term Liabilities
   
130.3
   
1.6
   
131.9
 
Deferred Income Taxes
   
73.6
   
1.6
   
75.2
 
Total Liabilities
   
1,579.7
   
88.7
   
1,668.4
 
                     
Minority Interest
   
15.5
   
(0.9
)
 
14.6
 
                     
Commitments and Contingencies (Note 17)
                   
                     
Common Stock
   
24.1
   
-
   
24.1
 
Class B Stock
   
-
   
-
   
-
 
Capital in Excess of Par Value
   
103.8
   
1.8
   
105.6
 
Common and Class B Stock in Treasury, at cost
   
(397.8
)
 
(11.4
)
 
(409.2
)
Retained Earnings
   
1,528.9
   
(48.5
)
 
1,480.4
 
Accumulated Other Comprehensive Income
   
173.8
   
(6.0
)
 
167.8
 
Other Shareholders' Equity
   
(5.9
)
 
-
   
(5.9
)
Total Shareholders' Equity
   
1,426.9
   
(64.1
)
 
1,362.8
 
Total Liabilities and Shareholders' Equity
 
$
3,022.1
 
$
23.7
 
$
3,045.8
 




PAGE 80

Significant adjustments to the balance sheet, reflected above, include the following:

·  
The Company's comprehensive review of its accounting for income taxes had the following impact:
·  
other current assets increased $12.9, primarily reflecting the reclassification of tax on intercompany profit reserves from current deferred income tax assets to prepaid tax;
·  
current deferred income tax assets increased $44.9 primarily reflecting the reconciliation of tax effects on the differences between financial reporting and tax bases in various current assets and liability accounts including inventories $10.3, accrued employee benefits $10.6, and other current liabilities $13.0;
·  
goodwill decreased $54.1 reflecting restatement adjustments made to goodwill associated with a 1998 acquisition;
·  
non-current deferred income tax assets increased $14.2 primarily reflecting restatement adjustments of $55.5 to deferred tax assets associated with certain acquired entities, partially offset by an adjustment of $45.4 to deferred tax liabilities on earnings of foreign subsidiaries which are not re-invested; and
·  
federal, state & foreign income taxes payable increased $11.8, reflecting the adjusted tax liability associated with the restatement adjustments in aggregate.
·  
Accrued liabilities increased $62.4 primarily reflecting restatement adjustments made to record deferred consignment revenue of $27.7 for Asia revenue recognition matters, other accrued liabilities of $26.6 for Brazil matters, and deferred compensation liability of $15.3 for the deferred compensation plan matter.
·  
Common and Class B stock in treasury, at cost, increased $11.4 reflecting restatement adjustments associated with the deferred compensation plan matter.
·  
The $48.5 decrease in retained earnings reflects the cumulative impact of restatement adjustments.

The following table presents the major subtotals for the Company’s Statements of Cash Flows and the related impact of the restatement adjustments discussed above for the years ended December 25, 2004 and December 27, 2003:


   
2004
 
2003
 
   
As Previously Reported
 
Restated
 
As Previously Reported
 
Restated
 
Net Cash Provided by (Used In):
                 
Operating activities
 
$
280.5
 
$
284.5
 
$
248.2
 
$
252.4
 
Investing activities
   
(121.6
)
 
(121.7
)
 
(94.1
)
 
(94.1
)
Financing activities
   
(225.3
)
 
(229.2
)
 
(79.6
)
 
(83.8
)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
   
5.6
   
5.6
   
23.0
   
23.0
 
Net Change in Cash and Cash Equivalents
   
(60.8
)
 
(60.8
)
 
97.5
   
97.5
 
Cash and Cash Equivalents, Beginning of Year
   
562.6
   
562.6
   
465.1
   
465.1
 
Cash and Cash Equivalents, End of Year
 
$
501.8
 
$
501.8
 
$
562.6
 
$
562.6
 





PAGE 81

    The following table presents the impact of the restatement adjustments discussed above on the Company's consolidated comprehensive income for the years ended December 25, 2004 and December 27, 2003:

   
2004
 
2003
 
   
As Previously Reported
 
 
Restated
 
As Previously Reported
 
 
Restated
 
Net Income
 
$
159.6
 
$
153.9
 
$
125.5
 
$
106.0
 
Currency Translation Adjustments
   
70.7
   
63.7
   
135.1
   
123.5
 
Net Loss on Cash Flow Hedges
   
-
   
-
   
(0.2
)
 
(0.2
)
Reclassification Adjustment into Net Income for Net Loss
  on Cash Flow Hedges
   
1.9
   
1.9
   
1.7
   
3.2
 
Minimum Additional Pension Liability
   
(1.6
)
 
(5.3
)
 
4.7
   
4.4
 
Total Comprehensive Income
 
$
230.6
 
$
214.2
 
$
266.8
 
$
236.9
 


Adjustments to the Company’s consolidated comprehensive income for the years ended December 25, 2004 and December 27, 2003 are mainly attributable to the following:

2004

·  
Restated net income decreased from $159.6 to $153.9.
·  
Currency translation adjustments decreased from $70.7 to $63.7 primarily as a result of adjustments made as part of the Company's comprehensive review of its accounting for income taxes, of which, $6.3 represents adjustments to tax liabilities recorded under APB 23.
·  
The change in minimum additional pension liability increased from $(1.6) to $(5.3) reflecting tax adjustments made as part of the Company’s comprehensive review of its accounting for income taxes as well as other adjustments made for accounting entries not in accordance with GAAP.

2003

·  
Restated net income decreased from $125.5 to $106.0.
·  
Currency translation adjustments decreased from $135.1 to $123.5 primarily representing adjustments made as part of the Company's comprehensive review of its accounting for income taxes, of which, $10.1 represents adjustments to tax liabilities recorded under APB 23. The decrease in currency translation adjustments as a result of these tax entries was partially offset by a $4.3 increase to currency translation adjustments reflecting a reclassification adjustment related to the reversal of the liquidation of a non-U.S. subsidiary as it was determined that this transaction should have been viewed as a change in functional currency rather than as a liquidation.
·  
The change in minimum additional pension liability decreased from $4.7 to $4.4 reflecting tax adjustments made as part of the Company's comprehensive review of its accounting for income taxes.

The notes to the financial statements also reflect the impact of the restatement adjustments discussed above.





PAGE 82

3.  Acquisitions

On September 26, 2005, the Company acquired a 55-percent controlling interest in the Shandong Chia Tai Freda Pharmaceutical Group (Freda), the leading ophthalmic pharmaceutical company in China, from Sino Biopharmaceutical Ltd. (Sino). Freda develops, manufactures and markets medications used to treat ocular inflammation and infection, glaucoma and dry eye including the Moisten and Mioclear lines of eye drops. In November 2005, the Company effectively acquired an additional 15-percent interest in Freda held by two other entities for an amount equivalent on a per-share basis to the price paid to Sino. Total purchase price for the Freda acquisition was $254.5, or $248.1 net of cash acquired. Additionally, the Company incurred direct transaction costs of $5.6. As of December 31, 2005, total cash paid for the acquisition (excluding acquisition costs) was $226.8 or $220.4 net of cash acquired. In January 2006, an additional cash payment of $26.6 was made and the remaining $1.1 will be paid no later than January 2009. The acquisition of the 55-percent interest was partially financed with $175.0 of borrowings under the Company's syndicated revolving credit facility, which was repaid in December 2005. The additional 15-percent interest was partially financed with a $26.8 non-U.S. line of credit borrowing, which was repaid in January 2006.
The acquisition brings immediate presence in a rapidly growing market through the broadest ophthalmic pharmaceuticals sales and distribution organization in China. It also provides in-country regulatory expertise and a state-of-the-art manufacturing facility, which management believes should help the Company bring branded products to the Chinese market.
Supplemental pro forma information per SFAS No. 141, Business Combinations, and SFAS No. 142, Goodwill and Other Intangible Assets, are not provided, as the impact of the Freda acquisition did not have a material effect on the Company’s 2005 results of operations, cash flows or financial position. The results of operations of Freda were included in the consolidated financial statements of the Company beginning in the fourth quarter 2005.
The purchase price allocation was substantially complete at the end of 2005. In accordance with the purchase method of accounting, the excess of the purchase price over the fair value of the identified assets and liabilities has been recorded as goodwill. As part of the purchase price allocation, $7.8 was recorded as a minority interest liability representing the minority shareholders’ 30-percent interest in Freda. The following table summarizes the fair values of the assets acquired and liabilities assumed in the Freda acquisition:

Current Assets (includes $6.4 of cash acquired) 1
 
$
26.4
 
Property, Plant & Equipment
   
23.8
 
Other Long-Term Assets
   
0.9
 
Intangible Assets Subject to Amortization 2
       
Distributor Relationships
   
57.9
 
Tradenames
   
23.7
 
Technology
   
7.1
 
Non-Compete Agreements
   
1.8
 
Goodwill
   
160.5
 
Total Assets Acquired
   
302.1
 
         
Current Liabilities
   
20.2
 
Long-Term Liabilities
   
14.0
 
Minority Interest
   
7.8
 
Total Liabilities Assumed
   
42.0
 
         
Net Assets Acquired
 
$
260.1
 

1
Includes a purchase accounting adjustment of $1.9 associated with the step-up of inventory which was fully amortized in the fourth quarter of 2005.
2
Weighted average remaining useful life of acquired intangible assets were as follows: distributor relationships - 16 years; tradenames - 24 years; technology - 19 years; and non-compete agreements - 3 years.

Consistent with the integration objectives of the acquisition, the Company ascribed $154.9 of goodwill to the Global Operations & Engineering business segment and $5.6 to its Asia business segment. None of the goodwill is deductible for tax purposes.





PAGE 83

4.  Earnings Per Share

Basic earnings per share is computed based on the weighted average number of Common and Class B shares outstanding during a period. Diluted earnings per share reflect the assumed conversion of dilutive stock. In computing the per share effect of assumed conversion, funds which would have been received from the exercise of options were considered to have been used to repurchase Common shares at average market prices for the period, and the resulting net additional Common shares are included in the calculation of average Common shares outstanding.
In a given period there may be outstanding stock options considered anti-dilutive as the options' exercise price was greater than the average market price of Common shares during that period and, therefore, excluded from the calculation of diluted earnings per share. Anti-dilutive stock options to purchase approximately 0.1 million shares of Common stock at an exercise price of $83.55 were outstanding at December 31, 2005. Anti-dilutive stock options to purchase 1.1 million shares of Common stock at exercise prices ranging from $61.97 to $72.97 were outstanding at December 25, 2004. At December 27, 2003, anti-dilutive stock options to purchase 3.5 million shares of Common stock with exercise prices ranging from $40.31 to $72.97 were outstanding.
In August 2003, the Company issued $160.0 variable-rate Convertible Senior Notes (Old Notes) due in 2023. The Old Notes were convertible into shares of the Company's Common stock under certain conditions, such as when the closing sale price of the Company's Common stock is greater than 120 percent of the initial conversion price of $61.44 for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of a calendar quarter. In December 2004, the Company completed its offer to exchange up to $160.0 of the Old Notes for an equal amount of its 2004 Senior Convertible Securities due 2023 (New Securities). The terms of the New Securities are consistent with those of the Old Notes except that settlement upon conversion of the New Securities will be paid in cash up to the principal amount of the converted New Securities with any excess of the conversion value settled in shares of the Company's stock. An amount equal to $155.9 of the Old Notes, or 97.4 percent of the outstanding issue, was tendered in exchange for an equal amount of the New Securities. None of the conditions that would permit conversion had been satisfied during fiscal 2004. The conversion right was triggered on June 17, 2005, and the Old Notes and New Securities were convertible at the option of the holder beginning July 1, 2005. In the event a holder elects to convert its note, the Company expects to fund a cash settlement of any such conversion from borrowings under its syndicated revolving credit facility as described in Note 11 — Debt.
The exchange of the majority of the outstanding Old Notes has essentially eliminated the potential dilution under the provisions of EITF Issue 04-8, The Effect of Contingently Convertible Debt on Diluted Earnings per Share. The impact of the Old Notes on the diluted EPS calculation was an adjustment of approximately $0.2 to net income for 2005 and less than $0.1 for 2004 and 2003, representing the interest and amortization expense attributed to the remaining Old Notes. The effects of the Old Notes and the New Securities on dilutive shares for fiscal years 2005, 2004 and 2003 are reflected in the table below.
The following table summarizes the amounts used to calculate basic and diluted EPS:

   
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
Income Before Cumulative Effect of Change in Accounting Principle
 
$
19.2
 
$
153.9
 
$
106.9
 
Cumulative Effect of Change in Accounting Principle, Net of Taxes
   
-
   
-
   
(0.9
)
Net Income
 
$
19.2
 
$
153.9
 
$
106.0
 
                     
Weighted Average Basic Shares Outstanding (000s)
   
53,146
   
52,433
   
52,426
 
Effect of Dilutive Shares
   
1,981
   
2,004
   
1,065
 
Effect of Convertible Senior Notes Shares (Old Notes)
   
67
   
67
   
28
 
Effect of 2004 Senior Convertible Securities Shares (New Securities)
   
490
   
-
   
-
 
Weighted Average Diluted Shares Outstanding (000s)
   
55,684
   
54,504
   
53,519
 
                     
Basic Earnings Per Share
 
$
0.36
 
$
2.94
 
$
2.02
 
                     
Diluted Earnings Per Share
 
$
0.35
 
$
2.83
 
$
1.98
 





PAGE 84

5.   Business Segment and Geographic Information

The Company is organized on a regionally based management structure for commercial operations. The research and development and product supply functions of the Company are managed on a global basis. Beginning in 2005, the Company’s engineering function, which had previously been part of the research and development segment, became part of the product supply function. The Company's segments, after the realignment of the engineering function, are the Americas region; the Europe, Middle East and Africa region (Europe); the Asia region; the Research & Development organization and the Global Operations & Engineering organization.
Operating income is the primary measure of segment income. No items below operating income are allocated to segments. Restructuring charges and charges related to certain significant events, although related to specific segments, are also excluded from management basis results. The accounting policies used to generate segment results are the same as the Company's overall accounting policies. Inter-segment sales were $725.8, $666.9 and $498.6 for the years ended December 31, 2005, December 25, 2004, and December 27, 2003, respectively. All inter-segment sales have been eliminated upon consolidation and have been excluded from the amounts in the tables on the following pages.
Segment assets for the three geographic regions represent net trade receivables; net inventories; net property, plant and equipment; goodwill; net intangibles and other current and long-term assets. In the Research & Development organization, assets are comprised of net property, plant and equipment and other current and long-term assets. Assets in the Global Operations & Engineering organization segment include net inventories; net property, plant and equipment; goodwill; net intangibles and other current and long-term assets. Corporate administration assets are mainly cash and cash equivalents; deferred income taxes; net property, plant and equipment and other current and long-term assets not allocated to other segments.




PAGE 85

Business Segment The following table presents sales and other financial information by business segment for the years 2005, 2004 and 2003:

   
Net Sales
 
Operating Income
 
Depreciation and Amortization
 
Capital Expenditures
 
Assets1
 
2005
                     
Americas
 
$
1,005.3
 
$
333.0
 
$
8.3
 
$
3.5
 
$
327.9
 
Europe
   
859.9
   
250.8
   
10.4
   
3.9
   
359.9
 
Asia
   
488.6
   
123.6
   
7.6
   
4.8
   
297.8
 
Research & Development
   
-
   
(200.5
)
 
5.3
   
24.9
   
54.7
 
Global Operations & Engineering
   
-
   
(131.7
)
 
73.3
   
70.8
   
1,344.8
 
     
2,353.8
   
375.2
   
104.9
   
107.9
   
2,385.1
 
Corporate administration
   
-
   
(89.8
)
 
20.9
   
8.1
   
1,031.3 
 
Other significant charges 2
     -    
(1.9
)
  -     -     -  
   
$
2,353.8
 
$
283.5
 
$
125.8
 
$
116.0
 
$
3,416.4
 
                                 
2004 (Restated)
                               
Americas
 
$
960.2
 
$
326.1
 
$
8.7
 
$
3.5
 
$
313.7
 
Europe
   
818.9
   
251.2
   
16.5
   
2.8
   
401.9
 
Asia
   
454.4
   
128.5
   
5.9
   
3.7
   
224.1
 
Research & Development
   
-
   
(180.6
)
 
5.4
   
12.5
   
50.8
 
Global Operations & Engineering
   
-
   
(157.2
)
 
69.3
   
69.4
   
1,167.5
 
     
2,233.5
   
368.0
   
105.8
   
91.9
   
2,158.0
 
Corporate administration
   
-
   
(88.9
)
 
18.5
   
27.0
   
887.8
 
   
$
2,233.5
 
$
279.1
 
$
124.3
 
$
118.9
 
$
3,045.8
 
                                 
2003 (Restated)
                               
Americas
 
$
903.3
 
$
282.6
 
$
13.0
 
$
5.0
       
Europe
   
724.4
   
201.5
   
16.2
   
4.2
       
Asia
   
390.8
   
106.1
   
6.9
   
3.3
       
Research & Development
   
-
   
(166.1
)
 
6.0
   
8.1
       
Global Operations & Engineering
   
-
   
(123.1
)
 
73.6
   
42.7
       
     
2,018.5
   
301.0
   
115.7
   
63.3
       
Corporate administration
   
-
   
(73.5
)
 
8.7
   
28.2
       
Restructuring reversal
   
-
   
6.3
   
-
   
-
       
Other significant charges 2
   
-
   
(5.6
)
 
-
   
-
       
   
$
2,018.5
 
$
228.2
 
$
124.4
 
$
91.5
       

1
Assets by business segment for 2005 and 2004 reflect restatement adjustments made to goodwill in association with the comprehensive tax review.
2
Other significant charges in 2005 represent purchase accounting adjustments related to the acquisition of Freda (see Note 3 — Acquisitions). Other significant charges in 2003 pertain to research and development expense associated with the acquisition of an early-stage pharmaceutical technology.




PAGE 86

In each geographic segment, the Company markets products in five product categories: contact lens, lens care, pharmaceuticals, cataract and vitreoretinal, and refractive (see Note 1 — Significant Accounting Policies; Revenue Recognition for a discussion of specific products under each product category). There are no transfers of products between product categories. The following table presents sales by product category for the years 2005, 2004 and 2003:

   
Net Sales
 
   
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
Contact Lens
 
$
728.5
 
$
671.0
 
$
593.2
 
Lens Care
   
522.2
   
523.3
   
496.5
 
Pharmaceuticals
   
584.8
   
528.2
   
471.2
 
Cataract and Vitreoretinal
   
377.8
   
358.2
   
327.1
 
Refractive
   
140.5
   
152.8
   
130.5
 
   
$
2,353.8
 
$
2,233.5
 
$
2,018.5
 

Geographic Region The following table presents sales and long-lived assets by geography for the years 2005, 2004 and 2003. Sales to unaffiliated customers represent net sales originating in entities physically located in the identified geographic area.

   
Non-U.S.
 
U.S.
 
Consolidated
 
2005
             
Sales to unaffiliated customers
 
$
1,462.8
 
$
891.0
 
$
2,353.8
 
Long-lived assets
   
275.5
   
328.9
   
604.4
 
                     
2004 (Restated)
                   
Sales to unaffiliated customers
 
$
1,370.0
 
$
863.5
 
$
2,233.5
 
Long-lived assets
   
259.0
   
321.8
   
580.8
 
                     
2003 (Restated)
                   
Sales to unaffiliated customers
 
$
1,204.0
 
$
814.5
 
$
2,018.5
 
Long-lived assets
   
234.7
   
310.0
   
544.7
 

No non-U.S. country, or single customer, generated more than 10 percent of total product net sales in 2005. On a restated basis, no non-U.S. country, or single customer, generated more than 10 percent of total product net sales during 2004 or 2003. Long-lived assets represent net property, plant and equipment, of which $92.6, $76.9 and $68.9 of the total non-U.S. long-lived assets for 2005, 2004 and 2003, respectively, were located in Ireland. No other non-U.S. country individually held more than 10 percent of long-lived assets.





PAGE 87

6.   Net Investment in Sales-Type and Operating Leases

Transactions that involve surgical equipment manufactured by the Company, whereby the Company grants temporary possession and use of that equipment to a customer, usually for a specified period of time that approximates the equipment's economic life at a periodic charge, are accounted for in accordance with SFAS No. 13, Accounting for Leases. The components of the Company's net investment in sales-type and operating leases as of December 31, 2005 and December 25, 2004 are as follows:


   
 
December 31, 2005
 
December 25, 2004
(Restated)
 
Net Investment in Sales-Type Leases
         
Total minimum lease payments to be received 1
 
$
30.6
 
$
36.0
 
Less amounts due from service agreements included in total minimum lease payments
   
(2.5
)
 
(2.8
)
Less allowance for doubtful accounts 1
   
(0.4
)
 
(0.6
)
Net minimum lease payments receivables
   
27.7
   
32.6
 
Less unearned income 2
   
(2.1
)
 
(2.5
)
Net investment in sales-type leases
 
$
25.6
 
$
30.1
 

1
The current portion of minimum lease payments receivable and the related allowance for doubtful accounts are included in Trade receivables on the Balance Sheets. Minimum lease payments receivable and the related allowance for doubtful accounts due after one year are included with Other Long-Term Assets.
2
The current portion of unearned income is included in Accrued liabilities on the Balance Sheets. Unearned income due after one year is included with Other Long-Term Liabilities.

Minimum future lease payments on sales-type leases are contractually due as follows: 2006, $16.4; 2007, $9.9; 2008, $3.9 and 2009, $0.4 and none thereafter.


   
December 31, 2005
 
December 25, 2004
 
Net Investment in Operating Leases
         
Equipment on operating lease
 
$
14.4
 
$
16.5
 
Less accumulated depreciation
   
(7.6
)
 
(6.9
)
Equipment on operating lease, net
 
$
6.8
 
$
9.6
 


Net equipment on operating lease is included in Property, Plant and Equipment, net on the Balance Sheets. Equipment on operating lease is depreciated for financial reporting purposes using the straight-line method based on its estimated useful life, as described in Note 1 — Significant Accounting Policies; Property, Plant and Equipment.
Minimum future rentals on operating leases are contractually due as follows: 2006, $0.3; 2007, $0.2; 2008, $0.1 and 2009, $0.1 and none thereafter.
Contingent rentals are received under certain operating leases. Contingent rentals for 2005, 2004 and 2003 amounted to $4.3, $4.2 and $0.8, respectively.


7.   Goodwill
 
In the fourth quarter of 2005, the Company completed its acquisition of a 70-percent controlling interest in Freda. The purchase price was first allocated to identifiable assets and liabilities based upon their respective fair values. The excess of the purchase price over the value of the identified assets and liabilities has been recorded as goodwill and is reflected in the table below. See Note 3 — Acquisitions for further discussion.



PAGE 88

The changes in the carrying amount of goodwill for the years ended December 25, 2004 and December 31, 2005 are as follows:

   
Americas
 
Europe
 
Asia
 
Global Operations & Engineering
 
Research & Development
 
Total
 
Balance as of December 27, 2003
(Restated) 1, 2
 
$
38.3
 
$
60.4
 
$
12.5
 
$
544.1
 
$
-
 
$
655.3
 
Other (primarily currency)
   
-
   
3.5
   
0.7
   
22.7
   
-
   
26.9
 
Balance as of December 25, 2004 (Restated)
 
$
38.3
 
$
63.9
 
$
13.2
 
$
566.8
 
$
-
 
$
682.2
 
Acquisition of Freda
   
-
   
-
   
5.6
   
154.9
   
-
   
160.5
 
Other (primarily currency)
   
-
   
(5.8
)
 
(0.7
)
 
(37.2
)
 
-
   
(43.7
)
Balance as of December 31, 2005
 
$
38.3
 
$
58.1
 
$
18.1
 
$
684.5
 
$
-
 
$
799.0
 

1
Due to the Company’s restatement of previously issued financial statements as discussed in Note 2 — Restatement, the amounts originally reported for goodwill prior to December 27, 2003 have changed in the disclosure above. Goodwill associated with a 1998 acquisition was reduced by $51.9 prior to December 31, 2003, representing the net impact of a reduction of $58.0 to reflect findings from a comprehensive review of the Company's accounting for income taxes and an increase of $6.1 to correctly reflect the purchase method of accounting. The adjustments reduced goodwill in the Americas by $8.4 and in Global Operations & Engineering by $43.5. Goodwill in Europe associated with a 2002 acquisition was reduced $1.8 to correctly reflect periodic re-measurement at historical rates. See discussion in Note 2 — Restatement.
2
During 2003, the Company acquired additional interests in its commercial and manufacturing joint ventures located in Korea. The $3.5 excess of the purchase price of $6.2 over the value of identifiable assets and liabilities was recorded as goodwill in the Company's Asia business segment.

During the fourth quarter of 2004, the Company reevaluated its allocation of goodwill arising from vertically integrated acquisitions. The Company determined that a portion of the goodwill previously assigned to the Global Operations & Engineering segment related to synergies realized by its commercial operations from vertically integrated acquisitions occurring prior to the beginning of the 2002 fiscal year. As such, the Company reallocated goodwill among the Global Operations & Engineering, Americas, Europe and Asia segments using a relative fair value allocation approach. During the first quarter of 2005, the method used to reallocate goodwill at the end of 2004 was further evaluated and adjusted for the impact of historical changes in exchange rates as a majority of the goodwill is held in non-U.S. legal entities which operate in currencies other than U.S. dollar. The revised carrying value of each of the Company's reporting units, including goodwill, was less than their respective fair values determined in connection with annual impairment tests completed during the fourth quarters of 2003, 2004 and 2005. The revised allocation and adjustments have been reflected in all balances included in the previous table.


8.   Acquired Intangible Assets

In April 2005, the FDA approved the Company's single-indication orphan drug Retisert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This FDA approval represents the achievement of a milestone under an agreement with a former partner in the development of implant technology, which triggered a $3.5 obligation. In connection with the settlement of this obligation, the Company capitalized $3.5 for the technology and this amount is reflected in the table below under technology and patents (see Note 9 — Related Party Transaction).
During the first quarter of 2005, the Company paid $12.2 to Pharmos Corporation to acquire additional rights in connection with the FDA approval of Zylet ophthalmic suspension. In March 2005, the Company acquired a license agreement for $0.4 to assume full licensing rights of a Japanese pharmaceutical company to commercialize Lotemax anti-inflammatory eye drops in South Korea. These acquired intangibles are reflected in the following table.
Acquired intangibles in connection with the Freda acquisition consisted of distributor relationships ($57.9), tradenames ($23.7), technology ($7.1) and non-compete agreements ($1.8) and are reflected in the table below (see Note 3 — Acquisitions for further discussion).




PAGE 89

    The components of intangible assets as of December 31, 2005 and December 25, 2004 are as follows:

   
December 31, 2005
 
December 25, 2004
 
   
Gross Carrying Amount
 
Accumulated Amortization
 
Gross Carrying Amount
 
Accumulated Amortization
 
Tradenames
 
$
117.7
 
$
44.3
 
$
97.1
 
$
36.7
 
Technology and patents
   
96.1
   
74.5
   
86.4
   
68.9
 
Developed technology
   
77.6
   
20.7
   
83.6
   
18.1
 
Distributor relationships
   
57.9
   
0.9
   
-
   
-
 
Intellectual property
   
38.2
   
10.6
   
25.9
   
7.0
 
License agreements
   
36.2
   
18.4
   
39.8
   
18.5
 
Physician information & customer database
   
21.8
   
3.9
   
24.3
   
3.6
 
Non-Compete agreements
   
1.8
   
0.2
   
-
   
-
 
   
$
447.3
 
$
173.5
 
$
357.1
 
$
152.8
 

Amortization expense of intangibles was $27.3 and $24.9 for 2005 and 2004, respectively. Estimated amortization expense of intangibles presently owned by the Company for each of the next five succeeding fiscal years is as follows:

Fiscal Year Ending
 
Amount
 
December 30, 2006
 
$
29.3
 
December 29, 2007
   
28.4
 
December 27, 2008
   
25.5
 
December 26, 2009
   
22.0
 
December 25, 2010
   
20.6
 


9.   Related Party Transaction

In April 2003, the Company advanced $9.3 to Control Delivery Systems (CDS), then a partner in the development of implant technology for treating retinal and other back-of-the-eye diseases in which the Company has an equity interest. Such advances were recoverable through the Company's ability to apply such amounts to future obligations due under an arrangement with CDS to provide research and development (R&D) activities as to certain technologies; the achievement of certain milestones such as the completion of clinical testing, NDA filings, and FDA approvals; royalty payments; or through cash repayment by CDS. In May 2003, the Company and CDS announced a delay of up to three years in the regulatory filing for the diabetic macular edema indication for its proposed Retisert implant. As a result, the Company decided to conduct and directly supervise the day-to-day development and clinical activities after a brief transition period and subsequently announced that it would not at that time pursue approval of the diabetic macular edema indication for the proposed Retisert implant.
The Company primarily based the recoverability of the funds advanced on the future milestones and royalties or repayment by CDS, as CDS was no longer performing R&D activity on the Company's behalf. The Company recorded a $4.1 reserve in the second quarter of 2003 to reflect the uncertainty relative to the achievement of such milestones given that the eventual commercialization was subject to the ordinary risks associated with the development and approval of any FDA regulated product. During the fourth quarter of 2003, the Company renegotiated its arrangement with CDS to formalize the change in the ongoing development and approval process and as a result received $4.0 from CDS.
In June 2004, the Company determined that it had incurred an obligation for an additional $3.0 milestone payment under the original agreement. As such, the $3.0 was applied against funds advanced resulting in a charge to R&D expenses. This charge was partially offset by a decrease in selling, administrative and general expenses to adjust the reserve established in the second quarter of 2003.



PAGE 90

In April 2005, the FDA approved the Company's single-indication orphan drug Retisert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. This FDA approval represented the achievement of a milestone and triggered a $3.5 obligation under the original agreement. The Company capitalized $3.5 for the developed technology, paid $0.7 to CDS and applied $2.8 against the remaining funds previously advanced. Also, the Company recorded a decrease in selling, administrative and general expenses to reverse the remainder of the previously established reserve. On June 28, 2005, the Company advanced a royalty payment of $3.0 to CDS. During the fourth quarter of 2005, the Company recognized approximately $0.4 of royalty expense.
Effective December 31, 2005, CDS merged with pSivida Inc., a wholly owned subsidiary of pSivida Limited. In connection with the merger the Company's 600,000 shares of CDS' common stock (minority equity interest valued at $0 on the Company's balance sheet) were converted into 2,113,694 American Depositary Shares, representing 21,136,940 ordinary shares of pSivida Limited (5.5 percent of such issued and outstanding ordinary shares). There have been no other changes in the Company's relationship or arrangement with CDS.


10.   Provision for Income Taxes

An analysis of the components of income before income taxes and minority interest and the related provision for income taxes is presented below:

   
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
(Loss) income before income taxes and minority interest
             
U.S.
 
$
(12.3
)
$
(24.8
)
$
(33.6
)
Non-U.S.
   
258.7
   
267.5
   
208.9
 
   
$
246.4
 
$
242.7
 
$
175.3
 
Provision for income taxes
                   
Federal
                   
Current
 
$
46.8
 
$
28.3
 
$
16.7
 
Deferred
   
94.2
   
(27.9
)
 
(16.6
)
State
                   
Current
   
4.7
   
2.4
   
0.5
 
Deferred
   
1.9
   
(2.2
)
 
(1.6
)
Foreign
                   
Current
   
70.8
   
74.5
   
63.0
 
Deferred
   
3.0
   
8.7
   
3.3
 
   
$
221.4
 
$
83.8
 
$
65.3
 




PAGE 91

Deferred taxes, detailed below, recognize the expected future tax consequences of events that have been recognized in the financial statements or tax returns. The Company assesses the available positive and negative evidence regarding the recoverability of its deferred tax assets and applies judgment in estimating whether, and how much, of the assets are more likely than not to be realized. In general, deferred tax assets, including carryforwards and other attributes, are reviewed for expected realization and a valuation allowance is established to reduce the assets to their net realizable value. Expected realization is dependent upon sufficient taxable income in the appropriate jurisdiction and period that is also of the appropriate character. The Company has evaluated the availability of such taxable income, the nature of its deferred tax assets and the relevant tax laws in determining the net realizable value of its deferred tax assets. During 2005, the Company established a valuation allowance against its U.S. net deferred tax assets because, based upon the weight of the available positive and negative evidence, including anticipated U.S. losses in early future years and uncertainties surrounding when it will return to U.S. profitability, the Company believes it does not meet the “more likely than not” standard that is applied when determining the net realizable value of deferred tax assets. This adjustment was recorded as a third quarter event because that is the earliest reporting period for which the Company has not filed quarterly results on Form 10-Q. The Company continues to assess the recoverability of its deferred tax assets, including strategies that will enable such assets to be realized, and will reduce the valuation allowance at such time when it is determined that the assets, or some portion thereof, are "more likely than not" to be realized. At December 31, 2005, $0.5 of the year-end valuation allowance balance was recorded to goodwill of an acquired entity and, therefore, if such valuation allowance is reduced, the associated tax benefit will be allocated to reduce goodwill or non-current intangible assets of the acquired entity.
At December 31, 2005, the Company had deferred tax assets related to tax loss carryforwards of $15.5 [$1.5 of non-U.S. net operating losses, $2.0 U.S. federal net operating losses (these losses were acquired by the Company and are subject to certain limitations as a result of the change in ownership) and $12.0 of U.S. state net operating and capital losses] and credit carryforwards of $60.8 ($16.4 of which is related to foreign tax credits and $44.4 related to U.S. federal and state credits) available to offset future tax liabilities otherwise due. Of the $76.3 aggregate deferred tax assets related to these carryforwards, $75.0 will expire between 2006 and 2025, and $1.3 have no expiration. In addition, at December 31, 2005, the Company had cumulative earnings related to non-U.S. subsidiaries of $200.7 that it considered permanently reinvested. Deferred income taxes have not been provided on this income as the Company does not plan to initiate any action that would precipitate the payment of income taxes thereon. It is not practicable to estimate the amount of additional tax that might be payable on this undistributed foreign income.

   
 
Deferred Taxes
December 31, 2005
 
Deferred Taxes
December 25, 2004
(Restated)
 
   
Assets
 
Liabilities
 
Assets
 
Liabilities
 
Current:
                 
Sales and allowance accruals
 
$
45.1
 
$
-
 
$
40.1
 
$
-
 
Employee benefits and compensation
   
41.9
   
-
   
37.8
   
-
 
Inventories
   
12.5
   
-
   
10.9
   
-
 
Unrealized foreign exchange transactions
   
-
   
1.6
   
9.7
   
0.2
 
Other accruals
   
24.0
   
-
   
26.4
   
-
 
Valuation allowance
   
(52.2
)
 
-
   
(16.3
)
 
-
 
   
$
71.3
 
$
1.6
 
$
108.6
 
$
0.2
 
Non-current:
                         
Depreciation and amortization
 
$
152.5
 
$
82.7
 
$
133.8
 
$
74.1
 
Tax loss and credit carryforwards
   
76.3
   
-
   
95.9
   
-
 
Employee benefits and compensation
   
51.1
   
-
   
47.7
   
-
 
Other accruals
   
3.8
   
16.7
   
1.7
   
51.5
 
Valuation allowance
   
(136.9
)
 
-
   
(44.4
)
 
-
 
Intercompany investments
   
-
   
157.1
   
-
   
158.7
 
     
146.8
   
256.5
   
234.7
   
284.3
 
   
$
218.1
 
$
258.1
 
$
343.3
 
$
284.5
 




PAGE 92

A reconciliation of the statutory U.S. federal income tax rate to the effective tax rates for continuing operations are as follows:

   
 
2005
 
2004
(Restated)
 
2003
(Restated)
 
Statutory U.S. tax rate
   
35.0
%
 
35.0
%
 
35.0
%
Earnings impact of changes in valuation allowances
   
49.3
   
8.8
   
(0.9
)
Foreign, including earnings taxed at different rates
   
5.6
   
(6.1
)
 
6.8
 
State, net of federal benefit
   
2.7
   
0.7
   
(0.6
)
Tax return and audit adjustments
   
1.1
   
1.8
   
2.3
 
Orphan drug credit
   
(0.4
)
 
(2.2
)
 
(2.9
)
Other
   
(3.4
)
 
(3.6
)
 
(2.4
)
Effective tax rate
   
89.9
%
 
34.4
%
 
37.3
%

On October 22, 2004, the American Jobs Creation Act of 2004 (AJCA) was signed into law. The bill created a temporary incentive for U.S. corporations to repatriate accumulated income earned abroad by providing a dividend received deduction of 85 percent for certain dividends from controlled foreign corporations in excess of a “Base Period” dividend amount (“Qualifying Dividends”). During 2005, the Company repatriated $861.9, of which $792.7 were Qualifying Dividends eligible for the special dividend received deduction. The net tax expense related to the repatriation was $9.5 and is included the Foreign, including earnings taxed at different rates, section of the effective tax rate reconciliation above. The net tax expense related to the repatriation was reduced by available foreign tax credits, as well as tax liabilities related to the repatriated earnings that were accrued in prior years as part of the Company's restatement. See Note 2 — Restatement for further detail.
On August 3, 2005, the Company received approval from the U.S. Joint Committee on Taxation that its income tax refund request for tax years ended 1995 through 1997 was approved, concluding the Internal Revenue Service's examination of such years. In connection with the closure of this examination, the Company recognized $20.9 of tax benefits related primarily to favorable resolution of tax positions raised during the examinations and the reversal of tax reserves associated with the Company's previously divested oral care business.
In addition, on May 12, 2006, the Company received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999 for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of the partnership interests are held by certain of the Company's subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10.0, and increasing a long-term capital gain reported by Wilmington for that tax year by $189.9. The FPAA also proposes a $550.0 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of the Company's subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership's partners for the associated tax periods by more than $200.0, plus penalties and interest. The Company has not made any financial provision for the asserted additional taxes, penalties or interest as the Company believes the asserted adjustments are not probable and estimable.
Since 1999, the Company's consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157.1. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.
On August 7, 2006, the Company made a petition to the U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006, and the Company initiated a motion to strike portions of the answer on November 1, 2006. The Company believes it has numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While the Company intends to vigorously defend against the asserted adjustments, its failure to succeed in such a defense could significantly increase the liability of the partnership's partners for taxes, plus interest and penalties, which in turn would have a material adverse effect on the Company's financial results and cash flows.





PAGE 93

11.   Debt

To support its liquidity requirements, the Company generally maintains a U.S. revolving credit agreement. On July 26, 2005, the Company replaced its $250.0 syndicated revolving credit facility expiring in January 2008 with a new five-year, $400.0 syndicated revolving credit facility. The terms of the new revolving credit facility are favorable to the terms of the former facility including the fact that the Company will have the option to increase the limit to $550.0 at any time during the five-year term. The new facility includes covenants similar in nature to covenants contained in the former facility, which require the Company to maintain certain EBITDA to interest and debt ratios. In the event a violation of the covenants occurs, the facility would not be available for borrowing until the covenant provisions were waived, amended or satisfied. In November 2005, and subsequently in February, May, August, and December 2006, and January 2007, the Company obtained waivers under the revolving credit agreement of any breach of representation, covenant or default that may arise from any events disclosed in any public announcements or filings with the SEC through and including the Company's filing with the SEC on Form 12b-25, filed November 9, 2006. With respect to matters related to the Company's Brazil and Korea investigations, the waivers are effective to the extent that the impact does not result in reductions in after-tax profits of more than $50.0 in aggregate. The impact of the Brazil and Korea investigations did not exceed $50.0 in aggregate as further discussed in Note 2 — Restatement. The waivers, in the aggregate, also extended the Company's deadline to file its required financial statements for 2005 (including restatements for certain prior periods) and 2006 year-to-date until April 30, 2007. Delivery of required financial statements for 2005 was satisfied by filing this Annual Report on Form 10-K and delivery of its Annual Report on Form 10-K for fiscal year ending December 30, 2006 by April 30, 2007 will satisfy its obligation to file all 2006 periodic reports. There were no violations of the financial covenants under either the new or former revolving credit facilities during the fiscal years ended December 31, 2005 or December 25, 2004.
The interest rate under the new revolving credit facility is, at the Company’s option, based on the Company's credit rating plus LIBOR, or the base rate of one of the lending banks. On August 1, 2005, the Company borrowed $50.0 under its syndicated revolving credit facility to partially fund retirement of its $100.0 of debt maturing on that date. The Company borrowed an additional $175.0 on September 26, 2005 to partially fund the first $200.0 tranche of the Freda acquisition (see Note 3 — Acquisitions for further discussion). The total $225.0 revolving credit borrowing was repaid on December 7, 2005, and the effective annual borrowing rate for the period the funds were outstanding was approximately 4.6 percent. There were no outstanding borrowings under the syndicated revolving credit agreements as of December 31, 2005 or December 25, 2004.
In addition, a number of subsidiary companies outside the United States have credit facilities to meet their liquidity requirements. There were $26.8 of outstanding borrowings under these non-U.S. credit facilities as of December 31, 2005 with an interest rate of 4.82 percent (as further described in Note 17 — Commitments and Contingencies). There were no outstanding borrowings as of December 25, 2004. The non-U.S. credit facilities' covenants require the subsidiary companies to make payment when due and to comply with applicable local laws. There were no covenant violations under the non-U.S. credit facilities during the fiscal years ended December 31, 2005 or December 25, 2004.



PAGE 94

The components of long-term debt were:

       
December 31, 2005
 
December 25, 2004
 
 
Type
 
 
Maturity
 
Effective Interest Rate1
 
Amount Outstanding
 
Effective Interest Rate1
 
Amount Outstanding
 
Notes 2
   
2005
    -    
$
-
   
6.29%  
 
$
100.0
 
Notes 3, 4
   
2007
   
8.63%  
 
 
150.0
   
8.63%  
 
 
150.0
 
Notes 3, 5
   
2008
   
7.87%*
   
50.0
   
6.09%*
   
50.0
 
Debentures 3
   
2028
   
7.19%  
 
 
183.9
   
7.19%  
 
 
183.9
 
Convertible Notes 6
   
2023
   
5.90%*
   
4.1
   
2.41%*
   
4.1
 
Convertible Securities 6
   
2023
   
6.14%*
   
155.9
   
2.41%*
   
155.9
 
Bank Term Loan
   
2010
   
0.50%*
   
48.1
    -        
-
 
Bank Term Loan
   
2010
   
5.10%*
   
375.0
    -        
-
 
Other 7
   
Various
   
Various
   
25.4
    Various     
0.2
 
                 
992.4
         
644.1
 
Less current portion 7
               
(161.2
)
       
(100.8
)
               
$
831.2
       
$
543.3
 

* Represents debt with a variable interest rate.

1  The effective interest rate includes the impact of interest rate, derivative instruments and debt issuance costs.
2
Notes contained a put/call option exercisable at 100 percent of par in 2005. The Company had also entered into a remarketing agreement which allowed the agent to call the debt from the holders on the option exercisable date, and then remarket them. If the rights were exercised, the coupon rate paid by the Company would reset to a rate higher than the then current market rate. Following the Company's debt rating downgrade by Moody's Investors Service during March 2002, the agents exercised their right to put the remarketing agreement back to the Company. The debt was repaid during August 2005.
3
The Company, at its option, may call these notes/debentures at any time pursuant to a make-whole redemption provision, which would compensate holders for any changes in interest rate levels of the notes/debentures upon early extinguishment.
4
In May 2002, the Company entered into an interest rate lock agreement to hedge the benchmark interest rate associated with this debt issue. Losses associated with the hedge have been deferred to other comprehensive income and are being amortized to interest expense over the remaining life of the debt.
5
In August 2003, simultaneous with the issuance of this debt maturing in 2008, an interest rate swap agreement converted this note to a variable-rate liability at a rate of six-month LIBOR plus 2.37 percent. Also in May 2002, the Company entered into an interest rate lock agreement to hedge the benchmark interest rate associated with this debt issue. Losses associated with the hedge have been deferred to other comprehensive income and are being amortized to interest expense over the debt term.
6
These notes accrue interest at six-month LIBOR plus 0.5 percent, with the rate reset on a semi-annual basis in advance. The effective rate for 2005 includes the impact of the write-off of unamortized debt issuance costs for the convertible notes and securities due to the triggering of the conversion option, which resulted in an increase of $3.0 in interest expense for 2005.
7
The amounts outstanding under other and current portion at December 31, 2005 include the $26.8 of outstanding borrowings under non-U.S. credit facilities.

On September 20, 2006, the Company announced its intention to commence an undertaking to solicit consents with respect to all series of outstanding public debt securities and outstanding convertible debt under its indenture. The solicitation sought, for a fee, consent from the holders for amendments to the indenture applicable to each series of notes that would, among other things, extend to January 31, 2007 the Company's deadlines to file periodic reports with the SEC and to deliver compliance certificates to the Trustee under each indenture. The amendments waive all defaults relating to the failure to properly comply with these obligations prior to their effectiveness. On September 29, 2006, the Company announced that it received the requisite number of consents, giving effect to the amendments to the note indentures and the waiver of the specified defaults until January 31, 2007. The Company did not file certain periodic reports due for the periods prior to January 31, 2007. However, on January 30, 2007, the Company announced a consent solicitation, seeking consents to additional limited waivers of the reporting obligations from the holders of its public debt to extend until April 30, 2007 the period during which it may become current on its periodic reports without potential default under the indenture. If the Company is unable to obtain the requisite number of consents to the waiver, then the Trustee or the holders of 10 percent of the principal amount of any series of the outstanding public debt could give the Company a notice of default. If the Company does not file the reports within 60 days after that notice is given, and the Trustee or the holders of 25 percent of the principal amount of any series of the public debt outstanding give a further notice, all principal and accrued interest on that series of debt would be due and payable. Such an acceleration of any series of the Company's public debt may be satisfied by the Company's payment of principal and accrued interest on that series, but if not otherwise waived, may trigger defaults under other series of public debt or other indebtedness of the Company.



PAGE 95

On May 3, 2006, the Company announced its intention to commence cash tender offers and consent solicitations for three series of outstanding debt securities (the "Securities") totaling $383.9 and consent solicitations for the two series of outstanding convertible debt totaling $160.0. The consents requested in this solicitation were similar to the consents in the solicitation announced in September, except that the Company's deadline to file periodic reports with the SEC and to deliver compliance certificates to the Trustee was October 2, 2006. On June 5, 2006, the Company announced that $116.3 of the $383.9 aggregate principal amount of debt had been tendered and was retired, and further that the Company received the requisite number of consents necessary to grant the waivers sought at that time. On October 20, 2006, the Company retired an additional $17.9 of the debentures due in 2028.
In November 2005, the Company agreed to guarantee, on behalf of its Dutch subsidiary, a $375.0 unsecured variable-rate term loan agreement (BV Term Loan). The facility involves a syndicate of banks and was a component of the Company’s effort to repatriate foreign earnings previously invested in non-U.S. legal entities under the provisions of the AJCA (see Note 10 — Provision for Income Taxes for further discussion of the AJCA). Borrowings under the BV Term Loan totaled $375.0 at December 31, 2005, and will mature in December 2010 unless otherwise extended under the terms of the agreement. The interest rate is based on six-month LIBOR and is reset on a semi-annual basis. The BV Term Loan includes covenants similar in nature to covenants contained in the new U.S. revolving credit facility, which require the Company to maintain certain EBITDA to interest and debt ratios. The initial interest rate was set at 5.0 percent. In February 2006, May 2006, August 2006, December 2006 and January 2007, the Company obtained waivers from its banks of any breach of representation or covenant under the BV Term Loan, or any default associated with the events related to the Brazil and Korea investigations, or from the impact of such events to the extent that they did not result in reductions in after-tax profits of more than $50.0 in aggregate. The waivers also extended the Company’s deadline to file its required financial statements for 2005 (including restatements for certain prior periods) and 2006 year-to-date, with the most recent extension being until April 30, 2007. Delivery of required financial statements for 2005 was satisfied by filing this Annual Report on Form 10-K and delivery of its Annual Report on Form 10-K for fiscal year ending December 30, 2006 by April 30, 2007 will satisfy its obligation to file all 2006 periodic reports. The impact of the Brazil and Korea investigations did not exceed $50.0 in aggregate as further discussed in Note 2 — Restatement. There were no violations of the financial covenants under the BV Term Loan during the fiscal year ended December 31, 2005.
In July 2005, the Company agreed to guarantee, on behalf of its Japan subsidiary, a bank term loan denominated in Japanese yen, in an amount approximately equivalent to $50.0. The term loan was established in connection with the repatriation of foreign earnings under the provisions of the AJCA (see Note 10 —Provision for Income Taxes for further discussion of the AJCA). The interest rate is set at the six-month TIBOR plus 0.30 percent and resets on a semi-annual basis. The initial interest rate was set at 0.40 percent. This is a five-year facility that matures in July 2010. The outstanding borrowing under this Japan term loan at December 31, 2005 was approximately $48.1. The Japan term loan has covenants which require the Japan subsidiary to submit its statutory financial statements to the lenders once a year and to maintain a positive balance of net assets. There were no covenant violations under the Japan term loan during the fiscal year ended December 31, 2005.
In August 2003, the Company issued $160.0 variable-rate Convertible Senior Notes (Old Notes) due in 2023. In December 2004, the Company completed its offer to exchange up to $160.0 of the Old Notes for an equal amount of its 2004 Senior Convertible Securities due 2023 (New Securities). The terms of the New Securities are largely consistent with those of the Old Notes except that settlement upon conversion of the New Securities will be paid in cash up to the principal amount of the converted New Securities with any excess of the conversion value settled in shares of the Company’s stock. An amount equal to $155.9 of the Old Notes, or 97.4 percent of the outstanding issue, was tendered in exchange for an equal amount of the New Securities. On June 17, 2005, the conversion right was triggered giving the holders the option to convert the Company's Old Notes and New Securities beginning July 1, 2005. In the event a holder elects to convert its note, the Company expects to fund a cash settlement of any such conversion from borrowings under its syndicated revolving credit agreement.
During 2005, the Company retired $100.0 of various notes due in 2005. During 2004, the Company retired $194.6 of various notes due in 2004. Interest rate swap agreements on long-term debt issues resulted in an increase in the long-term effective interest rate from 6.4 percent to 6.8 percent in 2005, and a decrease in the long-term effective interest rate from 6.15 percent to 5.70 percent in 2004. At December 31, 2005 and December 25, 2004, the Company had $50.0 of outstanding interest rate swaps. The Company retired $133.3 of its 2007 and 2028 bonds through October 2006, and as a result long-term borrowing maturities during the next five years are expected to be $134.4 in 2006, $133.8 in 2007, $50.0 in 2008, $0 in 2009 and $423.1 in 2010.





PAGE 96

12.   Accounting for Derivatives and Hedging Activities

In accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, the Company records all derivative instruments on the balance sheet at their respective fair values. Changes in the fair value of derivatives are recorded each period in current income unless the instruments have been designated as cash flow or net investment hedges, in which case such changes are recorded in other comprehensive income. The Company does not apply hedge accounting to contracts utilized to offset foreign exchange exposures related to foreign currency denominated assets and liabilities because they are marked to market through income at the same time that the exposed asset/liability is remeasured through income; both are recorded in foreign exchange loss (gain).
Derivative gains and losses attributable to hedge ineffectiveness are also recorded in current earnings. For instruments designated as either fair value or cash flow hedges, net interest expense of $0.2 was recognized for hedge ineffectiveness for the year ended December 27, 2003. Hedge ineffectiveness had no impact on income for the years ended December 31, 2005 and December 25, 2004.

Fair Value Hedges In August 2003, the Company issued $210.0 in concurrent offerings of notes and convertible notes. The first was a $50.0 public offering of five-year fixed-rate senior notes with a coupon rate of 5.90 percent. The Company simultaneously executed a $50.0 interest rate swap agreement under which the Company receives interest at a fixed rate and pays interest at a variable rate. This swap is designated as a fair value hedge effectively converting the fixed-rate notes to a variable rate of interest, and was outstanding at December 31, 2005 and December 25, 2004. The second offering was a $160.0 placement of variable-rate convertible senior notes due in 2023 (see Note 11 — Debt for a discussion regarding the exchange of $155.9 principal amount of these notes for new Senior Convertible Securities due in 2023), containing two embedded derivatives, a bond parity clause and a contingent interest provision. The fair value of the embedded derivatives contained in both the $155.9 exchanged securities and the $4.1 original issue notes was $0 at December 31, 2005 and December 25, 2004.

Cash Flow Hedges The Company utilizes foreign exchange forward contracts to hedge foreign currency exposure associated with intercompany loans. The Company designated as cash flow hedges foreign exchange forward contracts in the notional amounts of $41.0 at December 25, 2004 to hedge foreign currency exposure associated with an intercompany loan denominated in Japanese yen. The intercompany loan was paid in July of 2005 with proceeds from a bank term loan (as further discussed in Note 11 — Debt) and the hedge was terminated. There were no cash flow hedges designated at December 31, 2005.
During 2002 and 2003, to hedge interest payments on forecasted borrowings, the Company entered into, extended and re-designated interest rate lock agreements with notional amounts totaling $200.0 which were designated as cash flow hedges of ten semi-annual interest payments based on the benchmark interest rate related to changes in the five-year U.S. Treasury rate. In November 2002, the Company issued $150.0 of fixed-rate debt and in July 2003, the Company issued another $50.0 of five-year fixed-rate debt. The proportionate amounts associated with the cash flow hedges were recorded to other comprehensive income and are being amortized to interest expense in the periods in which interest expense related to the hedged debt are being recognized.
Reclassifications from other comprehensive income into income for cash flow hedge transactions were net losses of $3.3, $1.9 and $3.2 for the years ended December 31, 2005, December 25, 2004 and December 27, 2003, respectively. As of December 31, 2005 an estimated $3.1 pre-tax loss was expected to be reclassified into income over the next twelve months.

Net Investment Hedges At December 25, 2004, the Company had designated foreign denominated intercompany loans with notional amounts of $194.9 as hedges of foreign currency exposure associated with net investments in non-U.S. subsidiaries. For derivatives designated as hedging instruments to hedge foreign currency exposures of net investments in non-U.S. subsidiaries, net after-tax hedging losses of $8.6 were included in the cumulative translation adjustment for the year ended December 25, 2004. There were no designated foreign denominated intercompany loans at December 31, 2005.





PAGE 97

13.   Financial Instruments

The carrying amount of cash and cash equivalents approximates fair value, as maturities are less than three months in duration. The Company's remaining financial instruments consisted of the following:

   
December 31, 2005
 
December 25, 2004
 
   
Carrying Value
 
Fair
Value
 
Carrying Value
 
Fair Value
 
Non-derivatives
                 
Other investments
 
$
5.9
 
$
5.9
 
$
5.5
 
$
5.5
 
Long-term debt, including current portion
   
(992.4
)
 
(1,065.7
)
 
(644.1
)
 
(718.2
)
                           
Derivatives held for purposes other than trading
                         
Foreign exchange instruments
                         
Other current assets
 
$
2.4
 
$
2.4
 
$
8.1
 
$
8.1
 
Accrued liabilities
   
(4.2
)
 
(4.2
)
 
(6.5
)
 
(6.5
)
Net foreign exchange instruments
 
$
(1.8
)
$
(1.8
)
$
1.6
 
$
1.6
 
                           
Interest rate instruments
                         
Accrued liabilities
 
$
(1.6
)
$
(1.6
)
$
(0.1
)
$
(0.1
)

At the end of 2005 and 2004, the Company held other investments in equity securities, which are accounted for using the cost method of accounting. As these investments do not have a readily determinable fair value and the Company does not have the ability to exercise significant influence, they are reviewed periodically for events or changes in circumstances that may have a significant adverse effect on the carrying amount of the investment. During 2005 and 2004, no such events or circumstances were identified. The carrying amount of these investments is reported in other long-term assets in the accompanying Balance Sheets.
Fair value of long-term debt was estimated using either quoted market prices for the same or similar issues or current rates offered to the Company for debt with similar maturities. The fair value of foreign exchange and interest rate instruments was determined using a model that estimates fair value at market rates, or was based upon quoted market prices for similar instruments with similar maturities.
The Company enters into foreign exchange forward contracts primarily to offset foreign exchange exposures related to foreign currency transactions and equity investments in non-U.S. subsidiaries. At December 31, 2005 and December 25, 2004, the Company managed aggregate exposures of $549.6 and $692.2, respectively, by entering into foreign exchange forward contracts requiring the purchase or sale of U.S. and foreign currencies. In addition, the Company selectively hedges firm commitments that represent both a right and an obligation, mainly for committed purchase orders for foreign-sourced equipment.
At December 31, 2005 and December 25, 2004, the Company was party to an interest rate instrument that had an aggregate notional amount of $50.0.
Counterparties to the financial instruments discussed above expose the Company to credit risks to the extent of non-performance. The credit ratings of the counterparties, which consist of a diversified group of high quality commercial or investment banks, are regularly monitored and thus credit loss arising from counterparty non-performance is not anticipated.


14.   Employee Benefits

The Company's benefit plans, which in the aggregate cover substantially all U.S. employees and employees in certain other countries, consist of defined benefit pension plans, a participatory defined benefit postretirement plan and defined contribution plans.




PAGE 98

Pension and Postretirement Benefit Plans The fair value of plan assets in the Company's U.S. defined benefit pension plan represent approximately 70 percent of the fair value of all defined benefit pension plan assets as of December 31, 2005. The plan is a noncontributory defined benefit pension plan covering eligible salaried and hourly employees. Prior to January 1, 2005, each participant earned a benefit, payable at normal retirement age, expressed as an account balance that was credited annually with a percentage of the participant’s compensation and stated interest. In October 2004, the Company’s Board of Directors passed a resolution to freeze the plan effective December 31, 2004. As of January 1, 2005, no new participants are being accepted into the plan and no current participants are accruing additional benefits except for an interest allocation on the December 31, 2004 account balance. All of the pension benefits that were earned up to December 31, 2004, however, were preserved and will be paid out when due in accordance with the normal provisions of the plan. During the fourth quarter of 2004, the Company recognized a $1.8 curtailment loss associated with the freezing of the pension plan which is reflected in the table below entitled Net Periodic Benefit Cost.
The Company’s postretirement benefit plan provides life and medical insurance benefits to participating employees of the Company upon retirement. Upon meeting the eligibility requirements based on age and years of service, retirees and their eligible dependents are able to retain medical and life insurance after retirement. Retirees are required to pay for a portion of the coverage provided at retirement, based upon their years of service. In October 2004, the Company’s Board of Directors passed a resolution amending the plan to eliminate Company contributions to postretirement medical and life insurance coverage for participants who did not meet the minimum requirements of age and service on January 1, 2005. However, future retirees who did not meet the minimum requirements of age and service on January 1, 2005, but who attain age 55 and 10 years of service, will be eligible, at retirement, to purchase retiree medical insurance through the Company. During the fourth quarter of 2004, the Company recognized a $0.7 curtailment gain associated with the elimination of coverage for those ineligible employees which is reflected in the table below entitled Net Periodic Benefit Cost.
In December 2003, the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the Act) was signed into law. The Act introduced a prescription drug benefit under Medicare, as well as a federal subsidy to sponsors of retiree health care benefit plans that provide a benefit that is at least actuarially equivalent to Medicare Part D. The Company adopted the provisions of FASB Staff Position No. FAS 106-2, Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act (FSP FAS 106-2) as of July 1, 2004 which provides final accounting guidance related to the Act. FSP FAS 106-2 required companies to record the expected subsidy under the Act as an actuarial gain to be amortized into income over the average working life of the Company's employees. The reduction in the accumulated postretirement benefit obligation due to the effect of the federal subsidy was $12.6 as of the date of adoption. The reduction in net periodic postretirement benefit cost due to the subsidy was $0.8 in 2004, which included a $0.2 reduction in service cost, a $0.4 reduction in interest cost and a $0.2 reduction in amortization of net loss.
Components of net periodic benefit cost, benefit obligation, change in plan assets, asset allocation and funded status are summarized below for the Company’s U.S. and major non-U.S. pension plans and the postretirement plan. For 2005 and 2004, the funded status of the pension and postretirement plans presented herein were measured as of December 31.
For additional unaudited information on the Company’s employee benefit plans and related accounting policies and assumptions, see Item 7. Management’s Discussion and Analysis - Critical Accounting Policies; Employee Benefits of this Annual Report on Form 10-K.




PAGE 99

Net Periodic Benefit Cost Components of net periodic benefit cost and weighted-average assumptions used to determine net periodic cost for the plans for fiscal years 2005, 2004 and 2003 were as follows:

   
Pension Benefit Plans
 
Postretirement Benefit Plan
 
   
 
2005
 
2004 2
(Restated)
 
2003 2
(Restated)
 
 
2005
 
 
2004
 
 
2003
 
Service cost 1
 
$
8.2
 
$
15.8
 
$
13.7
 
$
1.3
 
$
1.6
 
$
1.4
 
Interest cost
   
19.9
   
19.4
   
18.4
   
5.4
   
4.9
   
5.9
 
Expected return on plan assets
   
(22.0
)
 
(20.3
)
 
(16.6
)
 
(3.4
)
 
(3.1
)
 
(2.6
)
Amortization of transition obligation
   
0.1
   
0.1
   
0.2
   
-
   
-
   
-
 
Amortization of prior-service cost
   
-
   
0.5
   
2.2
   
(0.3
)
 
(0.1
)
 
(0.1
)
Amortization of net loss
   
8.6
   
6.6
   
7.5
   
0.9
   
-
   
0.3
 
Curtailment loss (gain)
   
-
   
1.1
   
0.4
   
-
   
(0.7
)
 
-
 
Settlement (gain) loss
   
(6.6
)
 
-
   
0.3
   
-
   
-
   
-
 
                                       
Net periodic benefit cost
 
$
8.2
 
$
23.2
 
$
26.1
 
$
3.9
 
$
2.6
 
$
4.9
 

1
The decline in service cost in 2005 for the pension benefit plans was primarily due to the freezing of the Company's U.S. defined benefit pension plan effective December 31, 2004.
2
Due to the Company's restatement of previously issued financial statements as discussed in Note 2 — Restatement certain amounts originally reported in net periodic benefit cost for 2004 and 2003 have changed in the disclosure above.

The 2005 settlement gain in the pension benefit plans was related to the divesture of the Company’s Woehlk subsidiary, which was sold to a local management group in July 2005. The 2004 curtailment loss in the Pension Benefit Plans primarily related to the freezing of the Company’s U.S. defined benefit pension plan. The 2004 curtailment gain in the Postretirement Benefit Plan was associated with the elimination of Company contributions to postretirement medical and life insurance coverage for participants who did not meet the minimum requirements of age and service on January 1, 2005. The 2003 curtailment and settlement losses in Pension Benefit Plans related to making lump-sum payments to the participants of one of the Company's foreign plans.

Weighted Average Assumptions Used to Determine Net Periodic Benefit Cost

   
Pension Benefit Plans
 
Postretirement Benefit Plan
 
   
2005
 
2004
 
2003
 
2005
 
2004
 
2003
 
U.S. Plans
                         
Discount rate
   
5.75
%
 
6.00
%
 
6.75
%
 
5.75
%
 
6.00
%
 
6.75
%
Expected return on plan assets
   
8.75
%
 
9.00
%
 
9.00
%
 
7.75
%
 
8.00
%
 
8.00
%
Rate of compensation increase
   
-
   
4.00
%
 
4.25
%
 
-
   
-
   
-
 
                                       
Non-U.S. Plans 1
                                     
Discount rate
   
4.43
%
 
4.90
%
 
5.23
%
                 
Expected return on plan assets
   
5.96
%
 
6.12
%
 
6.07
%
                 
Rate of compensation increase
   
3.76
%
 
3.09
%
 
3.05
%
                 

1  The Company does not have non-U.S. postretirement benefit plans.

For the Company's U.S. Pension Plan, the 2005 expected return was 8.75 percent. The expected return reflects the average rate of earnings expected on the funds invested to provide for the benefits included in the benefit obligations. The expected return was developed using forward-looking return assumptions for equity and fixed income asset classes taking into consideration the plans' mix of actively and passively managed investments. Passively managed portfolios with asset allocations similar to the Company's U.S. Pension Plan would have earned in the 9 percent to 12 percent range over the last 10, 20 and 30 years. In view of low current interest rates and the recent performance of the equity markets over the last several years, the Company believes that Plan returns over the near term may not achieve historical returns.




PAGE 100

    The following chart summarizes the change in benefit obligations, change in plan assets, funded status and amounts recognized in the Balance Sheets for the two-year period ended December 31, 2005:

   
Pension Benefit Plans
 
Postretirement Benefit Plan
 
   
 
2005
 
2004 1
(Restated)
 
 
2005
 
 
2004
 
Change in Benefit Obligation
                 
Obligation at beginning of year
 
$
387.8
 
$
355.3
 
$
78.7
 
$
96.5
 
Service cost
   
8.2
   
15.8
   
1.3
   
1.6
 
Interest cost
   
19.9
   
19.4
   
5.4
   
4.9
 
Participant contributions
   
1.8
   
1.6
   
1.2
   
1.5
 
Benefit payments
   
(19.4
)
 
(20.4
)
 
(9.1
)
 
(10.0
)
Currency translation adjustments
   
(13.9
)
 
9.1
   
-
   
-
 
Curtailment gain
   
(0.2
)
 
(22.4
)
 
-
   
(2.7
)
Settlement gain
   
(8.5
)
 
-
   
-
   
-
 
Actuarial loss (gain) 2
   
38.2
   
29.4
   
19.8
   
(13.1
)
Obligation at end of year
 
$
413.9
 
$
387.8
 
$
97.3
 
$
78.7
 

Change in Plan Assets
                 
Fair value of plan assets at beginning of year
 
$
281.7
 
$
239.0
 
$
43.6
 
$
37.0
 
Actual gain on plan assets
   
24.9
   
31.1
   
1.2
   
6.8
 
Employer contributions
   
19.2
   
25.6
   
7.4
   
8.3
 
Participant contributions
   
1.8
   
1.6
   
1.2
   
1.5
 
Benefit payments
   
(19.4
)
 
(20.4
)
 
(9.1
)
 
(10.0
)
Settlement payments
   
(0.5
)
 
-
   
-
   
-
 
Currency translation adjustments
   
(8.4
)
 
4.8
   
-
   
-
 
Fair value of plan assets at end of year
 
$
299.3
 
$
281.7
 
$
44.3
 
$
43.6
 

Funded Status at end of year
   
$
(114.6
)
 
$
(106.1
)
 
$
(53.0
)
 
$
(35.1
)
Unrecognized transition obligation
   
0.2
   
0.4
   
-
   
-
 
Unrecognized prior-service cost (benefit)
   
-
   
0.1
   
(1.2
)
 
(1.5
)
Unrecognized actuarial loss
   
111.6
   
89.1
   
22.1
   
1.0
 
Net amount recognized at end of year
 
$
(2.8
)
$
(16.5
)
$
(32.1
)
$
(35.6
)

Amounts recognized in the Balance Sheets consist of:
                 
Prepaid benefit cost
 
$
1.8
 
$
-
 
$
-
 
$
-
 
Accrued benefit liability
   
(91.1
)
 
(86.9
)
 
(32.1
)
 
(35.6
)
Intangible asset
   
-
   
0.6
   
-
   
-
 
Accumulated other comprehensive loss 3
   
86.5
   
69.8
   
-
   
-
 
Net amount recognized at end of year
 
$
(2.8
)
$
(16.5
)
$
(32.1
)
$
(35.6
)

1      2004 amounts reflect the Company's restatement of previously issued financial statements as discussed in Note 2 — Restatement.
2
Unrecognized actuarial losses increased in 2005 primarily due to reductions in the discount rate used to determine benefit obligations and an increase in the assumed life expectancy of plan participants. Unrecognized actuarial losses are deferred and amortized to expense over future periods. Unrecognized gains and losses that exceed ten percent of the greater of the plans' projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated future service period of the plan participants or the period until any anticipated final plan settlements.
3      The tax benefits related to the accumulated other comprehensive loss are $22.9 and $26.2 for 2005 and 2004, respectively.




PAGE 101

Weighted Average Assumptions Used to Determine Benefit Obligations

   
Pension Benefit Plans
 
Postretirement Benefit Plan
 
   
2005
 
2004
 
2005
 
2004
 
U.S. Plans
                 
Discount rate
   
5.50
%
 
5.75
%
 
5.50
%
 
5.75
%
Rate of compensation increase 1
   
-
   
-
   
-
   
-
 
                           
Non-U.S. Plans 2
                         
Discount rate
   
3.89
%
 
4.43
%
           
Rate of compensation increase
   
3.71
%
 
3.76
%
           

1
The rate of compensation increase assumption is not applicable to the U.S. Plans since plan participants are accruing no additional benefits except for an interest allocation on the December 31, 2004 account balance.
2  The Company does not have non-U.S. postretirement benefit plans.

Plan Assets Pension and postretirement benefit plan assets are invested in several asset classes. The weighted average asset allocations for the two-year period ended December 31, 2005, by asset category, are as follows:

   
Pension Benefit Plans
 
Postretirement Benefit Plan
 
   
2005
 
2004
 
2005
 
2004
 
U.S. Plans
                 
Equity securities
   
72
%
 
74
%
 
97
%
 
97
%
Fixed income (debt) securities
   
28
%
 
26
%
 
3
%
 
3
%
Total
   
100
%
 
100
%
 
100
%
 
100
%
                           
Non-U.S. Plans 1
                         
Equity securities
   
69
%
 
65
%
           
Fixed income (debt) securities
   
20
%
 
19
%
           
Other
   
11
%
 
16
%
           
Total
   
100
%
 
100
%
           

1  The Company does not have non-U.S. postretirement benefit plans.

The Company's U.S. Pension Plan has a target asset allocation of 60 percent U.S. equity securities, 10 percent non-U.S. equity securities and 30 percent fixed income (debt) securities. Approximately 70 percent of U.S. equity securities are passively managed; the remainder of plan assets are actively managed.
U.S. equity securities are diversified among large-, mid- and small-cap value and growth strategies. Non-U.S. equity securities are invested in a broad range of equity securities diversified among equity style and geographic location. Fixed income (debt) securities are invested in investment grade bonds and similar instruments.
Equity securities held by the U.S. Pension Benefit Plan include $3.6 (1.7 percent of total plan assets) and $3.4 (1.8 percent of total plan assets) of Company Common stock at December 31, 2005 and December 25, 2004, respectively.

Plan Funded Status A number of the Company’s pension benefit plans were underfunded at December 31, 2005, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded plans is presented in the following table:

   
Pension Benefit Plans
 
   
 
2005
 
2004
(Restated)
 
Projected benefit obligation
 
$
400.8
 
$
387.8
 
Accumulated benefit obligation
   
377.9
   
368.5
 
Fair value of plan assets
   
286.9
   
281.7
 




PAGE 102

As a result of the underfunding of the pension benefit plans, the Company has recognized accumulated other comprehensive loss of $86.5 at December 31, 2005. Accumulated other comprehensive loss recognized at December 25, 2004 was $69.8. The increase in accumulated other comprehensive loss in 2005 resulted in an after-tax adjustment to the minimum additional pension liability of $20.0 that was recorded as a decrease to shareholders’ equity. The 2005 increase in accumulated other comprehensive loss related primarily to reductions in the discount rate used to determine benefit obligations, an increase in the assumed life expectancy of plan participants and the valuation allowance recorded on U.S. deferred tax assets (see Note 10 — Provision for Income Taxes).
Information for pension benefit plans that are underfunded on a projected benefit obligation basis is presented below:

   
Pension Benefit Plans
 
   
 
2005
 
2004
(Restated)
 
Projected benefit obligation
 
$
413.9
 
$
387.8
 
Fair value of plan assets
   
299.3
   
281.7
 

The Company’s postretirement benefit plan was underfunded for each of the past two years.
The accumulated benefit obligation for both the funded and underfunded pension benefit plans was $388.3 and $368.5 at December 31, 2005 and December 25, 2004 (restated), respectively.

Contributions The Company’s funding policy for its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. Company contributions for its postretirement plan are made at intervals and in amounts determined by the plan administrator, based on actual claims incurred and reported by participants and providers. The Company contributed $10.2 to all pension benefit plans and $6.3 to its postretirement benefit plan in 2006.

Estimated Future Benefit Payments Future benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:

       
Postretirement Benefit Plan
 
 
Fiscal Year Ending
 
Pension Benefit Plans
 
Benefit Payments
 
Subsidy Receipts
 
December 30, 2006
 
$
23.5
 
$
7.6
 
$
0.6
 
December 29, 2007
   
23.8
   
7.8
   
0.6
 
December 27, 2008
   
23.5
   
8.1
   
0.6
 
December 26, 2009
   
25.2
   
8.2
   
0.6
 
December 25, 2010
   
22.2
   
8.4
   
0.6
 
Fiscal years 2011 - 2015
   
114.6
   
41.7
   
2.8
 

Health Care Cost Trend Rate Assumed health care cost trend rates have a significant effect on the amounts reported as postretirement benefits. For 2005, a 10 percent annual rate of increase in the per capita cost of covered health care benefits for all participants was assumed. The trend rate grades down by up to one percent per year to an ultimate annual rate of five percent in 2013. To demonstrate the significance of this rate on the expense reported, a one-percentage point change in the assumed health care cost trend rate would have the following effect:

   
1% Increase
 
1% Decrease
 
Effect on total service and interest cost components of net periodic postretirement health care benefit cost
 
$
0.7
 
$
(0.6
)
               
Effect on the health care component of the accumulated postretirement benefit obligation
   
8.6
   
(7.3
)




PAGE 103

Defined Contribution Plans The Company sponsors a 401(k) Plan which is a defined contribution plan covering substantially all U.S. employees of the Company. In 2005, the 401(k) Plan became the Company’s principal vehicle for providing retirement income to U.S. employees, replacing the defined benefit pension plan that was frozen effective December 31, 2004. Employees may elect to participate in the plan on their date of hire if they are scheduled to work at least 1,000 hours per plan year. In general, participants’ contributions up to 5.0 percent of compensation qualify for 150 percent Company match. The Company also provides a base contribution of 2.5 percent of a participant’s eligible compensation. Prior to January 1, 2005, the 401(k) Plan provided a 100 percent Company match on participants’ contributions up to 3.0 percent of compensation and a 50 percent Company match for the next 2.0 percent of participant contributions. Additionally, the Company provided a base contribution of 0.5 percent of eligible compensation for all participants that had completed one year of service. The Company sponsors defined contribution plans covering employees outside the U.S. which are managed on a local basis.
Total Company costs associated with defined contribution plans were $32.4, $13.5 and $11.6 for 2005, 2004 and 2003, respectively.


15.   Employee Stock Plans

2003 Long-Term Incentive Plan The 2003 Long-Term Incentive Plan was approved by the shareholders of the Company on April 29, 2003 and will terminate on April 29, 2013. Under this plan, a total of 6,000,000 shares were authorized for issuance, of which no more than 1,800,000 shares may be issued pursuant to awards other than options and stock appreciation rights. Any employee or non-employee director is eligible to participate under the plan. Any shares issued may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares purchased in the open market or otherwise. Stock options, stock appreciation rights, restricted stock, performance awards and other stock unit awards may be granted under such plan. As of December 31, 2005, the Company had issued stock options, restricted stock, restricted stock units and performance-based stock units under the plan.
Prior to the 2003 Long-Term Incentive Plan, the Company provided shares available for grant in each calendar year, equal to three percent of the total number of outstanding shares of Common stock as of the first day of each such year, under its Stock Incentive Plan, which had an evergreen provision. In October 2002, the Company's Board of Directors amended the plan to eliminate the evergreen feature and provide a pool of shares of 1,600,000 to be available for future grants. As of the adoption of the 2003 Long-Term Incentive Plan on April 29, 2003, no additional shares will be issued under this plan.
The Company had also adopted a stock incentive plan for non-officers effective January 22, 2001. The number of shares available for grant each year were no greater than two percent of the total number of outstanding shares of Common stock as of the first day of each such year. Options and awards under this plan were granted only to employees of the Company or any subsidiary corporation of the Company who were neither officers nor directors of the Company. Effective January 1, 2003, no additional shares will be issued under this plan.

Stock Options The Company has granted stock options under the plans discussed above. These options typically vest ratably over three years for employee options and 100% after one year for non-employee director options, and they expire ten years from the date of grant. For employee options, vesting is contingent upon a continued employment relationship with the Company. (See Note 1 — Significant Accounting Policies for a discussion relating to the Company's accounting for stock-based employee compensation plans).
For purposes of this disclosure in accordance with the requirements under SFAS No. 123, Accounting for Stock-Based Compensation, the fair value of each fixed option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions used for grants issued each year:

   
2005
 
2004
 
2003
 
Risk-free interest rate
   
4.33
%
 
3.06
%
 
3.37
%
Dividend yield
   
1.13
%
 
1.18
%
 
1.18
%
Volatility factor
   
34.61
%
 
35.97
%
 
36.02
%
Weighted average expected life (years)
   
5
   
6
   
6
 
Weighted average fair value
 
$
24.47
 
$
19.19
 
$
10.98
 




PAGE 104

A summary of the status of the Company's fixed stock option plans at year-end 2005, 2004 and 2003 is presented below:

   
2005
 
2004
     
2003
 
   
Numbers of Shares (000s)
 
Weighted Average Exercise Price (Per Share)
 
Number of Shares (000s)
 
Weighted Average Exercise Price (Per Share)
 
Number of Shares (000s)
 
Weighted Average Exercise Price (Per Share)
 
Outstanding at beginning of year
   
6,521
 
$
45.31
   
7,530
 
$
43.66
   
7,060
 
$
46.60
 
Granted
   
979
   
72.56
   
1,125
   
54.86
   
1,444
   
30.65
 
Exercised
   
(1,569
)
 
44.40
   
(1,853
)
 
42.27
   
(312
)
 
38.97
 
Forfeited and canceled
   
(107
)
 
54.83
   
(281
)
 
60.62
   
(662
)
 
48.68
 
Outstanding at year end
   
5,824
   
49.96
   
6,521
   
45.31
   
7,530
   
43.66
 
Options exercisable at year end
   
3,781
 
$
45.67
   
3,996
 
$
46.94
   
4,680
 
$
48.80
 

The following represents additional information about fixed stock options outstanding at December 31, 2005:

   
Options Outstanding
 
Options Exercisable
 
Range of Exercise Prices (Per Share)
 
Number Outstanding (000s)
 
Weighted Average Remaining Contractual Life (Years)
 
Weighted Average Exercise Price (Per Share)
 
Number Exercisable (000s)
 
Weighted Average Exercise Price (Per Share)
 
$26.00 to 40.49
   
2,356
   
6.3
 
$
34.15
   
1,928
 
$
34.97
 
  40.50 to 45.49
   
556
   
4.2
   
44.22
   
553
   
44.23
 
  45.50 to 55.49
   
1,043
   
7.0
   
53.64
   
442
   
52.84
 
  55.50 to 65.49
   
523
   
5.2
   
61.50
   
461
   
61.78
 
  65.50 to 75.49
   
1,292
   
7.3
   
72.24
   
397
   
72.96
 
  75.50 to 83.55
   
54
   
9.6
   
83.55
   
-
   
-
 
     
5,824
   
6.4
 
$
49.96
   
3,781
 
$
45.67
 

Restricted Stock The Company issues restricted stock awards to officers and other key personnel. These awards have vesting periods up to seven years with vesting criteria based on continued employment until applicable vesting dates and, with respect to certain awards prior to 2005, on the attainment of specific performance goals such as average sales and cumulative earnings per share targets. Compensation expense is recorded based on applicable vesting criteria and, for awards prior to 2005 with performance goals, as such goals are met. During 2005, 2004 and 2003, 89,750, 42,300 and 103,800 shares related to such awards were granted at weighted average market values of $74.54, $54.67 and $40.25 per share, respectively. As of December 31, 2005, 288,211 awards remain outstanding.

Performance Awards The Company issues performance-unit or performance-share awards to its corporate officers and other key executives selected by the Company’s CEO. Performance awards vest 50 percent upon completion of a performance cycle and 50 percent on the first anniversary of completion of a performance cycle. Performance cycles are typically two years, with a new cycle beginning upon completion of the prior cycle. Performance awards are paid in cash or shares on the attainment of vesting criteria and specific performance measures such as average sales growth and return on invested capital. For the 2004-2005-performance period, cash-denominated awards were granted in 2004 with a total value for the two-year cycle of $9.5. In 2005, additional awards were granted to newly hired officers for a one-year cycle valued at approximately $0.3. During 2004 and 2003, performance-share awards of 1,800 and 7,700 were granted to newly hired employees with average market values of $52.79 and $29.85, respectively.

Employee Stock Purchase Plan The Company has a stock purchase plan for all eligible employees. Shares of the Company’s Common stock may be purchased by employees at the market price on the first business day of the month.





PAGE 105

16.   Operating Leases

The Company leases land, buildings, machinery and equipment under noncancelable operating leases. Total annual rental expense for 2005, 2004 and 2003 amounted to $28.2, $31.3 and $28.0, respectively.
Minimum future rental commitments having noncancelable lease terms in excess of one year aggregated $75.5, net of aggregated sublease rentals of $1.8 as of December 25, 2005 and are payable as follows: 2006, $23.3; 2007, $15.7; 2008, $11.9; 2009, $8.2; 2010, $6.9 and beyond, $9.5.


17.   Commitments and Contingencies

Subsidiary Debt Guarantees The Company guarantees in writing for its subsidiaries certain indebtedness used for working capital and other obligations. Those written guarantees totaled approximately $482.2 and $24.3 at December 31, 2005 and December 25, 2004, respectively. The increase from 2004 to 2005 is principally attributed to the Company’s agreement to guarantee a July 2005 bank term loan facility on behalf of its Japan subsidiary, a December 2005 bank term loan facility on behalf of its Dutch subsidiary and a December 2005 bank line of credit on behalf of its Hong Kong subsidiary. The Hong Kong line of credit was to partially fund the acquisition of an additional 15 percent interest in Freda (further described in Note 11 — Debt). Outstanding balances under the guaranteed debt facilities were $449.9 at December 31, 2005 of which $26.8 was repaid by the Hong Kong subsidiary in January 2006. There were no outstanding balances at December 25, 2004. From time to time, the Company may also make verbal assurances with respect to indebtedness of its subsidiaries under certain lines of credit, also used for working capital.

Letters of Credit The Company had outstanding standby letters of credit totaling approximately $22.2 and $20.8 at the end of 2005 and 2004, respectively, to ensure payment of possible workers' compensation, product liability and other insurance claims. At the end of 2005 and 2004, the Company had recorded liabilities of approximately $9.9 and $11.1, respectively, related to workers' compensation, product liability and other insurance claims.

Guarantees As of December 25, 2004, the Company guaranteed a real property mortgage loan of a research and development partner. The mortgage was secured by the property with an appraised value of $4.0. The principal balance of the guaranteed loan totaled approximately $3.5 at December 25, 2004. In April 2005, the research partner sold the property and the outstanding debt was retired, thereby terminating the guarantee. The Company had not recorded any liabilities under this guarantee.
The Company guarantees a lease obligation of a customer in connection with a joint marketing alliance. The lease obligation has a term of ten years expiring November 2011. The amount guaranteed at the end of 2005 and 2004 was approximately $8.2 and $10.0, respectively. In the event of default, the guarantee would require payment from the Company. Sublease rights as specified under the agreement would reduce the Company's exposure. The Company believes the likelihood is remote that material payments will be required in connection with this guarantee and, therefore, has not recorded any liabilities under this guarantee.

Tax Indemnifications In connection with divestitures, the Company has agreed to indemnify certain tax obligations arising out of tax audits or administrative or court proceedings relating to tax returns for any periods ending on or prior to the closing date of the respective divestiture. The Company believes that any claim would not have a material impact on the Company's financial position. The Company has not recorded any liabilities associated with these claims.

Environmental Indemnifications The Company has certain obligations for environmental remediation and Superfund matters related to current and former Company sites. The Company has an ongoing program in place designed to identify and manage potential environmental liabilities through such actions as having a rotating schedule of regular assessments performed to identify and manage potential issues at Company sites before they occur, a domestic waste disposal contract which contains indemnification of the Company from the vendor for disposal of all waste once it leaves Company property, a regular schedule of training and prevention programs designed to keep employees in Company sites aware of their responsibilities, an environmental due diligence for business acquisitions and real estate transactions and ongoing tracking of significant laws and regulations affecting the Company in any of the countries where it operates. In those instances where the Company may identify environmental liability, the Company manages directly all remedial investigations, negotiation of approved remediation plans with applicable governmental authorities and implementation of all approved remediation activities.



PAGE 106

At December 31, 2005 and December 25, 2004, estimated future remediation costs of approximately $1.1 and $0.6, respectively, were accrued by the Company, excluding estimates for legal expenses. The estimate for future remediation costs follows guidelines established by the American Standards for Testing and Materials (ASTM) Document E2137-01. All known current potential Company environmental liabilities are considered in this estimate. It is reasonable to expect that the Company's recorded estimates of its liabilities may change and there is no assurance that additional costs greater than the amounts accrued will not be incurred, or that changes in environmental laws or their interpretation will not require additional amounts to be spent. The Company does not believe that its financial position, results of operations, and cash flows are likely to be materially affected by environmental liabilities.

Other Commitments and Contingencies The Company is involved in lawsuits, claims, investigations and proceedings, including patent, trademark, commercial and environmental matters, which are being handled and defended in the ordinary course of business. Pending material litigation matters are discussed further in Note 21 — Other Matters. In addition to pending litigation matters, the Company may from time to time learn of alleged non-compliance with laws or regulations or other improprieties through compliance hotlines, communications by employees, former employees or other third parties, as a result of its internal audit procedures, or otherwise. As disclosed in Note 2 — Restatement, in response to such allegations, the Company’s Audit Committee conducted certain investigations during 2005 and 2006, which led, among other things, to the restatement of previously reported financial information and the recording of current charges. The restatement, in turn, resulted in the Company’s being unable to file timely certain periodic financial information and the Company’s obtaining certain waivers from creditors as well as an extension from the NYSE to permit continued trading notwithstanding the delay in filing the Company’s 2005 Annual Report on Form 10-K.
The Audit Committee of the Board of Directors is currently investigating the potential U.S. Foreign Corrupt Practices Act implications of the Company’s Spanish subsidiary’s providing free product, principally intraocular lenses used in cataract surgery, and other things of value to doctors performing surgical procedures at public hospitals in Spain. This investigation was initiated following reports of potentially improper sales practices by a former employee. The investigation of the Company’s Spanish subsidiary has been voluntarily reported to the Northeast Regional Office of the SEC. We cannot predict the outcome of this pending investigation, and at this time cannot reasonably estimate the potential liability of the Company or its Spanish subsidiary in connection with these matters.
The Company’s policy is to comply with applicable laws and regulations in each jurisdiction in which it operates and, if the Company becomes aware of a potential or alleged violation, to conduct an appropriate investigation, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. There can be no assurance that any pending or future investigation or resulting remedial action will not have a material adverse financial, operational or other effect on the Company. The Company cannot at this time estimate with any certainty the impact of any pending litigation matters, allegations of non-compliance with laws or regulations or allegations of other improprieties on its financial position (see Note 21 — Other Matters for further discussion).

Product Warranties The Company estimates future costs associated with expected product failure rates, material usage and service costs in the development of its warranty obligations. Warranty reserves are established based on historical experience of warranty claims and generally will be estimated as a percentage of sales over the warranty period or as a fixed dollar amount per unit sold. In the event that the actual results of these items differ from the estimates, an adjustment to the warranty obligation would be recorded. Changes in the Company's product warranty liability during 2004 and 2005 were as follows:

Balance at December 27, 2003 (Restated)
 
$
8.0
 
Accruals for warranties issued
   
6.7
 
Changes in accruals related to pre-existing warranties
   
(1.0
)
Settlements made
   
(5.9
)
Balance at December 25, 2004 (Restated)
 
$
7.8
 
Accruals for warranties issued
   
6.9
 
Changes in accruals related to pre-existing warranties
   
(2.1
)
Settlements made
   
(6.7
)
Balance at December 31, 2005 1
 
$
5.9
 

1
Warranty reserve changes during 2005 and the 2005 year end balance do not include amounts in connection with the MoistureLoc recall.



PAGE 107

Deferred Service Revenue Service revenues are derived from service contracts on surgical equipment sold to customers and are recognized over the term of the contracts while costs are recognized as incurred. Changes in the Company's deferred service revenue during 2004 and 2005 were as follows:

Balance at December 27, 2003 (Restated)
 
$
6.5
 
Accruals for service contracts
   
14.0
 
Changes in accruals related to pre-existing service contracts
   
(0.3
)
Revenue recognized
   
(12.5
)
Balance at December 25, 2004 (Restated)
 
$
7.7
 
Accruals for service contracts
   
11.8
 
Revenue recognized
   
(12.6
)
Balance at December 31, 2005
 
$
6.9
 


18.   Forward Equity Contracts

During 2001, the Company's Board of Directors authorized the repurchase of up to 2,000,000 shares of the Company's Common stock. The Company executed an agreement with a financial institution for the future purchase of such shares through one or more forward purchase transactions. Such purchases, which may have had settlement dates as long as two years, could have been settled, at the Company's election, on a physical share, net cash or net share basis. During March 2003, at the expiration of the forward purchase agreement, the Company paid $30.7 for 750,000 shares, at an average price of $40.89 to settle its obligation. This repurchase of Common stock was recorded as treasury stock in the Company's consolidated financial statements during the quarter ended March 29, 2003.


19.   Supplemental Balance Sheet Information

   
 
December 31, 2005
 
December 25, 2004
(Restated)
 
December 27, 2003
(Restated)
 
Allowances for Losses on Trade Receivables
             
Balance at beginning of year
 
$
22.1
 
$
20.6
 
$
25.1
 
Change in provision
   
(0.6
)
 
4.2
   
2.9
 
Gross write-offs of trade receivables accounts
   
(5.4
)
 
(4.0
)
 
(9.3
)
Recoveries on trade receivables accounts previously written off
   
1.2
   
0.6
   
0.1
 
Currency effect
   
(1.1
)
 
0.7
   
1.8
 
Balance at end of year
 
$
16.2
 
$
22.1
 
$
20.6
 


   
 
December 31, 2005
 
December 25, 2004
(Restated)
 
Inventories, net
         
Raw materials and supplies
 
$
51.4
 
$
50.0
 
Work in process
   
19.5
   
17.8
 
Finished products
   
148.9
   
144.3
 
   
$
219.8
 
$
212.1
 




PAGE 108

   
 
December 31, 2005
 
December 25, 2004
(Restated)
 
Property, Plant and Equipment, net
         
Land
 
$
20.0
 
$
19.1
 
Buildings
   
344.8
   
341.5
 
Machinery and equipment
   
998.2
   
972.7
 
Leasehold improvements 1
   
25.5
   
28.7
 
Equipment on operating lease 2
   
14.4
   
16.5
 
     
1,402.9
   
1,378.5
 
Less accumulated depreciation
   
(798.5
)
 
(797.7
)
   
$
604.4
 
$
580.8
 

1
Upon initial application of SFAS No. 143, Accounting for Asset Retirement Obligations, the Company recorded an initial liability and an increase to leasehold improvements of $1.8. Cumulative accretion and accumulated depreciation were measured from the commencement date of the leases to the date of adoption. A cumulative charge of initially applying this statement of $0.9, net of tax, was reported in the first quarter of 2003 as a change in accounting principle in the Statements of Income.
2
See Note 6 — Net Investment in Sales-Type and Operating Leases for additional information regarding equipment on operating lease.


20.   Restructuring Charges and Asset Write-offs

Profitability Improvement Program and Transfer of PureVision Contact Lens Manufacturing In July 2002, the Company announced plans to improve operating profitability through a comprehensive plan which included plant closures and consolidations; manufacturing efficiencies and yield enhancements; procurement process enhancements; the rationalization of certain contact lens and surgical product lines; distribution initiatives; and the development of a global information technology (IT) platform. These plans included the elimination of approximately 465 jobs worldwide associated with those actions. Restructuring charges and asset write-offs of $22.8 before taxes associated with these initiatives were recorded in the third quarter of 2002. The Company also recorded a pre-tax amount of $3.7 during the third quarter of 2002 for severance associated with the elimination of approximately 145 jobs due to the transfer of PureVision extended wear contact lens manufacturing from the United States to Waterford, Ireland following a ruling against the Company in a U.S. patent law suit. During the fourth quarter of 2003, the Company reversed $6.3 in severance charges as certain termination actions and plant closures did not occur due to an increased demand for certain product lines.
At the conclusion of the Profitability Improvement Program and the transfer of PureVision contact lens manufacturing, 468 jobs were eliminated. Related expenses of $16.8 and $3.4 of asset write-offs were charged against the liability. Cash payments for severance and other related expenses were $10.8 and $6.0 in 2003 and 2002, respectively. All actions related to this restructuring plan were completed by the end of 2003.


21.   Other Matters

Legal Matters The Company is involved as a party in a number of material matters in litigation, including general litigation related to the restatement of the Company's financial information and the MoistureLoc withdrawal, material intellectual property litigation, and material tax litigation. The Company intends to vigorously defend itself in all of these matters. At this time, the Company is unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations, and matters concerning other allegations of other improprieties. The Company has not made any financial provision for potential liability in connection with these matters.




PAGE 109

Shareholder Securities Class Actions There is a consolidated securities class action, entitled In re Bausch & Lomb Incorporated Securities Litigation, Case Nos. 06-cv-6294 (master file), 06-cv-6295, 06-cv-6296, and 06-cv-6300, pending in Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, four separate shareholder actions were filed between March and May of 2006 in Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a putative class of shareholders who purchased Company stock at allegedly artificially inflated levels between January 27, 2005 and May 3, 2006. Among other things, plaintiffs allege that defendants issued materially false and misleading public statements regarding the Company's financial condition and operations by failing to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc, thereby inflating the price of Company stock during the alleged class period. Plaintiffs seek unspecified damages. The cases are currently awaiting appointment of lead plaintiff and lead plaintiff's counsel in accordance with the Private Securities Litigation Reform Act. Pursuant to a stipulated schedule ordered by the Court, the lead plaintiff appointed by the Court must file a consolidated amended complaint by the earlier of (a) 45 days after the Company files its Annual Report on Form 10-K for the year ended December 31, 2005, or (b) 90 days after entry of the Court's order appointing the lead plaintiff, provided, however, that, at a minimum, the lead plaintiff will have 45 days after entry of the Court's order appointing the lead plaintiff to file such consolidated amended complaint.

ERISA-Based Class Actions There is a consolidated ERISA class action, entitled In re Bausch & Lomb Incorporated ERISA Litigation, Case Nos. 06-cv-6297 (master file), 06-cv-6315, and 06-cv-6348, pending in the Federal District Court for the Western District of New York, Rochester Division, against the Company and certain present and former officers and directors. Initially, three separate actions were filed between April and May of 2006 in the Federal District Court for the Southern District of New York, and these were later transferred to the Western District of New York and consolidated into the above-captioned matter. Plaintiffs in these actions purport to represent a class of participants in the Company's defined contribution 401(k) Plan for whose individual accounts the plan held an interest in Company stock between May 25, 2000 and the present. Among other things, plaintiffs allege that the defendants breached their fiduciary duties to plan participants by allowing the plan to invest in Company Common stock despite the fact that it was allegedly artificially inflated due to the failure to disclose negative information relating to the Company's Brazilian and Korean subsidiaries, internal controls, and problems with MoistureLoc. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief. On August 28, 2006, the Court entered an order appointing co-lead plaintiffs and co-lead plaintiffs' counsel. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in the consolidated ERISA action will have until 10 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.

Shareholder Derivative Actions The shareholder derivative actions, in which a shareholder seeks to assert the rights of the Company derivatively against certain present and former officers and directors, fall into two categories: (a) those asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries; and (b) those asserting allegations relating to the MoistureLoc withdrawal.
There is a consolidated derivative action asserting allegations relating to accounting issues at the Company's Brazilian and Korean subsidiaries, entitled In re Bausch & Lomb Incorporated Derivative Litigation, Case Nos. 06-cv-6298 (master file) and 06-cv-6299, pending in Federal District Court for the Western District of New York, Rochester Division, against certain present and former officers and directors of the Company, and also naming the Company as nominal defendant. Initially, two separate derivative actions were filed in April 2006 in Federal District Court for the Southern District of New York, and were later transferred to the Western District of New York and consolidated. Among other things, plaintiffs allege that the individual defendants breached their fiduciary duties to the Company by causing or allowing the Company to issue materially false and misleading public statements regarding the Company's financial condition and operations that failed to disclose negative information about the Company's Brazilian and Korean subsidiaries and internal controls, thereby inflating the price of Company stock during the relevant time period. Plaintiffs purport to allege damage to the Company as a result of, among other things, a decrease in the Company's market capitalization, exposure to liability in securities fraud actions, and the costs of internal investigations and financial restatements. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief, including for misappropriation of inside information for personal benefit by certain of the individual defendants. Pursuant to a stipulated schedule ordered by the Court, plaintiffs in this consolidated derivative action will have until 30 days after a consolidated amended complaint is filed in the consolidated securities action described above, to file a consolidated amended complaint.



PAGE 110

On January 3, 2006, the Company received a demand letter dated December 28, 2005, from a law firm not involved in the derivative actions described above, on behalf of a shareholder who also is not involved in the derivative actions, demanding that the Board of Directors bring claims on behalf of the Company based on allegations substantially similar to those that were later alleged in the two derivative actions relating to accounting issues at the Brazilian and Korean subsidiaries. In response to the demand letter, the Board of Directors adopted a board resolution establishing an Evaluation Committee (made up of independent directors) to investigate, review and analyze the facts and circumstances surrounding the allegations made in the demand letter, but reserving to the full Board authority and discretion to exercise its business judgment in respect of the proper disposition of the demand. The Committee has engaged independent outside counsel to advise it.
There are also two purported derivative actions asserting allegations relating to the MoistureLoc withdrawal. The first case, entitled Little v. Zarrella, Case No. 06-cv-6337, was filed in June 2006 in the Federal District Court for the Southern District of New York and was transferred to the Western District of New York, Rochester Division, where it is currently pending against certain directors of the Company, and also naming the Company as nominal defendant. The second case, entitled Pinchuck v. Zarrella, Case No. 06-6377, was filed in June 2006 in the Supreme Court of the State of New York, County of Monroe, where it is currently pending against the directors of the Company, and also naming the Company as nominal defendant. Among other things, plaintiffs in these actions allege that the individual defendants breached their fiduciary duties to the Company in connection with the Company's handling of the MoistureLoc withdrawal. Plaintiffs purport to allege damage to the Company as a result of, among other things, costs of litigating product liability and personal injury lawsuits, costs of the product recall, costs of carrying out internal investigations, and the loss of goodwill and reputation. Plaintiffs seek unspecified damages as well as certain declaratory and injunctive relief.
Pursuant to a stipulated schedule ordered by the Court, plaintiff in the state-court Pinchuck action served an amended complaint on September 15, 2006 and defendants served a motion to dismiss the amended complaint on November 15, 2006; plaintiff's opposition to the motion was served on January 15, 2007, and defendants' reply is due February 15, 2007. Pursuant to a stipulated schedule ordered by the Court in the federal Little action, plaintiff in that case will have until 60 days after a ruling on a motion to dismiss in the consolidated securities action is entered or, if no such motion is filed, 60 days after defendants' answer to a consolidated amended complaint in the consolidated securities action is filed, to file an amended complaint.

Product Liability Lawsuits As of February 1, 2007, the Company has been served or is aware that it has been named as a defendant in approximately 196 product liability lawsuits pending in various federal and state courts as well as certain other non-U.S. jurisdictions. Of the 196 cases, 117 actions have been filed in U.S. federal courts, 77 cases have been filed in various U.S. state courts and two actions have been filed in non-U.S. jurisdictions. These also include 170 individual actions filed on behalf of individuals who claim they suffered personal injury as a result of using a ReNu solution and 26 putative class actions alleging personal injury as a result of using a ReNu solution and/or violations of one or more state consumer protection statutes. In the personal injury actions, plaintiffs allege liability based on, among other things, negligence, strict product liability, failure to warn, and breach of warranty. In the consumer protection actions, plaintiffs seek economic damages, claiming that they were misled to purchase products that were not as safe as advertised. Several lawsuits contain a combination of these allegations. On August 14, 2006, the Judicial Panel on Multidistrict Litigation (JPML) created a coordinated proceeding and transferred an initial set of MoistureLoc product liability lawsuits to the U.S. District Court for the District of South Carolina. The Company has advised the JPML of all federal cases available for transfer and has urged the issuance of conditional transfer orders. As of February 1, 2007, 104 of the 117 federal cases noted above have been transferred to the JPML.

Material Intellectual Property Litigation In October 2005, Rembrandt Vision Technologies, L.P. filed a patent infringement lawsuit against the Company and CIBA Vision Corporation. The action is entitled, Rembrandt Vision Technology, L.P. v. Bausch & Lomb Incorporated and CIBA Vision Corporation, bearing case number 2:05 CV 491, and is pending in the U.S. District Court for the Eastern District of Texas (Marshall Division). Rembrandt asserts that the Company and CIBA have infringed certain of Rembrandt’s oxygen permeability and tear-wettability technology that it claims to be protected by a U.S. Patent No. 5,712,327 entitled “Soft Gas Permeable Lens Having Improved Clinical Performance” (the 327 Patent). Rembrandt claims that the Company infringes the 327 Patent by selling soft gas permeable contact lenses that have tear-wettable surfaces in the U.S., which would include the Company’s PureVision silicone hydrogel lens products. The Company denies, and intends to vigorously defend itself against, Rembrandt’s claims. The Court has issued a scheduling order and has set a trial date of November 5, 2007.




PAGE 111

Material Tax Litigation As disclosed in Note 10 — Provision for Income Taxes, on May 12, 2006, the Company received a Notice of Final Partnership Administrative Adjustment from the Internal Revenue Service relating to partnership tax periods ended June 4, 1999 and December 25, 1999, for Wilmington Partners L.P. (Wilmington), a partnership formed in 1993 in which the majority of partnership interests are held by certain of the Company's subsidiaries. The Final Partnership Administrative Adjustment (FPAA) proposes adjustments increasing the ordinary income reported by Wilmington for its December 25, 1999 tax year by a total of $10.0, and increasing a long-term capital gain reported by Wilmington for that tax year by $189.9. The FPAA also proposes a $550.0 negative adjustment to Wilmington's basis in a financial asset contributed to it by one of its partners in 1993; this adjustment would also affect the basis of that partner — one of the Company's subsidiaries — in its partnership interest in Wilmington. The asserted adjustments could, if sustained in full, increase the tax liabilities of the partnership's partners for the associated tax periods by more than $200.0, plus penalties and interest. The Company has not made any financial provision for the asserted additional taxes, penalties or interest as the Company believes the asserted adjustments are not probable and estimable.
Since 1999, the Company's consolidated financial statements have included a deferred tax liability relating to the partnership. As of December 31, 2005, this deferred tax liability equaled $157.1. This deferred tax liability is currently reducing net deferred tax assets for which a valuation allowance has been recorded as of December 31, 2005.
On August 7, 2006, the Company made a petition to the U.S. Tax Court to challenge the asserted adjustments. Internal Revenue Service's answer was filed on October 4, 2006, and the Company initiated a motion to strike portions of the answer on November 1, 2006. The Company believes it has numerous substantive and procedural tax law arguments to dispute the adjustments. Tax, penalties and interest cannot be assessed until a Tax Court determination is made, and an assessment, if any, would likely not be made until some time after 2007. While the Company intends to vigorously defend against the asserted adjustments, its failure to succeed in such a defense could significantly increase the liability of the partnership's partner for taxes, plus interest and penalties, which in turn would have a material adverse effect on the Company's financial results and cash flows.

General Litigation Statement From time to time, the Company is engaged in, or is the subject of, various lawsuits, claims, investigations and proceedings, including product liability, patent, trademark, commercial and other matters, in the ordinary course of business.
In addition to pending litigation matters, the Company may from time to time learn of alleged non-compliance with laws or regulations or other improprieties through compliance hotlines, communications by employees, former employees or other third parties, as a result of its internal audit procedures, or otherwise. As disclosed in Note 2 — Restatement, in response to such allegations, the Company’s Audit Committee conducted certain investigations during 2005 and 2006, which led, among other things, to the restatement of previously reported financial information and the recording of current charges. The restatement, in turn, resulted in the Company’s being unable to file timely certain periodic financial information and the Company’s obtaining certain waivers from creditors, as well as an extension from the NYSE to permit continued trading notwithstanding the delay in filing the Company’s 2005 Annual Report on Form 10-K.
The Audit Committee of the Board of Directors is currently investigating the potential U.S. Foreign Corrupt Practices Act implications of the Company’s Spanish subsidiary’s providing free product, principally intraocular lenses used in cataract surgery, and other things of value to doctors performing surgical procedures at public hospitals in Spain. This investigation was initiated following reports of potentially improper sales practices by a former employee. The investigation of the Company’s Spanish subsidiary has been voluntarily reported to the Northeast Regional Office of the SEC. We cannot predict the outcome of this pending investigation, and at this time cannot reasonably estimate the potential liability of the Company or its Spanish subsidiary in connection with these matters.
The Company’s policy is to comply with applicable laws and regulations in each jurisdiction in which it operates and, if the Company becomes aware of a potential or alleged violation, to conduct an appropriate investigation, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. There can be no assurance that any pending or future investigation or resulting remedial action will not have a material adverse financial, operational or other effect on the Company.
The Company may become parties to, or the subject of, other claims, lawsuits, investigations or inquiries in the future. See Item 3. Legal Proceedings of this Annual Report on Form 10-K.





PAGE 112

22.   Quarterly Results, Stock Prices and Selected Financial Data (Unaudited)

Quarterly Results As described in Note 2 — Restatement, the Company restated its consolidated financial statements for fiscal years 2004 and 2003 and its quarterly consolidated financial statements for the first and second quarters of fiscal 2005. The following table presents unaudited quarterly financial information for each quarter during the past two years, reflecting the impact of restatement. Net sales, gross profit and operating income are reported on the same basis as amounts in the accompanying Statements of Income.

   
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
   
As Reported
 
As
Restated
 
As Reported
 
As Restated
         
2005
                         
Net Sales
 
$
554.3
 
$
554.7
 
$
608.3
 
$
605.4
 
$
567.3
 
$
626.4
 
Gross Profit
   
322.3
   
321.9
   
362.2
   
360.4
   
318.6
   
369.7
 
Operating Income
   
60.5
   
55.2
   
80.2
   
75.7
   
56.4
   
96.1
 
Net Income (Loss)
   
34.5
   
33.3
   
45.0
   
37.3
   
(105.2
)
 
53.8
 
Earnings (Loss) Per Share, Basic
 
$
0.65
 
$
0.63
 
$
0.85
 
$
0.70
 
$
(1.97
)
$
1.00
 
Earnings (Loss) Per Share, Diluted
 
$
0.63
 
$
0.60
 
$
0.81
 
$
0.67
 
$
(1.97
)
$
0.96
 


   
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
   
As Reported
 
As
Restated
 
As Reported
 
As
Restated
 
As Reported
 
As
Restated
 
As Reported
 
As Restated
 
2004
                                 
Net Sales
 
$
510.3
 
$
514.0
 
$
566.5
 
$
564.6
 
$
548.9
 
$
548.6
 
$
606.6
 
$
606.3
 
Gross Profit
   
289.9
   
291.6
   
338.9
   
338.2
   
317.5
   
319.5
   
351.1
   
355.1
 
Operating Income
   
43.5
   
39.7
   
75.2
   
71.2
   
76.8
   
77.9
   
84.1
   
90.3
 
Net Income
   
23.5
   
22.8
   
41.4
   
32.4
   
43.3
   
46.7
   
51.4
   
51.9
 
Earnings Per Share, Basic
 
$
0.45
 
$
0.44
 
$
0.78
 
$
0.62
 
$
0.81
 
$
0.89
 
$
0.97
 
$
0.99
 
Earnings Per Share, Diluted 1
 
$
0.43
 
$
0.42
 
$
0.76
 
$
0.59
 
$
0.79
 
$
0.86
 
$
0.94
 
$
0.95
 

1
Includes the diluted effect from the Company's application of EITF Issue 04-8, The Effect of Contingently Convertible Debt on Diluted Earnings Per Share (see Note 4 — Earnings Per Share). Diluted shares were retroactively restated for periods ended prior to December 25, 2004 with no change to previously reported EPS. Diluted shares outstanding for the first, second and third quarters of 2004 were restated to 54,566; 54,569 and 54,628 from 54,499; 54,431 and 54,460, respectively. Diluted shares outstanding for the 2003 third quarter and year to date periods were restated to 53,423 and 53,519 from 53,379 and 53,491, respectively.


Quarterly Stock Prices The Company's Common stock is listed on the NYSE and is traded under the symbol BOL. There were approximately 7,400 and 7,700 Common shareholders of record at year-end 2005 and 2004, respectively. The following table shows the price range of the Common stock for each quarter for the past two years:

   
2005
 
2004
 
   
Price Per Share
 
Price Per Share
 
   
High
 
Low
 
High
 
Low
 
First
 
$
75.85
 
$
61.82
 
$
61.64
 
$
50.70
 
Second
   
79.75
   
70.80
   
66.67
   
57.63
 
Third
   
87.89
   
74.50
   
69.00
   
57.42
 
Fourth
   
84.30
   
66.17
   
67.95
   
57.17
 





PAGE 113

The following tables present the impact of the restatement adjustments described in Note 2 — Restatement on the Company’s previously reported net earnings and diluted earnings per share for the first and second quarters of 2005 and for each quarter of 2004 (dollar amounts in millions, except per share data):

   
Quarters Ended
 
   
Jun 25,
2005
 
Mar 26,
2005
 
Dec 25,
2004
 
Sep 25,
2004
 
Jun 26,
2004
 
Mar 27,
2004
 
Net Income, as Previously Reported
 
$
45.0
 
$
34.5
 
$
51.4
 
$
43.3
 
$
41.4
 
$
23.5
 
Brazil Matters
   
(0.9
)
 
(0.7
)
 
(0.6
)
 
(0.6
)
 
(0.3
)
 
(0.3
)
Asia and Other Revenue Recognition Matters
   
(1.5
)
 
(0.6
)
 
(0.3
)
 
(0.7
)
 
(1.8
)
 
1.5
 
Tax Matters
   
(4.2
)
 
2.6
   
(0.8
)
 
3.1
   
(6.4
)
 
2.0
 
Deferred Compensation Plan
   
(1.7
)
 
(2.0
)
 
0.2
   
(0.2
)
 
(0.6
)
 
(1.3
)
Other Items
   
0.6
   
(0.5
)
 
2.0
   
1.8
   
0.1
   
(2.5
)
Net Income as Restated
 
$
37.3
 
$
33.3
 
$
51.9
 
$
46.7
 
$
32.4
 
$
22.8
 


   
Quarters Ended
 
   
Jun 25,
2005
 
Mar 26,
2005
 
Dec 25,
2004
 
Sep 25,
2004
 
Jun 26,
2004
 
Mar 27,
2004
 
Diluted Earnings Per Share, as Previously Reported
 
$
0.81
 
$
0.63
 
$
0.94
 
$
0.79
 
$
0.76
 
$
0.43
 
Brazil Matters
   
(0.02
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
 
(0.01
)
Asia and Other Revenue Recognition Matters
   
(0.03
)
 
(0.01
)
 
-
   
(0.01
)
 
(0.03
)
 
0.03
 
Tax Matters
   
(0.07
)
 
0.05
   
(0.02
)
 
0.06
   
(0.12
)
 
0.04
 
Deferred Compensation Plan
   
(0.03
)
 
(0.04
)
 
-
   
-
   
(0.01
)
 
(0.02
)
Other Items
   
0.01
   
(0.01
)
 
0.04
   
0.03
   
-
   
(0.05
)
Diluted Earnings Per Share, as Restated
 
$
0.67
 
$
0.60
 
$
0.95
 
$
0.86
 
$
0.59
 
$
0.42
 





PAGE 114

 

Selected Financial Data
Dollar Amounts in Millions - Except Per Share Data

               
2002
 
2001
 
   
 
2005
 
2004
(Restated) 2
 
2003
(Restated) 2
 
(As Reported)
 
 
(Restated) 2
 
(As Reported)
 
 
(Restated) 2
 
Results for the Year
                             
Net Sales 1
 
$
2,353.8
 
$
2,233.5
 
$
2,018.5
 
$
1,816.7
 
$
1,810.5
 
$
1,665.5
 
$
1,660.4
 
Income from Continuing Operations
   
19.2
   
153.9
   
106.9
   
72.5
   
20.8
   
42.0
   
45.9
 
Net Income
   
19.2
   
153.9
   
106.0
   
72.5
   
20.8
   
21.2
   
15.7
 
Continuing Operations - Basic earnings per share
   
0.36
   
2.94
   
2.04
   
1.35
   
0.39
   
0.78
   
0.86
 
Net Income - Basic earnings per share
   
0.36
   
2.94
   
2.02
   
1.35
   
0.39
   
0.39
   
0.29
 
Continuing Operations - Diluted earnings per share
   
0.35
   
2.83
   
2.00
   
1.34
   
0.39
   
0.78
   
0.85
 
Net Income - Diluted earnings per share
   
0.35
   
2.83
   
1.98
   
1.34
   
0.39
   
0.39
   
0.29
 
Dividends per share
   
0.52
   
0.52
   
0.52
   
0.65
   
0.65
   
1.04
   
1.04
 
 
1
Expenses totaling $46.4 originally reported as selling, administrative and general expenses in 2001 have been reclassified to a reduction of net sales to reflect the adoption of EITF 01-9.
2
See Note 2 — Restatement for further information regarding the restatement of the Company's consolidated financial statements and information.




PAGE 115

           
2003
 
2002
 
2001
 
   
 
2005
 
2004
(Restated) 1
 
(As Reported)
 
 
(Restated) 1
 
(As Reported)
 
 
(Restated) 1
 
(As Reported)
 
 
(Restated) 1
 
Year End Position
                                 
Working capital
 
$
617.7
 
$
528.0
 
$
545.0
 
$
528.9
 
$
455.7
 
$
457.5
 
$
693.7
 
$
673.1
 
Total assets
   
3,416.4
   
3,045.8
   
3,006.4
   
3,038.14
   
2,773.4
   
2,767.1
   
2,993.5
   
2,872.05
 
Short-term debt
   
161.4
   
103.4
   
195.0
   
197.2
   
187.9
   
189.4
   
123.3
   
123.3
 
Long-term debt
   
831.2
   
543.3
   
652.0
   
652.0
   
656.2
   
656.2
   
703.2
   
703.2
 
Retained earnings
   
1,471.6
   
1,480.4
   
1,396.9
   
1,354.12
   
1,298.9
   
1,275.62
   
1,261.4
   
1,289.82
 
Shareholders' equity
   
1,283.9
   
1,362.8
   
1,203.4
   
1,160.82
   
1,017.8
   
1,005.32
   
975.0
   
1,017.33
 

Other Ratios and Statistics
                                 
Return on average shareholders' equity
   
1.4
%
 
12.6
%
 
11.9
%
 
10.5
%
 
7.4
%
 
2.1
%
 
2.1
%
 
1.5
%
Return on invested capital
   
3.5
%
 
9.9
%
 
8.5
%
 
8.6
%
 
6.0
%
 
4.1
%
 
3.1
%
 
2.8
%
Effective income tax rate for continuing operations before minority interest
   
89.9
%
 
34.4
%
 
34.0
%
 
37.3
%
 
34.5
%
 
69.8
%
 
33.8
%
 
41.5
%
Current ratio
   
1.6
   
1.6
   
1.6
   
1.6
   
1.5
   
1.5
   
2.0
   
1.9
 
Capital expenditures
 
$
116.0
 
$
118.9
 
$
91.5
 
$
91.5
 
$
91.9
 
$
91.9
 
$
96.4
 
$
96.4
 

1
See Note 2 — Restatement for further information regarding the restatement of the Company's consolidated financial statements and information.
2
See the Statements of Changes in Shareholders' Equity for information regarding the impact of restatement adjustments on the Company's retained earnings and components of total shareholders' equity.
3
The $42.3 increase in shareholders' equity primarily reflects the cumulative impact of restatement adjustments on net earnings (see the following table) and the cumulative impact of restatement adjustments associated with the Company's comprehensive review of its accounting for income taxes partially offset by the impact of restatement adjustments associated with the deferred compensation matter.
4
The $31.7 increase in total assets primarily reflects the impact of restatement adjustments associated with the Company's comprehensive review of its accounting for income taxes which increased deferred income tax assets by $76.6, partially offset by a $53.8 decrease in goodwill reflecting adjustments also associated with this comprehensive review, specifically related to a 1998 acquisition.
5
The $121.5 decrease in total assets reflects the impact of restatement adjustments associated with the Company's comprehensive review of its accounting for income taxes.



PAGE 116

The following tables present the impact of the restatement adjustments described in Note 2 — Restatement on the Company’s previously reported net earnings and diluted earnings per share for fiscal years 2001, 2002, 2003 and 2004 as well as the impact of restatement adjustments on the Company's previously reported pre-2001 cumulative net earnings (dollar amounts in millions, except per share data):
 


   
Years Ended
 
   
Dec 25, 2004
 
Dec 27, 2003
 
Dec 28, 2002
 
Dec 29, 2001
 
Retained Earnings, as Previously Reported
 
$
1,528.9
 
$
1,396.9
 
$
1,298.9
 
$
1,261.4
 
Cumulative Retained Earnings Restatement Adjustments
   
(42.8
)
 
(23.3
)
 
28.4
   
33.9
 1
                           
Net Income, as Previously Reported
 
$
159.6
 
$
125.5
 
$
72.5
 
$
21.2
 
Brazil Matters
   
(1.8
)
 
(7.5
)
 
(8.3
)
 
(6.0
)
Asia and Other Revenue Recognition Matters
   
(1.3
)
 
(2.1
)
 
(0.8
)
 
(0.4
)
Tax Matters
   
(2.1
)
 
0.7
   
(40.0
)
 
1.6
 
Deferred Compensation Plan
   
(1.9
)
 
(2.3
)
 
0.2
   
0.3
 
Other Items
   
1.4
   
(8.4
)
 
(2.8
)
 
(1.0
)
Net Income, as Restated
 
$
153.9
 
$
106.0
 
$
20.8
 
$
15.7
 
Total Net Income Restatement Adjustments
   
(5.7
)
 
(19.5
)
 
(51.7
)
 
(5.5
)
Retained Earnings, as Restated
 
$
1,480.4
 
$
1,354.1
 
$
1,275.6
 
$
1,289.8
 
 
1  The increase reflects the following restatement adjustments recorded in periods prior to 2001: $39.3 associated with the Company's comprehensive review of its accounting for income taxes; $1.2 related to the deferred compensation plan matter; and $0.4 related to other matters. These increases were partially offset by a $4.4 decrease related to Asia and other revenue recognition matters and a $2.6 decrease related to the Brazil matters.

   
Years Ended
 
   
Dec 25, 2004
 
Dec 27, 2003
 
Dec 28, 2002
 
Dec 29, 2001
 
Diluted Earnings Per Share, as Previously Reported
 
$
2.93
 
$
2.34
 
$
1.34
 
$
0.39
 
Brazil Matters
   
(0.03
)
 
(0.14
)
 
(0.15
)
 
(0.11
)
Asia and Other Revenue Recognition Matters
   
(0.02
)
 
(0.04
)
 
(0.01
)
 
(0.01
)
Tax Matters
   
(0.04
)
 
0.01
   
(0.74
)
 
0.03
 
Deferred Compensation Plan
   
(0.04
)
 
(0.04
)
 
-
   
0.01
 
Other Items
   
0.03
   
(0.16
)
 
(0.05
)
 
(0.02
)
Diluted Earnings Per Share, as Restated
 
$
2.83
 
$
1.98
 
$
0.39
 
$
0.29
 


23.   Subsequent Event

Market Withdrawal of MoistureLoc Lens Care Solution On May 15, 2006, the Company announced a voluntary recall of its MoistureLoc lens care solution. The decision was made following months of investigation into an increase in fungal infections among contact lens wearers in the United States and certain Asian markets. The Company’s decision to recall the product represents a subsequent event occurring prior to its filing this Form 10-K, but related to product manufactured and sold in 2005. In accordance with GAAP, the Company has recorded certain items associated with the recall in its 2005 financial results. The adjustments were recorded as third-quarter events, because that is the earliest reporting period for which the Company has not filed quarterly financial results on Form 10-Q.



PAGE 117

The charges associated with the withdrawal reduced 2005 third-quarter earnings before taxes by $39.0 and net income by $25.0, or $0.45 per share (based on local statutory tax rates). Full-year 2005 earnings before taxes were reduced by $39.0 and full-year 2005 net income was reduced by $27.5, or $0.49 per share (based on local statutory tax rates). Of the pre-tax amount, $17.1 related to estimated customer returns and consumer rebates and was recorded as a reduction to net sales; $14.1 related to costs associated with returned product and the disposal and write-off of inventory, which was recorded as cost of products sold; and $7.9 related to costs associated with the notification to customers and consumers required in market withdrawal instances, which was recorded as selling, administrative and general expense. Charges include $1.7 for settled, unlitigated claims, however, the Company has not recorded any provisions for potential legal actions related to MoistureLoc because it is not yet able to estimate the magnitude of such charges, if any (see further discussion in Note 21 Other Matters).
The Company anticipates its decision to withdraw the product will negatively impact future financial performance. The Company recorded additional amounts for sales returns provisions and coupon redemptions in 2006, and performance was hampered by the impact from lost MoistureLoc revenues; lower revenues for other lens care products, reflecting market share losses caused by trade and consumer uncertainty; and the negative collateral effect on the Company’s non-lens care product categories, primarily in Asia; combined with higher expenses associated with the recall and legal expenses associated with product liability lawsuits, and increased marketing expense to support brand rebuilding activities. The Company incurred additional charges, primarily in Europe, associated with the MoistureLoc recall for product manufactured and sold in 2006. These charges approximated $26.7 on a pre-tax basis, of which approximately $19.1 is associated with sales returns and other reductions to reported net sales.
The Company considered the voluntary recall of MoistureLoc an event that would more likely than not reduce the fair value of a reporting unit. Therefore, in accordance with SFAS 142, the Company reviewed and updated the financial information and assumptions used in calculating reporting unit fair values in its 2005 annual impairment test (see Note 1 — Significant Accounting Policies for a discussion of the Company's annual impairment test) for purposes of assessing whether the withdrawal was likely to reduce any of the reporting unit fair values to below its carrying amount. The Company updated the financial information and made changes to assumptions (used in calculating the indications of value under the income and market approaches) to reflect the anticipated impact of the withdrawal on reporting unit operating results. The revised reporting unit fair values were compared to the carrying amounts from the 2005 annual impairment test. The revised fair values of each of the reporting units exceeded its carrying amount by a substantial margin. The Company therefore concluded that the probability of the voluntary recall reducing the fair value of any reporting unit below its carrying amount was remote and, as such, an impairment test was not required. In addition, a separate analysis was performed surrounding the valuation of the Company's acquisition of Freda (see Note 3 — Acquisition for further discussion), which was not completely integrated as of December 31, 2005. The Company determined that the fair value of Freda exceeded its carrying value. The Company will continue to monitor and assess the impact from the recall as it relates to the fair value of any of its reporting units.


Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not Applicable.


Item 9A.   Controls and Procedures

Evaluation of Disclosure Controls and Procedures As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of the Company's Chairman and Chief Executive Officer along with the Company's Senior Vice President and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Based on such evaluation and the identification of the material weaknesses in internal control over financial reporting described below, as well as our inability to file this Annual Report on Form 10-K within the statutory time period, the Company's Chairman and Chief Executive Officer and the Company's Senior Vice President and Chief Financial Officer have concluded that, as of December 31, 2005, the Company's disclosure controls and procedures were not effective.



PAGE 118

As previously reported in news releases dated October 26 and December 22, 2005, the Audit Committee of the Company's Board of Directors commenced in September 2005, an independent investigation into allegations of misconduct by the management of the Company's Brazilian subsidiary, BL Industria Otica, Ltda. (BLIO), which had been reported to the Company's senior management by a BLIO employee pursuant to the Company's established compliance program. In addition, as reported in the December 22 release, in late November 2005, following employee reports regarding possibly improper sales practices in the Company's Korean subsidiary (Bausch & Lomb Korea Co. Ltd. [BL Korea]), the Audit Committee commenced an independent investigation into revenue recognition and sales practices in the Korean subsidiary. In light of the investigations of the Company's Brazil and Korea subsidiaries, the Company undertook expanded year-end procedures at substantially all locations focused on, among other things, revenue recognition practices. In addition, following the discovery of evidence in the course of the Korea investigation, the Audit Committee commenced the investigation of the timing and appropriateness of reserve entries on a company-wide basis. In addition, as previously reported, in 2005 the Company undertook a comprehensive review of its accounting for income taxes. As a result of this review, the Company determined adjustments to prior period financial statements were necessary related to: differences between the tax and financial reporting basis of the Company's assets and liabilities pertaining to its deferred income tax assets and liabilities; the provision for income taxes and income taxes payable; and tax implications of certain non-routine transactions, including certain acquisitions.
As described in detail in Note 2 — Restatement to the consolidated financial statements, the Brazil, Korea and reserve entry investigations as well as the Company's expanded procedures and the comprehensive review of accounting for income taxes resulted in the identification of certain matters that required that adjustments including audit adjustments be made to prior period financial statements and to the 2005 third quarter interim and the 2005 annual financial statements. Such matters and the related adjustments were considered in connection with management's assessment of internal control over financial reporting that is set forth below.

Management’s Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process, under the supervision of the Company's Chief Executive Officer and Chief Financial Officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external reporting purposes in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).
A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material adverse effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2005 based on the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Management excluded Freda from its assessment of internal control over financial reporting as of December 31, 2005 because Freda was acquired by the Company in a purchase business combination during the fourth quarter of 2005. Freda represented one percent of the Company's net sales for the year ended December 31, 2005 and eight percent of the Company's total assets at December 31, 2005.



PAGE 119

A material weakness is a control deficiency, or a combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of annual or interim financial statements will not be prevented or detected. In connection with the assessment described above, management has identified the following material weaknesses as of December 31, 2005:
(1) Control Environment The Company did not maintain an effective control environment because of the following: (a) the Company did not adequately and consistently reinforce the importance of adherence to controls and the Company's code of conduct, which contributed to certain of the restatement items that occurred across a broad range of the Company's operational and functional areas; (b) the Company failed to institute all elements of an effective program to help prevent and detect fraud by Company employees; (c) the Company did not establish and maintain effective corporate and regional management oversight and monitoring of operations to detect subsidiaries' managements’ override of established financial controls and accounting policies, execution of improper transactions and accounting entries to impact revenue and earnings, and reporting of these transactions to the appropriate finance personnel or the Company’s independent registered public accounting firm; and (d) the Company did not maintain a sufficient complement of personnel with an appropriate level of knowledge, experience and training in the application of GAAP, including revenue recognition and accounting for income taxes, and in internal controls over financial reporting commensurate with its financial reporting requirements. This material weakness contributed to the additional material weaknesses discussed in items 2-4 below.
(2) Controls Over the Financial Reporting and Close Process The Company did not maintain effective controls to provide reasonable assurance of the completeness and accuracy of certain financial statement accounts in certain subsidiaries. Specifically, the Company did not maintain effective controls to ensure that account reconciliations and journal entries were supported by appropriate analysis and documentation in connection with the financial reporting and close process. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.
(3) Controls Over Revenue Recognition and Sales Practices The Company did not maintain effective controls over certain subsidiaries’ relationships with their key distributors, particularly in the Company’s Korea, Japan and India subsidiaries, and did not maintain effective controls over the installation of refractive laser surgery equipment in multiple locations where the Company does business, to ensure that revenue associated with such distributor and laser sales was recognized in accordance with GAAP. Specifically, the Company did not maintain effective controls to provide reasonable assurance that customer arrangements were adequately reviewed by the appropriate persons at such subsidiaries to identify and provide reasonable assurance regarding the proper application of the appropriate method of revenue recognition in accordance with GAAP. In addition, the Company did not maintain effective controls to prevent subsidiary management from overriding established financial controls or making errors in the application of policies concerning the accuracy and valuation of accounts receivable and the maintenance of distributor inventory at established threshold levels, as well as regarding administration of credit limits, extensions of credit terms, price discounting, sales returns and exchanges, transfer of the risk of ownership, and sales order entry and control. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.



PAGE 120

(4) Controls Over Tax Accounting The Company did not maintain effective controls over the determination and reporting of its income tax payable, deferred income tax assets and liabilities, the related valuation allowances and income tax expense. Specifically, effective controls were not designed and in place to: (i) ensure management maintained the appropriate level of personnel resources with adequate experience and expertise in the area of U.S. GAAP accounting for income taxes; (ii) ensure roles and responsibilities with respect to accounting for income taxes were clearly defined; (iii) identify and evaluate in a timely manner the tax implications of certain non-routine transactions, including transactions related to acquisitions; (iv) provide reasonable assurance as to the completeness and accuracy of the provision for income taxes and income taxes payable including tax reserves and return to provision adjustments; and (v) reconcile differences between the tax and financial reporting basis of its assets and liabilities with its deferred income tax assets and liabilities. In addition, the Company did not maintain effective controls over indirect taxes, including VAT and certain import related taxes related to its Brazilian subsidiary. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.
(5) Controls Over Deferred Compensation Plan The Company did not maintain effective controls to ensure that the Company’s Deferred Compensation Plan document was amended to accurately reflect the Plan’s intended design. This inaccurate amendment of the plan resulted in the Company not properly marking to market stock awards issued under the Company’s Long-Term Incentive Plan that were deferred under the Deferred Compensation Plan which impacted the completeness and accuracy of selling, administrative and general expense and accrued liabilities. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.

Additionally, each of these material weaknesses above could result in a material misstatement to the Company's interim or annual consolidated financial statements and disclosures which would not be prevented or detected.
As a result of these material weaknesses described above, management has concluded that, as of December 31, 2005, the Company's internal control over financial reporting was not effective based on the criteria in Internal Control-Integrated Framework issued by the COSO.
Management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2005 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included under the Report of Independent Registered Public Accounting Firm in this Annual Report on Form 10-K.

Remediation of Material Weaknesses in Internal Control Over Financial Reporting The Company has engaged in, and is continuing to engage in, substantial efforts to address the material weaknesses in its internal control over financial reporting. Several material weaknesses were remediated in 2006 and the Company is working to remediate the others as soon as practicable. Specific actions which have been or will be taken are outlined below:




PAGE 121

From a control environment and organizational perspective:

·  
Several individuals in management positions at its Brazilian and Korean operations have either left the Company or have been terminated. In addition, the Senior Vice President - Asia has been replaced.
·  
The Company has strengthened its management and financial ranks including the appointment of a Vice President, Compliance reporting directly to the Chief Executive Officer and the Audit Committee of the Board; and a Vice President, Financial Compliance reporting to the Corporate Controller.
·  
The Company further enhanced its whistleblower program related to the communication, investigation and resolution of whistleblower activities.
·  
The Company plans to further expand and strengthen its internal audit organization by hiring additional experienced audit staff.
·  
The Company has continued and expanded executive management's ongoing communications regarding the importance of adherence to internal controls and company policies.
·  
The Company has strengthened its tax department by hiring additional senior tax staff with expertise in accounting for income taxes.
·  
The Company realigned the global finance organization in its operating segments to have a direct reporting relationship to the Corporate Controller, rather than to management within the operating segments.
·  
The Company has modified the performance management objectives and individual bonus metrics for the global finance organization to be more heavily weighted to internal controls and financial reporting and close metrics.
·  
The Company has begun an initiative to provide additional training to finance, accounting and tax professionals regarding new and evolving areas in U.S. GAAP accounting. In addition, the Company is undertaking a review to ensure that the finance, accounting and tax functions are staffed in accordance with the required competencies, and has begun the process of making personnel changes where necessary.
·  
The Company is developing a formal training program for certain non-finance employees on revenue recognition and integrity of financial reporting and controls.
·  
The Company has reinforced the certification process to emphasize senior managers' accountability for maintaining an ethical environment.

In addition to strengthening its control environment and organizational capabilities:

·  
The Company, with the assistance of outside consultants other than its independent registered public accountants, undertook a project to perform a comprehensive review of its accounting for income taxes including deferred tax assets and liabilities, taxes payable and tax reserves. Further, the Company will initiate processes to improve proper tracking of deferred tax assets and liabilities.
·  
The Company has augmented the quarterly financial reporting and close process, including by implementing an expanded Quarterly Close Checklist which is completed by each Operating Segment Controller and reviewed by the Corporate Controller to focus on the specific areas identified in the material weaknesses.
·  
The Company has enhanced key control activities related to revenue recognition on laser installations and, sales to distributor/wholesalers, documentation and approval of terms of sales, including standard and extended credit terms and, analysis of sales returns and exchanges.
·  
The Company is in the process of enhancing policies and procedures designed to detect and prevent fraud including strengthening key region and entity-wide monitoring activities.
·  
The Company implemented a process requiring all subsidiaries outside of the United States to use one global professional tax advisor to review local income tax returns prior to filing and to provide services relating to tax assessments and positions.
·  
The Company has clarified responsibilities of the Regional Tax Directors to include review of VAT, customs and other indirect taxes.
·  
The Company will require formal review and approval of all new or amended employee benefit plans by Corporate Technical Accounting.




PAGE 122

The above actions are being considered in the Company's evaluation of its internal control over financial reporting for the year ended December 30, 2006. While the Company has not completed its 2006 internal control evaluation, it is expected that the Company will report one or more material weaknesses in internal control over financial reporting for 2006 when it files its Annual Report on Form 10-K for the year ended December 30, 2006.

Changes in Internal Control Over Financial Reporting During the fourth quarter of 2005, the Company continued to implement its global enterprise reporting system at its commercial and global operations businesses including the Company's U.S. Vision Care operation. In addition, the Company also changed to a new third-party payroll processor for its employees based in the United Kingdom. The Company also realigned the finance organization to have a direct reporting relationship to the Corporate Controller. As described above, there were changes in the Company's internal control over financial reporting that occurred during the Company's last fiscal quarter that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. The Company is continuing to implement the global enterprise reporting system, and in that process, expects that there will be future material changes in internal controls as a result of this implementation.


Item 9B.   Other Information

Not applicable.





PAGE 123

Part III

Item 10.   Directors and Executive Officers of Bausch & Lomb Incorporated

The Company's Board of Directors is comprised of the following members (information current as of December 1, 2006):
 
ALAN M. BENNETT
 
 
Director since 2004
Age: 55
 
Mr. Bennett has served since 2001 as senior vice president and chief financial officer of Aetna Inc., a leading provider of health, dental, group life, disability and long-term care benefits. He joined Aetna in 1995 as chief financial officer for Aetna Business Resources. He was named vice president and director of internal audit of Aetna Inc. in 1997 and in 1998 was named vice president and controller. From 1981 to 1995, Mr. Bennett held several executive positions with Pirelli Armstrong Tire Corporation. From 1972 to 1981, he was an audit manager at Ernst & Young. Mr. Bennett is a Director of Halliburton and a member of the American Institute of Certified Public Accountants.
 
DOMENICO DE SOLE
 
 
Director since 1996
Age: 62
 
Mr. De Sole has served since April 2005 as chairman of Tom Ford International, a fashion company which produces fragrances, sunglasses and a signature ready-to-wear men's line. He served from 1995 to 2004 as president and chief executive officer of Gucci Group N.V., a multibrand luxury goods company. He joined that company in 1984 as president and chief executive officer of Gucci America, Inc. and in 1994 was named chief operating officer of Gucci Group N.V. Mr. De Sole is a director of Delta Airlines, Inc., GAP Inc. and Telecom Italia and Ermenegildo Zegna. He is a member of the Harvard Law School Advisory Board.
 
PAUL A. FRIEDMAN, M.D.
 
 
Director since 2004
Age: 63
 
Dr. Friedman has served since 2001 as president and chief executive officer of Incyte Corporation, a biotechnology company. From 1998 until 2001, he served as president of DuPont Pharmaceuticals Research Laboratories. From 1994 until 1998, he served as president, Research and Development, of DuPont Merck Pharmaceutical Company. From 1991 to 1994, he was senior vice president of Research at Merck Sharp & Dohme Research Laboratories and from 1985 to 1991 he held several executive positions there. From 1974 to 1985, Dr. Friedman was associate professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Pharmacology and Experimental Therapeutics, the American Society of Clinical Investigation, and the American Society of Biological Chemistry.
 
JONATHAN S. LINEN
 
 
Director since 1996
Age: 63
 
Mr. Linen has served since January 2006 as advisor to the chairman of American Express Company, a diversified worldwide travel and financial services company. From 1993 to 2006, he served as vice chairman. He joined that company in 1969 and held various executive positions before being appointed president and chief executive officer of Shearson Lehman Brothers in 1989. In 1992, he was named president and chief operating officer of American Express Travel Related Services Company, Inc. Mr. Linen is chairman of the board of the International Golf Association, a trustee of the U.S. Council for International Business and a member of The Council on Foreign Relations. Mr. Linen presides on the policy committee of The Travel Business Roundtable and is vice chairman of the executive committee of the World Travel & Tourism Council. He serves as a member of the boards of Yum! Brands, Inc., Intercontinental Hotels, World Monuments Fund, the U.S. Travel & Tourism Promotion Advisory Board, and is an executive committee member of NYC & Company. Mr. Linen is a past chairman and now honorary member of the board of trustees of the National Urban League.



PAGE 124

 
RUTH R. McMULLIN
 
 
Director since 1987
Age: 64
 
Mrs. McMullin is the chairperson of trustees of the Eagle-Picher Trust. She was a member of the faculty of the Yale School of Management as a Management Fellow from 1994 to 1995. From 1992 to 1994, she was president and chief executive officer of the Harvard Business School Publishing Corporation. From 1990 to 1992, Mrs. McMullin was a consultant to private industry and from 1991 to 1992, she was also acting chief executive officer of UNR Industries, Inc. and a member of that company's chairman's committee. From 1989 to 1990, she was president and chief executive officer of John Wiley & Sons, Inc., a publishing company. Mrs. McMullin joined that company as executive vice president and chief operating officer in 1987. She is a director of The Mighty Eighth Foundation, Inc., and The Mighty Eighth Air Force Heritage Center, Inc.
 
LINDA JOHNSON RICE
 
 
Director since 1990
Age: 48
 
Mrs. Rice has served since 2002 as president and chief executive officer of Johnson Publishing Company, Inc., a multi-media company. She joined that company in 1980, became vice president in 1985 and president and chief operating officer in 1987. In addition to management of the company, she oversees the editorial content of Ebony and Jet magazines. She is also president of Fashion Fair Cosmetics, a division of Johnson Publishing. Mrs. Rice is a director of Kimberly-Clark Corporation, Omnicom Group, Inc., and Money Gram International, Inc.
 
WILLIAM H. WALTRIP
 
 
Director since 1985
Age: 69
 
Mr. Waltrip served from 1993 to 2003 as chairman of the board of Technology Solutions Company, a systems integration company, and from 1993 until 1995 he was chief executive officer of that company. Mr. Waltrip has served twice as Bausch & Lomb's interim chief executive officer, once in 1996 and once in 2001. He also served as the Company's chairman from 1996 to 1998 and again in 2001. From 1991 to 1993, he was chairman and chief executive officer of Biggers Brothers, Inc., a food service distribution company and was a consultant to private industry from 1988 to 1991. From 1985 to 1988, he served as president and chief operating officer of IU International Corporation, a transportation, environmental and distribution company. Earlier, he had been president, chief executive officer and a director of Purolator Courier Corporation. He is a director of Theravance, Inc., Charles River Laboratories International, Inc. and Thomas & Betts Corporation.
 
BARRY W. WILSON
 
 
Director since 2003
Age: 62
 
Mr. Wilson has served since 1997 as senior vice president and a member of the Executive Committee of Medtronic, Inc., a medical technology company. In 2006, he was appointed senior vice president, International Affairs and President Greater China, having had responsibility as president of Medtronic International since 2001. Mr. Wilson joined Medtronic as president of Europe, Middle East and Africa in 1995. From 1980 to 1993, he held various executive positions with Bristol-Myers Squibb, including president of Europe. Prior to that, he held executive positions with Pfizer, Inc. in nine different countries. Mr. Wilson was chairman of Eucomed, the European medical device industry association from 2000 to 2004 and now serves as its honorary chairman.
 
KENNETH L. WOLFE
 
 
Director since 1989
Age: 67
 
Mr. Wolfe served as chairman and chief executive officer of Hershey Foods Corporation, a food products manufacturing firm, from 1994 until his retirement in 2001. He joined that firm in 1967 and held various executive positions before being appointed vice president and chief financial officer in 1981. In 1984, Mr. Wolfe was named senior vice president. From 1985 until 1993, he was president and chief operating officer. Mr. Wolfe is a director of Adelphia Communications Corporation and Revlon, Inc. and is a trustee of Fidelity Funds.



PAGE 125

 
RONALD L. ZARRELLA
 
 
Director since 2001
Age: 57
 
Mr. Zarrella has served since 2001 as chairman and chief executive officer of Bausch & Lomb Incorporated. He was previously with General Motors Corporation, where he was executive vice president and president of General Motors North America from 1998 to 2001. From 1994 to 1998, Mr. Zarrella was vice president and group executive in charge of General Motors' North American Vehicle Sales, Service and Marketing Group. From 1985 to 1994, Mr. Zarrella held several executive positions at Bausch & Lomb, including serving as its president, chief operating officer and a member of its Board of Directors. Mr. Zarrella is a director of Avaya, Inc. He is a trustee of Rochester Institute of Technology, the International Agency for the Prevention of Blindness, and the Committee for Economic Development. Mr. Zarrella is a member of the board of the University of Rochester Medical Center, FIRST (For Inspiration and Recognition of Science and Technology), and the National Italian American Foundation.

The Board of Directors of the Company met nine times in 2005. Each of the directors attended 75% or more of the aggregate number of regularly scheduled and special Board and committee meetings held during the year, except for Linda Johnson Rice, who attended 71% of the meetings due to a serious family illness. Pursuant to a policy adopted by the Nominating and Governance Committee of the Board, directors are strongly encouraged to attend annual meetings of shareholders. Each of the directors attended the 2005 annual meeting.
Directors who are not employees of the Company received an annual retainer of $52,000 in 2005. No additional fees are paid for attending meetings. The Company does not pay an annual retainer or fees to directors who are employees of the Company. The Chair of the Audit Committee was paid an additional $10,000 fee and members of the Audit Committee were each paid an additional $5,000 fee. The Chairs of the Compensation Committee and Nominating and Governance Committee were each paid an additional $7,500 fee.
The Company's Annual Retainer Stock Plan for Non-Employee Directors includes director stock ownership guidelines. The guidelines provide that directors who own shares of Company stock or share equivalents with an aggregate market value of $260,000 or more have the option to receive their annual retainer in Company stock or cash or a combination of both. New Directors have five years to meet the guidelines. Directors who have not met the guidelines receive at least one-half of the annual retainer in Company stock. All of the current non-employee directors, except for Mr. Alan M. Bennett and Dr. Paul A. Friedman, who were both elected to the Board of Directors for the first time in 2004, have met the stock ownership guidelines.
Under the Company's 2003 Long-Term Incentive Plan, non-employee directors annually receive non-qualified options to purchase shares of Common stock of the Company that vest in one year. The number of options is determined by a fixed formula set forth in the Plan, and the exercise price of all such options is determined by the fair market value of the Company's Common stock on the date of grant. For fiscal year 2005, each non-employee director was granted 1,956 options to purchase Common shares at a price of $83.550 per share.
Under the Company's Deferred Stock Equivalent Program, non-employee directors of the Company receive an annual grant of 500 deferred stock equivalent units. These instruments are a contract right to receive, in cash, at the time of the director's retirement from the Board, an amount equal to the product of the market value of one share of the Company's Common stock at the time of the director's retirement from the Board multiplied by the number of deferred stock equivalent units. This element of compensation brings total director compensation into line with that of comparable companies, in part enhancing the Company's ability to attract and retain high-quality director candidates, and in part aligning directors' economic interests with those of shareholders. The program also provides for a one-time matching contribution of deferred stock equivalent units valued at $25,000 for new non-employee directors upon the acquisition of an equal number of shares of Company stock by the director.
From 1993 through 1996, the Company had a Charitable Contribution Plan in place for non-employee directors of the Company. The Plan was frozen in 1996. Under this plan, following the death of a participating director, the Company will make up to $250,000 in charitable contributions to bona fide tax-exempt organizations meeting the requirements of Section 501(c)(3) of the Internal Revenue Code selected by the participant. The plan covers the following retired directors: Franklin E. Agnew, William Balderston III, Bradford Boss, Daniel E. Gill, Jay T. Holmes, Thomas C. McDermott, John R. Purcell, and Alvin W. Trivelpiece; and current directors: Ruth R. McMullin, Linda Johnson Rice, William H. Waltrip and Kenneth L. Wolfe. The Company funds its obligations to make these contributions through insurance policies on the lives of the participating directors. As such, because the Company receives payment of the benefit, makes the required contribution and receives the charitable deductions, no director receives a financial or tax benefit under the Plan. The aggregate premiums paid on these policies in 2005 were $62,257.50.



PAGE 126

As appointed by the Board of Directors, William H. Waltrip serves as lead director of the Board of Directors. Mr. Waltrip received an annual retainer of $25,000 for his services as lead director for the 2005-2006 term of office, in addition to his annual retainer as a director and annual fee as chair of the Nominating and Governance Committee. His responsibilities include acting as chairman of executive sessions of the non-employee directors, acting as principal liaison between the non-employee directors and the chairman of the board and performing other duties designated by the Board to assist in the fulfillment of its responsibilities.

Executive Sessions Executive sessions of the independent directors are held at the end of each Board of Directors meeting. The Board has selected William H. Waltrip, the Board's lead director, to preside at all executive sessions of the independent directors.

Communications by Shareholders and Interested Parties Shareholders and interested parties may communicate with the Board or any individual director by sending such communications to the attention of the secretary of the Company, who will forward all such communications to the Board. Communications intended for the non-employee directors as a group should be sent to the secretary, addressed to the attention of the lead director of the Board.

Corporate Governance Principles, Board Matters and Code of Ethics The Company is committed to sound corporate governance principles. The Company's Corporate Governance Guidelines, Code of Business Conduct and Ethics, and Code of Ethics for CEO and Senior Financial Officers are available on the Company's web site at http://www.bausch.com/en_US/corporate/corpcomm/general/governance.aspx. Printed copies of these documents can be obtained by contacting the secretary of the Company.
At the 2005 annual meeting, shareholders approved amendments to the Company’s Certificate of Incorporation and By-laws that eliminated the Company's classified Board and reinstated the annual election of directors. Under the amendments, once a director's three-year term expired under the classified board structure, if elected, he or she would serve annual terms that expired at the subsequent annual meeting. At the anticipated 2007 annual meeting of shareholders, all director positions will be elected for annual terms under the Company's de-classified board structure.

Board Independence The Board of Directors has determined that each of the directors, other than Mr. Zarrella, has no material relationship with the Company and is independent within the meaning of the SEC and NYSE director independence standards, as currently in effect.

Committees of the Board The Board of Directors has established four standing committees to assist it in carrying out its responsibilities: the Executive Committee, the Audit Committee, the Compensation Committee, and the Nominating and Governance Committee. The Board of Directors may establish additional committees, such as the Evaluation Committee as discussed in Item 3. Legal Proceedings and in Item 8. Financial Statements and Supplementary Data under Note 21 — Legal Matters of this Annual Report on Form 10-K.
The membership and the function of each of the committees are described below. Each of the committees operates under its own written charter adopted by the Board of Directors. All of the committee charters are available on the Company's web site at http://www.bausch.com/en_us/corporate/ir/general/board_members.aspx. Printed copies of the committee charters can be obtained by contacting the secretary of the Company.

Executive Committee
Number of Members:
Members:
 
 
Four directors
Ronald L. Zarrella (Chair), Jonathan S. Linen, William H. Waltrip and Kenneth L. Wolfe
Number of Meetings in 2005:
 
None
Functions:
-
Holds meetings, as necessary, between regular Board of Directors meetings to take action necessary for the Company to operate efficiently
 
-
Possesses all of the authority of the full Board of Directors, except as limited by law and the By-laws of the Company



PAGE 127

Audit Committee
Number of Members:
Members:
 
 
Four independent directors
Kenneth L. Wolfe (Chair), Alan M. Bennett, Domenico De Sole and Barry W. Wilson
Number of Meetings in 2005:
 
Seventeen
Functions:
-
Reviews and evaluates the qualifications and performance of the independent accountants
 
-
Appoints and/or replaces the independent accountants
 
-
Responsible for compensating and overseeing the work of the independent accountants
 
-
Preapproves all audit services and permitted nonaudit services to be performed for the Company by its independent accountants
 
-
Reviews and discusses with management and the independent accountants the quarterly interim and annual audited financial statements and related Management's Discussion & Analysis
 
-
Provides for direct communication among the Board of Directors, the independent accountants and the internal auditors, including review of the disclosures and letter provided by the independent accountants pursuant to Independence Standards Board Standard No. 1
 
-
Discusses with management and the independent accountants significant financial reporting and internal control issues
 
-
Discusses with the independent accountants the matters required to be discussed by Statement on Auditing Standards No. 61
 
-
Meets with the independent accountants prior to the audit to discuss the planning and staffing of the audit
 
-
Oversees the Company's internal audit function
 
-
Reviews the receipt, retention and disposition of complaints received by the Company regarding accounting, internal accounting controls or auditing matters
 
-
Discusses with the Company's general counsel legal matters that may have a material impact on the financial statements or the Company's compliance policies
 
-
Retains independent legal, accounting or other advisors, as necessary
 
-
Presents the annual Report of the Audit Committee for the Company’s Proxy Statement
 
-
Reviews its own performance annually
Compensation Committee
Number of Members:
Members:
 
 
Four independent directors
Jonathan S. Linen (Chair), Ruth R. McMullin, William H. Waltrip and Barry W. Wilson
Number of Meetings in 2005:
 
Four
Functions:
-
Recommends to the Board of Directors remuneration of the chief executive officer and determines remuneration of other officers of the Company elected by the Board of Directors
 
-
Conducts evaluation of the chief executive officer for submission to the Board of Directors
 
-
Grants options under and otherwise administers the Company's stock incentive plans and approves and administers any other compensation plan in which officers of the Company participate
 
-
Reviews succession planning for the CEO and senior executives, and reports on such matters to the Board of Directors
 
-
Retains compensation consultants and obtains advice from internal or external advisors, as necessary
 
-
Presents the annual Compensation Committee Report on Executive Compensation for the Company's Proxy Statement
 
-
Reviews its own performance annually



PAGE 128

Nominating and Governance Committee
Number of Members:
Members:
 
 
 
Four independent directors
William H. Waltrip (Chair), Paul A. Friedman, Jonathan S. Linen and Linda Johnson Rice
Number of Meetings in 2005:
 
Five
Functions:
-
Seeks and evaluates individuals qualified to become board members for recommendation to the Board of Directors
 
-
Reviews the qualifications of any director candidate proposed by a shareholder in accordance with the Company's By-laws
 
-
Reviews and makes recommendations to the Board of Directors with respect to the compensation and benefits of directors
 
-
Reviews the adequacy of the Company's Corporate Governance Guidelines and recommends any proposed changes to the Board of Directors for approval
 
-
Retains any search firm to be used to identify director candidates and obtains advice from internal or external advisors, as necessary
 
-
Reviews its own performance annually

As set forth in the Nominating and Governance Committee Charter, the Committee has responsibility for identifying individuals qualified to become directors and to make appropriate director nominee recommendations to the Board of Directors. The Committee periodically assesses the composition and performance of the Board of Directors and determines when it is appropriate to identify new director nominees. The Committee will then actively search for individuals qualified to become directors. The selection criteria for director nominees is detailed in a committee resolution entitled: "Criteria for Selecting Director Nominees to the Board of Directors." Under this selection criterion, each nominee should have a background which demonstrates an understanding of the business and financial affairs and the complexities of a global business organization. Nominees are typically active as a current chief executive officer, chief operating officer or other senior executive or director of a significant business enterprise or other business institution, public or private. Other characteristics of director nominee candidates include interest in the Company, time and energy to devote to the Company, sound business judgment and independence.
    The Committee uses a third party search firm to identify director candidates and also seeks names of potential nominees from other directors, executive officers and other contacts. The Committee will consider director candidates proposed by shareholders, provided that the recommendation includes sufficient information concerning the potential nominee, and is submitted in a timely manner, so as to permit appropriate review by the Committee. The Committee will use the same process for evaluating a shareholder director candidate as it uses for any other potential nominee. For a description of certain bylaw procedures permitting shareholders to directly nominate directors, see below in this section of Item 10. Directors and Executive Officers of Bausch & Lomb Incorporated.
The qualifications of director candidates are reviewed by the Committee to determine which candidates should be contacted. If a third party search firm is involved, the search firm will make the initial contact with potential candidates to assess their qualifications and motivation. A member of the Committee will make the initial contact if a search firm is not involved. Reference checks are also conducted. Following this initial screening process, the Committee meets with each of the candidates and determines which candidate will be recommended to the Board of Directors. During this process, the chief executive officer also meets with the candidates and provides input to the Committee. The Company's By-laws are available at the Company's web site at http://www.bausch.com/en_us/corporate/corpcomm/general/governance.aspx.
The members of the Audit Committee of the Board of Directors are Kenneth L. Wolfe (Chair), Alan M. Bennett, Domenico De Sole and Barry W. Wilson. The Board of Directors has reviewed the qualifications of each member of the Audit Committee and has determined that each member of the Audit Committee is "independent" under the current listing standards of the NYSE applicable to Audit Committee members. None of the Audit Committee members has a relationship with the Company other than being a director and shareholder of the Company. In addition, there is no Audit Committee member who is employed as an executive of another firm where any of the Company's executives serves on that other firm's compensation committee. No member of the Audit Committee is an immediate family member of an individual who is an executive officer of the Company or any of its affiliates. The Audit Committee members do not serve on more than two audit committees of other public companies.



PAGE 129
 
Each member of the Audit Committee is financially literate, as assessed by the Company's Board of Directors in its business judgment. In addition, the Board of Directors has determined that Kenneth L. Wolfe qualifies as an "audit committee financial expert," as defined by applicable SEC rules, and Mr. Wolfe is "independent" under the current listing standards of the NYSE applicable to Audit Committee members.
        In 2005, the Audit Committee met 17 times and they met 36 times in 2006. The Board of Directors has adopted a written Charter setting forth the authority and responsibilities of the Audit Committee. A copy of the Charter is available at the Company's web site at http://www.bausch.com/en_us/corporate/ir/general/board_members.aspx. Consistent with its Charter, the Audit Committee took the actions identified in the description of the Committee's functions contained in this Item 10. Directors and Executive Officers of Bausch & Lomb Incorporated. In addition, the Audit Committee recommended for Board approval, based on the full scope of its activities, that (i) the audited financial statements be incorporated in the Company's annual report on Form 10-K for the year ended December 31, 2005, and (ii) its appointment of PricewaterhouseCoopers LLP as the Company's independent accountants for 2006 be ratified.
A shareholder wishing to nominate a candidate for election to the Board at the 2007 Annual Meeting of Shareholders is required to give written notice addressed to the secretary, Bausch & Lomb Incorporated, One Bausch & Lomb Place, Rochester, New York 14604-2701 of his or her intention to make such a nomination. The notice of nomination must be received by the Company’s secretary at the address above during the period commencing on March 15, 2007 and ending at the close of business on the 10th day following the date on which public announcement of the date of the 2007 Annual Meeting is first made.
The notice of nomination is required to contain certain information about both the nominee and the shareholder making the nomination as set forth in the Company’s By-laws. A nomination which does not comply with the above requirements will not be considered.
If the shareholder intends to present the proposal at the Company’s 2007 Annual Meeting of Shareholders and have it included in the Company’s proxy materials for that meeting, the proposal must be received by the Company no later than the close of business on March 15, 2007, and must comply with the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, as amended. The Company is not obligated to include any shareholder proposal in its proxy materials for the 2007 Annual Meeting of Shareholders if the proposal is received after the above date.
If a shareholder wishes to present the proposal at the 2007 Annual Meeting of Shareholders but is not seeking to have it included in the Company’s proxy materials for that meeting, the proposal: (1) must be received by the Company during the period commencing on March 15, 2007 and ending at the close of business on the 10th day following the date on which public announcement of the date of the 2007 Annual Meeting is first made and (2) must be submitted in a manner that is consistent with the submission requirements provided in the Company’s By-laws.

For a listing of our executive officers, refer to Item 4. Submissions of Matters to a Vote of Security Holders of this Annual Report on Form 10-K.

Section 16(a) Beneficial Ownership Reporting Compliance The Company's directors and executive officers are required to file reports with the SEC concerning their ownership of Company stock. Based upon a review of filings with the SEC, we believe that all of our directors and executive officers complied during fiscal 2005 with the reporting requirements of Section 16(a) of the Securities Exchange Act of 1934.





PAGE 130

Item 11.   Executive Compensation

Report of the Compensation Committee The Compensation Committee of the Board of Directors is comprised entirely of independent directors who are also non-employee directors as defined in Rule 16b-3 under the Securities Exchange Act of 1934 and outside directors as defined in Section 162(m) of the Internal Revenue Code of 1986 (Code). The Compensation Committee is responsible for reviewing and approving the strategy and principles of the compensation and benefits programs for Bausch & Lomb executive officers, including the Chief Executive Officer, to ensure that they are aligned with the Company’s business strategy and shareholder interests. These responsibilities include approving adjustments to base salary, establishing targets and determining payouts for the payment of annual bonuses, granting and vesting of long-term incentive compensation, and reviewing leadership development and succession planning. In 2005, the Compensation Committee met formally four times and had informal interim discussions. In advance of each formal meeting, management reviews the agenda with the committee chair and sends each committee member a complete briefing book that details each topic to be considered. The committee chair reports to the Board of Directors on committee discussions and key actions. The Compensation Committee has retained the services of a nationally recognized compensation consulting firm that serves as an independent advisor in matters related to executive compensation.

Compensation Philosophy and Policy The objective of executive compensation at Bausch & Lomb is to provide competitive overall compensation and to align components of executive compensation with the interests of shareholders on both a short-term and long-term basis. The executive compensation arrangements strive to meet these objectives through a mix of base salary, annual incentives and long-term incentives. The overall program ties "at risk" pay components to key drivers of long-term Company performance while providing a competitive level of total compensation structured to attract, motivate and retain high caliber executives.
To ensure that compensation levels are reasonably competitive with market rates, the Compensation Committee engages an independent consulting firm to conduct an annual survey of executive compensation in a defined group of companies comparable to the Company. The surveyed comparable companies are selected based on: (i) similarity of their product lines to those of Bausch & Lomb; (ii) comparability to Bausch & Lomb based on size, as measured through annual revenue, market capitalization and other financial measures of organizational scope and complexity; and (iii) the competitive market for executive talent. The companies in the S&P 500 Healthcare Index used in the Comparison of Five-Year Cumulative Total Shareholder Return chart in this Item 11. Executive Compensation represents 35% of the surveyed comparable companies. In determining compensation levels and mix, the Company also uses information from proxy statements and general industry survey information of companies that the Company views as being comparable. In 2005, the target compensation package for the Chief Executive Officer of the Company, Ronald L. Zarrella, was based on the terms of his employment agreement that was entered into in 2001.
After considering the proxy statements and survey data of comparable companies, the Company's business objectives and compensation philosophy and strategy, the Compensation Committee determines targeted levels of base compensation, short-term and long-term incentives, stock option and stock grant award levels for the officers of the Company. In approving salary and incentive payments for individuals other than the Chief Executive Officer, the Compensation Committee also considers recommendations made by the Chief Executive Officer. The compensation of individual executive officers can and does vary from the benchmark compensation based on such factors as individual performance, potential for future advancement, the value of the executive's position to the market, difficulty of replacement, current responsibilities, length of time in their current positions, and for recently hired executives, their prior compensation packages.

Base Pay Base pay levels for each officer take into consideration the individual's current performance, experience, the scope and complexity of his or her position within the Company and the external competitive marketplace for similar positions at comparable companies. Base pay for officers is reviewed annually, and is adjusted if necessary based on market comparisons and trends. To ensure long-term focus, officers are not eligible for automatic annual "merit increases." The executive officers named in the Summary Compensation Table appearing in this Item 11. Executive Compensation did not receive a base salary adjustment in 2005.
In 2005, Mr. Zarrella's base pay remained the same as in 2004 and has not changed since his employment in 2001. Mr. Zarrella's base pay is determined in accordance with his employment agreement.




PAGE 131

Annual Incentive Awards The Company's Annual Incentive Compensation Plan is designed to reward employees at the management level and above annually for their contribution to operating unit and corporate objectives. The plan is funded based on combined achievement of Company and operating unit performance against targets established by the Compensation Committee at the beginning of the year within parameters identified in the plan. To ensure that 2005 incentive compensation was tied to a key shareholder return indicator, the Compensation Committee measured overall Company performance against targets established for growth in comparable basis earnings per share (EPS) and, an additional metric for 2005, sales growth. Operating unit performance is measured against targets established for sales, earnings, free cash flow, cost improvement initiatives, and strategic projects. In accordance with the plan, the Compensation Committee sets performance targets at various levels so that the aggregate bonus pool funding yields an amount ranging from 0% to 200% of the bonus targets. The Compensation Committee has the authority to modify the Chief Executive Officer’s incentive award and the awards for all other executive officers based on an overall assessment of the manner in which such performance was achieved.
For 2005, the annual incentive for executive officers without individual operating unit responsibility was based primarily on Company performance against the EPS and sales growth targets. For executive officers who managed business units, 25% of their annual incentive was based on performance against their operating unit’s objectives and the remainder was based on Company performance against the EPS and sales growth targets. The bonus targets for executive officers, excluding the Chief Executive Officer, ranged from 50% to 75% of base salary. The bonus target for the Chief Executive Officer was 100% of base salary, with a payout range from 0% to 150% of target, in accordance with his employment agreement.
As previously reported, the Company announced on December 22, 2005 that its financial statements for certain periods would be restated. In addition, until recently the Company’s audited financial results for fiscal year 2005 were not available. While the Company believes that the timing of rewards should be in close proximity to actual performance, the Compensation Committee determined that no bonuses would be paid to any executive officer, including the Chief Executive Officer, until the restated and audited financial results were known. Once the restated and audited results were available, the Compensation Committee used those data to calculate the bonus pool for executive officers. Although performance measures for 2005 incentives using the restated results calculated to a higher level of bonus pool funding, the Compensation Committee, in its discretion and at the recommendation of the Chief Executive Officer, modified the pool downward to 75% to reflect its assessment of the overall performance of the Company. Bonuses for individual executive officers ranged from 56% to 95% of target factoring in their operating unit’s performance against their targets. Furthermore, the Compensation Committee determined that several executive officers would receive either no bonus or a reduced bonus and that the Chief Executive Officer and the Chief Financial Officer would not receive a bonus.

Long-Term Incentive Awards Long-term incentive compensation awarded to officers is designed to ensure that total direct compensation is market competitive, performance based, and aligned with the interests of the Company’s shareholders. Under the 2003 Long-Term Incentive Plan, officers of the Company are eligible to receive awards of stock options and stock grants, as approved by the Compensation Committee. The Compensation Committee approved a target long-term incentive award for each officer, which is based on market data for comparable companies in combination with an assessment of each position's scope and complexity. The performance of the Company and the individual officer are considered in determining the final award.
In January 2005, the Compensation Committee awarded stock options within this framework to officers, including those identified in the Summary Compensation Table in this Item 11. Executive Compensation. The Company granted Mr. Zarrella 125,000 stock options, which vest in three equal installments over a three-year period. All stock options are exercisable at the fair market value of the underlying stock as of the date of the grant. In setting Mr. Zarrella's stock option award level, the Compensation Committee considered performance against Company objectives, competitive compensation data and practices, and progress against longer-term drivers of shareholder value.



PAGE 132

The stock grant component of long-term incentive awards is delivered through programs that are developed under the 2003 Long-Term Incentive Plan to ensure alignment with the strategic direction of the Company. Starting in 2004, long-term incentive awards were provided to officers under the Long-Term Performance Unit Program. This award cycle covered 2004-2005. Awards under this program vest based on attainment of pre-established objectives for return on net assets and average sales growth over the two-year performance cycle. Awards would have been payable 50% in 2006 and 50% in 2007, however, determination of the amount of any payout with respect to 2005 was delayed until the Company finalized its 2005 audited financial statements and the 2006 payout has not yet been made. The entire payout earned with respect to the 2004-2005 cycle is expected to occur in 2007, upon review by the Compensation Committee of the 2005 audited financial statements and its determination of the final awards based on Company performance against the objectives. Amounts earned under the program will be paid in cash or, if the officer has not met stock ownership targets, in stock. The awards, including the Chief Executive Officer's award, were targeted to comprise 40% of each participant's aggregate long-term compensation for the period covering 2004 and 2005 (the remaining 60% of the total long-term incentive compensation is composed of stock options as discussed above). Based on the Compensation Committee’s determination of the Company’s performance against the pre-established objectives for the 2004-2005 period, Performance Unit Program awards granted for the two-year cycle ended December 31, 2005 to the Company’s executive officers, including Mr. Zarrella, paid out at 83% of the target award. The value set forth under the Long-Term Incentive Payouts in the Summary Compensation Table in this Item 11. Executive Compensation reflects the value of the awards as of the settlement date.

Supplemental Executive Retirement Plan An additional element of total compensation for the Chief Executive Officer is the Supplemental Executive Retirement Plan (SERP) II, under which Mr. Zarrella was vested immediately as part of his employment agreement, in consideration of his prior service with the Company and in view of similar benefits with his former employer that were forfeited. This benefit is described further in the “Defined Benefit Retirement Plans” section of this Item 11. Executive Compensation. SERP II, funded by life insurance to minimize the cost to the Company, is designed to provide a competitive retirement benefit with annual value, payable for life, equal up to 60% of average salary and bonus earned over any three full calendar years during the participant's last ten full years of employment with the Company preceding retirement. Selected other executive officers participate in SERP III, described in the Defined Benefit Retirement Plans section of this Item 11. Executive Compensation. Contributions made under SERP II and SERP III Plans do not result in taxable income to the participants until the date at which benefits commence to be paid. In 2005, the Compensation Committee decided that SERP III would be frozen as of December 31, 2005 and discontinued future contributions under the Plan.

Long-Term Equity Equivalent Accumulation Plan On October 23, 2005, the Compensation Committee approved the Long-Term Equity Equivalent Accumulation Plan (LEAP) to commence in 2006 as a means to attract and retain key officers and, through the award and long-term retention of Company common stock equivalents, to further align the interests of officers with the interests of the Company’s shareholders. Under LEAP, officers may elect annually to receive either 5% of their eligible wages in cash or 15% of their eligible wages in units equivalent to common stock. Cash awards are paid bi-weekly. Company stock unit awards vest in full five years from the first day of the plan year to which the award relates.

Response to Internal Revenue Code Limits on Deductibility of Certain Compensation Section 162(m) of the Code limits to $1,000,000 per person the Company's tax deduction of certain non-performance-based compensation paid in a given year to its most highly compensated officers. The levels of non-performance-based salary, bonus and other compensation paid by the Company do not typically exceed this level, except that Mr. Zarrella's compensation exceeded this amount by $161,131 in 2005. In order to minimize the potential for lost tax deductibility, the Compensation Committee recommended, and shareholders approved in 1998, plans and amendments to certain Company plans that were designed to assure that performance-based compensation plans currently in place achieve compliance with the requirements of Section 162(m) of the Code. The Compensation Committee's present intention is to use the requirements of Section 162(m) as a guide in determining elements of compensation paid by the Company. However, the requirements of Section 162(m) will not limit the Compensation Committee in making any compensation decisions where the best interest of the Company and its shareholders dictate otherwise.




PAGE 133

Conclusion Each element of the Chief Executive Officer and other executive officer compensation packages is reviewed by the Compensation Committee to ensure that base pay and incentive opportunities are at competitive levels and to provide incentive systems reflecting financial performance and an alignment with shareholder interests. In summary, we believe the total compensation philosophy and compensation program described herein serve the best interests of the shareholders.

 
Compensation Committee
 
 
Jonathan S. Linen, Chair
Ruth R. McMullin
William H. Waltrip
Barry W. Wilson


Employment Agreements, Change of Control Agreements and Severance Arrangements See Item 13. Certain Relationships and Related Transactions of this Annual Report on Form 10-K for a discussion of these agreements and arrangements.
For a discussion regarding compensation of directors, see Item 10. Directors and Executive Officers of Bausch & Lomb Incorporated of this Annual Report on Form 10-K.




PAGE 134

Compensation Tables The individuals named in the following tables include the Company's chief executive officer and the four other most highly compensated executive officers of the Company for the fiscal year ended December 31, 2005.


SUMMARY COMPENSATION TABLE

       
Annual Compensation
 
Long-Term Compensation
 
           
Awards
 
Payouts
 
 
 
Name and Principal Position
 
 
 
 
Year
 
 
 
 
Salary
 
 
 
 
Bonus
 
 
Other Annual Compensation  1
 
 
Restricted Stock Award(s) 2
 
Securities Underlying Options/ SARs
 
 
 
LTIP Payouts 3
 
 
All Other Compensation  4
 
R. L. Zarrella
Chairman and CEO
 
   
2005
2004
2003
 
$
1,100,000
1,142,308
1,100,000
 
$
-
1,650,000
1,628,000
 
$
94,977
82,078
78,857
 
$
-
-
-
   
125,000
117,650
180,000
 
$
1,666,000
2,383,049
1,745,178
 
$
275,000
124,664
86,600
 
P. Tyle
Sr. V.P. Research & Development and Chief Scientific Officer
   
2005
2004
2003
 
$
410,001
181,347
-
 
$
295,000
235,706
-
 
$
38,673
28,254
-
 
$
1,457,800
488,800
-
   
25,000
35,000
-
 
$
666,400
-
-
 
$
62,994
203,238
-
 
D. L. Hahs
Sr. V.P. Global Operations & Engineering
   
2005
2004
2003
 
$
405,600
421,200
403,685
 
$
280,000
565,145
315,000
 
$
50,362
31,795
32,221
 
$
842,400
-
-
   
20,000
25,000
30,000
 
$
416,500
268,130
130,907
 
$
$
$
71,251
19,465
18,432
 
P. G. Howes
Sr. V.P. & President - Americas Region
   
2005
2004
2003
 
$
400,000
415,385
184,615
 
$
150,000
500,020
150,000
 
$
34,058
37,748
4,423
 
$
-
-
937,750
   
22,000
25,000
100,000
 
$
533,120
107,252
-
 
$
289,433
26,161
130,813
 
A. H. Farnsworth 5
Sr. V.P. & President - Europe, Middle East and Africa Region
   
2005
2004
2003
 
$
310,000
321,923
308,539
 
$
200,000
367,717
200,000
 
$
361,730
128,029
128,321
 
$
-
-
-
   
19,000
22,000
25,000
 
$
466,480
312,819
152,707
 
$
92,537
23,487
19,364
 

1
This column includes the aggregate incremental cost to the Company of providing various perquisites. For Mr. Zarrella, the amount that represents more than 25% of the aggregate value of his reportable perquisites in 2005 is $48,663 for use of the Company’s aircraft. The value of personal aircraft use is based on incremental direct operating costs. A weighted average usage per mile cost of fuel, maintenance, landing fees, crew travel-related expenses, and other miscellaneous variable costs have been included. Since the Company’s aircraft are used mainly for business travel, fixed costs such as pilots’ and other employees’ salaries and aircraft lease costs are not included. For Mr. Hahs, the amount that represents more than 25% of the aggregate value of his reportable perquisites in 2005 is $30,957 for auto expenses.
2
The value of grants is equal to the number of shares of restricted stock multiplied by the closing market price on the date of the grant. Holders of restricted stock, including restricted stock granted under the Company's Cumulative Long-Term Incentive Program, are entitled to dividend and voting rights on the shares. At December 31, 2005, the aggregate number of shares, including restricted stock awarded under the Cumulative Long-Term Incentive Program, and corresponding value as of such date of restricted stock owned by named individuals were as follows: Mr. Zarrella, 65,561 shares valued at $4,451,592; Dr. Tyle, 28,000 shares valued at $1,901,200; Mr. Hahs, 10,000 shares valued at $679,000 and Mr. Howes, 25,000 shares valued at $1,697,500.
3
The amounts shown represent payments of the Company’s cash-denominated Long-Term Incentive Award Program. Payment may be in cash or shares provided stock holding guidelines are met. Payments must be made in shares if the participant’s stock holding requirements are not met. This payment will be in 2007, upon review by and approval of the Compensation Committee and in accordance with audited 2005 financial results.
4
The amounts reported in this column, for all officers other than Mr. Howes, Dr. Tyle and Mr. Farnsworth consist solely of the Company’s matching contributions under its 401(k) Plan and 401(k) Excess Plan. Relocation expenses for Dr. Tyle in 2004 totaled $203,238. In 2005, for Mr. Howes and Mr. Farnsworth, relocation expenses totaling $204,500 and $33,137, respectively, are included. A 2005 tax gross-up of $7,431 is reflected for Mr. Howes.
5
Mr. Farnsworth’s Other Annual Compensation includes expatriate allowances of $337,044, $105,659 and $100,486 for 2005, 2004 and 2003, respectively. Mr. Farnsworth is on expatriate assignment in the UK and receives the following allowances in accordance with the Company’s Global Service Policy: goods and services differential, housing/utilities (less employee contribution), annual home leave, and tax differential. The tax differential portion of the allowances in the amounts of $207,317, $57,064 and $55,624 for 2005, 2004 and 2003, respectively, represents actual income tax payments made by the Company on behalf of Mr. Farnsworth, less amounts withheld for the years stated. These amounts adjust Mr. Farnsworth’s taxes to amounts he would have paid in the U.S. under the Company’s Tax Equalization Program.




PAGE 135

Options/SAR Grants in Last Fiscal Year

   
Individual Grants
 
 
 
 
 
Name
 
Number of Securities Underlying Options/SARs
Granted 1
 
% of Total Options/SARs Granted to Employees in Fiscal Year 2
 
 
 
Exercise or Base Price ($/Sh) 3
 
 
 
 
 
Expiration Date
 
 
 
Grant Date Present Value 4
 
R. L. Zarrella
   
125,000
   
12.76
%
$
71.8450
   
Jan. 31, 2015
 
$
3,068,750
 
P. Tyle
   
25,000
   
2.55
%
 
71.8450
   
Jan. 31, 2015
   
613,750
 
D. L. Hahs
   
20,000
   
2.04
%
 
71.8450
   
Jan. 31, 2015
   
491,000
 
P. G. Howes
   
22,000
   
2.25
%
 
71.8450
   
Jan. 31, 2015
   
540,100
 
A. H. Farnsworth
   
19,000
   
1.94
%
 
71.8450
   
Jan. 31, 2015
   
466,450
 

1
All of the above stock options were granted to the named executives on January 31, 2005 and vest annually in one-third increments.
2      Based on total number of shares underlying options granted to employees of 979,314 shares.
3  Exercise price is equal to the fair market value based on the average of the high and the low stock price on the date of grant.
4
The estimated grant date present value reflected in the above table is determined using the Black-Scholes model based on all awards issued on that date. The ultimate realizable value of the options will depend on the future market price of the Company's stock, which cannot be forecast with reasonable accuracy. The actual value, if any, an optionee will realize upon exercise will depend on the excess of the market value of the Company's common stock over the exercise price on the date the option is exercised. The material assumptions and adjustments incorporated in the estimated valuation of the options include: (a) an option term of 10 years; (b) an expected life of five years; (c) an interest rate of 4.34% that represents a U.S. Treasury strip rate for the nearest quarter end with a maturity date corresponding to the expected life; (d) volatility of 35.146% calculated using daily stock prices for the five year period prior to the grant date; and (e) dividends at the rate of $.52 per share representing the annualized dividends paid with respect to a share of common stock at the date of grant, and a corresponding dividend yield of 1.138% calculated using average of the high and the low stock price over the expected term.

Aggregated Option/SAR Exercises in Last Fiscal Year and FY-End Option/SAR Values

           
Number of Securities Underlying Unexercised Options/SARs at FY-End
 
Value of Unexercised, In-the-Money Options/SARs at FY-End
 
 
 
Name
 
Number of Shares Acquired on Exercise
 
 
 
Value Realized 1
 
 
 
Exercisable
 
 
 
Unexercisable
 
 
 
Exercisable 2
 
 
 
Unexercisable 2
 
R. L. Zarrella
   
60,000
 
$
2,823,928
   
919,217
   
263,433
 
$
29,146,234
 
$
3,324,055
 
P. Tyle
   
-
   
-
   
11,667
   
48,333
   
74,494
   
148,981
 
D. L. Hahs
   
-
   
-
   
107,334
   
46,666
   
2,425,709
   
602,274
 
P. G. Howes
   
-
   
-
   
75,001
   
71,999
   
2,145,936
   
1,240,814
 
A. H. Farnsworth
   
4,200
   
139,335
   
117,355
   
41,999
   
2,547,970
   
512,327
 

1      Market value of Company's common stock at exercise, minus the exercise price.
2
Fair market value of Company's common stock at year-end 2005 ($67.69), minus the exercise price.





PAGE 136

Long-Term Incentive Program--Awards in Last Fiscal Year 1

           
Estimated Future Payments - Non-Stock
 
 
 
Name
 
 
 
Value
 
Performance Period (Years) 1
 
 
 
Threshold
 
 
 
Target
 
 
 
Maximum (200%)
 
R. L. Zarrella
 
$
2,000,000
   
2
 
$
-
 
$
2,000,000
 
$
4,000,000
 
P. Tyle
   
800,000
   
2
   
-
   
800,000
   
1,600,000
 
D. L. Hahs
   
500,000
   
2
   
-
   
500,000
   
1,000,000
 
P. G. Howes
   
640,000
   
2
   
-
   
640,000
   
1,280,000
 
A. H. Farnsworth
   
560,000
   
2
   
-
   
560,000
   
1,120,000
 

1
The program began in 2004 with the cycle covering 2004-2005. Payment will be made in 2007 upon review and approval of the Compensation Committee and in accordance with audited 2005 financial results. As a result of the two-year nature of this program, no awards were granted in 2005 except as a part of a hiring package for new officers.

Total Return to Shareholders
Comparison of Five-Year Cumulative Total Shareholder Return
December 2000 Through December 2005

Assumes $100 invested on the last day of December 2000 with dividends reinvested quarterly.
 



 
 
 
Date
 
 
 
 
Bausch & Lomb Incorporated
 
 
S&P Healthcare Index
 
 
 
 
S&P 500
 
S&P Healthcare Equipment Index
 
                   
December 2000
 
$
100.00
 
$
100.00
 
$
100.00
 
$
100.00
 
December 2001
   
95.86
   
88.08
   
88.17
   
94.91
 
December 2002
   
93.22
   
71.54
   
68.73
   
82.90
 
December 2003
   
136.13
   
82.28
   
88.41
   
109.45
 
December 2004
   
170.45
   
83.66
   
98.00
   
123.24
 
December 2005
   
180.78
   
89.05
   
102.80
   
123.31
 





PAGE 137

Defined Benefit Retirement Plans The Retirement Benefits Plan and Retirement Benefit Restoration Plan were frozen in 2004, ceasing future benefit accruals, resulting in a lower “Estimated Annual Benefit Payable at Age 63” calculation than reported in prior years. However, interest continues to accrue in the hypothetical accounts on a monthly basis. Under the Company's Retirement Benefits Plan, all employees of the Company and certain subsidiaries who reached age 21 and had at least one year of service, prior to December 31, 2004, are participants. The plan is a cash balance retirement plan, in which benefits can be paid either as a single lump sum or converted to a lifetime monthly annuity at time of retirement or separation from the Company. In addition, the Company maintains a separate Retirement Benefit Restoration Plan, which provides eligible employees additional retirement benefits, which would otherwise be provided under the Retirement Benefits Plan but were excluded from that plan by specific federal regulatory limitations. Benefits vest after five years of service as defined in the Retirement Benefits Plan and the Retirement Benefit Restoration Plan.
Each of Messrs. Zarrella, Hahs and Farnsworth is a vested participant under the Retirement Benefits Plan. Due to his announced departure from the Company, Mr. Howes will not be a vested participant of the Retirement Benefits Plan. Messrs. Hahs and Farnsworth are vested participants in the Retirement Benefit Restoration Plan. Neither Mr. Zarrella nor Mr. Howes is a participant in the Retirement Benefit Restoration Plan. Dr. Tyle is not a participant of either the Retirement Benefits Plan or the Retirement Benefit Restoration Plan.
The estimated annual benefit provided in total by the cash balance interest accrual described above, expressed in the form of a single life annuity, is as follows:

 
Executive
 
Estimated Annual Benefit Payable at Age 63
 
 
R. L. Zarrella
 
$
10,411*
 
P. Tyle
   
-
 
D. L. Hahs
   
112,128
 
P. G. Howes
   
-
 
A. H. Farnsworth
   
36,223
 

*Estimated annual benefit payable at age 60.

The Company maintains two Supplemental Executive Retirement Plans (SERP II and SERP III), under which officers may become eligible for retirement benefits in addition to those provided under the Company's Retirement Benefits Plan. No officer is eligible to participate in more than one Company SERP, and the officers named in the Summary Compensation Table of Item 11. Executive Compensation are participants in one of the SERPs described below. Participants who vest under SERP II will receive annual benefits, payable monthly, in an amount equal to a percentage of their final average salary and bonus compensation. Final Average Compensation is the highest average of a participant's compensation for any three full calendar years during the participant's last ten full calendar years of employment with the Company. The percentage used is a function of age at retirement: 32% at age 55, up to 60% at age 60. Effective as of 2005, SERP III, a cash balance retirement plan, was frozen, ceasing future benefit accruals, resulting in a lower “Estimated Annual Benefit Payable at Age 63” calculation than reported in prior years. Interest continues to accrue in the hypothetical accounts on a monthly basis. Benefits are paid either as a single lump sum or converted to a lifetime monthly annuity at time of retirement or separation from the Company. Generally, benefits under both SERP II and SERP III vest upon the completion of five years of service. The plans also provide for the payout of the net present value of all benefits in the event of a change in control of the Company.
Mr. Zarrella has vested benefits under SERP II. Messrs. Hahs and Farnsworth have vested benefits under SERP III. Dr. Tyle participates in, but will not have vested benefits under SERP III until 2009. Due to his announced departure from the Company, Mr. Howes will not vest under SERP III. Assuming continued employment to age 60, the estimated annual benefit payable for Mr. Zarrella under SERP II is $1,613,651. Under SERP III, the benefit payable is stated as a cash balance. The annual payments stated below are calculated by applying an actuarial-based conversion factor against the projected value of the individual's cash balance account at normal retirement age:



PAGE 138

 
Executive
 
Estimated Annual Benefit Payable at Age 63 - SERP III
 
 
P. Tyle
 
$
5,981
 
D. L. Hahs
   
29,748
 
P. G. Howes
   
-
 
A. H. Farnsworth
   
16,553
 


Beneficial Owners of More than 5% of the Company's Common Stock

 
 
 
 
Name and Address of Beneficial Owners
 
Number of Shares and Nature of Beneficial Ownership
 
 
Percent of Outstanding Common Stock
 
Franklin Mutual Advisors, LLC
51 John F. Kennedy Parkway
Short Hills, NJ 07078
   
4,439,987 1
   
8.27
%
Lord, Abbett & Co., LLC
90 Hudson Street
Jersey City, NJ 07302
   
3,212,290 2
   
5.99
%

1
Shares are as of September 30, 2006 and include 4,439,987 shares with respect to which there is sole power to vote; 4,439,987 shares with respect to which there is sole power of disposition; and 1,495 shares with respect to which there is shared power of disposition.
2
Shares are as of September 30, 2006 and include 3,083,590 shares with respect to which there is sole power to vote; 3,083,590 shares with respect to which there is sole power of disposition; and 128,700 shares with respect to which Lord Abbett & Co., LLC provides non-discretionary investment advice with respect to voting authority and disposition.




PAGE 139

Except for Class B stock, which is transferable only in accordance with the terms of the Company's stock incentive plan under which it was acquired, and except as otherwise indicated, sole voting and investment power exists with respect to all shares listed as beneficially owned. No individual named below beneficially owns more than 1% of the Company's outstanding voting stock, other than Mr. Zarrella, who owns 2%, and the shares beneficially owned by all directors and executive officers as a group constitute 5% of the Company's outstanding voting stock.

 
 
 
Name of Beneficial Owner
 
Amount and Nature of Beneficial Ownership
 
Alan M. Bennett
   
5,382 1
 
Domenico De Sole
   
22,917 2
 
Alan H. Farnsworth
   
163,203 3
 
Paul A. Friedman
   
3,466 4
 
Dwain L. Hahs
   
178,642 5
 
Paul G. Howes
   
151,242 6
 
Jonathan S. Linen
   
40,447 2
 
Ruth R. McMullin
   
33,926 2
 
Linda Johnson Rice
   
25,864 7
 
Praveen Tyle
   
60,206 8
 
William H. Waltrip
   
46,257 9
 
Barry W. Wilson
   
13,970 10
 
Kenneth L. Wolfe
   
27,867 11
 
Ronald L. Zarrella
   
1,087,964 12
 
All directors and executive officers as a group (27 persons)
   
2,932,425    
 

1
Includes 4,882 shares which may be acquired within 60 days through the exercise of stock options.
2
Includes 22,917 shares which may be acquired within 60 days through the exercise of stock options.
3
Includes 133,403 shares and 2,925 shares, respectively, which may be acquired within 60 days through the exercise of stock options and acquired under the 401(k) Plan.
4
Includes 1,956 shares which may be acquired within 60 days through the exercise of stock options
5
Includes 132,334 shares and 1,596 shares, respectively, which may be acquired within 60 days through the exercise of stock options and acquired under the 401(k) Plan and 10,000 shares of restricted stock subject to satisfaction of certain vesting conditions.
6
Includes 124,001 shares and 541 shares, respectively, which may be acquired within 60 days through the exercise of stock options and acquired under the 401(k) Plan and 16,667 shares of restricted stock subject to satisfaction of certain vesting conditions.
7
Includes 19,151 shares which may be acquired within 60 days through the exercise of stock options.
8
Includes 31,667 shares and 258 shares, respectively, which may be acquired within 60 days through the exercise of stock options and acquired under the 401(k) Plan and 28,000 shares of restricted stock subject to satisfaction of certain vesting conditions.
9
Includes 40,890 shares which may be acquired within 60 days through the exercise of stock options.
10
Includes 8,970 shares which may be acquired within 60 days through the exercise of stock options.
11
Includes 20,750 shares which may be acquired within 60 days through the exercise of stock options.
12
Includes 1,060,100 shares and 1,335 shares, respectively, which may be acquired within 60 days through the exercise of stock options and acquired under the 401(k) Plan.

In addition to shares beneficially owned by directors and executive officers of the Company, as indicated above, such persons may also own Common stock equivalents under deferred compensation plans of the Company, reflecting further their economic stake in the value of the Company's Common stock. As of December 1, 2006, the following Common stock equivalents were owned by (i) the Company's executive officers: Mr. Zarrella, 190,011; Mr. Farnsworth, 10,582; Mr. Hahs, 13,790; Mr. Howes, 1,298; Dr. Tyle, 1,298; (ii) the Company's directors: Mr. Bennett, 2,666; Mr. De Sole, 7,041; Dr. Friedman, 1,625; Mr. Linen, 1,532; Mrs. McMullin, 1,532; Mrs. Rice, 4,989; Mr. Waltrip, 1,532; Mr. Wilson, 4,920; Mr. Wolfe, 1,532; and (iii) all executive officers and directors of the Company as a group, 333,192.
As of December 1, 2006, the following Common stock equivalents were owned by the Company’s executive officers under the Long-Term Equity Equivalent Accumulation Plan, which will vest on January 1, 2011: Dr. Tyle, 1,063 shares; Mr. Hahs, 1,052 shares; Mr. Howes, 1,037 shares; Mr. Farnsworth, 843 shares; and all executive officers and directors of the Company as a group, 12,665.





PAGE 140

Item 13.   Certain Relationships and Related Transactions

In connection with Class B shares purchased under the Company's stock incentive plans prior to 2002, the Company could loan the participant an amount equal to the full amount of the purchase price of those shares, with the shares held by the Company as collateral for the loan. The rate of interest on loans to participants was the lesser of the applicable federal rates announced monthly by the Internal Revenue Service pursuant to Section 1274(d) of the Code, or 9%. To the extent applicable, the largest aggregate amount of indebtedness outstanding which exceeded $60,000 at any time in the Company's 2005 fiscal year for executive officers of the Company was as follows: Mr. Alan H. Farnsworth, $338,842; Mr. Dwain L. Hahs, $432,973; Mr. Jurij Z. Kushner, $215,411; Mr. John M. Loughlin, $175,933; Ms. Angela J. Panzarella, $202,336; and Mr. Robert B. Stiles, $180,387. As of December 1, 2006, the outstanding amount of such indebtedness of the Company's executive officers was as follows: Mr. Farnsworth, $332,099; Mr. Hahs, $155,189; and Ms. Panzarella, $198,310. All loans to directors were paid in full in 2003.
Mr. Zarrella and the Company signed a five-year employment agreement, dated November 9, 2001, which has automatically renewed for a one-year term in accordance with the agreement and will renew for successive one-year terms, unless otherwise terminated. The terms of the agreement provide for a base salary of $1.1 million during the first two employment years and a target bonus of 100% of base pay. On November 9, 2001, the Compensation Committee of the Board of Directors awarded Mr. Zarrella immediately-vested options to purchase 500,000 shares of the Company's Common stock at an exercise price of $31.91 under the 1990 Stock Incentive Plan. An additional 500,000 options under this Plan were granted to Mr. Zarrella on January 2, 2002 at an exercise price of $37.685. These options vested in one-third increments over a three-year period. The Company also agreed to pay Mr. Zarrella an amount up to $5 million in cash and stock to compensate him for benefits forfeited at his prior employer in accepting employment with the Company (including annual bonus incentive compensation, long-term incentive payments, and stock option value). That obligation was satisfied on January 2, 2002, with a cash payment of $2.1 million and a restricted stock grant of 65,561 shares to Mr. Zarrella. The restricted stock grant was made under the 1990 Stock Incentive Plan and vested in its entirety on the fifth anniversary of Mr. Zarrella's appointment.
The agreement also provides for a performance-based long-term incentive plan for one, two, and three-year award cycles, each of which has a target award of $1 million paid in Company restricted stock. Although the agreement provided for target awards of $1 million for subsequent three-year award cycles, for 2004-2005 Mr. Zarrella will be covered by the new cash-denominated program described in the Report of the Compensation Committee in Item 11. Executive Compensation of this Annual Report on Form 10-K. In addition, the agreement provides for Mr. Zarrella's participation in employee welfare and benefits plans and other standard senior executive perquisites. This includes participation in SERP II. On the effective date of the employment agreement, he was vested in SERP II at 26% of final average compensation (based on 1999, 2000, and 2001 compensation with his prior employer). The benefit will increase each year of his employment up to a maximum of 60% of final average compensation achieved at age 60. If Mr. Zarrella is terminated without cause, or if Mr. Zarrella terminates employment for good reason, both as defined in the agreement, he will be entitled to his annual base salary and the highest annual bonus, plus medical and other benefits, for the remaining period of his employment agreement, and he will vest immediately in the SERP II benefit which would have been received at the end of the employment period under the agreement.
Mr. Zarrella has also entered into a change of control agreement with the standard features described below. In the event his employment is terminated following a change in the control of the Company, he would be entitled to the greater of (i) his remaining benefits under his employment agreement or (ii) benefits under the change of control agreement.
Under a 1996 Incentive Stock Option Agreement and a 1996 Non-Qualified Stock Option Agreement, Mr. William H. Waltrip, a director, was granted options to purchase 2,539 shares and 97,461 shares of Class B stock, respectively, at a price of $39.38 per share. The options were granted to Mr. Waltrip in connection with his service as interim Chairman and Chief Executive Officer of the Company and to provide Mr. Waltrip with the full benefit of any appreciation in the value of the Company’s stock during his tenure in that role. Under an agreement with the Company, dated January 15, 1996, Mr. Waltrip was entitled to receive from the Company $2.43 per share upon the exercise of each of the options granted to him. Mr. Waltrip exercised the options under the Incentive Stock Option Agreement on March 17, 1999 (2,539 options), and exercised the options under the Non-Qualified Stock Option Agreement on May 13, 2005 (47,461 options), August 1, 2005 (25,000 options) and November 1, 2005 (25,000 options). In total, pursuant to the terms of the January 15, 1996 agreement, Mr. Waltrip has received $243,000 from the Company.



PAGE 141

Dr. Tyle is and Mr. Howes 1 was party to additional individual employment arrangements with the Company: Dr. Tyle’s arrangement commenced in 2004 and Mr. Howes’ arrangement commenced in 2003. However, Dr. Tyle and Mr. Howes did not become named executive officers until 2006 and 2005, respectively. Dr. Tyle is and Mr. Howes was eligible to participate in certain Company management plans that have been previously filed with the SEC, including the Annual Incentive Compensation Plan and the 2003 Long-Term Incentive Plan. In addition, Dr. Tyle is and Mr. Howes was entitled to receive employee benefits made available to other employees and officers of the Company and their eligible dependents.
Dr. Tyle also received upon commencement of his employment, a stock option award of 35,000 shares granted on July 19, 2004, which vests in three equal installments over a three-year period, and a restricted stock award of 8,000 shares granted on July 19, 2004, which vests in three equal installments in three, five and seven years from the date of grant. Mr. Howes received upon commencement of his employment, a stock option award of 100,000 shares granted on July 1, 2003 at a price of $37.18 per share, vesting in three equal installments over a three-year period and a restricted stock award of 25,000 shares granted on July 1, 2003, vesting in three equal installments in three, five and seven years from the date of grant.
Dr. Tyle’s 2004 employment arrangement modified severance benefits payable to him under the Company’s Officer Separation Plan. Under the arrangement, if Dr. Tyle’s employment terminates prior to July 19, 2007, under circumstances which would otherwise entitle him to severance protection under the Company’s Officer Separation Plan: (i) unvested portions of his restricted stock and his stock option award granted under his 2004 employment arrangement vest immediately upon the termination date; and (ii) if accelerated vesting is not approved under the Company’s 2003 Long-Term Incentive Plan, the Company will pay him, subject to withholdings, an amount equal to the fair market value of the unvested restricted stock award and the excess, if any, of the fair market value of the unvested stock option award over the option’s exercise price. In addition, if Dr. Tyle is involuntarily terminated after three years from his hire date under circumstances providing him with benefits under the Officer Separation Plan, then remaining unvested portions of Dr. Tyle’s restricted stock grant, if any, shall immediately vest on such date of termination. In the event of a termination due to a change of control, Dr. Tyle’s severance arrangement would be superseded by the change of control agreement described below.
Mr. Howes’ 2003 employment arrangement also modified his severance benefits under the Officer Separation Plan. If Mr. Howes’ employment had terminated prior to July 1, 2006, and under circumstances which would have otherwise entitled him to severance protection under the Company’s Officer Separation Plan, excluding a change of control, the Company would have provided Mr. Howes with a cash payout equal to the fair market value of the restricted stock granted to him under his 2003 employment arrangement. If his employment had terminated due to a change of control, Mr. Howes’ severance arrangement would have been superseded by the change of control agreement described below.
The Company has entered into a change of control agreement, for an indefinite term, with each individual in the Summary Compensation Table in Item 11. Executive Compensation of this Annual Report on Form 10-K. Each agreement provides that, in the event of a change of control (as defined in the agreements) which is followed within three years, as determined under the agreements, by: (i) a termination of the officer's employment, (ii) a downgrading of the officer's position, or (iii) a voluntary termination under circumstances specified in the agreements, the officer will be entitled to salary and pro rata bonus then due, and a lump sum separation payment equal to three times annual base salary and bonus as determined under the agreements. Each officer will also be entitled to a continuation of certain benefits and perquisites for up to three additional years as determined under the agreements. These benefits and perquisites may be reduced by corresponding benefits or perquisites provided by a subsequent employer during the period in which they are provided.
In January 2005, the Company established a Charitable Contribution Program for officers of the Company. Under this program, the Company matches contributions made by officers on a dollar-for-dollar basis up to $10,000 annually. The match must be made to no more than two bona fide exempt organizations meeting the requirements of Section 501(3)(c) of the Internal Revenue Code selected by the participant.

1 As announced in the Company's Current Report on Form 8-K, filed January 5, 2007, Mr. Howes intends to resign from the Company.




PAGE 142

Item 14.   Principal Accounting Fees and Services

The Audit Committee's policy is to pre-approve all audit and permissible non-audit services provided by the independent accountants. The Audit Committee pre-approved all such audit and non-audit services provided by the independent accountants. These services have included audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent accountants and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent accountants in accordance with this pre-approval and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis.

Audit Fees In its review, the Audit Committee examined a report from PricewaterhouseCoopers LLP of the fees billed to the Company for fiscal years 2005 and 2004 of $15,390,000 and $7,495,000, respectively, for the audit of the Company's annual financial statements and reviews of quarterly reports on Form 10-Q. The 2005 and 2004 fees also include an attestation to the Company's assessment and effectiveness of internal controls over financial reporting.

Audit-Related Fees PricewaterhouseCoopers LLP received fees of $821,000 in 2005, including $131,000 for benefit plan reviews and other audit-related projects totaling $690,000. In 2004, the audit-related fees totaled $216,000 including $99,000 for benefit plan reviews, and $117,000 for various other audit-related projects.

Tax Fees PricewaterhouseCoopers LLP received no fees for tax-related services in 2005 or 2004.

All Other Fees PricewaterhouseCoopers LLP received $17,000 of other fees in 2005 relating primarily to accounting research software. In 2004, all other fees totaled $47,000 relating primarily to accounting research software and participation by the Company in an industry coalition coordinated by PricewaterhouseCoopers LLP.

Prior to approving PricewaterhouseCoopers LLP as the Company's independent accountants for 2006, the Committee considered whether PricewaterhouseCoopers LLP's provision of services other than audit services is compatible with maintaining the accountants' independence.





PAGE 143

Part III

Item 15.   Exhibits, Financial Statement Schedules

The following documents or the portions thereof indicated are filed as a part of this Report.

(a)
Index to Financial Statements and Financial Statement Schedules Covered by Reports of Independent Auditors.
Page
 
1.
Financial statements filed herewith:
 
   
 
Report of Independent Registered Public Accounting Firm
 
145
   
 
Balance Sheets at December 31, 2005 and December 25, 2004
 
61
   
 
For the years ended December 31, 2005, December 25, 2004 and December 27, 2003:
 
   
 
     Statements of Income
 
60
   
 
     Statements of Cash Flows
 
62
   
 
     Statements of Changes in Shareholders' Equity
 
63
   
 
     Notes to Financial Statements
 
65
 
All schedules have been omitted because the required information is not present or not present in amounts sufficient to require submission of the schedule, or because the information required is included in the financial statements or the notes thereto.

 
(b)
 
Item 601 Exhibits
 
 
 
Those exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits filed herewith and such listing is incorporated herein by reference. Each of Exhibits (10)-a through (10)-w, (10)-hh through (10)-kk, (10)-nn and (10)-pp is a management contract or compensatory plan or arrangement required to be filed as an exhibit to this Form pursuant to Item 15(c) of this Annual Report on Form 10-K.
 





PAGE 144

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) Bausch & Lomb Incorporated        

By (Signature and Title) /s/ Ronald L. Zarrella       
Ronald L. Zarrella
Chairman and Chief Executive Officer

Date February 7, 2007          


Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Principal Executive Officer

By (Signature and Title) /s/ Ronald L. Zarrella       
Ronald L. Zarrella
Chairman and Chief Executive Officer

Date February 7, 2007          

Principal Financial Officer

By (Signature and Title) /s/ Stephen C. McCluski       
Stephen C. McCluski
Senior Vice President and Chief Financial Officer

Date February 7, 2007          

Controller

By (Signature and Title) /s/ Jurij Z. Kushner        
Jurij Z. Kushner
Vice President and Controller

Date February 7, 2007          

Directors

Alan M. Bennett
Domenico De Sole
Paul A. Friedman
Jonathan S. Linen
Ruth R. McMullin
Linda Johnson Rice
William H. Waltrip
Barry W. Wilson
Kenneth L. Wolfe
Ronald L. Zarrella

Date February 7, 2007          
By (Signature and Title) /s/ Robert B. Stiles          
Robert B. Stiles
Attorney-in-Fact



PAGE 145

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Bausch & Lomb Incorporated:

We have completed integrated audits of Bausch & Lomb Incorporated’s December 31, 2005 and December 25, 2004 consolidated financial statements and of its internal control over financial reporting as of December 31, 2005, and an audit of its December 27, 2003 consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Our opinions, based on our audits, are presented below.

Consolidated Financial Statements In our opinion, the consolidated financial statements listed in the index appearing under Item 15(a)(1) present fairly, in all material respects, the financial position of Bausch & Lomb Incorporated and its subsidiaries at December 31, 2005 and December 25, 2004, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2005 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit of financial statements includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
As described in Note 2 — Restatement to the consolidated financial statements, the Company restated its 2004 and 2003 consolidated financial statements.
As described in Note 14 — Employee Benefits to the consolidated financial statements, as of July 1, 2004 the Company adopted FSP FAS 106-2, Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003.
As described in Note 19 — Supplemental Balance Sheet Information to the consolidated financial statements, as of December 27, 2003, the Company adopted Statement of Financial Accounting Standards No. 143, Accounting for Asset Retirement Obligations.




PAGE 146

Internal Control Over Financial Reporting Also, we have audited management's assessment, included in Management's Report on Internal Control Over Financial Reporting appearing under Item 9A Controls and Procedures, that Bausch & Lomb Incorporated did not maintain effective internal control over financial reporting as of December 31, 2005, because (1) the Company did not maintain an effective control environment, (2) the Company did not maintain effective controls to provide reasonable assurance of the completeness and accuracy of certain financial statement accounts in certain subsidiaries, (3) the Company did not maintain effective controls over certain subsidiaries' relationships with their key distributors nor over the installation of refractive laser surgery equipment in multiple locations to ensure that revenue associated with such distributor and laser sales was recognized in accordance with generally accepted accounting principles (GAAP), (4) the Company did not maintain effective controls over its accounting for income taxes and indirect taxes, including VAT and certain import related taxes related to its Brazilian subsidiary, and (5) the Company did not maintain effective controls to ensure that the Company's Deferred Compensation Plan document was amended to accurately reflect the Plan's intended design, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express opinions on management's assessment and on the effectiveness of the Company's internal control over financial reporting based on our audit.
We conducted our audit of internal control over financial reporting in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. An audit of internal control over financial reporting includes obtaining an understanding of internal control over financial reporting, evaluating management's assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we consider necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinions.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



PAGE 147

A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. The following material weaknesses have been identified and included in management's assessment as of December 31, 2005:
(1) The Company did not maintain an effective control environment because of the following: (a) the Company did not adequately and consistently reinforce the importance of adherence to controls and the Company's code of conduct, which contributed to certain of the restatement items that occurred across a broad range of the Company's operational and functional areas; (b) the Company failed to institute all elements of an effective program to help prevent and detect fraud by Company employees; (c) the Company did not establish and maintain effective corporate and regional management oversight and monitoring of operations to detect subsidiaries' managements' override of established financial controls and accounting policies, execution of improper transactions and accounting entries to impact revenue and earnings, and reporting of these transactions to the appropriate finance personnel or the Company's independent registered public accounting firm; and (d) the Company did not maintain a sufficient complement of personnel with an appropriate level of knowledge, experience and training in the application of GAAP, including revenue recognition and accounting for income taxes, and in internal control over financial reporting commensurate with its financial reporting requirements. This material weakness contributed to the additional material weaknesses discussed in items 2-4 below.
(2) The Company did not maintain effective controls to provide reasonable assurance of the completeness and accuracy of certain financial statement accounts in certain subsidiaries. Specifically, the Company did not maintain effective controls to ensure that account reconciliations and journal entries were supported by appropriate analysis and documentation in connection with the financial reporting and close process. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004 and the first two quarters of 2005, as well as adjustments, including audit adjustments, to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.
(3) The Company did not maintain effective controls over certain subsidiaries' relationships with their key distributors, particularly in the Company's Korea, Japan and India subsidiaries, and did not maintain effective controls over the installation of refractive laser surgery equipment in multiple locations where the Company does business, to ensure that revenue associated with such distributor and laser sales was recognized in accordance with GAAP. Specifically, the Company did not maintain effective controls to provide reasonable assurance that customer arrangements were adequately reviewed by the appropriate persons at such subsidiaries to identify and provide reasonable assurance regarding the proper application of the appropriate method of revenue recognition in accordance with GAAP. In addition, the Company did not maintain effective controls to prevent subsidiary management from overriding established financial controls or making errors in the application of policies concerning the accuracy and valuation of accounts receivable and the maintenance of distributor inventory at established threshold levels, as well as regarding administration of credit limits, extensions of credit terms, price discounting, sales returns and exchanges, transfer of the risk of ownership, and sales order entry and control. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments, to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.



PAGE 148

(4) The Company did not maintain effective controls over the determination and reporting of its income tax payable, deferred income tax assets and liabilities, the related valuation allowances and income tax expense. Specifically, effective controls were not designed and in place to: (i) ensure management maintained the appropriate level of personnel resources with adequate experience and expertise in the area of U.S. GAAP accounting for income taxes; (ii) ensure roles and responsibilities with respect to accounting for income taxes were clearly defined; (iii) identify and evaluate in a timely manner the tax implications of certain non-routine transactions, including transactions related to acquisitions; (iv) provide reasonable assurance as to the completeness and accuracy of the provision for income taxes and income taxes payable including tax reserves and return to provision adjustments; and (v) reconcile differences between the tax and financial reporting basis of its assets and liabilities with its deferred income tax assets and liabilities. In addition, the Company did not maintain effective controls over indirect taxes, including VAT and certain import related taxes related to its Brazilian subsidiary. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments, to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.
(5) The Company did not maintain effective controls to ensure that the Company's Deferred Compensation Plan document was amended to accurately reflect the Plan's intended design. This inaccurate amendment of the plan resulted in the Company not properly marking to market stock awards issued under the Company's Long-Term Incentive Plan that were deferred under the Deferred Compensation Plan which impacted the completeness and accuracy of selling, administrative and general expense and accrued liabilities. This material weakness resulted in the restatement of the Company's 2004 and 2003 annual consolidated financial statements and all quarterly periods of 2004, and the first two quarters of 2005, as well as adjustments, including audit adjustments, to the 2005 third quarter interim and the 2005 annual consolidated financial statements. In addition, the Company restated beginning shareholders' equity for the impact of the restatement for periods prior to 2003.

Additionally, each of these material weaknesses above could result in a material misstatement to the Company's interim or annual consolidated financial statements and disclosures which would not be prevented or detected.
These material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2005 consolidated financial statements, and our opinion regarding the effectiveness of the Company’s internal control over financial reporting does not affect our opinion on those consolidated financial statements.
As described in Management's Report on Internal Control Over Financial Reporting, management has excluded Freda from its assessment of internal control over financial reporting as of December 31, 2005 because it was acquired by the Company in a purchase business combination during the fourth quarter of 2005. We have also excluded Freda from our audit of internal control over financial reporting. Freda is a majority-owned subsidiary whose total assets and total net sales represent eight percent and one percent, respectively, of the related consolidated financial statement amounts as of and for the year ended December 31, 2005.
In our opinion, management's assessment that Bausch & Lomb Incorporated did not maintain effective internal control over financial reporting as of December 31, 2005, is fairly stated, in all material respects, based on criteria established in Internal Control - Integrated Framework issued by the COSO. Also, in our opinion, because of the effects of the material weaknesses described above on the achievement of the objectives of the control criteria, Bausch & Lomb Incorporated has not maintained effective internal control over financial reporting as of December 31, 2005, based on criteria established in Internal Control - Integrated Framework issued by the COSO.


/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Rochester, New York
February 7, 2007




PAGE 149

Exhibit Index

 
S-K Item
601 No.
Document
   
(3)-a
Restated Certificate of Incorporation of Bausch & Lomb Incorporated (filed herewith).
   
(3)-b
Amended and Restated By-Laws of Bausch & Lomb Incorporated, effective April 26, 2005 (filed as Exhibit (3)-e to the Company's Form 10-Q for the quarter ended June 25, 2005, File No. 1-4105, and incorporated herein by reference).
   
(4)-a
See Exhibit (3)-a.
   
(4)-b
Form of Indenture, dated as of September 1, 1991, between the Company and Citibank, N.A., as Trustee, with respect to the Company's Medium-Term Notes (filed as Exhibit (4)-a to the Company's Registration Statement on Form S-3, File No. 33-42858 and incorporated herein by reference).
   
(4)-c
Supplemental Indenture No. 1, dated May 13, 1998, between the Company and Citibank, N.A. (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K, dated July 24, 1998, File No. 1-4105 and incorporated herein by reference).
   
(4)-d
Supplemental Indenture No. 2, dated as of July 29, 1998, between the Company and Citibank, N.A. (filed as Exhibit 3.2 to the Company's Current Report on Form 8-K, dated July 24, 1998, File No. 1-4105 and incorporated herein by reference).
   
(4)-e
Supplemental Indenture No. 3, dated November 21, 2002, between the Company and Citibank, N.A. (filed as Exhibit 4.8 to the Company's Current Report on Form 8-K, dated November 18, 2002, File No. 1-4105 and incorporated herein by reference).
   
(4)-f
Supplemental Indenture No. 4, dated August 1, 2003, between the Company and Citibank, N.A. (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K, dated August 6, 2003, File No. 1-4105 and incorporated herein by reference).
   
(4)-g
Fifth Supplemental Indenture, dated August 4, 2003, between the Company and Citibank, N.A. (filed as Exhibit 4.2 to the Company's Current Report on Form 8-K, filed August 6, 2003, File No. 1-4105, and incorporated herein by reference).
   
(4)-h
Sixth Supplemental Indenture, dated December 20, 2004, between the Company and Citibank, N.A. (filed as Exhibit (4)-j to the Company's Annual Report on Form 10-K for the fiscal year ended December 25, 2004, File No. 1-4105 and incorporated herein by reference).
   
(4)-i
Supplemental Indenture No. 7, dated as of June 6, 2006 (filed as Exhibit (4) to the Company's Current Report on Form 8-K, filed June 12, 2006 and incorporated herein by reference).
   
(4)-j
Supplemental Indenture No. 8, dated as of November 8, 2006 (filed herewith).
   
(4)-k
Amended and Restated Supplemental Indenture No. 8, effective as of November 8, 2006 (filed herewith).
   
(10)-a
Change of Control Employment Agreement with certain executive officers of the Company (filed as Exhibit (10)-a to the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105 and incorporated herein by reference).
   
(10)-b
Change of Control Employment Agreement with certain executive officers of the Company (filed as Exhibit (10)-b to the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, File No. 1-4105 and incorporated herein by reference).
   



PAGE 150

(10)-c
Amended and Restated Supplemental Retirement Income Plan II (filed as Exhibit (10)-f to the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 1990, File No. 1-4105 and incorporated herein by reference).
   
(10)-d
Amended and Restated Supplemental Retirement Income Plan III, dated December 31, 2000 filed as Exhibit (10)-d to the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2000, File No. 1-4105 and incorporated herein by reference).
   
(10)-e
Annual Retainer Stock Plan for Non-Employee Directors (filed as Exhibit (10)-dd to the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, File No. 1-4105 and incorporated herein by reference).
   
(10)-f
Management Incentive Compensation Plan (filed as Exhibit (10)-b to the Company's Form 10-Q for the quarter ended June 27, 1998, File No. 1-4105 and incorporated herein by reference).
   
(10)-g
Employment Agreement dated November 9, 2001 between Bausch & Lomb Incorporated and Ronald L. Zarrella, Chairman and Chief Executive Officer (filed as Exhibit (10)-z to the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2001, File No. 1-4105 and incorporated herein by reference).
   
(10)-h
Amended and Restated 1990 Stock Incentive Plan (filed as Exhibit (10)-s to the Company's Annual Report on Form 10-K for the year ended December 28, 2002, File No. 1-4105 and incorporated herein by reference).
   
(10)-i
Amendment No. 6 to the Bausch & Lomb Incorporated 1990 Stock Incentive Plan (filed as Exhibit (10)-t to the Company's Annual Report on Form 10-K for the year ended December 28, 2002, File No. 1-4105 and incorporated herein by reference).
   
(10)-j
Corporate Officer Separation Plan (filed as Exhibit (10)-v to the Company's Annual Report on Form 10-K for the year ended December 28, 2002, File No. 1-4105 and incorporated herein by reference).
   
(10)-k
Amended and Restated 2001 Stock Incentive Plan for Non-Officers, as approved by the Committee on Management on January 22, 2001 and amended on July 23, 2001 (filed as Exhibit (10)-w to the Company's Annual Report on Form 10-K for the year ended December 28, 2002, File No. 1-4105 and incorporated herein by reference).
   
(10)-l
Amendment No. 2 to the Bausch & Lomb Incorporated 2001 Stock Incentive Plan for Non-Officers, effective January 1, 2003 (filed as Exhibit (10)-x to the Company's Annual Report on Form 10-K for the year ended December 28, 2002, File No. 1-4105 and incorporated herein by reference).
   
(10)-m
2003 Long-Term Incentive Plan as amended and restated on July 15, 2003 (filed as Exhibit (10)-b to the Company's Form 10-Q for the quarter ended June 28, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-n
Amendment No. 1 to the Amended and Restated Supplemental Retirement Income Plan III (filed as Exhibit (10)-b to the Company's Form 10-Q for the quarter ended September 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-o
Stock Unit Award Agreement pursuant to the 2003 Long-Term Incentive Plan (filed as Exhibit (10)-c to the Company's Form 10-Q for the quarter ended September 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-p
Restricted Stock Award Agreement pursuant to the 2003 Long-Term Incentive Plan (filed as Exhibit (10)-d to the Company's Form 10-Q for the quarter ended September 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-q
Bausch & Lomb Incorporated Annual Incentive Compensation Plan, as amended and restated on July 25, 2006 (filed herewith).
   



PAGE 151

(10)-r
Director Deferred Compensation Plan as amended and restated on December 1, 2003 (filed as Exhibit (10)-w to the Company's Annual Report on Form 10-K for the year ended December 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-s
Restricted Stock Deferred Compensation Plan, as amended and restated on December 1, 2003 (filed as Exhibit (10)-x to the Company's Annual Report on Form 10-K for the year ended December 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-t
Executive Deferred Compensation Plan, as amended and restated on December 1, 2003 (filed as Exhibit (10)-y to the Company's Annual Report on Form 10-K for the year ended December 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-u
Stock Option Agreement Pursuant to 2003 Long-Term Incentive Plan (filed as Exhibit (10)-z to the Company's Annual Report on Form 10-K for the year ended December 27, 2003, File No. 1-4105 and incorporated herein by reference).
   
(10)-v
Long-Term Equity Equivalent Accumulation Plan (filed herewith).
   
(10)-w
Amendment No. 2 to the Amended and Restated Supplemental Retirement Income Plan III (filed herewith).
   
(10)-x
Credit Agreement by and among Bausch & Lomb Incorporated, certain banks, financial institutions and other institutional lenders and issuers of letter of credit, Citigroup Global Markets Inc., Keybank National Association and Citibank, N.A., dated July 26, 2005 (filed as Exhibit (10)-b to the Company's Form 10-Q for the quarter ended June 25, 2005, File No. 1-4105 and incorporated herein by reference).
   
(10)-y
Credit Agreement between, among others, Citibank International PLC, as facility agent, Bausch & Lomb B.V. and Bausch & Lomb Incorporated, dated November 29, 2005 (filed herewith).
   
(10)-z
Letter Waiver (U.S. Credit Agreement), dated November 23, 2005 (filed herewith).
   
(10)-aa
Letter Waiver (U.S. Credit Agreement), dated February 24, 2006 (filed herewith).
   
(10)-bb
Letter Waiver (B.V. Term Loan), dated February 24, 2006 (filed herewith).
   
(10)-cc
Letter Waiver (U.S. Credit Agreement), dated May 17, 2006 (filed herewith).
   
(10)-dd
Letter Waiver (B.V. Term Loan), dated May 17, 2006 (filed herewith).
   
(10)-ee
Letter Waiver (U.S. Credit Agreement), dated August 28, 2006 (filed herewith).
   
(10)-ff
Letter Waiver (B.V. Term Loan), dated August 30, 2006 (filed herewith).
   
(10)-gg
Agreement for the Sale and Purchase of the Entire Issued Capital of Sino Concept Technology Limited, by and between Sino Biopharmaceutical Limited and Bausch & Lomb Incorporated, dated July 2, 2005 (filed herewith).
   
(10)-hh
Summary of employment arrangement for Praveen Tyle, Senior Vice President and Chief Scientific Officer (filed herewith).
   
(10)-ii
Summary of terms for agreement to authorize Company contribution for certain participants in the 401(k) Excess Program under the non-qualified Executive Deferred Compensation Plan (filed herewith).
   
(10)-jj
Executive Deferred Compensation Plan for Post-2004 Deferrals, dated November 7, 2006 (filed herewith).
   



PAGE 152

(10)-kk
Amendment to Executive Deferred Compensation Plan, dated November 7, 2006 (filed herewith).
   
(10)-ll
Letter Waiver (U.S. Credit Agreement), dated December 13, 2006 (filed herewith).
   
(10)-mm
Letter Waiver (B.V. Term Loan), dated December 13, 2006 (filed herewith).
   
(10)-nn
Description of certain employment terms for Paul G. Howes, Senior Vice President and President, Americas Region, dated November 12, 2003 (filed as Exhibit (10)-w of the Company's Annual Report on Form 10-K for the fiscal year ended December 25, 2004, File No. 1-4105 and incorporated herein by reference).
   
(10)-oo
License Agreement between and among CIBA Vision AG and Bausch & Lomb Incorporated, dated July 1, 2004 (filed herewith). (Portions of this exhibit are omitted pursuant to a confidential treatment request and filed separately with the SEC.)
   
(10)-pp
Long Term Performance Unit Agreement Pursuant to 2003 Long-Term Incentive Plan (filed herewith).
   
(10)-qq
Letter Waiver (U.S. Credit Agreement), dated January 26, 2007 (filed herewith).
   
(10)-rr
Letter Waiver (B.V. Term Loan), dated January 29, 2007 (filed herewith).
   
(12)
Statement Regarding Computation of Ratio of Earnings to Fixed Charges (filed herewith).
   
(21)
Subsidiaries (filed herewith).
   
(24)
Power of Attorney with respect to the signatures of directors in this Annual Report on Form 10-K (filed herewith).
   
(31)-a
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
   
(31)-b
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
   
(32)-a
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (furnished herewith).
   
(32)-b
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (furnished herewith).


EX-3.A 2 form10k2005e3a.htm EXHIBIT (3)-A Exhibit (3)-a


Exhibit (3)-a
 
RESTATED CERTIFICATE OF INCORPORATION
 
OF
 
BAUSCH & LOMB INCORPORATED
 
UNDER SECTION 807 OF THE BUSINESS CORPORATION LAW
 
The undersigned, being respectively Senior Vice President and General Counsel and Secretary of Bausch & Lomb Incorporated, hereby certify that:
First. The name of the Corporation is Bausch & Lomb Incorporated (the “Company”). The name under which the Company was formed was Bausch & Lomb Optical Company.
Second. The Certificate of Incorporation by which the Company was incorporated was filed in the Office of the Secretary of State of the State of New York on March 20, 1908. Restated Certificates of Incorporation of the Company were filed by the Department of State on April 22, 1976 and on September 13, 1985.
Third. This Restated Certificate of Incorporation restates the text of the Certificate of Incorporation without making any amendment or change.
Fourth. The text of the Company’s Certificate of Incorporation is hereby restated to read in full as follows:



CERTIFICATE OF INCORPORATION
OF
BAUSCH & LOMB INCORPORATED
 
1.  The name of the Corporation is Bausch & Lomb Incorporated.
2.  The purposes for which it is formed are:
To develop, manufacture, produce, mine, purchase, lease, sell, import, export, install, repair, modify, service and otherwise acquire and dispose of, work with and on, and deal with and in, scientific, physical, chemical, mechanical, engineering, nuclear, electronic, optical and ophthalmic, photographic, and other image reproduction, measuring, analytical, control, testing, laboratory, astronomical, medical, computer, information storage and retrieval, office, and similar and related tools, implements, machinery, instruments, apparatus, furniture, processes, systems, devices, components, parts, supplies, materials and equipment of all kinds, types and combinations, in all applications, and of all substances, materials and matter of any state and combination;
To engage in scientific and technological research and pursuits of every lawful kind and description and to utilize, employ and exploit any and all knowledge resulting therefrom;
To purchase, lease or otherwise acquire, hold, own, encumber, sell or otherwise dispose of, invest, trade and deal in and with real property and personal property, tangible and intangible, of every kind and description.
3.  Its duration shall be perpetual.
4.  Its principal business office shall be located in the City of Rochester, County of Monroe and State of New York.
5.  Subject to the provisions of this Certificate relating to the rights of the holders of any class or series of stock having a preference over the Common Stock or Class B Stock as to dividends or upon liquidation to elect additional directors under specified circumstances, the number of the directors of the Corporation shall be not less than three nor more than twenty-five persons. The exact number of directors within the minimum and maximum limitations specified in the preceding sentence shall be determined from time to time upon the vote of a majority of the shareholders voting at a meeting or a majority of the entire Board of Directors. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director. Each director, other than those who may be elected by the holders of any class or series of stock having a preference over the Common stock or Class B stock as to dividends or upon liquidation, shall be elected for a term expiring at the annual meeting of shareholders immediately following their election, or when their successor is elected and qualified. The foregoing sentence shall not, however, have the effect of limiting the elected term of any director in office prior to the 2005 annual meeting of shareholders.
6.  The total number of shares which the Corporation may have is Two Hundred Million (200,000,000) shares of Common Stock of the par value of Forty Cents ($.40) per share, Fifteen Million (15,000,000) shares of Class B Stock of the par value of Eight Cents ($.08) per share, Ten Thousand (10,000) shares of 4% Cumulative Preferred Stock of the par value of One Hundred Dollars ($100) per share and Twenty Five Million (25,000,000) shares of Class A Preferred Stock of the par value of One Dollar ($1) per share.
7.  The designations, preferences, privileges and voting powers of the shares of 4% Cumulative Preferred Stock and the restrictions or qualifications thereof shall be as follows:
(A)  Dividends on 4% Cumulative Preferred Stock.
Out of the assets and/or net profits of the Corporation available for dividends, the holders of each share of 4% Cumulative Preferred Stock at the time outstanding shall be entitled to receive, if and when declared by the Board of Directors, dividends in lawful money of the United States of America at, but not exceeding, the rate of 4% per annum, payable in equal quarterly installments on the first days of January, April, July and October in each year, or on such other dates as the Board of Directors may from time to time determine. Such dividends on the 4% Cumulative Preferred Stock shall be preferential and cumulative (whether or not earned in whole or in part) so that if full dividends upon the outstanding 4% Cumulative Preferred Stock at the rate aforesaid from the date from which the dividends thereon became cumulative to the end of the then current quarterly dividend period shall not have been paid or declared and set apart for payment, the amount of the deficiency, without interest, shall be paid in full and dividends upon such stock for the current quarterly period shall be declared and set apart for payment before any dividends shall be declared or paid upon or set apart for, or other distribution shall be ordered or made in respect of, the Common Stock or Class A Preferred Stock and before any sums shall be paid or set apart for the purchase or retirement of the Common Stock, for the purchase or redemption of the Class A Preferred Stock or for the purchase or redemption of less than all of the outstanding 4% Cumulative Preferred Stock. Dividends on all shares of the 4% Cumulative Preferred Stock shall commence to accrue and be cumulative from the quarterly dividend date next preceding the date of issue or from said date of issue, if that be a dividend date; but in the event of the issue of additional shares of 4% Cumulative Preferred Stock subsequent to the date of the initial issue of shares thereof, all dividends paid on the 4% Cumulative Preferred Stock prior to the issue of such additional shares, and all dividends declared payable to holders of record of 4% Cumulative Preferred Stock at a date prior to such issue, shall be deemed to have been paid in respect of the additional shares so issued.
(B)  Voting Rights of 4% Cumulative Preferred Stock.
The holders of 4% Cumulative Preferred Stock shall not be entitled to any voting rights except as otherwise required by law and except as hereinafter stated; and without limiting the generality of the foregoing, the holders of 4% Cumulative Preferred Stock are hereby specifically excluded from the right to vote in a proceeding (a) for mortgaging the property and franchises of the Corporation pursuant to the Business Corporation Law of the State of New York, (b) for authorizing any guaranty pursuant to said law, (c) for sale of the franchises and property of the Corporation pursuant to said law, (d) for consolidation pursuant to said law, (e) for voluntary dissolution pursuant to said law, or (f) for change of name pursuant to said law.
If and whenever dividends on the outstanding 4% Cumulative Preferred Stock shall be in arrears or unpaid in an aggregate amount equal to or exceeding four full quarterly dividends thereon, that is, in an amount equal to or exceeding $4 on each share of outstanding 4% Cumulative Preferred Stock, then the holders of 4% Cumulative Preferred Stock, shall thereupon have the right, voting as a class, by plurality vote, to elect two members of the Board of Directors or one-third of the total number of directors (disallowing any fraction), whichever is greater, (such number of directors being hereinafter called “the minority”). During the continuance of such right of the 4% Cumulative Preferred Stock to elect the minority of the directors, the holders of the Common Stock, voting as another class, shall, subject to any rights thereto then possessed by holders of Class A Preferred Stock, have the right, by plurality vote, to elect the remaining members (hereinafter called “the majority”) of the Board of Directors.
If and whenever the right of the holders of 4% Cumulative Preferred Stock to elect the minority of the Board of Directors shall accrue, the terms of office of all persons who may be directors of the Corporation at such time shall terminate upon the election of their successors; and such election may be held at a special meeting of all shareholders of the Corporation which shall be convened at any time after the accrual of such right upon notice similar to that provided in the By-Laws of the Corporation for calling the annual meeting of the shareholders, at the request in writing of the holders of record of at least 2% of the number of shares of 4% Cumulative Preferred Stock then outstanding. In default of the calling of said meeting by a proper officer of the Corporation within five days after the making of such request, such meeting may be called on like notice by any holder of record of 4% Cumulative Preferred Stock, for which purpose any such holder of 4% Cumulative Preferred Stock shall have the right to have access to the stock books of the Corporation. If for any reason such special meeting shall not be called prior to the next annual meeting, then at such meeting the holders of 4% Cumulative Preferred Stock and of the Common Stock (subject to any rights thereto then possessed by holders of Class A Preferred Stock) respectively, shall elect the minority and the majority of the members of the Board of Directors as aforesaid unless previously thereto all such defaults in dividend shall have been made good.
The right of the holders of 4% Cumulative Preferred Stock so to elect the minority of the Board of Directors shall continue until all accrued dividends on the 4% Cumulative Preferred Stock at the full cumulative rate aforesaid to the next preceding quarterly dividend payment date shall have been paid or declared and set apart for payment, in full, at which time such right shall cease.
If and whenever the right of the holders of 4% Cumulative Preferred Stock to elect the minority of the Board of Directors shall terminate, then the terms of office of all persons who may be directors of the Corporation at such time shall terminate upon the election of their successors; and such election may be held at a special meeting of the holders of Common Stock of the Corporation (subject to any rights thereto then possessed by holders of Class A Preferred Stock) which shall be convened at any time after the termination of such right upon notice similar to that provided in the By-Laws of the Corporation for calling the annual meeting of the shareholders at the request in writing of the holders of record of at least 2% of the number of shares of Common Stock then outstanding. In default of the calling of said meeting by a proper officer of the Corporation within five days after the making of such request, such meeting may be called on like notice by any holder of record of Common Stock, for which purpose any holder of Common Stock shall have the right to have access to the stock books of the Corporation. If such special meeting be not called prior to the next annual meeting, then at such meeting the holders of the Common Stock (subject to any rights thereto then possessed by holders of Class A Preferred Stock) shall elect all of the members of the Board of Directors.
If and whenever during any interval between annual meetings of shareholders for the election of directors while holders of 4% Cumulative Preferred Stock shall be entitled to elect the minority of the directors, the number of directors in office who shall have been elected by the holders of 4% Cumulative Preferred Stock or Common Stock, and/or Class A Preferred Stock, as the case may be, shall become less than the total number of directors subject to election by the holders of shares of such class, whether by reason of the resignation, death or removal of any director or directors, or an increase in the total number of directors, (1) the vacancy or vacancies shall be filled by a majority vote of the remaining directors if they constitute a quorum, but in each such case, the majority vote must include the votes of a majority of the directors then in office who were either elected by the votes of shares of such class or substituted to a vacancy originally filled by the votes of the shares of such class, and (2) if the remaining directors do not constitute a quorum, a special meeting of the holders of shares of such class shall be held in the manner and on notice as above provided and such vacancy or vacancies shall be filled at such special meeting.
At any meeting of shareholders at which the holders of 4% Cumulative Preferred Stock shall be entitled to elect the minority of directors as aforesaid, a quorum shall, insofar as the election of such minority is concerned but not otherwise, be such number of shares of 4% Cumulative Preferred Stock as shall be represented in person or by proxy at said meeting.
(C)  Restriction on Certain Corporate Action.
The consent, by affirmative vote or in writing, of the holders of two-thirds of the outstanding shares of 4% Cumulative Preferred Stock shall be required for any of the following actions:
(a)  Any change in or modification of any of the preferences, priorities, special rights or powers of the 4% Cumulative Preferred Stock, adversely affecting such stock;
(b)  The authorization or issuance of any shares of stock of any other class (as distinguished from additional shares of 4% Cumulative Preferred Stock) of the Corporation ranking prior to or on a parity with the 4% Cumulative Preferred Stock as to dividends or assets, or the authorization or issuance of any stock or other security of the Corporation convertible into any stock having such priority or parity;
(c)  The issuance by the Corporation of any shares of 4% Cumulative Preferred Stock other than the 10,000 shares of 4% Cumulative Preferred Stock to be presently authorized, unless:
(1)  average annual Consolidated Net Earnings (after adding thereto all interest paid on outstanding Consolidated Funded Debt and dividends paid or accrued on outstanding preferred stock of any Domestic Subsidiary) for the three preceding fiscal years shall be at least equal to two and one-half times the sum of (i) annual interest requirements on Consolidated Funded Debt to be outstanding immediately after the issuance of such additional 4% Cumulative Preferred Stock and (ii) annual dividend requirements on all 4% Cumulative Preferred Stock and on any other stock of the Corporation ranking prior to or on a parity with the 4% Cumulative Preferred Stock and on any preferred stock of any Domestic Subsidiary to be so outstanding; and
(2)  at June 30th or December 31st, as the case may be, next preceding the date of the issuance of such additional 4% Cumulative Preferred Stock, but after giving effect to such issuance, the sum of (i) the par or stated value of all of the outstanding shares of stock of the Corporation ranking junior to the 4% Cumulative Preferred Stock both as to dividends and assets and (ii) Consolidated Surplus, shall be at least 100% of the sum of (iii) Consolidated Funded Debt, the involuntary liquidating preference of any outstanding shares of preferred stock of any Domestic Subsidiary and the proportion of net assets applicable to minority interests evidenced by shares of Common Stock of Domestic Subsidiaries and (iv) the par or stated value of all the outstanding shares of 4% Cumulative Preferred Stock and of any other class of stock ranking prior to or on a parity with the 4% Cumulative Preferred Stock as to dividends or assets.
(d)  The creation, incurring, assumption or guarantee by the Corporation or any Domestic Subsidiary of any Funded Debt (except (1) in connection with the renewal or extension of Funded Debt in an amount not exceeding the principal amount of Funded Debt so renewed or extended or (2) Funded Debt owing to the Corporation or a Wholly-Owned Subsidiary), or the issuance by any Domestic Subsidiary, other than to the Corporation or a Wholly-Owned Subsidiary, of any shares of preferred stock; unless, as at June 30th or December 31st, as the case may be, next preceding the date of such creation, incurring, assumption or guarantee or issuance, but after giving effect thereto, the sum of (i) the par or stated value of all outstanding stock of the Corporation ranking junior to the 4% Cumulative Preferred Stock both as to dividends and assets and (ii) Consolidated Surplus, shall be at least 100% of the sum of (iii) Consolidated Funded Debt, the involuntary liquidating preference of any outstanding shares of preferred stock of any Domestic Subsidiary and the proportion of net assets applicable to minority interests evidenced by shares of Common Stock of Domestic Subsidiaries and (iv) the par or stated value of all the outstanding shares of 4% Cumulative Preferred Stock and of any other class of stock ranking prior to or on a parity with the 4% Cumulative Preferred Stock as to dividends or assets.
                (e)     The consolidation of the Corporation with or the merger of the Corporation into another corporation or corporations, but this restriction shall not apply to the purchase by the Corporation of assets or securities of another corporation or the merger of another corporation or corporations into the Corporation if the Corporation is the surviving Corporation.
The consent by affirmative vote or in writing of the holders of a majority of the outstanding shares of 4% Cumulative Preferred Stock shall be required to effect or validate the sale or lease of substantially all of the assets of the Corporation.
Except as provided above, the Common Stock shall have the exclusive right, so far as the holders of 4% Cumulative Preferred Stock are concerned, to vote for the election of directors and for all other purposes.
Except as otherwise required by law holders of 4% Cumulative Preferred Stock shall not be entitled to receive notice of any meeting of the holders of any class of stock at which they were not entitled to vote.
Notwithstanding any provisions to the contrary herein contained, the holders of 4% Cumulative Preferred Stock shall not have any right, under the provisions of this paragraph (C), to vote in respect of any matter specified in said paragraph if, in connection therewith, provision is to be made for the redemption of all of the 4% Cumulative Preferred Stock at the time outstanding or for the voluntary dissolution, liquidation or winding up of the Corporation.
In exercising voting rights given to the 4% Cumulative Preferred Stock by the provisions of paragraphs (B) and (C), the holders of such stock shall be entitled to one vote for each share of such stock held by them, respectively.
(D)  Dividend Restrictions on Junior Stock.
So long as any of the 4% Cumulative Preferred Stock shall remain outstanding, no dividends (other than dividends payable in stock of the Corporation ranking junior to the 4% Cumulative Preferred Stock both as to dividends and assets) shall be paid upon, nor shall any other distribution be made to, any class of stock ranking junior to the 4% Cumulative Preferred Stock as to either dividends or assets (hereinafter sometimes referred to as junior stock) nor shall any shares of junior stock be purchased, redeemed or otherwise acquired for a consideration by the Corporation or any Domestic Subsidiary:
(a)  if the aggregate amount so paid, distributed or applied subsequent to December 31, 1944, would thereupon exceed the sum of (i) Consolidated Net Earnings after December 31, 1944, after deduction therefrom of all dividends which shall accrue after that date on the 4% Cumulative Preferred Stock and on any class of stock ranking prior thereto or on a parity therewith as to dividends or assets, (ii) the aggregate net proceeds received by the Corporation from the issue or sale subsequent to December 31, 1944, of shares of any class of stock ranking junior to the New Preferred Stock both as to dividends and assets after deducting therefrom the net proceeds received by the Corporation from the issuance or sale during the year 1945 of 152,500 shares of Common Stock of the Corporation (such Consolidated Net Earnings to be determined in each case as of the end of the latest month preceding the event which requires the making of such determination for which financial statements are available, but in no event earlier than the second calendar month preceding such event); and (iii) $500,000; or
(b)  if, as at June 30th or December 31st, as the case may be, next preceding the date of the making of such payment, distribution, purchase, redemption or acquisition, but after giving effect thereto, the sum of (i) the par or stated value of all of the outstanding shares of stock of the Corporation ranking junior to the 4% Cumulative Preferred Stock both as to dividends and assets and (ii) Consolidated Surplus shall be less than 100% of the sum of (iii) Consolidated Funded Debt, the involuntary liquidating preference of any outstanding shares of preferred stock of any Domestic Subsidiary and the proportion of net assets applicable to minority interests evidenced by shares of Common Stock of Domestic Subsidiaries and (iv) the par or stated value of all the outstanding shares of 4% Cumulative Preferred Stock and of any other class of stock ranking prior to or on a parity with the 4% Cumulative Preferred Stock as to dividends or assets.
(E)  Liquidation Rights of 4% Cumulative Preferred Stock.
In the event that the Corporation is liquidated, dissolved or wound up, the holders of 4% Cumulative Preferred Stock shall be entitled to receive, if such liquidation, dissolution or winding up be involuntary, the sum of $100 per share, and if such liquidation, dissolution or winding up be voluntary, a sum equal to the redemption price in effect at the time of such liquidation, dissolution or winding up, out of the assets of the Corporation available for distribution to its shareholders, whether capital, surplus or earnings, plus all dividends accrued or in arrears thereon, before any amount shall be paid or distributed to the holders of the Class A Preferred Stock or to the holders of the Common Stock; but the holders of 4% Cumulative Preferred Stock shall be entitled to no further participation in such distribution. If upon such liquidation, dissolution or winding up, the assets of the Corporation available for distribution to its shareholders shall be insufficient to permit the payment to the holders of 4% Cumulative Preferred Stock of the full preferential amounts aforesaid, then all said assets shall be distributed among the holders of 4% Cumulative Preferred Stock then outstanding ratably in proportion to the full preferential amounts to which they are respectively entitled. The expression “dividends accrued or in arrears” means, in respect of each share of 4% Cumulative Preferred Stock, an amount equal to simple interest upon the sum of $100 at the rate of 4% per annum from the date from which dividends thereon became cumulative to the date as of which the computation is to be made, less the aggregate amount (without interest) of all dividends theretofore paid or declared and set apart for payment in respect of such share or deemed so to be. The consolidation or merger of the Corporation and any other corporation or corporations, or the sale of all or substantially all of the assets of the Corporation as an entirety, or the purchase or redemption of 4% Cumulative Preferred Stock, or the purchase or redemption of Class A Preferred Stock, or the purchase of Common Stock in any manner permitted by law or by the provisions hereof, shall not be regarded as a liquidation, dissolution or winding up of the Corporation.
(F)  Redemption and Repurchase of 4% Cumulative Preferred Stock.
The 4% Cumulative Preferred Stock may be redeemed by the Corporation at the option of the Board of Directors as a whole at any time, or, subject to the provisions of paragraph A, in part from time to time, at $104 per share, plus in each case a sum equal to accrued or unpaid dividends thereon to the date of redemption. If less than all of the outstanding 4% Cumulative Preferred Stock is to be redeemed, the redemption shall be in such amount and shall be effected in such manner, whether by lot or pro rata, and subject to such conditions and provisions of expediency and convenience as may be prescribed by resolution of the Board of Directors. Notice of any proposed redemption of 4% Cumulative Preferred Stock shall be given by the Corporation by mailing a copy of such notice at least 30 days prior to the date fixed for such redemption to the holders of record of 4% Cumulative Preferred Stock to be redeemed at their respective addresses appearing on the books of the Corporation. From and after the date specified in such notice as the date of redemption (unless default shall be made by the Corporation in providing moneys at the time and place specified for the payment of the redemption funds pursuant to said notice), all dividends on the 4% Cumulative Preferred Stock to be redeemed shall cease to accrue, and from and after said date (unless default be made as aforesaid) or the date of the earlier deposit by the Corporation in trust, with a bank or trust company doing business in the State of New York, of funds sufficient for such redemption (a statement of the intention so to deposit having been included in said notice), all rights of the holders of the shares of 4% Cumulative Preferred Stock so to be redeemed as shareholders of the Corporation, including, without limitation, any right to vote or otherwise participate in the determination of any proposed corporate act, except only the right to receive the redemption price when due, shall cease and determine and such shares shall be deemed to be no longer outstanding. The Corporation shall be entitled to all moneys so deposited which shall remain unclaimed by the holders of such 4% Cumulative Preferred Stock at the end of six years after the redemption date, together with any interest thereon which shall have been allowed by the bank or trust company with which the deposit was made, and such moneys shall be paid over to the Corporation on its demand by said bank or trust company without liability to any holders of such 4% Cumulative Preferred Stock for so doing and also without the necessity of any notice to them. Subject to the provisions of paragraph (A), the Corporation may also from time to time purchase shares of its 4% Cumulative Preferred Stock at a price not exceeding the price at which the same might then be redeemed. Shares of 4% Cumulative Preferred Stock redeemed or purchased by the Corporation shall not be re-issued by it.
(G)  Preemptive Rights.
The holders of 4% Cumulative Preferred Stock, as such, shall have no preemptive rights to subscribe to or purchase or otherwise acquire any shares of stock of the Corporation of any series or class issued, sold or offered by the Corporation for property, cash or otherwise.
(H)  Definitions.
The following terms used above shall have the following meanings:
(a)  The term “Funded Debt” shall mean all indebtedness, direct or guaranteed, other than indebtedness maturing by its terms not more than twelve months from the date of incurring the same, except that there shall not be included in Funded Debt any indebtedness for the payment or redemption of which provision shall have been or is being made. Such term shall exclude notes or other indebtedness, maturing not more than twelve months from the date of their issuance or creation, issued or incurred pursuant to the provisions of any credit or loan agreement or other arrangement, the principal purpose of which is to provide funds in connection with war production or the carrying of receivables, inventory or claims with respect to terminated contracts relating to war production, notwithstanding that such agreement may contain provisions for the renewal or extension of such notes or indebtedness or for the suspension of the maturity thereof in connection with the cancellation of war production contracts; but shall include any notes or indebtedness issued or incurred under the Corporation’s Reconversion and Post-War Loan Agreement dated July 6, 1945, with Lincoln Rochester Trust Company and certain other banking institutions.
(b)  The term “Consolidated Funded Debt”, shall mean the sum of all Funded Debt of the Corporation and its Domestic Subsidiaries after eliminating all intercompany items, as computed from a consolidated balance sheet and as determined in accordance with generally accepted accounting principles.
(c)  The term “Consolidated Surplus” shall mean the earned surplus and capital surplus as determined from a consolidated balance sheet of the Corporation and its Domestic Subsidiaries in accordance with generally accepted accounting principles.
(d)  The term “Consolidated Net Earnings” shall mean the consolidated net income of the Corporation and its Domestic Subsidiaries available for dividends, determined in accordance with generally accepted accounting principles, after all proper charges (including provision for dividends on outstanding preferred stock of Domestic Subsidiaries and for net profits applicable to minority interests in subsidiaries represented by Common Stock and after provision for interest and for income and profits taxes and other taxes), but excluding therefrom capital gains and losses and including therein the amount of any tax refunds received or tax credit allowed or obtained, and provision for any additional tax assessments during any period in question whether the same arose in or shall be allocable in whole or in part to any prior period. In determining “Consolidated Net Earnings” no deduction shall be made for discounts or commissions on any shares of 4% Cumulative Preferred Stock or any other securities hereafter issued by the Corporation or any Domestic Subsidiary nor for the premium paid upon the redemption of any thereof.
(e)  The term “Subsidiary” or “Subsidiaries” shall mean any corporation or corporations at least 51% of the shares of the capital stock of which having voting power, other than as effected by failure to pay dividends or other events of default, is owned by the Corporation, either directly or through one or more other Subsidiaries.
(f)  The term “Domestic Subsidiary” shall mean any Subsidiary the greater portion of the business of which is transacted, or the greater portion of the assets of which is located, within the continental United States (excluding Alaska) and/or within the Dominion of Canada.
The term “Wholly-Owned Subsidiary” shall mean any Subsidiary all of the outstanding stock of which, except directors’ qualifying shares, is owned by the Corporation either directly or through one or more other Wholly-Owned Subsidiaries.
(g)  The term “outstanding” as applied to Funded Debt or preferred stock of the Corporation or any Domestic Subsidiary, shall be deemed to exclude any such Funded Debt or preferred stock owned by the Corporation or any Domestic Subsidiary.
(h)  The term “Common Stock”, when referring to Common Stock of the Corporation, shall be deemed to include Class B Stock.
8.  The Corporation shall have authority to issue its Class A Preferred Stock in series. The Board of Directors is vested with authority to establish and designate series and to fix the number of shares to be included in each such series and the relative rights, preferences and limitations of such series, subject to the provisions set forth below, and to the limitation that the Board of Directors shall not have any authority to subordinate rights of holders of 4% Cumulative Preferred Stock by authorizing preferences for holders of any series of Class A Preferred Stock which would be in any respect superior to the rights of the holders of 4% Cumulative Preferred Stock, and to the further limitation that, if the stated dividends and amounts payable on liquidation are not paid in full, the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in accordance with the sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution of assets other than by way of dividends in accordance with the sums which would be payable in such distribution if all sums payable were discharged in full. The authority of the Board of Directors with respect to each series of Class A Preferred Stock shall include, but not be limited to, determination of the following:
(a) The number of shares constituting that series and the distinctive designation of that series;
(b) The dividend rate on the shares of that series, whether dividends shall be cumulative, and, if so, from which date or dates;
(c) Whether that series shall participate in unlimited dividend rights, and, if so, the extent of such participation;
(d) Whether that series shall have voting rights, in addition to the voting rights provided by law, and, if so, the terms of such voting rights;
(e) Whether that series shall have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the Board of Directors shall determine;
(f) Whether or not the shares of that series shall be redeemable, and, if so, the terms and conditions of such redemption, including the date or dates upon or after which they shall be redeemable, and the amount per share payable in case or redemption, which amount may vary under different conditions and at different redemption dates;
(g) The amounts payable on the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the Corporation;
(h) Any other relative rights, preferences and limitations of that series.
Dividends on outstanding Class A Preferred Stock of each series shall be declared and paid, or set apart for payment, before any dividends shall be declared and paid, or set apart for payment, on the Common Stock with respect to the same dividend period.
Upon any dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the Class A Preferred Stock shall be entitled to receive out of the assets of the Corporation, before any distribution shall be made to the holders of the Common Stock, the amounts determined to be payable on the Class A Preferred Stock of each series in the event of voluntary or involuntary liquidation.
No holder of Class A Preferred Stock shall be entitled to any preemptive rights.
The term “Common Stock”, when used in this Paragraph 8, shall be deemed to include Class B Stock.
9.  The designations, preferences, privileges and voting powers of a series of Class A Preferred Stock designated as “Class A Preferred Stock, Series A” and the restrictions or qualifications thereof shall be as follows:
(A)  Designation and Amount. The shares of such series shall be designated as “Class A Preferred Stock, Series A” (the “Series A Preferred Shares”) and the number of shares constituting the Series A Preferred Shares shall be Three Hundred Fifty Thousand (350,000). Such number of shares may be increased or decreased by resolution of the Board of Directors; provided, that no decrease shall reduce the number of Series A Preferred Shares to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Corporation convertible into Series A Preferred Shares.
(B)  Dividends and Distributions.
(i) Subject to the rights of the holders of any shares of any class of capital stock of the Corporation ranking prior and superior to the Series A Preferred Shares with respect to dividends, the holders of Series A Preferred Shares, in preference to the holders of the Corporation’s Common Stock and Class B Stock (which, for the purposes of this Paragraph 9, are hereinafter referred to together as the “Common Shares”) and of any other junior stock, shall be entitled to receive, when, as and if declared by the Board of Directors out of funds legally available for the purpose, quarterly dividends payable in cash (except as provided below with respect to non-cash dividends) on the first day of January, April, July and October in each year (each such date being referred to herein as a “Quarterly Dividend Payment Date”), commencing on the first Quarterly Dividend Payment Date after the first issuance of a share or fraction of a share of Series A Preferred Shares, in an amount per share (rounded to the nearest cent) equal to the greater of (a) $1 or (b) subject to the provision for adjustment hereinafter set forth, 100 times the aggregate per share amount of all cash dividends, and 100 times the aggregate per share amount (payable in kind) of all non-cash dividends or other distributions, other than a dividend payable in shares of Common Stock or a subdivision of the outstanding shares of Common Stock (by reclassification or otherwise), declared on the Common Stock since the immediately preceding Quarterly Dividend Payment Date or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series A Preferred Shares. In the event the Corporation shall at any time declare or pay any dividend on the Common Share payable in shares of Common Stock, or effect a subdivision or combination or consolidation of the outstanding Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the amount to which holders of Series A Preferred Shares were entitled immediately prior to such event under clause (b) of the preceding sentence shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of Common Shares outstanding immediately after such event and the denominator of which is the number of Common Shares that were outstanding immediately prior to such event.
(ii) The Corporation shall declare a dividend or distribution on the Series A Preferred Shares as provided in subparagraph (i) of this Paragraph 9 immediately prior to declaring a dividend or distribution on the Common Stock (other than a dividend payable in Common Stock); provided, that in the event no dividend or distribution shall have been declared on the Common Stock during the period between any Quarterly Dividend Payment Date and the next subsequent Quarterly Dividend Payment Date or, with respect to the first Quarterly Dividend Payment Date, since the first issuance of any share or fraction of a share of Series A Preferred Shares, a dividend of $1 per share of the Series A Preferred Shares shall nevertheless be payable on such subsequent or first Quarterly Dividend Payment Date, as the case may be.
(iii) Dividends shall begin to accrue and be cumulative on outstanding Series A Preferred Shares from the Quarterly Dividend Payment Date next preceding the date of issue of such shares, unless the date of issue of such shares is prior to the record date for the first Quarterly Dividend Payment Date, in which case dividends on such shares shall begin to accrue from the date of issue of such shares, or unless the date of issue is a Quarterly Dividend Payment Date or is a date after the record date for the determination of holders of Series A Preferred Shares entitled to receive a quarterly dividend and before such Quarterly Dividend Payment Date, in either of which events such dividends shall begin to accrue and be cumulative from such Quarterly Dividend Payment Date. Accrued but unpaid dividends shall not bear interest. Dividends paid on the Series A Preferred Shares in an amount less than the total amount of such dividends at the time accrued and payable on such shares shall be allocated pro rata on a share-by-share basis among all such shares at the time outstanding. The Board of Directors may fix a record date for the determination of holders of Series A Preferred Shares entitled to receive payment of a dividend or distribution declared thereon, which record date shall be not more than 60 days prior to the date fixed for the payment thereof.
(C)  Voting Rights. The holders of Series A Preferred Shares shall have the following voting rights:
(i)        Subject to the provisions for adjustment hereinafter set forth, each share of Series A Preferred Shares shall entitle the holder thereof to 100 votes on all matters submitted to a vote of the shareholders of the Corporation. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision or combination or consolidation of the outstanding Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the number of votes per share to which holders of Series A Preferred Shares were entitled immediately prior to such event shall be adjusted by multiplying such number by a fraction, the numerator of which is the number of Common Shares outstanding immediately after such event and the denominator of which is the number of Common Shares that were outstanding immediately prior to such event.
(ii)      Except as otherwise provided herein, in any other Certificate of Amendment creating a series of Class A Preferred Stock, par value $1.00 per share, of the Corporation (the “Preferred Shares”) or any similar stock, or by law, the holders of Series A Preferred Shares and the holders of Common Shares and any other capital shares of the Corporation having general voting rights shall vote together as one class on all matters submitted to a vote of shareholders of the Corporation.
(iii)      Except as set forth herein, or as otherwise provided by law, holders of Series A Preferred Shares shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Shares as set forth herein) for taking any corporate action.
(D)  Certain Restrictions.
(i)       Whenever quarterly dividends or other dividends or distributions payable on the Series A Preferred Shares as provided in subparagraph (B) of this Paragraph 9 are in arrears, thereafter and until all accrued and unpaid dividends and distributions, whether or not declared, on Series A Preferred Shares outstanding shall have been paid in full, the Corporation shall not:
(a) declare or pay dividends, or make any other distributions, on any shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Preferred Shares;
(b) declare or pay dividends, or make any other distributions, on any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred Shares, including, without limitation, shares of any other series of Class A Preferred Stock, except dividends paid ratably on the Series A Preferred Shares and all such parity stock on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled;
(c) redeem or purchase or otherwise acquire for consideration shares of any stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Preferred Shares; provided, that the Corporation may at any time redeem, purchase or otherwise acquire shares of any such junior stock in exchange for shares of any stock of the Corporation ranking junior (either as to dividends or upon dissolution, liquidation or winding up) to the Series A Preferred Shares; or
(d) redeem or purchase or otherwise acquire for consideration any Series A Preferred Shares, or any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred Shares, including, without limitation, shares of any other series of Class A Preferred Stock, except in accordance with a purchase offer made in writing or by publication (as determined by the Board of Directors) to all holders of such shares upon such terms as the Board of Directors, after consideration of the respective annual dividend rates and other relative rights and preferences of the respective series and classes, shall determine in good faith will result in fair and equitable treatment among the respective series or classes.
(ii)      The Corporation shall not permit any subsidiary of the Corporation to purchase or otherwise acquire for consideration any shares of stock of the Corporation unless the Corporation could, under subparagraph (D)(i) of this Paragraph 9, purchase or otherwise acquire such shares at such time and in such manner.
(E)  Reacquired Shares. Any Series A Preferred Shares purchased or otherwise acquired by the Corporation in any manner whatsoever shall be retired and cancelled promptly after the acquisition thereof. All such shares shall upon their cancellation become authorized but unissued shares of Class A Preferred Stock and may be reissued as part of a new series of Class A Preferred Stock subject to the conditions and restrictions on issuance set forth herein, in the Restated Certificate of Incorporation, or in any other Certificate of Amendment creating a series of Class A Preferred Stock or any similar stock or as otherwise required by law.
(F)  Liquidation, Dissolution or Winding Up. Upon any liquidation, dissolution or winding up of the Corporation, no distribution shall be made (1) to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A Preferred Shares unless, prior thereto, the holders of Series A Preferred Shares shall have received $100 per share, plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, to the date of such payment, provided that the holders of Series A Preferred Shares shall be entitled to receive an aggregate amount per share, subject to the provision for adjustment hereinafter set forth, equal to 100 times the aggregate amount to be distributed per share to holders of shares of Common Stock, or (2) to the holders of Series A Preferred Shares or shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A Preferred Shares, including, without limitation, shares of any other series of Class A Preferred Stock, except distributions made ratably on the Series Preferred Shares and all such parity stock in proportion to the total amounts to which the holders of all such shares are entitled upon liquidation, dissolution or winding up. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision or combination or consolidation of the outstanding Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock) into a greater or lesser number of shares of Common Stock, then in each such case the aggregate amount to which holders of Series A Preferred Shares were entitled immediately prior to such event under the proviso in clause (1) of the preceding sentence shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of Common Shares outstanding immediately after such event and the denominator of which is the number of Common Shares that were outstanding immediately prior to such event.
(G)  Consolidation, Merger, etc. In case the Corporation shall enter into any consolidation, merger, combination or other transaction in which the shares of the Corporation’s Common Stock are exchanged for or changed into other stock or securities, cash and/or any other property, then in any such case each share of Series A Preferred Shares shall at the same time be similarly exchanged for or changed into an amount per share, subject to the provision for adjustment hereinafter set forth, equal to 100 times the aggregate amount of stock, securities, cash and/or any other property (payable in kind), as the case may be, for which or into which each share of Common Stock is exchange or changed. In the event the Corporation shall at any time declare or pay any dividend on the Common Stock payable in shares of Common Stock, or effect a subdivision or combination or consolidation of the outstanding Common Stock (by reclassification or otherwise than by payment of a dividend in shares of Common Stock into a greater or lesser number of shares of Common Stock), then in each such case the amount set forth in the preceding sentence with respect to the exchange or change of Series A Preferred Shares shall be adjusted by multiplying such amount by a fraction, the numerator of which is the number of Common Shares outstanding immediately after such event and the denominator of which is the number of Common Shares that were outstanding immediately prior to such event.
(H)  No Redemption. The Series A Preferred Shares shall not be redeemable.
(I)  Amendment. The Restated Certificate of Incorporation of the Corporation shall not be amended in any manner which would materially alter or change the powers, preferences or special rights of the Series A Preferred Shares so as to affect them adversely without the affirmative vote of the holders of at least two-thirds of the outstanding Series A Preferred Shares, voting together as a single class.
10.  The designations, preferences, privileges and voting powers of the shares of Common Stock and Class B Stock and the restrictions or qualifications thereof shall be as follows:
(A)  Dividends on Common Stock and Class B Stock.
Subject to the restrictions contained in Paragraph 7(D), and to the provisions respecting the prior payment or declaration and setting apart for payment of dividends on the 4% Cumulative Preferred Stock, the Board of Directors in its discretion may declare and pay, equally per share, dividends on the Common Stock and Class B Stock out of the assets and/or net profits of the Corporation available for dividends, to the exclusion of the 4% Cumulative Preferred Stock. No dividend, distribution, split-up, combination, reclassification or other change shall be paid or made with respect to shares of Common Stock without the same action being taken with respect to shares of Class B Stock.
(B)  Purchases of Common Stock and Class B Stock.
Subject to the restrictions contained in Paragraph 7(D), and to the provisions respecting the prior payment or declaration and setting apart for payment of the dividends on the 4% Cumulative Preferred Stock and on any Class A Preferred Stock, the Corporation may at any time purchase shares of its Common Stock or shares of its Class B Stock in any manner now or hereafter permitted by law.
(C)  Distribution of Assets to Common Stock and Class B Stock.
In the event that the Corporation is liquidated, dissolved or wound up, after there shall have been paid to or set apart for the holders of 4% Cumulative Preferred Stock and the holders of any Class A Preferred Stock the full preferential amounts to which they are respectively entitled, the holders of the Common Stock and Class B Stock shall be entitled to receive, equally per share, and to the exclusion of the 4% Cumulative Preferred Stock and the Class A Preferred Stock, the remaining assets of the Corporation available for distribution to its shareholders.
(D)  Voting Power of Common Stock and Class B Stock.
Subject to the provisions of Paragraphs 7(B) and (C), and any provisions for voting by holders of Class A Preferred Stock, the holders of the Common Stock and of the Class B Stock (voting together as a single class) shall possess full and exclusive voting power for the election of directors and for all other purposes, each share of Common Stock and each share of Class B Stock having one vote.
(E)  Preemptive Rights.
The holders of Common Stock and the holders of Class B Stock, as such, shall have no preemptive rights to subscribe to or purchase or otherwise acquire any shares of stock of the Corporation of any series or class, or any rights, options or securities of any kind.
11.  The Secretary of State is designated the agent of the Corporation upon whom process against the Corporation may be served. The Post Office address to which the Secretary of State shall mail a copy of any process against the Corporation so served upon him is Bausch & Lomb Incorporated, One Bausch & Lomb Place, Rochester, New York 14604.
12.  (A)    Except as expressly permitted in subparagraph 12(B), any purchase by the Corporation of shares of Voting Stock (as hereinafter defined) from a 5% Shareholder (as hereinafter defined) at a per share price in excess of the Market Price (as hereinafter defined) at the time of such purchase of the shares so purchased shall require the affirmative vote of the holders of that amount of the voting power of the Voting Stock equal to the sum of (i) the voting power of the shares of Voting Stock of which the 5% Shareholder is the beneficial owner (as hereinafter defined) and (ii) a majority of the voting power of the remaining outstanding shares of Voting Stock, voting together as a single class.
(B)  The provisions of subparagraph 12(A) shall not be applicable to any purchase of shares of Voting Stock (i) pursuant to an offer, made available on the same terms to the holders of all of the outstanding shares of the same class of Voting Stock as those so purchased or (ii) in the open market and not as a result of a privately-negotiated transaction.
13.  In addition to any affirmative vote required by law, this Certificate of Incorporation or the Corporation’s By-Laws,
(A)  any merger or consolidation of the Corporation or any Subsidiary (as hereinafter defined) with (i) any 5% Shareholder or (ii) any other corporation (whether or not itself a 5% Shareholder) which is, or after such merger or consolidation would be, an Affiliate (as hereinafter defined) of a 5% Shareholder; or
(B)  any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) to or with any 5% Shareholder or any Affiliate of any 5% Shareholder of any assets of the Corporation or any Subsidiary having an aggregate Fair Market Value (as hereinafter defined) of $10,000,000 or more; or
(C)  the issuance or transfer by the Corporation or any Subsidiary (in one transaction or a series of transactions) of any securities of the Corporation or any Subsidiary having an aggregate Fair Market Value of $10,000,000 or more to any 5% Shareholder or any Affiliate of any 5% Shareholder in exchange for cash, securities or other property (or a combination thereof); or
(D)  the adoption of any plan or proposal for the liquidation or dissolution of the Corporation proposed by or on behalf of a 5% Shareholder or any Affiliate of any 5% Shareholder; or
(E)  any reclassification of securities (including any reverse stock split), or recapitalization of the Corporation, or any merger or consolidation of the Corporation with any of its Subsidiaries or any other transaction (whether or not with or into or otherwise involving a 5% Shareholder) which has the effect, directly or indirectly, of increasing the proportionate share of the outstanding shares of any class of equity or convertible securities of the Corporation or any Subsidiary which is directly or indirectly owned by any 5% Shareholder or any Affiliate of any 5% Shareholder; shall require the affirmative vote of the holders of that amount of the voting power of the Voting Stock equal to the sum of (i) the voting power of the shares of Voting Stock of which the 5% Shareholder is the beneficial owner and (ii) a majority of the voting power of the remaining outstanding shares of Voting Stock, voting together as a single class; provided, however, that no such vote shall be required (a) if the Business Combination (as hereinafter defined) has been approved by the Board of Directors prior to the time the 5% Shareholder became a 5% Shareholder or (b) for the purchase by the Corporation of shares of Voting Stock from a 5% Shareholder unless such vote is required by Paragraph 12A.
14.  (A)    For the purposes of Paragraphs 12 through 14:
(i) A “person” shall mean any individual, firm, corporation or other entity.
(ii) “Voting Stock” shall mean the outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors.
(iii) “5% Shareholder” shall mean any person (other than the Corporation or any Subsidiary) who or which:
(a) is the beneficial owner, directly or indirectly, of more than five percent of the voting power of the outstanding Voting Stock; or
(b) is an Affiliate of the Corporation and at any time within the two-year period immediately prior to the date in question was the beneficial owner, directly or indirectly, of more than five percent of the voting power of the then outstanding Voting Stock; or
(c) is an assignee of or has otherwise succeeded to any shares of Voting Stock which were at any time within the two-year period immediately prior to the date in question beneficially owned by any 5% Shareholder, if such assignment or succession shall have occurred in the course of a transaction or series of transactions not involving a public offering within the meaning of the Securities Act of 1933.
(iv) A person shall be a “beneficial owner” of any Voting Stock:
(a) which such person or any of its Affiliates or Associates (as hereinafter defined) beneficially owns, directly or indirectly; or
(b) which such person or any of its Affiliates or Associates has (1) the right to acquire (whether such right is exercisable immediately or only after the passage of time), pursuant to any agreement, arrangement or understanding or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise, or (2) the right to vote pursuant to any agreement, arrangement or understanding; or
(c) which are beneficially owned, directly or indirectly, by any other person with which such person or any of its Affiliates or Associates has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting or disposing of any shares of Voting Stock.
(v) For the purposes of determining whether a person is a 5% Shareholder pursuant to subparagraph (iii) of this subparagraph 14(A), the number of shares of Voting Stock deemed to be outstanding shall include shares deemed owned through application of subparagraph (iv) of this Subparagraph 14(A), but shall not include any other shares of Voting Stock which may be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options, or otherwise.
(vi) “Affiliate” or “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as in effect on April 25, 1985.
(vii) “Subsidiary” means any corporation of which a majority of any class of equity security is owned, directly or indirectly, by the Corporation; provided, however, that for the purposes of the definitions of a 5% Shareholder set forth in paragraph (iii) of this Paragraph 14 the term “Subsidiary” shall mean only a corporation of which a majority of the voting power of the capital stock entitled to vote generally in the election of directors is owned, directly or indirectly, by the Corporation.
(viii) “Market Price” means the last closing sale price immediately preceding the time in question of a share of the stock in question on the Composite Tape for New York Stock Exchange - Listed Stocks, or, if such stock is not quoted on the Composite Tape, on the New York Stock Exchange, or, if such stock is not listed on such Exchange, on the principal United States securities exchange registered under the Securities Exchange Act of 1934 on which such stock is listed, or, if such stock is not listed on any such exchange, the last closing bid quotation with respect to a share of such stock immediately preceding the time in question on the National Association of Securities Dealers, Inc. Automated Quotations System or any system then in use (or any other system of reporting or ascertaining quotations then available), or if such stock is not so quoted, the fair market value at the time in question of a share of such stock as determined by a majority of the entire Board in good faith.
(ix) “Fair Market Value” means: (a) in the case of stock, the Market Price, and (b) in the case of property other than cash or stock, the fair market value of such property on the date in question as determined by the Board in good faith.
(x) “Business Combination” means any transaction specified in subparagraphs (A) through (E) of Paragraph 13 hereof.
(B)  The Board of Directors of the Corporation shall have the power and duty to determine for the purposes of Paragraphs 12 through 14, on the basis of information known to them after reasonable inquiry, (i) whether a person is a 5% Shareholder, (ii) the number of shares of Voting Stock beneficially owned by any person, (iii) whether a person is an Affiliate or an Associate of another person and (iv) whether a transaction or a series of transactions constitutes a Business Combination. The good faith determination of the Board of Directors shall be conclusive and binding for all purposes of Paragraphs 12 through 14.
(C)  Notwithstanding any other provisions of this Certificate of Incorporation or the By-Laws of the Corporation (and notwithstanding the fact that a lesser percentage may be specified by law, this Certificate of Incorporation or the By-Laws of the Corporation), the affirmative vote of the holders of at least eighty percent of the voting power of the outstanding Voting Stock, voting together as a single class, shall be required to amend or repeal, or adopt any provisions inconsistent with, Paragraphs 12 through 14 hereof.
15.  (A)    A director of the Corporation shall not be liable to the Corporation or its shareholders for damages for breach of duty as a director, except to the extent such exemption from liability is not permitted under the Business Corporation Law as the same exists or may hereafter be amended.
(B)  Any repeal or modification of the foregoing paragraph (A) by the shareholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing hereunder with respect to any act or omission occurring prior to, or at the time of, such repeal or modification.
16.  This Restated Certificate of Incorporation was authorized by the unanimous written consent of the Company’s Board of Directors.
IN WITNESS WHEREOF, we have made and subscribed this certificate this 21st day of September, 2005.

/s/ Robert B. Stiles 
Robert B. Stiles
Senior Vice President, and General Counsel
 
/s/ Jean F. Geisel 
Jean F. Geisel
Secretary


EX-4.J 3 form10k20054ej.htm EXHIBIT (4)-J Exhibit (4)-j


Exhibit (4)-j
 

SUPPLEMENTAL INDENTURE NO. 8

This Supplemental Indenture No. 8 (“Supplemental Indenture”), effective as of November 8, 2006, is between Bausch & Lomb Incorporated (the “Company”) and Citibank, N.A., as trustee (the “Trustee”), and amends the Indenture, dated as of September 1, 1991, between the Company and the Trustee, as amended by Supplemental Indenture, dated as of May 13, 1998, Supplemental Indenture No. 2, dated July 29, 1998, Supplemental Indenture No. 3, dated November 21, 2002, Supplemental Indenture No. 4, dated August 1, 2003, Supplemental Indenture No. 5, dated August 4, 2003, Supplemental Indenture No. 6, dated December 20, 2004, and Supplemental Indenture No. 7, dated as of June 5, 2006 (as so amended, the “Original Indenture”), with respect to the following series of Securities issued under the Original Indenture and various indentures supplemental thereto:
 
6.95% Notes due 2007 (CUSIP No. 071707AH6)
5.90% Notes due 2008 (CUSIP No. 071707AL7)
2004 Senior Convertible Securities due August 1, 2023 (CUSIP No. 071707AM5)
Floating Rate Convertible Senior Notes due August 1, 2023 (CUSIP No. 071707AK9)
6.56% Medium-term Notes, Series B due 2026 (CUSIP No. 07171 AE 6)
7.125% Debentures due 2028 (CUSIP No. 071707AG8)

The foregoing Securities are referred to herein as the “Affected Securities” and no series of Securities are amended or otherwise affected by this Supplemental Indenture other than the Affected Securities. Capitalized terms used in this Supplemental Indenture and not defined are used with the meanings given to such terms in the Original Indenture. This Supplemental Indenture is effective as of the date hereof.

WHEREAS, Section 902 of the Original Indenture provides that the Company and the Trustee may enter into a supplemental indentures for the purposes of adding any provisions to or changing in any manner or eliminating any of the provisions of the Original Indenture or of modifying in any manner the rights of the Holders of Securities of each series with the consents of the Holders of not less than a majority in principal amount of each series affected by such supplemental indenture; and
 
WHEREAS, the Company has received written consents of the Holders of not less than a majority in principal amount of each series of the Affected Securities to the amendments to the Original Indenture set forth in this Supplemental Indenture and related waivers with respect to such series; and
 
WHEREAS, all other things necessary in order to execute and deliver this Supplemental Indenture and effect the amendments set forth herein have been obtained;
 
NOW, THEREFORE, in order to amend the terms of the Original Indenture with respect to all outstanding Securities of each series of the Affected Securities, in consideration of the premises, it is mutually agreed by the Company and the Trustee, for the equal and ratable benefit of all Holders of the Affected Securities, as follows:
 
1. Supplemental Indenture. This Supplemental Indenture supplements and amends the Original Indenture, as modified by the applicable supplemental indenture(s) with respect to each series of Affected Securities, as set forth below:
 
(a) The 2004 Senior Convertible Securities due August 1, 2023, issued pursuant to Supplemental Indenture No. 6, dated as of December 20, 2004 (the “Senior Convertible Securities”);

(b) The Floating Rate Convertible Senior Notes due August 1, 2023, issued pursuant to Supplemental Indenture No. 5, dated as of August 4, 2003 (the “Convertible Senior Notes”);

(c) The 7.125% Debentures due 2028, issued pursuant to Supplemental Indenture No. 2, dated July 29, 1998 (the “2028 Debentures”);

(d) The 6.95% Notes due 2007, issued pursuant to Supplemental Indenture No. 3, dated November 21, 2002 (the “2007 Notes”);

(e) The 5.90% Notes due 2008, issued pursuant to Supplemental Indenture No. 4, dated August 1, 2003 (the “2008 Notes”); and

(f) The 6.56% Medium-Term Notes, Series B due 2026, issued pursuant to the original indenture.

The Senior Convertible Securities and the Convertible Senior Notes are sometimes collectively referred to in the Supplemental Indenture as the “Convertible Securities” and the 2028 Debentures, the 2007 Notes and the 2008 Notes are sometimes collectively referred to herein as the “Notes”.

2. Definitions. Section 101 of the Original Indenture is hereby amended to add the following definitions in appropriate alphabetical order:
 
“Consent Fee” means the payment defined as such with respect to the Affected Securities in the Solicitation Documents.
 
“Covenant Reversion Date” means 5:30 p.m., New York City time, on the earlier of (i) the Business Day following the Company’s failure to pay the Consent Fee, if due, for the Affected Securities in accordance with the Solicitation Documents, and (ii) January 31, 2007.
 
“Solicitation Documents” means the Company’s Consent Solicitation Statement, dated as of September 20, 2006, and the related Consent Form, each as may be amended and supplemented from time to time.
 
2. Defaults.
 
(a) Clause (4) of Section 501 of the Original Indenture is hereby amended to read in its entirety as follows:
 
(4) except as otherwise provided in this Section 501, default in the performance, or breach, of any covenant or warranty of the Company in this Indenture (other than a covenant or warranty a default in whose performance or whose breach is elsewhere in this Section specifically dealt with or which has expressly been included in this Indenture solely for the benefit of series of Securities other than that series), and continuance of such default or breach for a period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 10% in principal amount of the Outstanding Securities of that series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or
 
(b) The following language is hereby added at the end of Section 501:
 
Notwithstanding any of the foregoing, the failure of the Company to comply with Sections 704 and 1004 of this Indenture, or §314 of the Trust Indenture Act, before 5:30 p.m., New York City time on the Covenant Reversion Date shall not constitute an Event of Default under clause (4) above.
 
3. Reports by Company. Section 704 of the Original Indenture is hereby amended to read in its entirety as follows:
 
Section 704: Reports by Company.
 
The Company shall, except as otherwise provided in this Section 704, file with the Trustee and the Commission, and transmit to Holders, such information, documents and other reports, and such summaries thereof, as may be required pursuant to the Trust Indenture Act at the times and in the manner provided pursuant to such Act; provided that any such information, documents or reports required to be filed with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 shall be filed with the Trustee within 15 days after the same is so required to be filed with the Commission. Notwithstanding any other provision of this Section 704 or this Indenture, the documents and reports referred to in this Section 704 that the Company would have been required to file with the Commission or the Trustee on any date on or before the Covenant Reversion Date but for this sentence will not be required to be filed by the Company until the Covenant Reversion Date.
 
4. Statement by Officers as to Default. Section 1004 of the Original Indenture is hereby amended to read in its entirety as follows:
 
Section 1004: Statement by Officers as to Default.
 
The Company will deliver to the Trustee, within 120 days after the end of each fiscal year of the Company ending after the date hereof, an Officers’ Certificate, stating whether or not to the best knowledge of the signers thereof the Company is in default in the performance and observance of any of the terms, provisions and conditions of this Indenture (without regard to any period of grace or requirement of notice provided hereunder) and, if the Company shall be in default, specifying all such defaults and the nature and status thereof of which they may have knowledge. Notwithstanding any other provision of this Section 1004 or this Indenture, the Company will have no obligation to deliver an Officer’s Certificate, as referred to in the preceding sentence, relating to the breach of a covenant contained in Sections 704 or 1004 of this Indenture that occurred prior to the Covenant Reversion Date.
 
5. Waiver of Past Defaults. Pursuant to Section 513 of the Original Indenture, the Holders of a majority in aggregate principal amount of the relevant series of the Affected Securities have waived all defaults with respect to any breaches of Sections 501(4), 704 and 1004 of the Original Indenture and any defaults that shall have occurred with prior to the effective date of this Supplemental Indenture are deemed to have been cured for all purposes.
 
6. Miscellaneous.
 
(a) Recitals by the Company. The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the Original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of the Affected Securities and of this Supplemental Indenture as fully and with like effect as if set forth herein in full.
 
(b) Ratification and Incorporation of Original Indenture. As supplemented hereby, the Original Indenture is in all respects ratified and confirmed, and the Original Indenture and this Supplemental Indenture shall be read, taken and construed as one and the same instrument.
 
(c) Executed in Counterparts. This Supplemental Indenture may be executed in several counterparts, each of which shall be deemed to be an original, and such counterparts shall together constitute but one and the same instrument.
 
(d) Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE CHOICE OF LAW PRINCIPLES THEREOF.
 


IN WITNESS WHEREOF, each party hereto has caused this instrument to be signed in its name and behalf by its duly authorized officers, to be effective as of the day and year first above written.
 
BAUSCH & LOMB INCORPORATED

By: /s/ Efrain Rivera 
Name: Efrain Rivera
Title: Vice President and Treasurer
November [8], 2006

 
Attest:
 
/s/ Jean F. Geisel
Name: Jean F. Geisel
Title: Secretary
 

CITIBANK, N.A.,
as Trustee

By: /s/ John J. Byrnes, Jr. 
Name: John J. Byrnes, Jr.
Title: Vice President
November [8], 2006

Attest:
 
/s/ Wafaa Orfy
Name: Wafaa Orfy
Title: Vice President
 

 
EX-4.K 4 form10k2005e4k.htm EXHIBIT (4)-K Exhibit (4)-k


Exhibit (4)-k

AMENDED AND RESTATED
SUPPLEMENTAL INDENTURE NO. 8
 
This Amended and Restated Supplemental Indenture No. 8 (“Supplemental Indenture”), effective as of November 8, 2006, is between Bausch & Lomb Incorporated (the “Company”) and Citibank, N.A., as trustee (the “Trustee”), and amends and restates Supplemental Indenture No. 8, dated as of November 8, 2006 between the Company and the Trustee and the Indenture, dated as of September 1, 1991, between the Company and the Trustee, as amended by Supplemental Indenture, dated as of May 13, 1998, Supplemental Indenture No. 2, dated July 29, 1998, Supplemental Indenture No. 3, dated November 21, 2002, Supplemental Indenture No. 4, dated August 1, 2003, Supplemental Indenture No. 5, dated August 4, 2003, Supplemental Indenture No. 6, dated December 20, 2004, and Supplemental Indenture No. 7, dated as of June 5, 2006 (as so amended, the “Original Indenture”), with respect to the following series of Securities issued under the Original Indenture and various indentures supplemental thereto:
 
6.95% Notes due 2007 (CUSIP No. 071707AH6)
5.90% Notes due 2008 (CUSIP No. 071707AL7)
2004 Senior Convertible Securities due August 1, 2023 (CUSIP No. 071707AM5)
Floating Rate Convertible Senior Notes due August 1, 2023 (CUSIP No. 071707AK9)
6.56% Medium-term Notes, Series B due 2026 (CUSIP No. 07171JAE6)
7.125% Debentures due 2028 (CUSIP No. 071707AG8)

The foregoing Securities are referred to herein as the “Affected Securities” and no series of Securities are amended or otherwise affected by this Supplemental Indenture other than the Affected Securities. Capitalized terms used in this Supplemental Indenture and not defined are used with the meanings given to such terms in the Original Indenture. This Supplemental Indenture is effective as of the date hereof.

WHEREAS, Section 902 of the Original Indenture provides that the Company and the Trustee may enter into a supplemental indentures for the purposes of adding any provisions to or changing in any manner or eliminating any of the provisions of the Original Indenture or of modifying in any manner the rights of the Holders of Securities of each series with the consents of the Holders of not less than a majority in principal amount of each series affected by such supplemental indenture; and
 
WHEREAS, the Company has received written consents of the Holders of not less than a majority in principal amount of each series of the Affected Securities to the amendments to the Original Indenture set forth in this Supplemental Indenture and related waivers with respect to such series;
 
WHEREAS, original Supplemental Indenture No. 8 inadvertently omitted a clause from the amendments to Section 704 which was approved by the Holders of not less than a majority in principal amount of each series of Affected Securities; and
 
WHEREAS, all other things necessary in order to execute and deliver this Amended and Restated Supplemental Indenture and effect the amendments set forth herein have been obtained;
 
NOW, THEREFORE, in order to amend the terms of the Original Indenture with respect to all outstanding Securities of each series of the Affected Securities, in consideration of the premises, it is mutually agreed by the Company and the Trustee, for the equal and ratable benefit of all Holders of the Affected Securities, as follows:
 
1. Supplemental Indenture. This Supplemental Indenture supplements and amends the Original Indenture, as modified by the applicable supplemental indenture(s) with respect to each series of Affected Securities, as set forth below:
 
(a) The 2004 Senior Convertible Securities due August 1, 2023, issued pursuant to Supplemental Indenture No. 6, dated as of December 20, 2004 (the “Senior Convertible Securities”);

(b) The Floating Rate Convertible Senior Notes due August 1, 2023, issued pursuant to Supplemental Indenture No. 5, dated as of August 4, 2003 (the “Convertible Senior Notes”);

(c) The 7.125% Debentures due 2028, issued pursuant to Supplemental Indenture No. 2, dated July 29, 1998 (the “2028 Debentures”);

(d) The 6.95% Notes due 2007, issued pursuant to Supplemental Indenture No. 3, dated November 21, 2002 (the “2007 Notes”);

(e) The 5.90% Notes due 2008, issued pursuant to Supplemental Indenture No. 4, dated August 1, 2003 (the “2008 Notes”); and

(f) The 6.56% Medium-Term Notes, Series B due 2026, issued pursuant to the original indenture.

The Senior Convertible Securities and the Convertible Senior Notes are sometimes collectively referred to in the Supplemental Indenture as the “Convertible Securities” and the 2028 Debentures, the 2007 Notes and the 2008 Notes are sometimes collectively referred to herein as the “Notes”.

2. Definitions. Section 101 of the Original Indenture is hereby amended to add the following definitions in appropriate alphabetical order:
 
“Consent Fee” means the payment defined as such with respect to the Affected Securities in the Solicitation Documents.
 
“Covenant Reversion Date” means 5:30 p.m., New York City time, on the earlier of (i) the Business Day following the Company’s failure to pay the Consent Fee, if due, for the Affected Securities in accordance with the Solicitation Documents, and (ii) January 31, 2007.
 
“Solicitation Documents” means the Company’s Consent Solicitation Statement, dated as of September 20, 2006, and the related Consent Form, each as may be amended and supplemented from time to time.
 
2. Defaults.
 
(a) Clause (4) of Section 501 of the Original Indenture is hereby amended to read in its entirety as follows:
 
(4) except as otherwise provided in this Section 501, default in the performance, or breach, of any covenant or warranty of the Company in this Indenture (other than a covenant or warranty a default in whose performance or whose breach is elsewhere in this Section specifically dealt with or which has expressly been included in this Indenture solely for the benefit of series of Securities other than that series), and continuance of such default or breach for a period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 10% in principal amount of the Outstanding Securities of that series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or
 
(b) The following language is hereby added at the end of Section 501:
 
Notwithstanding any of the foregoing, the failure of the Company to comply with Sections 704 and 1004 of this Indenture, or §314 of the Trust Indenture Act, before 5:30 p.m., New York City time on the Covenant Reversion Date shall not constitute an Event of Default under clause (4) above.
 
3. Reports by Company. Section 704 of the Original Indenture is hereby amended to read in its entirety as follows:
 
Section 704: Reports by Company.
 
The Company shall, except as otherwise provided in this Section 704, file with the Trustee and the Commission, and transmit to Holders, such information, documents and other reports, and such summaries thereof, as may be required pursuant to the Trust Indenture Act at the times and in the manner provided pursuant to such Act; provided that any such information, documents or reports required to be filed with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 shall be filed with the Trustee within 15 days after the same is so required to be filed with the Commission. Notwithstanding any other provision of this Section 704 or this Indenture, the documents and reports referred to in this Section 704 that the Company would have been required to file with the Commission or the Trustee on any date on or before the Covenant Reversion Date but for this sentence will not be required to be filed the Company until the Covenant Reversion Date and the filing by the Company of its Annual Report on Form 10-K for December 31, 2005 shall satisfy the requirement to file reports for any periods prior to December 31, 2005.
 
4. Statement by Officers as to Default. Section 1004 of the Original Indenture is hereby amended to read in its entirety as follows:
 
Section 1004: Statement by Officers as to Default.
 
The Company will deliver to the Trustee, within 120 days after the end of each fiscal year of the Company ending after the date hereof, an Officers’ Certificate, stating whether or not to the best knowledge of the signers thereof the Company is in default in the performance and observance of any of the terms, provisions and conditions of this Indenture (without regard to any period of grace or requirement of notice provided hereunder) and, if the Company shall be in default, specifying all such defaults and the nature and status thereof of which they may have knowledge. Notwithstanding any other provision of this Section 1004 or this Indenture, the Company will have no obligation to deliver an Officer’s Certificate, as referred to in the preceding sentence, relating to the breach of a covenant contained in Sections 704 or 1004 of this Indenture that occurred prior to the Covenant Reversion Date.
 
5. Waiver of Past Defaults. Pursuant to Section 513 of the Original Indenture, the Holders of a majority in aggregate principal amount of the relevant series of the Affected Securities have waived all defaults with respect to any breaches of Sections 501(4), 704 and 1004 of the Original Indenture and any defaults that shall have occurred with prior to the effective date of this Supplemental Indenture are deemed to have been cured for all purposes.
 
6. Miscellaneous.
 
(a) Recitals by the Company. The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the Original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of the Affected Securities and of this Supplemental Indenture as fully and with like effect as if set forth herein in full.
 
(b) Ratification and Incorporation of Original Indenture. As supplemented hereby, the Original Indenture is in all respects ratified and confirmed, and the Original Indenture and this Supplemental Indenture shall be read, taken and construed as one and the same instrument.
 
(c) Executed in Counterparts. This Supplemental Indenture may be executed in several counterparts, each of which shall be deemed to be an original, and such counterparts shall together constitute but one and the same instrument.
 
(d) Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE CHOICE OF LAW PRINCIPLES THEREOF.
 

 
 

 

IN WITNESS WHEREOF, each party hereto has caused this instrument to be signed in its name and behalf by its duly authorized officers, to be effective as of the day and year first above written.
 
BAUSCH & LOMB INCORPORATED

By: /s/Efrain Rivera
Name: Efrain Rivera
Title: Vice President and Treasurer
January 23, 2007

 
Attest:
 
/s/ Jean F. Geisel
Name: Jean F. Geisel
Title: Secretary
 
 
CITIBANK, N.A.,
as Trustee

By: /s/ John J. Byrnes, Jr.
Name: John J. Byrnes, Jr.
Title: Vice President
January 24, 2007
 
Attest:
 
/s/ Wafaa Orfy 
Name: Wafaa Orfy
Title: Vice President
 

 
EX-10.Q 5 form10k2005e10q.htm EXHIBIT (10)-Q Exhibit (10)-q


Exhibit (10)-q
Amended and Restated as of
February 25, 2003
Amended January 27, 2004
Amended July 19, 2004
Amended January 25, 2005
Amended July 25, 2006

Bausch & Lomb Incorporated
ANNUAL INCENTIVE COMPENSATION PLAN

I.     Introduction.

The Bausch & Lomb Incorporated Annual Incentive Compensation Plan (the “Plan”) is established to create effective incentives for managers of Bausch & Lomb Incorporated (the “Company”) to set and achieve objectives that are designed to enhance business performance and increase shareholder value. The Plan is also designed to provide competitive levels of compensation to enable the Company to attract and retain managers who are able to exert a significant impact on the value of the Company for its shareholders.

II.
Plan Participants.

 
Employees of the Company who are in the mid management band and above and are selected to participate in the Plan are eligible to participate in the Plan (“Participants”).

III.
Definitions. Capitalized terms not otherwise defined when used in this Plan shall have the following meanings.

 
A.  
Approved Incentive Award” or “Bonus”. An Approved Incentive Award or Bonus is the incentive which has been approved in accordance with this Plan to be paid by the Company to the Participant.

 
B.  
Bonus Pool”. shall have the meaning set forth in Section VI.A.1.

C.  
Committee”. means Compensation Committee of the Company’s Board of Directors.

D.  
Performance Management Process (PMP) objectives”. PMP objectives are team or individual performance measures which are established in accordance with guidelines issued by the Corporate Senior Vice President - Human Resources, and approved by the immediate manager of the individual or team to whom the measure applies and that person’s immediate manager, as further defined in Section IV B hereof.

E.  
Operating Unit Objective”. An Operating Unit Objective is a performance target for one or more of the Company’s geographic regional businesses (e.g. Americas; Asia; Europe, Middle East and Africa) or functional centers (Research Development & Engineering; Global Supply Chain or Global Category Groups), which is established early in a Plan Year with approval from the relevant Operating Unit head, the Corporate Senior Vice President-Human Resources, the Senior Vice President and Chief Financial Officer and the Chief Executive Officer, as further defined in Article IV B hereof.

F.  
Plan Year” means each one year period coincident with a fiscal year of the Company.

G.  
Standard Incentive Funding”. is the Bonus Pool funding at Standard Incentive percentage for all Participants in a particular group or Operating Unit. A standard incentive percentage has been established by job band and is applied to eligible base salary earnings to determine the appropriate funding.

H.  
stretch goal”. Defined in Article V.

I.  
target goal”. Defined in Article V.

J.  
threshold goal”. Defined in Article V.

K.  
Total Company Objective”. A Total Company Objective is a performance target set for the Company as a whole, which is established early in a Plan Year with approval by the Committee, as further defined in Article IV B hereof.

IV.
Performance Measurement.

 
A. 
Each Plan Year, the Company and each Operating Unit and eligible Participant will set objectives in accordance with this Plan. These will be applied for Incentive Plan purposes either to fund a Bonus Pool (as to Total Company and Operating Unit Objectives) or to allocate a Bonus Pool among Participants.

 
B. 
Total Company, Operating Unit and PMP Objectives will be set early in the Plan Year in which performance is to occur. Total Company performance will be evaluated based on Total Company Objectives which are set with approval from the Committee. Operating Unit Objectives for commercial business units shall be based on objective identifiable measures of business performance, including, for example, sales and operating earnings, return on assets/equity and cash flow. Operating Unit Objectives for units other than commercial business units (e.g., RD&E, Global Supply Chain) shall be based on deliverables required to meet annual plan and longer term objectives, including, for example, cost containment, cost improvement, product launch, product quality and cash flow goals. Global Category Group objectives shall be based on financial measures such as category sales, category distribution margin and/or strategic imperatives such as market share goals. All Operating Unit Objectives shall be approved by the relevant Operating Unit head as well as the Senior Vice President- Human Resources, Senior Vice President and Chief Financial Officer, and the Chief Executive Officer.

   
Company and Operating Unit Objectives will be assigned a weighting for Bonus Pool funding purposes, assuming Company performance at threshold levels as set forth in Section VI.A.1 below . (Bonus Pool funding is described further under Section VI of this Plan). The weighting of Company and Operating Unit Objectives will be approved by the Committee at the time Company Objectives are approved. 2003 Annual Incentive Plan weightings for Bonus Pool Funding are set forth in Appendix B hereto.

   
PMP objectives will be team or individual measures which will, where possible, impact the Operating Unit Objectives and ultimately the Total Company Objectives. PMP objectives shall be set in accordance with guidelines issued by the Senior Vice President-Human Resources, and shall be approved by the immediate manager of the individual or team to whom the measure applies, and that person’s immediate manager (i.e., a “one-over-one” approval).

V.  
Threshold, Target and Stretch Goals

Total Company and Operating Unit Objectives will be set with a “target” goal, a “stretch” goal and a “threshold” goal. Achievement of the “target” goal should reflect performance which is in line with expected performance, and which supports expected Company performance. “Stretch” goals should assume performance well in excess of that required to achieve the target goal, while “threshold” goals should define a minimum level of performance warranting funding of a Bonus Pool. “Stretch” and “threshold” goals must be approved with respect to each Objective at the same time and in the same manner that the respective Objective is approved.

VI.
Bonus Calculation. 

 
A.  
The amount of an individual Participant’s Approved Incentive Award (or Bonus) in any Plan Year is determined as follows:

1.  
A Bonus Pool for Corporate Officers, Corporate Staff and for each Operating Unit will be calculated and funded based on a factor taking into account (a) Standard Incentive Funding within the Operating Unit or Staff and (b) performance against Company Objectives and, where applicable, Operating Unit Objectives. Where an Operating Unit has multiple Operating Unit Objectives, performance will be assessed in accordance with guidelines established by the Corporate Senior Vice President - Human Resources. In order for the Operating Unit portion of a Bonus Pool to be funded, the Company must achieve at least the threshold level of performance.

2.  
The Bonus Pool which is so determined shall then be allocated among the individual participants within a group (Corporate Officers or Corporate Staff) or Operating Unit based upon achievement by the members of that group or Operating Unit against PMP objectives. The total of Annual Incentive Awards with respect to a group or Operating Unit shall not exceed the Bonus Pool for such group or Operating Unit but may be less than the Bonus Pool

 
3.  
The Approved Incentive Award is based on the extent to which the relevant Bonus Pool is funded and on an assessment of performance against PMP objectives. Assessment of performance against PMP objectives shall be in accordance with guidelines issued by the Senior Vice President, Human Resources, and shall be subject to discretionary upward or downward modification in accordance with such guidelines.

 
4.  
Where performance against Company or Operating Unit Objectives meets or exceeds the “stretch goal” established with respect to that Objective, the calculation of the funded Bonus Pool which is attributable to that Objective shall be 200% of the Standard Incentive Funding. Conversely, where performance against a Company or Operating Unit Objective meets the “threshold goal” established with respect to that Objective, the calculation of the funded Bonus Pool will start at 0% of the Standard Incentive Funding.

 
5.  
Where actual performance on a particular Objective falls between “threshold”, “target” and “stretch” goals, the Bonus Pool Funding which is attributable to that Objective shall be calculated on a pro-rata basis with respect to the payouts set for achievement of goals (50%, 100%, and 200%) depending on where performance lies between such goals.

 
B.  
Bonus Pool Funding may be modified as a result of the following:

 
1.  
Performance against Company or Operating Unit Objectives may be modified by the Committee based on the Committee’s overall assessment of the manner in which such performance was achieved or, with respect to Operating Unit performance, relative contribution to Total Company Performance.

2.  
In addition, Bonus Pool Funding for a group or Operating Unit may be modified by the Chief Executive Officer, in his sole discretion, to reflect a group’s or Operating Unit’s relative contribution to Total Company performance, provided that such modification shall not have the effect of increasing the total Funded Bonus Pool for the Company as a whole beyond the level approved by the Committee.

3.  
Any modification to the Chief Executive Officer’s Approved Incentive Award shall be approved by the Committee.

 
C.  
An individual Participant’s Approved Incentive Award shall be determined based upon relevant performance against PMP objectives, which will allow for allocation to the Participant of a portion of the funded Bonus Pool of such Participant’s group or Operating Unit. Assessment of performance against PMP objectives shall be in accordance with guidelines issued by the Senior Vice President, Human Resources. Approved Incentive Awards may vary upward or downward against the targeted level based on evaluation of a participant’s performance against PMP objectives. The total of all Bonuses within each group or Operating Unit cannot exceed 100% of the funded Bonus Pool as to such group or Operating Unit.

VII.
Change in Status During Plan Year

 
A.  
New Hires and Promotions

   
For Plan Years 2006 and Prior:

 
1.  
A newly hired or recently promoted employee of the Company who is a Participant in the Plan for at least six months of his/her first Plan Year will be eligible for a Bonus which is based on salary paid during the partial Plan Year after the effective date of hire or promotion, as the case may be.

 
2.  
A newly hired or recently promoted employee of the Company who is a Participant for less than six months in his/her initial Plan Year will be eligible for a Bonus for a portion of that Plan Year after the effective date of hire or promotion, as the case may be, only if the terms of such partial Plan Year bonus are agreed to in writing between the Participant and the Company at the time of hire. These arrangements must be approved in writing in advance by Corporate Senior Vice President Human Resources and normal one-over-one approval matrix.

   
For Plan Years 2007 and Forward:
   
1.  
A newly hired or recently promoted employee of the Company who is a Participant in the Plan will be eligible for a pro-rata Bonus which is based on eligible wages and applicable target percentage during the partial Plan Year after the effective date of hire or promotion, as the case may be.

 
B.  
Transfers.

 
1.  
Where a Participant transfers from one Operating Unit or group to another during a Plan Year, the Bonus for the Plan Year in which the transfer occurs will be based on Bonus Pool Funding as to the particular Operating Unit or group in which the Participant worked for the majority of the Plan Year, or as otherwise approved by the Corporate Senior Vice President Human Resources.

        C.  Terminations.

 
1.  
A Participant who terminates voluntarily (other than retirement) from the Company either (i) during a Plan Year or (ii) after the Plan Year ends but before the date on which the Approved Incentive Award or Bonus with respect to such Plan Year is actually paid by the Company to the Participant will not be eligible for any bonus for that Plan Year, or the Plan Year in which the termination occurs.

 
2.  
In cases of retirement or involuntary termination due to death, disability, reduction in work force, or the sale or closing of a plant or business unit before completion by the Participant of at least six months service as an eligible Participant during the Plan Year, such Participant will not be eligible for any Bonus for that Plan Year. In cases of retirement or involuntary termination due to death, disability, reduction in work force, or the sale or closing of a plant or business unit after completion by the Participant of at least six months service as an eligible Participant during the Plan Year, a pro rata Bonus will be calculated and paid in accordance with the Plan.

 
3.  
A Participant who is terminated involuntarily for any other reason either (i) during a Plan Year or (ii) after the Plan Year ends but before the date on which the Approved Incentive Award or Bonus with respect to such Plan Year is actually paid by the Company to the Participant will not be eligible for any Bonus for that Plan Year, or the Plan Year in which the termination occurs.

 
D.  
Leave of Absence.

   
An employee whose status as an active employee is changed during a Plan Year as a result of a leave of absence may, at the discretion of the Committee, be eligible for a pro rata Bonus determined in the same way as in Subsection VII A.

 
E.  
Demotions.
   
For Plan Years 2006 and Prior:
 
1.  
An employee who is transferred into a non-eligible group of employees after having served six months during the Plan Year shall be paid a pro-rata Bonus determined in the same manner as in Subsection VII A.

 
2.  
An employee who is transferred into a non-eligible group of employees prior to having served six months during the Plan Year in an eligible group of employees shall not be entitled to a Bonus.

 
3.  
Where an employee is transferred into a lower band position within a Plan Year, such employee’s Standard Incentive Award percentage shall be based on the band or position in which the employee spent the majority of the Plan Year.

   
For Plan Years 2007 and Forward:
 
1.  
An employee who is transferred into a lower band or a non-eligible group of employees during the Plan Year shall be paid a pro-rata Bonus determined in the same manner as in Subsection VII A.

VIII.     Change of Control.

   
Notwithstanding any other provision of this Plan, a special incentive bonus shall be paid to Participants if there is a change in control of the Company during the Plan Year.

1.  
The amount of the special incentive bonus shall equal the greater of (a) the Bonus based upon “target” performance without regard to any other calculations under the Plan, prorated where applicable, through the date of termination of the Participant’s employment where it is terminated involuntarily other than for good cause, or (b) the Bonus which would be payable to the Participant based on results for the full Plan Year, prorated where applicable, through the date of termination of the Participant’s employment where it is terminated involuntarily other than for good cause, as applicable.

A change of control of the Company is defined as follows:

(a) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (i) the then outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company (excluding an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company), (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a reorganization, merger or consolidation, if, following such reorganization, merger or consolidation, the conditions described in clauses (i), (ii) and (iii) of subsection (c) of this Section are satisfied; or

(b) Individuals who, as of February 25, 2003, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to February 25, 2003 whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

(c) Approval by the shareholders of the Company of a reorganization, merger, binding share exchange or consolidation, in each case, unless, following such reorganization, merger, binding share exchange or consolidation, (i) more than 60% of, respectively, the then outstanding shares of common stock of the corporation resulting from such reorganization, merger, binding share exchange or consolidation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such reorganization, merger, binding share exchange or consolidation in substantially the same proportions as their ownership, immediately prior to such reorganization, merger, binding share exchange or consolidation, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding the Company, any employee benefit plan (or related trust) of the Company or such corporation resulting from such reorganization, merger, binding share exchange or consolidation and any Person beneficially owning, immediately prior to such reorganization, merger, binding share exchange or consolidation, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such reorganization, merger, binding share exchange or consolidation or the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (iii) at least a majority of the members of the board of directors of the corporation resulting from such reorganization, merger, binding share exchange or consolidation were members of the Incumbent Board at the time of the execution of the initial agreement providing for such reorganization, merger, binding share exchange or consolidation; or

(d) Approval by the shareholders of the Company of (i) a complete liquidation or dissolution of the Company or (ii) the sale or other disposition of all or substantially all of the assets of the Company, other than to a corporation, with respect to which following such sale or other disposition, (A) more than 60% of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Company and any employee benefit plan (or related trust) of the Company or such corporation and any Person beneficially owning, immediately prior to such sale or other disposition, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (C) at least a majority of the members of the board of directors of such corporation were members of the Incumbent Board at the time of the execution of the initial agreement or action of the Board providing for such sale or other disposition of assets of the Company.

IX.
Miscellaneous.

 
A.  
Amendments. The Committee shall have the right to modify or amend this Plan from time to time, or suspend it or terminate it entirely; provided that no such modification, amendment, suspension, or termination may, without the consent of any affected Participants (or beneficiaries of such Participants in the event of death), reduce the rights of any such Participants (or beneficiaries, as applicable) to a payment or distribution already payable under Plan terms in effect prior to such change.

 
B.  
Role of the Committee. (i) Interpretation of the Plan. Any decision of the Committee with respect to any issue concerning individuals selected as Participants, the amount, terms, form and time of payment of bonuses, and interpretation of any Plan guideline, definition, term or requirement shall be final and binding.

(ii) Administration. The Committee has designated the Corporate Senior Vice President Human Resources to control and manage the operation and administration of the Plan. The Corporate Senior Vice President Human Resources shall administer the Plan in accordance with its terms and shall have all powers necessary to carry out the provisions of the Plan, except such powers as are specifically reserved to the Committee or some other person. These powers include the power to make and publish such rules and regulations as he or she may deem necessary to carry out the provisions of the Plan.

(iii) Adjustment to Objectives. If any event occurs during a performance period which requires changes to preserve the incentive features of this Plan, the Committee may make appropriate upward or downward adjustments in the specified performance levels.

 
C.  
Right to Continued Employment; Additional Awards. Participation in the Plan or the receipt of a bonus under the Plan shall not give the recipient any right to continued employment (such employment shall be “at will”), and the right and power to dismiss any employee is specifically reserved to the Company. In addition, the receipt of a bonus with respect to any Plan Year shall not entitle the recipient to any bonus with respect to any subsequent Plan Year, except as expressly provided in the Plan.

 
D.  
Withholding Taxes. The Company shall have the right to deduct from all payments under this Plan any Federal or state taxes required by law to be withheld with respect to such payments.

 
E.  
Deferred Compensation. Participants may elect to defer all or part of a Bonus in accordance with the procedures set forth in the Company’s Executive Deferred Compensation Plan.

 
F.  
Interaction with Management Incentive Compensation Plan. Amounts payable under this Plan shall be offset against amounts actually paid to a Participant under the Bausch & Lomb Incorporated Management Incentive Compensation Plan, dated as of January 1, 1998.

 
G.  
Governing Law. This Plan shall be construed in accordance with and governed by the laws of the State of New York.


BAUSCH & LOMB INCORPORATED


By: ___/s/ David Nachbar___________
David Nachbar
Corporate Senior Vice President
Human Resources
 
Dated: July 25, 2006



 
 

 

APPENDIX LIST



Appendix A - STANDARD INCENTIVE PERCENTAGE TABLE





Appendix B - INCENTIVE WEIGHTINGS

 
 

 

APPENDIX A
Amended and Restated as of February 25, 2003
Amended January 27, 2004
Amended July 19, 2004
Amended January 25, 2005
Amended July 25, 2006


STANDARD INCENTIVE PERCENTAGE



BAND/GRADE
STANDARD INCENTIVE PERCENTAGE (AS A % OF BASE SALARY)
 
 
 
NON-OFFICERS:
 
Manager/Technical
15%
   
Director/Country Manager
30%
   
Vice President/General Manager
35%
   
 
 
OFFICERS*:
 
   
   
*Standard incentive levels will range from 50% to 100% of base salary, depending on position, as approved at the beginning of each Plan Year by the Compensation Committee of the Board of Directors.



 
 

 


Amended and Restated as of February 25, 2003
Amended January 27, 2004
Amended July 19, 2004
Amended January 25, 2005
Amended July 25, 2006

Appendix B

Bonus Pool Funding


 
 
Total Company
 
Operating Unit
Corporate Officers(1)
 
100%
 
--
 
Corporate Staff
 
100%
 
--
 
Global Operations and Engineering:
 
75%
25%
Global Research and Development
 
75%
25%
Regional/Commercial:
 
75%
25%
Global Category Groups
75%
25%
 
Other Operating Units as approved by the CEO
75%
25%
 

(1) Includes officers with no operating unit responsibilities.

EX-10.V 6 form10k2005e10v.htm EXHIBIT (10)-V Exhibit (10)-v

 
Exhibit (10)-v
 
Effective January 1, 2006
 
 
BAUSCH & LOMB INCORPORATED
 
LONG TERM EQUITY EQUIVALENT ACCUMULATION PLAN
 
ARTICLE ONE  
 
Definitions
 
1.1  
“Board” means the Board of Directors of Bausch & Lomb Incorporated.
 
1.2  
“Change of Control” means a Change of Control as defined in Section 7.3 of this Plan.
 
1.3  
“Code” means the Internal Revenue Code of 1986, as amended.
 
1.4  
“Committee” or “Compensation Committee” means the Compensation Committee of the Board.
 
1.5  
“Company” means Bausch & Lomb Incorporated.
 
1.6  
“Company Stock Unit” means a hypothetical unit having a value at any time equal to the closing price of a share of Company Common Stock at such time. The closing price shall be unless otherwise determined by the Committee, the closing price during normal business hours for the Shares as reported on the New York Stock Exchange (or on any national securities exchange on which the Shares are then listed) for a date or, if no such price is reported for that date, the closing price on the preceding date for which such prices were reported, all as reported by such source as the Committee may select.
 
1.7  
“Compensation” means, for any calendar year, the gross remuneration (including any amount salary reduced under Code sections 125, 132(f), or 401(k)) paid to a Participant by the Company for personal services actually rendered including salary, wages, overtime, annual incentive bonuses, and base severance benefits but not including long-term incentive awards, suggestion awards, tuition refunds, relocation expenses, enhanced severance benefits or other extra remuneration of whatever nature, contributions made under any other employee benefit or deferred compensation plan, or any amount in excess of the amount permitted under Section 401(a)(17) of the Code.
 
1.8  
“Effective Date” means January 1, 2006.
 
1.9  
“Officer” means any corporate officer of the Company elected by the Board.
 
1.10  
“Participant” means an eligible Officer.
 
1.11  
“Participant Account” or “Account” means the hypothetical account maintained to record contributions awarded to a Participant plus adjustments thereto to reflect earnings (and losses) and withdrawals.
 
1.12  
“Plan” means this Bausch & Lomb Incorporated Long Term Equity Equivalent Accumulation Plan.
 
1.13  
“Trust” means any rabbi trust established by the Company for the purposes of providing funds for the Company to meet its obligations to pay benefits under this Plan. The rabbi trust established under the Executive Deferred Compensation Plan may be used as the Trust vehicle for both this Plan and the Executive Deferred Compensation Plan.
 
1.14  
“Year” or “Plan Year” means the calendar year.
 
ARTICLE TWO
 
Purpose of Plan
 
2.1  
The purpose of this Plan is to provide a means to attract and retain key officers and, through the award of Company Stock Units, to further align the interests of Officers with the interests of the Company’s shareholders.
 
ARTICLE THREE
 
Eligibility
 
3.1  
Any Officer designated in the sole discretion of the Compensation Committee, shall be eligible to participate in this Plan, provided that no Officer shall be eligible unless he or she is within a “select group of management or highly compensated employees” as this term is defined in Title I of ERISA.
 
ARTICLE FOUR
 
Awards/Contributions
 
4.1  
Type and Amount of Awards. Each Plan Year the Company shall, at each Participant’s election, allocate to his or her Account either a dollar amount equal to five percent of the Participant’s Compensation for the Year or Company Stock Units with a notional value of 15 percent of the Participant’s Compensation for the Plan Year. Company contributions shall be allocated to a Participant’s Account as soon as administratively practicable following the end of each calendar quarter, based on the Participant’s Compensation during such period, or more frequently as determined by the Company in its administration of the Plan.
 
4.2  
Vesting. Cash awards shall be immediately and fully vested at all times. Company Stock Unit awards shall vest at the earliest of the following:
 
§  
Five years from the first day of the calendar year to which the award relates;
 
§  
The Participant’s termination of employment on account of disability as defined under the Company’s long-term disability plan or, in the absence of such a plan, the Participant’s entitlement to Social Security disability benefits;
 
§  
The Participant’s death;
 
§  
In the event of the Participant’s retirement from the Company at or after age 55, unvested Company Stock Unit Awards shall vest partially and in 20% increments depending on how many years out of five have passed since the first day of the calendar year to which the award relates (such that, for example, a Participant who retires with a Company Stock Unit Award that was granted more than three but less than four years before retirement will be vested in 60% of that particular Company Stock Unit Award); or
 
§  
The Compensation Committee shall have the ability to accelerate vesting under any other circumstances in its sole discretion.
 
Until vesting occurs under one of the foregoing events, all Company Stock Units are forfeitable and, if the Participant terminates employment during the period of forfeitability, all unvested Company Stock Units shall be irrevocably forfeited.
 
4.3  
Officer Contributions. Participant contributions to this Plan are neither required nor permitted.
 
ARTICLE FIVE
 
Deferral of Awards
 
5.1  
Participant Elections. Each Participant shall have the right to make the following elections with respect to Company Stock Unit (but not cash) contributions made on his or her behalf
 
·  
Whether to receive payment, adjusted for earnings and losses, if any, as soon as administratively practicable after it vests or to defer payment pursuant to Section 5.2 to a fixed date or to the Participant’s date of retirement;
 
·  
The method of deferred payment desired (i.e., equal annual installments or lump sum) and, if annual installments, the number of years of installment payments; and
 
·  
The designation of a beneficiary to receive any benefit payable on account of the Participant’s death.
 
5.2  
Deferral Elections to follow Deferred Compensation Plan. For all Participants who are initially eligible to participate on the Effective Date of this Plan, the elections under Section 5.1 must be made to the Company in writing no later than December 31, 2005, and shall be effective only with respect to Compensation earned after the election is made. Except as specified in the prior sentence with respect to the timing requirements for the initial election following the Effective Date, all deferrals of awards under this Plan shall be made in accordance with the terms of Sections 5 and 6 of the Company’s Executive Deferred Compensation Plan whose terms are incorporated by this reference.
 
ARTICLE SIX
 
Investment of Participant Accounts
 
6.1  
Earnings on Accounts. Company Stock Unit awards shall have earnings determined independently as follows. The rate of return on deferred Company Stock Unit awards shall match the rate of return on the Company’s Common Stock. Each Company Stock Unit shall have an initial value equal to the closing price of a share of Company Common Stock on the date, no less than once per quarter, as determined by the Company in its administration of the Plan, that allocated contributions are converted to Company Stock Units. Its value on any date thereafter shall equal the value of the Company Common Stock on such later date. If any dividends are issued on Company Common Stock while Company Stock Units are held in the Plan, each unit shall be deemed to generate on the date dividends on Company Common Stock are paid, dividend equivalents equal to the dividends on the Common Stock and the amount of such dividend equivalents shall be converted to additional Company Stock Units based on the closing price of Company Common Stock on such conversion date. No amounts credited to deferred Company Stock Unit accounts may be transferred from these accounts to other investment accounts under the Plan.
 
6.2  
Account Recordkeeping. All Company Stock Unit accounts under the Plan are hypothetical. The value of a Participant’s Company Stock Unit Accounts will fluctuate in accordance with the actual performance of Company Stock. That is, earnings and losses on Company Stock Unit accounts shall track changes in the fair market value of Company Common Stock as determined by the Compensation Committee or its designee. Dividends on the imputed shares also will be credited to the Participant’s Company Stock Unit accounts.
 
ARTICLE SEVEN
 
Payment of Benefits
 
7.1  
Normal Payment Date. On the payment date elected by the Participant in the deferral election (but in no event later than the date the Participant terminates employment other than for retirement after age 55, or death), the vested amount credited to the Participant’s Account as of the Plan’s valuation date immediately preceding the distribution date shall be payable to the Participant or, in the event of death, to his or her beneficiary. The form of payment shall be a single lump sum payment or equal annual installment payments. Regardless of the form of benefit, all payments shall be made in cash. No benefits shall be payable in Company stock or other property. The value of a Participant’s Account shall be based on the hypothetical value of the accumulated contributions and earnings credited to the Account under ARTICLE SIX regardless of the value of any actual investments, if any, invested by the trustee of the Rabbi Trust.
 
7.2  
Hardship Distribution. In the case of an unforeseeable emergency, the Committee shall distribute all or a portion of the vested portion of an Account before the fixed date specified in the Participant’s deferral election, but the amount of the distribution shall not exceed the amount needed to relieve the unforeseeable emergency. For this purpose, the Committee shall determine the existence of an unforeseeable emergency under such rules as it may establish provided that in no event shall a distribution be made that fails to satisfy the definition of an unforeseeable emergency as set forth in Code Section 409A. Currently, Section 409A defines the term “unforeseeable emergency” as a severe financial hardship to the Participant resulting from an illness or accident of the Participant, the Participant’s spouse, or a dependent (as defined in Code Section 152(a)) of the Participant, loss of the Participant’s property due to casualty, or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant.
 
7.3  
Change of Control Distribution. Upon a Change of Control (as defined below), notwithstanding a Participant’s payment date with respect to any compensation deferred hereunder, all amounts in a Participant’s Account (including earnings credited thereto) shall be due and payable to the Participant in a lump sum cash payment within 15 days following the Change of Control. For purposes of this Plan, Change of Control shall mean an event that satisfies one of the conditions in (i) through (iv) below and is either a “change in the ownership or effective control” or a “change in the ownership of a substantial portion of the assets of the Company” as these terms are defined in Code Section 409A and the regulations thereunder:
 
(i) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (i) the then outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the election of directors (the "Outstanding Company Voting Securities"); provided, however, that the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company (excluding an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company), (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a reorganization, merger or consolidation, if, following such reorganization, merger or consolidation, the conditions described in clauses (i), (ii) and (iii) of subsection (c) of this Section 9(h) are satisfied; or
 
(ii) Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or
 
(iii) Approval by the shareholders of the Company of a reorganization, merger, binding share exchange or consolidation, in each case, unless, following such reorganization, merger, binding share exchange or consolidation, (i) more than 60% of, respectively, the then outstanding shares of common stock of the corporation resulting from such reorganization, merger, binding share exchange or consolidation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such reorganization, merger, binding share exchange or consolidation in substantially the same proportions as their ownership, immediately prior to such reorganization, merger, binding share exchange or consolidation, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding the Company, any employee benefit plan (or related trust) of the Company or such corporation resulting from such reorganization, merger, binding share exchange or consolidation and any Person beneficially owning, immediately prior to such reorganization, merger, binding share exchange or consolidation, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such reorganization, merger, binding share exchange or consolidation or the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (iii) at least a majority of the members of the board of directors of the corporation resulting from such reorganization, merger, binding share exchange or consolidation were members of the Incumbent Board at the time of the execution of the initial agreement providing for such reorganization, merger, binding share exchange or consolidation; or
 
(iv) Approval by the shareholders of the Company of (i) a complete liquidation or dissolution of the Company or (ii) the sale or other disposition of all or substantially all of the assets of the Company, other than to a corporation, with respect to which following such sale or other disposition, (A) more than 60% of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Company and any employee benefit plan (or related trust) of the Company or such corporation and any Person beneficially owning, immediately prior to such sale or other disposition, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors and (C) at least a majority of the members of the board of directors of such corporation were members of the Incumbent Board at the time of the execution of the initial agreement or action of the Board providing for such sale or other disposition of assets of the Company.
 
7.4  
Death Distribution. In the case of the death of any Participant before distribution of the full amount of his or her Account, any remaining amounts shall be distributed to the Participant’s beneficiary in a single cash sum. If a Participant has not designated a beneficiary, or if no designated beneficiary is living on the date of distribution, then, notwithstanding any provision herein to the contrary, such amounts shall be distributed to such Participant’s estate in a lump sum cash distribution as soon as administratively feasible following such Participant’s death.
 
7.5  
Termination Distribution. Notwithstanding any payout election a Participant may have made, upon his or her termination of employment with the Company, a Participant’s Account balance shall be automatically paid in a lump sum cash payment no later than 60 days after the end of the Plan Year of the Participant’s termination of employment; provided, however, that any Participant who is a Specified Employee and who incurs a termination of employment with the Company shall not be entitled to receive his or her Plan account balance under this paragraph prior to the date which is six (6) months after the date of his or her termination of employment (or, if earlier, his or her death). For purposes of the Plan, the term “Specified Employee” shall mean a key employee, as defined in Code Section 416(i) (without regard to paragraph (5) thereof). As of the Effective Date, this section defines a key employee to mean an employee of the Company who, at any time during the Plan Year, is (1) an officer of the Company having an annual compensation greater than one hundred thirty-five thousand dollars ($135,000) for 2005 (indexed for inflation in future years); (ii) a five percent (5%) owner of the Company; or (iii) a one percent (1%) owner of the Company having an annual compensation from the Company of more than one hundred fifty thousand dollars ($150,000). Termination of employment shall mean the separation of service with the Company (within the meaning of Code Section 409A), voluntarily or involuntarily, for any reason other than retirement, death, or authorized leave of absence.
 
7.6  
Taxes. All payments made to Participants under the Plan shall be subject to all taxes required to be withheld under applicable laws and regulations of any governmental authorities.
 
ARTICLE EIGHT
 
Miscellaneous
 
8.1  
Fail Safe Provision.(a)This Section shall become operative upon the enactment of any change in applicable statutory law or the promulgation by the Internal Revenue Service of a final regulation or other pronouncement having the force of law, which statutory law, as changed, or final regulation or pronouncement, as promulgated, would cause any Participant to include in his or her federal gross income amounts accrued by the Participant under the Plan on a date (an "Early Taxation Event") prior to the date on which such amounts are made available to him or her hereunder; provided, however, that no portion of this Section shall become operative to the extent that portion would result in a violation of Section 409A (e.g., by causing an impermissible distribution under Section 409A).
 
b) Notwithstanding any other Section of this Plan to the contrary (but subject to subsection (c), below), as of an Early Taxation Event, the feature or features of this Plan that would cause the Early Taxation Event shall be null and void, to the extent, and only to the extent, required to prevent the Participant from being required to include in his or her federal gross income amounts accrued by the Participant under the Plan prior to the date on which such amounts are made available to him or her hereunder. If only a portion of a Participant's Account is impacted by the change in the law, then only such portion shall be subject to this Section, with the remainder of the Account not so affected being subject to such rights and features as if the law were not changed. If the law only impacts Participants who have a certain status with respect to the Company, then only such Participants shall be subject to this Section.
 
c) If an Early Taxation Event is earlier than the date on which the statute, regulation or pronouncement giving rise to the Early Taxation Event is enacted or promulgated, as applicable (i.e., if the change in the law is retroactive), there shall be distributed to each Participant, as soon as practicable following such date of enactment or promulgation, the amounts that became taxable on the Early Taxation Event.
 
8.2  
Administration. The Treasurer of the Company, as the designee of the Compensation Committee, shall be the plan administrator and has the authority to control and manage the operation and administration of the Plan.
 
8.3  
Assignability. No right to receive payments under the Plan is transferable or assignable by a Participant except by will or by the laws of descent and distribution.
 
8.4  
Business Days. In the event any date specified falls on a Saturday, Sunday, or holiday, such date will be deemed to refer to the next business day thereafter.
 
8.5  
Amendment. The Plan may at any time or from time to time be amended or modified by the Board of Directors or the Compensation Committee. No such amendment or modification will, without the consent of the Participant, adversely affect the Participant's accruals in his or her Participant Account.
 
8.6  
Termination. Although the Company anticipates that it will continue the Plan for an indefinite period of time, there is no guarantee that the Company will continue the Plan or will not terminate the Plan at any time in the future. Accordingly, the Company (through its Board of Directors or the Compensation Committee) reserves the right to terminate the Plan at any time. Upon a complete or partial termination of the Plan, the deferral elections of the affected Participants shall terminate and their Plan Account balances, determined as if they had experienced a termination of employment on the date of Plan termination, shall be immediately paid to the Participants; provided however, if immediate distribution of a Participant's account balance on termination is not permitted by Section 409A, the payment of the Account balance shall be made only after Plan benefits otherwise become due hereunder. The termination of the Plan shall not adversely affect any Participant or beneficiary who has become entitled to the payment of any benefits under the Plan as of the date of termination.
 
8.7  
Prohibited Acceleration/Distribution Timing. This Section shall take precedence over any other provision of the Plan to the contrary. No provision of this Plan shall be followed if following the provision would result in the acceleration of the time or schedule of any payment from the Plan as would require immediate income tax to Participants based on the law in effect at the time the distribution is to be made, including Section 409A. In addition, if the timing of any distribution election would result in any tax or other penalty (other than ordinarily payable Federal, state or local income or payroll taxes), which tax or penalty can be avoided by payment of the distribution at a later time, then the distribution shall be made (or commence, as the case may be) on (or as soon as practicable after) the first date on which such distributions can be made (or commence) without such tax or penalty.
 
 
IN WITNESS WHEREOF, the Company has caused this Plan document to be executed by its duly authorized officer this 23rd day of October, 2005.
 
BAUSCH & LOMB INCORPORATED
 
By /s/ David Nachbar
David Nachbar
Senior Vice President, Human Resources

EX-10.W 7 form10k2005e10w.htm EXHIBIT (10)-W Exhibit (10)-w


Exhibit (10)-w
 
BAUSCH & LOMB INCORPORATED
 
SUPPLEMENTAL RETIREMENT INCOME PLAN III
 
Amendment No. 2 to the 2001 Restatement
 
Pursuant to Section 6.1, the Plan is amended and frozen, effective December 31, 2005, by adding to the end of ARTICLE SIX the following new Section 6.3:
 
6.3 Freeze Provision. Effective December 31, 2005, the Plan is frozen pursuant to the following terms and conditions:
 
§  
All Plan benefits that have accrued as of December 31, 2005 shall be frozen at their then-accrued levels and thereafter additional benefit accruals, including contribution credits based on compensation paid after December 31, 2005, shall cease. Notwithstanding the foregoing, interest credits shall continue to be credited on the frozen benefit accruals in such amount and determined in accordance with such procedures as are used to credit interest to Steady Growth Accounts under the Funded Plan.
 
§  
No service or compensation earned by a Participant after December 31, 2005 shall be taken into account in determining a Participant’s accrued benefit under this Plan.
 
§  
All vested accrued benefits as of December 31, 2005 shall remain vested and any unvested benefits shall vest in accordance with the Plan’s terms.
 
§  
No Employee not already a Participant shall be eligible to become a Participant on or after December 31, 2005.
 
 
IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this amendment on its behalf this 23rd day of October, 2005.
 
 
BAUSCH & LOMB INCORPORATED
 
By:  /s/ David R. Nachbar
David R. Nachbar
Senior Vice President
Human Resources

EX-10.Y 8 form10k2005e10y.htm EXHIBIT (10)-Y Exhibit (10)-y


Exhibit (10)-y

 
 
 
CONFORMED COPY
 
 
AGREEMENT
 
 
 
 
 
Arranged by
 
CITIGROUP GLOBAL MARKETS LIMITED
 
J. P. MORGAN PLC
 
and
 
KEYBANC CAPITAL MARKETS
 
with
 
CITIBANK INTERNATIONAL PLC
as Facility Agent
 
 
CREDIT FACILITY
US$375,000,000 for
BAUSCH & LOMB B.V.
 
 



Clause
 
Page
     
1.
 
Interpretation
 
1
 
2.
 
Facility
 
13
 
3.
 
Purpose
 
15
 
4.
 
Conditions Precedent
 
15
 
5.
 
Utilisation - Loan
 
16
 
6.
 
Repayment
 
17
 
7.
 
Prepayment and Cancellation or Assignment
 
17
 
8.
 
Interest
 
20
 
9.
 
Interest Periods
 
22
 
10.
 
Market Disruption
 
22
 
11.
 
Taxes
 
23
 
12.
 
Increased Costs
 
26
 
13.
 
Mitigation
 
26
 
14.
 
Payments
 
27
 
15.
 
Guarantee and Indemnity
 
29
 
16.
 
Representations and Warranties
 
32
 
17.
 
Positive Covenants
 
35
 
18.
 
Negative Covenants and Financial Covenants
 
38
 
19.
 
Default
 
41
 
20.
 
The Administrative Parties
 
45
 
21.
 
Evidence and Calculations
 
50
 
22.
 
Fees
 
51
 
23.
 
Indemnities and Break Costs
 
51
 
24.
 
Expenses
 
53
 
25.
 
Amendments and Waivers
 
53
 
26.
 
Changes to the Parties
 
54
 
27.
 
Disclosure of Information
 
59
 
28.
 
Set-off
 
60
 
29.
 
Pro Rata Sharing
 
60
 
30.
 
Severability
 
61
 
31.
 
Counterparts
 
61
 
32.
 
Notices
 
61
 
33.
 
Language
 
64
 
34.
 
Governing Law
 
64
 
35.
 
Enforcement
 
64
 



Schedule
 
Page
 
1.
 
Original Parties
 
66
 
 
Part 1 Original Lenders and Commitments
 
66
 
 
Part 2 Mandated Lead Arrangers
 
67
 
2.
 
Conditions Precedent Documents
 
68
 
3.
 
Form of Request
 
69
 
4.
 
Calculation of the Mandatory Cost
 
70
 
5.
 
Forms of Transfer Certificate
 
73
 
 
Part 1 Form for Transfers by Assignment
 
73
 
 
Part 2 Form for Transfers by Novation
 
75
 
6.
 
Material Subsidiaries
 
77
 
7.
 
Form of Standing Payment Instructions
 
78
 
     
Signatories
 
 
79
 


 
   

 
  THIS AGREEMENT is dated 29 November, 2005
 
  BETWEEN:
 
(1)  
BAUSCH & LOMB B.V. (the Company);
 
(2)  
BAUSCH & LOMB INCORPORATED, a New York corporation (the Guarantor);
 
(3)  
THE FINANCIAL INSTITUTIONS listed in Part 2 of Schedule 1 (Mandated Lead Arrangers) as Mandated Lead Arrangers;
 
(4)  
THE FINANCIAL INSTITUTIONS listed in Part 1 of Schedule 1 (Original Lenders and Commitments) as Original Lenders;
 
(5)  
CITIBANK INTERNATIONAL PLC as facility agent (in this capacity the Facility Agent).
 
  IT IS AGREED as follows:
 
1.  
INTERPRETATION
 
1.1  
Definitions
 
  In this Agreement:
 
  Administrative Party means a Mandated Lead Arranger or the Facility Agent.
 
  Affiliate means, as to any person, any other person that, directly or indirectly, controls, is controlled by or is under common control with such person or is a director or officer of such person. For the purposes of this definition, the term control (including the terms controlling, controlled by and under common control with) of a person means the possession, direct or indirect, of the power to vote 5 per cent. or more of the Voting Stock of such person or to direct or cause the direction of the management and policies of such person, whether through the ownership of Voting Stock, by contract or otherwise.
 
  Availability Period means the period from and including the date of this Agreement to and including 31 December, 2005.
 
  Bankruptcy Code means the United States Bankruptcy Code 1978 or any other United States Federal or State bankruptcy, insolvency or similar law.
 
  Break Costs means the amount (if any) which a Lender is entitled to receive under Clause 23.3 (Break Costs).
 
  Business Day means a day (other than a Saturday or a Sunday) on which banks are open for general business in London and New York.
 
  Commitment means:
 
(a)  
for an Original Lender, the amount set opposite its name in Part 1 of Schedule 1 (Original Lenders and Commitments) under the heading Commitment (US$) and the amount of any other Commitment it acquires; and
 
(b)  
for any other Lender, the amount of any Commitment it acquires,
 
  to the extent not cancelled, transferred or reduced under this Agreement.
 
  Consolidated refers to the consolidation of accounts in accordance with GAAP.
 
  Debt of any person means, without duplication:
 
(a)  
all indebtedness of such person for borrowed money;
 
(b)  
all obligations of such person for the deferred purchase price of property or services (other than trade payables not overdue by more than 60 days incurred in the ordinary course of such person's business);
 
(c)  
all obligations of such person evidenced by notes, bonds, debentures or other similar instruments;
 
(d)  
all obligations of such person created or arising under any conditional sale or other title retention agreement with respect to property acquired by such person (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property);
 
(e)  
all obligations of such person as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital leases;
 
(f)  
all obligations, contingent or otherwise, of such person in respect of acceptances, letters of credit or similar extensions of credit;
 
(g)  
all net obligations of such person in respect of Hedge Agreements;
 
(h)  
all Debt of others referred to in (a) through (g) above or (i) below guaranteed directly or indirectly in any manner by such person, or in effect guaranteed directly or indirectly by such person through an agreement:
 
(i)  
to pay or purchase such Debt or to advance or supply funds for the payment or purchase of such Debt;
 
(ii)  
to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to make payment of such Debt or to assure the holder of such Debt against loss;
 
(iii)  
to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is received or such services are rendered), primarily for the purpose of enabling the debtor to make payment of such Debt or to assure the holder of such Debt against loss; or
 
(iv)  
otherwise to assure a creditor against loss; and
 
(i)  
all Debt referred to in (a) through (h) above secured by (or for which the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any Security Interest on property (including, without limitation, accounts and contract rights) owned by such person, even though such person has not assumed or become liable for the payment of such Debt.
 
  Debt for Borrowed Money of any person means all items that, in accordance with GAAP, would be classified as notes payable, long term debt or current portion of long term debt on a Consolidated balance sheet of such person.
 
  Default means:
 
(a)  
an Event of Default; or
 
(b)  
an event or circumstance which would be (with the expiry of a grace period, the giving of notice or the making of any determination under the Finance Documents or any combination of them) an Event of Default.
 
  Dutch Banking Act means the Dutch Act on the Supervision of the Credit System 1992 (Wet toezicht Kredietwezen 1992).
 
  Dutch Exemption Regulation means the Exemption Regulation of the Minister of Finance (Vrijstellingsregeling WtK 1992).
 
  EBITDA means, for any period, net income (or net loss) plus, to the extent deducted in calculating net income (or net loss) for such period, the sum of:
 
(a)  
interest expense;
 
(b)  
income tax expense;
 
(c)  
depreciation expense;
 
(d)  
amortisation expense;
 
(e)  
other non-cash non-recurring charges;
 
(f)  
extraordinary losses deducted in calculating net income less extraordinary gains added in calculating net income; and
 
(g)  
non-cash charges associated with expensing of stock options,
 
  in each case (unless otherwise specified) determined in accordance with GAAP for such period.
 
  Environmental Action means any action, suit, demand, demand letter, claim, notice of non-compliance or violation, notice of liability or potential liability, investigation, proceeding, consent order or consent agreement relating in any way to any Environmental Law, Environmental Permit or Hazardous Materials or arising from alleged injury or threat of injury to health, safety or the environment, including, without limitation:
 
(a)  
by any governmental or regulatory authority for enforcement, cleanup, removal, response, remedial or other actions or damages; and
 
(b)  
by any governmental or regulatory authority or any third party for damages, contribution, indemnification, cost recovery, compensation or injunctive relief.
 
  Environmental Law means any federal, state, local or foreign statute, law, ordinance, rule, regulation, code, order, judgment, decree or judicial or agency interpretation, policy or guidance relating to pollution or protection of the environment, health, safety or natural resources, including, without limitation, those relating to the use, handling, transportation, treatment, storage, disposal, release or discharge of Hazardous Materials.
 
  Environmental Permit means any permit, approval, identification number, licence or other authorisation required under any Environmental Law.
 
  ERISA means the U.S. Employee Retirement Income Security Act of 1974, as amended from time to time, and the regulations promulgated and rulings issued thereunder.
 
  ERISA Affiliate means any person that for purposes of Title IV of ERISA is a member of the Guarantor's controlled group, or under common control with the Guarantor, within the meaning of Section 414 of the U.S. Internal Revenue Code.
 
  ERISA Event means:
 
(a)   (i)    the occurrence of a reportable event, within the meaning of Section 4043 of ERISA, with respect to any Plan unless the 30-day notice requirement with respect to such event has been waived by the PBGC; or
 
 
(ii)    the requirements of subsection (1) of Section 4043(b) of ERISA (without regard to subsection (2) of such Section) are met with respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, of a Plan, and an event described in paragraph (9), (10), (11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such Plan within the following 30 days;
 
(b)  
the application for a minimum funding waiver with respect to a Plan;
 
(c)  
the provision by the administrator of any Plan of a notice of intent to terminate such Plan pursuant to Section 4041(a)(2) of ERISA (including any such notice with respect to a plan amendment referred to in Section 4041(e) of ERISA);
 
(d)  
the cessation of operations at a facility of the Guarantor or any ERISA Affiliate in the circumstances described in Section 4062(e) of ERISA;
 
(e)  
the withdrawal by the Guarantor or any ERISA Affiliate from a Multiple Employer Plan during a plan year for which it was a substantial employer, as defined in Section 4001(a)(2) of ERISA;
 
(f)  
the conditions for the imposition of a lien under Section 302(f) of ERISA shall have been met with respect to any Plan;
 
(g)  
the adoption of an amendment to a Plan requiring the provision of security to such Plan pursuant to Section 307 of ERISA; or
 
(h)  
the institution by the PBGC of proceedings to terminate a Plan pursuant to Section 4042 of ERISA, or the occurrence of any event or condition described in Section 4042 of ERISA that constitutes grounds for the termination of, or the appointment of a trustee to administer, a Plan.
 
  Event of Default means an event specified as such in Clause 19 (Default).
 
  Existing Guarantor Credit Agreement means the US$400,000,000 credit agreement dated 26 July, 2005 between, among others, the Guarantor as borrower and Citibank, N.A. as administrative agent, including any extensions, renewals, amendments or modifications executed from time to time.
 
  Facility means the credit facility made available under this Agreement.
 
  Facility Office means the office(s) notified by a Lender to the Facility Agent:
 
(a)  
on or before the date it becomes a Lender; or
 
(b)  
by not less than five Business Days' notice,
 
  as the office(s) through which it will perform its obligations under this Agreement.
 
  Fee Letter means any letter entered into by reference to this Agreement between one or more Administrative Parties and the Company setting out the amount of certain fees referred to in this Agreement.
 
  Final Maturity Date means the fifth anniversary of the Utilisation Date subject to any extension in accordance with Clause 2.3 (Extension Option).
 
  Finance Document means:
 
(a)  
this Agreement;
 
(b)  
a Fee Letter;
 
(c)  
a Transfer Certificate; or
 
(d)  
any other document designated as such by the Facility Agent, the Company and the Guarantor.
 
  Finance Party means a Lender or an Administrative Party.
 
  Fitch means Fitch Ratings or any successor to its rating business.
 
  GAAP means generally accepted accounting principles consistent with those applied in the preparation of the Consolidated balance sheet of the Guarantor and its Subsidiaries as at 25 December, 2004, and the related Consolidated statements of income and cash flows of the Guarantor and its Subsidiaries for the fiscal year then ended and the Consolidated balance sheet of the Guarantor and its Subsidiaries as at 25 June, 2005 and the related Consolidated statements of income and cash flows of the Guarantor and its Subsidiaries for the six months then ended.
 
  Group means the Guarantor and its Subsidiaries.
 
  Hazardous Materials means:
 
(a)  
petroleum and petroleum products, byproducts or breakdown products, radioactive materials, asbestos-containing materials, polychlorinated biphenyls and radon gas; and
 
(b)  
any other chemicals, materials or substances designated, classified or regulated as hazardous or toxic or as a pollutant or contaminant under any Environmental Law.
 
  Hedge Agreements means interest rate swap, cap or collar agreements, interest rate future or option contracts, currency swap agreements, currency future or option contracts and other similar agreements.
 
  Increased Cost means:
 
(a)  
an additional or increased cost;
 
(b)  
a reduction in the rate of return from a Facility or on a Finance Party's overall capital; or
 
(c)  
a reduction of an amount due and payable under any Finance Document,
 
  which is incurred or suffered by a Finance Party or any of its Affiliates but only to the extent attributable to that Finance Party having entered into any Finance Document or funding or performing its obligations under any Finance Document.
 
  Information Memorandum means the information memorandum prepared on behalf of, and approved by, the Company and the Guarantor in connection with this Agreement.
 
  Interest Period means each six-month period determined under this Agreement by reference to which interest on the Loan is calculated or such other period as the Facility Agent may select in accordance with this Agreement in respect of calculating interest on an overdue amount.
 
  Legal Reservations means:
 
(a)  
the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement by laws relating to insolvency, reorganisation and other laws generally affecting the rights of creditors;
 
(b)  
the time barring of claims under the Limitation Acts or any equivalent legislation in other countries and defences of set-off or counterclaim;
 
(c)  
similar principles, rights and defences under the laws of any Relevant Jurisdiction; and
 
(d)  
any other general principles which are set out as qualifications as to matters of law in the legal opinions delivered to the Facility Agent in respect of any of the Finance Documents.
 
  Lender means:
 
(a)  
an Original Lender; or
 
(b)  
any person which becomes a Lender after the date of this Agreement.
 
  LIBOR means for an Interest Period of the Loan or overdue amount:
 
(a)  
the applicable Screen Rate; or
 
(b)  
if no Screen Rate is available for the relevant currency or Interest Period of the Loan or overdue amount, the arithmetic mean (rounded upward to four decimal places) of the rates, as supplied to the Facility Agent at its request, quoted by the Reference Banks to leading banks in the London interbank market,
 
  as of 11.00 a.m. on the Rate Fixing Day for the offering of deposits in the currency of the Loan or overdue amount for a period comparable to that Interest Period.
 
  Loan means, unless otherwise stated in this Agreement, the principal amount of the borrowing made or to be made under this Agreement or the principal amount outstanding for the time being of that borrowing.
 
  Majority Lenders means, at any time, Lenders:
 
(a)  
whose share in the outstanding Loans and whose undrawn Commitments then aggregate more than 50 per cent. of the aggregate of all the outstanding Loans and the undrawn Commitments of all the Lenders;
 
(b)  
if there is no Loan then outstanding, whose undrawn Commitments then aggregate more than 50 per cent. of the Total Commitments; or
 
(c)  
if there is no Loan then outstanding and the Total Commitments have been reduced to zero, whose Commitments aggregated more than 50 per cent. of the Total Commitments immediately before the reduction.
 
  Mandatory Cost means the percentage rate per annum calculated by the Facility Agent in accordance with Schedule 4 (Calculation of the Mandatory Cost).
 
  Margin means the rate per annum calculated in accordance with Clause 8.3 (Margin).
 
  Material Adverse Change means any material adverse change in the business, condition (financial or otherwise), operations, performance, properties or prospects of the Guarantor or the Group as a whole.
 
  Material Adverse Effect means a material adverse effect on:
 
(a)  
the business, condition (financial or otherwise), operations, performance, properties or prospects of the Guarantor or the Group as a whole;
 
(b)  
the ability of any Obligor to perform its obligations under this Agreement or a Fee Letter;
 
(c)  
the validity or enforceability of this Agreement or a Fee Letter; or
 
(d)  
any right or remedy of a Finance Party in respect of this Agreement or a Fee Letter.
 
  Material Subsidiary means, at any time, the Company and a Subsidiary of the Guarantor having:
 
(a)  
assets (excluding inter-company receivables) with a value that exceeds 5 per cent. of the value of total assets shown on the Consolidated statement of financial condition of the Group; or
 
(b)  
net sales that exceed 5 per cent. of the Consolidated net sales of the Group,
 
  in each case as of the end of the most recently completed fiscal quarter of the Guarantor for which audited financial statements are available.
 
  If there is a dispute as to whether or not a member of the Group is a Material Subsidiary, a certificate of the auditors of the Guarantor will be, in the absence of manifest error, conclusive.
 
  Moody's means Moody's Investors Service, Inc. or any successor to its rating business.
 
  Multiemployer Plan means a multiemployer plan, as defined in Section 4001(a)(3) of ERISA, to which the Guarantor or any ERISA Affiliate is making or accruing an obligation to make contributions, or has within any of the preceding five plan years made or accrued an obligation to make contributions.
 
  Multiple Employer Plan means a single employer plan, as defined in Section 4001(a)(15) of ERISA, that:
 
(a)  
is maintained for employees of the Guarantor or any ERISA Affiliate and at least one person other than the Guarantor and the ERISA Affiliates; or
 
(b)  
was so maintained and in respect of which the Guarantor or any ERISA Affiliate could have liability under Section 4064 or 4069 of ERISA in the event such plan has been or were to be terminated.
 
  Obligor means the Company or the Guarantor.
 
  Original Financial Statements means the audited consolidated financial statements of the Guarantor for the year ended 25 December, 2004.
 
  Participating Member State means a member state of the European Communities that adopts or has adopted the euro as its lawful currency under the legislation of the European Community for Economic Monetary Union.
 
  Party means a party to this Agreement.
 
  Patriot Act means the U.S. Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. 107-56, signed into law 26 October, 2001.
 
  PBGC means the Pension Benefit Guaranty Corporation (or any successor).
 
  Permitted Security Interests means such of the following as to which no enforcement, collection, execution, levy or foreclosure proceeding shall have been commenced or as to which are not being contested by appropriate proceedings with appropriate reserves:
 
(a)  
Security Interests for taxes, assessments and governmental charges or levies to the extent not required to be paid under Clause 17.3 (Payment of taxes) hereof;
 
(b)  
Security Interests imposed by law, such as materialmen's, mechanics', carriers', workmen's and repairmen's Security Interests and other similar Security Interests arising in the ordinary course of business securing obligations that are not overdue for a period of more than 30 days;
 
(c)  
pledges or deposits to secure obligations under workers' compensation laws or similar legislation or to secure public or statutory obligations or bids or tenders or surety, appeal or performance bonds in the ordinary course of business;
 
(d)  
easements, rights of way and other encumbrances on title to real property that do not render title to the property encumbered thereby unmarketable or materially adversely affect the use of such property for its present purposes; and
 
(e)  
any interests arising under clause 18 of the general terms and conditions (Algemene Voorwaarden) of any member of the Dutch Bankers’ Association (Nederlandse Vereniging van Banken) or any similar term applied by a financial institution in the Netherlands pursuant to its general conditions.
 
  Plan means a Single Employer Plan or a Multiple Employer Plan.
 
  Professional Market Party means a professional market party (professionele marktpartij) under the Dutch Exemption Regulation.
 
  Pro Rata Share means:
 
(a)  
for the purpose of determining a Lender's share in the utilisation of the Facility, the proportion which its Commitment bears to the Total Commitments; and
 
(b)  
for any other purpose on a particular date:
 
(i)  
the proportion which a Lender's share of the Loan bears to all of the Loan;
 
(ii)  
if there is no Loan outstanding on that date, the proportion which its Commitment bears to the Total Commitments on that date; or
 
(iii)  
if the Total Commitments have been cancelled, the proportion which its Commitment bore to the Total Commitments immediately before being cancelled.
 
  Rate Fixing Day means the second Business Day before the first day of an Interest Period or such other day as is generally treated as the rate fixing day by market practice in the relevant interbank market.
 
  Rating Agency means Fitch, Moody's, S&P or any other rating agency approved by the Majority Lenders, the Company and the Guarantor.
 
  Reference Banks means the Facility Agent, J.P. Morgan plc and KeyBanc Capital Markets and any other bank or financial institution appointed as such by the Facility Agent under this Agreement.
 
  Relevant Jurisdiction means, in relation to an Obligor:
 
(a)  
its jurisdiction of incorporation; or
 
(b)  
any jurisdiction where it conducts its business.
 
  Repeating Representations means at any time the representations and warranties which are then made or deemed to be repeated under Clause 16.17 (Times for making representations and warranties).
 
  Request means a request for the Loan, substantially in the form of Schedule 3 (Form of Request).
 
  S&P means Standard & Poor's Rating Services, a division of The McGraw-Hill Companies, Inc. or any successor to its rating business.
 
  Screen Rate means the British Bankers Association Interest Settlement Rate for the relevant currency and Interest Period displayed on the appropriate page of the Telerate screen. If the relevant page is replaced or the service ceases to be available, the Facility Agent (after consultation with the Company, the Guarantor and the Lenders) may specify another page or service displaying the appropriate rate.
 
  SEC means the U.S. Securities and Exchange Commission, or any governmental authority succeeding to any of its principal functions.
 
  Security Interest means any mortgage, pledge, lien, charge, assignment, hypothecation, encumbrance or security interest or any other agreement or arrangement having a similar effect, including without limitation, the lien or retained security title of a conditional vendor but does not include, for the avoidance of doubt, any netting or set-off arrangement entered into by any member of the Group in the ordinary course of its banking arrangements for the purpose of netting debit and credit balances.
 
  Single Employer Plan means a single employer plan, as defined in Section 4001(a)(15) of ERISA, that:
 
(a)  
is maintained for employees of the Guarantor or any ERISA Affiliate and no person other than the Guarantor and the ERISA Affiliates; or
 
(b)  
was so maintained and in respect of which the Guarantor or any ERISA Affiliate could have liability under Section 4069 of ERISA in the event such plan has been or were to be terminated.
 
  Subsidiary of any person means any corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50 per cent. of:
 
(a)  
the issued and outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency);
 
(b)  
the interest in the capital or profits of such limited liability company, partnership or joint venture; or
 
(c)  
the beneficial interest in such trust or estate,
 
  is at the time directly or indirectly owned or controlled by such person, by such person and one or more of its other Subsidiaries or by one or more of such person's other Subsidiaries.
 
  Tax means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any related penalty or interest).
 
  Tax Deduction means a deduction or withholding for or on account of Tax from a payment under a Finance Document.
 
  Tax Payment means a payment made by an Obligor to a Finance Party in any way relating to a Tax Deduction or under any indemnity given by that Obligor in respect of Tax under any Finance Document.
 
  Total Commitments means the aggregate of the Commitments of all the Lenders.
 
  Transfer Certificate means:
 
(a)  
for a transfer by assignment, a certificate, substantially in the form of Part 1 of Schedule 5 (Forms of Transfer Certificate); and
 
(b)  
for a transfer by novation, a certificate, substantially in the form of Part 2 of Schedule 5 (Forms of Transfer Certificate),
 
  in each case with such amendments as the Facility Agent may approve or reasonably require or any other form agreed between the Facility Agent, the Company and the Guarantor.
 
  U.K. means the United Kingdom.
 
  U.S. means the United States of America.
 
  US$ means the lawful currency for the time being of the United States of America.
 
  Utilisation Date means the date on which the Facility is utilised and funds are advanced to the Company in accordance with the provisions of this Agreement.
 
  Voting Stock means capital stock issued by a corporation, or equivalent interests in any other person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such person, even if the right so to vote has been suspended by the happening of such a contingency.
 
1.2  
Construction
 
(a)  
In this Agreement, unless the contrary intention appears, a reference to:
 
(i)  
an amendment includes a supplement, novation, restatement or re-enactment and amended will be construed accordingly;
 
(ii)  
assets includes present and future properties, revenues and rights of every description;
 
(iii)  
an authorisation includes an authorisation, consent, approval, resolution, licence, exemption, filing, registration or notarisation;
 
(iv)  
disposal means a sale, transfer, grant, lease or other disposal, whether voluntary or involuntary, and dispose will be construed accordingly;
 
(v)  
indebtedness includes any obligation (whether incurred as principal or as surety) for the payment or repayment of money;
 
(vi)  
know your customer requirements are the identification checks that a Finance Party requests in order to meet its obligations under any applicable law or regulation to identify a person who is (or is to become) its customer;
 
(vii)  
an assignment or transfer by a Lender of its rights and obligations under this Agreement at par means an assignment or transfer of the principal amounts of a Lender's share in the Loan at par plus all other amounts accrued and/or owing under any Finance Document;
 
(viii)  
a person includes any individual, company, corporation, unincorporated association or body (including a partnership, trust, joint venture or consortium), government, state, agency, organisation or other entity whether or not having separate legal personality;
 
(ix)  
a regulation includes any regulation, rule, official directive, request or guideline (whether or not having the force of law but, if not having the force of law, being of a type with which any person to which it applies is accustomed to comply) of any governmental, inter-governmental or supranational body, agency, department or regulatory, self-regulatory or other authority or organisation;
 
(x)  
a currency is a reference to the lawful currency for the time being of the relevant country;
 
(xi)  
a Default being outstanding or continuing means that it has not been remedied or waived;
 
(xii)  
a provision of law is a reference to that provision as extended, applied, amended or re-enacted and includes any subordinate legislation;
 
(xiii)  
a Clause, a Subclause or a Schedule is a reference to a clause or subclause of, or a schedule to, this Agreement;
 
(xiv)  
a Party or any other person includes its successors in title, permitted assigns and permitted transferees;
 
(xv)  
a Finance Document or other document includes (without prejudice to any prohibition on amendments) all amendments however fundamental to that Finance Document or other document, including any amendment providing for any increase in the amount of a facility or any additional facility; and
 
(xvi)  
a time of day is a reference to London time.
 
(b)  
Unless the contrary intention appears, a reference to a month or months is a reference to a period starting on one day in a calendar month and ending on the numerically corresponding day in the next calendar month or the calendar month in which it is to end, except that:
 
(i)  
if the numerically corresponding day is not a Business Day, the period will end on the next Business Day in that month (if there is one) or the preceding Business Day (if there is not);
 
(ii)  
if there is no numerically corresponding day in that month, that period will end on the last Business Day in that month; and
 
(iii)  
notwithstanding subparagraph (i) above, a period which commences on the last Business Day of a month will end on the last Business Day in the next month or the calendar month in which it is to end, as appropriate.
 
(c)  
Unless expressly provided to the contrary in a Finance Document, a person who is not a party to a Finance Document may not enforce any of its terms under the Contracts (Rights of Third Parties) Act 1999 and, notwithstanding any term of any Finance Document, no consent of any third party is required for any amendment (including any release or compromise of any liability) or termination of any Finance Document.
 
(d)  
Unless the contrary intention appears:
 
(i)  
a reference to a Party will not include that Party if it has ceased to be a Party under this Agreement;
 
(ii)  
a word or expression used in any other Finance Document or in any notice given in connection with any Finance Document has the same meaning in that Finance Document or notice as in this Agreement; and
 
(iii)  
any obligation of an Obligor under the Finance Documents which is not a payment obligation remains in force for so long as any payment obligation of an Obligor is or may be outstanding under the Finance Documents.
 
(e)  
The headings in this Agreement do not affect its interpretation.
 
1.3  
Dutch terms
 
  In this Agreement, where it relates to a Dutch entity, a reference to:
 
(a)  
duly authorised by all necessary corporate action where applicable, includes without limitation:
 
(i)  
any action required to comply with the Works Councils Act of the Netherlands (Wet op de ondernemingsraden); and
 
(ii)  
obtaining an unconditional positive advice (advies) from the competent works council(s);
 
(b)  
a security interest includes any mortgage (hypotheek), pledge (pandrecht), retention of title arrangement (eigendomsvoorbehoud), privilege (voorrecht), right of retention (recht van retentie), right to reclaim goods (recht van reclame), and, in general, any right in rem (beperkt recht), created for the purpose of granting security (goederenrechtelijk zekerheidsrecht);
 
(c)  
(i)a winding-up or dissolution (and any of those terms) includes a Dutch entity being declared bankrupt (failliet verklaard) or dissolved (ontbonden);
 
(ii)  
any procedure taken in connection with insolvency proceedings includes a Dutch entity having filed a notice under section 36 of the Tax Collection Act of the Netherlands (Invorderingswet 1990) or Section 16d of the Social Insurance Co-ordination Act of the Netherlands (Coördinatiewet Sociale Verzekeringen); and
 
(iii)  
a trustee in connection with insolvency proceedings includes a curator.
 
2.  
FACILITY
 
2.1  
Facility
 
  Subject to the terms of this Agreement, the Lenders make available to the Company a term loan facility in an aggregate amount equal to the Total Commitments.
 
2.2  
Nature of a Finance Party's rights and obligations
 
  Unless all the Finance Parties agree otherwise:
 
(a)  
the obligations of a Finance Party under the Finance Documents are several;
 
(b)  
failure by a Finance Party to perform its obligations does not affect the obligations of any other Party under the Finance Documents;
 
(c)  
no Finance Party is responsible for the obligations of any other Finance Party under the Finance Documents;
 
(d)  
the rights of a Finance Party under the Finance Documents are separate and independent rights;
 
(e)  
a Finance Party may, except as otherwise stated in the Finance Documents, separately enforce those rights; and
 
(f)  
a debt arising under the Finance Documents to a Finance Party is a separate and independent debt.
 
2.3  
Extension Option
 
(a)  
The Company may request that the Final Maturity Date be extended for a further period (the Relevant Period) from the then current Final Maturity Date by giving notice to the Facility Agent no more than 120 days nor less than 45 days before each of the first anniversary (the First Extension Request) and the second anniversary (the Second Extension Request) of the Utilisation Date.
 
(b)  
The Relevant Period will be:
 
(i)  
in the case of the First Extension Request, 364 days; and
 
(ii)  
in the case of the Second Extension Request:
 
(A)  
if the First Extension Request was made, then in respect of the Lenders who agreed to the First Extension Request, 364 days; and in respect of the Lenders who did not agree to the First Extension Request, 728 days; or
 
(B)  
if the First Extension Request was not made, 364 days or 728 days, at the option of the Company and as indicated in the Second Extension Request.
 
(c)  
Each Lender participating in the Facility shall notify the Facility Agent within 30 days after receiving the First Extension Request (or Second Extension Request, as the case may be) from the Company but in no event later than 10 days prior to the relevant anniversary of the Utilisation Date whether or not it agrees to the then current Final Maturity Date being extended for the Relevant Period. No Lender is under any obligation to extend the then current Final Maturity Date. If, by the date falling 10 days prior to the relevant anniversary of the Utilisation Date, no notice is received by the Facility Agent from a Lender which has confirmed receipt of the First Extension Request or Second Extension Request (as applicable) no less than 20 days prior to the relevant anniversary of the Utilisation Date, the then current Final Maturity Date shall automatically be extended for the Relevant Period with regard to such Lender.
 
(d)  
As soon as practicable after it establishes which of the relevant Lenders, if any, agree to extend the then current Final Maturity Date for the Relevant Period, the Facility Agent shall, by notice to the Company, the Guarantor and each Lender, confirm those Lenders which have agreed to extend the then current Final Maturity Date for the Relevant Period (each an Extending Lender), whereupon such extension shall become effective with regard to those Extending Lenders.
 
(e)  
At any time prior to the then current Final Maturity Date, the Company and/or the Guarantor will have the option to identify a Lender that is willing to accept an assignment or transfer of the rights and obligations under this Agreement from a Lender who does not agree to extend the Final Maturity Date, in which event, and at such time, the Lender who does not agree (or has not confirmed receipt of the First Extension Request or Second Extension Request (as applicable) pursuant to paragraph (c) above) to extend the Final Maturity Date shall assign or transfer its rights and obligations under this Agreement to the other Lender at par.
 
(f)  
Subject to (e) above, the share in the Loan of any Lender who does not agree to extend the Final Maturity Date applicable to it for the Relevant Period together with any other sums owed to any such Lender under this Agreement shall be repaid in full on or prior to the Final Maturity Date applicable to that Lender.
 
(g)  
No more than two requests for an extension under this Clause may be given, and any such request is irrevocable.
 
(h)  
For the avoidance of doubt, the Final Maturity Date cannot be after the seventh anniversary of the Utilisation Date.
 
3.  
PURPOSE
 
3.1  
Loans
 
  The Loan may only be used for the general corporate purposes of the Company, including, but not limited to, payment of dividends.
 
3.2  
No obligation to monitor
 
  No Finance Party is bound to monitor or verify the utilisation of the Facility.
 
4.  
CONDITIONS PRECEDENT
 
4.1  
Conditions precedent documents
 
  A Request may not be given until the Facility Agent has notified the Company and the Lenders that it has received all of the documents and evidence set out in Schedule 2 (Conditions Precedent Documents) in form and substance satisfactory to the Facility Agent. The Facility Agent must give this notification to the Company and the Lenders promptly upon being so satisfied.
 
4.2  
Further conditions precedent
 
  The obligations of each Lender to participate in the Loan are subject to the further conditions precedent that on both the date of the Request and the Utilisation Date for the Loan:
 
(a)  
the Repeating Representations are correct in all material respects; and
 
(b)  
no Default is outstanding or would result from the Loan.
 
4.3  
Maximum number
 
  Unless the Facility Agent agrees, a Request may not be given if, as a result, there would be more than 1 Loan outstanding.
 
5.  
UTILISATION - LOAN
 
5.1  
Giving of Requests
 
(a)  
The Company may borrow the Loan by giving to the Facility Agent a duly completed Request.
 
(b)  
Unless the Facility Agent otherwise agrees, the latest time for receipt by the Facility Agent of the duly completed Request is 11.00 a.m. (London time) three Business Days before the proposed Utilisation Date.
 
(c)  
The Request is irrevocable.
 
5.2  
Completion of Requests
 
  The Request for the Loan will not be regarded as having been duly completed unless:
 
(a)  
the Utilisation Date is a Business Day falling within the Availability Period;
 
(b)  
the amount of the Loan requested is:
 
(i)  
a minimum of US$5,000,000 and an integral multiple of US$1,000,000;
 
(ii)  
equal to or less than the Total Commitments; or
 
(iii)  
such other amount as the Facility Agent may agree; and
 
(c)  
the proposed Interest Period complies with this Agreement.
 
  Only one Loan may be requested in a Request and is available under this Facility.
 
5.3  
Advance of Loan
 
(a)  
The Facility Agent must promptly notify each Lender of the details of the requested Loan and the amount of its share in the Loan.
 
(b)  
The amount of each Lender’s share of the Loan will be its Pro Rata Share on the proposed Utilisation Date.
 
(c)  
No Lender is obliged to participate in the Loan if, as a result:
 
(i)  
its share in the Loan would exceed its Commitment; or
 
(ii)  
the Loan would exceed the Total Commitments.
 
(d)  
If the conditions set out in this Agreement have been met, each Lender must make its share in the Loan available to the Facility Agent for the Company through its Facility Office on the Utilisation Date.
 
6.  
REPAYMENT
 
  The Company must repay each Lender's share in the Loan in full on or before the Final Maturity Date applicable to it.
 
7.  
PREPAYMENT AND CANCELLATION OR ASSIGNMENT
 
7.1  
Mandatory prepayment or assignment - illegality
 
(a)  
A Lender must notify the Facility Agent, the Company and the Guarantor promptly if it becomes aware that it is unlawful in any applicable jurisdiction for that Lender to perform any of its obligations under a Finance Document or to fund or maintain its share in the Loan.
 
(b)  
After notification under paragraph (a) above the Facility Agent must notify the Company and the Guarantor and, subject to paragraph (d) below:
 
(i)  
the Company must repay or prepay the share of that Lender in the Loan on the date specified in paragraph (c) below; and
 
(ii)  
the Commitment of that Lender will be immediately cancelled.
 
(c)  
The date for repayment or prepayment of a Lender's share in the Loan will be:
 
(i)  
the last day of the current Interest Period of the Loan; or
 
(ii)  
if earlier, the date specified by the Lender in the notification under paragraph (a) above and which must not be earlier than the last day of any applicable grace period allowed by law.
 
(d)  
At any time prior to the date for repayment or prepayment specified in paragraph (c) above, the Company and/or the Guarantor will have the option to identify a Lender that is willing to accept an assignment or transfer of the rights and obligations under this Agreement of a Lender who has made a notification under this Clause 7.1, in which event, and at such time, the Lender who has made such notification shall assign or transfer its rights and obligations under this Agreement to the other Lender at par (such assignment or transfer to be effective on or before the date for repayment or prepayment specified in paragraph (c) above).
 
(e)  
Unless the Facility Agent otherwise agrees, in the event that a transfer or assignment requested by the Company and/or the Guarantor under this Clause 7.1 takes effect, the Company must pay to the Facility Agent for its own account a fee of US$3,500.
 
7.2  
Voluntary prepayment
 
(a)  
The Company may, by giving not less than two Business Days' prior notice to the Facility Agent, prepay the Loan at any time in whole or in part.
 
(b)  
A prepayment of part of the Loan must be in a minimum amount of US$5,000,000 and an integral multiple of US$1,000,000.
 
7.3  
Automatic cancellation
 
  The unutilised Commitment of each Lender will be automatically cancelled on the earlier of:
 
(i)  
the date of (and immediately following) the advance of the Loan; and
 
(ii)  
the close of business on the last day of the Availability Period.
 
7.4  
Voluntary cancellation
 
(a)  
The Company may, by giving not less than three Business Days' prior notice to the Facility Agent, cancel the unutilised amount of the Total Commitments in whole or in part.
 
(b)  
Partial cancellation of the Total Commitments must be in a minimum amount of US$5,000,000 and an integral multiple of US$1,000,000.
 
(c)  
Any cancellation in part will be applied pro rata against the Commitment of each Lender.
 
7.5  
Right of repayment and cancellation of a single Lender
 
(a)  
If the Company is, or will be, required to pay to a Lender (the Notified Lender or that Lender):
 
(i)  
a Tax Payment; or
 
(ii)  
an Increased Cost,
 
  provided that no Default has occurred and is continuing, and the Company has satisfied all its obligations under this Agreement to that Lender, the Company may, while the requirement continues, give notice to the Facility Agent requesting assignment or prepayment and cancellation in respect of that Lender.
 
(b)  
After notification under paragraph (a) above and subject to paragraph (d) below:
 
(i)  
the Company must repay or prepay that Lender's share in the Loan on the date specified in paragraph (c) below; and
 
(ii)  
the Commitment of that Lender will be immediately cancelled.
 
(c)  
The date for repayment or prepayment of that Lender's share in the Loan will be:
 
(i)  
the last day of the current Interest Period for the Loan; or
 
(ii)  
if earlier, the date specified by the Company in its notification.
 
(d)  
At any time prior to the date for repayment or prepayment specified in paragraph (c) above, the Company and/or the Guarantor will have the option to identify a Lender that is willing to accept an assignment or transfer of the rights and obligations under this Agreement of the Notified Lender, in which event, and at such time, the Notified Lender shall assign or transfer its rights and obligations under this Agreement to the other Lender at par (such assignment or transfer to be effective on or before the date for repayment or prepayment specified in paragraph (c) above).
 
(e)  
Unless the Facility Agent otherwise agrees, in the event that a transfer or assignment requested by the Company and/or the Guarantor under this Clause 7.5 takes effect, the Company must pay to the Facility Agent for its own account a fee of US$3,500.
 
7.6  
Mandatory Cost
 
(a)  
The Company will not be required to pay any Lender any amount in respect of any Mandatory Cost until after both:
 
(i)  
the rate of Mandatory Cost has increased from the rate in effect at the date of this Agreement; and
 
(ii)  
that Lender has notified the Facility Agent that it requires the Company to pay Mandatory Cost.
 
(b)  
If any Lender provides a notification to the Facility Agent in accordance with (a) above, the Company may, provided that no Default has occurred and is continuing, and the Company has satisfied all its obligations under this Agreement to that Lender, while the requirement continues, give notice to the Facility Agent requesting assignment or prepayment and cancellation in respect of that Lender (the Notified Lender or that Lender).
 
(c)  
After notification by the Company to the Facility Agent under paragraph (b) above and subject to paragraph (e) below:
 
(i)  
the Company must repay or prepay that Lender's share in the Loan on the date specified in paragraph (d) below; and
 
(ii)  
the Commitment of that Lender will be immediately cancelled.
 
(d)  
The date for repayment or prepayment of a Lender's share in the Loan will be:
 
(i)  
the last day of the current Interest Period for the Loan; or
 
(ii)  
if earlier, the date specified by the Company in its notification.
 
(e)  
At any time prior to the date for repayment or prepayment specified in paragraph (d) above, the Company and/or the Guarantor will have the option to identify a Lender that is willing to accept an assignment or transfer of the rights and obligations under this Agreement of the Notified Lender, in which event, and at such time, the Notified Lender shall assign or transfer its rights and obligations under this Agreement to the other Lender at par (such assignment or transfer to be effective on or before the date for repayment or prepayment specified in paragraph (d) above).
 
(f)  
Unless the Facility Agent otherwise agrees, in the event that a transfer or assignment requested by the Company and/or the Guarantor under this Clause 7.6 takes effect, the Company must pay to the Facility Agent for its own account a fee of US$3,500.
 
7.7  
Partial prepayment of the Loan
 
  No amount of the Loan prepaid under this Agreement may subsequently be re-borrowed.
 
7.8  
Miscellaneous provisions
 
(a)  
Any notice of prepayment and/or cancellation under this Agreement is irrevocable and must specify the relevant date(s) and the affected Loan and Commitments. The Facility Agent must notify the Lenders promptly of receipt of any such notice.
 
(b)  
All prepayments under this Agreement must be made with accrued interest on the amount prepaid. No premium or penalty is payable in respect of any prepayment except for the Agent's fee in Clause 7.5(e) or Break Costs.
 
(c)  
The Majority Lenders may agree a shorter notice period for a voluntary prepayment or a voluntary cancellation.
 
(d)  
No prepayment or cancellation is allowed except in accordance with the express terms of this Agreement.
 
(e)  
No amount of the Total Commitments cancelled under this Agreement may subsequently be reinstated.
 
8.  
INTEREST
 
8.1  
Calculation of interest
 
  The rate of interest on the Loan for its Interest Period is the percentage rate per annum equal to the aggregate of the applicable:
 
(a)  
Margin;
 
(b)  
LIBOR; and
 
(c)  
Mandatory Cost, subject to the provisions of Clause 7.6(a) (Mandatory Cost) above.
 
8.2  
Payment of interest
 
  Except where it is provided to the contrary in this Agreement, the Company must pay accrued interest on the Loan made to it on the last day of each Interest Period.
 
8.3  
Margin
 
(a)  
In this Subclause:
 
  Quoting Rating Agency means at any time a Rating Agency which has a Debt Rating of the Guarantor (as defined in paragraph (b) below) at the relevant time.
 
(b)  
The Margin applicable to the Loan will be the percentage rate per annum specified in Column 3 below which corresponds to the criteria in relation to the long-term senior unsecured, non-credit enhanced debt rating assigned to the Guarantor in Column 2 below by Fitch, Moody's and/or S&P (as the case may be) (the Debt Rating of the Guarantor) at the relevant time.

 
  Column 1
 
  Pricing Level
 
Column 2
 
Debt Rating of the Guarantor
 
  Column 3
 
  Margin (per cent. per annum)
 
Fitch
Moody's
S&P
 
         
I
≥ A
≥ A2
≥ A
0.225
II
A-
A3
A-
0.25
III
BBB+
Baa1
BBB+
0.30
IV
BBB
Baa2
BBB
0.35
V
BBB-
Baa3
BBB-
0.425
VI
≤ BB+
≤ Ba1
≤ BB+
0.60
 
(c)  
(i)If the Debt Rating of the Guarantor is split, such that a different Margin is applicable to each Quoting Rating Agency's rating, the applicable Margin will be determined as follows:
 
(A)  
if the Debt Rating of the Guarantor is split and all three ratings fall in different pricing levels, the Margin applicable to the middle rating as set out in the table in paragraph (b) above shall apply; or
 
(B)  
if the Debt Rating of the Guarantor is split and two of the ratings fall in the same pricing level (the Majority Level) and the third rating falls in a different pricing level, the Margin applicable to the Majority Level as set out in the table in paragraph (b) above shall apply.
 
(ii)  
If only two Rating Agencies issue a Debt Rating of the Guarantor, the Margin applicable to the higher rating shall apply, provided that, if the higher rating is two or more pricing levels above the lower rating, the Margin applicable to the rating that is one pricing level higher than the lower of the split ratings as set out in the table in paragraph (b) above shall apply.
 
(iii)  
If only one Rating Agency issues a Debt Rating of the Guarantor, the Margin applicable to that rating as set out in the table in paragraph (b) above shall apply.
 
(iv)  
If no Rating Agency issues a Debt Rating of the Guarantor, the Margin applicable to Pricing Level VI as set out in the table in paragraph (b) above shall apply.
 
(d)  
Any change in the Margin resulting from a publicly announced change in the Debt Rating of the Guarantor shall be effective, subject to paragraph (e) below, as of the date of such public announcement.
 
(e)  
For so long as an Event of Default is outstanding, the Margin will be increased by 2 per cent. per annum.
 
8.4  
Interest on overdue amounts
 
(a)  
If an Obligor fails to pay any amount payable by it under the Finance Documents, it must immediately on demand by the Facility Agent pay interest on the overdue amount from its due date up to the date of actual payment, before, on and after judgment.
 
(b)  
Interest on an overdue amount is payable at the rate which would have been payable (including any increase to the Margin under Clause 8.3(e) above) if the overdue amount had, during the period of non-payment, constituted the Loan in the currency of the overdue amount. For this purpose, the Facility Agent may (acting reasonably):
 
(i)  
select successive Interest Periods of any duration of up to six months; and
 
(ii)  
determine the appropriate Rate Fixing Day for that Interest Period.
 
(c)  
Notwithstanding paragraph (b) above, if the overdue amount is a principal amount of the Loan and becomes due and payable before the last day of its current Interest Period, then the first Interest Period for that overdue amount will be the unexpired portion of that Interest Period. After the expiry of the first Interest Period for that overdue amount, the rate on the overdue amount will be calculated in accordance with paragraph (b) above.
 
(d)  
Interest (if unpaid) on an overdue amount will be compounded with that overdue amount at the end of each of its Interest Periods but will remain immediately due and payable.
 
8.5  
Notification of rates of interest
 
  The Facility Agent must promptly notify each relevant Party of the determination of a rate of interest under this Agreement.
 
9.  
INTEREST PERIODs
 
9.1  
Selection
 
(a)  
The Loan has successive six month Interest Periods.
 
(b)  
Each Interest Period for the Loan will be six months, starting on the Utilisation Date or on the expiry of the preceding Interest Period, as the case may be.
 
9.2  
No overrunning the Final Maturity Date
 
  If an Interest Period would otherwise overrun the last applicable Final Maturity Date, it will be shortened so that it ends on the Final Maturity Date.
 
10.  
MARKET DISRUPTION
 
10.1  
Failure of a Reference Bank to supply a rate
 
  If LIBOR is to be calculated by reference to the Reference Banks but a Reference Bank does not supply a rate by 12.00 noon on a Rate Fixing Day, the applicable LIBOR will, subject as provided below, be calculated on the basis of the rates of the remaining Reference Banks.
 
10.2  
Market disruption
 
(a)  
In this Clause, each of the following events is a market disruption event:
 
(i)  
LIBOR is to be calculated by reference to the Reference Banks but no, or only one, Reference Bank supplies a rate by 12.00 noon on the Rate Fixing Day; or
 
(ii)  
the Facility Agent receives by close of business on the Rate Fixing Day notification from Lenders whose shares in the relevant Loan exceed 50 per cent. of that Loan that the cost to them of obtaining matching deposits in the relevant interbank market is in excess of LIBOR for the relevant Interest Period.
 
(b)  
The Facility Agent must promptly notify the Company, the Guarantor and the Lenders of a market disruption event.
 
(c)  
After notification under paragraph (b) above, the rate of interest on each Lender's share in the affected Loan for the relevant Interest Period will be the aggregate of the applicable:
 
(i)  
Margin;
 
(ii)  
rate notified to the Facility Agent by that Lender as soon as practicable, and in any event within 10 Business Days after the start of that Interest Period, to be that which expresses as a percentage rate per annum the cost to that Lender of funding its share in that Loan from whatever source it may reasonably select, provided that in the absence of such notice the rate of interest in respect of that Lender's share in the Loan for that Interest Period will be the same rate of interest that was in effect for the immediately preceding Interest Period; and
 
(iii)  
Mandatory Cost.
 
10.3  
Alternative basis of interest or funding
 
(a)  
If a market disruption event occurs and the Facility Agent, the Company or the Guarantor so requires, the Company, the Guarantor and the Facility Agent must enter into negotiations for a period of not more than 30 days with a view to agreeing an alternative basis for determining the rate of interest and/or funding for the affected Loan.
 
(b)  
Any alternative basis agreed will be, with the prior consent of all the Lenders, the Company and the Guarantor, binding on all the Parties.
 
11.  
TAXES
 
11.1  
General
 
  In this Clause:
 
  Obligor's Tax Jurisdiction means the jurisdiction in which the relevant Obligor is resident for Tax purposes.
 
  Qualifying Lender means a Lender which is:
 
(a)  
a Treaty Lender; or
 
(b)  
a Lender (other than a Lender within paragraph (a) above) that is entitled to receive interest in respect of an amount payable to that Lender under a Finance Document without a Tax Deduction imposed by the relevant Obligor's Tax Jurisdiction.
 
  Tax Credit means a credit against any Tax or any relief or remission for Tax (or its repayment).
 
  Tax Deduction means a deduction or withholding for or on account of Tax from a payment under any Finance Document.
 
  Treaty Lender means a Lender which is:
 
(a)  
resident (as defined in the appropriate double taxation agreement) in a country with which the Obligor's Tax Jurisdiction has a double taxation agreement giving residents of that country full exemption from the taxation on interest imposed by that Obligor's Tax Jurisdiction; and
 
(b)  
does not carry on a business in the Obligor's Tax Jurisdiction through a permanent establishment with which the payment is effectively connected.
 
11.2  
Tax gross-up
 
(a)  
Each Obligor must make all payments to be made by it under the Finance Documents without any Tax Deduction, unless a Tax Deduction is required by law.
 
(b)  
If:
 
(i)  
a Lender is not, or ceases to be, a Qualifying Lender; or
 
(ii)  
an Obligor or a Lender is aware that an Obligor must make a Tax Deduction (or that there is a change in the rate or the basis of a Tax Deduction),
 
  it must promptly notify the Facility Agent. The Facility Agent must then promptly notify the affected Parties.
 
(c)  
Except as provided below, if a Tax Deduction is required by law to be made by an Obligor or the Facility Agent, the amount of the payment due from the Obligor will be increased to an amount which (after making the Tax Deduction) leaves an amount equal to the payment which would have been due if no Tax Deduction had been required.
 
(d)  
Except as provided below, an Obligor is not required to make an increased payment under paragraph (c) above for a Tax Deduction in respect of tax imposed by the Obligor's Tax Jurisdiction to a Lender that is not, or has ceased to be, a Qualifying Lender in excess of the amount that the Obligor would have had to pay had the Lender been, or not ceased to be, a Qualifying Lender.
 
(e)  
Paragraph (d) above will not apply if the Lender has ceased to be a Qualifying Lender by reason of any change after the date it became a Lender under this Agreement in (or in the interpretation, administration, or application of) any law or double taxation agreement or any published practice or concession of any relevant taxing authority.
 
(f)  
An Obligor is not required to make an increased payment to a Lender under paragraph (c) above for a Tax Deduction in respect of tax imposed by the Obligor's Tax Jurisdiction if that Lender is a Treaty Lender and the Obligor making the payment is able to demonstrate that the Tax Deduction would not have been required if the Lender had complied with its obligations under paragraph (i) below.
 
(g)  
If an Obligor is required to make a Tax Deduction, that Obligor must make the minimum Tax Deduction allowed by law and must make any payment required in connection with that Tax Deduction within the time allowed by law.
 
(h)  
Within 30 days of making either a Tax Deduction or a payment required in connection with a Tax Deduction, the Obligor making that Tax Deduction or payment must deliver to the Facility Agent for the relevant Finance Party entitled to the payment an original receipt (or a certified copy thereof) satisfactory to that Finance Party (acting reasonably) that the Tax Deduction has been made or (as applicable) the appropriate payment has been paid to the relevant taxing authority.
 
(i)  
A Treaty Lender must co-operate with each Obligor by using its reasonable endeavours to complete any procedural formalities necessary for that Obligor to obtain authorisation to make that payment without a Tax Deduction.
 
11.3  
Tax indemnity
 
(a)  
Except as provided below, the Company must indemnify a Finance Party against any loss or liability which that Finance Party (in its reasonable discretion) determines will be or has been suffered (directly or indirectly) by that Finance Party for or on account of Tax in relation to a payment received or receivable (or any payment deemed to be received or receivable) under a Finance Document.
 
(b)  
Paragraph (a) above does not apply to any Tax assessed on a Finance Party under the laws of the jurisdiction in which:
 
(i)  
that Finance Party is incorporated or, if different, the jurisdiction (or jurisdictions) in which that Finance Party has a Facility Office and is treated as resident for tax purposes; or
 
(ii)  
that Finance Party's Facility Office is located in respect of amounts received or receivable in that jurisdiction,
 
  if that Tax is imposed on or calculated by reference to the net income received or receivable by that Finance Party. However, any payment deemed to be received or receivable, including any amount treated as income but not actually received by the Finance Party, such as a Tax Deduction, will not be treated as net income received or receivable for this purpose.
 
(c)  
A Finance Party making, or intending to make, a claim under paragraph (a) above must promptly notify the Company of the event which will give, or has given, rise to the claim.
 
11.4  
Tax Credit
 
  If an Obligor makes a Tax Payment and the relevant Finance Party (in its absolute discretion) determines that:
 
(a)  
a Tax Credit is attributable to that Tax Payment; and
 
(b)  
that Finance Party has obtained, utilised and fully retained that Tax Credit on an affiliated group basis,
 
  the Finance Party must pay an amount to the Obligor which that Finance Party determines (in its absolute discretion) will leave it (after that payment) in the same after-Tax position as it would have been if the Tax Payment had not been required to be made by the Obligor.
 
11.5  
Stamp taxes
 
  The Company must pay and indemnify each Finance Party against any stamp duty, stamp duty land tax, registration or other similar Tax payable in connection with the entry into, performance or enforcement of any Finance Document, except for any such Tax payable in connection with the entry into a Transfer Certificate.
 
11.6  
Value added taxes
 
(a)  
Any amount payable under a Finance Document by an Obligor is exclusive of any value added tax or any other Tax of a similar nature which might be chargeable in connection with that amount. If any such Tax is chargeable, the Obligor must pay to the Finance Party (in addition to and at the same time as paying that amount) an amount equal to the amount of that Tax.
 
(b)  
Where a Finance Document requires any Party to reimburse a Finance Party for any costs or expenses, that Party must also at the same time pay and indemnify the Finance Party against all value added tax or any other Tax of a similar nature incurred by the Finance Party in respect of those costs or expenses but only to the extent that the Finance Party (acting reasonably) determines that it is not entitled to credit or repayment from the relevant tax authority in respect of the Tax.
 
12.  
INCREASED COSTS
 
12.1  
Increased Costs
 
  Except as provided below in this Clause, the Company must pay to a Finance Party the amount of any Increased Cost incurred by that Finance Party as a result of:
 
(a)  
the introduction of, or any change in, or any change in the interpretation, administration or application of, any law or regulation; or
 
(b)  
compliance with any law or regulation made after the date of this Agreement.
 
12.2  
Exceptions
 
  The Company need not make any payment for an Increased Cost to the extent that the Increased Cost is:
 
(a)  
compensated for under another Clause or would have been but for an exception to that Clause;
 
(b)  
attributable to a Finance Party wilfully failing to comply with any law or regulation; or
 
(c)  
incurred more than six months prior to the date that such Finance Party notifies the Company of such Finance Party's intention to claim compensation therefore; provided that, if the circumstances giving rise to such claim have a retroactive effect, then such six-month period shall be extended to include the period of such retroactive effect.
 
12.3  
Claims
 
(a)  
A Finance Party intending to make a claim for an Increased Cost must notify the Facility Agent of the circumstances giving rise to and the amount of the claim, following which the Facility Agent will promptly notify the Company and the Guarantor.
 
(b)  
Each Finance Party must, as soon as practicable after a demand by the Facility Agent, provide a certificate confirming the amount of its Increased Cost.
 
13.  
MITIGATION
 
13.1  
Mitigation
 
(a)  
Each Finance Party must, in consultation with the Company and the Guarantor, take all reasonable steps to mitigate any circumstances which arise and which result or would result in:
 
(i)  
any Tax Payment or Increased Cost being payable to that Finance Party;
 
(ii)  
that Finance Party being able to exercise any right of prepayment and/or cancellation under this Agreement by reason of any illegality; or
 
(iii)  
that Finance Party incurring any cost of complying with the minimum reserve requirements of the European Central Bank,
 
  including transferring its rights and obligations under the Finance Documents to an Affiliate or changing its Facility Office.
 
(b)  
Paragraph (a) above does not in any way limit the obligations of any Obligor under the Finance Documents.
 
(c)  
The Company must indemnify each Finance Party for all costs and expenses reasonably incurred by that Finance Party as a result of any step taken by it under this Subclause, provided that the Guarantor has been consulted with regard to such costs and expenses prior to their incurrence.
 
(d)  
A Finance Party is not obliged to take any step under this Subclause if, in the opinion of that Finance Party (acting reasonably), to do so might be prejudicial to it.
 
13.2  
Conduct of business by a Finance Party
 
  No term of this Agreement will:
 
(a)  
interfere with the right of any Finance Party to arrange its affairs (Tax or otherwise) in whatever manner it thinks fit;
 
(b)  
oblige any Finance Party to investigate or claim any credit, relief, remission or repayment available to it in respect of Tax or the extent, order and manner of any claim; or
 
(c)  
oblige any Finance Party to disclose any information relating to its affairs (Tax or otherwise) or any computation in respect of Tax.
 
14.  
PAYMENTS
 
14.1  
Place
 
  Unless a Finance Document specifies that payments under it are to be made in another manner, all payments by a Party (other than the Facility Agent) under the Finance Documents must be made to the Facility Agent to its account at such office or bank in New York, as it may notify to that Party for this purpose by not less than five Business Days' prior notice.
 
14.2  
Funds
 
  Payments under the Finance Documents to the Facility Agent must be made for value on the due date at such times and in such funds as the Facility Agent may specify to the Party concerned as being customary at the time for the settlement of transactions in that currency in the place for payment.
 
14.3  
Distribution
 
(a)  
In this Subclause, Standing Payment Instruction means:
 
(i)  
in relation to a Lender which is a Lender on the date of this Agreement, payment instructions set below the name of that Lender in Schedule 7 (Form of Standing Payment Instructions); or
 
(ii)  
in relation to a Lender which becomes a Lender after the date of this Agreement, payment instructions set out in the Transfer Certificate to which that Lender is a party,
 
  or such other payment instructions the Lender may notify to the Facility Agent but not less than five Business Days' prior notice.
 
(b)  
Each payment received by the Facility Agent under the Finance Documents for another Party must, except as provided below, be made available by the Facility Agent to that Party by payment (as soon as practicable after receipt) to its account with such office or bank in New York, as it may notify to the Facility Agent for this purpose by not less than five Business Days' prior notice.
 
(c)  
Notwithstanding paragraph (a) above, any payment to be made under the Finance Documents by the Facility Agent to a Lender must be made in accordance with that Lender's Standing Payment Instruction.
 
(d)  
The Facility Agent may apply any amount received by it for an Obligor in or towards payment (on the date and in the currency and funds of receipt) of any amount due from that Obligor under the Finance Documents or in or towards the purchase of any amount of any currency to be so applied.
 
(e)  
Where a sum is paid to the Facility Agent under this Agreement for another Party, the Facility Agent is not obliged to pay that sum to that Party until it has established that it has actually received it. However, the Facility Agent may assume that the sum has been paid to it, and, in reliance on that assumption, make available to that Party a corresponding amount. If it transpires that the sum has not been received by the Facility Agent, that Party must immediately on demand by the Facility Agent refund any corresponding amount made available to it together with interest on that amount from the date of payment to the date of receipt by the Facility Agent at a rate calculated by the Facility Agent to reflect its cost of funds.
 
14.4  
Currency
 
(a)  
Unless a Finance Document specifies that payments under it are to be made in a different manner, the currency of each amount payable under the Finance Documents is determined under this Clause.
 
(b)  
Amounts payable in respect of Taxes, fees, costs and expenses are payable in the currency in which they are incurred.
 
(c)  
Each other amount payable under the Finance Documents is payable in US$.
 
(d)  
If a change in any currency of a country occurs, the Finance Documents will be amended in accordance with Clause 25.3 (Change of currency).
 
14.5  
No set-off or counterclaim
 
  All payments made by an Obligor under the Finance Documents must be calculated and made without (and free and clear of any deduction for) set-off or counterclaim.
 
14.6  
Business Days
 
(a)  
If a payment under the Finance Documents is due on a day which is not a Business Day, the due date for that payment will instead be the next Business Day in the same calendar month (if there is one) or the preceding Business Day (if there is not).
 
(b)  
During any extension of the due date for payment of any principal under this Agreement interest is payable on that principal at the rate payable on the original due date.
 
14.7  
Partial payments
 
(a)  
If any Administrative Party receives a payment insufficient to discharge all the amounts then due and payable by the Obligors under the Finance Documents, the Administrative Party must apply that payment towards the obligations of the Obligors under the Finance Documents in the following order:
 
(i)  
first, in or towards payment pro rata of any unpaid fees of the Administrative Parties as well as any costs and expenses of the Facility Agent payable in accordance with the terms of the Finance Documents;
 
(ii)  
secondly, in or towards payment pro rata of any accrued interest or fee due but unpaid under this Agreement;
 
(iii)  
thirdly, in or towards payment pro rata of any principal amount due but unpaid under this Agreement; and
 
(iv)  
fourthly, in or towards payment pro rata of any other sum due but unpaid under the Finance Documents.
 
(b)  
The Facility Agent must, if so directed by the Lenders, vary the order set out in subparagraphs (a)(ii) to (iv) above and promptly notify the Obligors of such change.
 
(c)  
This Subclause will override any appropriation made by an Obligor.
 
14.8  
Timing of payments
 
  If a Finance Document does not provide for when a particular payment is due, that payment will be due within ten Business Days of demand by the relevant Finance Party.
 
15.  
GUARANTEE AND INDEMNITY
 
15.1  
Guarantee and indemnity
 
  The Guarantor irrevocably and unconditionally:
 
(a)  
guarantees to each Finance Party punctual performance by the Company of all its obligations under the Finance Documents;
 
(b)  
undertakes with each Finance Party that, whenever the Company does not pay any amount when due under or in connection with any Finance Document, the Guarantor must within two Business Days of demand by the Facility Agent pay that amount as if it were the principal obligor in respect of that amount; and
 
(c)  
indemnifies each Finance Party immediately on demand against any cost, loss or liability suffered by that Finance Party if any obligation guaranteed by it is or becomes unenforceable, invalid or illegal; the amount of the cost, loss or liability under this indemnity will be equal to the amount the Finance Party would otherwise have been entitled to recover from the Company under the Finance Documents had such guaranteed obligation not been unenforceable, invalid or illegal.
 
15.2  
Continuing guarantee
 
  This guarantee is a continuing guarantee and will extend to the ultimate balance of all sums payable by the Company under the Finance Documents, regardless of any intermediate payment or discharge in whole or in part.
 
15.3  
Reinstatement
 
(a)  
If any payment by an Obligor or any discharge given by a Finance Party (whether in respect of the obligations of an Obligor or any security for those obligations or otherwise) or arrangement is made in whole or in part on the faith of any payment, security or other disposition which is avoided or must be restored on insolvency, liquidation, administration or other similar event, the liability of the Guarantor under this Clause will continue or be reinstated as if the discharge or arrangement had not occurred.
 
(b)  
Each Finance Party may concede or compromise any claim that any payment, security or other disposition is liable to avoidance or restoration.
 
15.4  
Waiver of defences
 
  The obligations of the Guarantor under this Clause will not be affected by any act, omission or thing which, but for this provision, would reduce, release or prejudice any of its obligations under this Clause (without limitation and whether or not known to it or any Finance Party). This includes:
 
(a)  
any time, consent or waiver granted to, or composition with, any Obligor or other person;
 
(b)  
any release of any Obligor or any other person under the terms of any composition or arrangement with any creditor of any member of the Group;
 
(c)  
the taking, variation, compromise, exchange, renewal or release of, or refusal or neglect to perfect, take up or enforce, any rights against, or security over assets of, any Obligor or any other person;
 
(d)  
any non-presentation or non-observance of any formality or other requirement in respect of any instrument or any failure to realise the full value of any security;
 
(e)  
any incapacity or lack of power, authority or legal personality of or dissolution or change in the members or status of any Obligor or any other person;
 
(f)  
any amendment (however fundamental) or replacement of a Finance Document or any other document or security;
 
(g)  
any unenforceability, illegality, invalidity or non-provability of any obligation of any person under any Finance Document or any other document or security; or
 
(h)  
any insolvency or similar proceedings.
 
15.5  
Immediate recourse
 
(a)  
The Guarantor waives any right it may have of first requiring any Finance Party (or any trustee or agent on its behalf) to proceed against or enforce any other right or security or claim payment from any person before claiming from the Guarantor under this Clause.
 
(b)  
This waiver applies irrespective of any law or any provision of a Finance Document to the contrary.
 
15.6  
Appropriations
 
  Until all amounts which may be or become payable by the Obligors under or in connection with the Finance Documents have been irrevocably paid in full, each Finance Party (or any trustee or agent on its behalf) may without affecting the liability of the Guarantor under this Clause:
 
(a)  
(i)refrain from applying or enforcing any other moneys, security or rights held or received by that Finance Party (or any trustee or agent on its behalf) against those amounts; or
 
(ii)  
apply and enforce them in such manner and order as it sees fit (whether against those amounts or otherwise); and
 
(b)  
hold in an interest-bearing suspense account any moneys received on account of the Guarantor's liability under this Clause.
 
15.7  
Non-competition
 
  Unless:
 
(a)  
all amounts which may be or become payable by the Obligors under or in connection with the Finance Documents have been irrevocably paid in full; or
 
(b)  
the Facility Agent otherwise directs,
 
  the Guarantor will not, after a claim has been made or by virtue of any payment or performance by it under this Clause:
 
(i)  
be subrogated to any rights, security or moneys held, received or receivable by any Finance Party (or any trustee or agent on its behalf);
 
(ii)  
be entitled to any right of contribution or indemnity in respect of any payment made or moneys received on account of the Guarantor's liability under this Clause;
 
(iii)  
claim, rank, prove or vote as a creditor of the Company or its estate in competition with any Finance Party (or any trustee or agent on its behalf) unless it immediately turns over to the Finance Parties any proceeds that it recovers as a creditor; or
 
(iv)  
receive, claim or have the benefit of any payment, distribution or security from or on account of the Company, or exercise any right of set-off as against the Company.
 
  The Guarantor must hold in trust for and immediately pay or transfer to the Facility Agent for the Finance Parties any payment or distribution or benefit of security received by it contrary to this Clause or in accordance with any directions given by the Facility Agent under this Clause.
 
15.8  
Additional security
 
  This guarantee is in addition to and is not in any way prejudiced by any other guarantee or security now or subsequently held by any Finance Party.
 
16.  
REPRESENTATIONS AND WARRANTIES
 
16.1  
Representations and warranties
 
  The representations and warranties set out in this Clause are made by each Obligor or (if it so states) either one of them to each Finance Party and are subject to Clause 19.11 (BLIO Matters).
 
16.2  
Status
 
  It is a limited liability company or corporation duly organised, validly existing and in good standing under the laws of its jurisdiction of incorporation.
 
16.3  
Powers, authority and non-conflict
 
  The execution, delivery and performance by it of the Finance Documents to which it is a party, and the consummation of the transactions contemplated hereby, are within its corporate powers, have been duly authorised by all necessary corporate action, and do not contravene:
 
(a)  
any of its constitutional documents; or
 
(b)  
any law or contractual restriction binding on or affecting it.
 
16.4  
Authorisations
 
  No authorisation or approval or other action by, and no notice to or filing with, any governmental authority or regulatory body or any other third party is required for the due execution, delivery and performance by it of any Finance Document to which it is a party.
 
16.5  
Legal validity
 
  Each Finance Document to which it is a party has been duly executed and delivered by it. Subject to the Legal Reservations, each Finance Document to which it is a party, is its legal, valid and binding obligations enforceable against it in accordance with such Finance Document's respective terms.
 
16.6  
Financial statements
 
  The Guarantor represents and warrants that the Consolidated balance sheet of the Guarantor as at 25 December, 2004, and the related Consolidated statements of income and cash flows of the Group for the fiscal year then ended, accompanied by an opinion of PricewaterhouseCoopers LLP, independent public accountants, and the Consolidated balance sheet of the Group as at 25 June, 2005 and the related Consolidated statements of income and cash flows of the Group for the six months then ended, duly certified by the chief financial officer of the Guarantor, copies of which have been furnished to each Lender, fairly present, subject, in the case of said balance sheet as at 25 June, 2005 and said statements of income and cash flows for the six months then ended, to year-end audit adjustments, the Consolidated financial condition of the Group as at such dates and the Consolidated results of the operations of the Group for the periods ended on such dates, all in accordance with generally accepted accounting principles consistently applied. At the date of this Agreement there has been no Material Adverse Change since 25 December, 2004, other than as publicly disclosed prior to the date of this Agreement.
 
16.7  
Litigation
 
  At the date of this Agreement there is no pending or threatened action, suit, investigation, litigation or proceeding, including, without limitation, any Environmental Action, affecting any member of the Group before any court, governmental agency or arbitrator that:
 
(a)  
could be reasonably likely to have a Material Adverse Effect (other than matters as are identified in the periodic report of the Guarantor, which are filed prior to the date of this Agreement with the SEC); or
 
(b)  
purports to affect the legality, validity or enforceability of this Agreement or any other Finance Document or the consummation of the transactions contemplated hereby.
 
16.8  
Use of credit
 
  It is not engaged in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulation U issued by the Board of Governors of the Federal Reserve System), and no proceeds of any Loan will be used to purchase or carry any margin stock or to extend credit to others for the purpose of purchasing or carrying any margin stock.
 
16.9  
Title to property
 
  The Company represents and warrants that it, and the Guarantor represents and warrants that each member of the Group has good title to, or valid leasehold interests in, all its real and personal property material to its business, except for defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilise such properties for their intended purposes and that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
 
16.10  
Intellectual property
 
  The Company represents and warrants that it, and the Guarantor represents and warrants that each member of the Group owns, or is licensed to use, all trademarks, trade names, copyrights, patents and other intellectual property material to its business, and the use thereof by each member of the Group does not infringe upon the rights of any other person, except for any such infringements that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
 
16.11  
Compliance with laws
 
  The Company represents and warrants that it, and the Guarantor represents and warrants that each member of the Group is in compliance with all laws (including, without limitation, ERISA, Environmental Laws and the Patriot Act), regulations and orders of any governmental authority applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
 
16.12  
Investment Company Act
 
  The Company represents and warrants that it is not, and the Guarantor represents and warrants that no member of the Group is:
 
(a)  
an "investment company" as defined in, or subject to regulation under, the Investment Company Act of 1940; or
 
(b)  
a "holding company" as defined in, or subject to regulation under, the Public Utility Holding Company Act of 1935.
 
16.13  
Taxes
 
(a)  
The Company represents and warrants that it, and the Guarantor represents and warrants that each member of the Group has timely filed or caused to be filed all tax returns and reports required to have been filed and has paid or caused to be paid all taxes required to have been filed and has paid or caused to be paid all taxes required to have been paid by it, except:
 
(i)  
taxes that are being contested in good faith by appropriate proceedings and for which such person has set aside on its books reserves where required by GAAP; or
 
(ii)  
to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect.
 
(b)  
The Company represents and warrants that for Tax purposes, it is resident only in the jurisdiction of its incorporation.
 
16.14  
Ownership of the Company
 
  The Company is a wholly-owned Subsidiary of the Guarantor.
 
16.15  
Material Subsidiaries
 
  Attached hereto at Schedule 6 is a list of each Material Subsidiary on the date hereof.
 
16.16  
Dutch Banking Act
 
(a)  
If the Company is a credit institution (kredietinstelling) under the Dutch Banking Act, it is in compliance with the applicable provisions of the Dutch Banking Act and any implementing regulation, including the Dutch Exemption Regulation.
 
(b)  
On the date of this Agreement the Company has verified the status of each person which is a Lender under this Agreement either as:
 
(i)  
a Professional Market Party under the Dutch Exemption Regulation; or 
 
(ii)  
exempted from the requirement to be a Professional Market Party because it forms part of a closed circle (besloten kring) with the Company.
 
(c)  
The Company will be deemed to have complied with its verification obligation set out under (b)(i) above, if it could reasonably assume that the Lender concerned is a Professional Market Party on the basis of:
 
(i)  
information from public registers;
 
(ii)  
information from a recognised rating institution within the meaning of the Dutch capital adequacy rules for credit institutions as set out in the Credit System Supervision Manual (Handboek Wtk) part 9001-02;
 
(iii)  
information received from such Lender; or
 
(iv)  
an express confirmation from such Lender.
 
16.17  
Times for making representations and warranties
 
(a)  
The representations and warranties set out in this Clause are made by each Obligor on the date of this Agreement.
 
(b)  
Unless a representation and warranty is expressed to be given at a specific date, each representation and warranty is deemed to be repeated by each Obligor on the Utilisation Date and the first day of each Interest Period.
 
(c)  
When a representation and warranty is repeated, it is applied to the circumstances existing at the time of repetition.
 
17.  
POSITIVE COVENANTS
 
17.1  
General
 
  For so long as any amount is outstanding under any of the Finance Documents or any Lender shall have any Commitment under this Agreement, each Obligor agrees to be bound by the covenants set out in this Clause relating to it and, where the covenant is expressed to apply to each member of the Group, each Obligor must ensure that each of its Subsidiaries performs that covenant. Each covenant is subject to Clause 19.11 (BLIO Matters).
 
17.2  
Compliance with laws
 
  The Guarantor must comply, and cause each of its Subsidiaries to comply, with all applicable laws, rules, regulations and orders, such compliance to include, without limitation, compliance with ERISA, Environmental Laws and the Patriot Act to the extent that the failure to do so could reasonably be expected to result in a Material Adverse Effect.
 
17.3  
Payment of taxes
 
  The Guarantor must pay and discharge, and cause each of its Subsidiaries to pay and discharge, before the same shall become delinquent:
 
(a)  
all taxes, assessments and governmental charges or levies imposed upon it or upon its property; and
 
(b)  
all lawful claims that, if unpaid, might by law become a Security Interest upon its property,
 
  provided, however, that neither the Guarantor nor any of its Subsidiaries shall be required to pay or discharge any such tax, assessment, charge or claim that is being contested in good faith and by proper proceedings and as to which appropriate reserves are being maintained where required by GAAP, unless and until any Security Interest resulting therefrom attaches to its property and enforcement, collection, execution, levy or foreclosure proceedings shall have been commenced with respect to one or more such taxes, assessments, charges, levies or claims that, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.
 
17.4  
Insurance
 
  The Guarantor must maintain, and cause each of its Subsidiaries to maintain, insurance with responsible and reputable insurance companies or associations in such amounts and covering such risks as is usually carried by companies engaged in similar businesses and owning similar properties in the same general areas in which the Guarantor or such Subsidiary operates.
 
17.5  
Preservation of corporate existence
 
  The Guarantor must preserve and maintain, and cause each of its Material Subsidiaries to preserve and maintain, its corporate existence, rights (charter and statutory) and franchises; provided, however, that the Guarantor and its Material Subsidiaries may consummate any merger or consolidation permitted under Clause 18.3 (Mergers) and provided further that neither the Guarantor nor any of its Material Subsidiaries shall be required to preserve any right or franchise if the board of directors of the Guarantor or such Subsidiary shall reasonably determine that the preservation thereof is no longer desirable in the conduct of the business of the Guarantor or such Subsidiary, as the case may be, and that the loss thereof is not disadvantageous in any material respect to the Guarantor, such Subsidiary or the Lenders.
 
17.6  
Inspection rights
 
  The Guarantor must, at any reasonable time and from time to time upon no less than 5 Business Days' prior notice to the Guarantor, permit the Facility Agent or any of the Lenders or any agents or representatives thereof, to examine and make copies of and abstracts from the records and books of account of, and visit the properties of, any member of the Group, and to discuss the affairs, finances and accounts of any member of the Group with any of their officers or directors and with their independent certified public accountants.
 
17.7  
Maintenance of accounts
 
  The Guarantor must keep, and cause each of its Material Subsidiaries to keep, proper books of record and account, in which full and correct entries shall be made of all financial transactions and the assets and business of the Guarantor and each such Subsidiary in accordance with generally accepted accounting principles in effect from time to time.
 
17.8  
Maintenance of properties
 
  The Guarantor must maintain and preserve, and cause each of its Material Subsidiaries to maintain and preserve, all of its properties that are used or useful in the conduct of its business in good working order and condition, ordinary wear and tear excepted.
 
17.9  
Ownership of the Company
 
  The Guarantor must maintain 100 per cent. direct or indirect ownership of the Company.
 
17.10  
Reporting requirements
 
(a)  
The Guarantor (or the Company in the case of (ii) below) must supply to the Facility Agent in sufficient copies for all the Lenders:
 
(i)  
as soon as available and in any event within 60 days after the end of each of the first three quarters of each fiscal year of the Guarantor, a Consolidated balance sheet of the Group as of the end of such quarter and Consolidated statements of income and cash flows of the Group for the period commencing at the end of the previous fiscal year and ending with the end of such quarter, duly certified (subject to year-end audit adjustments) by the chief financial officer, treasurer or controller of the Guarantor as having been prepared in accordance with GAAP and certificates of the chief financial officer, treasurer or controller of the Guarantor as to compliance with the terms of this Agreement and setting forth in reasonable detail the calculations necessary to demonstrate compliance with Clause 18.8 (Financial covenants), provided that in the event of any change in GAAP used in the preparation of such financial statements, the Guarantor shall also provide, if necessary for the determination of compliance with Clause 18.8 (Financial covenants), a statement of reconciliation conforming such financial statements to GAAP;
 
(ii)  
as soon as available and in any event within 60 days after the end of each of the first half of each fiscal year of the Company, interim financial statements of the Company;
 
(iii)  
as soon as available and in any event within 105 days after the end of each fiscal year of the Guarantor, a copy of the audited annual report for such year for the Group, containing a Consolidated balance sheet of the Group as of the end of such fiscal year and Consolidated statements of income and cash flows of the Group for such fiscal year, in each case accompanied by an opinion acceptable to the Majority Lenders by PricewaterhouseCoopers, LLP or other independent public accountants acceptable to the Majority Lenders and certificates of the chief financial officer, treasurer or controller of the Guarantor as to compliance with the terms of this Agreement and setting forth in reasonable detail the calculations necessary to demonstrate compliance with Clause 18.8 (Financial covenants), provided that in the event of any change in GAAP used in the preparation of such financial statements, the Guarantor shall also provide, if necessary for the determination of compliance with Clause 18.8 (Financial covenants), a statement of reconciliation conforming such financial statements to GAAP;
 
(iv)  
as soon as possible and in any event within five days after the occurrence of each Default continuing on the date of such statement, a statement of the chief financial officer, treasurer or controller of the Guarantor setting forth details of such Default and the action that the Guarantor has taken and proposes to take with respect thereto;
 
(v)  
promptly after the sending or filing thereof, copies of all reports that the Guarantor sends to any of its securityholders, and copies of all reports and registration statements that the Guarantor or any of its Subsidiaries files with the Securities and Exchange Commission or any national securities exchange;
 
(vi)  
promptly after the commencement thereof, notice of all actions and proceedings before any court, governmental agency or arbitrator affecting any member of the Group of the type described in Clause 16.7 (Litigation); and
 
(vii)  
such other information respecting any member of the Group as any Lender through the Facility Agent may from time to time reasonably request.
 
(b)  
Reports required to be delivered pursuant to (i), (iii), (v) and (vi) above shall be deemed to have been delivered on the date on which such report is posted on the SEC's website at www.sec.gov, and such posting shall be deemed to satisfy the reporting requirements of (i), (iii), (v) and (vi) above; provided that the Guarantor shall deliver paper copies of the certificate required by (i) and (iii) above to the Facility Agent and each of the Lenders until such time as the Facility Agent shall provide the Company or Guarantor written notice otherwise.
 
17.11  
Know your customer requirements
 
(a)  
Each Obligor must as soon as reasonably practicable following receipt of written request from any Finance Party supply to that Finance Party any documentation or other evidence which is reasonably requested by that Finance Party (whether for itself, on behalf of any Finance Party or any prospective new Lender) to enable a Finance Party or prospective new Lender to carry out and be satisfied with the results of all applicable know your customer requirements.
 
(b)  
Each Lender must promptly on the request of the Facility Agent supply to the Facility Agent any documentation or other evidence which is reasonably required by the Facility Agent to carry out and be satisfied with the results of all know your customer requirements.
 
18.  
NEGATIVE COVENANTS AND FINANCIAL COVENANTS
 
18.1  
General
 
  For so long as any amount is outstanding under any of the Finance Documents or any Lender shall have any Commitment under this Agreement, each Obligor agrees to be bound by the covenants set out in this Clause relating to it and, where the covenant is expressed to apply to each member of the Group, each Obligor must ensure that each of its Subsidiaries performs that covenant.
 
18.2  
Negative pledge
 
  The Guarantor must not create or suffer to exist, or permit any of its Subsidiaries to create or suffer to exist, any Security Interest on or with respect to any of its properties, whether now owned or hereafter acquired, or assign, or permit any of its Subsidiaries to assign, any right to receive income, other than:
 
(a)  
Permitted Security Interests;
 
(b)  
purchase money Security Interests upon or in any real property or equipment acquired or held by any member of the Group in the ordinary course of business to secure the purchase price of such property or equipment or to secure Debt incurred solely for the purpose of financing the acquisition of such property or equipment, or Security Interests existing on such property or equipment at the time of its acquisition (other than any such Security Interests created in contemplation of such acquisition that were not incurred to finance the acquisition of such property) or extensions, renewals or replacements of any of the foregoing for the same or a lesser amount, provided, however, that no such Security Interest shall extend to or cover any properties of any character other than the real property or equipment being acquired, and no such extension, renewal or replacement shall extend to or cover any properties not theretofore subject to the Security Interest being extended, renewed or replaced, provided further that the aggregate principal amount of the indebtedness secured by the Security Interests referred to in this paragraph shall not exceed US$100,000,000 at any time outstanding;
 
(c)  
Security Interests arising in connection with any court action or other legal proceeding so long as no Default under Clause 19.7 (Final judgment) has occurred and is continuing;
 
(d)  
other Security Interests securing Debt in an aggregate principal amount not to exceed US$50,000,000 at any time outstanding; and
 
(e)  
the replacement, extension or renewal of any Security Interest permitted by paragraph (a) above upon or in the same property theretofore subject thereto or the replacement, extension or renewal (without increase in the amount or change in any direct or contingent obligor) of the Debt secured thereby.
 
18.3  
Mergers
 
  The Guarantor must not merge or consolidate with or into, or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to, any person, or permit any of its Material Subsidiaries to do so, except that:
 
(a)  
any Material Subsidiary may merge or consolidate with or into, or dispose of assets to, any other Subsidiary of the Guarantor;
 
(b)  
any Subsidiary of the Guarantor may merge into or dispose of assets to the Guarantor or to the Company; and
 
(c)  
the Guarantor and/or the Company may merge with any other person so long as the Guarantor and/or the Company (as the case may be) is the surviving corporation,
 
  provided, in each case, that no Default shall have occurred and be continuing at the time of such proposed transaction or would result therefrom.
 
18.4  
Accounting changes
 
  The Guarantor must not make or permit, or permit any of its Subsidiaries to make or permit, any change in accounting policies or reporting practices, except as required or permitted by generally accepted accounting principles.
 
18.5  
Change of business
 
  The Guarantor must not make, or permit any of its Material Subsidiaries to make, any material change in the nature of the business carried on at the date hereof by the Guarantor and its Material Subsidiaries, taken as a whole, provided that the Guarantor and its Material Subsidiaries may expand into other lines of business in the health products industry.
 
18.6  
Restrictive agreements
 
  The Guarantor must not directly or indirectly enter into, incur or permit to exist, or permit any of its Subsidiaries to enter into, incur or permit to exist, any agreement or other arrangement that prohibits, restricts or imposes any condition upon:
 
(a)  
the ability of the Guarantor or any of its Subsidiaries to create, incur or permit to exist any Security Interest upon any of its property or assets; or
 
(b)  
the ability of any Subsidiary of the Guarantor to pay dividends or other distributions with respect to any shares of its capital stock or to make or repay loans or advances to the Guarantor or any other Subsidiary of the Guarantor or to guarantee Debt of the Guarantor or any other Subsidiary of the Guarantor;
 
  provided that:
 
(i)  
paragraph (a) above and this paragraph (b) shall not apply to restrictions and conditions imposed by law or by this Agreement or the Existing Guarantor Credit Agreement;
 
(ii)  
paragraph (a) above and this paragraph (b) shall not apply to restrictions and conditions that could not be reasonably expected to cause a material adverse effect on the ability of the Guarantor to perform any of its obligations under this Agreement;
 
(iii)  
paragraph (a) above and this paragraph (b) shall not apply to restrictions and conditions existing on the date hereof (but shall apply to any extension or renewal of, or any amendment or modification expanding the scope of, any such restriction or condition);
 
(iv)  
paragraph (a) above and this paragraph (b) shall not apply to customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary of the Guarantor pending such sale, provided such restrictions and conditions apply only to the Subsidiary of the Guarantor that is to be sold and such sale is permitted hereunder;
 
(v)  
paragraph (a) above shall not apply to restrictions or conditions imposed by any agreement relating to secured Debt permitted by this Agreement if such restrictions or conditions apply only to the property or assets securing such Debt; and
 
(vi)  
paragraph (a) above shall not apply to customary provisions in leases and licences restricting the assignment thereof.
 
18.7  
Use of credit
 
  The Guarantor must not use, or permit any of its Subsidiaries to use, the proceeds of any Loan to purchase or carry margin stock (within the meaning of Regulation U of the Board of Governors of the Federal Reserve System) or to extend credit to others for the purpose of purchasing or carrying margin stock.
 
18.8  
Financial covenants
 
  So long as any Loan shall remain unpaid or any Lender shall have any Commitment hereunder, the Guarantor must:
 
(a)  
maintain a ratio of Consolidated Debt for Borrowed Money to Consolidated EBITDA of the Group for the four fiscal quarters most recently ended of not greater than 3.0:1.0; and
 
(b)  
maintain a ratio of Consolidated EBITDA of the Group for the four fiscal quarters most recently ended to interest payable on, and amortisation of debt discount in respect of, all Debt for Borrowed Money during such period, by the Group of not less than 4.0:1.0.
 
  The ratios referred to in this Clause 18.8 shall be tested by reference to the financial statements most recently delivered by the Guarantor to the Facility Agent in accordance with Clause 17.10(a)(i) and Clause 17.10(a)(iii).
 
19.  
DEFAULT
 
19.1  
Events of Default
 
  Subject to Clause 19.11 (BLIO Matters) below, each of the events or circumstances set out in this Clause is an Event of Default.
 
19.2  
Non-payment
 
  An Obligor does not pay on the due date any amount payable pursuant to a Finance Document unless:
 
(i)  
its failure to pay is caused by administrative or technical error; and
 
(ii)  
payment is made within two Business Days of receiving notice that the payment was not made on its due date.
 
19.3  
Misrepresentation
 
  Any representation or warranty made by an Obligor herein or by an Obligor (or any of its officers) in connection with this Agreement shall prove to have been incorrect in any material respect when made.
 
19.4  
Breach of other obligations
 
(a)  
An Obligor shall fail to perform or observe any term, covenant or agreement contained in Clauses 17.5 (Preservation of corporate existence), 17.6 (Inspection rights), 17.10 (Reporting requirements), or 18 (Negative Covenants and Financial Covenants); or
 
(b)  
an Obligor shall fail to perform or observe any other term, covenant or agreement contained in this Agreement on its part to be performed or observed if such failure shall remain unremedied for 30 days after the earlier of:
 
(i)  
written notice thereof shall have been given to the Company and the Guarantor by the Facility Agent or any Lender; and
 
(ii)  
a responsible financial officer of the Company and the Guarantor otherwise becomes aware of such failure.
 
19.5  
Cross-default
 
(a)  
The Guarantor or any of its Subsidiaries shall fail to pay any principal of or premium or interest on any Debt that is outstanding in a principal or notional amount of at least US$50,000,000 in the aggregate (but excluding Debt outstanding hereunder) of the Guarantor or such Subsidiary (as the case may be), when the same becomes due and payable (whether by scheduled maturity, required prepayment, acceleration, demand or otherwise), and such failure shall continue after the applicable grace period, if any, specified in the agreement or instrument relating to such Debt;
 
(b)  
any other event shall occur or condition shall exist under any agreement or instrument relating to any such Debt and shall continue after the applicable grace period, if any, specified in such agreement or instrument, if the effect of such event or condition is to accelerate, or to permit the acceleration of, the maturity of such Debt; or
 
(c)  
any such Debt shall be declared to be due and payable, or required to be prepaid or redeemed (other than by a regularly scheduled required prepayment or redemption), purchased or defeased, or an offer to prepay, redeem, purchase or defease such Debt shall be required to be made, in each case prior to the stated maturity thereof.
 
19.6  
Insolvency
 
  Except as provided below, any of the following occurs in respect of the Guarantor or any of its Material Subsidiaries:
 
(a)  
it shall generally not pay its debts as such debts become due;
 
(b)  
it admits in writing its inability to pay its debts generally;
 
(c)  
it makes a general assignment for the benefit of its creditors;
 
(d)  
any proceeding shall be instituted by or against it:
 
(i)  
seeking to adjudicate it a bankrupt or insolvent;
 
(ii)  
seeking liquidation, winding up, reorganisation, arrangement, adjustment, protection, relief, or composition of it or its debts under any law relating to bankruptcy, insolvency or reorganisation or relief of debtors; or
 
(iii)  
seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar official for it or for any substantial part of its property; and
 
  in the case of any such proceeding instituted against it (but not instituted by it):
 
(iv)  
either such proceeding shall remain undismissed or unstayed for a period of 60 days; or
 
(v)  
any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against, or the appointment of a receiver, trustee, custodian or other similar official for, it or for any substantial part of its property) shall occur; or
 
(e)  
the Guarantor or any of its Material Subsidiaries shall take any corporate action to authorise any of the actions set forth above in this Clause.
 
19.7  
Final judgment
 
(a)  
Any judgments or orders for the payment of money in excess of US$25,000,000 in the aggregate shall be rendered against the Guarantor or any of its Subsidiaries and either:
 
(i)  
enforcement proceedings shall have been commenced by any creditor upon such judgment or order;
 
(ii)  
other than in respect of a settlement order, there shall be any period of 30 consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect; or
 
(iii)  
the Guarantor or any of its Subsidiaries shall be in default under a settlement order.
 
(b)  
Any non-monetary judgment or order shall be rendered against the Guarantor or any of its Subsidiaries that could be reasonably expected to have a Material Adverse Effect, and there shall be any period of 30 consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect.
 
19.8  
Change of control
 
(a)  
Any person or two or more persons acting in concert shall have acquired beneficial ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934), directly or indirectly, of Voting Stock of the Guarantor (or other securities convertible into such Voting Stock) representing 30 per cent. or more of the combined voting power of all Voting Stock of the Guarantor;
 
(b)  
during any period of up to 12 consecutive months, commencing before or after the date of this Agreement, individuals who at the beginning of such 12-month period were directors of the Guarantor shall cease for any reason to constitute a majority of the board of directors of the Guarantor; or
 
(c)  
any person or two or more persons acting in concert shall have acquired by contract or otherwise, or shall have entered into a contract or arrangement that, upon consummation, will result in its or their acquisition of the power to exercise, directly or indirectly, a controlling influence over the management or policies of the Guarantor.
 
19.9  
ERISA
 
  The Guarantor or any of its ERISA Affiliates shall incur, or shall be reasonably likely to incur liability in excess of US$50,000,000 in the aggregate as a result of one or more of the following:
 
(a)  
the occurrence of any ERISA Event;
 
(b)  
the partial or complete withdrawal of the Guarantor or any of its ERISA Affiliates from a Multiemployer Plan; or
 
(c)  
the reorganisation or termination of a Multiemployer Plan.
 
19.10  
Acceleration
 
  If an Event of Default occurs, the Facility Agent shall at the request, or may with the consent, of the Majority Lenders, by notice to the Company and the Guarantor:
 
(a)  
declare the obligation of each Lender to advance Loans to be terminated, whereupon the same shall forthwith terminate; and
 
(b)  
declare the Loans, all interest thereon and all other amounts payable under this Agreement to be forthwith due and payable, whereupon the Loans, all such interest and all such amounts shall become and be forthwith due and payable, without presentment, demand, protest or further notice of any kind, all of which are hereby expressly waived by the Company; provided, however, that in the event of an actual or deemed entry of an order for relief with respect to the Guarantor under the Bankruptcy Code:
 
(i)  
the obligation of each Lender to make Loans shall automatically be terminated; and
 
(ii)  
the Loans, all such interest and all such amounts shall automatically become and be due and payable, without presentment, demand, protest or any notice of any kind, all of which are hereby expressly waived by the Company.
 
19.11  
BLIO Matters
 
(a)  
Solely for the Waiver Period, it is agreed that, the BLIO Matters described in the BLIO Announcements will not result in or constitute a breach of this Agreement (including, without limitation, any misrepresentation or breach of covenant) or an Event of Default) to the extent that:
 
(i)  
any restatements of the Guarantor's financial statements for prior financial periods do not result in reductions in profits after tax of the Guarantor of more than US$50,000,000 in the aggregate; and
 
(ii)  
with respect to any delay in delivery of financial statements required to be delivered under this Agreement, such delay does not extend beyond 1 March, 2006.
 
(b)  
In this Clause:
 
  BLIO Announcements means the Guarantor's:
 
(i)  
press releases dated 26 October, 2005 and 3 November, 2005; and
 
(ii)  
filings with the SEC on Form 8-K dated 27 October, 2005 and on Form 12(b)-25 dated 3 November, 2005,
 
  in each case relating to the Guarantor's Subsidiary, BL Industria Otica, Ltda (BLIO) and the Guarantor's related investigation.
 
  BLIO Matters means the events including, without limitation, the allegations of improper management, improper accounting and unpaid taxes of BLIO, and the Guarantor's related investigation, which may result in the need for the Guarantor to:
 
(i)  
delay delivery of its financial statements to the Facility Agent under this Agreement;
 
(ii)  
delay certain of its filings with the SEC; and
 
(iii)  
restate its financial statements for prior periods, and that such a restatement, if necessary, would also require unrelated out-of-period entries made in prior periods to be reclassified to the appropriate prior period.
 
  Waiver Period means the period beginning on the date of this Agreement and ending on the Waiver Termination Date.
 
  Waiver Termination Date means the date (if any) on which holders of any Debt owed by the Guarantor or any of its Subsidiaries in a principal or notional amount of at least US$50,000,000 shall accelerate or give notice of acceleration of such Debt.
 
(c)  
Notwithstanding the foregoing, with respect to the BLIO Matters, nothing in this Clause 19.11 shall constitute an admission (i) of liability with respect to the BLIO Matters, (ii) that any misrepresentation or breach of warranty, covenant or other provision of this Agreement has occurred, or (iii) that an Event of Default has occurred under this Agreement.
 
(d)  
On the Waiver Termination Date, without any further action by any Finance Party, all of the terms and provisions set forth in this Agreement that are waived pursuant to this Clause 19.11 and not cured prior to the Waiver Termination Date shall have the same force and effect as if this Clause 19.11 did not exist, and the Finance Parties shall have all of the rights and remedies afforded to them under this Agreement with respect to any such waived terms and provisions as though this Clause 19.11 did not exist.
 
20.  
THE ADMINISTRATIVE PARTIES
 
20.1  
Appointment of the Facility Agent
 
(a)  
Each Finance Party (other than the Facility Agent) irrevocably appoints the Facility Agent to act as its agent under and in connection with the Finance Documents.
 
(b)  
Each Finance Party irrevocably authorises the Facility Agent to:
 
(i)  
perform the duties and to exercise the rights, powers, authorities and discretions that are specifically given to it under or in connection with the Finance Documents, together with any other incidental rights, powers, authorities and discretions; and
 
(ii)  
execute each Finance Document expressed to be executed by the Facility Agent.
 
(c)  
The Facility Agent has only those duties which are expressly specified in the Finance Documents. Those duties are solely of a mechanical and administrative nature.
 
20.2  
Role of the Mandated Lead Arrangers
 
  Except as specifically provided in the Finance Documents, no Mandated Lead Arranger has any obligations of any kind to any other Party in connection with any Finance Document.
 
20.3  
No fiduciary duties
 
(a)  
Nothing in the Finance Documents makes an Administrative Party a trustee or fiduciary for any other Party or any other person; and
 
(b)  
no Administrative Party need hold in trust any moneys paid to it or recovered by it for a Party in connection with the Finance Documents or be liable to account for interest on those moneys.
 
20.4  
Individual position of an Administrative Party
 
(a)  
If it is also a Lender, each Administrative Party has the same rights and powers under the Finance Documents as any other Lender and may exercise those rights and powers as though it were not an Administrative Party.
 
(b)  
Each Administrative Party may:
 
(i)  
accept deposits from, lend money to and generally engage in any kind of banking or carry on any other business with an Obligor or its related entities (including acting as an agent or a trustee for any other financing); and
 
(ii)  
retain any profits or remuneration it receives under the Finance Documents or in relation to any other business it carries on with an Obligor or its related entities.
 
20.5  
Reliance
 
  The Facility Agent may:
 
(a)  
rely on any representation, notice or document believed by it to be genuine and correct and to have been signed by, or with the authority of, the proper person;
 
(b)  
rely on any statement made by any person regarding any matters which may reasonably be assumed to be within his knowledge or within his power to verify;
 
(c)  
assume, unless the context otherwise requires, that any communication made by an Obligor is made on behalf of and with the consent and knowledge of each Obligor;
 
(d)  
engage, pay for and rely on the advice or services of any professional advisers selected by it (including those representing a Party other than the Facility Agent); and
 
(e)  
act under the Finance Documents through its personnel and agents.
 
20.6  
Majority Lenders' instructions
 
(a)  
Unless any contrary indication appears in a Finance Document, the Facility Agent is fully protected if it acts (or refrains from taking action) on the instructions of the Majority Lenders in the exercise of any right, power, authority or discretion or any matter not expressly provided for in the Finance Documents. Unless any contrary indication appears in a Finance Document, any such instructions given by the Majority Lenders will be binding on all the Lenders. In the absence of instructions from the Majority Lenders (or if appropriate, the Lenders), the Facility Agent may act (or refrain from taking action) as it considers to be in the best interests of all the Lenders.
 
(b)  
The Facility Agent may assume that unless it has received notice to the contrary in its capacity as Facility Agent for the Lenders, any right, power, authority or discretion vested in any Party or the Majority Lenders has not been exercised.
 
(c)  
The Facility Agent may refrain from acting in accordance with the instructions of the Majority Lenders (or, if appropriate, the Lenders) until it has received security satisfactory to it, whether by way of payment in advance or otherwise, against any liability or loss which it may incur in complying with the instructions.
 
(d)  
The Facility Agent is not authorised to act on behalf of a Lender (without first obtaining that Lender's consent) in any legal or arbitration proceedings in connection with any Finance Document.
 
20.7  
Responsibility
 
(a)  
No Administrative Party is responsible for the adequacy, accuracy and/or completeness of any statement or information (whether written or oral) supplied by an Administrative Party, an Obligor or any other person given in or in connection with any Finance Document including the Information Memorandum.
 
(b)  
No Administrative Party is responsible for the legality, validity, effectiveness, adequacy, completeness or enforceability of any Finance Document or any other agreement, arrangement or document entered into, made or executed in anticipation of or in connection with any Finance Document.
 
(c)  
Without affecting the responsibility of any Obligor for information supplied by it or on its behalf in connection with any Finance Document, each Lender confirms that it:
 
(i)  
has been, and will continue to be, solely responsible for making its own independent appraisal investigation of all risks arising under or in connection with the Finance Documents including but not limited to:
 
(A)  
the financial conditions, status and nature of each member of the Group;
 
(B)  
the legality, validity, effectiveness, adequacy or enforceability of any Finance Document and any other agreement, arrangement or document entered into, made or executed in anticipation of, under or in connection with any Finance Document;
 
(C)  
whether that Lender has recourse, and the nature and extent of that recourse, against any Party or any of its respective assets under or in connection with any Finance Document, the transactions contemplated by the Finance Documents or any other agreement, arrangement or document entered into, made or executed in anticipation of, under or in connection with any Finance Document; and
 
(D)  
the adequacy, accuracy and/or completeness of the Information Memorandum and any other information provided by the Facility Agent, any Party or by any other person under or in connection with any Finance Document, the transactions contemplated by the Finance Documents or any other agreement, arrangement or document entered into, made or executed in anticipation of, under or in connection with any Finance Document; and
 
(ii)  
has not relied exclusively on any information provided to it by any Administrative Party in connection with any Finance Document or agreement entered into in anticipation of or in connection with any Finance Document.
 
20.8  
Exclusion of liability
 
(a)  
Without limiting paragraph (b) below, the Facility Agent is not liable or responsible for any action taken or not taken by it under or in connection with any Finance Document, unless directly caused by its gross negligence or wilful misconduct.
 
(b)  
No Party (other than the relevant Administrative Party) may take any proceedings against any officers, employees or agents of another Administrative Party in respect of any claim it might have against that Administrative Party or in respect of any act or omission of any kind by that officer, employee or agent in connection with any Finance Document. Any officer, employee or agent of an Administrative Party may rely on this Subclause and enforce its terms under the Contracts (Rights of Third Parties) Act 1999.
 
(c)  
The Facility Agent is not liable for any delay (or any related consequences) in crediting an account with an amount required under the Finance Documents to be paid by the Facility Agent if the Facility Agent has taken all necessary steps as soon as reasonably practicable to comply with the regulations or operating procedures of any recognised clearing or settlement system used by the Facility Agent for that purpose.
 
(d)            (i)  
Nothing in this Agreement will oblige any Administrative Party to carry out any know your customer requirement or other checks in relation to any person on behalf of any Finance Party.
 
(ii)  
Each Finance Party confirms to each Administrative Party that it is solely responsible for any know your customer requirements or checks it is required to carry out and that it may not rely on any statement in relation to those requirements or checks made by any of the Administrative Parties.
 
20.9  
Default
 
(a)  
The Facility Agent is not obliged to monitor or enquire whether a Default has occurred. The Facility Agent is not deemed to have knowledge of the occurrence of a Default.
 
(b)  
If the Facility Agent:
 
(i)  
receives notice from a Party referring to this Agreement, describing a Default and stating that the circumstances described is a Default; or
 
(ii)  
is aware of the non-payment of any principal, interest or fee payable to a Finance Party (other than the Facility Agent or a Mandated Lead Arranger) under this Agreement,
 
  it must promptly notify the other Finance Parties.
 
20.10  
Information
 
(a)  
The Facility Agent must promptly forward to a Party the original or a copy of any document which is delivered to the Facility Agent by a Party for any other Party.
 
(b)  
Except where a Finance Document specifically provides otherwise, the Facility Agent is not obliged to review or check the adequacy, accuracy or completeness of any document it forwards to another Party.
 
(c)  
Except as provided above, the Facility Agent has no duty:
 
(i)  
either initially or on a continuing basis to provide any Lender with any credit or other information concerning the risks arising under or in connection with the Finance Documents (including any information relating to the financial condition or affairs of any Obligor or its related entities or the nature or extent of recourse against any Party or its assets) whether coming into its possession before, on or after the date of this Agreement; or
 
(ii)  
unless specifically requested to do so by a Lender in accordance with a Finance Document, to request any certificate or other document from any Obligor.
 
(d)  
In acting as Facility Agent for the Finance Parties, the agency division of the Facility Agent is treated as a separate entity from its other divisions and departments. If information is received by another division or department of the Facility Agent, it may be treated as confidential to that division or department and the Facility Agent shall not be deemed to have notice of it.
 
(e)  
The Facility Agent is not obliged to disclose to any person any confidential information supplied to it by or on behalf of a member of the Group solely for the purpose of evaluating whether any waiver or amendment is required in respect of any term of the Finance Documents.
 
(f)  
Each Obligor irrevocably authorises the Facility Agent to disclose to the other Finance Parties any information which, in its opinion, is received by it in its capacity as the Facility Agent.
 
20.11  
Indemnities
 
(a)  
Without limiting the liability of any Obligor under the Finance Documents, each Lender must indemnify the Facility Agent, within three Business Days of demand, for that Lender's Pro Rata Share of any cost, loss or liability incurred by the Facility Agent in acting as the Facility Agent under the Finance Documents (unless the Facility Agent has been reimbursed by an Obligor under a Finance Document), except to the extent that the cost, loss or liability is caused by the Facility Agent's gross negligence or wilful misconduct.
 
(b)  
If a Party owes an amount to the Facility Agent under the Finance Documents, the Facility Agent may, after giving notice to that Party:
 
(i)  
deduct from any amount received by it for that Party any amount due to the Facility Agent from that Party under a Finance Document but unpaid; and
 
(ii)  
apply that amount in or towards satisfaction of the owed amount.
 
  That Party will be regarded as having received the amount so deducted.
 
20.12  
Compliance
 
  Each Administrative Party may refrain from doing anything (including disclosing any information) which might, in its opinion, constitute a breach of any law or regulation or be otherwise actionable at the suit of any person, and may do anything which, in its opinion, is necessary or desirable to comply with any law or regulation.
 
20.13  
Resignation of the Facility Agent
 
(a)  
The Facility Agent may resign and appoint any of its Affiliates as successor Facility Agent by giving notice to the other Finance Parties, the Company and the Guarantor.
 
(b)  
Alternatively, the Facility Agent may resign by giving notice to the Finance Parties, the Company and the Guarantor, in which case the Majority Lenders may appoint a successor Facility Agent.
 
(c)  
If no successor Facility Agent has been appointed under paragraph (b) above within 30 days after notice of resignation was given, the Facility Agent may appoint a successor Facility Agent.
 
(d)  
The person(s) appointing a successor Facility Agent must, if practicable, consult with the Company and the Guarantor prior to the appointment. Any successor Facility Agent must have an office in the U.K.
 
(e)  
The resignation of the Facility Agent and the appointment of any successor Facility Agent will both become effective only when the successor Facility Agent notifies all the Parties that it accepts its appointment. On giving the notification, the successor Facility Agent will succeed to the position of the Facility Agent and the term Facility Agent will mean the successor Facility Agent.
 
(f)  
The retiring Facility Agent must, at its own cost, make available to the successor Facility Agent such documents and records and provide such assistance as the successor Facility Agent may reasonably request for the purposes of performing its functions as the Facility Agent under the Finance Documents.
 
(g)  
Upon its resignation becoming effective, this Clause will continue to benefit the retiring Facility Agent in respect of any action taken or not taken by it in connection with the Finance Documents while it was the Facility Agent, and, subject to paragraph (f) above, it will have no further obligations under any Finance Document.
 
20.14  
Relationship with Lenders
 
(a)  
The Facility Agent may treat each Lender as a Lender, entitled to payments under this Agreement and as acting through its Facility Office(s) unless it has received not less than five Business Days' prior notice from that Lender to the contrary in accordance with the terms of this Agreement.
 
(b)  
The Facility Agent may at any time, and must if requested to do so by the Majority Lenders, convene a meeting of the Lenders.
 
(c)  
The Facility Agent must keep a record of all the Parties and supply any other Party with a copy of the record on request. The record will include each Lender's Facility Office(s) and contact details for the purposes of this Agreement.
 
(d)  
Each Lender must supply the Facility Agent with any information required by the Facility Agent in order to calculate the Mandatory Cost in accordance with Schedule 4 (Calculation of the Mandatory Cost).
 
20.15  
Notice period
 
  Where this Agreement specifies a minimum period of notice to be given to the Facility Agent, the Facility Agent may, at its discretion, accept a shorter notice period.
 
20.16  
Deduction from amounts payable by the Facility Agent
 
  If any Party owes an amount to the Facility Agent under the Finance Documents the Facility Agent may, after giving notice to that Party, deduct an amount not exceeding that amount from any payment to that Party which the Facility Agent would otherwise be obliged to make under the Finance Documents and apply the amount deducted in or towards satisfaction of the amount owed. For the purposes of the Finance Documents that Party must be regarded as having received any amount so deducted.
 
21.  
EVIDENCE AND CALCULATIONS
 
21.1  
Accounts
 
  Accounts maintained by a Finance Party in connection with this Agreement are prima facie evidence of the matters to which they relate for the purpose of any litigation or arbitration proceedings.
 
21.2  
Certificates and determinations
 
  Any certification or determination by a Finance Party of a rate or amount under the Finance Documents will be, in the absence of manifest error, conclusive evidence of the matters to which it relates.
 
21.3  
Calculations
 
  Any interest or fee accruing under this Agreement accrues from day to day and is calculated on the basis of the actual number of days elapsed and a year of 360 days or if market practice differs, in accordance with market practice.
 
22.  
FEES
 
22.1  
Facility Agent's fee
 
  The Company must pay to the Facility Agent for its own account an agency fee in the manner agreed in the Fee Letter between the Facility Agent and the Company.
 
22.2  
Participation fees
 
  The Company must pay to the Mandated Lead Arrangers or the Facility Agent, as applicable, the participation fees in the manner agreed in the Fee Letter between the Mandated Lead Arrangers and the Company.
 
22.3  
Arrangement fees
 
  The Company must pay to each of the Mandated Lead Arrangers for their own account the arrangement fees in the manner agreed in each Fee Letter between a Mandated Lead Arranger and the Company.
 
23.  
INDEMNITIES AND BREAK COSTS
 
23.1  
Currency indemnity
 
(a)  
The Company must, as an independent obligation, indemnify each Finance Party against any loss or liability which that Finance Party incurs as a consequence of:
 
(i)  
that Finance Party receiving an amount in respect of an Obligor's liability under the Finance Documents; or
 
(ii)  
that liability being converted into a claim, proof, judgment or order,
 
  in a currency other than the currency in which the amount is expressed to be payable under the relevant Finance Document.
 
(b)  
Unless otherwise required by law, each Obligor waives any right it may have in any jurisdiction to pay any amount under the Finance Documents in a currency other than that in which it is expressed to be payable.
 
23.2  
Other indemnities
 
(a)  
The Company must indemnify each Finance Party against any loss or liability which that Finance Party incurs as a consequence of:
 
(i)  
the occurrence of any Event of Default;
 
(ii)  
any failure by an Obligor to pay any amount due under a Finance Document on its due date, including any resulting from any distribution or redistribution of any amount among the Lenders under this Agreement;
 
(iii)  
(other than by reason of the gross negligence, wilful misfeasance or default by that Finance Party) the Loan not being made after the Request has been delivered;
 
(iv)  
the Loan (or part of the Loan) not being prepaid in accordance with this Agreement; or
 
(v)  
any representation made under Clause 16.16 (Dutch Banking Act) or Clause 26.2 (Assignments and transfers by Lenders) being incorrect when made or deemed to be made. A Lender which makes a representation which is untrue in relation to its status as a Professional Market Party or its status as part of a closed circle (besloten kring) cannot make a demand under this paragraph.
 
  The Company's liability in each case includes any loss or expense on account of funds borrowed, contracted for or utilised to fund any amount payable under any Finance Document or any Loan.
 
(b)  
The Company must indemnify the Facility Agent against any loss or liability incurred by the Facility Agent (acting reasonably) as a result of:
 
(i)  
investigating any event which the Facility Agent reasonably believes to be a Default; or
 
(ii)  
acting or relying on any notice which the Facility Agent reasonably believes to be genuine, correct and appropriately authorised.
 
23.3  
Break Costs
 
(a)  
The Company must pay to each Lender its Break Costs if the Loan or an overdue amount is repaid or prepaid other than on the last day of any Interest Period applicable to it.
 
(b)  
Break Costs are the amount (if any) determined by the relevant Lender acting reasonably, by which:
 
(i)  
the interest (excluding Margin) which that Lender would have received for the period from the date of receipt of any part of its share in the Loan or an overdue amount to the last day of the applicable Interest Period for that Loan or overdue amount if the principal or overdue amount received had been paid on the last day of that Interest Period;
 
  exceeds
 
(ii)  
the amount which that Lender would be able to obtain by placing an amount equal to the amount received by it on deposit with a leading bank in the appropriate interbank market for a period starting on the Business Day following receipt and ending on the last day of the applicable Interest Period.
 
(c)  
Each Lender must supply to the Facility Agent for the Company and the Guarantor details of the amount of any Break Costs claimed by it under this Subclause.
 
24.  
EXPENSES
 
24.1  
Initial costs
 
  The Company must pay to the Facility Agent the amount of all costs and expenses (including fees of legal counsel to the Facility Agent only) reasonably and properly incurred by it in connection with the negotiation, preparation, printing, entry into, syndication and execution of the Finance Documents provided that the Company and the Guarantor approved such costs and expenses prior to their being incurred.
 
24.2  
Subsequent costs
 
  The Company must pay to the Facility Agent the amount of all costs and expenses (including legal fees) reasonably incurred by it in connection with:
 
(a)  
the negotiation, preparation, printing and entry into of any Finance Document (other than a Transfer Certificate) executed after the date of this Agreement;
 
(b)  
any amendment, waiver or consent requested by or on behalf of an Obligor provided that the Company and the Guarantor approved such costs and expenses prior to their being incurred; and
 
(c)  
any amendment, waiver or consent specifically allowed by this Agreement.
 
24.3  
Enforcement costs
 
  The Company must pay to each Finance Party the amount of all costs and expenses (including legal fees) incurred by it in connection with the enforcement of, or the preservation of any rights under, any Finance Document.
 
24.4  
Timing for payments of costs
 
  All payments under this Clause will be due within thirty days of demand by the relevant Finance Party.
 
25.  
AMENDMENTS AND WAIVERS
 
25.1  
Procedure
 
(a)  
Except as provided in this Clause, any term of the Finance Documents may only be amended, replaced or waived with the agreement of the Company, the Guarantor and the Majority Lenders. The Facility Agent may effect, on behalf of any Finance Party, an amendment or waiver allowed under this Clause.
 
(b)  
The Facility Agent must promptly notify the other Parties of any amendment or waiver effected by it under paragraph (a) above. Any such amendment or waiver is binding on all the Parties.
 
25.2  
Exceptions
 
(a)  
An amendment or waiver which relates to:
 
(i)  
the definition of Majority Lenders in Clause 1.1 (Definitions);
 
(ii)  
an extension of the date of payment of any amount to a Lender under the Finance Documents;
 
(iii)  
a reduction in the Margin or a reduction in the amount of any payment of principal, interest, fee or other amount payable to a Lender under the Finance Documents;
 
(iv)  
an increase in, or an extension of, a Commitment or the Total Commitments (except as expressly provided in Clause 2.3 (Extension Option);
 
(v)  
a release of an Obligor other than in accordance with the terms of this Agreement;
 
(vi)  
a term of a Finance Document which expressly requires the consent of each Lender;
 
(vii)  
the right of a Lender to assign or transfer its rights or obligations under the Finance Documents; or
 
(viii)  
this Clause,
 
  may only be made with the consent of all the Lenders.
 
(b)  
An amendment or waiver which relates to the rights or obligations of an Administrative Party may only be made with the consent of that Administrative Party.
 
(c)  
A Fee Letter may be amended or waived with the agreement of the Administrative Party that is a party to that Fee Letter and the Company and the Guarantor.
 
25.3  
Change of currency
 
  If a change in any currency of a country occurs (including where there is more than one currency or currency unit recognised at the same time as the lawful currency of a country), the Finance Documents will be amended to the extent the Facility Agent (acting reasonably and after consultation with the Company) determines is necessary to reflect the change.
 
25.4  
Waivers and remedies cumulative
 
  The rights and remedies of each Finance Party under the Finance Documents:
 
(a)  
may be exercised as often as necessary;
 
(b)  
are cumulative and not exclusive of its rights or remedies under the general law; and
 
(c)  
may be waived only in writing and specifically.
 
  Delay in exercising or non-exercise of any right or remedy is not a waiver of that right or remedy.
 
26.  
CHANGES TO THE PARTIES
 
26.1  
Assignments and transfers by Obligors
 
  Neither Obligor may assign or transfer any of its rights and obligations under the Finance Documents without the prior consent of all the Lenders.
 
26.2  
Assignments and transfers by Lenders
 
(a)  
A Lender (the Existing Lender) may, subject to the following provisions of this Subclause, at any time assign or transfer (including by way of novation) any of its rights and obligations under this Agreement to any other person (the New Lender).
 
(b)  
Unless the Guarantor and the Facility Agent otherwise agree and except as provided below, a transfer of part of a Commitment or part of its rights and obligations under this Agreement by the Existing Lender must be in a minimum amount of US$5,000,000 and an integral multiple of US$1,000,000.
 
(c)  
The consent of the Guarantor is required for any assignment or transfer unless:
 
(i)  
the assignment is by way of security to any U.S. Federal Reserve Bank;
 
(ii)  
the New Lender is another Lender or an Affiliate of a Lender, in which case prior written notice must be given by the Existing Lender to the Company, the Guarantor and the Facility Agent; or
 
(iii)  
an Event of Default is outstanding.
 
  The consent of the Guarantor must not be unreasonably withheld or delayed. The Guarantor will be deemed to have given its consent five Business Days after the Guarantor is given notice of the request unless it is expressly refused by the Guarantor within that time.
 
(d)  
The Facility Agent is not obliged to execute a Transfer Certificate or otherwise give effect to an assignment or transfer until it has completed all know your customer requirements to its satisfaction. The Facility Agent must promptly notify the Existing Lender and the New Lender if there are any such requirements.
 
(e)  
If the consent of the Guarantor is required for any assignment or transfer (irrespective of whether it may be unreasonably withheld or not), the Facility Agent is not obliged to execute a Transfer Certificate if the Guarantor withholds its consent.
 
(f)    (i)  
If, on the date of an assignment or transfer, it is a requirement of Dutch law that each Lender must be a Professional Market Party:
 
(A)  
unless the New Lender is a Professional Market Party, the consent of the Company is required for any assignment or transfer;
 
(B)  
the Company's consent must not be unreasonably withheld or delayed;
 
(C)  
the Company will be deemed to have given its consent five Business Days after the Company and the Guarantor are given written notice of the request together with a copy of a Transfer Certificate signed by the New Lender confirming that it is a Professional Market Party or forms part of a closed circle with the Company unless it is expressly refused by the Company within that time because either:
 
I.  
the proposed New Lender is not a Professional Market Party or does not form part of a closed circle (besloten kring) with the Company; or
 
II.  
the Company has demonstrated that it is in good faith unable to determine with certainty whether the proposed New Lender is a Professional Market Party or forms part of a closed circle (besloten kring) with the Company;
 
(D)  
the New Lender must comply with the obligations set out in paragraph (ii) below;
 
(E)  
the Company must make the representation set out in paragraph (iii) below; and
 
(F)  
no assignment or transfer will be effective unless both the New Lender and the Company have complied with the requirements of this Subclause.
 
(ii)  
On the date the assignment or transfer becomes effective the New Lender must make the representation on the terms set out in paragraph 3 of the Transfer Certificate.
 
(iii)  
On the date that a New Lender becomes party to this Agreement as a Lender the Company represents that on that date it has verified the status of that New Lender either as:
 
(A)  
a Professional Market Party under the Dutch Exemption Regulation; 
 
(B)  
exempted from the requirement to be a Professional Market Party because it forms part of a closed circle (besloten kring) with the Company; or
 
(C)  
The Company will be deemed to have complied with its verification obligation set out under (A) above, if it could reasonably assume that the New Lender concerned is a Professional Market Party on the basis of:
 
I.  
information from public registers;
 
II.  
information from a recognised rating institution within the meaning of the Dutch capital adequacy rules for credit institutions as set out in the Credit System Supervision Manual (Handboek Wtk) part 9001-02;
 
III.  
information received from such New Lender; or
 
IV.  
an express confirmation from such New Lender.
 
(g)  
An assignment of rights will only be effective if the New Lender confirms to the Facility Agent, the Company, and the Guarantor in form and substance satisfactory to the Facility Agent that it is bound by obligations to the other Finance Parties under this Agreement equivalent to those it would have been under if it were an Original Lender.
 
(h)  
A transfer of obligations will be effective only if either:
 
(i)  
rights are assigned and obligations released and equivalent obligations assumed in accordance with the following provisions of this Clause; or
 
(ii)  
the obligations are novated in accordance with the following provisions of this Clause.
 
(i)  
Unless the Facility Agent otherwise agrees, the New Lender must pay to the Facility Agent for its own account, on or before the date any assignment or transfer occurs, a fee of US$3,500.
 
(j)  
Any reference in this Agreement to a Lender includes a New Lender but excludes a Lender if no amount is or may be owed to or by it under this Agreement.
 
26.3  
Transfer Certificates
 
(a)  
In this Subclause:
 
  Transfer Date means, for a Transfer Certificate, the later of:
 
(i)  
the proposed Transfer Date specified in that Transfer Certificate;
 
(ii)  
the date on which the Facility Agent executes that Transfer Certificate; and
 
  a reference to an assignment includes any related release and assumption.
 
(b)  
An assignment or novation is effected if:
 
(i)  
the Existing Lender and the New Lender deliver to the Facility Agent a duly completed Transfer Certificate; and
 
(ii)  
the Facility Agent executes it.
 
  The Facility Agent must execute as soon as reasonably practicable a Transfer Certificate delivered to it and which appears on its face to be in order.
 
(c)  
Each Finance Party (other than the Existing Lender and the New Lender) irrevocably authorises the Facility Agent to execute any duly completed Transfer Certificate on its behalf.
 
(d)  
For a transfer by assignment on the Transfer Date:
 
(i)  
the Existing Lender will assign absolutely to the New Lender the Existing Lender's rights expressed to be the subject of the assignment in the Transfer Certificate;
 
(ii)  
the Existing Lender will be released from the obligations expressed to be the subject of the release in the Transfer Certificate; and
 
(iii)  
the New Lender will become a Lender under this Agreement and will be bound by obligations equivalent to those from which the Existing Lender is released under sub-paragraph (ii) above.
 
(e)  
For a transfer by novation on the Transfer Date:
 
(i)  
the New Lender will assume the rights and obligations of the Existing Lender expressed to be the subject of the novation in the Transfer Certificate in substitution for the Existing Lender;
 
(ii)  
the Existing Lender will be released from those obligations and cease to have those rights; and
 
(iii)  
the New Lender will become a Lender under this Agreement and be bound by the terms of this Agreement as a Lender.
 
(f)  
The Facility Agent must, as soon as reasonably practicable after it has executed a Transfer Certificate, send a copy of that Transfer Certificate to the Company and the Guarantor.
 
26.4  
Limitation of responsibility of Existing Lender
 
(a)  
Unless expressly agreed to the contrary, an Existing Lender makes no representation or warranty and assumes no responsibility to a New Lender for:
 
(i)  
the financial condition of an Obligor; or
 
(ii)  
the legality, validity, effectiveness, enforceability, adequacy, accuracy, completeness or performance of:
 
(A)  
any Finance Document or any other document;
 
(B)  
any statement or information (whether written or oral) made in or supplied in connection with any Finance Document, or
 
(C)  
any observance by any Obligor of its obligations under any Finance Document or any other documents,
 
  and any representations or warranties implied by law are excluded.
 
(b)  
Each New Lender confirms to the Existing Lender and the other Finance Parties that it:
 
(i)  
has made, and will continue to make, its own independent appraisal of all risks arising under or in connection with the Finance Documents (including the financial condition and affairs of each Obligor and its related entities and the nature and extent of any recourse against any Party or its assets) in connection with its participation in this Agreement; and
 
(ii)  
has not relied exclusively on any information supplied to it by the Existing Lender in connection with any Finance Document.
 
(c)  
Nothing in any Finance Document requires an Existing Lender to:
 
(i)  
accept a re-transfer from a New Lender of any of the rights and obligations assigned or transferred under this Clause; or
 
(ii)  
support any losses incurred by the New Lender by reason of the non-performance by either Obligor of its obligations under any Finance Document or otherwise.
 
26.5  
Participations
 
  Any Lender may at any time, without the consent of the Company, the Guarantor or the Facility Agent and without notice to the Facility Agent, sell participations to any person in all or a portion of such Lender's rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans owing to it) provided that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement.
 
26.6  
Costs resulting from change of Lender or Facility Office
 
  If:
 
(a)  
a Lender assigns or transfers any of its rights and obligations under the Finance Documents or changes its Facility Office; and
 
(b)  
as a result of circumstances existing at the date the assignment, transfer or change occurs, an Obligor would be obliged to pay a Tax Payment or an Increased Cost,
 
  then the relevant Obligor need only pay that Tax Payment or Increased Cost to the same extent that it would have been obliged to if no assignment, transfer or change had occurred.
 
26.7  
Changes to the Reference Banks
 
  If a Reference Bank (or, if a Reference Bank is not a Lender, the Lender of which it is an Affiliate) ceases to be a Lender, the Facility Agent must (in consultation with the Company and the Guarantor) appoint another Lender or an Affiliate of a Lender to replace that Reference Bank.
 
27.  
DISCLOSURE OF INFORMATION
 
(a)  
Each Finance Party must keep confidential any information supplied to it by or on behalf of any Obligor in connection with the Finance Documents. However, subject to the terms of any confidentiality agreement then binding between an Obligor and the Finance Party, a Finance Party is entitled to disclose information:
 
(i)  
which is publicly available, other than as a result of a breach by that Finance Party of this Clause;
 
(ii)  
in connection with any legal or arbitration proceedings provided that to the extent practicable under the circumstances and lawful, that Finance Party shall provide the Obligors with prompt notice of the requested disclosure so that any Obligor may seek an order protecting against or limiting such disclosure;
 
(iii)  
if required to do so under any law or regulation;
 
(iv)  
to a governmental, banking, taxation or other regulatory authority;
 
(v)  
to its professional advisers;
 
(vi)  
to any rating agency;
 
(vii)  
to the extent allowed under paragraph (b) below;
 
(viii)  
to another Obligor; or
 
(ix)  
with the agreement of the relevant Obligor.
 
(b)  
A Finance Party may disclose to an Affiliate or any person with whom it may enter, or has entered into, any kind of transfer, participation or other agreement in relation to this Agreement (a participant):
 
(i)  
a copy of any Finance Document; and
 
(ii)  
any information which that Finance Party has acquired under or in connection with any Finance Document.
 
  However, before a participant may receive any confidential information, it must agree with the relevant Finance Party to keep that information confidential on the terms of paragraph (a) above.
 
28.  
SET-OFF
 
  A Finance Party may set off any matured obligation owed to it by an Obligor under the Finance Documents (to the extent beneficially owned by that Finance Party) against any matured obligation owed by that Finance Party to an Obligor, regardless of the place of payment, booking branch or currency of either obligation. If the obligations are in different currencies, the Finance Party may convert either obligation at a market rate of exchange in its usual course of business for the purpose of the set-off.
 
29.  
PRO RATA SHARING
 
29.1  
Redistribution
 
  If any amount owing by an Obligor under this Agreement to a Finance Party (the recovering Finance Party) is discharged by payment, set-off or any other manner other than in accordance with this Agreement (a recovery), then:
 
(a)  
the recovering Finance Party must, within three Business Days, supply details of the recovery to the Facility Agent;
 
(b)  
the Facility Agent must calculate whether the recovery is in excess of the amount which the recovering Finance Party would have received if the recovery had been received and distributed by the Facility Agent under this Agreement; and
 
(c)  
the recovering Finance Party must pay to the Facility Agent an amount equal to the excess (the redistribution).
 
29.2  
Effect of redistribution
 
(a)  
The Facility Agent must treat a redistribution as if it were a payment by the relevant Obligor under this Agreement and distribute it among the Finance Parties, other than the recovering Finance Party, accordingly.
 
(b)  
When the Facility Agent makes a distribution under paragraph (a) above, the recovering Finance Party will be subrogated to the rights of the Finance Parties which have shared in that redistribution.
 
(c)  
If and to the extent that the recovering Finance Party is not able to rely on any rights of subrogation under paragraph (b) above, the relevant Obligor will owe the recovering Finance Party a debt which is equal to the redistribution, immediately payable and of the type originally discharged.
 
(d)  
If:
 
(i)  
a recovering Finance Party must subsequently return a recovery, or an amount measured by reference to a recovery, to an Obligor; and
 
(ii)  
the recovering Finance Party has paid a redistribution in relation to that recovery,
 
  each Finance Party must reimburse the recovering Finance Party all or the appropriate portion of the redistribution paid to that Finance Party, together with interest for the period while it held the redistribution. In this event, the subrogation in paragraph (b) above will operate in reverse to the extent of the reimbursement.
 
29.3  
Exceptions
 
  Notwithstanding any other term of this Clause, a recovering Finance Party need not pay a redistribution to the extent that:
 
(a)  
it would not, after the payment, have a valid claim against the relevant Obligor in the amount of the redistribution; or
 
(b)  
it would be sharing with another Finance Party any amount which the recovering Finance Party has received or recovered as a result of legal or arbitration proceedings, where:
 
(i)  
the recovering Finance Party notified the Facility Agent of those proceedings; and
 
(ii)  
the other Finance Party had an opportunity to participate in those proceedings but did not do so or did not take separate legal or arbitration proceedings as soon as reasonably practicable after receiving notice of them.
 
30.  
SEVERABILITY
 
  If a term of a Finance Document is or becomes illegal, invalid or unenforceable in any respect under any jurisdiction, that will not affect:
 
(a)  
the legality, validity or enforceability in that jurisdiction of any other term of the Finance Documents; or
 
(b)  
the legality, validity or enforceability in other jurisdictions of that or any other term of the Finance Documents.
 
31.  
COUNTERPARTS
 
  Each Finance Document may be executed in any number of counterparts. This has the same effect as if the signatures on the counterparts were on a single copy of the Finance Document.
 
32.  
NOTICES
 
32.1  
In writing
 
(a)  
Any communication to be made under or in connection with a Finance Document must be in writing and, unless otherwise stated, may be given:
 
(i)  
in person, by post, fax; or
 
(ii)  
to the extent agreed by the Parties making and receiving communication, by e-mail or other electronic communication.
 
(b)  
For the purpose of the Finance Documents, an electronic communication will be treated as being in writing.
 
(c)  
Unless it is agreed to the contrary, any consent or agreement required under a Finance Document must be given in writing.
 
32.2  
Contact details
 
(a)  
Except as provided below, the contact details of each Party for all communications in connection with the Finance Documents are those notified by that Party for this purpose to the Facility Agent on or before the date it becomes a Party.
 
(b)  
The contact details of the Company for this purpose are:
 
  Address:Koolhovenlaan 110, 1119 NH Schiphol-Rijk, The Netherlands
       Fax number: +31 20 6554 651
       Attention: Financial Controller.
 
(c)  
The contact details of the Guarantor for this purpose are:
 
  Address:One Bausch & Lomb Place, Rochester, New York 14604
       Fax number: +1 585 338 8188
       Attention: Corporate Treasury Operations.
 
(d)  
The contact details of the Facility Agent for this purpose are:
 
  Address:Citigroup Centre, 33 Canada Square, Canary Wharf, London E14 5LB
       Fax number: +44 (0) 20 8636 3825
       E-mail: julian.wheeler@citigroup.com
       Attention: Julian Wheeler.
 
(e)  
Any Party may change its contact details by giving five Business Days' notice to the Facility Agent or (in the case of the Facility Agent) to the other Parties.
 
(f)  
Where a Party nominates a particular department or officer to receive a communication, a communication will not be effective if it fails to specify that department or officer.
 
32.3  
Effectiveness
 
(a)  
Except as provided below, any communication in connection with a Finance Document will be deemed to be given as follows:
 
(i)  
if delivered in person, at the time of delivery;
 
(ii)  
if posted, when received;
 
(iii)  
if by fax, when received in legible form; and
 
(iv)  
if by e-mail or any other electronic communication, when received in legible form.
 
(b)  
A communication given under paragraph (a) above but received on a non-working day or after business hours in the place of receipt will only be deemed to be given on the next working day in that place.
 
(c)  
A communication to the Facility Agent will only be effective on actual receipt by it.
 
32.4  
Obligors
 
(a)  
All communications under the Finance Documents to or from an Obligor must be sent through the Facility Agent.
 
32.5  
Use of websites
 
(a)  
Except as provided below, the Company may deliver any information under this Agreement to those Lenders (the Website Lenders) who accept this method of communication by posting it on to an electronic website if:
 
(i)  
the Facility Agent and the Lender expressly agree (after consultation with each of the Lenders);
 
(ii)  
the Company and the Facility Agent designate an electronic website for this purpose (the Designated Website);
 
(iii)  
both the Company and the Facility Agent are aware of the address of and relevant password specifications for the Designated Website; and
 
(iv)  
the information posted is in a format previously agreed between the Company and the Facility Agent.
 
  The Facility Agent must supply each Website Lender, the Company and the Guarantor with the address of and any relevant password specifications for the Designated Website following designation of that website by the Company and the Facility Agent.
 
(b)  
If any Lender (a Paper Form Lender) does not agree to the delivery of information electronically then the Facility Agent must notify the Company accordingly and the Company must supply the information to the Facility Agent (in sufficient copies for each Paper Form Lender) in paper form. In any event the Company must supply the Facility Agent with at least one copy in paper form of any information required to be provided by it.
 
(c)  
The Company must, promptly upon becoming aware of its occurrence, notify the Facility Agent if:
 
(i)  
the Designated Website cannot be accessed due to technical failure;
 
(ii)  
the Company becomes aware that the Designated Website or any information posted on to the Designated Website is or has been infected by any electronic virus or similar software;
 
(iii)  
any new information which is required to be provided and this Agreement is posted on to the Designated Website;
 
(iv)  
the password specifications for the Designated Website change; or
 
(v)  
any existing information which has been provided under this Agreement and posted on to the Designated Website is amended.
 
  If the Company notifies the Facility Agent under paragraph (c)(i) or paragraph (c)(v) above, all information to be provided by the Company under this Agreement after the date of that notice must be supplied in paper form unless and until the Facility Agent and each Website Lender is satisfied that the circumstances giving rise to the notification are no longer continuing.
 
(d)  
Notwithstanding paragraphs (a), (b) and (c) above, the Company may deliver any information under this Agreement to a Lender and/or the Facility Agent by posting it on the SEC's website at www.sec.gov, and such posting shall be deemed to satisfy any requirement to deliver such information.
 
33.  
LANGUAGE
 
(a)  
Any notice given in connection with a Finance Document must be in English.
 
(b)  
Any other document provided in connection with a Finance Document must be:
 
(i)  
in English; or
 
(ii)  
(unless the Facility Agent otherwise agrees) accompanied by a certified English translation. In this case, the English translation prevails unless the document is a statutory or other official document.
 
34.  
GOVERNING LAW
 
  This Agreement is governed by English law.
 
35.  
ENFORCEMENT
 
35.1  
Jurisdiction
 
(a)  
The English courts have exclusive jurisdiction to settle any dispute in connection with any Finance Document.
 
(b)  
The English courts are the most appropriate and convenient courts to settle any such dispute in connection with any Finance Document. Each Party agrees not to argue to the contrary and waives objection to those courts on the grounds of inconvenient forum or otherwise in relation to proceedings in connection with any Finance Document.
 
(c)  
This Clause is for the benefit of the Finance Parties only. To the extent allowed by law, a Finance Party may take:
 
(i)  
proceedings in any other court; and
 
(ii)  
concurrent proceedings in any number of jurisdictions.
 
(d)  
References in this Clause to a dispute in connection with a Finance Document includes any dispute as to the existence, validity or termination of that Finance Document.
 
35.2  
Service of process
 
(a)  
Each Obligor not incorporated in England and Wales irrevocably appoints Bausch & Lomb Incorporated of 106 - 114 London Road, Kingston-upon-Thames, Surrey KT2 6QJ as its agent under the Finance Documents for service of process in any proceedings before the English courts in connection with any Finance Document.
 
(b)  
If any person appointed as process agent under this Clause is unable for any reason to so act, the Company (on behalf of the Obligors) must immediately (and in any event within five days of the event taking place) appoint another agent on terms acceptable to the Facility Agent. Failing this, the Facility Agent may appoint another process agent for this purpose.
 
(c)  
Each Obligor agrees that failure by a process agent to notify it of any process will not invalidate the relevant proceedings.
 
(d)  
This Clause does not affect any other method of service allowed by law.
 
35.3  
Waiver of immunity
 
  Each Obligor irrevocably and unconditionally:
 
(a)  
agrees not to claim any immunity from proceedings brought by a Finance Party against it in relation to a Finance Document and to ensure that no such claim is made on its behalf;
 
(b)  
consents generally to the giving of any relief or the issue of any process in connection with those proceedings; and
 
(c)  
waives all rights of immunity in respect of it or its assets.
 
35.4  
Waiver of trial by jury
 
  EACH PARTY WAIVES ANY RIGHT IT MAY HAVE TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION IN CONNECTION WITH ANY FINANCE DOCUMENT OR ANY TRANSACTION CONTEMPLATED BY ANY FINANCE DOCUMENT. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO TRIAL BY COURT.
 
35.5  
Patriot Act
 
  Each Lender that is subject to the Patriot Act and the Facility Agent (for itself and not on behalf of any Lender) hereby notifies each Obligor that pursuant to the requirements of the Patriot Act, it is required to obtain, verify and record information that identifies the Obligors, which information includes the name and address of each Obligor and other information that will allow such Lender or the Facility Agent, as applicable, to identify the Obligors in accordance with the Patriot Act.
 
  THIS AGREEMENT has been entered into on the date stated at the beginning of this Agreement.
 

SCHEDULE 1 
ORIGINAL PARTIES
PART 1
 
ORIGINAL LENDERS AND COMMITMENTS
 

 
Original Lender
 
Commitment (US$)
 
CITIBANK INTERNATIONAL PLC
 
JPMORGAN CHASE BANK, N.A.
 
KEYBANK NATIONAL ASSOCIATION
 
 
 
BANK OF TOKYO-MITSUBISHI TRUST COMPANY
 
MIZUHO CORPORATE BANK, LTD.
 
SOCIÉTÉ GÉNÉRALE
 
 
 
BARCLAYS BANK PLC
 
USBANK
 
THE NORTHERN TRUST COMPANY
 
85,000,000
 
60,000,000
 
60,000,000
 
 
 
40,000,000
 
40,000,000
 
40,000,000
 
 
 
20,000,000
 
20,000,000
 
10,000,000
 
Total Commitments
 
  ___________
 
  US$375,000,000
 
      ___________
 
 

PART 2  
 
MANDATED LEAD ARRANGERS
 
  CITIGROUP GLOBAL MARKETS LIMITED
 
  J. P. MORGAN PLC
 
  KEYBANC CAPITAL MARKETS
 

 

SCHEDULE 2
 
CONDITIONS PRECEDENT DOCUMENTS
 
Obligors
 
1.  
A copy of the constitutional documents of each Obligor.
 
2.  
A copy of (or a certified copy of an extract of) a resolution of the board of directors of each Obligor approving the terms of, and the transactions contemplated by, this Agreement.
 
3.  
A specimen of the signature of each person authorised on behalf of an Obligor to enter into or witness the entry into of any Finance Document or to sign or send any document or notice in connection with any Finance Document.
 
4.  
A certificate of each Obligor (signed by a director in the case of the Company and the company secretary in the case of the Guarantor) confirming that borrowing or guaranteeing, as appropriate, the Total Commitments would not cause any borrowing, guarantee or similar limit binding on any Obligor to be exceeded.
 
5.  
A certificate of an authorised signatory of each Obligor certifying that each copy document specified in this Schedule that relates to it is correct, complete and in full force and effect as at a date no earlier than the date of this Agreement.
 
6.  
Evidence that the agent of the Obligors under the Finance Documents for service of process in England and Wales has accepted its appointment.
 
7.  
A copy of a resolution of the managing board/supervisory board/shareholders in general meeting of the Company approving the terms of, and the transactions contemplated by, this Agreement.
 
8.  
An unconditional positive works council advice (advies) in respect of the transactions contemplated by this Agreement.
 
9.  
An extract of the registration of the Company in the trade register of the chamber of commerce.
 
Legal opinions
 
10.  
A legal opinion of A. Robert D. Bailey, Vice President, Assistant General Counsel and Assistant Secretary to the Guarantor, addressed to the Finance Parties.
 
11.  
A legal opinion of Allen & Overy LLP, legal advisers in the Netherlands to the Mandated Lead Arrangers and the Facility Agent, addressed to the Finance Parties.
 
12.  
A legal opinion of Allen & Overy LLP, legal advisers in England to the Mandated Lead Arrangers and the Facility Agent, addressed to the Finance Parties.
 
Other documents and evidence
 
13.  
Evidence that all fees and expenses then due and payable from the Company under this Agreement have been or will be paid by the first Utilisation Date.
 

SCHEDULE 3
 
FORM OF REQUEST
 
  
 
  To:    CITIBANK INTERNATIONAL PLC as Facility Agent
 
  From:   [                               ]
 
  Date:    [                               ]
 
  
 
  BAUSCH & LOMB B.V. - US$375,000,000 Credit Agreement
dated 29 November, 2005 (the Agreement)
 
1.  
We refer to the Agreement. This is a Request.
 
2.  
We wish to borrow a Loan on the following terms:
 
(a)  
Utilisation Date: [                               ]
 
(b)  
Amount: [US$                                         ]
 
(c)  
Interest Period: 6 months.
 
3.  
Our payment instructions are: [                                    ].
 
4.  
We confirm that each condition precedent under the Agreement which must be satisfied on the date of this Request is so satisfied.
 
5.  
This Request is irrevocable.
 
  
 
  By:
 
  [                               ]
 
 

SCHEDULE 4
 
 
1.  
General
 
(a)  
The Mandatory Cost is to compensate a Lender for the cost of compliance with:
 
(i)  
the requirements of the Bank of England and/or the Financial Services Authority (or, in either case, any other authority which replaces any of its functions); or
 
(ii)  
the requirements of the European Central Bank.
 
(b)  
The Mandatory Cost is expressed as a percentage rate per annum.
 
(c)  
The Mandatory Cost is the weighted average (weighted in proportion to the percentage share of each Lender in the relevant Loan) of the rates for the Lenders calculated by the Facility Agent in accordance with this Schedule on the first day of an Interest Period (or as soon as possible after then).
 
(d)  
The Facility Agent must distribute each amount of Mandatory Cost among the Lenders on the basis of the rate for each Lender.
 
(e)  
Any determination by the Facility Agent pursuant to this Schedule will be, in the absence of manifest error, conclusive and binding on all the Parties.
 
2.  
For a Lender lending from a Facility Office in the U.K.
 
(a)  
The relevant rate for a Lender lending from a Facility Office in the U.K. is calculated in accordance with the following formula:
    
        Ex 0.01 per cent. per annum
           300
    where on the day of application of the formula, E is calculated by the Facility Agent as being the average of the rates of  
      charge under the fees rules supplied by the Reference Banks to the Facility Agent under paragraph (d) below and expressed
      in pounds per £1 million.
 
(b)  
For the purposes of this paragraph 2:
 
(i)  
fees rules means the then current rules on periodic fees in the Supervision Manual of the FSA Handbook or any other law or regulation as may then be in force for the payment of fees for the acceptance of deposits;
 
(ii)  
fee tariffs means the fee tariffs specified in the fees rules under fee-block Category A1 (Deposit acceptors) (ignoring any minimum fee or zero rated fee required pursuant to the fees rules but applying any applicable discount rate); and
 
(iii)  
tariff base has the meaning given to it in, and will be calculated in accordance with, the fees rules.
 
(c)  
Each rate calculated in accordance with the formula is, if necessary, rounded upward to four decimal places.
 
(d)  
If requested by the Facility Agent, each Reference Bank must, as soon as practicable after publication by the Financial Services Authority, supply to the Facility Agent the rate of charge payable by that Reference Bank to the Financial Services Authority under the fees rules for that financial year of the Financial Services Authority (calculated by that Reference Bank as being the average of the fee tariffs applicable to that Reference Bank for that financial year) and expressed in pounds per £1 million of the tariff base of that Reference Bank.
 
(e)  
Each Lender must supply to the Facility Agent the information required by it to make a calculation of the rate for that Lender. In particular, each Lender must supply the following information on or prior to the date on which it becomes a Lender:
 
(i)  
the jurisdiction of its Facility Office; and
 
(ii)  
any other information that the Facility Agent reasonably requires for that purpose.
 
        Each Lender must promptly notify the Facility Agent of any change to the information supplied to it under this paragraph.
 
(f)  
The rates of charge of each Reference Bank for the purpose of E above are determined by the Facility Agent based upon the information supplied to it under paragraphs (d) and (e) above. Unless a Lender notifies the Facility Agent to the contrary, the Facility Agent may assume that the Lender's obligations in respect of cash ratio deposits and special deposits are the same as those of a typical bank from its jurisdiction of incorporation with a Facility Office in the U.K.
 
(g)  
The Facility Agent has no liability to any Party if its calculation over or under compensates any Lender. The Facility Agent is entitled to assume that the information provided by any Lender or Reference Bank under this Schedule is true and correct in all respects.
 
3.  
For a Lender lending from a Facility Office in a Participating Member State
 
(a)  
The relevant rate for a Lender lending from a Facility Office in a Participating Member State is the percentage rate per annum notified by that Lender to the Facility Agent. This percentage rate per annum must be certified by that Lender in its notice to the Facility Agent as its reasonable determination of the cost (expressed as a percentage of that Lender's share in all Loans made from that Facility Office) of complying with the minimum reserve requirements of the European Central Bank in respect of Loans made from that Facility Office.
 
(b)  
If a Lender fails to specify a rate under paragraph (a) above, the Facility Agent will assume that the Lender has not incurred any such cost.
 
4.  
Changes
 
(a)  
The Facility Agent may, after consultation with the Company and the Lenders, determine and notify all the Parties of any amendment to this Schedule which is required to reflect:
 
(i)  
any change in law or regulation; or
 
(ii)  
any requirement imposed by the Bank of England, the Financial Services Authority or the European Central Bank (or, in any case, any successor authority).
 
(b)  
If the Facility Agent, after consultation with the Company, determines that the Mandatory Cost for a Lender lending from a Facility Office in the U.K. can be calculated by reference to a screen, the Facility Agent may notify all the Parties of any amendment to this Agreement which is required to reflect this.
 
 

SCHEDULE 5 
 
FORMS OF TRANSFER CERTIFICATE
 
PART 1 
 
FORM FOR TRANSFERS BY ASSIGNMENT

 
  To:CITIBANK INTERNATIONAL PLC as Facility Agent
 
From:[THE EXISTING LENDER] (the Existing Lender) and [THE NEW LENDER] (the New Lender)
 
  Date:[            ]
 
  
  BAUSCH & LOMB B.V. - US$375,000,000 Credit Agreement
dated 29 November, 2005 (the Agreement)
 
  We refer to the Agreement. This is a Transfer Certificate.
 
1.  
In accordance with the terms of the Agreement:
 
(a)  
the Existing Lender assigns absolutely to the New Lender all the rights of the Existing Lender under the Agreement specified in the Schedule;
 
(b)  
the Existing Lender is released from all its obligations under the Agreement which correspond to the Existing Lender's rights specified in the Schedule; and
 
(c)  
the New Lender becomes a Lender under the Agreement and is bound by obligations equivalent to those from which the Existing Lender is released under paragraph (b) above.
 
2.  
The proposed Transfer Date is [        ].
 
3.  
[On the Transfer Date, the New Lender represents to the Existing Lender, the other Finance Parties, Bausch & Lomb Incorporated and Bausch & Lomb B.V. that it is [a Professional Market Party under the Dutch Exemption Regulation] [exempted from the requirement to be a Professional Market Party because it forms part of a closed circle (besloten kring) with Bausch & Lomb B.V.].]
 
4.  
The administrative details of the New Lender for the purposes of the Agreement are set out in the Schedule.
 
5.  
[The New Lender is a Qualifying Lender.]1
 
6.  
This Transfer Certificate is governed by English law.
 
1    Include if applicable.
 
 

  THE SCHEDULE
  Rights and obligations to be transferred by assignment
[insert relevant details, including applicable Commitment (or part)]
 
  Administrative details of the New Lender
[insert details of Facility Office, address for notices and payment details etc.]
 
 
  [EXISTING LENDER]                      [NEW LENDER]
 
  By:                                By:
 
  The Transfer Date is confirmed by the Facility Agent as [            ].
 
  CITIBANK INTERNATIONAL PLC
as Facility Agent, for and on behalf
of each of the parties to the
Agreement (other than the Existing Lender and
the New Lender)
 
  By:
 
  
 
 
Note: It is the responsibility of each individual New Lender to ascertain whether any other document or formality is required to perfect the transfer contemplated by this Transfer Certificate.
 
  
 

PART 2
 
FORM FOR TRANSFERS BY NOVATION
 
  To:CITIBANK INTERNATIONAL PLC as Facility Agent
 
 
From:[THE EXISTING LENDER] (the Existing Lender) and [THE NEW LENDER] (the New Lender)
 
  Date:[                         ]
 
  
 
  BAUSCH & LOMB B.V. - US$375,000,000 Credit Agreement
dated 29 November, 2005 (the Agreement)
 
  We refer to the Agreement. This is a Transfer Certificate.
 
1.  
The Existing Lender transfers by novation to the New Lender the Existing Lender's rights and obligations referred to in the Schedule below in accordance with the terms of the Agreement.
 
2.  
The proposed Transfer Date is [     ].
 
3.  
[On the Transfer Date, the New Lender represents to the Existing Lender, the other Finance Parties, Bausch & Lomb Incorporated and Bausch & Lomb B.V. that it is [a Professional Market Party under the Dutch Exemption Regulation] [exempted from the requirement to be a Professional Market Party because it forms part of a closed circle (besloten kring) with Bausch & Lomb B.V.].]
 
4.  
The administrative details of the New Lender for the purposes of the Agreement are set out in the Schedule.
 
5.  
[The New Lender is a Qualifying Lender.]2
 
6.  
The New Lender expressly acknowledges the limitations on the Existing Lender's obligations in respect of this Transfer Certificate contained in the Agreement.
 
7.  
This Transfer Certificate may be executed in any number of counterparts and this has the same effect as if the signatures on the counterpart were on a single copy of the Transfer Certificate.
 
8.  
This Transfer Certificate is governed by English law.
 
2    Include if applicable.
 
 

  THE SCHEDULE
 
  Rights and obligations to be transferred by novation
[insert relevant details, including applicable Commitment (or part)]
 
  Administrative details of the New Lender
[insert details of Facility Office, address for notices and payment details etc.]
 
  
 
  [EXISTING LENDER]                      [NEW LENDER]
 
  By:                                By:
 
  The Transfer Date is confirmed by the Facility Agent as [                  ].
 
  CITIBANK INTERNATIONAL PLC
 
  By:
 
  
 
 
Note:It is the responsibility of each individual New Lender to ascertain whether any other document or formality is required to perfect the transfer contemplated by this Transfer Certificate.
 
 

SCHEDULE 6  
 
MATERIAL SUBSIDIARIES
 
  Material Subsidiaries of Bausch & Lomb Incorporated
stated in US$000s as of 25 December, 2004
 

 
  
 
  Material Subsidiary
 
  Consolidated Subsidiary assets (excluding inter-company assets)
 
  Per cent. of total Consolidated assets
 
  Net Subsidiary sales (excluding inter-company sales)
 
  Per cent. of total Consolidated sales
 
  BLJ Company Ltd
 
  US$141,761
 
  4.7%
 
  US$226,554
 
  10.1%
 
  B&L France
 
  US$378,993
 
  12.5%
 
  US$182,242
 
  8.2%
 
  Dr. Mann
 
  US$164,538
 
  5.4%
 
  US$113,518
 
  5.1%
 
  B&L UK
 
  US$81,912
 
  2.7%
 
  US$121,853
 
  5.5%
 
  Bausch & Lomb B.V.
 
  US$183,232
 
  6.1%
 
  US$99,581
 
  4.5%
 
  Bausch & Lomb Ireland
 
  US$230,450
 
  7.6%
 
  US$0
 
  0%
  
 
 

SCHEDULE 7 
 
 
  Bank Name:  []
 
  A/C Name:    [   ]
 
  A/C No:      [   ]


 

SIGNATORIES
 
 
  Company
 
  BAUSCH & LOMB B.V.
 
  By:  /s/ Efrain Rivera
  EFRAIN RIVERA
 
  
  Guarantor
 
  BAUSCH & LOMB INCORPORATED
 
  By:  /s/ Stephen C. McCluski
  STEPHEN C. MCCLUSKI
 
 
  Mandated Lead Arrangers
 
  CITIGROUP GLOBAL MARKETS LIMITED
 
  By:  /s/ Paul Gibbs
  PAUL GIBBS
 
  
  J. P. MORGAN PLC
 
  By:  /s/ Neville G. Crow
  NEVILLE G. CROW
 
  
  KEYBANC CAPITAL MARKETS
 
  By:  /s/ Laurie Muller-Girard
  LAURIE MULLER-GIRARD
 
  
  Original Lenders
 
  BANK OF TOKYO-MITSUBISHI TRUST COMPANY
 
  By:  /s/ Harumi Kambara
  HARUMI KAMBARA
 
  
  BARCLAYS BANK PLC
 
  By:  /s/ Nicholas A. Bell
  NICHOLAS A. BELL
 
 
CITIBANK INTERNATIONAL PLC
 
  By:  /s/ Paul Gibbs
  PAUL GIBBS
 
 
JPMORGAN CHASE BANK, N.A.
 
By:  /s/ Alastair A. Stevenson
ALASTAIR A. STEVENSON
 

KEYBANK NATIONAL ASSOCIATION
 
By:  /s/ Marianne Meil
MARIANNE MEIL
 
 
MIZUHO CORPORATE BANK, LTD.
 
By:  /s/ Raymond Ventura
RAYMOND VENTURA
 
 
SOCIÉTÉ GÉNÉRALE
 
By:  /s/ Mary Brickley
MARY BRICKLEY
 
 
THE NORTHERN TRUST COMPANY
 
By:  /s/ Ashish S. Bhagwat
ASHISH S. BHAGWAT
 
 
USBANK
 
By:  /s/ Michael P. Dickman
MICHAEL P. DICKMAN
 
 
 
  Facility Agent
 
  CITIBANK INTERNATIONAL PLC
 
  By:  /s/ Paul Gibbs
  PAUL GIBBS


 
 
EX-10.Z 9 form10k2005e10z.htm EXHIBIT (10)-Z Exhibit (10)-z


Exhibit (10)-z

EXECUTION COPY
 
LETTER WAIVER

 
Dated as of November 23, 2005

To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Citibank, N.A.,
as agent (the "Agent") for the Lenders
 
Ladies and Gentlemen:
 
We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you. Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement.
 
Reference is made to the Borrower's (1) press releases, dated October 26, 2005 and November 3, 2005, and (2) filings with the U.S. Securities and Exchange Commission on Form 8-K, dated October 27, 2005, and on Form 12(b)-25, dated November 3, 2005, related to its subsidiary, BL Industria Otica, Ltda ("BLIO") and the Borrower's related investigation (collectively the "BLIO Announcements"). The events include, without limitation, allegations of improper management, improper accounting and unpaid taxes of BLIO, which may result in the need for the Borrower to delay delivery of its financial statements to you under the Credit Agreement, delay certain of its filings with the Securities and Exchange Commission and to restate its financial statements for prior periods, and that such a restatement, if necessary, would also require that out-of-period entries made in prior periods, unrelated to the BLIO events, be reclassified to the appropriate prior period. The Borrower has requested, and the Required Lenders have agreed, to waive the impact of the matters described in the BLIO Announcements, including, without limitation, the impact of the events described in the foregoing sentence, to the extent that any restatements of the Borrower's financial statements for prior financial periods do not result in reductions in profits after tax of the Borrower of more than $50,000,000 in aggregate and, with respect to the delay in delivery of the financial statements required to be delivered under the Credit Agreement, the extent that such delay does not extend beyond March 1, 2006 (the "Waived BLIO Matters").
 
We hereby request that you evidence your agreement to waive, solely for the period commencing on the date first above written through Waiver Termination Date (as defined below), solely with respect to Waived BLIO Matters, any breach of the Credit Agreement (including, without limitation, any misrepresentation, any breach of covenant and any Event of Default) by execution of this Letter Waiver.
 
On the Waiver Termination Date, without any further action by the Agent and the Lenders, all of the terms and provisions set forth in the Credit Agreement with respect to Defaults thereunder that are waived hereunder and not cured prior to the Waiver Termination Date shall have the same force and effect as if this Letter Waiver had not been entered into by the parties hereto, and the Agent and the Lenders shall have all of the rights and remedies afforded to them under the Credit Agreement with respect to any such Defaults as though no waiver had been granted by them hereunder. The "Waiver Termination Date" is the date, if any, that holders of any Debt outstanding in a principal or notional amount of at least $50,000,000 shall accelerate or give notice of acceleration of such Debt.
 
This Letter Waiver shall become effective as of the date first above written when, and only when, the Agent shall have received counterparts of this Letter Waiver executed by us and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver. The effectiveness of this Letter Waiver is conditioned upon the accuracy of the factual matters described herein in all material respects. This Letter Waiver is subject to the provisions of Section 8.01 of the Credit Agreement.
 
The Credit Agreement and the Notes, except to the extent of the waiver specifically provided above, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of this Letter Waiver shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under the Credit Agreement, nor constitute a waiver of any provision of the Credit Agreement.
 
If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.
 
With respect to the Waived BLIO matters, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to the Waived BLIO matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred or (3) that an Event of Default has occurred under the Credit Agreement.
 
This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 

 
 

 

This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.
 
Very truly yours,
 
BAUSCH & LOMB INCORPORATED
 
By /s/ Efrain Rivera
Title: Vice President & Treasurer
 
Agreed as of the date first above written:
 
CITIBANK, NA.,
as Agent and as Lender
 
By /s/ Robert A. Kane
Title: Managing Director

 
 

 


KEYBANK NATIONAL ASSOCIATION

By /s/ Marianne T. Meil
Title: Vice President

BARCLAYS BANK PLC

By____________________________
Title:

THE BANK OF TOKYO-MITSUBISHI TRUST
COMPANY

By /s/ Harumi Kambara
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By /s/ Bruce Yoder
Title: Vice President

MIZUHO CORPORATE BANK, LTD.

By /s/ Raymond Ventura
Title: General Manager


 
 

 

U.S. BANK NATIONAL ASSOCIATION

By /s/ David Dannemiller
Title: Vice President

ALLIED IRISH BANKS, P.L.C.

By /s/ Germaine Reusch     /s/ Anthony O’Reilly
Title: Director         Title: Senior Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By /s/ John Carroll
Title: Vice President

THE NORTHERN TRUST COMPANY

By /s/ Ashish S. Bhagwat
Title: Vice President

EX-10.AA 10 form10k2005e10aa.htm EXHIBIT (10)-AA Exhibit (10)-aa


Exhibit (10)-aa

LETTER WAIVER

 
Dated as of February 17, 2006
 
To the banks, financial institutions
   and other institutional lenders
   (collectively, the "Lenders")
   parties to the Credit Agreement
   referred to below and to Citibank, N.A.,
   as agent (the "Agent") for the Lenders
 
Ladies and Gentlemen:
 
We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you. Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement.
 
Reference is made to the Borrow's (1) press releases, dated October 26, 2005 and November 3, 2005, and (2) filings with the U.S. Securities and Exchange Commision on Form 8-K, dated October 27, 2005, November 29, 2005 and December 22, 2005, and on Form 12(b)-25, dated November 3, 2005, related to its subsidiary, BL Industria Otica, Ltda ("BLIO"), (3) press release dated December 22, 2005, related to its subsidiary Bausch & Lomb Korea Co. Ltd. ("BL Korea"), press release dated January 26, 2006 related to the Borrower's expected reporting of preliminary 2005 fourth quarer results and 2005 full year results in March 2006 and the Borrower's related investigations (collectively the "Announcements"). The events, include, without limitation, allegations of improper management, improper accounting and unpaid taxes of BLIO, and improper sales practices at BL Korea, and have resulted in the need for the Borrower to delay delivery of its 2005 fourth quarter and 2005 full year financial statements to you under the Credit Agreement, have resulted in the delay of certain of the Borrower's filings with the Securities and Exchange Commission and will require the Borrower to restate its financial statements for prior periods, and that such a restatement will also require that out-of-period entries made in prior periods, unrelated to the BLIO or BL Korea events, be reclassified to the appropriate prior period. The Borrower has requested, and the Required Lenders have agreed, to waive the impact of the matters described in the Announcements, including, without limitation, the impact of the events described in the foregoing sentence, to the extent that any restatements of the Borrower's financial statements for prior financial periods do not result in redutions in profits after tax of the Borrower of more than $50,000,000 in aggregate and, with respect to the delay in delivery of the financial statements required to be delivered under the Credit Agreement, to the extent that any delay in delivery or filing does not extend beyond May 31, 2006 (the "Waived Matters").
 
Your execution of this Letter Waiver evidences your agreement to waive, solely for the period commencing on July 26, 2005 through the Waiver Termination Date (as defined below), and solely with respect to Waived Matters, any breach of the Credit Agreement (including, without limitation, any misrepresentation or any breach of covenant) or any Event or Default that may arise therefrom.
 
On the Waiver Termination Date, without any further action by the Agent and the Lenders, all of the terms and provisions set forth in the Credit Agreement with respect to Defaults thereunder that are waived under the immediately preceding paragraph and not cured prior to the Waiver Termination Date shall have the same force and effect as if this Letter Waiver had not been entered into by the parties hereto, and the Agent and the Lenders shall have all of the rights and remedies afforded to them under the Credit Agreement with respect to any such Defaults as though no waiver had been granted by them hereunder. The "Waiver Termination Date" is the earliest of (a) May 31, 2006 (6:00 p.m. (Rochester, New York time)), (b) the Borrower's delivery of the management certification required under the Credit Agreement confirming compliance with the terms of the Credit Agreement (as modified by this Letter Waiver and incorporating all waivers granted hereunder) together with the filing of the Borrower's 2005 Annual Report on Form 10-K (the "2005 10-K"), (c) the date, if any, that holders of any Debt outstanding in a principal or notional amount of at least $50,000,000 shall accelerate or give notice of acceleration of such Debt and (d) April 3, 2006, but only if (x) the Borrower fails to file its 2005 10-K on or prior to March 31, 2006 (by 6:00 p.m. Rochester, New York time) and (y) the Borrower has failed to pay to the Agent, for the ratable account for the Lenders, the one-time fee equal to 0.05% of the aggregate commitments as described below.
 
The 2005 10-K will contain financial statements for 2005 and restated financial statements for certain prior periods. Accordingly, in addition to the waiver granted above, your execution of this Letter Waiver evidences (a) your agreement to permanently and irrevocably waive the reporting requirements of Section 5.01(h)(i) and (ii) of the Credit Agreement for 2005 and those portions of 2006 prior to the filing of the 2005 10-K and (b) your acknowledgement that the Borrower's filing of the 2005 10-K will satisfy Borrower's reporting requirements under, and constitutes the timely delivery of such reports required under, Section 5.01(h)(i) and (ii) of the Credit Agreement for the period from July 26, 2005 through the date the 2005 10-K is filed. In addition, since the 2005 10-K will contain restate financial statements for certain prior periods, including but not limited to the Borrower's 2004 fiscal year, upon the filing of that annual report, you agree to permanently and irrevocably waive any misrepresentation of Section 4.01(e) of the Credit Agreement, or any Event of Default arising therefrom, to the extent related to the matters described in the Announcements.
 
As further consideration for this Letter Waiver, in the event that the Borrower has not filed the 2005 10-K by March 31, 2006 at 6:00 p.m. (Rochester, New York time), the Borrower will agree to pay a one-time fee equal to 0.05% of their aggregate commitments to each Lender that has executed this Letter Waiver. Payment of such amounts will be due on April 3, 2006.
 
This Letter Waiver shall become effective as of the date first above written when, and only when, the Agent shall have received counterparts of this Letter Waiver executed on behalf of the Borrower and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver. The effectiveness of this Letter Waiver is conditioned upon the accuracy of the factual matters described herein in all material respects. This Letter Waiver is subject to the provisions of Section 8.01 of the Credit Agreement.
 
The Credit Agreement and the Notes, except to the extent of the waiver specifically provided above, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. The execution, delivery and effectieness of this Letter Waiver shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under the Credit Agreement, nor constitute a waiver of any provision of the Credit Agreement.
 
If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.
 
With respect to the Waived matters, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to the Waived matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred or (3) that an Event of Default has occurred under the Credit Agreement.
 
This Letter Waiver shall represent the entire agreement with respect to the matters contained herein and shall supersede any prior agreements whether written or oral. This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 
 

 
 

 

This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.
 
Very truly yours,
 
BAUSCH & LOMB INCORPORATED
 
By /s/ Efrain Rivera
Title: Vice President & Treasurer
Signed: February 24, 2006
 
Agreed as of the date first above written:
 
CITIBANK, NA.,
 
as Agent and as Lender
 
By__/s/ Robert A. Kane____________
Title: Vice President and Managing Director

KEYBANK NATIONAL ASSOCIATION

By__/s/ Marianne T. Meil__________
Title: Vice President

BARCLAYS BANK PLC

By__/s/ David Barton______________
Title: Associate Director

THE BANK OF TOKYO-MITSUBISHI TRUST
COMPANY

By___/s/ Harumi Kambara __________
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By__/s/ Bruce Yoder______________
Title: Vice President

MIZUHO CORPORATE BANK, LTD.

By___/s/ Raymond Ventura__________
Title: Deputy General Manager


 
 

 

U.S. BANK NATIONAL ASSOCIATION

By___/s/ Eric Cosgrove___________
Title: Assistant Vice President

ALLIED IRISH BANKS, P.L.C.

By___/s/ Germain Reusch________   By___/s/ Denise Magyer________
Title: Director     Title: Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By___/s/ John Carrol_____________
Title: Vice President

THE NORTHERN TRUST COMPANY

By /s/ Ashish S. Bhagwat 
Title: Vice President


 
EX-10.BB 11 form10k2005e10bb.htm EXHIBIT (10)-BB Exhibit (10)-bb

 
Exhibit (10)-bb
 
 
  
To: Bausch & Lomb B.V. (the Company)
Koolhovenlaan 110
1119 NH Schiphol-Rijk
The Netherlands

Attn: Financial Controller

Fax: +31 20 6554 651
 
  Monday, February 20, 2006
 
  Dear Sirs,
 
  US$375,000,000 credit agreement (the Agreement) dated 29 November 2005 between (among others) the Company, the Guarantor and Citibank International plc as facility agent
 
1.  
Background
 
(a)  
This letter is supplemental to and amends the Agreement.
 
(b)  
Pursuant to Clause 25 (Amendments and Waivers) of the Agreement, the Majority Lenders have consented to the amendments to the Agreement contemplated by this letter. Accordingly, we are authorised to execute this letter on behalf of the Finance Parties.
 
2.  
Interpretation
 
(a)  
Capitalised terms defined in the Agreement have the same meaning when used in this letter unless expressly defined in this letter.
 
(b)  
The provisions of Clause 1.2 (Construction) of the Agreement apply to this letter as though they were set out in full in this letter except that references to the Agreement are to be construed as references to this letter.
 
(c)  
Effective Date means the date on which the Facility Agent gives notification to the Obligors that it has received a copy of this letter countersigned by the Company and the Guarantor; provided that the Facility Agent must provide such notification as soon as reasonably practicable but no later than one (1) business day after the Facility Agent has received a copy of the fully countersigned letter.

 
 

 

 
    3. Amendments
 
(a)  
Subject to subparagraph (b) below, the Agreement will be amended from the Effective Date in accordance with subparagraph (c) below.
 
(b)  
The Agreement will not be amended by this letter unless the Facility Agent has received a copy of this letter countersigned by the Company and the Guarantor.
 
(c)  
The Agreement will be amended as follows:
 
(i)  
Clause 19.11(a)(ii) (BLIO Matters) of the Agreement will be amended by deleting the reference to “1 March” in the last line thereof and replacing it with “31 May”;
 
(ii)  
the definition of BLIO Announcements in Clause 19.11(b) of the Agreement shall be amended by:
 
(A)  
deleting “and” at the end of subparagraph (i);
 
(B)  
deleting subparagraph (ii) and replacing it with the following:
 
 
“(ii) filings with the SEC on Form 8-K dated 27 October, 2005, 29 November, 2005 and 22 December, 2005 and on Form 12(b)-25 dated 3 November, 2005,”;
 
(C)  
deleting the full stop after the words “Guarantor's related investigation" and replacing it with a semi-colon; and
 
(D)  
inserting new subparagraphs (iii) and (iv) as follows:
 
 
“(iii) press release dated 22 December, 2005 relating to the Guarantor’s Subsidiary, Bausch & Lomb Korea Co. Ltd. (BL Korea), and the Guarantor’s related investigation; and
 
 
(iv) press release dated 26 January, 2006 relating to the Guarantor’s expected reporting of preliminary 2005 fourth quarter results and 2005 full year results in March 2006, and the Guarantor’s related investigation.”;
 
(E)  
the definition of BLIO Matters in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
 
BLIO Matters means the events including, without limitation, the allegations of improper management, improper accounting and unpaid taxes of BLIO, and improper sales practices at BL Korea, and the Guarantor’s related investigations, which have resulted, or may result, in the need for the Guarantor to:
 
 
(i) delay delivery of its financial statements to the Facility Agent under this Agreement;
             (ii) delay certain of its filings with the SEC; and
 
 
(iii) restate its financial statements for prior periods, and that such a restatement, if necessary, will also require unrelated out-of-period entries made in prior periods to be reclassified to the appropriate prior period.”; and
 
(F)  
the definition of Waiver Termination Date in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
 
  Waiver Termination Date means the earlier of:
             (i) 6.00 p.m. (Rochester, New York time) on 31 May, 2006;
 
 
(ii) the date on which the Guarantor delivers the certificate required under Clause 17.10(a)(iii) (Reporting requirements) of the Agreement confirming, inter alia, compliance with the terms of the Agreement, together with the filing of the Guarantor’s 2005 annual report on Form 10-K;
 
 
(iii) the date (if any) on which holders of any Debt owed by the Guarantor or any of its Subsidiaries in a principal or notional amount of at least US$50,000,000 shall accelerate or give notice of acceleration of such Debt; and
 
 
 
(iv) 3 April, 2006, but only in the event that the Guarantor fails to file its 2005 annual report on Form 10-K on or before 6.00 p.m. (Rochester, New York time) on 31 March, 2006 and has failed to pay the fee set out in the Fee Letter dated 17 February 2006”.
 
3.  
Further Waiver
 
  The Guarantor’s 2005 annual report on Form 10-K will contain financial statements for 2005 and restated financial statements for certain prior periods, including but not limited to the Guarantor’s 2004 fiscal year. Accordingly, in addition to the BLIO Matters not resulting in or constituting a breach of the Agreement or Event of Default during the Waiver Period, as set forth in Clause 19.11(a), the Majority Lenders further agree, upon the filing of that annual report on Form 10-K, in accordance with the terms of this letter, that any representation under Clause 16.6 (Financial statements) of the Agreement which is incorrect in any material respect, or any Event of Default arising therefrom shall be permanently and irrevocably waived, to the extent related to the matters described in the BLIO Announcements.
 
4.  
Guarantee
 
  The Guarantor:
 
(a)  
agrees to the amendment of the Agreement as contemplated by this letter; and
 
(b)  
with effect from the Effective Date, confirms that the guarantee given by it under the Agreement will:
 
(i)  
continue in full force and effect; and
 
(ii)  
extend to the liabilities and obligations of the Company to the Finance Parties under the Finance Documents as amended by this letter.
 
5.  
Amendment fee
 
(a)  
In the event that the Guarantor has not filed its 2005 annual report on Form 10-K by 31 March, 2006 at 6.00 p.m. (Rochester, New York time), the Company must pay to the Facility Agent for the account of the Lenders which consented on or before 17 February, 2006 to the amendments to the Agreement contemplated by this letter (the Consenting Lenders) a one-time fee equal to 0.05 per cent. of the total Commitments of the Consenting Lenders. Such fee shall be payable no later than 3 April, 2006, to the account notified to the Company by the Facility Agent for this purpose. The Facility Agent shall provide the Obligors with a listing of the Consenting Lenders by 20 February, 2006.
 
(b)  
All amounts payable under this letter are exclusive of any value added tax or other taxes of any nature and will not be subject to counterclaim or set-off for, or be otherwise affected by, any claim or dispute relating to any matter whatsoever and all such payments shall be made free and clear and without deduction for or on account of any present or future taxes, charges, deductions or withholdings.
 
6.  
Miscellaneous
 
(a)  
This letter is a Finance Document and a Fee Letter.
 
(b)  
From the Effective Date, the Agreement and this letter will be read and construed as one document.
 
(c)  
Except as otherwise provided in this letter, the Finance Documents remain in full force and effect.
 
(d)  
Except to the extent expressly waived in this letter, no waiver of any provision of any Finance Document is given by the terms of this letter and the Finance Parties expressly reserve all their rights and remedies in respect of any breach of, or other Default under, the Finance Documents.
 
7.  
Governing law
 
  This letter is governed by English law.
 

 
/s/ Olufunmilayo Dada  /s/ John Nelson
For
CITIBANK INTERNATIONAL PLC
as Facility Agent for and on behalf of the Finance Parties
 
 
We agree with the terms of this letter.
 
 
/s/ Efrain Rivera
For
BAUSCH & LOMB B.V.
 
Date: February 24, 2006
 
 
/s/Stephen C. McCluski
For
BAUSCH & LOMB INCORPORATED
 
Date: February 24, 2006
EX-10.CC 12 form10k2005e10cc.htm EXHIBIT (10)-CC Exhibit (10)-cc


Exhibit (10)-cc

LETTER WAIVER


Dated as of May 15, 2006
To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Citibank, N.A.,
as agent (the "Agent") for the Lenders

Ladies and Gentlemen:

We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you, and the letter waivers thereunder dated November 23, 2005 (referred to herein as the “First Letter Waiver”) and February 17, 2006 (effective February 24, 2006 and referred to herein as the “Second Letter Waiver”). Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement, the First Letter Waiver and the Second Letter Waiver.
 
Reference is made to each of Borrower’s Announcements and the events described thereunder, and the prior definitions of Announcements are amended hereby to include Borrower’s: (i) press releases dated March 17, 2006, March 31, 2006, April 10, 2006, April 13, 2006 and May 15, 2006 and (ii) Borrower’s filings with the U.S. Securities and Exchange Commission on Forms 12(b)-25, dated March 17, 2006 and May 11, 2006, and on Forms 8-K, dated April 12, 2006, April 14, 2006, May 4, 2006, May 8, 2006 and May 15, 2006.

In light of these events described in the Announcements, and other confidential information which Borrower disclosed to Agent and Lenders verbally and in writing prior to the date hereof under the terms of confidentiality agreements executed with each Lender (the “Confidential Disclosures”), Borrower has requested, and the Required Lenders hereby agree:

(i) to waive, for the period from July 26, 2005 through the Waiver Termination Date (as defined below), any Default that may have been caused by the breach of a representation or warranty or failure to perform any covenant under the following Sections of the Credit Agreement: 4.01(e), 4.01(f), 4.01(k), 4.01(m), 5.01(a), 5.01(b), 5.01(f), 5.01(h)(i)-(ii), 5.01(h)(v), by reason of the events or circumstances described in the Announcements and Confidential Disclosures, provided, however, that the waivers set forth in this clause (i) extend to matters related to BL Industria Otica, Ltda and Bausch & Lomb Korea Co. Ltd. described in the Announcements and Confidential Disclosures only to the extent that the impact of those matters do not result in reductions in profits after tax of Borrower of more than $50,000,000 in the aggregate;

(ii) that, prior to the Waiver Termination Date, Borrower’s non-performance of the covenants set forth in Section 5.01(h)(i) or (ii) by reason of the circumstances or events described in the Announcements and Confidential Disclosures shall not create or constitute a Default or an Event of Default under the Credit Agreement, and that no repayment of an Advance will be accelerated (as may be permitted under Section 6.01 of the Credit Agreement) as a result of any such non-performance, and that Borrower’s filing of its Form 10-K Annual Report for the fiscal year ended December 31, 2005 (the “2005 10-K”) prior to the Waiver Termination Date shall cure in their entirety any such non-performance; and

(iii) to waive any Default which may otherwise arise in the event that Borrower receives “Notice of Default” due to default of performance, or breach of, any covenant or warranty by Borrower under Section 501(4) of its Indenture with Citibank, N.A., dated September 1, 1991, as supplemented and amended (the “Indenture”), so that receipt of a “Notice of Default” under the Indentures does not and will not constitute a Default or other failure by Borrower to satisfy the conditions precedent for any Borrowing or for each Lender to make an Advance under Section 3.02 of the Credit Agreement.
 
The Waiver Termination Date as defined in the First Letter Waiver and Second Letter Waiver are superseded and the term "Waiver Termination Date" is hereby defined for all purposes as October 2, 2006.
 
Notwithstanding the foregoing, in the event that Borrower receives notice of an “Event of Default” due to default of performance, or breach of, any covenant or warranty by Borrower under Section 501(4) of its Indenture, Borrower will immediately provide a copy of such notice to the Agent, and if: (a) Borrower fails to cure the defaults specified in such notice of an “Event of Default” within the 60-day period, (b) the Notice of Default has not been waived as provided in the Indenture, and (c) the Trustee, or holders of not less than 25% of the principal amount of outstanding securities under any series with an outstanding principal amount of at least $50,000,000 under the Indenture, have given to Borrower notice that the principal amount of such securities plus any accrued interest, is due and payable immediately, then the Agent upon request of the Required Lenders, or with the consent of the Required Lenders, may (i) declare the obligation of each Lender to make Advances (other than Advances by an Issuing Bank or a Lender pursuant to Section 2.03(c) of the Credit Agreement), and of the Issuing Banks to issue Letters of Credit to be terminated, and/or (ii) provide Borrower with a written notice declaring the Advances, all interest thereon and all other amounts payable under the Credit Agreement to be due and payable.

In addition to the foregoing, when filed with the SEC, Borrower’s 2005 10-K will contain restatements of prior period financial statements, including, without limitation, for the fiscal year 2004 (the “Restatements”). In addition to the waiver granted above, automatically and without further action by the parties hereto, upon the filing by Borrower of the 2005 10-K, your execution of this Letter Waiver evidences your permanent and irrevocable waiver of any misrepresentation of the matters set forth in Sections 4.01(e) and 4.01(k) of the Credit Agreement and any breach of Borrower’s covenants and agreements set forth in Sections 5.01(f) or 5.01(h) of the Credit Agreement with respect to periods covered thereby.

As further consideration for this Letter Waiver, Borrower hereby agrees to pay a fee equal to 0.10% of their aggregate commitments (the “Monthly Fee”) to each Lender that has executed this Letter Waiver on or before the Effective Date, as hereinafter defined. Payment of the Monthly Fee will be due and payable on June 1, 2006 and on the first of each month thereafter that Borrower is delayed in filing its financial statements prior to the Waiver Termination Date.

This Letter Waiver shall become effective as of the date first above written when the Agent shall have received counterparts of this Letter Waiver executed on behalf of Borrower and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver (“Effective Date”).

The Credit Agreement and the Notes, except to the extent of the waiver specifically provided above, are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of this Letter Waiver shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under the Credit Agreement, nor constitute a waiver of any provision of the Credit Agreement.

If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.

With respect to the matters waived hereunder, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to such matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred, or (3) that any Default or Event of Default has occurred under the Credit Agreement.

This Letter Waiver shall represent the entire agreement with respect to the matters contained herein and shall supersede any prior agreements whether written or oral. This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 
This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.

Very truly yours,

BAUSCH & LOMB INCORPORATED

By: /s/ Efrain Rivera   
Name: Efrain Rivera
Title: Vice President & Treasurer

Agreed as of the date first above written:
CITIBANK, NA.,
as Agent and as Lender

By___/s/ David Lowther___________
Title: Vice President


 
 

 

KEYBANK NATIONAL ASSOCIATION

By_ /s/ Marianne T. Meil________
Title: Senior Vice President

BARCLAYS BANK PLC

By_/s/ Nicolas Bell_______________
Title: Director

THE BANK OF TOKYO-MITSUBISHI TRUST
COMPANY

By___/s/ Harumi Kambara __________
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By__/s/ Benedict A. Smith __________
Title: Senior Vice President

MIZUHO CORPORATE BANK, LTD.

By___/s/ Raymond Ventura___ _____
Title: Deputy General Manager
 
U.S. BANK NATIONAL ASSOCIATION

By___/s/ Derek S. Roudebush______
Title:

ALLIED IRISH BANKS, P.L.C.

By___/s/ Germain Reusch________   By___/s/ Anthony O’Reilly________
Title: Director     Title: Senior Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By___/s/ John Carrol_____________
Title: Vice President

THE NORTHERN TRUST COMPANY

By____/s/ Alex Nicolov___________
Title: Second-Vice President

EX-10.DD 13 form10k2005e10dd.htm EXHIBIT (10)-DD Exhibit (10)-dd


  Exhibit (10)-dd
 
  
 
  LETTER WAIVER
 
  
To: Bausch & Lomb B.V. (the Company)
Koolhovenlaan 110
1119 NH Schiphol-Rijk
The Netherlands

Fax: +31 20 6554 651
Attn: Financial Controller


and:  Bausch & Lomb Incorporated (the Guarantor)
One Bausch & Lomb Place
Rochester
New York 14604
United States of America

Fax: +1 585 338 8188
Attn:  Corporate Treasury Operations
 
  17 May, 2006
 
  Dear Sirs,
 
  US$375,000,000 credit agreement (the Agreement) dated 29 November 2005 (as amended) between (among others) the Company, the Guarantor and Citibank International plc as facility agent
 
1.  
Background
 
(a)  
This letter is supplemental to and amends the Agreement.
 
(b)  
Pursuant to Clause 25 (Amendments and Waivers) of the Agreement, the Majority Lenders have consented to the amendments to the Agreement contemplated by this letter. Accordingly, we are authorised to execute this letter on behalf of the Finance Parties.
 
2.  
Interpretation
 
(a)  
Capitalised terms defined in the Agreement have the same meaning when used in this letter unless expressly defined in this letter.
 
(b)  
The provisions of Clause 1.2 (Construction) of the Agreement apply to this letter as though they were set out in full in this letter except that references to the Agreement are to be construed as references to this letter.
 
(c)  
Effective Date means the date on which the Facility Agent gives notification to the Obligors that it has received a copy of this letter countersigned by the Company and the Guarantor; provided that the Facility Agent must provide such notification as soon as reasonably practicable but no later than one (1) business day after the Facility Agent has received a copy of the fully countersigned letter.
 
3.  
Amendments
 
(a)  
Subject to subparagraph (b) below, the Agreement will be amended from the Effective Date in accordance with subparagraph (c) below.
 
(b)  
The Agreement will not be amended by this letter unless the Facility Agent has received a copy of this letter countersigned by the Company and the Guarantor.
 
(c)  
The Agreement will be amended as follows:
 
(i)  
Clause 19.11(a) (BLIO Matters) of the Agreement will be amended by deleting the introductory sentence in its entirety and replacing it with the following:
 
 
"Solely for the Waiver Period, it is agreed that the BLIO Matters described in the BLIO Announcements and Confidential Disclosures, and the Other Matters described in the Other Announcements and Confidential Disclosures will not result in or constitute a breach of this Agreement (including, without limitation, any misrepresentation or breach of covenant) or a Default to the extent that:";
 
(ii)  
the first line of Clause 19.11(a)(i) (BLIO Matters) of the Agreement will be amended by adding the words: "with respect to the BLIO Matters," before the words "any restatements";
 
(iii)  
Clause 19.11(a)(ii) (BLIO Matters) of the Agreement will be amended by:
 
(A)  
adding the words "with respect to the BLIO Matters, and" before the words "with respect to any delay" in the first line thereof; and
 
(B)  
deleting the reference to “31 May” in the last line thereof and replacing it with “2 October”;
 
(iv)  
the following sentence shall be inserted as a new paragraph at the end of Clause 19.11(a) (BLIO Matters):
 
 
"Furthermore, solely for the Waiver Period, the Lenders agree to waive any Default which may arise in the event that the Guarantor receives a 'Notice of Default' due to default of performance, or breach of, any covenant or warranty by the Guarantor under section 501(4) of the Indenture.";
 
(v)  
the definition of BLIO Announcements in Clause 19.11(b) of the Agreement shall be amended by:
 
(A)  
deleting “and” at the end of subparagraph (iii);
 
(B)  
deleting the full stop after the words "Guarantor's related investigation" at the end of subparagraph (iv) and replacing it with a semi-colon; and
 
(C)  
inserting new subparagraphs (v) to (ix), inclusive as follows:
 
 
“(v) press release dated 17 March, 2006 relating to updated status of the Guarantor’s financial reporting;
 
 
(vi) Form 12(b)-25, dated 17 March, 2006, with respect to delay in filing of Form 10-K Annual Report for the fiscal year ended 31 December, 2005;
 
 
(vii) Form 12(b)-25, dated 11 May, 2006 relating to delay in filing of Form 10-Q Quarterly Report for the quarterly period ended 1 April, 2006;
 
 
(viii) Form 8-K, dated 4 May, 2006, relating to current litigation and debt tender offers and consent solicitations; and
 
 
(ix) Form 8-K, dated 8 May, 2006 relating to tender offer and consent solicitation under the Indenture.";
 
(vi)  
the following definitions shall be inserted into Clause 19.11(b) of the Agreement between the definitions of BLIO Matters and Waiver Period:
 
 
"Confidential Disclosures means the confidential information which the Guarantor disclosed to the Facility Agent and Lenders verbally and in writing prior to 16 May, 2006 under the terms of confidentiality agreements executed with each Lender.
 
 
Indenture means the Guarantor's indenture with Citibank, N.A., dated 1 September, 1991, as supplemented and amended.
 
 
Other Announcements means the Guarantor's:
 
 
(i) press release dated 31 March, 2006 relating to collaborative investigations regarding fungal eye infections;
 
 
(ii) press releases dated 10 April, 2006 relating to temporary suspension of shipments of ReNu® with MoistureLoc® produced at Greenville, S.C. manufacturing facility;
 
 
(iii) press release dated 13 April, 2006 relating to removing US manufactured ReNu® with MoistureLoc® from retailers’ shelves;
 
 
(iv) press release dated 15 May, 2006 relating to worldwide withdrawal of ReNu® with MoistureLoc®;
 
 
(v) Form 12(b)-25, dated 11 May, 2006 relating to delay in filing of Form 10-Q Quarterly Report for the quarterly period ended 1 April, 2006;
 
 
(vi) Form 8-K, dated 12 April, 2006, relating to the 10 April, 2006 press release;
 
 
(vii) Form 8-K, dated 14 April, 2006, relating to the 13 April, 2006 press release;
 
 
(viii) Form 8-K, dated 4 May, 2006, relating to current litigation and debt tender offers and consent solicitations;
 
 
(ix) Form 8-K dated 8 May, 2006 relating to tender offer and consent solicitation under the Indenture; and
 
 
(x) Form 8-K, dated 15 May, 2006, relating to the 15 May, 2006 press release.
        
            Other Matters means (in both cases, including any such information contained in the Other Announcements) the:
 
 
(i) financial, accounting and tax matters (other than the BLIO Matters); and
 
 
(ii) increased reports of fungal eye infections among contact wearers and any relationship, impact or affect such reports have on the ReNu® with MoistureLoc® product."; and
 
(vii)  
the definition of Waiver Termination Date in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
 
 
Waiver Termination Date means the earlier of:
          (i) 6.00 p.m. (Rochester, New York time) on 2 October, 2006; and
 
 
(ii) the date (if any) on which the trustee or holders of not less than 25 per cent. of the principal amount of outstanding securities under any series with an outstanding principal amount of at least US$50,000,000 under the Indenture have given to the Guarantor notice that the principal amount of such securities is due and payable immediately.".
 
4.  
Further Waiver
 
  The Guarantor’s 2005 annual report on Form 10-K will contain financial statements for 2005 and restated financial statements for certain prior periods, including but not limited to the Guarantor’s 2004 fiscal year. Accordingly, in addition to the BLIO Matters and Other Matters not resulting in or constituting a breach of the Agreement or Default during the Waiver Period, as set forth in Clause 19.11(a), the Majority Lenders further agree, upon the filing of that annual report on Form 10-K, in accordance with the terms of this letter, that any representation under Clauses 16.6 (Financial statements) and 16.11 (Compliance with laws) of the Agreement which is incorrect in any material respect, or any breach of the covenants at Clauses 17.7 (Maintenance of accounts) and 17.10 (Reporting requirements) or any Default arising therefrom, with respect to periods covered thereby, shall be permanently and irrevocably waived, to the extent related to the matters described in the BLIO Announcements, Other Announcements or Confidential Disclosures.
 
5.  
Indenture
 
  In the event that the Guarantor receives notice of an "Event of Default" due to default of performance, or breach of any covenant or warranty by the Guarantor under section 501(4) of the Indenture, the Guarantor will immediately provide a copy of such notice to the Facility Agent.
 
6.  
Guarantee
 
  The Guarantor:
 
(a)  
agrees to the amendment of the Agreement as contemplated by this letter; and
 
(b)  
with effect from the Effective Date, confirms that the guarantee given by it under the Agreement will:
 
(i)  
continue in full force and effect; and
 
(ii)  
extend to the liabilities and obligations of the Company to the Finance Parties under the Finance Documents as amended by this letter.
 
7.  
Amendment fee
 
(a)  
In further consideration for the matters contemplated by this letter, the Company must pay to the Facility Agent for the account of the Lenders which consented on or before the date of this letter to the amendments to the Agreement contemplated by this letter (the Consenting Lenders) a monthly fee equal to 0.10 per cent. of the total Commitments of the Consenting Lenders. The Facility Agent shall provide the Obligors with a listing of the Consenting Lenders by 19 May, 2006. The first such monthly fee shall be payable no later than 1 June, 2006, and subsequent monthly fees will be due on the first Business Day of each month thereafter that the Guarantor is delayed in filing its financial statements prior to the Waiver Termination Date. Payments will be made to the account notified to the Company by the Facility Agent for this purpose.
 
(b)  
All amounts payable under this letter are exclusive of any value added tax or other taxes of any nature and will not be subject to counterclaim or set-off for, or be otherwise affected by, any claim or dispute relating to any matter whatsoever and all such payments shall be made free and clear and without deduction for or on account of any present or future taxes, charges, deductions or withholdings.
 
8.  
Miscellaneous
 
(a)  
This letter is a Finance Document and a Fee Letter.
 
(b)  
From the Effective Date, the Agreement and this letter will be read and construed as one document.
 
(c)  
Except as otherwise provided in this letter, the Finance Documents remain in full force and effect.
 
(d)  
Except to the extent expressly waived in this letter, no waiver of any provision of any Finance Document is given by the terms of this letter and the Finance Parties expressly reserve all their rights and remedies in respect of any breach of, or other Default under, the Finance Documents.
 
9.  
Governing law
 
  This letter is governed by English law.
 
 
/s/ Olufunmilayo Dada   /s/ Patrick McCawley.

For
CITIBANK INTERNATIONAL PLC
as Facility Agent for and on behalf of the Finance Parties
 
We agree with the terms of this letter.
 
 
/s/ Efrain Rivera
Efrain Rivera, Treasurer
For
BAUSCH & LOMB B.V.
 
Date: May 17, 2006
 
 
/s/ Stephen C. McCluski
Stephen C. McCluski
Sr. Vice President and CFO
For
BAUSCH & LOMB INCORPORATED
 
Date: May 17, 2006
EX-10.EE 14 form10k2005e10ee.htm EXHIBIT (10)-EE Exhibit (10)-ee


Exhibit (10)-ee

LETTER WAIVER


Dated as of August 28, 2006
To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Citibank, N.A.,
as agent (the "Agent") for the Lenders

Ladies and Gentlemen:

We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you, and the letter waivers thereunder dated November 23, 2005 (referred to herein as the “First Letter Waiver”), February 17, 2006 (effective February 24, 2006 and referred to herein as the “Second Letter Waiver”) and May 15, 2006 (the “Third Letter Waiver” and collectively, with the First Letter Waiver and the Second Letter Waiver, the “Waivers”). Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement, the Waivers.
 
Reference is made to each of Borrower’s Announcements and the events described under the prior Waivers, and the prior definitions of Announcements are amended hereby to include Borrower’s: (i) press release May 19, 2006 (IRS Notice of Administrative Adjustment for 1999 Tax Year), (ii) Borrower’s filings with the U.S. Securities and Exchange Commission (the “SEC”) on Form 8-K, filed May 19, 2006, (iii) Borrower’s filing with the SEC on Form 8-K, filed August 8, 2006 and (iv) Borrower’s filing with the SEC on Form 12b-25, filed August 8, 2006.

In light of these events described in the Announcements, and other confidential information which Borrower disclosed to Agent and Lenders verbally and in writing prior to the date hereof under the terms of confidentiality agreements executed with each Lender (the “Confidential Disclosures”), Borrower has requested, and the Required Lenders hereby agree that the term “Waiver Termination Date” as defined in the Waivers is superseded and is hereby defined for all purposes as December 15, 2006. The terms of the Third Letter Waiver shall remain in full force and effect, as modified by this Letter Waiver, including, without limitation, paragraphs (and any subparagraphs) three, five, six and seven thereof, provided that subparagraph (iii) of the third paragraph of the Third Letter Waiver shall not be effective after October 2, 2006.

This Letter Waiver shall become effective as of October 2, 2006 if, as of that date, the Agent has received counterparts of this Letter Waiver executed on behalf of Borrower and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver (“Effective Date”).

If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.

With respect to the matters waived hereunder, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to such matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred, or (3) that any Default or Event of Default has occurred under the Credit Agreement.

The Waivers, as modified by each other and this Letter Waiver, shall represent the entire agreement with respect to the matters contained herein and, except where otherwise noted herein or therein, shall supersede any prior agreements whether written or oral. This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 
This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.

Very truly yours,

BAUSCH & LOMB INCORPORATED

By /s/ Efrain Rivera
Title: Vice President & Treasurer

Agreed as of the date first above written:
CITIBANK, NA.,
as Agent and as Lender

By /s/ Robert J. Kane
Title: Managing Director


 
 

 

KEYBANK NATIONAL ASSOCIATION

By /s/ Marianne Meil   
Title: Senior Vice President

BARCLAYS BANK PLC

By /s/ David Barton   
Title: Associate Director

BANK OF TOKYO-MITSUBISHI UFJ TRUST
COMPANY (f/k/a Bank of Tokyo-Mitsubishi Trust
Company)

By /s/ Harumi Kambara  
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By /s/ Bruce Yoder   
Title: Vice President

MIZUHO CORPORATE BANK, LTD.

By /s/ Raymond Ventura  
Title: Deputy General Manager
 
U.S. BANK NATIONAL ASSOCIATION

By /s/ Eric Cosgrove   
Title: Assistant Vice President

ALLIED IRISH BANKS, P.L.C.

By___/s/ Germain Reusch     By___/s/ Anthony O’Reilly  
Title: Director     Title: Senior Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By /s/ J. Carroll   
Title: First Vice President

THE NORTHERN TRUST COMPANY

By /s/ Karen E. Dahl   
Title: Vice President
EX-10.FF 15 form10k2005e10ff.htm EXHIBIT (10)-FF Exhibit (10)-ff

 
Exhibit (10)-ff
 
  
LETTER WAIVER
 
  
To:    Bausch & Lomb B.V. (the Company)
   Koolhovenlaan 110
   1119 NH Schiphol-Rijk
   The Netherlands

Fax:    +31 20 6554 651
Attn:   Financial Controller


and:    Bausch & Lomb Incorporated (the Guarantor)
One Bausch & Lomb Place
Rochester
New York 14604
United States of America

Fax:   +1 585 338 8188
Attn:     Corporate Treasury Operations
 
  Wednesday, August 30th, 2006
 
  Dear Sirs,
 
  US$375,000,000 credit agreement dated 29 November 2005 (as amended) between (among others) the Company, the Guarantor and Citibank International plc as facility agent (the Agreement)
 
1.  
Background
 
(a)  
This letter is supplemental to and amends the Agreement.
 
(b)  
Pursuant to Clause 25 (Amendments and Waivers) of the Agreement, the Majority Lenders have consented to the amendments to the Agreement contemplated by this letter. Accordingly, we are authorised to execute this letter on behalf of the Finance Parties.
 
2.  
Interpretation
 
(a)  
Capitalised terms defined in the Agreement have the same meaning when used in this letter unless expressly defined in this letter.
 
(b)  
The provisions of Clause 1.2 (Construction) of the Agreement apply to this letter as though they were set out in full in this letter except that references to the Agreement are to be construed as references to this letter.
 
(c)  
Effective Date means 6:00 p.m. (Rochester, New York time) 2 October, 2006, provided that the Facility Agent shall have given notification to the Obligors that it has received a copy of this letter countersigned by the Company and the Guarantor.
 
3.  
Amendments
 
(a)  
Subject to subparagraph (b) below, the Agreement will be amended from the Effective Date in accordance with subparagraph (c) below.
 
(b)  
The Agreement will not be amended by this letter unless the Facility Agent has received a copy of this letter countersigned by the Company and the Guarantor on or before the Effective Date.
 
(c)  
The Agreement will be amended as follows:
 
(i)  
Clause 19.11(a)(ii) (BLIO Matters) of the Agreement shall be amended by deleting the reference to “2 October” in the last line thereof and replacing it with “15 December”;
 
(ii)  
the definition of Other Announcements shall be amended as follows:
 
 
 (i) deleting the word “and” at the end of subparagraph (ix);
 
 
(ii) deleting the full stop after the words "15 May, 2006 press release" at the end of subparagraph (x) and replacing it with a semi-colon; and
 
 
(iii) inserting new subparagraphs (xi) to (xiv), inclusive as follows:
 
 
"(xi) press release dated 19 May, 2006 (IRS Notice of Administrative Adjustment for 1999 Tax Year);
 
 
(xii) Form 8-K, filed 19 May, 2006;
 
 
(xiii) Form 8-K, filed 8 August, 2006; and
 
 
(xiv) Form 12b-25, filed 8 August 2006."; and
 
(iii)  
the definition of Waiver Termination Date in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
 
  Waiver Termination Date means the earlier of:
          (i) 6:00 p.m. (Rochester, New York time) on 15 December, 2006; and
 
 
(ii) the date (if any) on which the trustee or holders of not less than 25 per cent. of the principal amount of outstanding securities under any series with an outstanding principal amount of at least US$50,000,000 under the Indenture have given to the Guarantor notice that the principal amount of such securities is due and payable immediately.".
 
4.  
Guarantee
 
  The Guarantor:
 
(a)  
agrees to the amendment of the Agreement as contemplated by this letter; and
 
(b)  
with effect from the Effective Date, confirms that the guarantee given by it under the Agreement will:
 
 
(i) continue in full force and effect; and
 
  
(ii) extend to the liabilities and obligations of the Company to the Finance Parties under the Finance Documents as amended by this letter.
 
5.  
Amendment fee
 
(a)  
In further consideration for the matters contemplated by this letter, the Company must pay to the Facility Agent for the account of the Lenders which consented on or before the date of this letter to the amendments to the Agreement contemplated by this letter (the Consenting Lenders) a monthly fee equal to 0.10 per cent. of the total Commitments of the Consenting Lenders. The first such monthly fee shall be payable no later than 3 October, 2006, and subsequent monthly fees will be due on the first Business Day of each month thereafter that the Guarantor is delayed in filing its financial statements prior to the Waiver Termination Date. Payments will be made to the account notified to the Company by the Facility Agent for this purpose. Any payment that would have otherwise been due and payable for October 2006 under the 17 May, 2006 amendment to this Agreement shall be covered by the above payment.
 
(b)  
All amounts payable under this letter are exclusive of any value added tax or other taxes of any nature and will not be subject to counterclaim or set-off for, or be otherwise affected by, any claim or dispute relating to any matter whatsoever and all such payments shall be made free and clear and without deduction for or on account of any present or future taxes, charges, deductions or withholdings.
 
6.  
Miscellaneous
 
(a)  
This letter is a Finance Document and a Fee Letter.
 
(b)  
From the Effective Date, the Agreement and this letter will be read and construed as one document.
 
(c)  
Except as otherwise provided in this letter, the Finance Documents remain in full force and effect.
 
(d)  
Except to the extent expressly waived in this letter, no waiver of any provision of any Finance Document is given by the terms of this letter and the Finance Parties expressly reserve all their rights and remedies in respect of any breach of, or other Default under, the Finance Documents.
 
7.  
Governing law
 
      This letter is governed by English law.
 

 
…/s/ Olu Dara and Jane Horner ..
For
CITIBANK INTERNATIONAL PLC
as Facility Agent for and on behalf of the Finance Parties
 
We agree with the terms of this letter.
 
 
…/s/ Efrain Rivera………………………..
Efrain Rivera, Vice President & Treasurer
For
BAUSCH & LOMB B.V.
 
Date: August 28, 2006
 
 
…/s/ Stephen C. McCluski………………...
Stephen C. McCluski
Sr. Vice President and CFO
For
BAUSCH & LOMB INCORPORATED
 
Date: August 28, 2006
EX-10.GG 16 form10k2005e10gg.htm EXHIBIT (10)-GG Exhibit (10)-gg


Exhibit (10)-gg
Execution Copy

DATED July 2, 2005


(1) SINO BIOPHARMACEUTICAL LIMITED

AND

(2) BAUSCH & LOMB INCORPORATED


 

AGREEMENT FOR THE
SALE AND PURCHASE OF
THE ENTIRE ISSUED CAPITAL OF
SINO CONCEPT TECHNOLOGY LIMITED 中外科技有榰公司
 









Baker &
14th Floor Hutchison House
Hong Kong

Telephone: (852) 2846-1888
Fax: (852) 2845-0476

 
 

 

CONTENTS

Number
Clause Headings
Page
1.
Definitions and Interpretation
5
2.
Sale of Sale Shares
17
3.
Consideration
17
4.
Conditions
17
5.
Completion
21
6.
Post-Completion
29
7.
Restriction of Vendor and Undertaking of Purchaser
30
8.
Warranties
33
9.
Pre-Completion
34
10.
Confidentiality and Restriction on Announcements
38
11.
Costs
39
12.
General
39
13.
Notices
41
14.
Governing Law and Arbitration
42
15.
English and Chinese Versions
42
     
SCHEDULE 1
Details of the Company
44
SCHEDULE 2
Details of the Subsidiaries
45
SCHEDULE 3
The Properties
49
SCHEDULE 4
Deed of Indemnity
50
SCHEDULE 5
Warranties
61
SCHEDULE 6
Intellectual Property
98
SCHEDULE 7
Hong Kong Legal Opinion
99
SCHEDULE 8
Patents
103
SCHEDULE 9
Patent License Contract
106
SCHEDULE 10
Deed of Undertaking
107
SCHEDULE 11
List of Key Employees
111
SCHEDULE 12
Principal Terms of Key Management Retention Agreement
112
SCHEDULE 13
Resignation Letter
113
SCHEDULE 14
Irrevocable Power of Attorney
114
SCHEDULE 15
Confirmation and Declaration of Shandong Research Institute
117
     
Annex I
Accounts
118
Annex II
Management Accounts
119
Annex III
Subsidiary Accounts
120
Annex IV
Subsidiary Management Accounts
121
Annex V
Approved Extraordinary Expenditures
122
     
Execution
 
122




 
 

 

DATE: July 2, 2005

PARTIES:

(1)
SINO BIOPHARMACEUTICAL LIMITED, a company incorporated in the Cayman Islands, whose registered office is at Century Yard, Cricket Square, Hutchins Drive, P.O. Box 2681 GT, George Town, Grand Cayman, British West Indies and whose principal place of business in Hong Kong is Unit 09, 41st Floor, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong (the “Vendor”).
(2)
BAUSCH & LOMB INCORPORATED, a company incorporated in the State of New York, United States of America, whose principal place of business is at One Bausch & Lomb Place, Rochester, New York 14604-2701, United States of America (the “Purchaser”).

RECITALS:

(A)
The Company (as defined below) is a limited liability company incorporated in Hong Kong with registered number 300326 and as at the date of this Agreement has an authorised share capital of HK$10,100 divided into 10,100 ordinary shares of HK$1.00 each, all of which have been issued and are fully paid up and are beneficially owned by the Vendor. Further particulars of the Company are set out in Schedule 1.

(B)
The Vendor wishes to sell and the Purchaser wishes to purchase the Sale Shares (as defined below) on the terms and conditions set out in this Agreement.

TERMS AGREED:

1.  
Definitions and Interpretation

1.1
In this Agreement where the context so admits the following words and expressions shall have the following meanings:

“Accounting Date”
December 31, 2004;
“Accounts”
the audited consolidated financial statements of the Company for the accounting period which ended on the Accounting Date (each such financial statement comprising the consolidated profit and loss account, consolidated balance sheet, consolidated summary statement of changes in equity, consolidated cash flow statement, a balance sheet for the Company, directors’ and auditors’ reports, and notes to the financial statements as at and for the period ended on the Accounting Date), copies of which are annexed hereto as Annex I and initialled for the purposes of identification by the Parties;
“Approved Extraordinary Expenditures”
the expected extraordinary expenditures for the Subsidiaries for the three (3) months immediately after the date of this Agreement which have been approved by the Purchaser, a list of which is annexed hereto as Annex V and initialled for the purposes of identification by the Parties;
“Auditors”
Ernst & Young;
“Board”
the board of directors of the Company for the time being;
“Business Day”
a day on which banks are generally open for business in Hong Kong and which is not a Saturday, a Sunday, a public holiday or a day on which typhoon signal no. 8 or a “black” rainstorm warning is hoisted in Hong Kong;
“Company”
Sino Concept Technology Limited 中外科技有榰公司, details of which are set out in Schedule 1;
“company”
any company or body corporate wherever incorporated;
“Companies Ordinance”
Companies Ordinance (Chapter 32 of the Laws of Hong Kong);
“Completion”
completion of the sale and purchase of the Sale Shares as specified in Clause 5;
“Completion Date”
the date of Completion, being the fifth Business Day after the fulfilment or waiver (as the case may be) of all of the Conditions specified in Clause 4.1 (save for the Conditions set out in Clauses 4.1.2, 4.1.3, 4.1.4 and 4.1.7) (or such later date as the Parties may agree in writing);
“Conditions”
the conditions specified in Clause 4.1;
“Consideration”
the amount of US$200,000,000 (United States Dollars Two Hundred Million);
“Control”
a person or persons (each a “controller”) shall be taken to have Control of another person (“the controlled person”) if one or more of the controllers, whether by law or in fact has, or is entitled to acquire, the right or the power to secure whether directly or indirectly, that the controlled person’s affairs are conducted in accordance with the wishes of the controller and in particular, but without prejudice to the generality of the foregoing, if one or more of the controllers holds:
 
(i)    the greater part of the share capital of the controlled person or of the voting rights attaching to the controlled person’s shares; or
 
(ii)    the power to control the composition of any board of directors or governing body of the controlled person;
 
For the purposes of the foregoing and without limitation there shall be attributed to any controller:
 
(i)     any rights or powers which another person possesses on his behalf or is or may be required to exercise on his direction or behalf; and
 
(ii)     all rights and powers of any body corporate of which any controller alone or together with another or other controllers has control or of any two or more such bodies corporate;
“CTF”
山东正大福瑞灂制粑有榰公司 (Shandong Chia Tai Freda Pharmaceutical Co. Ltd.), details of which are set out in Part A of Schedule 2;
“CTFP”
山东正大福瑞灂包眻新材料有榰公司 (Shandong Chia Tai Freda New Packaging Resources Co. Ltd.), details of which are set out in Part B of Schedule 2;
“Deed of Indemnity”
the deed of indemnity to be entered into between the Vendor, the Company and the Purchaser in the form set out in Schedule 4;
“Dermatitis Products”
cremes, emollients and other topical medicines sold and administered principally for therapeutic purposes, and distinguished from products sold and administered principally for cosmetic purposes, which are not the subject of a restrictive covenant;
“Directors”
the persons listed as directors of the Company in Schedule 1;
“Disclosure Letter”
the letter of today’s date from the Vendor to the Purchaser in the approved terms;
“Environment”
all or any of the following media, namely, the air, water and land; and the medium of air includes the air within buildings and the air within other natural or man-made structures above or below ground;
“Environmental Law”
all and any laws, directives, regulations, notices, standards having force of law, codes of practice, guidance notes, by-laws, judgments, decrees or orders of and within the PRC, relating to pollution, contamination or protection of the Environment or to the storage, labelling, handling, release, treatment, manufacture, processing, deposit, transportation or disposal of Hazardous Substances;
“Environmental Licence”
any permit, licence, authorisation, consent or other approval, that may be required by any Environmental Law;
“Equity Interests”
the 55% equity interests held by the Company in each of CTF and CTFP;
“Formulation Information”
the written statement of ingredients, concentrations and manufacturing instructions, specifications and procedures for each of the following products of the Subsidiaries:
 
(i) Moisten Eye Drops,
(ii) Mioclear Eye Drops,
(iii) Renown Eye Drops,
(iv) Levsaxin Eye Drops,
(v) Mioclear Eye Cleaning Solution, and
(vi) Sodium Hyaluronate Injection;
“Group”
the group of companies comprising the Company and the Subsidiaries; the expression “member of the Group” shall mean any or a specific one of them;
“HA”
hyaluronic acid or hyaluronate, a polysaccharide made up of two repeating monosaccharide units (N-acetylglucosamine and Naglucuronate) present in the intercellular matrix of nearly all connective tissues;
“Hazardous Substances”
all substances of whatever description which may cause or have a harmful effect on the Environment, including, without limitation, all poisonous, toxic, noxious, dangerous and offensive substances;
“HK$”
Hong Kong dollars, the lawful currency of Hong Kong;
“HKIAC”
has the meaning ascribed to it in Clause 14.2;
“Hong Kong”
the Hong Kong Special Administrative Region of the People’s Republic of China;
“Intellectual Property”
includes patents, knowhow, trade secrets and other confidential information, registered designs, copyrights, Internet domain names of any level, design rights, rights in circuit layouts, moral rights, trade marks, service marks, trade dress, business names, registrations of, applications to register and rights to apply for registration of any of the aforesaid items, rights in the nature of any of the aforesaid items in any country, rights in the nature of unfair competition rights and rights to sue for passing off;
Key Employees”
those individuals whose names are set out in Schedule 11;
Key Management Retention Agreements”
the services retention agreements to be entered into between the relevant member of the Group and the Key Employees which will incorporate the principal terms set out in Schedule 12;
“Leases”
all the leases, sub-leases, tenancy agreements, sub-tenancy agreements, licences or other documents (including any options for extension relating thereto) granted or agreed to be granted to any member of the Group or pursuant to which any member of the Group holds or occupies any property, details of which are set out in Schedule 3;
“Leased Properties”
the properties short particulars of which are set out in Part 2 of Schedule 3;
“Listing Rules”
the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited;
“Management Accounts”
the unaudited consolidated balance sheet of the Company as at May 31, 2005 and the unaudited consolidated profit and loss account of the Company for the period commencing from January 1, 2005 and ending on May 31, 2005, copies of which are annexed hereto as Annex II and initialled for the purpose of identification by the Parties;
“Material Adverse Effect”
a material adverse effect on the assets, business, liabilities, operations, property or financial condition of the Group taken as a whole;
“Owned Properties”
the properties, short particulars of which are set out in Part 1 of Schedule 3;
“Parties”
the named parties to this Agreement and their respective successors and assigns and “Party” means each or any specific one of them;
“Patents”
the patents and patent applications listed in Schedule 8 and such unpatented products and technology (including unfiled, abandoned or not yet filed patents and patent applications on inventions) as are used by the Subsidiaries in the production, use or sale of its products (including pipeline products) at the date hereof and where applicable, patents and patent applications filed by the Subsidiaries even if they are not used in any of the products of the Subsidiaries;
“PRC”
the People’s Republic of China and for the purposes of this Agreement, shall exclude Hong Kong, the Macau Special Administrative Region and Taiwan;
“Properties”
the Owned Properties and the Leased Properties;
“Purchaser’s Patent Review”
the review to be conducted by the Purchaser’s Solicitors as described in Clause 4.1.9;
“Purchaser’s Solicitors”
Baker & McKenzie of 14th Floor Hutchison House, 10 Harcourt Road, Central, Hong Kong;
“Relevant Scheme”
has the meaning ascribed to it in Clause 9.1.9;
“Restricted Businesses”
the manufacturing and sale of (i) ophthalmic chemical products regardless of whether they incorporate HA as the key compound or agent (the “Restricted Ophthalmic Business”) and (ii) osteoarthritis products or Dermatitis Products for external applications incorporating HA as the key compound or agent (the “Restricted Other Businesses”);
“RMB”
Renminbi, the lawful currency of the PRC;
“Sale Shares”
the 10,100 ordinary shares of HK$1.00 each in the share capital of the Company, being the entire issued share capital of the Company;
“Shandong Research Institute”
Shandong Biopharmaceutical Research Institute, a biopharmaceutical research laboratory in Shandong Province, PRC;
“Subsidiaries”
CTF and CTFP;
“Subsidiary Accounts”
the audited financial statements of each Subsidiary for the accounting period which ended on the Accounting Date (each such financial statement comprising a balance sheet, profit and loss account, statement of cash flow, auditors’ report, and any notes, reports or statements included therein or annexed thereto), copies of which are annexed hereto as Annex III and initialled for the purposes of identification by the Parties;
“Subsidiary Management Accounts”
the unaudited balance sheet of each Subsidiary as at May 31, 2005, and the unaudited profit and loss account of each Subsidiary for the period commencing from January 1, 2005 and ending on May 31, 2005, copies of which are annexed hereto as Annex IV and initialled for the purpose of identification by the Parties;
“Tax”
all forms of taxation, estate duties, deductions, withholdings, duties, imposts, levies, fees, charges, social security contributions and rates imposed, levied, collected, withheld or assessed by any local, municipal, regional, urban, governmental, state, federal or other body in Hong Kong, the PRC, or elsewhere and any interest, additional taxation, penalty, surcharge or fine in connection therewith;
“US$”
United States dollars, the lawful currency of the United States of America;
“Vendor’s Solicitors”
Morrison & Foerster of 21st Floor, Entertainment Building, 30 Queen’s Road Central, Hong Kong; and
“Warranties”
the representations, warranties and undertakings contained or referred to in Clause 8 and set out in Schedule 5; “Warranty” means any or a specific one of them.
1.2
Save where the context otherwise requires words and phrases the definitions of which are contained or referred to in the Companies Ordinance shall be construed as having the meaning thereby attributed to them.

1.3
Any references, express or implied, to statutes or statutory provisions shall be construed as references to those statutes or provisions as respectively amended or re-enacted or as their application is modified from time to time by other provisions (whether before or after the date hereof) and shall include any statutes or provisions of which they are re-enactments (whether with or without modification) and any orders, regulations, instruments or other subordinate legislation under the relevant statute or statutory provision. References to Sections of consolidating legislation shall, wherever necessary or appropriate in the context, be construed as including references to the Sections of the previous legislation from which the consolidating legislation has been prepared.

1.4
References in this Agreement to Clauses and Schedules are to clauses in and schedules to this Agreement (unless the context otherwise requires). The Recitals and Schedules to this Agreement shall be deemed to form part of this Agreement.

1.5
Headings are inserted for convenience only and shall not affect the construction of this Agreement.

1.6
The expressions “the Vendor” and “the Purchaser” include their respective successors and assigns.

1.7
References to “persons” shall include individuals, bodies corporate, unincorporated associations and partnerships (whether or not having separate legal personality).

1.8
References to writing shall include any methods of producing or reproducing words in a legible and non-transitory form.

1.9
The masculine gender shall include the feminine and neuter and the singular number shall include the plural and vice versa.

1.10
A document expressed to be “in the approved terms” means a document the terms of which have been approved by or on behalf of the Parties in writing.

1.11   In construing this Agreement:

 
1.11.1
the rule known as the ejusdem generis rule shall not apply and, accordingly, general words introduced by the word “other” shall not be given a restrictive meaning by reason of the fact that they are preceded by words indicating a particular class of acts, matters or things; and

 
1.11.2
general words shall not be given a restrictive meaning by reason of the fact that they are followed by particular examples intended to be embraced by the general words.

2.            
Sale of Sale Shares

2.1
Subject to the terms of this Agreement, the Vendor shall sell as legal and beneficial owner and the Purchaser shall purchase, the Sale Shares, free from all liens, charges and encumbrances and together with all rights now or hereafter attaching to them, including all rights to any dividend or other distribution declared, made or paid after the date of this Agreement.

2.2
The Vendor hereby waives and agrees to procure the waiver of any restrictions on transfer (including pre-emption rights), if any, which may exist in relation to the Sale Shares, whether under the articles of association of the Company or otherwise.

3.            
Consideration

3.1
The total consideration payable for the Sale Shares shall be the Consideration.

3.2
The Consideration shall be payable on Completion in accordance with Clause 5.2.1.

4.            
Conditions

4.1  The sale and purchase of the Sale Shares is conditional upon:

 
4.1.1
no notice having been received from the PRC Ministry of Commerce (“MOFCOM”) and/or the PRC State Administration of Industry and Commerce (“SAIC”) pursuant to the Provisional Rules on Mergers with and Acquisitions of Domestic Enterprises by Foreign Investors, promulgated by the Ministry of Foreign Trade and Economic Cooperation (the predecessor of MOFCOM), State Administration of Taxation, SAIC and State Administration of Foreign Exchange on 7 March 2003 and effective as of 12 April 2003, ordering an anti-trust filing to be made in respect of the sale and purchase of the Sale Shares pursuant to this Agreement; in the event such order to file is received, this condition shall be satisfied after the Vendor and the Purchaser have jointly made the necessary anti-trust filing and MOFCOM and SAIC having consented to the sale and purchase of the Sale Shares pursuant to this Agreement;

 
4.1.2
the Warranties not being untrue or inaccurate or misleading at Completion which results in a Material Adverse Effect;

 
4.1.3
the Vendor having complied fully with the obligations specified in Clause 9.1 and otherwise having performed all of the covenants and agreements required to be performed by it under this Agreement;

 
4.1.4
no statute, regulation or decision which would prohibit, restrict or materially delay the sale and purchase of the Sale Shares or the operation of any member of the Group after Completion having been proposed, enacted or taken by any governmental or official authority;

 
4.1.5
(i) Mr. Ling Peixue having entered into a license contract with CTF, acknowledged by the Shandong Research Institute, substantially in the form set out in Schedule 9 (the “Patent License Contract”); (ii) Mr. Hu Hongjie having executed a license contract with CTF, acknowledged by Shandong Research Institute, substantially similar in form to the Technology License Contract; (iii) Mr. Ling, Mr. Hu and, if necessary, the Shandong Research Institute having executed the relevant governmental license recordal forms requested by Purchaser in respect of the Technology License Contracts referred to in sub-clauses (i) and (ii) above; and (iv) the Shandong Research Institute having executed a Confirmation and Declaration substantially in the form set out in Schedule 15;

 
4.1.6
the approval of the shareholders of the Vendor (or, if required under the Listing Rules, the approval of the independent shareholders of the Vendor), being obtained in respect of the sale and purchase of the Sale Shares pursuant to this Agreement;

 
4.1.7
there being no change in the business or operations of the Group which has a Material Adverse Effect any time between the date of this Agreement and Completion;

 
4.1.8
each of the Key Employees having entered into a Key Management Retention Agreement;

 
4.1.9
the Purchaser’s Solicitors (through Chiang Ling Li) shall have been provided with the Formulation Information and shall not have within a period of fifteen (15) Business Days (counted, for the sake of clarity, beginning with the first Business Day after Formulation Information is actually delivered) determined based on a review of the Formulation Information so provided, that one or more claim of a published patent in the PRC or patent application in the PRC is infringed by one or more of the products which are the subject of the Formulation Information. The foregoing condition shall be deemed satisfied unless the Purchaser’s Solicitors’ conclusion that there is such infringement, with detailed findings, is provided to the Vendor’s Solicitors in writing on or before the end of such fifteen (15) Business Day period. For purposes of the foregoing, the Vendor shall not be required to provide the Formulation Information to the Purchaser’s Solicitors as stated above unless and until the Conditions set out in Clauses 4.1.5 and 4.1.8 shall have been fulfilled or waived in writing.(pursuant to Clause 4.2); and

 
4.1.10
a contract to terminate the existing license granted by Mr. Ling Peixue and any other licensor(s) thereto (if any) to Shandong Freda Biotechnology Engineering Co. Ltd. in respect of eye wash solutions containing hyaluronic acid and salts and their preparation methods and technology which are the subject of patent application number 200410035712.3 at an aggregate termination costs not exceeding RMB150,000 and and such termination contract must contain a provision obliging and requiring Shandong Freda Biotechnology Engineering Co. Ltd. to cease production, use and sale of all products containing the foregoing Intellectual Property by December 31, 2005.

4.2
Save for the Conditions set out in Clauses 4.1.1, 4.1.4 and 4.1.6, the Purchaser may waive in whole or in part all or any of the Conditions at any time by notice in writing to the Vendor.

4.3
The Vendor shall in good faith use his best efforts and proceed diligently to procure the fulfilment of the Conditions set out in Clauses 4.1.3, 4.1.5, 4.1.6, 4.1.7, 4.1.8 and 4.1.10 on or before the date specified in Clause 4.5 below, provided that best efforts shall not require the payment of amounts which are not ordinarily required to be paid to ensure the performance by a third party of actions necessary to ensure the fulfilment of the relevant Condition.

4.4
The Vendor shall give the Purchaser notice in writing and provide relevant evidence reasonably satisfactory to the Purchaser of the satisfaction of each relevant Condition (save for the Conditions set out in Clauses 4.1.1, 4.1.2, 4.1.3, 4.1.4 and 4.1.7) within three (3) Business Days of becoming aware of the same.

4.5
In the event that any of the Conditions (other than the Conditions set out in Clause 4.1.2) shall not have been fulfilled (or waived pursuant to Clause 4.2) by September 30, 2005 (the “Drop Dead Date”), then neither the Purchaser nor the Vendor shall be bound to proceed with the sale and purchase of the Sale Shares and this Agreement shall cease to be of any effect except Clauses 1, 10, 11, 12, 13, 14 and 15 which shall remain in force and save in respect of claims arising out of any antecedent breach of this Agreement, provided that (i) if the Condition(s) which has (have) not been fulfilled by the Drop Dead Date is (are) any of the Conditions set out in any of Clauses 4.1.3, 4.1.5, 4.1.6, 4.1.7, 4.1.8 or 4.1.10 and such non-fulfilment is the result of the Vendor’s breach of its obligations under Clause 4.3 in relation to such Condition(s), then the Purchaser shall have the right upon notice in writing to the Vendor, to extend the last date for the fulfilment of the said Condition(s) past the Drop Dead Date and this Agreement shall remain in full force and effect in all respects; and (ii) if the fifteen (15) Business Day period referred to in Clause 4.1.9 is not completed prior to the Drop Dead Date, then the Drop Dead Date shall be automatically extended to allow for the end of such fifteen (15) Business Day period and all references in this Agreement to the Drop Dead Date shall be construed accordingly.

4.6
In the event that the Purchaser shall waive any of the Conditions (save for the Conditions set out in Clauses 4.1.1, 4.1.4 and 4.1.6), such waiver shall not, except to the limited extent set forth below, imply that the Purchaser is not relying on the Warranties but rather only that it is prepared, in reliance upon the Warranties and such comfort, if any, as it has taken from its investigations, to proceed with the transaction. Without limiting the requirement of Clause 5.3.1.7, each Party agrees to promptly notify the other Party in writing upon becoming aware of any breach of any of the Warranties by the Vendor after the date of this Agreement and before Completion. In the event the Purchaser elects to proceed to Completion after being notified by the Vendor in writing that the Vendor is aware of a breach of a Warranty which cannot be cured, notwithstanding the best efforts of the Vendor, the Purchaser will, in such case, no longer be entitled to make a claim in respect of such breach of Warranty after the Completion Date.

5.            
Completion

5.1
Subject to the provisions of Clause 4, Completion shall take place on the Completion Date at the offices of the Purchaser’s Solicitors (or such other place as the Parties may agree in writing) when all of the events described in this Clause 5 shall occur.

5.2    At Completion, the Purchaser shall:

 
5.2.1
pay an amount equal to the Consideration to the Vendor by telegraphic bank transfer to the following bank account (and/or such other account(s) as may be designated in writing by the Vendor at least five (5) Business Days prior to the Completion Date);

Name of Bank: Citic Ka Wah Bank Limited
Address of Bank: 116 Hennessy Road, Wan Chai, Hong Kong
Name of Account Holder: Sino Biopharmaceutical Ltd.
Account Number: 725103608801

 
5.2.2
deliver to the Vendor an original counterpart of the Deed of Indemnity duly executed by the Purchaser; and

 
5.2.3
deliver to the Vendor a certified copy of the minutes of a duly held meeting of the board of directors of the Purchaser approving and authorising the execution of this Agreement, the performance of this Agreement and all transactions contemplated herein.

5.3    At Completion, the Vendor shall:

5.3.1     deliver to the Purchaser:

 
5.3.1.1
duly executed transfers and sold notes in respect of all of the Sale Shares in favour of the Purchaser or its nominee together with the relative share certificates;

 
5.3.1.2
a cheque for an amount equal to 0.1% of the HK$ equivalent of the Consideration as at the Completion Date in respect of the Vendor’s share of stamp duty drawn in favour of the Government of the Hong Kong Special Administrative Region;

 
5.3.1.3
an original counterpart of the Deed of Indemnity duly executed by the Vendor and the Company;

 
5.3.1.4
duly executed letter of resignation of the Auditors, resigning as the auditors of the Company, such letter to comply with the requirements of Section 140A of the Companies Ordinance, and duly executed letter from Shandong Sincere Certified Public Accountants Co., Ltd. confirming that it has no claim against the Subsidiaries, whether for any outstanding fees or otherwise;

 
5.3.1.5
(if any) the title deeds, Leases and all other relevant deeds, documents and correspondence relating to the Properties, the land use rights certificates and building ownership certificates relating to the Owned Properties, and leases in respect of the Leased Properties of the Subsidiaries, which are in the possession or under the control of the Vendor or the Company;

 
5.3.1.6
all the statutory and other books and records (including financial records) duly written up to date of the Company and the certificate of incorporation, current business registration certificate, common seal and chop of the Company and any other papers and documents of the Company in its possession or under its control; and (if any) the Certificates of Approval, business licences, chops, capital contribution reports, tax registration certificates, and foreign exchange registration certificates for each of the Subsidiaries, all the statutory and other books and records (including financial records) duly written up to date of the Subsidiaries and any other papers and documents of the Subsidiaries which are in the possession or under the control of the Vendor or the Company;

 
5.3.1.7
a completion certificate duly executed by the Vendor pursuant to which it confirms that (1) the Warranties remain true and accurate and not misleading as given as of the Completion Date, save for any breach of the Warranties which the Vendor has notified the Purchaser in writing at least five (5) Business Days prior to the Completion Date and matters fairly and specifically disclosed in the Disclosure Letter; and (2) the Vendor has complied fully with its obligations, covenants, undertakings and agreements under this Agreement on or prior to the Completion Date;

 
5.3.1.8
unconditional letters of release from the bankers to each member of the Group (if any) evidencing the release and discharge of all guarantees, debentures and charges (if any) granted by any member of the Group in favour of the Vendor and/or any subsidiaries of the Vendor, or in favour of third parties in respect of the performance of the obligations of the Vendor and/or any subsidiaries of the Vendor or any other person not being a member of the Group;

 
5.3.1.9
a certified copy of the minutes of a duly held meeting of the board of directors of the Vendor approving and authorising the execution of this Agreement and the performance of this Agreement and all transactions contemplated herein;

 
5.3.1.10
duly executed letters of resignation dated as of the Completion Date in the form set out in Schedule 13 (or the Chinese equivalent) from the Directors and the secretary of the Company and the directors of each of the Subsidiaries who are nominated or appointed by the Vendor (and in case of the Subsidiaries, through the Company);

 
5.3.1.11
a duly executed confirmation or release from the Vendor (for itself and on behalf of its subsidiaries) and from Mr. Tse Ping (for himself and on behalf of entities Controlled by him) (as applicable) under seal, in the approved terms, releasing the Company and the Subsidiaries from any liability whatsoever (whether actual or contingent) (other than trade debts) which may be owing to the Vendor or any of its subsidiaries or to Mr. Tse Ping or to any persons Controlled by any of them, by the Company or any of the Subsidiaries at Completion;

 
5.3.1.12
irrevocable powers of attorney (in the form set out in Schedule 14) executed under seal by each of the holders of the Sale Shares in favour of the Purchaser or such person(s) as may be nominated by the Purchaser;

 
5.3.1.13
a legal opinion issued by the Vendor’s Solicitors, in the form set out in Schedule 7;

 
5.3.1.14
a legal opinion issued by a firm of lawyers qualified to advise on PRC law and is satisfactory to the Purchaser, in the form and substance satisfactory to the Purchaser, to state that each Subsidiary has been duly established and registered as a PRC legal person with limited liability, and is validly existing under PRC law, and 55% of the equity interests of each of the Subsidiaries is legally owned by the Company;

 
5.3.1.15
all documents evidencing registration or filing (as applicable) of all registrable Intellectual Property owned by the Group, including, without limitation, registration certificates and applications, in the possession or under the control of the Vendor or the Company (if any);

 
5.3.1.16
a deed of undertaking by Mr. Tse Ping in favour of the Purchaser in the form set out in Schedule 10 duly executed by Mr. Tse Ping;

 
5.3.1.17
true and correct copies of the Key Management Retention Agreements entered into between the Key Employees and the relevant members of the Group;

 
5.3.1.18
a true and correct copy of a new HA Compound supply agreement duly executed by CTF and the existing supplier of HA compound to CTF;

 
5.3.1.19
true and correct copies of the approval of the shareholders of the Vendor (or, if required under the Listing Rules, the approval of the independent shareholders of the Vendor), in respect of the sale and purchase of the Sale Shares pursuant to this Agreement;

 
5.3.1.20
a true and correct copy of the Patent Licence Contract duly executed by Shandong Research Institute and Mr. Ling Peixue; and

 
5.3.1.21
a true and correct copy of the Property Title Certificate in respect of CTF’s ownership of the property located at Guanhai Building, northwest corner, Madian Qiao, Bei Sanhuan Zhong Lu, Haidian District, Beijing;

 
5.3.2
make available to the Purchaser in the PRC for inspection purposes:

 
5.3.2.1
the title deeds, Leases and all other relevant deeds, documents and correspondences relating to the Properties, the land use rights certificates and building ownership certificates relating to the Owned Properties, and leases in respect of the Leased Properties of the Subsidiaries;

 
5.3.2.2
the Certificates of Approval, business licences, chops, capital contribution reports, tax registration certificates, and foreign exchange registration certificates for each of the Subsidiaries, all the Statutory and other books and records (including financial records) duly written up to date of the Subsidiaries and all other papers and documents of the Subsidiaries; and

 
5.3.2.3
all documents evidencing registration or filing (as applicable) of all registrable Intellectual Property owned by the Group, including, without limitation, registration certificates and applications;

 
5.3.3
cause the Directors to hold a meeting of the Board at which the Directors shall pass resolutions to:

 
5.3.3.1
approve the transfer of the Sale Shares pursuant to this Agreement and the registration of the Purchaser or its nominees as members of the Company subject only to the production of duly stamped and completed transfers in respect of the Sale Shares;

 
5.3.3.2
approve and authorise the execution by the Company of the Deed of Indemnity;

 
5.3.3.3
accept the resignation of the Auditors, Directors and secretary of the Company referred to in Clauses 5.3.1.4 and 5.3.1.10;

 
5.3.3.4
appoint the directors and secretary of the Company nominated by the Purchaser; and

 
5.3.3.5
(if any bank account of the Company remains on the Completion Date) revoke all of the authorities to the bankers of the Company relating to bank accounts and authorise such persons as the Purchaser may nominate to operate the same;

 
5.3.4
cause such persons as the Purchaser may nominate (at least three (3) Business Days prior to the Completion Date) to be validly appointed as directors and secretary of the Company and upon such appointment forthwith cause the Directors and the secretary of the Company to resign from their respective offices and as employees, each delivering to the Purchaser a resignation letter under seal in the form set out in Schedule 13;

 
5.3.5
cause the Legal Representative of each of the Subsidiaries to arrange for the filing with the relevant authorities in the PRC in relation to the new directors of the Subsidiaries nominated or appointed by the Purchaser through the Company, subject to the new directors having signed the appointment forms;

 
5.3.6
cause such persons as the Purchaser may nominate (at least three (3) Business Days prior to the Completion Date) to be validly appointed as directors of each of the Subsidiaries nominated or appointed by the Vendor through the Company in accordance with the Joint Venture Contract and Articles of Association of the relevant Subsidiary and upon such appointment forthwith cause the directors of each of the Subsidiaries nominated or appointed by the Vendor through the Company to resign from their respective offices and as employees, each delivering to the Purchaser a letter acknowledging that the person so retiring has no claim outstanding for compensation or otherwise; and

 
5.3.7
(i) procure revocation of all authorities to the bankers of the Company relating to bank accounts and use best efforts to procure the giving of authority to such persons as the Purchaser may nominate to operate the same, or if no bank account of the Company remains on the Completion Date, deliver a bank cashier order made payable to the Company for all credit balances therein prior to their closure in excess of HK$10,000; and (ii) procure the delivery to a representative of the Purchaser of the chops held by the Chief Financial Officer of the Subsidiaries which are required in order to operate the bank accounts of the Subsidiaries in the PRC.

5.4
Without prejudice to any other remedies available to the relevant Party, if in any respect the provisions of Clause 5 (other than Clause 5.3.1.21) are not complied with by the relevant Party on the Completion Date, the Party not in default may:

 
5.4.1
defer Completion to a date not more than 28 days after the Completion Date (and so that the provisions of this Clause 5.4 shall apply to Completion as so deferred);

 
5.4.2
proceed to Completion so far as practicable (without prejudice to its rights under this Agreement); or

 
5.4.3
terminate this Agreement.

6.            
Post-Completion

6.1
The Vendor shall use all reasonable endeavours to procure Ms. Zhao Yanping will, during the period from the Completion Date to the date falling six (6) months thereafter, provide services to any member of the Group for the purpose of and as is reasonably necessary for post-Completion transition.

6.2
The Vendor shall fully indemnify and hold harmless the Purchaser and the members of the Group and their directors, officers and employees for a period of ten years after the date hereof against any and all liability, loss, damage, claim or expense, including attorney’s fees and costs arising out of failure to obtain state asset valuation with respect to the Patents which were alleged to have been developed by the Shandong Research Institute.

6.3
In the event the Vendor does not deliver to the Purchaser the Property Title Certificate on the Completion Date pursuant to Clause 5.3.1.21, the Vendor shall fully indemnify and hold harmless the Purchaser against any and all liability, loss, damage, claim or expense, including attorney’s fees and costs incurred by the Purchaser and 55% of any and all liability, loss, damage, claim or expense, including attorney’s fees and costs incurred by CTF arising out of the failure of CTF to obtain the necessary Property Title Certificate in respect of CTF’s ownership of the property located at Guanhai Building, northwest corner, Madian Qiao, Bei Sanhuan Zhong Lu, Haidian District, Beijing.

7.            
Restriction of Vendor and Undertaking of Purchaser

7.1
Subject to Completion, the Vendor undertakes with the Purchaser (for itself and as trustee for the Company and each of the Subsidiaries) that, except with the consent in writing of the Purchaser and subject to the provisions of Clause 7.3:

 
7.1.1
for the period of five years after the Completion Date in respect of the Restricted Ophthalmic Business and a period of three years in respect of the Restricted Other Businesses, it will not within any country or place in which any member of the Group has carried on business during the year preceding the Completion Date, either on its own account or in conjunction with or on behalf of any person, firm or company carry on or be engaged, concerned or interested, directly or indirectly, whether as shareholder, director, employee, partner, agent or otherwise in carrying on the relevant Restricted Businesses (other than as a holder of not more than 5 per cent of the issued shares or debentures of any company listed on a recognised stock exchange);

 
7.1.2
for the period of five years after the Completion Date, it will not either on its own account or in conjunction with or on behalf of any other person, firm or company solicit or entice away or attempt to solicit or entice away from any member of the Group the custom of any person, firm, company or organisation who shall at any time within the year preceding the date hereof have been a customer or identified prospective customer of any member of the Group in respect of any Restricted Businesses;

 
7.1.3
for the period of three years after the Completion Date, it will not either on its own account or in conjunction with or on behalf of any other person, firm or company solicit, entice away or attempt to solicit or entice away from any member of the Group (which for the avoidance of doubt, shall exclude any advertisement or solicitation targeted at or made available to the general public) any person who at the time of such solicitation, enticement or attempt is an officer, manager, consultant or employee of any member of the Group whether or not such person would commit a breach of contract by reason of leaving such employment;

 
7.1.4
it will not at any time hereafter make use of or disclose or divulge to any person (other than to officers or employees of the Vendor, the Company or any of the Subsidiaries whose province it is to know the same) any information (other than any information properly available to the public or disclosed or divulged pursuant to an order of a court of competent jurisdiction or the requirements of The Stock Exchange of Hong Kong Limited or of the Securities and Futures Commission in Hong Kong, or disclosed or divulged to the auditors of the Vendor solely for the purpose of performing an audit in respect of the Vendor (provided always that the Vendor shall procure its auditors will observe the provisions of this Clause 7.1.4), or disclosed or divulged to professional advisers or designated employees of the Vendor strictly on a need-to-know basis (provided always that the Vendor shall procure such professional advisers and employees will observe the provisions of this Clause 7.1.4)) relating to any member of the Group, the identity of its customers and suppliers, its products, finance, contractual arrangements, business or methods of business;

 
7.1.5
if, in connection with the business or affairs of any member of the Group, it shall have obtained trade secrets or other confidential information belonging to any third party under an agreement purporting to bind any member of the Group which contained restrictions on disclosure it will not without the previous written consent of the Purchaser at any time infringe or take any action which would or might result in an infringement of such restrictions;

 
7.1.6
it will not at any time hereafter in relation to any trade, business or company use or register a name, trade mark, service mark, trade dress or business name including the words or symbol “Chia Tai Freda”, “CT Freda”, “CP Freda”, “CTF Freda”, “CPF Freda” and/or “Freda”, or their Chinese equivalents or any word or symbol confusingly similar thereto in such a way as to be capable of or likely to be confused with the name, any trade mark, service mark, trade dress or business name of any member of the Group and shall use his best endeavours to procure that no such name, trade mark, service mark, trade dress or business name shall be used by any person, firm or company with which is under its Control, and it will not take any action contrary to the Intellectual Property of any member of the Group, including, without limitation, challenging the ownership of such right, title or interest or contesting any registration or application for any Intellectual Property of any member of the Group. For the avoidance of doubt, the foregoing restriction does not apply to the words “Chia Tai”, “CTF”, “CPF”, “CT” or “CP” individually or their Chinese equivalents.

7.2
The Vendor shall procure that all entities Controlled by the Vendor will observe the restrictions contained in the foregoing provisions of this Clause 7 and shall use all reasonable endeavours to procure that the respective employees of itself, its subsidiaries and its Controlled entities will observe the confidentiality restrictions contained in Clause 7.1.4.

7.3
While the restrictions contained in this Clause 7 are considered by the Parties to be reasonable in all the circumstances, it is recognised that restrictions of the nature in question may fail for technical reasons and accordingly it is hereby agreed and declared that if any of such restrictions shall be adjudged to be void as going beyond what is reasonable in all the circumstances for the protection of the interests of the Purchaser but would be valid if part of the wording thereof were deleted or the periods thereof reduced or the range of activities or area dealt with thereby reduced in scope the said restriction shall apply with such modifications as may be necessary to make it valid and effective.

7.4    Subject to Completion, the Purchaser undertakes to the Vendor that:-

 
7.4.1
it shall not, and shall procure that its Controlled entities (including without limitation the Group) shall not, in relation to any new product of the Group with effect from the Completion Date use the words “正大” or “Chia Tai” or “CP” (save as part of “Chia Tai Freda”, “CP Freda” or their Chinese equivalent), as part of its name, trade mark, service mark, trade dress or business name, or any word or symbol confusingly similar thereto in such a way as to be capable of or likely to be confused with such word or symbol;

 
7.4.2
it shall not, and shall procure that its Controlled entities in the PRC (including without limitation the Group) shall not, directly or indirectly, with effect from the date falling five (5) years from the Completion Date, in relation to any product, trade, business or company use or register a name, trade mark, service mark, trade dress or business name including the words or symbol “正大” or “Chia Tai” or “CP” or “CT” (including as part of “Chia Tai Freda”, “CP Freda”, “CT Freda”, “CTF”, “CPF” or their Chinese equivalents), or any word or symbol confusingly similar thereto in such a way as to be capable of or likely to be confused with such word or symbol;

Provided that for the avoidance of doubt, the Purchaser shall not be restricted from the use of “Freda” or its Chinese equivalent, either alone or in connection with any other term or word except as stated above.

8.            
Warranties

8.1
The Vendor represents, warrants and undertakes to and with the Purchaser that each of the statements set out in Schedule 5 is now and will at Completion (with all references in any such statement to “the date of this Agreement”, or “the date hereof”, or any other comparable references being changed to “the Completion Date”) be true and accurate.

8.2
The Warranties (other than Warranties in respect of title and ownership of the Sale Shares, the equity interests of the Subsidiaries held by the Company, and approvals and authorizations of the Vendor necessary for the Vendor to enter into this Agreement and perform its obligations under this Agreement (the “Fundamental Warranties”), in respect of which no qualification is accepted) are given subject to matters fairly and specifically disclosed in the Disclosure Letter but no other information relating to the Company or the Subsidiaries of which the Purchaser has knowledge (actual or constructive) and no investigation by or on behalf of the Purchaser shall prejudice any claim made by the Purchaser under the Warranties or operate to reduce any amount recoverable, and liability in respect thereof shall not be confined to breaches discovered before Completion. No letter, document or other communication shall be deemed to constitute a disclosure for the purposes of this Agreement unless the same is expressly referred to in the Disclosure Letter.

8.3
The Vendor acknowledges that the Purchaser has entered into this Agreement in reliance upon the Warranties.

8.4
Subject to Completion, in the event that any of the Warranties is breached or (as the case may be) proves to be untrue or misleading and without prejudice to any other equitable relief a court of competent jurisdiction may see fit to award, the Vendor shall, on demand, pay to the Purchaser:

 
8.4.1
the amount necessary to put the Purchaser and the Company, and 55% of the amount necessary to put the relevant Subsidiary (or Subsidiaries), into the position which would have existed if the Warranties had not been breached or (as the case may be) had been true and not misleading; and

 
8.4.2
all costs and expenses incurred by the Purchaser and the Company, and 55% of all costs and expenses incurred by the relevant Subsidiary (or Subsidiaries), in connection with or as a result of such breach and any costs (including legal costs on a solicitor and own client basis), expenses or other liabilities which the Purchaser and the Company, and 55% of any such costs, expenses or other liabilities which any of the Subsidiaries may incur either before or after the commencement of any action in connection with (i) any legal proceedings in which the Purchaser claims that any of the Warranties has been breached or is untrue or misleading and in which judgement or an arbitral award is given for the Purchaser or (ii) the enforcement of any settlement of, or judgement or an arbitral award in respect of, such claim.

8.5
Each of the Warranties shall be separate and independent and, save as expressly provided to the contrary, shall not be limited by inference from or non-specific reference to any other Warranty or any other term of this Agreement, nor by anything in the Disclosure Letter which is not expressly referenced to the Warranty concerned, notwithstanding any contrary or conflicting provision in the Disclosure Letter.

8.6
The Vendor hereby agrees with the Purchaser (for itself and as trustee for the Company and each of the Subsidiaries) to waive any rights which it may have in respect of any misrepresentation or inaccuracy in, or omission from, any information or advice supplied or given by the Company or its Subsidiaries or their officers, employees or advisers in connection with the giving of the Warranties and the preparation of the Disclosure Letter.

8.7
The Vendor shall procure that (save only as may be necessary to give effect to this Agreement) neither it nor any member of the Group shall do, allow or procure any act or omission before Completion which would constitute a breach of any of the Warranties if they were given at Completion or which would make any of the Warranties inaccurate or misleading if they were so given.

8.8
The Vendor hereby agrees to disclose promptly to the Purchaser in writing immediately upon becoming aware of the same, any matter, event or circumstance (including any omission to act) which may arise or become known to it after the date of this Agreement and before Completion which constitutes a breach of or is inconsistent with any of the Warranties.

8.9
The benefit of the Warranties may be assigned to other members of the Bausch & Lomb group in whole or in part and without restriction by the person for the time being entitled thereto.

8.10
If any sum payable by the Vendor under this Clause 8 shall be subject to Tax (whether by way of deduction or withholding or direct assessment of the person entitled thereto) such payment shall be increased by such an amount as shall ensure that after deduction, withholding or payment of such Tax the recipient shall have received a net amount equal to the payment otherwise required hereby to be made. If the Vendor pays any sum to the Purchaser under this Clause 8, the Consideration shall be deemed to be reduced by the amount of such payment.

8.11
Where any statement in the Warranties is qualified by the expression “to the best of the Vendor’s knowledge and belief” or any similar expression, that statement shall be deemed to include an additional statement that it has been made after reasonable and careful enquiry and shall be deemed to include the knowledge of the senior management of the Vendor (including, without limitation, Mr. Tse Ping, Ms. Zhao Yanping, the directors, officers and senior managers of the Vendor, and the officers and senior managers and factory managers of the Subsidiaries).

8.12
The liabilities of the Vendor under the Warranties:

 
8.12.1
together with the liabilities of the Vendor under the Deed of Indemnity, shall, except for the Fundamental Warranties, be limited to a maximum aggregate amount equal to 50% of the Consideration;

 
8.12.2
shall in relation to those Warranties in respect of Tax (“Tax Warranties”) cease seven years after the Completion Date, except in respect of matters which have been the subject of a written claim made before such date by the Purchaser to the Vendor;

 
8.12.3
shall, except for the Fundamental Warranties, cease two years after the Completion Date, except in respect of matters which have been the subject of a written claim made before such date by the Purchaser to the Vendor;

 
8.12.4
shall be exempted in respect of any breach of Warranties which arises as a result of any PRC tax laws, including an increase in the rate of Tax, not in force as at the date of this Agreement and which is retrospective in effect; and

 
8.12.5
shall be exempted in respect of a claim for breach of Warranty to the extent that provision or reserve in respect of the matter or thing giving rise to such claim has been specifically provided for in the Accounts or the Management Accounts, or has been specifically disclosed in this Agreement or the Disclosure Letter;

unless the relevant claim or claims has arisen by reason of fraud, wilful concealment, dishonesty on the part of the Vendor, in which event there shall be no limit under this Agreement on the amount recoverable by the Purchaser from the Vendor in respect of such claim or claims or the time period within which such claims may be brought.

8.13
The Vendor shall not be liable for a claim under the Warranties if a claim in respect of the same event or circumstance has already been made under the Deed of Indemnity.

8.14
The Parties agree that no liability shall attach to the Vendor in relation to any Warranty claim to the extent that such claim would not have arisen but for an omission or a voluntary act (other than an omission or act carried out pursuant to a legally binding obligation created on or before Completion) of the Purchaser or any member of the Group occurring after Completion which constitutes fraud or wilful misconduct.

8.15
The Parties agree that no liability shall attach to the Vendor in relation to any Warranty claim until the aggregate amount of all claims, each of which (including on an aggregated basis where the individual claim is associated with or forms part of a series of related claims arising from or with respect to the same facts or circumstances) is of an amount (for the sake of clarify, prior to reduction in respect of the Subsidiaries as may be required by Clause 8.4) of US$30,000 or higher, exceeds US$4,500,000 and in such event, the Vendor shall be liable only for the excess of the aggregate amount of all claims over the said US$4,500,000, subject, as the case may be, to limitation in respect of the Subsidiaries as may be required by Clause 8.4. For the sake of clarity, the limitations under this Clause 8.15 shall not apply to the obligations under the Deed of Indemnity or under Clause 6.2 hereof.

8.16
If the Purchaser shall become aware of any material breach of Warranty in respect of which a claim could be made under this Agreement, it shall give reasonable written notice thereof to the Vendor and provide the Vendor with the opportunity to cure such breach (only if such breach is curable) within ten Business Days of its receipt of such notice from the Purchaser. In addition, the Purchaser shall (provided that the Vendor shall indemnify and hold harmless the Purchaser and the Company and the Subsidiaries, as applicable, to the Purchaser’s reasonable satisfaction, against any and all liabilities, costs, damages and/or expenses which may be incurred thereby) take such action and procure that the Company take such action as may reasonably be necessary to mitigate the loss or damage incurred relating to the Warranty claim; provided that neither the Company nor the relevant Subsidiary nor the Purchaser shall in any event be required to take any steps which would require any admission of guilt or liability relating to matters connected with the claim in question or which would affect the conduct of the business of the Purchaser or the Company or any of the Subsidiaries. For the avoidance of doubt, under no circumstances shall the failure by the Purchaser to provide prior reasonable written notice to the Vendor or the opportunity of the Vendor to cure such breach reduce or limit the liability of the Vendor in respect of such breach, unless and to the extent the Vendor is actually and materially prejudiced by such failure by the Purchaser.

9.            
Pre-Completion

9.1
The Vendor shall procure that, during the period from the date of this Agreement to the Completion Date or the termination of this Agreement pursuant to the terms hereof, each member of the Group shall carry on business in the same manner as it was operated prior hereto and in the normal and usual course and in furtherance of the foregoing, no member of the Group shall undertake any of the matters listed below without the prior written consent of the Purchaser:

 
9.1.1
enter into any contract, make any material change to the terms of the existing contracts or assume any liability which will result in any long term, unusual or onerous liability or commitment of any member of the Group;

 
9.1.2
save for the Approved Extraordinary Expenditures, enter into any capital commitment with an individual contract value of more than HK$500,000 (whether by way of purchase, lease, hire purchase or otherwise);

 
9.1.3
make any change in the nature, scope or organisation of its business or dispose of the whole of its undertaking or property or a substantial part thereof;

 
9.1.4
acquire or form any subsidiary or acquire any shares in any company or acquire the whole or any substantial part of the undertaking, assets or business of any other company or any firm or person or enter into any joint venture or partnership with any other person;

 
9.1.5
make any loans or grant any credit (other than credit given in the normal course of trading and advances made to employees against expenses incurred by them on its behalf);

 
9.1.6
borrow any money or make any payments out of or drawings on its bank accounts (except routine payments in the ordinary course of business);

 
9.1.7
enter into any guarantee, indemnity or surety;

 
9.1.8
save as required by any applicable laws or regulations and as contemplated under Condition 4.1.8, make any changes to the terms of employment or of any profit sharing, share option, profit related, bonus or incentive scheme of any of its employees or in any arrangements with its consultants, or make any special or extraordinary payments to any of its employees or consultants;

 
9.1.9
save as required by any applicable laws or regulations, change (or announce to employees any proposal to change) the terms of any retirement scheme or pension plan in which that member of the Group participates (“Relevant Scheme”), or exercise any discretionary power under the Relevant Scheme, or cause the Relevant Scheme to be terminated or wound up (or otherwise fail to maintain the Relevant Scheme in full force and effect) or fail to make any required contribution (or other payment) to the Relevant Scheme, or fail to meet any obligation of any kind whatsoever to the Relevant Scheme;

 
9.1.10
acquire or dispose of or grant any option or right of pre-emption in respect of any material asset (including, without limitation, any of its Intellectual Property) or any interest nor give nor receive any service otherwise than at market value;

 
9.1.11
acquire or dispose of any freehold or leasehold property or grant any lease or third party right in respect of any of the Properties;

 
9.1.12
enter into any leasing, hire purchase agreement or any agreement or arrangements for payment on deferred terms;

 
9.1.13
grant or enter into any assignment, licence, franchise or other agreement or arrangement concerning any part of its name, trading names, know-how, patents, trademarks, service marks, trade dress, copyright, inventions or any other of its Intellectual Property;

 
9.1.14
declare, authorize, make or pay any dividend or other distribution (whether in cash or in specie) or reduce its paid-up capital;

 
9.1.15
incur or pay any management charges;

 
9.1.16
permit any of its insurances to lapse or do anything which would make any policy of insurance void or voidable;

 
9.1.17
make any payments to either the Vendor or any of its subsidiaries or to Mr. Tse Ping or to any persons (other than members of the Group) affiliated with any of the foregoing (for the purpose of this Clause, a person shall be considered to be “affiliated” with another person if that person either Controls, is Controlled by or under the common Control with such person);

 
9.1.18
other than in the ordinary course of business, apply for, surrender or agree any variations to any Environmental Licences;

 
9.1.19
agree, conditionally or otherwise, to do any of the foregoing;

 
9.1.20
commence the prosecution or defence of, or settle, any legal or arbitration proceedings (other than in connection with the collection of ordinary trade debts);

 
9.1.21
make any changes in the pricing of any products of any member of the Group, other than in the ordinary course of business or as required by applicable laws or regulations;

 
9.1.22
make any changes to any of its constitutional documents;

 
9.1.23
amend the accounting policies or practices or reporting practices existing as of the date of this Agreement;

 
9.1.24
terminate, enter into or amend any supply or distribution agreement or arrangement; or

 
9.1.25
create, allot or issue or agree to create, allot or issue any share or loan capital or other security, or equity interests, or grant any option over or other right to subscribe for any share or loan capital or other security, or equity interests.

9.2
The Vendor undertakes and covenants with the Purchaser that during the period from the date hereof until the Completion Date or the termination of this Agreement pursuant to the terms hereof, it will not:

 
9.2.1
sell, mortgage, grant an option over or otherwise dispose of or encumber to any person the whole or any part of the shares or equity interests of any member of the Group owned by the Vendor or the Company or the business or assets of any member of the Group, or indicate a willingness to consider any offer to do any of the foregoing;

 
9.2.2
engage in discussions or negotiations with any person in relation to the sale, mortgage or other disposition of, or grant of an option or other encumbrance in respect of, the whole or any part of the shares or equity interests of any member of the Group owned by the Vendor or the Company or the business or assets of any member of the Group; or

 
9.2.3
provide to any prospective purchaser of the whole or any part of the business, assets or shares or equity interests of any member of the Group any non-public information concerning any member of the Group;

provided that the foregoing shall not prevent the sale or other disposal or any discussions or negotiations in respect of any such sale or other disposal by any member of the Group of any of its assets in the usual and ordinary course of business.

9.3
The Vendor undertakes that it will after the signing of this Agreement and before Completion make available to the Purchaser upon its request personnel with knowledge of the history and development of the Group’s products for the purpose of providing information thereon to the Purchaser.

10.          
Confidentiality and Restriction on Announcements

10.1
Subject to Clause 10.2, each Party shall treat as confidential all information received or obtained by it or its directors, employees, agents or advisers as a result of entering into or performing this Agreement including (i) information relating to the provisions of this Agreement; (ii) the negotiations leading up to this Agreement;(iii) the subject matter of this Agreement; or (iv) the business or affairs of the other Party, and shall not at any time make use of, disclose or divulge to any person any such information or make any announcement on any such information without the prior written consent of the other Party.

10.2
The restrictions contained in Clause 10.1 shall not apply so as to prevent a Party from disclosing or making any announcement of any information which would otherwise be confidential if and to the extent: (i) required by law of any relevant jurisdiction; (ii) required by any securities exchange, supervisory, regulatory or governmental body to which such Party is subject (including but not limited to The Stock Exchange of Hong Kong limited and the Securities and Futures Commission in Hong Kong) whether or not the requirement for information has the force of law; (iii) disclosed to any professional advisers of such Party (provided always that such Party shall procure such professional advisers will observe the provision of this Clause 10); (iv) disclosed in a press announcement in a form agreed by both Parties or consistent with a mutually agreed set of questions and answers; or (v) any information which comes into the public domain through no fault of such Party.

11.          
Costs

11.1
Each Party shall pay its own costs of and incidental to this Agreement and the sale and purchase hereby agreed to be made.

11.2
The Vendor and the Purchaser shall each equally bear any stamp duty payable as a result of the sale and purchase of the Sale Shares pursuant to this Agreement.

11.3
The Vendor confirms that no costs or expenses of whatever nature relating to the sale of the Sale Shares has been or is to be borne by any member of the Group and if any such costs or expenses have been or are to be borne by any member of the Group, the Vendor shall forthwith reimburse any and all such costs and expenses to the relevant member of the Group.

12.          
General

12.1
This Agreement shall be binding upon and enure for the benefit of the estates, personal representatives or successors of the Parties. Save for an assignment of this Agreement by the Purchaser to a subsidiary of the Purchaser, no Party may assign or transfer its rights or obligations under this Agreement without the prior written consent of the other Party.

12.2
This Agreement (together with any documents referred to herein or executed contemporaneously by the Parties in connection herewith) constitutes the whole agreement between the Parties and supersedes any previous agreements or arrangements between them relating to the subject matter hereof; it is expressly declared that no variations hereof shall be effective unless made in writing signed by duly authorised representatives of the Parties. Notwithstanding the foregoing, the Confidentiality Agreement entered into between the Vendor and the Purchaser dated November 21, 2004, as amended on July 2, 2005, survives the signing of the Agreement, but shall terminate upon Completion.

12.3
All of the provisions of this Agreement shall remain in full force and effect notwithstanding Completion (except insofar as they set out obligations which have been fully performed at Completion).

12.4
If any provision or part of a provision of this Agreement shall be, or be found by any authority or court of competent jurisdiction to be, invalid or unenforceable, such invalidity or unenforceability shall not affect the other provisions or parts of such provisions of this Agreement, all of which shall remain in full force and effect.

12.5
Any right of rescission conferred upon any Party hereby shall be in addition to and without prejudice to all other rights and remedies available to it (and, without prejudice to the generality of the foregoing, shall not extinguish any right to damages to which that Party may be entitled in respect of the breach of this Agreement) and no exercise or failure to exercise such a right of rescission shall constitute a waiver by that Party of any such other right or remedy.

12.6
No failure of any Party to exercise, and no delay or forbearance in exercising, any right or remedy in respect of any provision of this Agreement shall operate as a waiver of such right or remedy.

12.7
Upon and after Completion the Vendor shall do and execute or procure to be done and executed all such further acts, deeds, documents and things as may be reasonably necessary to give effect to the terms of this Agreement and to place control of the Company and the Subsidiaries in the hands of the Purchaser and to deliver and make available to the Purchaser all documents and records (if any) of the Company and the Subsidiaries, and all documents (if any) evidencing registration or filing (as applicable) of all registrable Intellectual Property owned by the Group, which are in the possession or under the control of the Vendor, and pending the doing of such acts, deeds, documents and things, the Vendor shall as from Completion hold the legal estate in the Sale Shares in trust for the Purchaser.

12.8
This Agreement may be executed in one or more counterparts (including by facsimile signature), but shall not be effective until each Party has executed at least one counterpart and each such counterpart shall constitute an original of this Agreement but all the counterparts shall together constitute one and the same instrument.

13.          
Notices

Each notice, demand or other communication given or made under this Agreement shall be in writing and delivered or sent to the relevant Party at its address or fax number set out below (or such other address or fax number as the addressee has by five (5) Business Days’ prior written notice specified to the other Party):

To the Vendor:                     Sino Biopharmaceutical Limited
Unit 09, 41st Floor
Office Tower
Convention Plaza
1 Harbour Road
Wanchai
Hong Kong
Attention: Mr. Tse Ping
Fax Number: (852) 2880 0847

To the Purchaser:                 Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, New York 14604-2701
United States of America
Attention: Vice President - Business Development
Fax Number: (1-585) 338-5043

With a copy to:                    Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, New York 14604-2701
United States of America
Attention: Senior Vice President and
General Counsel
Fax Number: (1-585) 338-8706

Any notice, demand or other communication so addressed to the relevant Party shall be deemed to have been delivered (a) if given or made by letter, when actually delivered to the relevant address and (b) if given or made by fax, when despatched.

14.          
Governing Law and Arbitration

14.1
This Agreement shall be governed by and construed in accordance with the laws of Hong Kong.

14.2
Any dispute, controversy or claim arising out or relating to this Agreement, or the breach, termination or invalidity thereof, shall be settled by final and binding arbitration in accordance with the UNCITRAL Arbitration Rules as at present in force and as may be amended by the rest of this Clause. The appointing body shall be the Hong Kong International Arbitration Centre (“HKIAC”). The place of arbitration shall be in Hong Kong at HKIAC. The tribunal for any arbitration shall consist of three (3) arbitrators with each of the Purchaser and the Vendor having the right to appoint one arbitrator and the third arbitrator shall be appointed by the Secretary General of HKIAC. The language to be used in the arbitral proceedings shall be English.

15.          
English and Chinese Versions

The Parties hereby acknowledge and agree that even though they will each execute both an English and a Chinese version of this Agreement, if and to the extent that there is any conflict or inconsistencies between the English and Chinese versions of this Agreement, the English version of this Agreement shall prevail at all times and no Party shall take any steps which may be inconsistent with the foregoing.



IN WITNESS WHEREOF the Parties have executed this document on the date appearing at the head hereof.


SIGNED by                                                                                  )
Tse Hsin                                                                                      )
for and on behalf of      ) /s/ Tse Hsin
SINO BIOPHARMACEUTICAL LIMITED      )
in the presence of:                                                                      )

/s/ Oh Chee Hwa


SIGNED by       )
John M. Loughlin                                                                      )
for and on behalf of      ) /s/ John M. Loughlin
BAUSCH & LOMB INCORPORATED       )
in the presence of:                    )

/s/ Stephen Chan
EX-10.HH 17 form10k2005e10hh.htm EXHIBIT (10)-HH Exhibit (10)-hh
 
Exhibit (10)-hh
 
 
Summary of Employment Arrangement of Dr. Praveen Tyle
 
 
Dr. Praveen Tyle entered into an employment arrangement in or around June 2004. He became a named executive officer based on 2005 compensation. His terms of employment include:
 
 
·  
Eligible to participate in certain Company management plans that have been previously filed with the Securities and Exchange Commission, including the Annual Incentive Compensation Plan, the Bausch & Lomb Stock Incentive Plan, and Long-Term Incentive Plan;
 
·  
Entitled to receive employee benefits made available to other employees and officers of the Company and their eligible dependents;
 
·  
Received a stock option award of 35,000 shares, which vests in three equal installments over a three-year period, and a restricted stock award of 8,000 shares, which vests in three equal installments in three, five and seven years from the date of grant;
 
·  
Modified severance benefits payable to him under the Company’s Officer Separation Plan - if Dr. Tyle’s employment terminates prior to July 19, 2007, under circumstances which would otherwise entitle him to severance protection under the Company’s Officer Separation Plan: (i) unvested portions of his restricted stock and his stock option award granted under his 2004 employment arrangement vest immediately upon the termination date; and (ii) if accelerated vesting is not approved under the Company’s 2003 Long-Term Incentive Plan, the Company will pay him, subject to withholdings, an amount equal to the fair market value of the unvested restricted stock award and the excess, if any, of the fair market value of the unvested stock option award over the option’s exercise price. In addition, if Dr. Tyle is involuntarily terminated after three years from his hire date under circumstances providing him with benefits under the Officer Separation Plan, then remaining unvested portions of Dr. Tyle’s restricted stock grant, if any, shall immediately vest on such date of termination. In the event of a termination due to a change of control, Dr. Tyle’s severance arrangement would be superseded by the Change of Control Agreement between Dr. Tyle and the Company.
 

EX-10.II 18 form10k2005e10ii.htm EXHIBIT (10)-II Exhibit (10)-ii


Exhibit (10)-ii

Summary of Terms For Company Contribution For Certain Participants in the 401(k) Excess Program


On February 27, 2006, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) approved a one-time arrangement to make limited contributions for the benefit of employees, including named executive officers of the Company, participating in the 401(k) Excess Program (“Excess Program”) under the Company’s non-qualified Executive Deferred Compensation Plan.  The contributions were made as a technical correction in the administration of the Excess Program.  As a standard feature of the Excess Program, the Company made a matching contribution based on a percentage of the employee’s salary and level of contribution into that program.
 
However, the Company determined that because changes in IRS regulations under Internal Revenue Code Section 409A did not allow previously elected deferrals of certain performance-based bonuses, affected employees would not be entitled to receive the expected benefits of the Company matching contribution on those deferrals.  In order to preserve the intended matching contribution, the Compensation Committee authorized affected employees to receive Company contributions into their Excess Program deferral accounts in the amounts they would have received if the Company had been able to permit deferral of performance-based bonus compensation into the Excess Program under their elections.

EX-10.JJ 19 form10k2005e10jj.htm EXHIBIT (10)-JJ Exhibit (10)-jj


Exhibit (10)-jj

BAUSCH & LOMB INCORPORATED
EXECUTIVE DEFERRED COMPENSATION PLAN
FOR POST-2004 DEFERRALS


1.
Introduction
This Executive Deferred Compensation Plan for Post-2004 Deferrals (the "Plan") provides that Bausch & Lomb Incorporated (the "Company") will make certain contributions on behalf of eligible executives and permits eligible executives to defer a portion of their compensation as more particularly described in Section 2. The Plan is effective for eligible compensation deferred on and after January 1, 2005 (the “Effective Date”) and amounts deferred before that date under the Bausch & Lomb Incorporated Executive Deferred Compensation Plan that are subject to Section 409A (as defined below). Provisions which specify a later effective date shall be effective on the date specified. The Plan shall be administered on the basis of a calendar year starting each January 1 (the “Plan Year”).
 
This Plan is intended to be unfunded for tax and ERISA Title I purposes and to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the "Code"), and the Treasury regulations and other authoritative guidance issued thereunder ("Section 409A"). This Plan and each of the transactions authorized or permitted under the terms of this Plan have been approved by the Board of Directors of the Company.
 
2.
Types of Deferrals
(a) Participant Deferrals. Participants may elect, on a voluntary basis, to defer the following compensation:
 
(1) For plan years prior to 2007, base salary;
 
(2) Payments under the Annual Incentive Compensation Program ("AICP") or, for plan years prior to 2007, payments made under a Sales Incentive Program ("SIP");
 
(3) Cash payments made under the Long-Term Performance Unit Plan; and
 
(4) To the extent permitted by Sections 401(k) and 409A of the Code, an elected percentage of base salary that shall commence after such percentage election under the 401(k) Account Plan results in a cessation of contributions to the 401(k) Account Plan due to the application of the Code's limitations on compensation and contributions. A participant who elects to make this deferral must elect to contribute the same percentage of compensation to this Plan as he/she elects to contribute to the 401(k) Account Plan for the Plan Year, and the deferral rules that apply to this Plan shall apply to his/her deferral election under the 401(k) Account Plan (e.g., once made the election is irrevocable for the Plan Year, and, with certain exceptions, the election must be made before the last day of the Plan Year preceding the Plan Year in which the services giving rise to the compensation relates are to be performed, etc.).
 
(b) Company Deferrals. The Company shall contribute the following amounts on behalf of participants:
 
(1) If a participant has contributed to the 401(k) Account Plan for the Plan Year the maximum amounts permitted by the Code, the Company shall make a matching contribution to this Plan on the excess base salary contributions the participant makes to this Plan under subsection (a)(4) in the same amount it would have contributed on behalf of the participant if his or her excess contribution had been made to the 401(k) Account Plan (ignoring Code limits). Effective for Plan Years beginning on or after January 1, 2008, the Company shall make a matching contribution to this Plan on those AICP contributions that the participant elects to defer into this Plan in the same amount the Company would have contributed on behalf of the participant if such contribution had been made to the 401(k) Account Plan (as if the Code limits did not apply). For the 2006 and 2007 Plan Years, the Company's matching contribution to this Plan shall be calculated as if the participant had contributed 5% of this AICP to this Plan even if such amount was not deferred into this Plan.
 
(2) Whether or not a participant actually contributes to the 401(k) Account Plan, if he or she is eligible to receive a base contribution and/or transition credit under the 401(k) Account Plan and has compensation for the Plan Year in excess of the compensation limit under Code Section 401(a)(17), the Company shall contribute to this Plan the amount of the base contribution and transition credit it would otherwise have made to the 401(k) Account Plan for the Plan Year on the participant's compensation in excess of the compensation limit as if the Code limits did not apply. Effective for Plan Years beginning 2008 and thereafter, for purposes of this subsection, compensation shall include AICP payments that were paid in such Plan Years but were deferred into this Plan.
 
(3) If for a Plan Year the participant is entitled to receive a Company contribution to the 401(k) Account Plan based on transition credits, as soon as administratively practicable following discrimination testing for the 401(k) Account Plan, the Company shall make a contribution to this Plan that is equal to the transition credit (plus interest) that the Company was not able to make to the 401(k) Account Plan because of the Code Section 401(a)(4) nondiscrimination rules that apply to the 401(k) Account Plan.
 
3.
Eligible Employees
Commencing on the Effective Date, all U.S. employees who have the title of Senior Executive/Vice President, General Manager, Executive/Director, Country Manager or officer of the Company are eligible to make participant deferrals and to receive Company deferrals as described in Sections 2(a) and (b) above. In addition, certain designated U.S. executives not otherwise eligible to make participant deferrals shall be eligible to receive Company deferrals as described in Section 2(b)(2) and (3).
 
4.
Participant Deferrals
(a) An eligible employee who chooses to defer all or part of the compensation referred to in Section 2 shall become a participant in the Plan.
 
(b) For deferrals of compensation otherwise payable as base salary, a minimum amount as determined from time to time by the Plan Administrator (as defined in Section 10 hereof) must be deferred. A deferral period must be for a minimum 12 months or any other minimum period established by the Plan Administrator. For deferrals of salary to the Plan in excess of the 401(k) Account Plan limit, there is no minimum amount of deferral. For deferrals of compensation otherwise payable under the Long-Term Performance Unit Plan, 100% of the amount payable must be deferred. Prior to the crediting of deferrals under this Plan, all applicable FICA and Medicare taxes will be withheld.
 
(c) Except as provided below, a participant's election to defer compensation must be made by written notice to the Plan Administrator before the last day of the Plan Year preceding the Plan Year in which the services giving rise to the compensation relates are to be performed.
 
(1) Effective January 1, 2007, notwithstanding the preceding, if and to the extent permitted under Section 409A and by the Plan Administrator, an employee who first attains a position that permits him/her to become eligible in the Plan (or any similar deferred compensation plan) in the first six months of a Plan Year may become eligible to participate in the Plan on the following July 1 and may make an election no later than thirty (30) days after the date he or she becomes eligible to become a Plan participant to defer compensation earned for services to be performed after the election. Prior to January 1, 2007, notwithstanding the preceding, if and to the extent permitted under Section 409A and by the Plan Administrator, a newly hired employee who is in the class of employees eligible to participate in the Plan may make an election no later than thirty (30) days after the date he or she is hired to defer compensation earned for services to be performed after the election.
 
(2) Also notwithstanding the preceding, if and to the extent permitted by Section 409A and by the Plan Administrator, a participant may make an election to defer that portion (if any) of his or her compensation which qualifies as Performance-Based Compensation no later than six (6) months prior to the last day of the period over which the services giving rise to the Performance-Based Compensation are performed. For purposes of the Plan, the term "Performance-Based Compensation" shall mean that portion of a participant's compensation which is based on the performance by the participant of services for the Company over a period of at least twelve (12) months and which qualifies as "performance-based compensation" under Section 409A.
 
(3) Also notwithstanding the preceding, to the extent permitted under Section 409A and by the Plan Administrator, a participant may make an election to defer compensation for services performed on or before December 31, 2005 (including, but not limited to, AICP payments earned in 2004 which are payable in 2005 and AICP payments earned in 2005 which are payable in 2006) no later than the earlier of (i) March 15, 2005, or (ii) the date such compensation is otherwise payable to the participant.
 
(4) Finally, notwithstanding the preceding, deferrals of sales commissions for the 2006 Plan Year consist of four quarterly payments beginning with the May payment and ending with the fourth payment in the first quarter of 2007. As of January 1, 2007, the Plan Administrator has the discretion to change the deferral cycle or take other action to correct for the one quarter lag attributable to there being no deferral for the first payment made in 2006.
 
(d) Unless renewed, a deferral election will expire on December 31 of the year after it is executed.
 
(e) A participant may not elect to change his or her deferral election that is in effect for a Plan Year, except if and to the extent permitted by the Plan Administrator and made in accordance with the provisions of Section 409A specifically relating to the change and/or revocation of deferral elections.
 
(f) A participant's deferrals and the earnings thereon shall be fully and immediately vested at all times.
 
5.
Participants' Deferral Elections
(a) To defer compensation under the Plan, a participant must give written notice to the Plan Administrator on such forms or in such manner designated by the Plan Administrator. This notice must include (1) the amount of percentage of compensation to be deferred; (2) the selection of an investment account(s) (as described in Section 7 hereof); (3) the payment commencement date (i.e., retirement or a date certain); (4) the method of payment desired (i.e., annual installments or lump sum) and, if annual, the number of years of substantially equal installment payments (as permitted by the Plan Administrator); and (5) the designation of payment to the participant's estate or beneficiary (which may be the participant's estate or a trust) in the event of the participant's death.
 
(b) In connection with each election to defer compensation, a participant may irrevocably elect to receive a payout at a specified future date. The date certain payout shall be a lump sum payment in an amount that is equal to the compensation deferred, plus, if any, vested Company contributions described in Section 2(b), together with amounts credited or debited on both such amounts in the manner provided in Section 7(d). Each date certain payout designated by the participant must be as of January 1 of a year that is at least two years after the Plan Year from which the amount is actually deferred, as specifically elected by the participant. The amount of the payout will be calculated based on the value of the participant's benefit as of the January 15th following the designated payout date, and the actual payment will be made within forty-five (45) days following the January 15th valuation date. By way of example, if a date certain payout is elected for base salary and/or SIP payments earned during 2005, the earliest date that the participant could elect his benefit to be paid out would be after January 1, 2008. As another example, if a participant elects to defer AICP payments earned during 2005 and normally paid in 2006 (but for the deferral election), the earliest date that the participant could elect to receive his date certain payout would be after January 1, 2009. Notwithstanding the foregoing, a participant's designated payment date is subject to the overriding requirements of Section 8 of the Plan and Code Section 409A.
 
A participant who is an active employee may, with respect to each date certain payout, on a form determined by the Plan Administrator, make one or more additional deferral elections (a "Subsequent Election") to defer payment of such date certain payout to a Plan Year subsequent to the Plan Year originally (or subsequently) elected; provided that (i) such Subsequent Election may not take effect until at least 12 months after the date on which the Subsequent Election is made, (ii) the payment with respect to which such Subsequent Election is made must be deferred for a period of not less than 5 years from the date such payment would otherwise have been made; and (iii) the Subsequent Election must be made at least 12 months prior to the date of the first scheduled payment. By way of example, a participant who previously elected to have a date certain payout beginning on January 1, 2008 in respect of his or her base salary and/or SIP payments earned and deferred during 2005 may elect no later than January 1, 2007 to defer payment of such amounts to a new date certain payout beginning January 1, 2013.
 
(c) For deferral amounts where the participant has selected retirement as the payment commencement date, the participant's lump sum payment shall be paid, or in the case of a participant who elects installment payments, shall commence after the end of the Plan Year when the participant retires; provided that the participant retires in the first six months of a Plan Year. The amount of the payout will be calculated based on the value of the participant's vested benefit as of the January 15 following the year of retirement, and the actual payment will be made within forty-five (45) days following the January 15 valuation date. If such a participant retires in the last 6 months of a Plan Year, the participant's lump sum payment shall be paid, or in the case of a participant who elects installment payments, shall commence after the July 1 following the end of the Plan Year when the participant retires. The amount of the payout will be calculated based on the value of the participant's vested benefit as of the July 15 following the year of retirement and the actual payment will be made within forty-five (45) days following the July 15 valuation date. For example, if a participant elected to receive his/her benefit as lump sum with retirement as the payment commencement date and the participant retires on March 15, 2007, the participant's benefit would be paid within the first 60 days of 2008. If such a participant retired on September 15, 2007, the participant's benefit would be paid within the 60 day period following July 1, 2008. The above rules apply to retirement payout dates commencing on or after January 1, 2007. Prior to January 1, 2007, retirement payouts shall commence within 60 days after the end of the Plan Year when the participant retired, provided that payments to "specified employees" (within the meaning of Section 409A) are delayed until 6 months after termination of employment.
 
A participant who is an active employee and who has selected retirement as the payment commencement date may, on a form determined by the Plan Administrator, make one or more additional deferral elections (a "Subsequent Election") to defer payment and/or change the form of payment to a Plan Year subsequent to the Plan Year following his Retirement; provided that (i) such Subsequent Election may not take effect until at least 12 months after the date on which the Subsequent Election is made, and (ii) the payment with respect to which such Subsequent Election is made must be deferred for a period of not less than 5 years from the date such payment would otherwise have been made.
 
(d) If a participant elects to receive his or her deferred compensation in installments, the installment payments will be calculated in the following manner: the participant's vested account balance as of the January 15 following the payment date will be multiplied by a fraction, the numerator of which is 1, and the denominator of which is the number of remaining installment periods. The payment date shall be the January 1 when payments commence (and each anniversary thereof), and the actual payment shall be made within 60 days of such date. For payouts commencing prior to January 1, 2007, the payment date is such date in January that is designated for purposes of calculating installment payouts.
 
(e) Retirement, for purposes of the Plan shall mean the date on which the participant has incurred a separation of service with the Company (within the meaning of Section 409A) after first attaining age 55.
 
(f) If a participant names someone other than his or her spouse as a beneficiary in the event of participant's death, a spousal consent form must be signed by that participant's spouse and returned to the Company.
 
6.
Company Deferrals
(a) Company contributions under Section 2(b) shall be made or credited to an eligible participant's account at such times determined by the Plan Administrator, but in no event later than a reasonable period of time after the end of the Plan Year to which the contribution relates. A participant is not required to make any election to defer Company contributions; such contributions shall be made automatically on behalf of all eligible participants. If the participant has provided a written notice with respect to participant deferrals under Section 5 for the Plan Year, the terms set forth in that notice (except for the amount of the contribution) shall apply equally to all Company contributions made with respect to the same Plan Year. If the participant has not provided a notice for participant deferrals for the Plan Year, benefits attributable to the Company contributions (if vested) will be paid in accordance with Section 8(e) (assuming for this purpose that “Termination of Employment” includes Retirement).
 
(b) For participants first hired by the Company prior to January 1, 2005, Company contributions and the earnings thereon shall be fully and immediately vested at all times. For participants first hired by the Company or after January 1, 2005, Company contributions and the earnings thereon shall be vested in accordance with the vesting provisions of the Company’s 401(k) Account Plan as from time to time in effect. Amounts that are unvested at the time of payout shall be forfeited.
 
7.
Investment Accounts
(a) Monies deferred under the Plan will be transferred to a trusted subject to a “Rabbi” Trust Agreement between the Company and a trustee designated by the Plan Administrator (the “Trust”); provided that no such transfer shall be made if such transfer would result in adverse tax consequences under Section 409A.
 
(b) The rate of return on deferred compensation is determined by the performance of one or more deferred compensation investment accounts selected by the participant pursuant to the Plan. Deferred compensation investment accounts available under the Plan are selected by the Company’s Investment Committee (“Investment Account(s)”). Information on each Investment Account currently available under the Plan may be obtained from the Plan Administrator. The Investment Committee may, from time to time, in its discretion, deem it necessary or advisable to add or delete Investment Accounts or substitute new Investment Accounts for existing Investment Accounts. In such an event, the Plan Administrator will provide participants with reasonable notice of the effective date of the change to permit participants to change their future investment elections.
 
(c) All investments in Investment Accounts under the Plan are hypothetical. At the time of each deferral of compensation into the Plan, a participant will be credited with an imputed number of shares for the Investment Account(s) selected by the participant. Thereafter, the value of a participant’s Investment Accounts will fluctuate in accordance with the actual performance of the Investment Accounts. Dividends and interest on the imputed shares also will be credited to the participant’s Investment Account.
 
(d) Earnings/losses on Investment Accounts hypothetically invested in mutual funds or other assets for which daily pricing is available (“Daily-Priced Investments”) shall be valued daily in accordance with the relevant terms and conditions of the Daily-Priced Investments. Earnings/losses on Investment Accounts hypothetically invested in investments other than Daily-Priced Investments shall be credited effective on the last business day of each month. All such earnings are net of expenses.
 
(e) The deferral of compensation on a current basis will be allocated into Investment Account(s) pursuant to the deferral election determined by the participant. The allocation must be in whole percentages (e.g., 100% into one Investment Account, a 60-20-20 split among three Investment Accounts, etc.).
 
(f) A participant may elect to reallocate amounts already in his/her Investment Accounts among the various Investment Accounts at such times and in accordance with such procedures as the Plan Administrator may, in its sole discretion, prescribe; except that a reallocation into or out of the Bausch & Lomb Common Stock Investment Account by officers of the Company subject to Section 16 of the Securities Exchange Act of 1934 (i.e., Section 16(b) regulations) may not be made more than once in any six (6) month period. Company contributions shall initially be credited to the Bausch & Lomb Common Stock Investment Account. Prior to August 1, 2005, Company contributions must remain in Company common stock equivalents. On and after August 1, 2005, a participant may reallocate Company contributions that have been made to his or her account in the form of Company common stock equivalents.
 
8.
Payment of Deferred Compensation
(a) A participant’s right to payment of deferred compensation under the Plan is a contractual obligation of the Company to the participant, and his or her right to such monies shall be an unsecured claim against the general assets of the Company. However, the Company has established the Trust as an irrevocable rabbi trust for participants for the purpose of holding assets used to pay deferred compensation required by this Plan. The Company shall make periodic contributions to the Trust as may be required to fund amounts payable under the Plan; provided that no contributions shall be made if such contributions would result in adverse tax consequences under Section 409A. The Trust is intended to provide a participant with assurance that deferred monies will be paid to the participant in accordance with the Plan, except in the event of the Company’s bankruptcy or insolvency. Notwithstanding the establishment of the Trust, the Company remains ultimately responsible to pay deferred compensation to each participant. This obligation shall be met from the general assets of the Company if the Trust has insufficient funds to pay benefits.
 
(b) If, in the discretion of the Plan Administrator, a participant has a need for funds due to an Unforeseeable Financial Emergency, a payment may be made to the participant from the vested funds in his or her account at a date earlier than the payment commencement date chosen by the participant at the time of deferral. A distribution based upon Unforeseeable Financial Emergency shall not exceed the lesser of the participant’s vested account balance, or the amount reasonably needed to satisfy the Unforeseeable Financial Emergency plus amounts necessary to pay taxes reasonably anticipated as a result of the payouts, after taking into account the extent to which the Unforeseeable Financial Emergency is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the participant’s assets (to the extent the liquidation of assets would not itself cause severe financial hardship). A distribution based upon Unforeseeable Financial Emergency shall be permitted solely to the extent permitted under Section 409A.
 
For purposes of the Plan, the term “Unforeseeable Financial Emergency” shall mean an unanticipated emergency that is caused by an event beyond the control of the participant that would result in severe financial hardship to the participant resulting from(i) an illness or accident of the participant, the participant’s spouse or a dependent of the participant, (ii) a loss of the participant’s property due to casualty, or (iii) such other extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the participant, all as determined in the sole discretion of the Plan Administrator.
 
A participant requesting a distribution on account of an Unforeseeable Financial Emergency must supply the Plan Administrator with a statement indicating the nature of the need creating the Unforeseeable Financial Emergency, the fact that all other available resources are insufficient to meet the need, and any other information that the Plan Administrator deems necessary to evaluate whether an Unforeseeable Financial Emergency exists.
 
(c) In the event of a participant’s death before he or she has received all of the vested deferred compensation payments to which he or she is entitled, payments will be made to the participant’s estate or beneficiary (as elected by the participant or, in the absence of an election, to the participant’s estate) in a single lump sum payment. The amount of the payout will be calculated based on the value of the participant’s vested benefit as of the January 15th following the year of the participant’s death, and the actual payment will be made within forty-five (45) days following the January 15th valuation date.
 
(d) All payments made to participants under the Plan shall be subject to all taxes required to be withheld under applicable laws and regulations of any governmental authorities.
 
(e) Notwithstanding any payout election a participant may have made under Section 5, if a participant experiences a Termination of Employment with the Company within the first six months of the Plan Year, the participant’s vested account balance shall be paid in a lump sum after the end of a Plan Year of the participant’s Termination of Employment. The amount of the payout will be calculated based on the value of the participant’s vested benefit as of the January 15th following the year of such termination, and the actual payment will be made within forty-five (45) days following the January 15th valuation date. Notwithstanding any payout election a participant may have made under Section 5, if a participant experiences a Termination of Employment with the Company within the last six months of a Plan Year, the participant’s vested account balance shall be paid in a lump sum after the July 1 following the Plan Year of the participant’s Termination of Employment. The amount of the payout will be calculated based on the value of the participant’s vested benefit as of the July 15th following the year of such termination, and the actual payment will be made within forty-five (45) days following the July 15th valuation date. The above rules apply to Termination of Employment payout dates commencing on or after January 1, 2007. Prior to that time, Termination of Employment payouts commenced within 60 days after the end of the Plan Year when the participant terminated employment, provided that payments to “specified employees” (within the meaning of Section 409A) were delayed until 6 months after Termination of Employment.
 
“Termination of Employment” shall mean the separation from service with the Company within the meaning of Section 409A, voluntarily or involuntarily, for any reason other than Retirement or death. No deferrals shall be permitted from severance benefits that are paid in lieu of base compensation. For individuals who separate from service with the Company due to a Retirement (i.e., after first attaining age 55), refer to Section 5(c) for the distribution rules that apply to participants who elect retirement as the payment commencement date and Section 5(b) for the rules that apply to participants who elect a date certain payout.
 
(f) Subject to Section 409A, upon a Change in Control, notwithstanding a participant’s payment commencement date with respect to any compensation deferred hereunder or method of payout with respect to any compensation deferred hereunder, all amounts in a participant’s deferred compensation account (including earnings credited thereto) shall be due and payable to the participant in a cash lump sum within 15 days following the Change in Control.
 
For purposes of this Plan, a “Change in Control” shall mean any of the following events:
 
(1) Any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act (a "Person") acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such Person) beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of either (A) the then-outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (B) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that, for purposes of this Section 8(f), the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the Company, (B) any acquisition by the Company, (C) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any of its Affiliates or Subsidiaries or (D) any acquisition pursuant to a transaction that complies with Sections 8(f)(3)(A), 8(f)(3)(B) and 8(f)(3)(C);
 
(2) Any time at which, during the preceding 12-month period, individuals who, as of the beginning of such 12-month period, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director during such 12-month period whose election, or nomination for election by the Company's stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board;
 
(3) Consummation of a reorganization, merger, statutory share exchange or consolidation or similar transaction involving the Company or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its Subsidiaries (each, a "Business Combination"), in each case unless, following such Business Combination, (A) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Stock and the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company Common Stock and the Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding any corporation resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 35% or more of, respectively, the then-outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such corporation, except to the extent that such ownership existed prior to the Business Combination, and (C) individuals who were members of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination constitute at least a majority of the members of the board of directors (or, for a non-corporate entity, equivalent governing body) of the entity resulting from such Business Combination; or
 
(4) Approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.
 
9.
Fail-Safe Provision
(a) This Section shall have become operative upon the enactment of any change in applicable statutory law or the promulgation by the Internal Revenue Service of a final regulation or other pronouncement having the force of law, which statutory law, as changed, or final regulation or pronouncement, as promulgated, would cause any participant to include in his or her federal gross income amounts accrued by the participant under the Plan on a date (an "Early Taxation Event") prior to the date on which such amounts are made available to him or her hereunder; provided, however, that no portion of this Section shall become operative to the extent that portion would result in a violation of Section 409A.
 
(b) Notwithstanding any other Section of this Plan to the contrary, as of an Early Taxation Event, the feature or features of this Plan that would cause the Early Taxation Event shall be null and void, to the extent, and only to the extent, required to prevent the participant from being required to include in his or her federal gross income amounts accrued by the participant under the Plan prior to the date on which such amounts are made available to him or her hereunder. By way of example, but not by way of limiting the generality of the foregoing, if a statue is enacted that would require a participant to include in his or her federal gross income amounts accrued by the participant under the Plan prior to the date on which such amounts are made available to him or her because of the participant's right to receive a distribution of a portion of his or her account under Section 8(b) (a withdrawal for an Unforeseeable Financial Emergency), the right of all participants to receive distributions under Section 8(b) shall be null and void as of the effective date of that statute. If only a portion of a participant's account is impacted by the change in the law, then only such portion shall be subject to this Section, with the remainder of the account not so affected being subject to such rights and features as if the law were not changed. If the law only impacts participants who have a certain status with respect to the Company, then only such participants shall be subject to this Section.
 
10.
Administration
The Plan Administrator shall be the Executive Benefits Committee which shall be comprised of such individuals designated by the Compensation Committee of the Board of Directors. The Plan Administrator and has the authority to control and manage the operation and administration of the Plan. The Plan Administrator has full and sole discretionary authority to interpret the Plan, to establish rules and forms for the Plan and to determine all questions arising in connection with the Plan. The Investment Committee responsible for investments under the Plan shall be the Investment Committee of Bausch & Lomb Incorporated.
 
11.
Assignability
No right to receive payments under the Plan is transferable or assignable by a participant except by will or by the laws of descent and distribution.
 
12.
Business Days
In the event any date specified falls on a Saturday, Sunday, or holiday, such date will be deemed to refer to the next business day thereafter.
 
13.
Amendment
The Plan may at any time or from time to time be amended or modified by the Board of Directors or the Compensation Committee. No such amendment or modification will, without the consent of the participant, adversely affect the participant's accruals in his or her deferred compensation account.
 
14.
Termination
Although the Company anticipates that it will continue the Plan for an indefinite period of time, there is no guarantee that the Company will continue the Plan or will not terminate the Plan at any time in the future. Accordingly, the Company (through its Board of Directors or the Compensation Committee) reserves the right to terminate the Plan at any time under such circumstances as may be permitted from time to time under Section 409A. Upon a complete or partial termination of the Plan, the deferral elections of the affected participants shall terminate and their Plan account balances, determined as if they had experienced a Termination of Employment on the date of Plan termination, shall, subject to Section 15, be immediately paid to the participants; provided however, if immediate distribution of a Participant's account balance on termination is not permitted by Section 409A, the payment of the account balance shall be made only after Plan benefits otherwise become due hereunder.
 
15.
Prohibited Acceleration/Distribution Timing
This Section shall take precedence over any other provision of the Plan to the contrary. No provision of this Plan shall be followed if following the provision would result in the acceleration of the time or schedule of any payment from the Plan as would require immediate income tax to participants based on the law in effect at the time the distribution is to be made, including Section 409A.
 
16.
Claims Procedures
(a) Claim Denials. The Plan Administrator shall maintain procedures with respect to the filing of claims for benefits under the Plan. Pursuant to such procedures, any Participant or beneficiary (hereinafter called "claimant") whose claim for benefits under the Plan is denied shall receive written notice of such denial. The notice shall set forth: (i) the specific reasons for the denial of the claim; (ii) a reference to the specific provisions of the Plan on which the denial is based; (iii) any additional material or information necessary to perfect the claim and an explanation why such material or information is necessary; and (iv) a description of the procedures for review of the denial of the claim and the time limits applicable to such procedures, including a statement of the claimant's right to bring a civil action under ERISA following a denial on review.
 
Such notice shall be furnished to the claimant within a reasonable period of time, but no later than 90 days after receipt of the claim by the Plan, unless the Plan Administrator determines that special circumstances require an extension of time for processing the claim. In no event shall such an extension exceed a period of 90 days from the end of the initial 90-day period. If such an extension is required, written notice thereof shall be furnished to the claimant before the end of the initial 90-day period, which shall indicate the special circumstances requiring an extension of time and the date by which the Plan Administrator expects to render a decision.
 
(b) Right to a Review of the Denial. Every claimant whose claim for benefits under the Plan is denied in whole or in part by the Plan Administrator shall have the right to request a review of the denial. Review shall be granted if it is requested in writing by the claimant no later than 60 days after the claimant receives written notice of the denial. The review shall be conducted by the Plan Administrator.
 
(c) Decision of the Plan Administrator on Appeal. The claimant may submit written comments, documents, records and other information relating to the claim, and may review documents, records and other information relevant to the claim under the applicable standards under ERISA. The Plan Administrator's decision shall be rendered within 60 days following receipt of the request for review. If additional processing time is required, the Plan Administrator shall provide the claimant with written notice thereof, which shall indicate the special circumstances requiring the additional time and the date by which the Plan Administrator expects to render a decision. If the Plan Administrator denies the claim on review, it shall provide the claimant with written notice of its decision, which shall set forth (i) the specific reasons for the decision, (ii) reference to the specific provisions of the Plan on which the decision is based, (iii) a statement of the claimant's right to reasonable access to, and copies of, all documents, records and other information relevant to the claim under the applicable standards under ERISA, and (iv) and a statement of the claimant's right to bring a civil action under ERISA. The Plan Administrator's decision shall be final and binding on the claimant, and the claimant's heirs, assigns, administrator, executor, and any other person claiming through the claimant.
 
 
BAUSCH & LOMB INCORPORATED
 
 
By:          /s/ David R. Nachbar  
Corporate Senior Vice President
Human Resources
 
Dated: November 7, 2006

EX-10.KK 20 form10k2005e10kk.htm EXHIBIT (10)-KK Exhibit (10)-kk


Exhibit (10)-kk

BAUSCH & LOMB INCORPORATED
EXECUTIVE DEFERRED COMPENSATION PLAN
 
Amendment
 
Pursuant to Section 13 of the Executive Deferred Compensation Plan (the “Plan”), the Plan is amended as of the date set forth below, as follows:
1.    Section 7(f) is amended by adding the following sentence to the end of such section:
 
In addition, for company-matching amounts contributed on behalf of a participant who is subject to Section 16 of the Securities Exchange Act of 1934 as of August 1, 2005, such amounts (including earnings credited on those amounts) must remain in Company common stock equivalents.
 
2.    Section 10 is amended by deleting such Section and substituting in its place the following:
 
10. Administration

The Plan Administrator shall be the Executive Benefits Committee which shall be comprised of such individuals designated by the Compensation Committee of the Board of Directors. The Plan Administrator and has the authority to control and manage the operation and administration of the Plan. The Plan Administrator has full and sole discretionary authority to interpret the Plan, to establish rules and forms for the Plan and to determine all questions arising in connection with the Plan. The Investment Committee responsible for investments under the Plan shall be the Investment Committee of Bausch & Lomb Incorporated.
 
3.    The Plan is amended by adding the following new Section 14:
 
14. Claims Procedures

(a) Claim Denials. The Plan Administrator shall maintain procedures with respect to the filing of claims for benefits under the Plan. Pursuant to such procedures, any Participant or beneficiary (hereinafter called “claimant”) whose claim for benefits under the Plan is denied shall receive written notice of such denial. The notice shall set forth: (i) the specific reasons for the denial of the claim; (ii) a reference to the specific provisions of the Plan on which the denial is based; (iii) any additional material or information necessary to perfect the claim and an explanation why such material or information is necessary; and (iv) a description of the procedures for review of the denial of the claim and the time limits applicable to such procedures, including a statement of the claimant’s right to bring a civil action under ERISA following a denial on review.
 
Such notice shall be furnished to the claimant within a reasonable period of time, but no later than 90 days after receipt of the claim by the Plan, unless the Plan Administrator determines that special circumstances require an extension of time for processing the claim. In no event shall such an extension exceed a period of 90 days from the end of the initial 90-day period. If such an extension is required, written notice thereof shall be furnished to the claimant before the end of the initial 90-day period, which shall indicate the special circumstances requiring an extension of time and the date by which the Plan Administrator expects to render a decision.
 
(b) Right to a Review of the Denial. Every claimant whose claim for benefits under the Plan is denied in whole or in part by the Plan Administrator shall have the right to request a review of the denial. Review shall be granted if it is requested in writing by the claimant no later than 60 days after the claimant receives written notice of the denial. The review shall be conducted by the Plan Administrator.
 
(c) Decision of the Plan Administrator on Appeal. The claimant may submit written comments, documents, records and other information relating to the claim, and may review documents, records and other information relevant to the claim under the applicable standards under ERISA. The Plan Administrator’s decision shall be rendered within 60 days following receipt of the request for review. If additional processing time is required, the Plan Administrator shall provide the claimant with written notice thereof, which shall indicate the special circumstances requiring the additional time and the date by which the Plan Administrator expects to render a decision. If the Plan Administrator denies the claim on review, it shall provide the claimant with written notice of its decision, which shall set forth (i) the specific reasons for the decision, (ii) reference to the specific provisions of the Plan on which the decision is based, (iii) a statement of the claimant’s right to reasonable access to, and copies of, all documents, records and other information relevant to the claim under the applicable standards under ERISA, and (iv) and a statement of the claimant’s right to bring a civil action under ERISA. The Plan Administrator’s decision shall be final and binding on the claimant, and the claimant’s heirs, assigns, administrator, executor, and any other person claiming through the claimant.
 
.


Dated:                    November 7, 2006                BAUSCH & LOMB INCORPORATED

By: /s/ David R. Nachbar  

Title: Corporate Senior Vice President
  Human Resources

EX-10.LL 21 form10k2005e10ll.htm EXHIBIT (10)-LL Exhibit (10)-ll


Exhibit (10)-ll

LETTER WAIVER


Dated as of December 8, 2006
To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Citibank, N.A.,
as agent (the "Agent") for the Lenders

Ladies and Gentlemen:

We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you, and the letter waivers thereunder dated November 23, 2005 (referred to herein as the “First Letter Waiver”), February 17, 2006 (effective February 24, 2006 and referred to herein as the “Second Letter Waiver”), May 15, 2006 (the “Third Letter Waiver”) and August 23, 2006 (the “Fourth Letter Waiver” and collectively, with the First Letter Waiver, the Second Letter Waiver, the Third Letter Waiver and the Forth Letter Waiver, the “Waivers”). Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement and the Waivers.
 
Reference is made to each of Borrower’s Announcements and the events described under the prior Waivers, and the prior definitions of Announcements are amended hereby to include Borrower’s: (i) press releases, dated September 29, 2006 and November 9, 2006, (ii) Borrower’s filings with the U.S. Securities and Exchange Commission (the “SEC”) on Forms 8-K, filed September 20, 2006 (request to New York Stock Exchange for additional trading period and commencement of second consent solicitation on public debt) , September 28, 2008 (relating to public debt consent solicitation), September 29, 2006 (completion of consent solicitation), September 29, 2006 (grant of additional trading period from New York Stock Exchange) and November 9, 2006 (execution of Supplemental Indenture No. 8 extending waivers on the Borrower’s public debt, release of expected financial results for the third quarter of 2006 and certain director and officer compensation matters) and (iii) Borrower’s filing on Form 12b-25, filed with the SEC on November 9, 2006.

In light of these events described in the Announcements, and other confidential information which Borrower has disclosed to Agent and Lenders orally and in writing prior to the date hereof under the terms of confidentiality agreements executed with each Lender (the “Confidential Disclosures”), Borrower has requested, and the Required Lenders hereby agree that the term “Waiver Termination Date” as defined in the Waivers is superseded and is hereby defined for all purposes as January 31, 2007. The terms of the Third Letter Waiver and the Fourth Letter Waiver shall remain in full force and effect, as modified by this Letter Waiver,

 
 

 

including, without limitation, paragraphs (and any subparagraphs) three, five and six of the Third Letter Waiver.

The amount of the Monthly Fee, as defined in paragraph seven of the Third Letter Waiver, shall remain as set forth therein. However, payment of the Monthly Fee will be made on December 1, 2006 and on January 2, 2007.

This Letter Waiver shall become effective as of December 15, 2006 if, as of that date, the Agent has received counterparts of this Letter Waiver executed on behalf of Borrower and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver.

If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.

With respect to the matters waived hereunder, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to such matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred, or (3) that any Default or Event of Default has occurred under the Credit Agreement.

The Waivers, as modified by each other and this Letter Waiver, shall represent the entire agreement with respect to the matters contained herein and, except where otherwise noted herein or therein, shall supersede any prior agreements whether written or oral. This Letter Waiver may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier or other electronic means shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 
This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.

Very truly yours,

BAUSCH & LOMB INCORPORATED

By  /s/ Efrain Rivera  
Title: Vice President and Treasurer

Agreed as of the date first above written:
CITIBANK, NA.,
as Agent and as Lender

By /s/ Robert J. Kane
Title: Managing Director
KEYBANK NATIONAL ASSOCIATION

By /s/ Marianne Meil
Title: Senior Vice President

BARCLAYS BANK PLC

By /s/ Nicholas Bell
Title: Director

BANK OF TOKYO-MITSUBISHI UFJ TRUST
COMPANY (f/k/a Bank of Tokyo-Mitsubishi Trust
Company)

By /s/ Harumi Kambara
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By /s/ Bruce Yoder
Title: Vice President

MIZUHO CORPORATE BANK, LTD.

By /s/ Raymond Ventura
Title: Deputy General Manager
 
U.S. BANK NATIONAL ASSOCIATION

By /s/ Eric Cosgrove
Title: Assistant Vice President

ALLIED IRISH BANKS, P.L.C.

By /s/ Anthony O’Reilly
Title: Senior Vice President

By /s/ Denise Magyer
Title: Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By /s/ John M. Carroll
Title: First Vice President

 
 

 



THE NORTHERN TRUST COMPANY

By /s/ Alex Nikolov
Title: Second Vice President
EX-10.MM 22 form10k2005e10mm.htm EXHIBIT (10)-MM Exhibit (10)-mm


 
  Exhibit (10)-mm
 
LETTER WAIVER
 
  
To:   Bausch & Lomb B.V. (the Company)
      Koolhovenlaan 110
      1119 NH Schiphol-Rijk
      The Netherlands

Fax:       +31 20 6554 651
Attn:     Financial Controller


and:      Bausch & Lomb Incorporated (the Guarantor)
      One Bausch & Lomb Place
      Rochester
      New York 14604
      United States of America

Fax:       +1 585 338 8188
Attn:     Corporate Treasury Operations
 
  6 December, 2006
 
  Dear Sirs,
 
  US$375,000,000 credit agreement dated 29 November 2005 (as amended) between (among others) the Company, the Guarantor and Citibank International plc as facility agent (the Agreement)
 
1.  
Background
 
(a)  
This letter is supplemental to and amends the Agreement.
 
(b)  
Pursuant to Clause 25 (Amendments and Waivers) of the Agreement, the Majority Lenders have consented to the amendments to the Agreement contemplated by this letter. Accordingly, we are authorised to execute this letter on behalf of the Finance Parties.
 
2.  
Interpretation
 
(a)  
Capitalised terms defined in the Agreement have the same meaning when used in this letter unless expressly defined in this letter.
 
(b)  
The provisions of Clause 1.2 (Construction) of the Agreement apply to this letter as though they were set out in full in this letter except that references to the Agreement are to be construed as references to this letter.
 
(c)  
Effective Date means 15 December, 2006, provided that the Facility Agent shall have given notification to the Obligors that it has received a copy of this letter countersigned by the Company and the Guarantor.
 
3.  
Amendments
 
(a)  
Subject to subparagraph (b) below, the Agreement will be amended from the Effective Date in accordance with subparagraph (c) below.
 
(b)  
The Agreement will not be amended by this letter unless the Facility Agent has received a copy of this letter countersigned by the Company and the Guarantor on or before the Effective Date.
 
(c)  
The Agreement will be amended as follows:
 
(i)  
Clause 19.11(a)(ii) (BLIO Matters) of the Agreement shall be amended by deleting the reference to “15 December 2006” in the last line thereof and replacing it with “31 January 2007”;
 
(ii)  
the definition of Other Announcements shall be amended as follows:
 
 
 (i) deleting the word “and” at the end of subparagraph (xiii);
 
 
(ii) deleting the full stop after the words "8 August 2006 " at the end of subparagraph (xiv) and replacing it with a semi-colon; and
 
 
(iii) inserting new subparagraphs (xv) to (xxii), inclusive as follows:
 
 
"(xv) press release, dated 29 September 2006;
 
 
(xvi) press release dated 9 November, 2006;
 
 
(xvii) Form 8-K, filed 20 September, 2006 (Guarantor’s request to New York Stock Exchange for additional trading period and commencement of second consent solicitation on public debt);
 
 
(xviii) Form 8-K, filed 28 September, 2008 (relating to public debt consent solicitation);
 
 
(xix)Form 8-K, filed 29 September, 2006 (completion of consent solicitation);
 
 
(xx) Form 8-K, filed 29 September, 2006 (grant of additional trading period from New York Stock Exchange);
 
 
(xxi) Form 8-K, filed 9 November, 2006 (execution of Supplemental Indenture No. 8 extending waivers on Guarantor’s public debt, release of expected financial results for the third quarter of 2006 and certain director and officer compensation matters); and
 
 
(xxii) Form 12b-25, filed 9 November, 2006.”; and
 
(iii)  
the definition of Waiver Termination Date in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
 
               Waiver Termination Date means the earlier of:
 
          (i) 6:00 p.m. (Rochester, New York time) on 31 January, 2007; and
 
 
(ii) the date (if any) on which the trustee or holders of not less than 25 per cent. of the principal amount of outstanding securities under any series with an outstanding principal amount of at least US$50,000,000 under the Indenture have given to the Guarantor notice that the principal amount of such securities is due and payable immediately.".
 
4.  
Guarantee
 
       The Guarantor:
 
(a)  
agrees to the amendment of the Agreement as contemplated by this letter; and
 
(b)  
with effect from the Effective Date, confirms that the guarantee given by it under the Agreement will:
 
 
(i)  continue in full force and effect; and
 
 
(ii)  extend to the liabilities and obligations of the Company to the Finance Parties under the Finance Documents as amended by this letter.
 
5.  
Amendment fee
 
(a)  
In further consideration for the matters contemplated by this letter, the Company must pay to the Facility Agent for the account of the Lenders which consented on or before the date of this letter to the amendments to the Agreement contemplated by this letter (the Consenting Lenders) a monthly fee equal to 0.10 per cent. of the total Commitments of the Consenting Lenders. The first such monthly fee shall be payable no later than 1 December, 2006, and a subsequent monthly fee will be due on 2 January, 2007. Payments will be made to the account notified to the Company by the Facility Agent for this purpose. Any payment that would have otherwise been due and payable for December 2006 under the 30 August, 2006 amendment to this Agreement shall be covered by the above payment.
 
(b)  
All amounts payable under this letter are exclusive of any value added tax or other taxes of any nature and will not be subject to counterclaim or set-off for, or be otherwise affected by, any claim or dispute relating to any matter whatsoever and all such payments shall be made free and clear and without deduction for or on account of any present or future taxes, charges, deductions or withholdings.
 
6.  
Miscellaneous
 
(a)  
This letter is a Finance Document and a Fee Letter.
 
(b)  
From the Effective Date, the Agreement and this letter will be read and construed as one document.
 
(c)  
Except as otherwise provided in this letter, the Finance Documents remain in full force and effect.
 
(d)  
Except to the extent expressly waived in this letter, no waiver of any provision of any Finance Document is given by the terms of this letter and the Finance Parties expressly reserve all their rights and remedies in respect of any breach of, or other Default under, the Finance Documents.
 
7.  
Governing law
 
       This letter is governed by English law.
 

 
…/s/ Jane Horner ..
For
CITIBANK INTERNATIONAL PLC
as Facility Agent for and on behalf of the Finance Parties
 
Date: 13 December, 2006
 
 
We agree with the terms of this letter.
 
 
…/s/ Efrain Rivera……………………..
Efrain Rivera, Vice President & Treasurer
For
BAUSCH & LOMB B.V.
 
Date: 13 December, 2006
 

 
…/s/ Steven C. McCluski ……………...
Stephen C. McCluski
Sr. Vice President and CFO
For
BAUSCH & LOMB INCORPORATED
 
Date: 13 December, 2006


EX-10.OO 23 form10k205e10oo.htm EXHIBIT (10)-OO Exhibit (10)-oo

 
Exhibit (10)-pp
 
 
LICENSE AGREEMENT
 
BETWEEN AND AMONG
 
CIBA VISION AG,
 
AND
 
BAUSCH & LOMB INCORPORATED
 

 

 
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated with an asterisk (“*”). As part of our confidential treatment request, a complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
 

 


 
 

 


TABLE OF CONTENTS
 
 
Article I - Definitions
 
2
 
Article II - Grants Of Licenses
 
3
 
Article III - Payments
 
3
 
Article IV - Confidentiality and Publicity
 
5
 
Article V - Disclaimers
 
5
 
Article VI - Dispute Resolution
 
6
 
Article VII - Marking
 
7
 
Article VIII - Indemnity
 
7
 
Article IX - Notice
 
8
 
Article X - Assignment
 
8
 
Article XI - Most Favored Nation Terms
 
9
 
Article XII - Miscellaneous Provisions
 
10
 

 

 
 

 
 

This License Agreement, made and entered into simultaneously with the accompanying Settlement Agreement this 1st day of July 2004 (the "Effective Date"), by and among the following (hereinafter the “Parties”):
 
CIBA Vision AG, a Swiss corporation, with its principal place of business at Hardhofstrasse 15, CH-8424 Embrach, Switzerland;
 
Bausch & Lomb Incorporated, a New York corporation, with its principal place of business at 1 Bausch & Lomb Place, Rochester, New York; and
 
WITNESSETH
 
WHEREAS, the Parties are involved in various legal disputes relating to intellectual property rights and the enforcement thereof; and
 
WHEREAS, the Parties desire to resolve certain of such disputes while minimizing the burden and expense of further litigation and have entered into a Settlement Agreement executed concurrently with this License Agreement, a copy of which is attached hereto and incorporated herein by reference.
 
NOW, THEREFORE, the Parties hereby agree as follows:
 

 


 
 
 

 
 
Article I  - Definitions
 
1.01  “Affiliate” shall mean any and all persons, corporations or business entities which, directly or indirectly, are controlled by, control, or are under common control with a Party. For this purpose, the meaning of the word “control” shall mean direct or indirect ownership of at least fifty percent (50%) of the voting shares or interest of such corporation or business entity.
 
1.02  “B&L” shall mean Bausch & Lomb Incorporated, a New York corporation, with its principal place of business at 1 Bausch & Lomb Place, Rochester, New York, and its Affiliates.
 
1.03  “CIBA” shall mean CIBA Vision AG, a Swiss corporation, with its principal place of business at Hardhofstrasse 15, CH-8424 Embrach, Switzerland, and its Affiliates.
 
1.04  “Effective Date” shall mean the date first written hereinabove.
 
1.05  “CIBA Patent Rights” shall mean US Patent Nos. 5,760,100; 5,789,461; 5,849,811; 5,766,999; and 5,965,631; all other patents and patent applications in all countries of the world corresponding thereto, having priority derived therefrom; all divisional, continuation and continuation-in-part applications derived from any of the above applications or patents; all patents issuing as a result of the above patent applications; and all patents of addition, reissues, reexaminations, and extensions of any of the above patents.
 
1.06  “B&L’s Licensed Products” shall mean contact lenses, which in the absence of this license agreement would infringe at least one claim of CIBA Patent Rights; or contact lenses which are made using a process or machine covered by a claim of CIBA Patent Rights. However, B&L’s Licensed Products shall not encompass or include CIBA’s FOCUS Night & Day contact lenses or contact lenses made from the specific contact lens materials in Examples A1 - G6 of US Patent No. 5,760,100. For the purposes of determining the royalties under the Settlement, the Parties agree and stipulate that  *.
 
1.07  “B&L Patent Rights” are US Patent Nos. 6,312,706; 6,596,294; and 5,681,510; all other patents and patent applications in all countries of the world corresponding thereto, having priority derived therefrom; all divisional, continuation and continuation-in-part applications derived from any of the above applications or patents; all patents issuing as a result of the above patent applications; and all patents of addition, reissues, reexaminations, and extensions of any of the above patents.
 
1.08  “CIBA’s Licensed Products” shall mean contact lenses, which in the absence of this license agreement would infringe at least one claim of B&L Patent Rights; or contact lenses which are made using a process or machine covered by a claim of B&L Patent Rights.
 
1.09  “Net Sales” shall mean for the purposes of calculating the royalty due, in any case where a Licensed Product is sold or commercially disposed of for value by B&L or its Affiliate in an arm’s length transaction with a third party (other than an Affiliate of B&L) in any geographic location, the *.
 
 
Article II  - Grants Of Licenses
 
2.01  CIBA hereby grants to B&L a royalty bearing, irrevocable, worldwide, non-exclusive license, with no right to sublicense, under the CIBA Patent Rights to make, have made, import, use, sell, and offer to sell B&L’s Licensed Products.
 
2.02  B&L hereby grants to CIBA a royalty-free, worldwide, irrevocable, non-exclusive license, with no right to sublicense, under the B&L Patent Rights to make, have made, import, use, sell, and offer to sell CIBA’s Licensed Products.
 
 
Article III  - Payments
 
3.01  Royalties. In consideration of the settlement of litigation and rights granted herein, and in view of the accounting and other difficulties associated with B&L’s providing detailed reports for sales of B&L’s Licensed Products in individual countries on a worldwide basis, B&L shall pay CIBA Vision AG royalties during the term of this Agreement of * of the Net Sales of B&L’s Licensed Products; said royalties being understood and deemed to constitute a reasonable valuation of the license rights and other consideration granted to B&L herein. 
 
3.02  Effect of Claim Invalidity. If, in any proceeding in which the validity, infringement, or priority of invention of any claim of CIBA Patent Rights is in issue, a judgment or decree is entered which becomes not further reviewable through the exhaustion of all permissible applications for rehearing or review by a superior tribunal, or through the expiration of time permitted for such applications (hereinafter referred to as a "final judgment"), determining that all claims of the CIBA Patent Rights that cover the B&L Licensed Products are invalid, not infringed, and/or unenforceable, then, B&L shall be relieved prospectively from the date of such final judgment from paying royalties due for sales of B&L Licensed Products, which are both:
 
(a)  
manufactured in any country having no valid CIBA Patent Rights; and
 
(b)  
sold in that country or any other country having no valid CIBA Patent Rights.
 
3.03  Bundled Products. If B&L Licensed Products are sold in a single bundled sale (including a single invoice or transaction) with non-licensed products, the sales price of B&L’s Licensed Products shall, *.
 
3.04  Payment Schedule. Royalties under Section 3.01 of this Agreement shall be payable in US Dollars on a quarterly basis and shall be due within forty-five (45) days following the end of each of B&L’s fiscal quarters (the “Royalty Payment Dates”).
 
3.05  Reports. B&L shall report accrued royalties due under Section 3.04 to CIBA by submitting a written report with its payments. Each such report shall include a computation of the royalties so accrued, including the trade designation of each of B&L’s Licensed Products that has been sold; the Net Sales applicable to each such product; a computation of the total royalties for the quarter using the applicable royalty rate (including the currency exchange rates used in such calculations pursuant to Section 3.07); and any credit against royalties due B&L for returns. An authorized representative of B&L shall state that such report is computed in compliance with the contractual requirements of this Agreement. B&L shall pay to CIBA interest * per annum on all royalties not paid when due. In the event past due royalties, found by an arbitrator to be due and payable, are collected through bankruptcy or judicial proceedings by an attorney or placed in the hands of an attorney for collection, then B&L agrees to pay CIBA's reasonable attorneys' fees and other costs of collection.
 
3.06  Records and Inspection. B&L shall keep true and accurate records, files, and books of account containing all the data reasonably required for the full computation and verification of the royalties to be paid and the information to be given in accompanying reports. CIBA’s designated agent (under obligation of strict confidentiality), shall, upon written request to B&L, be entitled at CIBA's sole cost and expense to inspect pertinent books and records of B&L in Rochester, New York, once each calendar year to determine the accuracy and completeness of any report made to CIBA. In the event such examination reveals any discrepancy between the royalties actually paid by B&L during the period covered by the examination and the amount actually due under this Agreement, B&L shall pay to CIBA the amount of * in the case of an underpayment and CIBA shall reimburse B&L the amount of * in the event of an overpayment. In the event an underpayment represents ten percent (10%) or more of the amount payable for such period, B&L shall pay to CIBA the sum of * per annum. B&L agrees to retain such books, records and accounts for a period of at least three (3) years after the close of the period to which such books, records and accounts relate.
 
3.07  Currency. All royalty payments shall be made in United States Dollars. For purposes of determining the applicable royalty rate to be paid according to Section 3.01 above, the Net Sales shall be converted on a country-by-country basis each month from the currency used in each such country to United States Dollars. The relevant exchange rate shall be the rate set by B&L’s corporate finance department on a monthly basis, in accordance with its standard policies and procedures consistently applied, and consistent with the methodology applied in B&L’s consolidated audited financials.
 
 
Article IV  - Confidentiality and Publicity
 
4.01  The financial terms of this License Agreement are to be kept confidential and not disclosed to any third-party, except as required by law, court order, or the requirement of a securities exchange on which the Party's securities are traded, in each case as reasonably determined by such Party based on the opinion of its external counsel.
 
4.02   The Parties agree not to issue any press release disclosing the existence of or relating to this Agreement; except as attached at Appendix A, or upon mutual agreement, in writing, between the Parties.
 


* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.  
* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.  
 
* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.  
 

4.03  The Parties agree not to issue any press release disclosing the existence of or relating to this Agreement; except as attached at Appendix A, or upon mutual agreement, in writing, between the Parties.
 
4.04  In publicizing anything made, used, or sold under the licenses granted in this Agreement, no Party shall use the name of any other Party or otherwise refer to any Affiliate thereof, except with the written approval of the other Party.
 
 
Article V  - Disclaimers
 
5.01  Nothing in this Agreement shall be construed as:
 
(a)  
A warranty or representation by any Party as to the validity, enforceability, or scope of its own Patent Rights; or
 
(b)  
A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third persons; or
 
(c)  
A requirement that any Party shall file any patent application, secure any patent, or maintain any patent in force; or
 
(d)  
An obligation to bring or prosecute actions or suits against third parties for infringement of any patent; or
 
(e)  
An obligation to furnish any manufacturing or technical information, or any information concerning pending patent applications; or
 
(f)  
Conferring a right to use in advertising, publicity, or otherwise any trademark or tradename of any Party from which a license is received under this Agreement.
 
5.02  No non-assertion, immunity, covenant not to sue, or license is given, by implication or otherwise, with respect to any technology, patent application or patent, except as set forth in the accompanying Settlement Agreement and in Article II. Particularly, no rights are granted herein under US Patent No. 4,711,943 (the “Harvey Patent”); and B&L will remain enjoined from making, importing, using, offering for sale, or selling in the United States contact lens materials and contact lenses made from *, until after the expiration of the Harvey Patent, April 26, 2005.
 
 
Article VI  - Dispute Resolution
 
6.01  In the event of any dispute, claim, question, or disagreement arising from or relating to this agreement or the breach thereof, the parties hereto shall use their best efforts to settle the dispute, claim, question, or disagreement. To this effect, they shall consult and negotiate with each other in good faith and, recognizing their mutual interests, attempt to reach a just and equitable solution satisfactory to both parties. If they do not reach such solution within a period of 60 days, then, upon notice by either party to the other, all disputes, claims, questions, or differences shall be finally settled by arbitration administered by the American Arbitration Association (“AAA”) in accordance with the provisions of its Patent Arbitration Rules, and judgment may be entered by a court having jurisdiction thereof.
 
6.02  The arbitration shall be conducted by three (3) arbitrators selected in accordance with Rule 12 of the Patent Arbitration Rules. Prior to the commencement of hearings, each of the arbitrators appointed shall provide an oath or undertaking of impartiality.
 
6.03  The place of arbitration shall be Washington, District of Columbia.
 
6.04  In any arbitration between the Parties, the validity or enforceability of any B&L Patent Rights or of any CIBA Patent Rights shall not be contested and the claims of the CIBA Patent Rights shall be construed as set forth in Judge Richard Story’s Order on claim construction, dated March 14, 2003.
 
6.05  If the time limit of Section 6.06 is extended at the opposed request of, or made necessary by, B&L, then B&L shall place in escrow with the American Arbitration Association, as the escrow agent, disputed royalties due under this agreement, pending the outcome of the arbitration. The escrow agent shall be entitled to release the royalties as directed by the arbitrators in the award, unless the parties agree otherwise in writing.
 
6.06  The award shall be made within three (3) months of the filing of the notice of intention to arbitrate (demand), and the arbitrators shall agree to comply with this schedule before accepting appointment. However, this time limit may be extended by agreement of the parties or by the arbitrators if necessary.
 
6.07  The award shall be in writing, shall be signed by a majority of the arbitrators, and shall include a statement setting forth the reasons for the disposition of any claim.
 
6.08  The arbitrators shall award to the prevailing party, if any, as determined by the arbitrators, all of its costs and fees. "Costs and fees" mean all reasonable pre-award expenses of the arbitration, including the arbitrators' fees, administrative fees, travel expenses, out-of-pocket expenses such as copying and telephone, court costs, court reporters’ fees, witness fees, and attorneys' fees.
 
6.09  No party nor an arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both parties, except as may be required by law, court order, or the requirement of a securities exchange on which the Party's securities are traded, in each case as reasonably determined by such Party based on the opinion of its external counsel.
 
6.10  The United States Arbitration Act shall govern the interpretation and enforcement of Article VI, and any proceedings carried out thereunder. 
 
 
Article VII  - Marking
 
7.01  Upon execution of this Agreement, both Parties will make commercially reasonable efforts to begin affixing the applicable U.S. patent numbers for the other’s Patent Rights to the box packaging for all of their respective Licensed Products sold in the U.S. in accordance with 35 U.S.C. § 287.
 
7.02  Each Party shall ensure product marking is completed (for product packaged after the Effective Date) within a commercially reasonable time period after the Effective Date, but in no case shall it be completed later than April 26, 2005.
 
7.03  The Parties agree that the terms of this Article will be satisfied by listing the appropriate U.S. Patent Rights on the package preceded by the language, “Mfg. and/or Licensed under one or more of the following:” or substantially similar language.
 
 
Article VIII  - Indemnity 
 
8.01  B&L shall indemnify and hold CIBA and its predecessors, successors, assigns, parents, subsidiaries, and affiliated corporations, and each and all of their present and former officers, directors, partners, principals, employees, shareholders, trustees, attorneys, insurers, suppliers and customers (direct or indirect) acting in their capacity as suppliers to and/or customers of CIBA, their respective spouses, successors, heirs, executors, estates, administrators, representatives, attorneys and agents, harmless from and against any third party claims, judgments, damages, costs (including attorneys’ fees) and expenses arising out of B&L’s making, having made, importing, using, selling or offering for sale B&L’s Licensed Products.
 
8.02  CIBA shall indemnify and hold B&L and its predecessors, successors, assigns, parents, subsidiaries, and affiliated corporations, and each and all of their present and former officers, directors, partners, principals, employees, shareholders, trustees, attorneys, insurers, suppliers and customers (direct or indirect) acting in their capacity as suppliers to and/or customers of B&L, their respective spouses, successors, heirs, executors, estates, administrators, representatives, attorneys and agents, harmless from and against any third party claims, judgments, damages, costs (including attorneys’ fees) and expenses arising out of CIBA’s making, having made, importing, using, selling or offering for sale CIBA’s Licensed Products.
 
 
Article IX  - Notice
 
9.01  Notice. Any notice, report, or payment provided for in this agreement shall be deemed sufficiently given when sent by certified or registered mail addressed to the Party for whom intended at the address given below or at such changed address as the party shall have specified by written notice.
 
(a)  
For CIBA:                 CIBA Vision AG
   Hardhofstrasse 15
   CH-8324 Embrach
   SWITZERLAND
   ATTN: Legal Department
 
With a copy to                CIBA Vision Corporation
   Vice President and General Counsel
   11460 Johns Creek Parkway
   Duluth, GA 30092
 
(b)  
For B&L:                   Bausch & Lomb, Inc.
Senior Vice President & General Counsel
One Bausch & Lomb Place
Rochester, NY 14604
 
 
Article X  - Assignment
 
10.01  Assignment. The License Agreement imposes personal obligations on both Parties. Neither Party may assign any rights, except to an Affiliate, under the License Agreement without the written consent of the other Party. Any such attempt to assign shall be null and void. However, the License Agreement may be transferred without consent as part of the sale or transfer of substantially the entire business of a Party to which the Licensed Products relate.
 
10.02  Assigns. The rights and obligations of the Parties shall inure to the benefit of and shall be binding upon the Parties, their respective successors, assigns, heirs, and personal representatives.
 
 
 


* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.  
 

 
Article XI  - Most Favored Nation Terms
 
11.01  Financial Terms.“Financial Terms,” as used herein, shall include, but not be limited to, *.
 
11.02  Notice. If CIBA enters into a Future Agreement under which it grants a license under the CIBA Patent Rights for products competitive with the B&L Licensed Products, in any or all of the Major Markets, defined herein as the United States, Japan or Worldwide, CIBA shall notify a mutually acceptable independent accounting firm of recognized national standing (“Arbitrator”) of the Financial Terms of the Future Agreement. If the Arbitrator deems the Financial Terms for one or more of the Major Market, judged as a whole for each Major Market, to be potentially more favorable (“Potentially More Favorable Financial Terms”) than those set forth in this Agreement, then the Arbitrator shall give written notice to B&L of the More Favorable Financial Terms.
 
11.03  Substitution Right. If the parties agree or it is otherwise judged in arbitration as set forth hereinbelow that the Potentially More Favorable Financial Terms for a Major Market are actually more favorable than those in this Agreement, then B&L shall have the option of electing to substitute, as a whole for such Major Market, prospectively from the effective date of the Future Agreement, the Potentially More Favorable Financial Terms for said Major Market for the financial terms, as a whole, set forth in this Agreement for said Major Market. This option shall expire unless exercised by giving CIBA written notice within sixty (60) days of B&L’s receipt of notice of the More Favorable Financial Terms.
 
11.04  Valuation Basis. The parties expressly agree that the valuation shall be based solely on Financial Terms in the Future Agreement (including any other agreements which relate or refer to the Future Agreement) as compared solely to financial terms in this Agreement.
 
11.05  Arbitration. If, after negotiating in good faith, the parties fail to reach agreement on the valuation for each Major market within sixty (60) days after B&L receives notice of the More Favorable Financial Terms, then the valuation of the More Favorable Financial Terms relative to the financial terms of this Agreement shall be determined by a mutually acceptable independent accounting firm of recognized national standing by binding, final arbitration.
 
 
Article XII  - Miscellaneous Provisions
 
12.01  Governing Law and Jurisdiction. Except as provided for in Section 6.10, this Agreement shall be governed by and construed in accordance with the internal substantive and procedural laws of the State of New York without regard to conflict of laws principles. Further, to the extent necessary to enforce the provisions of Section 6.01 and awards granted pursuant thereto, the Parties agree that the United States District Court for the Northern District of Georgia will retain jurisdiction over the Parties and this matter pursuant to Kokkonen v. Guardian Life Ins. Co., 511 U.S. 375 (1994).
 
12.02  Term. This Agreement shall run from the Effective Date to the expiration of the last-to-expire of the Parties’ Patent Rights. However, the terms of Section 4.01 and Article VIII will survive the termination or expiration of the Settlement.
 
12.03  Headings. The headings appearing herein have been inserted solely for the convenience of the parties hereto and shall not affect the construction, meaning or interpretation of this Agreement.
 
12.04  Integration. The terms and provisions contained in this License Agreement and the attached Settlement Agreement constitute the entire agreement and understanding between the parties regarding the subject matter of this Agreement. No party to this Agreement has relied or will rely on any representation or agreement of the other except to the extent set forth herein, and no party to this Agreement shall be bound by or charged with any oral, written or implied agreements, representations, warranties, understandings, commitments or obligations not specifically set forth herein. This Agreement may not be released, discharged, abandoned, changed or modified in any manner except by an instrument in writing signed by a duly-authorized officer of each of the parties hereto.
 
12.05  Non-Waiver. The failure of either Party at any time to require performance by the other Party of any provisions of this Agreement shall in no way affect the right of such Party to require future performance of that provision. Any waiver by either Party of any breach of any provision of this Agreement shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver of the provision itself, or a waiver of any right under this Agreement.
 
12.06  Counterparts. This Agreement may be executed in separate counterparts, each of which so executed and delivered shall constitute an original, but all such counterparts shall together constitute one and the same instrument. Any such counterpart may comprise one or more duplicates or duplicate signature pages, any of which may be executed by less than all of the Parties, provided that each Party executes at least one such duplicate or duplicate signature page. The Parties stipulate that a photostatic copy of an executed original will be admissible in evidence for all purposes in any proceeding as between the Parties.
 
12.07  Power and Authorization. Each Party represents and warrants that it has all requisite power and authority (corporate and otherwise) to enter into this Agreement, and has duly authorized by all necessary action the execution and delivery hereof by the officer or individual whose name is signed on its behalf below.
 
12.08  Right to Grant License. CIBA represents and warrants in respect to the CIBA Patent Rights that it has legal power to extend the rights granted to B&L in this Agreement and that it has not made and will not make any commitments to others inconsistent with or in derogation of such rights. CIBA represents and warrants that CIBA Vision Corporation, a Delaware corporation, with its principal place of business at 11460 Johns Creek Parkway, Duluth, Georgia, is an Affiliate, as that term is defined herein, of CIBA Vision AG and that CIBA Vision AG has the entire right to extend the rights granted to B&L in this Agreement.
 
12.09  Interpretation and Construction. This Agreement has been fully and freely negotiated by the Parties hereto with the advice of legal counsel, shall be considered as having been drafted jointly by the Parties hereto, and shall be interpreted and construed as if so drafted, without construction in favor of or against any Party on account of its participation in the drafting hereof.
 
12.10  Acknowledgement. Each party has executed this Agreement without reliance upon any promise, representation or warranty other than those expressly set forth herein. Each party acknowledges that (i) it has carefully read this Agreement, (ii) it has had the assistance of legal counsel of its choosing (and such other professionals and advisors as it has deemed necessary) in the review and execution hereof, (iii) the meaning and effect of the various terms and provisions hereof have been fully explained to it by such counsel, (iv) it has conducted such investigation, review and analysis as it has deemed necessary to understand the provisions of this Agreement and the transactions contemplated hereby, and (v) it has executed this Agreement of its own free will.
 
[SIGNATURE PAGE FOLLOWS]
 

 
 

 

Each of the parties hereto has caused this Agreement to be executed by its respective duly-authorized officer as of the day and year first written above.
 
CIBA VISION AG
 

 
 
BY: __/s/ [Signatory Illegible]____________________
 
TITLE: Regional Finance Officer Europe
DATE: July 1, 2004
 
BAUSCH & LOMB INCORPORATED
 

 

 
BY: Robert B. Stiles
 
TITLE: Senior Vice President and general Counsel
 
DATE: July 1, 2004
 

 


* Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.  
 
EX-10.PP 24 form10k2005e10pp.htm EXHIBIT (10)-PP Exhibit (10)-pp


Exhibit (10)-pp

LONG TERM PERFORMANCE UNIT AGREEMENT PURSUANT TO
2003 LONG-TERM INCENTIVE PLAN

LONG TERM PERFORMANCE UNIT AGREEMENT, by Bausch & Lomb Incorporated, a New York corporation (referred to hereinafter as the "Company"), dated as of February 24, 2004 in favor of the individual employee of the Company or one of its subsidiaries (referred to hereinafter as the "Recipient") whose name appears in the Schedule of Awards included as Attachment I hereto (the “Schedule of Awards”).

Under the 2003 Long-Term Incentive Plan of the Company (referred to hereinafter as the "2003 LTI Plan"), approved by the shareholders of the Company on April 29, 2003, the Compensation Committee (the "Committee") of the Board of Directors of the Company has authorized the execution and delivery of this Agreement. Capitalized terms not defined in this Agreement shall have the meanings given to them in the 2003 LTI Plan, and the Schedule of Awards.

This Agreement provides for the award of Performance Units under Section 9 of the 2003 LTI Plan based on achievement, over the Performance Period, of Company performance criteria set forth in the Schedule of Awards included as Attachment I hereto, which may include sales growth, return on net assets, earnings or other Company performance measures.

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto agree as follows:

1. Award of Long Term Performance Unit. Subject to all the terms and conditions of the 2003 LTI Plan and this Agreement, the Company hereby grants to Recipient the Long Term Performance Unit of the Company with the Target Award Value identified on the Schedule of Awards included as Attachment I hereto.

Recipient acknowledges that Long Term Performance Units issued by the Company hereunder are an award and are neither options nor sales to Recipient.

2. Distribution of Performance Award.

(a) Calculation of Performance Award. All or a portion of the Performance Units hereunder shall vest and be paid as a Performance Award to the Recipient, in accordance with and subject to this Agreement, to the extent the Company’s performance over the two-year performance period meets or exceeds the Performance Criteria set forth on Attachment I. Company performance during the Performance Period shall be applied to the Award calculation matrix approved at the time of grant by the Committee. Actual Performance Awards will range from 0-200% of Target Award Value. Determination and approval of Performance Awards shall be in the sole discretion of the Committee, except for the limited circumstances set forth in Section 2(f).

(b) Payment of Performance Awards.

(i) Form of Payment. Performance Awards may be paid in cash, common stock of the Company, or deferred common stock units of the Company. Where payment is in common stock or deferred common stock units of the Company, the number of shares or deferred stock equivalent units of the Company that are paid to the Recipient or credited to the Recipient’s deferral account shall be based on the average of the high and low market prices for the Company’s Common Stock on the New York Stock Exchange on the date which immediately precedes the payment date. A Performance Award payable in cash may also be deferred into any investment choice under the Company’s Executive Deferral Compensation Plan.
 
                A Recipient may select payment of all or any portion of an Award in cash only if (1) the Recipient has at the time of payment satisfied stock ownership guidelines of the Company then in effect and (2) the Recipient has provided at least ten (10) days advance written notice to the Company’s Senior Vice President - Human Resources of the election to accept payment in cash. Deferrals of cash or stock awards must be under a valid election pursuant to the Company’s Executive Deferred Compensation Plan.



(ii) Time of Payment. Awards shall be paid in two equal installments, with the first payment after Committee approval of actual performance and Award following the Period End Date (generally, within 60 days after Period End Date) (the “First Payout Date”), and the second being (“Second Payout Date”) within thirty (30) days after the one year anniversary of the end of the Performance Period.

(c) General Conditions to Payment of Awards. Except for the specific exceptions contained in Section 2(f) hereof, the Recipient must be an active, full-time employee of the Company on each of the First Payout Date and the Second Payout Date as a condition precedent to payment of the portion of the Award payable on such date.

(d) Partial Performance Criteria Award. If actual company performance over the Performance Period is less than the Performance Criteria for that Performance Period, the Award payment shall be reduced to a percentage of the total Award which is based on application of the pre-approved performance matrix identified in the foregoing subparagraph 2(a).

(e) Awards in Excess of the Target Award. If actual company performance for the Performance Period exceeds the Performance Criteria, the Committee shall, at the time it determines such actual company performance, make an Award in excess of the Target Award in an amount which is based on application of the pre-approved performance matrix identified in the foregoing subparagraph 2(a).

(f) Waiver of Payout Conditions Upon Certain Events. The payout calculation and timing requirements of this Section 2 shall be waived automatically and all Awards hereunder shall be paid in cash pro rata based on actual performance immediately (i) upon a Change in Control (as defined below), or (ii) upon termination of Recipient’s employment due to death or disability (as defined in Section 105(d)(4) of the internal Revenue Code of 1986, as amended). Actual performance shall be determined in good faith by the Committee and shall be based on the most recently reported results of the Company. If, as a result of a Change in Control, the Committee ceases to exist, changes, or fails to make such a determination, such a determination shall be based on the most recently reported results of the Company.

For purposes of this Agreement "Change in Control" shall mean:

(i) the acquisition by any individual, entity or group (within the meaning of Section 13(d) (3) or 14(d) (2) of the Exchange Act) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (A) the then outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that the following acquisitions shall not constitute a Change of Control: (x) any acquisition directly from the Company (excluding an acquisition by virtue of the exercise of a conversion privilege unless the security being so converted was itself acquired directly from the Company), (y) any acquisition by the Company, (iii) any acquisition by any Recipient benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (z) any acquisition by any corporation pursuant to a reorganization, merger or consolidation, if, following such reorganization, merger or consolidation, the conditions described in clauses (A), (B) and (C) of paragraph iii below are satisfied; or


 
 

 

(ii) Individuals who, as of April 28, 2003, constitute the Board of Directors of the Company (the "Board" and the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to April 28, 2003 whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

(iii) Approval by the shareholders of the Company of a reorganization, merger binding share exchange or consolidation, in each case, unless, following such reorganization, merger, binding share exchange or consolidation, (A) (more than 60% of, respectively, the then outstanding shares of common stock of the corporation or other entity resulting from such reorganization, merger, binding share exchange or consolidation and the combined voting power of the then outstanding voting securities of such corporation or other entity entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such reorganization, merger, binding share exchange or consolidation, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Company, any Recipient benefit plan (or related trust) of the Company or such corporation resulting from such reorganization, merger, binding share exchange or consolidation and any Person beneficially owning, immediately prior to such reorganization, merger, binding share exchange or consolidation, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation or other entity resulting from such reorganization, merger, binding share exchange or consolidation or the combined voting power of the then outstanding voting securities of such corporation or other entity entitled to vote generally in the election of directors, and (C) at least a majority of the members of the board of directors of the corporation or other entity resulting from such reorganization, merger, binding share exchange or consolidation were members of the Incumbent Board at the time of the execution of the initial agreement providing for such reorganization, merger, binding share exchange or consolidation; or

        (iv) Approval by the shareholders of the Company of (A) a complete liquidation or dissolution of the Company or (B) the sale or other disposition of all or substantially all of the assets of the Company, other than to a corporation or other entity, with respect to which following such sale or other disposition, (1) more than 60% of, respectively, the then outstanding shares of common stock of such corporation or other entity and the combined voting power of the then outstanding voting securities of such corporation or other entity entitled to vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who are the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (2) no Person (excluding the Company and any Recipient benefit plan (or related trust) of the Company or such corporation or other entity and any Person beneficially owning, immediately prior to such sale or other disposition, directly or indirectly, 20% or more of the Outstanding Company Common Stock or Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, 20% or more at respectively, the then outstanding shares of common stock of such corporation or other entity and the combined voting power of the then outstanding voting securities of such corporation or other entity entitled to vote generally in the election of directors, and (3) at least a majority of the members of the board of directors of such corporation or other entity were members of the Incumbent Board at the time of the execution of the initial agreement or action of the Board providing for such sale or other disposition of assets of the company.

(g) Maximum Award. In no event shall the value of an actual Award paid hereunder exceed 200% of the Target Award Value set forth on the Schedule of Awards.

3. General Restriction. This award shall be subject to the requirement that if at any time the Board of Directors shall determine, in its discretion, that the listing, registration or qualification of the shares subject to such award upon any securities exchange or under any state or federal law, or the consent or approval of any government regulatory body, is necessary or desirable as to a condition at or in connection with, the granting of such award or the issue or vesting of shares thereunder, such award may not be effective in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Board of Directors.

4. Non-Transferability of Award. The award granted under this Agreement shall not be transferable by the Recipient except as may be set forth in the Plan.

5. Withholding Upon Award. Recipient also may elect to have a portion of the payment issuable to him or her withheld by the Company in order to satisfy applicable federal, state and local withholding tax requirements.

6. No Right to Employment

(a) Benefits and rights provided under the Plan are wholly discretionary and, although provided by the Company, do not constitute regular and periodic payments. The benefits and rights provided under the Plan are not to be considered part of the Recipient’s salary or compensation under Recipient’s employment for purposes of calculating any severance, resignation, redundancy or other end of service payments, vacation, bonuses, long-term service awards, indemnification, pension or retirement benefits, or any other payments, benefits or rights of any kind.

(b) The Award issued hereunder, and any future Awards under the Plan are entirely voluntary, and at the complete discretion of the Company. Neither the Award nor any future Award by the Company shall be deemed to create any obligation to any further Awards, whether or not such a reservation is explicitly stated at the time of such a grant. The Company has the right, at any time and/or on an annual basis, to amend, suspend or terminate the Plan; provided, however, that no such amendment, suspension, or termination shall adversely affect the Recipient’s rights hereunder.

(c) The Plan shall not be deemed to constitute, and shall not be construed by the Recipient to constitute, part of the terms and conditions of employment. The Company shall not incur any liability of any kind to the Recipient as a result of any change or amendment, or any cancellation, of the Plan at any time.

(d) Participation in the Plan shall not be deemed to constitute, and shall not be deemed by the Recipient to constitute, an employment or labor relationship of any kind with the Company.

7. Competing Work Activities.

(a) Notwithstanding anything to the contrary contained herein or in the Plan, if Recipient voluntarily terminates his or her employment with the Company or is terminated for misconduct or failure or refusal to perform his or her duties of employment (as determined by the Committee), and within a period of one year after such termination shall, directly or indirectly, engage in a competing activity (as defined below), Recipient shall be required to remit to the Company, with respect to any Awards granted or paid on or after the date six months prior to such termination, the fair market value of such Award on the date of payment. Such remittance shall be payable in cash or by certified or bank check or by delivery of shares of Common Stock of the Company registered in the name of the grantee duly assigned to the Company with the assignment guaranteed by a bank, trust company or member firm of the New York Stock Exchange, or by a combination of the foregoing. Any such shares so delivered shall be deemed to have a value per share equal to the fair market value of the shares on such date. This provision shall, however, become null and void, and Company's rights to any remittance under this provision automatically shall be deemed waived, upon a Change in Control (as defined in Section 2 of this Agreement).

(b) For purposes of this Section, Recipient will be deemed to be “engaged in a competing activity” if he or she owns (other than as the owner of a less than 5% interest in a company whose shares are publicly traded), manages, operates, controls, is employed by, or otherwise engages in or assists another to engage in any activity or business which competes with any business or activity of the Company in which Recipient was engaged or involved, or which, as of the time of Recipient's termination, was in a state of research or development by any such business of the Company.

(c) Nothing contained in this Section shall be interpreted as or deemed to constitute a waiver of, or diminish or be in lieu at any other rights the Company may possess as a result of Recipient's direct or indirect involvement with a business competing with the business of the Company.

8. Amendment of this Agreement. The Board of Directors of the Company or the Committee may, from time to time, require the termination, modification or amendment of the terms of this Agreement, including, without limiting the foregoing generality, the making of such amendments or revisions as the Board or the Committee shall deem advisable, provided, however, that no termination, modification or amendment of this Agreement shall, without the written consent of the Recipient, impair his or her rights hereunder.

9. Notices. Notices hereunder shall be in writing and if to the Company shall be delivered personally to the Secretary of the Company or mailed to its principal office, One Bausch & Lomb Place, Rochester, New York 14604-2701, addressed to the attention of the Secretary, and if to the Recipient shall be delivered personally or mailed to the Recipient at his or her address as the same appears on the records of the Company.

10. Interpretation of this Agreement. All decisions and interpretations made by the Board of Directors or the Committee with regard to any question arising hereunder or under the Plan shall be binding and conclusive on the Company and the Recipient. In the event there is any inconsistency between the provision of this Agreement and of the Plan, the provisions of the Plan shall govern.

11. Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and the successors and assigns of the Company and to the extent provided herein to the personal representatives, legatees and heirs of the Recipient.

12. Severability and Saving Provision. The parties intend that this Agreement shall be enforced to the maximum extent possible. If a court of competent jurisdiction: (i) finds any provision of this Agreement to be unenforceable, that provision shall be deemed excised and the remainder of the Agreement shall continue in full force and effect; and (ii) finds any provision of this Agreement to be unenforceable by reason of its being extended for too great a period of time, over too large a geographic area, or over too great a range of activities, the Agreement shall be interpreted to extend over the maximum period of time, geographic range and range of activities as to which it may be enforceable.

13. Tax Matters.

(a) The Company shall have the power and the right to deduct or withhold, or require Recipient to remit to the Company, an amount sufficient to satisfy taxes imposed under the laws of any country, state, province, city or other jurisdiction, including but not limited to income taxes, capital gain taxes, transfer taxes, and social security contributions, that are required by law to be withheld with respect to the Award, the sale of shares, if any, acquired upon payout of the Award, and/or payment of dividends on shares acquired upon payout of the Award.

(b) Recipient agrees to take all steps necessary to comply with all applicable provisions of laws of any country, state, province, city or other jurisdiction in exercising his or her rights under the Plan and this Agreement.

14. Administration and Compliance with Laws.

(a) This Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.

(b) The Company is issuing the Awards hereunder. Furthermore, this Agreement is not derived from any preexisting labor relationship between the Recipient and the Company, but rather from a mercantile relationship.

(c) The Company will administer the Plan from the U.S. and New York State law and the Federal laws of the United States (except those provisions relating to conflicts of law) will govern all Awards issued under the Plan.

15. Privacy. As a condition of the Award, the Recipient consents to the collection, use, and transfer of personal data as described in this Section to the full extent permitted by and in full compliance with applicable law.

(a) The Recipient understands that the Company holds, by means of an automated data file, certain personal information about the Recipient, including, but not limited to, name, home address and telephone number, date of birth, social insurance number, salary, nationality, job title, any shares or directorships held in the Company, details of all options or other entitlement to shares awarded, cancelled, exercised, vested, unvested, or outstanding in the Recipient’s favor, for the purpose of managing and administering the Plan (“Data”).

(b) The Recipient further understands that part or all of his/her Data may be also held by the Company and/or it Subsidiaries, pursuant to a transfer made in the past with his/her consent, in respect of any previous Award, which was made for the same purposes of managing and administering of previous award/incentive plans, or for other purposes.

(c) The Recipient further understands that his/her local employer will transfer Data to the Company and/or its Subsidiaries among themselves as necessary for the purposes of implementation, administration, and management of the Recipient’s participation in the Plan, and that the Company and/or its Subsidiary may transfer data among themselves, and/or each, in turn, further transfer Data to any third parties assisting the Company in the implementation, administration, and management of the Plan (“Data Transferees”).

(d) The Recipient understands that the Company and/or its Subsidiaries, as well as the Data Transferees, are or may be located in his or her country of residence or elsewhere, such as the United States. The Recipient authorizes the Company and/or its Subsidiaries, as well as Data Transferees to receive, possess, use, retain, and transfer Data in electronic or other form, for the purposes of implementing, administering, and managing his or her participation in the Plan, including any transfer of such Data, as may be required for the administration of the Plan and/or the subsequent holding of shares on his or her behalf, to a broker or third party with whom the shares acquired on exercise may be deposited.

(e) The Recipient understands that he or she may show his/her opposition to the processing and transfer of his/her Data, and, may at any time, review the Data, request that any necessary amendments be made to it, or withdraw his or her consent herein in writing by contacting the Company. The Recipient further understands that withdrawing consent may affect his or her ability to participate in the Plan.

 
 

 
16. General. The Recipient has received, and therefore has full knowledge of and understands, the terms and conditions of this Agreement. The Recipient acknowledges that copies of the complete rules of the Plan have also been made available to him/her at his/her work center with his/her local employer.

IN WITNESS WHEREOF, the Company and the Recipient have executed this Agreement on the day and year first above written.

BAUSCH & LOMB INCORPORATED

By:__________________________________
Jean F. Geisel
Secretary

RECIPIENT
By:   _____________________________________
Name Printed: _____________________________________


EX-10.QQ 25 form10k2005e10qq.htm EXHIBIT (10)-QQ Exhibit (10)-qq


Exhibit (10)-qq

LETTER WAIVER


Dated as of January 26, 2007

To the banks, financial institutions
and other institutional lenders
(collectively, the "Lenders")
parties to the Credit Agreement
referred to below and to Citibank, N.A.,
as agent (the "Agent") for the Lenders

Ladies and Gentlemen:

We refer to the Five Year Credit Agreement dated as of July 26, 2005 (the "Credit Agreement") among the undersigned and you, and the letter waivers thereunder dated November 23, 2005 (the “First Letter Waiver”), February 17, 2006 (the “Second Letter Waiver”), May 15, 2006 (the “Third Letter Waiver”), August 23, 2006 (the “Fourth Letter Waiver”) and December 8, 2006 (effective December 15, 2006 and referred to herein as the “Fifth Letter Waiver” and collectively, with the First Letter Waiver, the Second Letter Waiver, the Third Letter Waiver and the Forth Letter Waiver, the “Waivers”). Capitalized terms not otherwise defined in this Letter Waiver have the same meanings as specified in the Credit Agreement and the Waivers.
 
Reference is made to each of Borrower’s Announcements and the events described under the prior Waivers, and the prior definitions of Announcements are amended hereby to include Borrower’s Current Report on Form 8-K, filed December 21, 2006 (grant of second additional trading period from New York Stock Exchange (the “NYSE”) and compliance with certain NYSE corporate governance disclosure requirements).

In light of these events described in the Announcements, and other confidential information which Borrower has disclosed to Agent and Lenders orally and in writing prior to the date hereof under the terms of confidentiality agreements executed with each Lender (the “Confidential Disclosures”), Borrower has requested, and the Required Lenders hereby agree that the term “Waiver Termination Date” as defined in the Waivers is superseded and is hereby defined for all purposes as the earlier of (i) April 30, 2007 or (ii) the effective date of any Form 25 to strike Borrower's securities from listing filed by the NYSE with the U.S. Securities and Exchange Commission as a result of Borrower's failure to file its 2005 10-K within additional trading periods granted by the NYSE. The terms of the Third Letter Waiver, the Fourth Letter Waiver and the Fifth Letter Waiver shall remain in full force and effect, as modified by this Letter Waiver, including, without limitation, paragraphs (and any subparagraphs) three and five of the Third Letter Waiver; provided, however, that the sixth paragraph of the Third Letter Waiver shall be deleted in its entirety and replaced with the following:

“In addition to the foregoing:

(i) when filed with the SEC, Borrower’s 2005 10-K will contain restatements of prior period financial statements, including, without limitation, for the fiscal year 2004 (the “Restatements”). In addition to the waiver granted above, automatically and without further action by the parties hereto, upon the filing by Borrower of the 2005 10-K, your execution of this Letter Waiver evidences your permanent and irrevocable waiver of any misrepresentation of the matters set forth in Sections 4.01(e) and 4.01(k) of the Credit Agreement and any breach of Borrower’s covenants and agreements set forth in Sections 5.01(a) (as related to filings required by the Trust Indenture Act of 1939 (the “TIA”) for fiscal years 2004 and 2005), 5.01(f) or 5.01(h) of the Credit Agreement with respect to periods covered 2005 10-K; and

(ii) when filed with the SEC, Borrower’s 2006 Annual Report on Form 10-K (“2006 10-K”) will contain the selected quarterly financial information for fiscal year 2006. In addition to the waiver granted above, automatically and without further action by the parties hereto, upon the filing by Borrower of the 2006 10-K, your execution of this Letter Waiver evidences your permanent and irrevocable waiver of any misrepresentation of the matters set forth in Sections 4.01(k) of the Credit Agreement and any breach of Borrower’s covenants and agreements set forth in Sections 5.01(a) (as related to filings required by the TIA for fiscal year 2006), 5.01(f) or 5.01(h) of the Credit Agreement with respect to periods covered by the 2006 10-K.”

In addition, the Required Lenders hereby agree to amend Section 6.01(d) of the Credit Agreement to delete the figure “$50,000,000” and substitute therefor the figure “$70,000,000”.

The amount of the Monthly Fee, as defined in paragraph seven of the Third Letter Waiver, shall remain as set forth therein. However, payment of the Monthly Fee will be made on February 1, 2007, March 1, 2007 and April 2, 2007; provided, however, in the event Borrower files its 2006 Form 10-K on or before February 28, 2007, then it will have no obligation to make the March and April payments, and if the Borrower files its 2006 Form 10-K on or before March 31, 2007, then it will have no obligation to make the April payment.

This Letter Waiver shall become effective as of January 31, 2007 if, as of that date, the Agent has received counterparts of this Letter Waiver executed on behalf of Borrower and the Required Lenders or, as to any of the Lenders, advice satisfactory to the Agent that such Lender has executed this Letter Waiver.

If you agree to the terms and provisions of this Letter Waiver, please evidence such agreement by executing and returning at least two counterparts of this Letter Waiver to Susan Hobart, Shearman & Sterling LLP, 599 Lexington Avenue, New York, New York 10022.

With respect to the matters waived hereunder, nothing in this Letter Waiver shall constitute an admission (1) of liability with respect to such matters, (2) that a breach of any representation, warranty, covenant or other provisions of the Credit Agreement has occurred, or (3) that any Default or Event of Default has occurred under the Credit Agreement.

The Waivers, as modified by each other and this Letter Waiver, shall represent the entire agreement with respect to the matters contained herein and, except where otherwise noted herein or therein, shall supersede any prior agreements whether written or oral. This Letter Waiver may

 
 

 

be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Waiver by telecopier or other electronic means shall be effective as delivery of a manually executed counterpart of this Letter Waiver.
 
This Letter Waiver shall be governed by, and construed in accordance with, the laws of the State of New York.

Very truly yours,

BAUSCH & LOMB INCORPORATED

By  /s/ Efrain Rivera  
Efrain Rivera
Vice President and Treasurer

Agreed as of the date first above written:

CITIBANK, NA.,
as Agent and as Lender

By /s/ Bob Kane
Name: Bob Kane
Title: Managing Director

KEYBANK NATIONAL ASSOCIATION

By /s/ Marianne Meil
Name: Marianne Meil
Title: Senior Vice President

BARCLAYS BANK PLC

By /s/ David Barton
Name: David Barton
Title: Associate Director

BANK OF TOKYO-MITSUBISHI UFJ TRUST
COMPANY (f/k/a Bank of Tokyo-Mitsubishi Trust
Company)

By /s/ Harumi Kambara
Name: Harumi Kambara
Title: Assistant Vice President

JPMORGAN CHASE BANK, N.A.

By /s/ Bruce Yoder
Name: Bruce Yoder
Title: Vice Preisdent
MIZUHO CORPORATE BANK, LTD.

By /s Raymond Ventura
Name: Raymond Ventura
Title: Deputy General Manager

U.S. BANK NATIONAL ASSOCIATION

By /s/ Eric Cosgrove
Name: Eric Cosgrove
Title: Assistant Vice President

ALLIED IRISH BANKS, P.L.C.

By /s/ Germaine Reusch
Name: Germaine Reusch
Title: Director

By /s/ Anthony O’Reilly
Name: Anthony O’Reilly
Title: Senior Vice President

HSBC BANK USA, NATIONAL ASSOCIATION

By /s/ John Carroll
Name: John Caroll
Title: First Vice President

THE NORTHERN TRUST COMPANY

By /s/ Alex Nikolov
Name: Alex Nikolov
Title: Second Vice President
EX-10.RR 26 form10k2005e10rr.htm EXHIBIT (10)-RR Exhibit (10)-rr


 
  Exhibit (10)-rr
 
LETTER WAIVER
 
  
To:     Bausch & Lomb B.V. (the Company)
    Koolhovenlaan 110
    1119 NH Schiphol-Rijk
    The Netherlands

Fax:    +31 20 6554 651
Attn:    Financial Controller


and:    Bausch & Lomb Incorporated (the Guarantor)
            One Bausch & Lomb Place
    Rochester
    New York 14604
    United States of America

Fax:     +1 585 338 8188
Attn:    Corporate Treasury Operations
 
  29 January, 2007
 
  Dear Sirs,
 
  US$375,000,000 credit agreement dated 29 November 2005 (as amended) between (among others) the Company, the Guarantor and Citibank International plc as facility agent (the Agreement)
 
1.  
Background
 
(a)  
This letter is supplemental to and amends the Agreement.
 
(b)  
Pursuant to Clause 25 (Amendments and Waivers) of the Agreement, the Majority Lenders have consented to the amendments to the Agreement contemplated by this letter. Accordingly, we are authorised to execute this letter on behalf of the Finance Parties.
 
2.  
Interpretation
 
(a)  
Capitalised terms defined in the Agreement have the same meaning when used in this letter unless expressly defined in this letter.
 
(b)  
The provisions of Clause 1.2 (Construction) of the Agreement apply to this letter as though they were set out in full in this letter except that references to the Agreement are to be construed as references to this letter.
 
(c)  
Effective Date means 31 January, 2007, provided that the Facility Agent shall have given notification to the Obligors that it has received a copy of this letter countersigned by the Company and the Guarantor.
 
3.  
Amendments
 
(a)  
Subject to subparagraph (b) below, the Agreement will be amended from the Effective Date in accordance with subparagraph (c) below.
 
(b)  
The Agreement will not be amended by this letter unless the Facility Agent has received a copy of this letter countersigned by the Company and the Guarantor on or before the Effective Date.
 
(c)  
The Agreement will be amended as follows:
 
(i)  
Clause 19.5(a) (Cross-default) be amended by deleting the figure “US$50,000,000” and replacing it with the figure “US$70,000,000”;
 
(ii)  
Clause 19.11(a)(ii) (BLIO Matters) of the Agreement shall be amended by deleting the reference to “31 January 2007” in the last line thereof and replacing it with “30 April 2007”;
 
(iii)  
the definition of Confidential Disclosures shall be amended by replacing “16 May, 2006” with “the date of this letter”;
 
(iv)  
the definition of Other Announcements shall be amended as follows:
 
 
 (i) deleting the word “and” at the end of subparagraph (xxi);
 
 
(ii) deleting the full stop after the words "9 November 2006 " at the end of subparagraph (xxii) and replacing it with a semi-colon followed by the word “and”; and
 
 
(iii) inserting new subparagraph (xxiii as follows:
 
 
"(xxiii) Current Report on Form 8-K, filed 21 December, 2006 (grant of second additional trading period from New York Stock Exchange (NYSE) and compliance with certain NYSE corporate governance disclosure requirements).”; and
 
(v)  
the definition of Waiver Termination Date in Clause 19.11(b) of the Agreement shall be deleted in its entirety and replaced with the following:
        
                 Waiver Termination Date means the earlier of:
           (i) 6:00 p.m. (Rochester, New York time) on 30 April, 2007;
 
 
(ii) the date (if any) on which the trustee or holders of not less than 25 per cent. of the principal amount of outstanding securities under any series with an outstanding principal amount of at least US$50,000,000 under the Indenture have given to the Guarantor notice that the principal amount of such securities is due and payable immediately;
 
 
(ii)the effective date of any Form 25 to strike Guarantor’s securities from listing filed by NYSE with the SEC as a result of Guarantor’s failure to file its 2005 10-K within additional trading periods granted by the NYSE; and
 
 
(iii)the date on which the Guarantor’s 2006 annual report on Form 10-K is filed with the SEC.".
 
4.  
Guarantee
 
  The Guarantor:
 
(a)  
agrees to the amendment of the Agreement as contemplated by this letter; and
 
(b)  
with effect from the Effective Date, confirms that the guarantee given by it under the Agreement will:
 
(i)  
continue in full force and effect; and
 
(ii)  
extend to the liabilities and obligations of the Company to the Finance Parties under the Finance Documents as amended by this letter.
 
5.  
Further Waiver
 
The provisions of paragraph 4 of the 17 May, 2006 Letter Waiver shall be deleted in its entirety and replaced as follows:
 
(a)      
The Guarantor’s 2005 annual report on Form 10-K will contain financial statements for 2005 and restated financial statements for certain prior periods, including but not limited to the Guarantor’s 2004 fiscal year. Accordingly, in addition to the BLIO Matters and Other Matters not resulting in or constituting a breach of the Agreement or Default during the Waiver Period, as set forth in Clause 19.11(a), the Majority Lenders further agree, upon the filing of that annual report on Form 10-K, in accordance with the terms of this letter, that any representation under Clauses 16.6 (Financial statements) and 16.11 (Compliance with laws) of the Agreement which is incorrect in any material respect, or any breach of the covenants of Clauses 17.2 (Compliance with laws) (as related to filings required by the Trust Indenture Act of 1939 (the “TIA”) for fiscal years 2004 and 2005), 17.7 (Maintenance of accounts) and 17.10 (Reporting requirements) or any Default arising therefrom, with respect to periods covered by the 2005 10-K, shall be permanently and irrevocably waived, to the extent related to the matters described in the BLIO Announcements, Other Announcements or Confidential Disclosures.
 
       (b)
 
The Guarantor’s 2006 annual report on Form 10-K will contain selected quarterly financial statements for fiscal year 2006. Accordingly, in addition to the BLIO Matters and Other Matters not resulting in or constituting a breach of the Agreement or Default during the Waiver Period, as set forth in Clause 19.11(a), the Majority Lenders further agree, upon the filing of that annual report on Form 10-K, in accordance with the terms of this letter, that any representation under Clause 16.11 (Compliance with laws) of the Agreement which is incorrect in any material respect, or any breach of the covenants of Clauses 17.2 (Compliance with laws) (as related to filings required by the Trust Indenture Act of 1939 (the “TIA”)) for fiscal year 2006, 17.7 (Maintenance of accounts) and 17.10 (Reporting requirements) or any Default arising therefrom, respect to periods covered by 2006 10-K, shall be permanently and irrevocably waived, to the extent related to the matters described in the BLIO Announcements, Other Announcements or Confidential Disclosures.
 
6.  
Amendment fee
 
(a)  
In further consideration for the matters contemplated by this letter, the Company must pay to the Facility Agent for the account of the Lenders which consented on or before the date of this letter to the amendments to the Agreement contemplated by this letter (the Consenting Lenders) a monthly fee equal to 0.10 per cent. of the total Commitments of the Consenting Lenders. The first such monthly fee shall be payable no later than February 1, 2007, and subsequent monthly fees shall be payable no later than March 1, 2007 and April 2, 2007; provided, however, in the event Guarantor files its 2006 Form 10-K on or before February 28, 2007, then it will have not obligation to make the March and April payments, and if the Guarantor files its 2006 Form 10-K on or before March 31, 2007, then it will have no obligation to make the April payment. Payments will be made to the account notified to the Company by the Facility Agent for this purpose.
 
(b)  
All amounts payable under this letter are exclusive of any value added tax or other taxes of any nature and will not be subject to counterclaim or set-off for, or be otherwise affected by, any claim or dispute relating to any matter whatsoever and all such payments shall be made free and clear and without deduction for or on account of any present or future taxes, charges, deductions or withholdings.
 
7.  
Miscellaneous
 
(a)  
This letter is a Finance Document and a Fee Letter.
 
(b)  
From the Effective Date, the Agreement and this letter will be read and construed as one document.
 
(c)  
Except as otherwise provided in this letter, the Finance Documents remain in full force and effect.
 
(d)  
Except to the extent expressly waived in this letter, no waiver of any provision of any Finance Document is given by the terms of this letter and the Finance Parties expressly reserve all their rights and remedies in respect of any breach of, or other Default under, the Finance Documents.
 
8.  
Governing law
 
       This letter is governed by English law.
 

 
/s/ Casilda Clovis Olu Dada  
For
CITIBANK INTERNATIONAL PLC
as Facility Agent for and on behalf of the Finance Parties
 
Date: 29th January, 2007

 
 

 

 

 
We agree with the terms of this letter.
 

 
/s/ Efrain Rivera    
Efrain Rivera, Vice President & Treasurer
For
BAUSCH & LOMB B.V.
 
Date: 26th January, 2007
 
 
 
/s/ Stephen C. McCluski   
Stephen C. McCluski
Sr. Vice President and CFO
For
BAUSCH & LOMB INCORPORATED
 
Date: 26th January, 2007


EX-12 27 form10k2005e12.htm EXHIBIT 12 Exhibit 12


 

Exhibit 12
Bausch & Lomb Incorporated
 
Statement Regarding Computation of Ratio of Earnings to Fixed Charges
(Dollar Amounts In Millions)


   
December 31, 2005
 
December 25, 2004
 
Income before Income Taxes and Minority Interest
 
$
246.4
 
$
242.7
 
Fixed Charges
   
53.8
   
51.3
 
Current Period Amortization of Capitalized Interest
   
0.6
   
0.5
 
Capitalized Interest
   
0.0
   
(1.1
)
Total Earnings as Adjusted
 
$
300.8
 
$
293.4
 
Fixed Charges
             
Interest (Including Interest Expense and Capitalized Interest)
 
$
52.8
 
$
50.7
 
Portion of Rents Representative of the Interest Factor
   
1.0
   
0.6
 
Total Fixed Charges
 
$
53.8
 
$
51.3
 
Ratio of Earnings to Fixed Charges
   
5.6
   
5.7
 

EX-21 28 form10k2005e21.htm EXHIBIT 21 Exhibit 21




Exhibit 21
Bausch & Lomb Incorporated
Subsidiaries
(as of December 4, 2006)

Entity List Report

Affiliates
Jurisdiction
9079-8851 Quebec Inc.
Canada
B&L CRL Inc.
Delaware
B&L Financial Holdings Corp.
Delaware
B&L SPAF Inc.
Delaware
B&L VPLEX Holdings, Inc.
California
B.L.J. Company Limited
Japan
Bausch & Lomb (Australia) Pty. Limited
Australia
Bausch & Lomb (Hong Kong) Limited
Hong Kong
Bausch & Lomb (Jersey) Limited
Jersey
Bausch & Lomb (Malaysia) Sdn. Bhd.
West Malaysia
Bausch & Lomb (New Zealand) Limited
New Zealand
Bausch & Lomb (Philippines), Inc.
Philippines
Bausch & Lomb (Shanghai) Trading Co., Ltd.
Peoples Republic of China
Bausch & Lomb (Singapore) Private Limited
Singapore
Bausch & Lomb (South Africa) (Proprietary) Limited
South Africa
Bausch & Lomb (Thailand) Limited
Thailand
Bausch & Lomb AG
Switzerland
Bausch & Lomb Argentina S.R.L.
Argentina
Bausch & Lomb B.V.
Netherlands
Bausch & Lomb B.V.B.A.
Belgium
Bausch & Lomb Canada Inc.
Canada
Bausch & Lomb China, Inc.
Delaware
Bausch & Lomb Danmark A/S
Denmark
B&L Domestic Holdings Corp.
Delaware
Bausch & Lomb Eyecare (India) Private Limited
India
Bausch & Lomb Foundation, Inc.
New York
Bausch & Lomb France SAS
France
Bausch & Lomb Fribourg SA
Switzerland
Bausch & Lomb GmbH (Austria)
Austria
Bausch & Lomb GmbH
Germany
Bausch & Lomb International Inc.
New York
Bausch & Lomb Ireland
Ireland
Bausch & Lomb Korea Co. Ltd.
Republic of Korea
Bausch & Lomb Luxembourg Sarl
Luxembourg
Bausch & Lomb Mexico, S.A. de C.V.
Mexico
Bausch & Lomb Nordic AB
Sweden
Bausch & Lomb Polska sp. z o.o.
Poland
Bausch & Lomb Realty Corporation
New York
Bausch & Lomb S.A.
Spain
Bausch & Lomb Saglik Ve Optik Urunleri Tic. A.S.
Turkey
Bausch & Lomb Scotland Limited
Scotland
Bausch & Lomb South Asia, Inc.
Delaware
Bausch & Lomb Swiss AG
Switzerland
Bausch & Lomb Taiwan Limited
Taiwan
Bausch & Lomb U.K. Limited
England
Bausch & Lomb-IOM S.p.A.
Italy
Bausch & Lomb-Lord (BVI) Incorporated
British Virgin Islands
BCF SAS
France
Beijing Bausch & Lomb Eyecare Company, Ltd.
Republic of China




Page 2

Affiliates
Jurisdiction
BL Industria Otica Ltda.
Brazil
BL Participacoes Ltda.
Brazil
BLEP Holding Gmbh
Germany
Chauvin Ankerpharm GmbH
Germany
Chauvin Benelux
Belgium
Chauvin Opsia
France
Chauvin Pharmaceuticals Limited
United Kingdom
Cordelia BV
Netherlands
Cristallin Invest SA
Luxembourg
Domilens AB
Sweden
Dr. Gerhard Mann chem.-pharm. Fabrik GmbH
Germany
Dr. Robert Winzer Pharma GmbH
Germany
Echt Sylter Brisen-Klombjes Prod
Germany
Iolab Corporation
California
Laboratoire Chauvin S.A.
France
Parfumerie Osme SA
Switzerland
PT Bausch & Lomb Indonesia (Distributing)
Indonesia
PT Bausch & Lomb Manufacturing
Indonesia
RHC Holdings, Inc.
Delaware
Shandong B&L Freda Pharmaceutical Co. Ltd.
Peoples Republic of China
Shandong B&L Freda New Packaging Resource Co. Ltd.
People Republic of China
Sight Savers, Inc.
Delaware
Sino Concept Technology Limited
Hong Kong
Technolas GmbH Ophthalmologische Systeme
Germany
Wilmington Management Corp.
Delaware
Windmill Investments N.V.
Netherlands Antilles
Windmill Investors N.V.
Netherlands Antilles
Windvest I N.V.
Netherlands Antilles

EX-24 29 form10k2005e24.htm EXHIBIT (24) Exhibit (24)


Exhibit 24





POWER OF ATTORNEY


The undersigned directors of Bausch & Lomb Incorporated (the “Company”), each hereby constitutes and appoints Ronald L. Zarrella and Robert B. Stiles, or either of them, his or her respective true and lawful attorneys and agents, each with full power and authority to act as such without the other, to sign for and on behalf of the undersigned the Company's Annual Report on Form 10-K for the year ended December 31, 2005, to be filed with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1933 and the related rules and regulations thereunder, and any amendment or amendments thereto, the undersigned hereby ratifying and confirming all that said attorneys and agents, or either one of them, shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this instrument has been executed by the undersigned as of this * day of December, 2006.


 /s/ Alan M. Bennett
 Alan M. Bennett2
 /s/ Linda Johnson Rice
 Linda Johnson Rice2
 
 /s/ Domenico De Sole
 Domenico De Sole1
 
 /s/ William H. Waltrip
 William H. Waltrip2
 
 /s/ Paul A. Friedman
 Paul A. Friedman1
 
 /s/ Barry W. Wilson
 Barry W. Wilson3
 
 /s/ Jonathan S. Linen
 Jonathan S. Linen3
 
 /s/ Kenneth L. Wolfe
 Kenneth L. Wolfe1
 
 /s/ Ruth R. McMullin
 Ruth R. McMullin1
 
 /s/ Ronald L. Zarrella
 Ronald L. Zarrella4
 
* The Power of Attorney was signed as of: December 26, 2006 (1), December 27, 2006 (2); December 28, 2006 (3); and January 3, 2007 (4).
EX-31.A 30 form10k2005e31a.htm EXHIBIT (31)-A Exhibit (31)-a


 
EXHIBIT (31)-a
 
Bausch & Lomb Incorporated
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


I, Ronald L. Zarrella, certify that:

1.  
I have reviewed this annual report on Form 10-K of Bausch & Lomb Incorporated;

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)  
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)  
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 7, 2007

/s/ Ronald L. Zarrella 
Ronald L. Zarrella
Chairman and Chief Executive Officer
EX-31.B 31 form10k2005e31b.htm EXHIBIT (31)-B Exhibit (31)-b
 
EXHIBIT (31)-b
 
Bausch & Lomb Incorporated
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002


I, Stephen C. McCluski, certify that:

1.  
I have reviewed this annual report on Form 10-K of Bausch & Lomb Incorporated;

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)  
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)  
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 7, 2007

/s/ Stephen C. McCluski 
Stephen C. McCluski
Senior Vice President and
Chief Financial Officer

EX-32.A 32 form10k2005e32a.htm EXHIBIT (32)-A Exhibit (32)-a


EXHIBIT (32)-a



Bausch & Lomb Incorporated
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350


I, Ronald L. Zarrella, Chairman and Chief Executive Officer of Bausch & Lomb Incorporated (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1.  
the Annual Report on Form 10-K of the Company for the annual period ended December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.  
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Ronald L. Zarrella  
Ronald L. Zarrella
Chairman and Chief Executive Officer


Date: February 7, 2007

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed, nor in accordance with SEC Release No. 33-8238 is deemed to be filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-32.B 33 form10k2005e32b.htm EXHIBIT (32)-B Exhibit (32)-b
EXHIBIT (32)-b



Bausch & Lomb Incorporated
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
18 U.S.C. Section 1350


I, Stephen C. McCluski, Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

1.  
the Annual Report on Form 10-K of the Company for the annual period ended December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.  
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Stephen C. McCluski 
Stephen C. McCluski
Senior Vice President and
Chief Financial Officer


Date: February 7, 2007

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed, nor in accordance with SEC Release No. 33-8238 is deemed to be filed, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

GRAPHIC 34 bauschandlomb.jpg begin 644 bauschandlomb.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0`\17AI9@``24DJ``@````!`#$!`@`9 M````&@````````!%1$=!4FEZ97(@4V]F='=AH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U M]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`" M`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2 M\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U MMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`, M`P$``A$#$0`_`/W\HI-R^HI@`_&O,/B5^VA^R-\'O,3XG_M-^!=#EB'S6 MM_XIM8I1_P``+[_TKP;XC_\`!>O_`()??#IIK?\`X:&;7[F'K;^&_#]]=!O^ MVWDK!_Y$KKHY7F6,=J=&4O2+,*N,PE#XYI'V0`,\-^E.R.F[GZ5^7'Q'_P"# MI#]ES1S+%\-/V?/'&MSPCY1JUQ:Z;'(?8H\_\J\)^)'_``=,?M&ZF)/^%3_L MR>#=$V]/[?U:ZU/_`-$_9:]ZAP7Q+B/^7%O5I'G5<[RVC]L_;E22?O?G2L^. M&(K^D/ASPO9)CZ/.DKC_ONO!/B-^W M9^VI\55F'Q$_:Q^(6J0R_P"MLIO%-R+7_OPC[*]O"^&F;2?[VK&/_DW^1PU. M)L'_`,NXMG]0GC_XR?![X66XN_B?\5?#OAN$C>)=\;^YX;$^KG_`,DHY:_F_ M0\,,&O\`>,2W_A5OSN<5;BJK_P`NX(_>SXC_`/!S+^P+X1:6U\$>#_B%XKD' M^JGL/#\5M;-_P.YF1Q_WQ7@_Q%_X.J-?F,MO\(_V0K:#'^JO/$?BB23/U@A@ M7_T97Y%T5[E'@'AJCO&4O61YE7B#,JVTN4^^_B'_`,'(O_!1SQFDB>%+_P`# M^%O,7$1T3PP998OJ+QYQ^E?:W_!O+^VG^U'^V-J7QCO_`-I+XNWWBMM#_L#^ MR5GM+:&.R,W]I";RT@1.'\B+]*_"ZOU__P"#43=YOQ[V^GA;_P!R]<'%V1Y- MEW#%6IA:,8R]W6VOQ(WR3,,9B,R@JLW+<_8GI1117X>?H!^$W[?$?P-X!_:,U_3](TGQ=?6VFZ=;+%Y5O$DG^K&4KRG_AZE_P41_Z.M\4? ME#_\17[::A_P3>_8>U[QYJOQ5\2_LX^'M6US6K^2]U:\UI'O?.N'^\3',[(/ MH!BO2O`7P-^"_P`*X##\-?A'X:T"-!TT31+>V`_")%KE]C5O\9^6U.#.(Z^- MG4GCI1C)O9R9^(G@C]J;_@MG\1AN\!>(_BYJL,G2>Q\*221#_@?D5[)X!^&O M_!Q?X^8`^,/%6BVQ/%YKFNZ9;_\`D,?O/_(=?K9XTO)],\'ZOJ6GSB*:UT^: M6*7T=(R17X"?L=?M<_\`!;G]I_\`X)]?%?\`X*$Z+_P5-MM$3X/W-X)?"FN_ M#[3)HM5^S6$%Z3Y_D<2/YGE)'Y?4CUK14N\CV*/!59?Q<=6EZ2L?>_@+]AS_ M`(+<:T\<_P`0/^"@]AHD,RY:.PGDOI(?;'V6)3_WW7LW@']@+]K;3&#?$_\` MX*C_`!*U?'WX]"TJQL/_`$:+C%5'GJ<<=/:_V6/^"B_[$7[: MNH:AHO[+7[1GA[QA?Z3;B74=/L7EBN8(S@!S!,B/L]\4_9H]O"Y#A*"^.<^\]L1\UDVW_!1C]A_4OV?[G]J>U_:B\'-\.['4383^ M+QJPCM!>C_EW5CCS).?]6,GV.*[\-C<7A-:$G'T/4^K87X'$\9_XA\_^"67_ M`$0G5O\`PM-3_P#C]'_$/G_P2R_Z(3JW_A::G_\`'Z]G_98_X**?L4?MLZAJ M.E_LM?M%^'O&%]HT`DU*PL#)%<0(<`.89D2383WQ7*:Y_P`%BO\`@F'H'Q<' MP*UK]M3P(OB;^T?L!LHM4,D45SOV>6]RB^3&^3T,@[UW+/L]6V(G_P"!$_4, MO>])?<<'_P`0^?\`P2R_Z(3JW_A::G_\?H_XA\_^"67_`$0G5O\`PM-3_P#C M]?*G[*7_``5JU?X2_P#!7K]JSP5^W/\`M=#1?A;X(N;ZU\(:=XCNXDM;*4:G M&D<=LB)YDC^7QCGK7Z:_LR_M??LS_MD^!IOB3^S%\8]%\9Z-:W/V:ZN](N23 M;R@PZS_P47_8\TC]I$?LDO\66 MNOB!%?6EI>:#I7A_4KU+*XNMGD1W5U;P/;6Q?>.)9!U]J\H_X+U?M*_&_P#9 M,_X)C^-_CG^SSXXG\,^*]+U'1HM/U>WM(IGA2?4[>&3Y)D9/N2'J*7]OY]_T M$3_\"8?V?EW_`#Z7W%7_`(A\_P#@EE_T0G5O_"TU/_X_1_Q#Y_\`!++_`*(3 MJW_A::G_`/'Z]/\`^"5OQ=^(_P`?/^"='P@^-'Q?\13ZYXG\1>"[2_UG5+BW MBB>YN''+X0*@_"J_QM_X*U_\$W?V3>:0]\9I;& M3^Y<^2CK;'_KJ5H_M_/O^@B?_@3%_9^6_P#/I?<>RU-GC,J>3*FY9,HA((Z@=>E>?^&O^"Q/_!+[Q;\1 M[WX3^&_VX_AW-K-K%+),LNOB.VVHF]RET^()<#GY)#1_;^?6_P!XG_X$P_L_ M+?\`GU'[C@O^(?+_`()9GI\"]6_\+/4__DBO:/V0?^">_P"RM^PC+XA?]FCP M'/HA\4BU_MD3:OE0237>D:=1QFOSD_P""2W_!9R/PI\8_ MVII_^"DG[:=I:>'_``QX[L-,^'UIXGNHA);QM=ZRDT=K!"GGR\6]IOX/3M6% M;.S8Z6$PE!^TIP43]G**X'X"_M&?`_\`:A^&]E\7?V?OBCH_ MBWPSJ!DC@U;1;KS8O,3AT?O'(">8WP1Q7?5YQVA@>E%%%`&%\2?^1!U[_L"W M7_HHU_,__P`$S/\`@F'\.?VU?^"3'QQ^/OCS]J3QGX%_X03Q'?W-GHP\0PCP MU/);:;;W*2WMK(G,C2'RS+YGYGBOZ;]9T6WUK2+O1;G_`%5U;RQ2CVKK#"A/YT`?"/P7_`."O M/B7Q%_P2?^#/P7^)_P"QQ\._B;\0M2^,DW@[X-V7C7PM;1^'[?[!8Z?'!J$U MJNV!;B'^V?LV!Y0SSUS7:?L]_"C]H?\`9U_X.>/@UX3^/VK?"^#Q9XK^'FIW M?BC3O@MX?ETS288FT?6C';SQOM,LG^APR&0C/$%?I5^T-_P16_X)[_M'_LP^ M%/V3M9^#[>&_"/@:ZDNO!_\`PBER;6ZTF63_`%SI*P?S/._Y:>:)/,[UD?LS M?\$)/V"_V5_CQX6_:@^'>C>,;OX@>%6NY;?Q5KWC.ZNKF^DN;5[61KK)V3'R M',><8Q^H!^;O_!NWXAT#PW_P2+_;)M/$FJV^GRZ?IVK3:C'?W/ER6\;Z%.G[ MST^>,UR/[`G_``35U'_@I[_P00TWX/>"?BSI_AKQAHOQTUG6/"-KJDY-EK5T MFFP(]G)_RT(\L_ZP=.IX/'Z*^./^#:3_`()C^/\`X\Z[\<]2\,>,;2+Q-#_A8 M,&C^&/%5UXA\-Z[;^,6BU33+ZYC@6:2.5(]AXMXN'C.*`/ST^#7_``4;\0#] M@+]J+]CW6OV7?#_PK_:9^%WPDFTW7/$G@SPM:V4FM:/87,=A=;I+9$\NXMH[ M@_+/^"8O@;XMVOP4\"^*/&-UJ]U=^+M=UWP[ M;7U]8ZO;7TGDQ[YD=[S\1-\)O"6I>( M-7\8:=)IOBCQ#X[N8]2OM0L7/SVDO[M(?+?^,>7^\[YXKR?2_P#@V4_X)J:% M\88?BOX-E^)&@6D.LP:H/!6D>-I8=(-S#+YL)^Y]J^0_]-Z`/DS_`()K?L\? M!/\`:!_X.,?VN?\`A>?PJ\/>*X]`N=9NM(M/$6F17UK;W+ZG;PF3R9@Z>9Y? M?K]*Z7_@W5T31/AE_P`%7/VX_@IX"L;;2O#&D>/+JVTS0;%-EM;Q6>N:G!;1 MQC_8B)'XU^B/[/'_``3*_9R_9E_:\^(W[;'PXN/$7_"9?%`3?\)3_:.JI-99 MFN4N'\B,(OE_O(_7O2?LK_\`!,O]F_\`8_\`VE/BE^U/\*;SQ"?%7QYU# MQ=_:FII+:F:>]DO'\F,(OE#S)SW-`'P%\&/CQ\7?"GAG]M+_`(*-_P#!.._T M;PU\,;/Q#K>JZQIOQ)\/G5[KQ%XEL+7S;J]T[[-/:_8+-_,A_P"/B2Z[_NH: MUO\`@K'XI^)'Q)_X-ET^-?QB^).H>)O$/Q!T7P5XHU&ZO;6VMHK*74+K3+DV MEM';018MX2Y\O?\`O?6;T^L-9_X(J?LK/:?$'P]\//'OQ+\&>%?BCB?'7_@G!^SC^T+^Q!IW_!/OQI:Z MQ:?#G2=&T;2].ATG5/*O8;;3#`;6,3.K=/L\6>.<4`>0_P#!-+6/&OAO_@@E M\/\`Q'\.5/\`PD5A\";FZT+ROWC_`&Y+6=X,>O[S%?"?_!OM\!OV/OC;_P`$ MB?V@/'W[0V@:+K^MZMK6OQ?$+Q'XDMHKF_LK&/3()X9//<%X_ORW'F)/B+XC_X-Z_"VD^-;F>72-%_:INK3PLTX MYAM6\/&::*'_`*9?:)9_SK[;_P""Y/[#/[*'PO\`VB_V#?"'PW^!7A_0-+\; M:Y%X<\4V>AV<5K%J=C#?:(B";8!YLG^GS?O>9>>OI^FO[17_``1>_89_:,_9 M1\%_L3ZYX5UCPS\/O`>L_P!H^&],\*:J+61;CRIHSO>9)?-#"XF)SZ]>U=5^ MU?\`\$ROVN_$(O_@IK']H>"?[+U-(HQ-YMG+F<%&\T9L(. M..]`'YT?M'?!+X1?LX?\'5O[->B_`/X;Z+X-L=;^&7VK4=,\,:5'8VTTODZ] M:>88X0B?ZB"&+I7#?\&YOP(_9N^,?_!0C]KC4?C3X$\/>)?$&D>(YH_#NG^) M-,BN3]AN=3U--0=()M_'R6<9/_3?'.:_5KXF?\$V?V>OBU^W;X&_X*+>+KGQ M!_PL+X?:!_8^@"UU)(['[+_IF1)#L)8_Z=/SO'45\X^(O^#9[_@GQJ>O^*_& MN@>+_BWX=\2>+=1FNKSQ)X=\?&UN;832.\\$.(?+\N8R'>)$DSZT`?./_!L/ M9CPK^VC^V'\-_@Y>3R_";2?&A'AN+/F6\`34M0AM1'_OVD0/X5^T->(_L.?L M$_LV?\$\O@]_PI']F/P.VE:7)<&YU&YO;DW%[J=S@+Y\\QY9O?\`0 GRAPHIC 35 shareholders-chart.gif begin 644 shareholders-chart.gif M1TE&.#EA_P$X`7<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+!$`#`#H`?T`@@``````````_P#_`(``@("`@/\``/___P/_"!#< M_C#*2:N]..O-N_]@*(YD:9[HIP1*Z[YP+,]T;=]XKN]\[__`H'!(+!J/2!]K MD6PZG]"H=$JM6J_8UG*9[7J_X+!X3!9OKQ!C@[:..8#MLCR\YL97C]?[?;LO M&$U\,GYS16<^!HF*B3B`?VI<,(Z1+HYPE(69/P,[DUN'6I]Z=IAL=GA.EC.J MFD.@/(N+C:*&I:A,;K8ZK*V].`./N*&WQL=]P[RU-LR^/:\[L8JSQW%U MG]JAS("ZW99YX830Y2_`P;.4WI*TR,1_I)'>V>/RW)Z8^?;W\?#FDE;\H,9( M&386XQZQ8X>*%<*'^B+"HT>,(L"+"M"E4W>&_YX\7A$:/IQ(BR)#BPH5KB.E MLN)(?QC="*1!L*9-6VFO*1'=]0%4)J.F@;O<(XWVQY,K6EQ'[SGD4E_BQ]/OKSA\.;3JU_/W@OZ]O#CRY^O M!#&5.MRP$J+JG+[_5?\,W:;;2AZQ]A.!@:0AS'WDY/?#>ZF4),UH#EYUV7_^ MJ39A3WR559J!EQRV8"JH`0B'?3P(($`GRVR8C$22@8@A0`?4:*.-B\TT"5X. M9>4AAY!DLI(S,JZ"8@XJ)KFB.E)-YEQE8%"3[40%V&Z? M%6<;==,)V!"7_A3(WU,.:&./RBI9`Y\C+1;C\0!E=N48%V9)98< MA7;;;/CT21IC479FFF^YO?EHC&=9YB=A@NEY:3YL''F#G4FRR.8\!E)Z%:"& MV4C`JCCB69Q8<7U5FZR-"N4CHIVY9>FI@Y6YZV<^65K5()XJ`.JQR!Y;B5W_ M9OZFXZ92H@K&JM16BZ6@JEI+[;*XD>E9IE[R1>E>7[(%(Y3!HDNA6CU"IJEG M#98&!*BN*I?K,P'NZJRTOEQ9;8TYNHG0.UTR:BBMZ7[8X8[`*LQ5K>J6Q.Z0 M":MF*+'%U+DDGC"]VFT["%;([U%9EFQE'QVSN1S(R)$ISG/-D?JY7"VW#'+??<=-=M]]UXYZUWM&SW[??? M@`P__U17KOGF`0U\R.=D_HJ*=>XNF@J^XZZ@-#U7I0#11@^^VXYZ[[[KSW[OOOP`/?@&F>$6PL]G+K__^_/?O__\`#*``!TA`\]&O4VHHH`(7R,`& M.O"!$(R@_@YX'PE:\((8S*`&-\C![E%P"OGKH`A'2,(2FO"$'K1""%'(PA:Z M\(4PG*`*8TC#&MKPAC;\H!16B,,>^O"'0&R@#J/`PR`:\8A(3.+\9JC$)CKQ MB4\<(A2*",4J6O&*+I3B$_^HB,4N>O&+%M1B*L!(QC*:48%B#,09U\C&*M:$ M?VE,`A?;2,-,9P/+V<5S*D&=\.0F M.['HSFC$\Y[^2\0!YGG%>O(@F_@,J/@484E_=D*@"`VE`3QIT%TD]*'DT^Z45G&42*T);JLJ.^^>CLV$!4?)94F10=$^9* MU522+G2;/ZUD5;=I5&DV%$];U697M?G51H0UF4]59UG[<%9=CC6=:W5&6V7Y M5K4BL& MR-I1L@FEK"0LRT;#;E6S>N"L&3&;4=!60K1@).U(3:L%U'91M2ME[0I<^\-$ M>E:QLET`;7V(1]A^]JZ[I>%-@ENCW(J4N"+DIU^-B]P[_U9SM\QMKG"?2]OH M2A>&RL6K=:_+PN$V=[O<+:%O40O>\";7O-PK+WH1>=7U'DV][B5G>^-[(_C2 M-Y+S]>&U]HM"_F)+D<"][P+'RT(L&;B%!RZ9("LH8`?F]XA6BO`+)7RM!8.P MP?B%(K5BN.'^1=5'4^TKAN5YQ0I725LH3K&*5\SB%A_-Q!8.2^R`>KW!CAB` M!'8AJ[(%X_[NF)-Y68?0WG/<&Y\OQR;4UHU8%>$>CY#))P:RB3X:4Q3U],I8 MSC((#*!E$EA+`@KF;YY[ MLP25G,P/RPDPC\7S^O3LP#B+,_^KIQ2T0A'\K\`&6-&M?'`'#=W81T-:HT^F M]&$M?>EF2OI]_E7P]S1-5/MVVD:$!E^"G>RO#L_5U)U.M?@H_&)2+Y?3D)8U M^5P=9>CB6M"?#B"KJ_MK(^O:?+Q&+JQO?.SP[1C*/QZGBOZW[`8W>]0_#O6P M=0DJ#Q>;OM?N7K(3VFTI7UA_V@YKL.4W[H;W,D2`+R) MV#]:-[7>K;;BM"68;SO=J-QY_';Z[IU0@#,9O[O'?<'\B:*O$8D/WD2JXT^ M:/?X6-C_;CFUNKD(<5-XV^RE!JH]?KZ:/W'B:^0YLF,NZNY9'-E"WWA:>4U= M^2K]V$X_XKNO?D:I,Q#H_4XVTHG>S?V]'-31MCG:K:[O/IJ=X&2/'Z]MG3ZV M>]?32F]?V&EX\UG>?8-S%_R@N,=G!?J=Z4$'8K+..`!J*QR%B=\UMI!^8KYG MLNNJCCL!=(D;O'RF-R3J4<[@*F;^ M?[%W,^CM+7H%YMY&Q[=D4GA_;C#F/.V-+F#M`3CVWW^2.Y7?]Q3IF'R:-Q[= MQ8?@Y#&)_>7;:"G:WV(=036`)&6?@,'W7KH#KL'QN_#]_2N__T;.A_Z$IYR- MP*`BNW<`2@(,#/1]V3(H!O9Z!41Q!U=W+S2`YJ-_$A@_W.%_O;=&%W@T!6B` M!QA]G<=!#K@]%8A")4B!'JA$L'0Y^)-*'9B"#\2``S2"WE."%HB".(B#4<$P+=X"T2#)(A^ M5&A"2LA&M_0E5C9F8B@"2L(`29$"FX6# M@:9-([A_H.9Z_H.%7?@]@3A"&^B%/'B',E59\71[6XAX4SB(XU.(P;6"@-:" M"+6'?(AW`MB(I[8]=AA.&$6#G/@_[?_G?D+8B>*C>N($B)G8/?AWA.B`A:BX M1/_75++8B#9X?DHAB[.H/JJ(3[RX?`)8(TR!?$;8BY-T>1G%B^RW/;R(C*^D MC$0U@A'WC-"8C+6(6B1WC0/TBU75?=R8?F.$7*78@>'8C=+85JQWCAC8?,U% M>NP(0-X8CYTVC_0(:?9XCX*6C_K89OS8CS?VCP")80(YD`)6D`9)7PB9D.ZU MD`R)7@[YD.$5D1)Y7119D=^5CAA)D!JYD0?9D1ZID"`9D@TYDB0)D29YDA.9 MDBIID<)09P2CB"U9CX?H#D0VDZ?FA)%195&(DXKVA1W!DS-%AT19E$9YE$C9 M97;8,J>3AS[_Z8\UN69#$UI/^9,OR2W?W%I9T:5YM>9>;9I=ZZ9)\V9<9^9>`25QY M.9@!59B&>4^(F9A[-9>,&5N.^9BE%9F2N9<96)F32)F8.5F:N9F'V9F>J9B@ M&9J-*9BDJ5VC>9KCM)BJ&4RLV9IREIJPZ56R.9M059NV*4SN5%&;E9MR61\] MB#V^^9O1T!93J97#B9HATI0RF9QFB4V(>!Q).9W469W6>9T@<$X>163`P3>% MX)US`)YR()[C:1V7`&(R89Y=LYYR09YEX)YC`)_P^3KT69_V>9_X_YF?^KF? M_-F?_OF?`!J@`CJ@!%J@!GJ@")J@"9(Y]S.?#[(U>=$P*@2AN2"A@T2A!6,F M#,*@X9(%;^(A6>D=:0.%#EH?QVDD&5.BT1`Z/#FBC,2B0@6C+WJB&(.>*B2C MH*"BOJ!FI!(6>(@&4MFA,(D%/&JA$^*A06H4KZ"C72D[1BH[3-JD-!:3.1JE M0E)EU[%42$HG60I26RHO73HT5HHR7&IE4-H%016F08FF6&JF8JH>+:*F,7JC MSR*G5$:G'V*G,CJC>>JF0D:D,<4P/FH_7YH<08$88UJ>4^JGJEETIEA_JFYBGQH8#V(I*Z-%MAH_V!!JD:DR3! 8H9;3JO`"'1/:+K/JHT0JJX$A54B0```[ ` end
-----END PRIVACY-ENHANCED MESSAGE-----